FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Moreno, G Mangione, CM Meza, CE Kwon, I Seeman, T Trejo, L Moore, M Sarkisian, CA AF Moreno, Gerardo Mangione, Carol M. Meza, Carlos E. Kwon, Ivy Seeman, Teresa Trejo, Laura Moore, Mignon Sarkisian, Catherine A. TI PERCEPTIONS FROM LATINO AND AFRICAN AMERICAN OLDER ADULTS ABOUT BIOLOGICAL MARKERS IN RESEARCH SO ETHNICITY & DISEASE LA English DT Article DE Aging; African Americans; Latinos; Biomarkers ID REACTIVE PROTEIN-LEVELS; PARTICIPATORY RESEARCH; CLINICAL-TRIALS; RISK PROFILES; COMMUNITY; STRATEGIES AB Although older adult minorities face disparities in health and health care, they continue to be underrepresented in health research. Studies with biological markers of health often lack representation of older minority adults. The purpose of this study was to describe perceptions of biomarkers among ethnic minority seniors who might participate in studies of biological markers of health and to document barriers and facilitators to acceptance of biomarkers. Six focus groups (3 of Spanish-speaking Latinos and 3 of African Americans) were conducted in three community senior service organizations (two senior centers and one church). Ten semi-structured interviews were conducted to support and augment focus group data. Seventy-two community-dwelling minority older adults aged 62 years and older and 10 community stakeholders participated. A community-based partnered research approach was used and two community partners participated in the analysis and interpretation of results. Standard qualitative content-analysis methods were used to identify and organize themes in domains. Focus group participants were 49% Latino and 51% African American. Results included barriers: 1) mistrust, 2) fear of specimen collection/storage, 3) perceived harms, 4) competing demands, and 5) costs. Older Latinos cited issues of language as barriers to awareness and acceptance of biomarkers. African Americans had concerns over perceived harms of biomarkers. Facilitators to acceptance of biomarkers were community engagement through church and community leaders. Older Latino and African Americans identified many barriers and facilitators to the collection and storage of biomarkers. Participants identified community-partnered recommendations to overcome barriers to the acceptance, collection, and storage of biomarkers. C1 [Moreno, Gerardo; Meza, Carlos E.] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Kwon, Ivy; Seeman, Teresa; Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, Los Angeles, CA 90024 USA. [Trejo, Laura] City Los Angeles Dept Aging, Los Angeles, CA USA. [Moore, Mignon] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Moreno, G (reprint author), 10880 Wilshire Blvd,Suite 1800, Los Angeles, CA 90024 USA. EM gemoreno@mednet.ucla.edu OI Kwon, Ivy/0000-0003-4160-6546 FU NIA [K23 AG042961]; NIH/NCATS/UCLA [UL1TR000124, P30-AG021684]; L.A. CAPRA Center [1RC4AG038182, P30 AG028748] FX Funding from the NIA K23 AG042961 Paul B. Beeson Career Development Award in Aging Research, NIH/NCATS/UCLA #UL1TR000124, P30-AG021684, L.A. CAPRA Center 1RC4AG038182, and P30 AG028748. NR 30 TC 0 Z9 0 U1 1 U2 2 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD SUM PY 2015 VL 25 IS 3 BP 355 EP 362 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU7KW UT WOS:000363717800016 PM 26347148 ER PT J AU Alvarez, V Lee, JW Drislane, FW Westover, MB Novy, J Dworetzky, BA Rossetti, AO AF Alvarez, V. Lee, J. W. Drislane, F. W. Westover, M. B. Novy, J. Dworetzky, B. A. Rossetti, A. O. TI Is clonazepam an effective alternative as a first-line agent for status epilepticus management? SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Meeting Abstract CT 1st Congress of the European-Academy-of-Neurology CY JUN, 2015 CL Berlin, GERMANY SP European Acad Neurol C1 [Lee, J. W.; Dworetzky, B. A.] Brigham & Womens Hosp, Neurol, Boston, MA 02115 USA. [Drislane, F. W.] Beth Israel Deaconess Med Ctr, Neurol, Boston, MA 02215 USA. [Westover, M. B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. [Novy, J.; Rossetti, A. O.] CHU Vaudois, Neurol, CH-1011 Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD JUN PY 2015 VL 22 SU 1 SI SI MA O2108 BP 62 EP 62 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CL5WN UT WOS:000357033500100 ER PT J AU Drislane, F Alvarez, V Lee, JW Dworetzky, BA Westover, MB Curley, D Rossetti, AO AF Drislane, F. Alvarez, V. Lee, J. W. Dworetzky, B. A. Westover, M. B. Curley, D. Rossetti, A. O. TI Early misdiagnosis of the etiology of status epilepticus (SE) SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Meeting Abstract CT 1st Congress of the European-Academy-of-Neurology CY JUN, 2015 CL Berlin, GERMANY SP European Acad Neurol C1 [Lee, J. W.; Dworetzky, B. A.; Curley, D.] Brigham & Womens Hosp, Neurol, Boston, MA 02115 USA. [Westover, M. B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. [Rossetti, A. O.] CHU Vaudois, Neurol, CH-1011 Lausanne, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD JUN PY 2015 VL 22 SU 1 SI SI MA O2201 BP 75 EP 75 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CL5WN UT WOS:000357033500117 ER PT J AU Abdulaal, M Lin, MM Ledesma, M Pitoc, C Silva, PS Cheney, M Lammer, J Doctor, T Aiello, LP Sun, JK AF Abdulaal, Marwan Lin, Michael M. Ledesma, Migil Pitoc, Cloyd Silva, Paolo S. Cheney, Michael Lammer, Jan Doctor, Tahera Aiello, Lloyd Paul Sun, Jennifer K. TI Reproducibility of Disorganization of the Retinal Inner Layers (DRIL) Grading Across Spectral Domain Optical Coherence Tomography (SDOCT) Model and Scan Types in Eyes with Diabetic Macular Edema (DME) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Abdulaal, Marwan; Lin, Michael M.; Silva, Paolo S.; Cheney, Michael; Lammer, Jan; Doctor, Tahera; Aiello, Lloyd Paul; Sun, Jennifer K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Abdulaal, Marwan; Aiello, Lloyd Paul; Sun, Jennifer K.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Ledesma, Migil; Pitoc, Cloyd] Philippine Eye Res Inst, Manila, Philippines. [Lammer, Jan] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5959 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891107028 ER PT J AU Ajlan, R Silva, PS Cavallerano, JD Tolson, A Rodriquez, J Rodriguez, S Tolls, D Sun, JK Aiello, LP AF Ajlan, Radwan Silva, Paolo S. Cavallerano, Jerry D. Tolson, Ann Rodriquez, Jessica Rodriguez, Sashida Tolls, Dorothy Sun, Jennifer K. Aiello, Lloyd Paul TI Point-of-Care Evaluation of Diabetic Retinopathy Using Ultrawide Field Imaging in a Teleophthalmology Program SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ajlan, Radwan; Silva, Paolo S.; Cavallerano, Jerry D.; Tolson, Ann; Rodriquez, Jessica; Rodriguez, Sashida; Tolls, Dorothy; Sun, Jennifer K.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Silva, Paolo S.; Sun, Jennifer K.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3966 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102176 ER PT J AU Amparo, F Abud, T Jurkunas, UV Hamrah, P Dana, R AF Amparo, Francisco Abud, Tulio Jurkunas, Ula V. Hamrah, Pedram Dana, Reza TI Automated Assessment of Conjunctival Redness in Patients Undergoing Pterygium Surgery SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Amparo, Francisco; Abud, Tulio; Jurkunas, Ula V.; Hamrah, Pedram; Dana, Reza] Massachusetts Eye & Ear Infirm, Cornea Serv, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3376 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101016 ER PT J AU Ataer-Cansizoglu, E Bolon-Canedo, V Erdogmus, D Abrahams, K Ostmo, S Chan, RVP Kalpathy-Cramer, J Chiang, MF AF Ataer-Cansizoglu, Esra Bolon-Canedo, Veronica Erdogmus, Deniz Abrahams, Katherine Ostmo, Susan Chan, Robison Vernon Paul Kalpathy-Cramer, Jayashree Chiang, Michael F. TI A GMM-based Feature Extraction Technique for the Automated Diagnosis of Retinopathy of Prematurity SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ataer-Cansizoglu, Esra; Erdogmus, Deniz] Northeastern Univ, Elect & Comp Engn, Malden, MA USA. [Bolon-Canedo, Veronica] Univ A Coruna, Comp Sci, La Coruna, Spain. [Abrahams, Katherine; Ostmo, Susan; Chiang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chan, Robison Vernon Paul] Weill Cornell Med Coll, New York, NY USA. [Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Charlestown, MA USA. RI Bolon-Canedo, Veronica/A-5573-2015 OI Bolon-Canedo, Veronica/0000-0002-0524-6427 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5252 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105166 ER PT J AU Bailey, JC Gharahkhani, P Pasquale, LR Kang, JH Craig, JE MacGregor, S Burdon, KP Haines, JL Wiggs, JL AF Bailey, Jessica Cooke Gharahkhani, Puya Pasquale, Louis R. Kang, Jae H. Craig, Jamie E. MacGregor, Stuart Burdon, Kathryn P. Haines, Jonathan L. Wiggs, Janey L. CA NEIGHBORHOOD Consortium TI Sex-Specific Primary Open-Angle Glaucoma Loci identified in a Meta-analyzed Genome-Wide Imputed Dataset SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Bailey, Jessica Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Epidemiol & Biostat, Cleveland, OH 44106 USA. [Gharahkhani, Puya; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [Pasquale, Louis R.; Wiggs, Janey L.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Pasquale, Louis R.; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Kang, Jae H.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Craig, Jamie E.; Burdon, Kathryn P.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA 5001, Australia. RI Macgregor, Stuart/C-6442-2009 OI Macgregor, Stuart/0000-0001-6731-8142 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3663 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101288 ER PT J AU Barb, S Patel, A Stryjewski, T Andreoli, C Gardiner, M Lessell, S AF Barb, Scott Patel, Avni Stryjewski, Tomasz Andreoli, Christopher Gardiner, Matthew Lessell, Simmons TI Characteristics and outcomes of open globe injuries with clinical optic neuropathy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Barb, Scott; Patel, Avni; Stryjewski, Tomasz; Andreoli, Christopher; Gardiner, Matthew; Lessell, Simmons] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 6037 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891107106 ER PT J AU Borkar, DS Tham, VM Parker, JV Uchida, A Vinoya, AC Acharya, N AF Borkar, Durga S. Tham, Vivien M. Parker, John V. Uchida, Aileen Vinoya, Aleli C. Acharya, Nisha TI Incidence of Herpes Simplex Eye Disease: Results from the Pacific Ocular Inflammation (POI) Study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Borkar, Durga S.; Acharya, Nisha] Univ Calif San Francisco, FI Proctor Fdn, San Francisco, CA 94143 USA. [Borkar, Durga S.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Tham, Vivien M.] Pacific Vis Inst Hawaii, Honolulu, HI USA. [Parker, John V.; Uchida, Aileen; Vinoya, Aleli C.] Kaiser Permanente Hawaii, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5755 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891106252 ER PT J AU Brader, HS Pistilli, M Ying, GS Maguire, MG AF Brader, Hilary Smolen Pistilli, Maxwell Ying, Gui-Shuang Maguire, Maureen G. CA Complications Age-related Macular TI Early Progression of Geographic Atrophy in the Complications of Age-related macular degeneration Prevention Trial (CAPT) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Brader, Hilary Smolen] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Pistilli, Maxwell; Ying, Gui-Shuang; Maguire, Maureen G.] Univ Penn, Scheie Eye Inst, Ophthalmol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3790 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102002 ER PT J AU Buys, ES Hindle, A Jasien, JV Amin, K Allen, K Dordea, A Vandenwijngaert, S Wise, J Shaffer, J Ritch, R AF Buys, Emmanuel S. Hindle, Allyson Jasien, Jessica V. Amin, Krishna Allen, Kaitlin Dordea, Ana Vandenwijngaert, Sara Wise, Jasen Shaffer, Jonathan Ritch, Robert TI Developing micro-RNAs as biomarkers for Primary Open Angle Glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Buys, Emmanuel S.; Hindle, Allyson; Allen, Kaitlin; Dordea, Ana; Vandenwijngaert, Sara] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Anesthesia Crit Care & Pain Med, Boston, MA USA. [Jasien, Jessica V.; Ritch, Robert] New York Eye & Ear Infirm, Ophthalmol, New York, NY 10003 USA. [Amin, Krishna; Wise, Jasen; Shaffer, Jonathan] Qiagen, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3654 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101279 ER PT J AU Cho, H Siegel, NH Yu, HG Sobrin, L Patel, A Lim, HW Durand, M Miller, JW Husain, D AF Cho, Heeyoon Siegel, Nicole Hauptman Yu, Hyeong Gon Sobrin, Lucia Patel, Achal Lim, Han Woong Durand, Marlene Miller, Joan W. Husain, Deeba TI Endogenous Endophthalmitis in the American and Korean Population : An Eight-year Retrospective Study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Cho, Heeyoon; Sobrin, Lucia; Miller, Joan W.; Husain, Deeba] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. [Cho, Heeyoon; Lim, Han Woong] Hanyang Univ, Coll Med, Ophthalmol, Seoul 133791, South Korea. [Siegel, Nicole Hauptman; Patel, Achal] Boston Univ, Sch Med, Ophthalmol, Boston, MA 02118 USA. [Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Ophthalmol, Seoul, South Korea. [Durand, Marlene] Harvard Univ, Sch Med, Dept Med, Infect Dis Unit,Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4169 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102370 ER PT J AU Chodosh, J Singh, G Robinson, C Lee, JY Rajaiya, J Jones, M Dyer, D Seto, D AF Chodosh, James Singh, Gurdeep Robinson, Christopher Lee, Jeong Yoon Rajaiya, Jaya Jones, Morris Dyer, David Seto, Donald TI Proteotyping as a tool to study the evolution of human adenoviruses associated with epidemic keratoconjunctivitis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Chodosh, James; Singh, Gurdeep; Robinson, Christopher; Lee, Jeong Yoon; Rajaiya, Jaya] Mass Eye & Ear Infirmary HMS, Ophthalmol, Boston, MA USA. [Jones, Morris; Seto, Donald] George Mason Univ, Manassas, VA USA. [Dyer, David] Univ Oklahoma, Hlth Sci Ctr, Boston, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4843 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104201 ER PT J AU Clermont, AC Murugesan, N Feener, EP AF Clermont, Allen C. Murugesan, Nivetha Feener, Edward P. TI Vascular endothelial growth factor (VEGF)- and the kallikrein kinin system (KKS)-induced neuronal dysfunction in a rodent model of retinal edema SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Clermont, Allen C.; Murugesan, Nivetha; Feener, Edward P.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5487 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105399 ER PT J AU Crnej, A Eiglmeier, S Omoto, M Dohlman, TH Dohlman, CH Dana, R AF Crnej, Alja Eiglmeier, Susanne Omoto, Masahiro Dohlman, Thomas H. Dohlman, Claes H. Dana, Reza TI Corneal inflammation after penetrating keratoplasty and miniature keratoprosthesis implantation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Crnej, Alja; Dohlman, Claes H.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Eiglmeier, Susanne; Omoto, Masahiro; Dohlman, Thomas H.; Dana, Reza] Schepens Eye Res Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4023 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102224 ER PT J AU Dartt, DA Li, DY Hodges, RR Gilmore, M Gregory-Ksander, MS AF Dartt, Darlene A. Li, Dayu Hodges, Robin R. Gilmore, Michael Gregory-Ksander, Meredith S. TI Toxigenic Staphylococcus Aureus bacteria activate conjunctival goblet cell NLRP3 inflammasomes using TLR 2, TLR1, and alpha toxin SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Dartt, Darlene A.; Li, Dayu; Hodges, Robin R.; Gregory-Ksander, Meredith S.] Schepens Eye Res Inst MEEI, Boston, MA USA. [Dartt, Darlene A.; Li, Dayu; Hodges, Robin R.; Gilmore, Michael; Gregory-Ksander, Meredith S.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Gilmore, Michael] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4846 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104204 ER PT J AU Ecoiffier, T Hamrah, P Grimaldo, S Kang, GJ Sessa, R Truong, TN Harris, DL von Andrian, U Chen, L Zheng, LX AF Ecoiffier, Tatiana Hamrah, Pedram Grimaldo, Sammy Kang, Gyeong Jin Sessa, Roberto Tan Ngoc Truong Harris, Deshea L. von Andrian, Ulrich Chen, Lu Zheng, Lixin TI Nerve Growth Factor Mediates Corneal Lymphangiogenesis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ecoiffier, Tatiana; Grimaldo, Sammy; Kang, Gyeong Jin; Sessa, Roberto; Tan Ngoc Truong; Chen, Lu] Univ Calif Berkeley, Ctr Eye Dis & Dev, Program Vis Sci, Berkeley, CA 94720 USA. [Ecoiffier, Tatiana; Grimaldo, Sammy; Kang, Gyeong Jin; Sessa, Roberto; Tan Ngoc Truong; Chen, Lu] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA. [Hamrah, Pedram; Harris, Deshea L.; Zheng, Lixin] Harvard Univ, Massachusetts Eye & Ear, Dept Ophthalmol, Schepens Eye Res Inst,Med Sch, Boston, MA USA. [von Andrian, Ulrich] Harvard Univ, Program Cellular & Mol Med, Childrens Hosp Boston, Immune Dis Inst,Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4504 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103286 ER PT J AU Elze, T Shen, LO Wiggs, JL Boland, MV Wellik, S Bex, PJ Pasquale, LR AF Elze, Tobias Shen, Lucy O. Wiggs, Janey L. Boland, Michael V. Wellik, Sarah Bex, Peter J. Pasquale, Louis R. TI Patterns of early glaucomatous visual field loss and their evolution over time SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Elze, Tobias] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Elze, Tobias] Max Planck Inst Math Sci, Leipzig, Germany. [Shen, Lucy O.; Wiggs, Janey L.; Pasquale, Louis R.] Harvard Univ, Sch Med, Mass Eye & Ear Infirm, Boston, MA USA. [Boland, Michael V.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA. [Wellik, Sarah] Bascom Palmer Eye Inst, Miami, FL 33136 USA. [Bex, Peter J.] Northeastern Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 AR UNSP 3178 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100053 ER PT J AU Erdogmus, D Bolon-Canedo, V Ataer-Cansizoglu, E Kalpathy-Cramer, J Fontenla-Romero, O Alonso-Betanzos, A Chiang, MF AF Erdogmus, Deniz Bolon-Canedo, Veronica Ataer-Cansizoglu, Esra Kalpathy-Cramer, Jayashree Fontenla-Romero, Oscar Alonso-Betanzos, Amparo Chiang, Michael F. TI Dealing with inter-expert variability in Retinopathy of Prematurity through machine learning SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Erdogmus, Deniz; Ataer-Cansizoglu, Esra] Northeastern Univ, Boston, MA 02115 USA. [Bolon-Canedo, Veronica; Fontenla-Romero, Oscar; Alonso-Betanzos, Amparo] Univ A Coruna, La Coruna, Spain. [Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Charlestown, MA USA. [Chiang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RI Fontenla-Romero, Oscar/A-1142-2015; Bolon-Canedo, Veronica/A-5573-2015 OI Fontenla-Romero, Oscar/0000-0003-4203-8720; Bolon-Canedo, Veronica/0000-0002-0524-6427 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5251 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105165 ER PT J AU Farinha, CL Mira, F Santos, L Nunes, S Pedroso, A Lains, I Cachulo, ML Silva, R AF Farinha, Claudia Louro Mira, Filipe Santos, Lelita Nunes, Sandrina Pedroso, Ana Lains, Ines Cachulo, Maria Luz Silva, Rufino TI Nutritional and lifestyle risk factors in AMD. The Coimbra Eye Study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Farinha, Claudia Louro; Lains, Ines; Cachulo, Maria Luz; Silva, Rufino] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal. [Mira, Filipe; Santos, Lelita] Univ Coimbra, Fac Med FMUC, Coimbra, Portugal. [Santos, Lelita] Ctr Hosp & Univ Coimbra, Dept Internal Med, Coimbra, Portugal. [Nunes, Sandrina; Pedroso, Ana; Cachulo, Maria Luz; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal. [Lains, Ines] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3770 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101395 ER PT J AU Farkas, MH Sousa, M Pierce, EA AF Farkas, Michael H. Sousa, Maria Pierce, Eric A. TI Development and functional characterization of PRPF31 knockout ARPE-19 cells using genome editing technique SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Farkas, Michael H.; Sousa, Maria; Pierce, Eric A.] Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 4 U2 6 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4631 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103412 ER PT J AU Fei, F Krishnan, A Rothstein, AM Ksander, BR Gregory-Ksander, MS AF Fei, Fei Krishnan, Anitha Rothstein, Ann Marshak Ksander, Bruce R. Gregory-Ksander, Meredith S. TI Preventing glaucoma by blocking activation of the NLRP3 inflammasome in the optic nerve head SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Fei, Fei; Krishnan, Anitha; Ksander, Bruce R.; Gregory-Ksander, Meredith S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol,Schepens Eye Res Inst, Boston, MA USA. [Rothstein, Ann Marshak] Univ Massachusetts, Sch Med, Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3485 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101124 ER PT J AU Fernandez-Godino, R Pierce, EA Garland, D AF Fernandez-Godino, Rosario Pierce, Eric A. Garland, Donita TI The Role of Complement and the Extracellular Matrix in Early Stage Macular Degeneration SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Fernandez-Godino, Rosario; Pierce, Eric A.; Garland, Donita] Mass Eye & Ear Infirm, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3532 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101163 ER PT J AU Geisert, EE Struebing, FL King, R Pasquale, LR Ashley-Koch, AE Hauser, MA Allingham, RR Wiggs, JL AF Geisert, Eldon E. Struebing, Felix L. King, Rebecca Pasquale, Louis R. Ashley-Koch, Allison E. Hauser, Michael A. Allingham, R. Rand Wiggs, Janey L. TI GENOMIC LOCI MODULATING GANGLION CELL DEATH FOLLOWING ELEVATED IOP IN THE MOUSE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Geisert, Eldon E.; Struebing, Felix L.; King, Rebecca] Emory Univ, Ophthalmol, Atlanta, GA 30322 USA. [Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA. [Ashley-Koch, Allison E.; Hauser, Michael A.] Duke Univ, Med, Durham, NC USA. [Hauser, Michael A.; Allingham, R. Rand] Duke Univ, Ophthalmol, Durham, NC USA. [Wiggs, Janey L.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3665 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101290 ER PT J AU Gentile, RC Eliott, D Rosen, RB Benevento, J Reppucci, VS Iezzi, R AF Gentile, Ronald C. Eliott, Dean Rosen, Richard B. Benevento, Joseph Reppucci, Vincent S. Iezzi, Raymond TI The Combined Tractional-Hydration Theory of Idiopathic Macular Holes SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Gentile, Ronald C.; Rosen, Richard B.; Benevento, Joseph; Reppucci, Vincent S.] New York Eye & Ear Infirm Mt Sinai, Ophthalmol, New York, NY USA. [Gentile, Ronald C.] Winthrop Univ Hosp, Ophthalmol, Mineola, NY 11501 USA. [Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Iezzi, Raymond] Mayo Clin, Sch Med, Dept Ophthalmol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4325 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103114 ER PT J AU Gilbert, A Wan, MJ Kazlas, M Wu, C Hunter, DG Mantagos, I Shah, A AF Gilbert, Aubrey Wan, Michael J. Kazlas, Melanie Wu, Carolyn Hunter, David G. Mantagos, Iason Shah, Ankoor TI Botulinum Toxin-Augmented Strabismus Surgery versus Conventional Surgery in the Treatment of Large-Angle Infantile Esotropia SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Gilbert, Aubrey; Kazlas, Melanie] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Gilbert, Aubrey; Wan, Michael J.; Kazlas, Melanie; Wu, Carolyn; Hunter, David G.; Mantagos, Iason; Shah, Ankoor] Boston Childrens Hosp, Ophthalmol, Boston, MA USA. [Gilbert, Aubrey; Wan, Michael J.; Kazlas, Melanie; Wu, Carolyn; Hunter, David G.; Mantagos, Iason; Shah, Ankoor] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5217 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105147 ER PT J AU Greenwald, SH Staniszewska, MM Pierce, EA Liu, Q AF Greenwald, Scott H. Staniszewska, Magdalena Maria Pierce, Eric A. Liu, Qin TI Deficiency of Intraflagellar Transport Protein 139 in Rod Photoreceptors Causes Early-Onset Rod-Cone Degeneration in Mice SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Greenwald, Scott H.; Staniszewska, Magdalena Maria; Pierce, Eric A.; Liu, Qin] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5401 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105313 ER PT J AU Grob, SR Lee, NG Creighton, F Jakobiec, F Emerick, K Freitag, SK AF Grob, Seanna R. Lee, N. Grace Creighton, Francis Jakobiec, Frederick Emerick, Kevin Freitag, Suzanne K. TI Multispecialty approach to management of sebaceous carcinoma of the eyelids SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Grob, Seanna R.; Lee, N. Grace; Jakobiec, Frederick; Freitag, Suzanne K.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Grob, Seanna R.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Lee, N. Grace; Freitag, Suzanne K.] Massachusetts Eye & Ear Infirm, Oculoplast & Reconstruct Surg, Boston, MA 02114 USA. [Creighton, Francis; Emerick, Kevin] Massachusetts Eye & Ear Infirm, Otolaryngol, Boston, MA 02114 USA. [Jakobiec, Frederick] Massachusetts Eye & Ear Infirm, Ophthalm Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3430 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101070 ER PT J AU Harris, DL Lopez, MJ Jamali, A Hamrah, P AF Harris, Deshea L. Lopez, Maria J. Jamali, Arsia Hamrah, Pedram TI Expression of the Neuropeptide Adrenomedullin and its Receptors in Normal and Inflamed Murine Corneas SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Harris, Deshea L.; Lopez, Maria J.; Jamali, Arsia; Hamrah, Pedram] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA USA. [Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Cornea Serv, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4038 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102239 ER PT J AU Huang, XD Lopez, MJ Hamrah, P AF Huang, Xiaodan Lopez, Maria J. Hamrah, Pedram TI Effects of Sensory and Sympathetic Innervation on the Corneolimbal Neurovascular Complex SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Huang, Xiaodan; Lopez, Maria J.; Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA. [Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea & Refract Surg Serv,Dept Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4499 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103281 ER PT J AU Im, M Fried, SI AF Im, Maesoon Fried, Shelley I. TI Temporal properties of network-mediated responses to repetitive stimuli are different in ON vs. OFF retinal ganglion cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Im, Maesoon; Fried, Shelley I.] Massachusetts Gen Hosp HMS, Neurosurg, Boston, MA USA. [Im, Maesoon; Fried, Shelley I.] Boston VA Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3242 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100113 ER PT J AU Inomata, T Hua, J Di Zazzo, A Lee, SM Shiang, T Chiang, H Zhang, Q Dana, R AF Inomata, Takenori Hua, Jing Di Zazzo, Antonio Lee, Sang-Mok Shiang, Tina Chiang, Homer Zhang, Qiang Dana, Reza TI Corneal Grafts Proned to Rejection Exhibit Impaired Function of Peripherally Induced Regulatory T Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Inomata, Takenori; Hua, Jing; Di Zazzo, Antonio; Lee, Sang-Mok; Shiang, Tina; Chiang, Homer; Zhang, Qiang; Dana, Reza] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4027 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102228 ER PT J AU Jamali, A Lopez, MJ Sendra, V Harris, DL Hamrah, P AF Jamali, Arsia Lopez, Maria J. Sendra, Victor Harris, Deshea L. Hamrah, Pedram CA Harvard Med Sch TI Plasmacytoid Dendritic Cells Demonstrate Vital Neuro-protective Properties in the Cornea and Induce Corneal Nerve Regeneration SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Jamali, Arsia; Lopez, Maria J.; Sendra, Victor; Harris, Deshea L.; Hamrah, Pedram] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst,Massachusetts Eye & Ear, Boston, MA USA. [Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea & Refract Surg Serv,Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4355 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103143 ER PT J AU Kang, JH Aschard, H Hauser, MA Haines, JL Christen, WG Kraft, P Chasman, DI Bailey, JC Wiggs, JL Pasquale, LR AF Kang, Jae H. Aschard, Hugues Hauser, Michael A. Haines, Jonathan L. Christen, William Gerard Kraft, Peter Chasman, Daniel Ian Bailey, Jessica Cooke Wiggs, Janey L. Pasquale, Louis R. CA NEIGHBORHOOD TI Age at menopause genetic risk score in relation to primary open-angle glaucoma in the Augmented GLAUGEN study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kang, Jae H.; Christen, William Gerard; Chasman, Daniel Ian; Pasquale, Louis R.] Brigham & Womens Hosp, Med, Boston, MA 02115 USA. [Aschard, Hugues; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Epidemiol, Boston, MA 02115 USA. [Hauser, Michael A.] Duke Univ, Med Ctr, Med, Durham, NC USA. [Haines, Jonathan L.; Bailey, Jessica Cooke] Case Western Reserve Univ, Epidemiol & Biostat, Cleveland, OH 44106 USA. [Wiggs, Janey L.; Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3666 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101291 ER PT J AU Kim, LA Wong, LL Amarnani, D Bigger-Allen, AA Hu, Y Marko, C Shah, V Eliott, D Arboleda-Velasquez, JF D'Amore, PA AF Kim, Leo A. Wong, Lindsay L. Amarnani, Dhanesh Bigger-Allen, Alex A. Hu, Yang Marko, Christina Shah, Vinay Eliott, Dean Arboleda-Velasquez, Joseph F. D'Amore, Patricia A. TI Analysis and culture of cells from patient-derived membranes in proliferative diabetic retinopathy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kim, Leo A.; Eliott, Dean] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA. [Kim, Leo A.; Wong, Lindsay L.; Amarnani, Dhanesh; Bigger-Allen, Alex A.; Hu, Yang; Marko, Christina; Arboleda-Velasquez, Joseph F.; D'Amore, Patricia A.] Schepens Eye Res Inst Mass Eye & Ear, Ophthalmol, Boston, MA USA. [Shah, Vinay] Dean McGee Eye Inst, Ophthalmol, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4683 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104047 ER PT J AU Kron-Gray, MM Witkin, AJ Witkin, D Baumal, CR Engstrom, RE Albini, TA Batlle, IR Eliott, D Johnson, MW Shah, A AF Kron-Gray, Michelle M. Witkin, Andre J. Witkin, Deborah Baumal, Caroline R. Engstrom, Robert E. Albini, Thomas Arno Batlle, Ivan R. Eliott, Dean Johnson, Mark W. Shah, Anjali TI Hemorrhagic Occlusive Retinal Vasculitis after Cataract Extraction: A Vancomycin-Associated Reaction? SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kron-Gray, Michelle M.; Johnson, Mark W.; Shah, Anjali] Univ Michigan, Ophthalmol, Dexter, MI 02111 USA. [Witkin, Andre J.; Witkin, Deborah; Baumal, Caroline R.] Tufts Univ, Ophthalmol, Boston, MA 90024 USA. [Engstrom, Robert E.] Jules Stein Eye Inst, Los Angeles, CA USA. [Albini, Thomas Arno] Bascom Palmer Eye Inst, Miami, FL USA. [Batlle, Ivan R.] Retina Associates PA, Shawnee Mission, KS 02114 USA. [Eliott, Dean] Massachusetts Eye & Ear Infirm, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3853 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102065 ER PT J AU Lautz, J Pervan, CL Stubbs, EB AF Lautz, Jonathan Pervan, Cynthia Lynn Stubbs, Evan B. TI Transforming Growth Factor-beta 2 Attenuates Bradykinin B2 Receptor Expression in Human Trabecular Meshwork Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lautz, Jonathan] Loyola Univ Chicago, Program Neurosci, Maywood, IL USA. [Lautz, Jonathan; Pervan, Cynthia Lynn; Stubbs, Evan B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Pervan, Cynthia Lynn; Stubbs, Evan B.] Loyola Univ Chicago, Ophthalmol, Maywood, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3293 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100164 ER PT J AU Lawrence, MS Attwood, J Lewis, A Brookes, R Woodley, V Tucker, M Hu, WZ Goody, RJ Callanan, S Vavvas, D AF Lawrence, Matthew S. Attwood, Jordan Lewis, Alex Brookes, Rohn Woodley, Vernard Tucker, Meghan Hu, Wenzheng Goody, Robin J. Callanan, Sean Vavvas, Demetrios TI Characterization and application of a nonhuman primate model of non-arteritic anterior ischemic optic neuropathy for therapeutic screening SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lawrence, Matthew S.; Attwood, Jordan; Lewis, Alex; Brookes, Rohn; Woodley, Vernard; Tucker, Meghan; Hu, Wenzheng; Goody, Robin J.] RxGen, Res, Hamden, CT USA. [Callanan, Sean] Ross Univ, Basseterre, St Kitts & Nevi. [Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5544 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891106042 ER PT J AU Lee, J Shah, C Agemy, S Eliott, D Gentile, RC AF Lee, Jessica Shah, Chirag Agemy, Steven Eliott, Dean Gentile, Ronald C. CA Study Grp Annual Mass Eye Ear TI Qualities of the Ideal Surgical Retina Fellow and Attending: Perspective of the Attending and Fellow SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lee, Jessica; Agemy, Steven] New York Eye & Ear Infirm Mt Sinai, Retina, New York, NY USA. [Shah, Chirag; Gentile, Ronald C.] Stony Brook Sch Med, Stony Brook, NY USA. [Eliott, Dean; Study Grp Annual Mass Eye Ear] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Gentile, Ronald C.] Winthrop Univ Hosp, Mineola, NY 11501 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5126 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105057 ER PT J AU Li, E Greenberg, PB Krzystolik, MG AF Li, Emily Greenberg, Paul B. Krzystolik, Magdalena G. TI Nurse-administered intravitreal injections: a systematic review SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Li, Emily; Greenberg, Paul B.] Brown Univ, Div Ophthalmol, Warren Alpert Med Sch, Providence, RI 02912 USA. [Greenberg, Paul B.; Krzystolik, Magdalena G.] Providence Vet Affairs Med Ctr, Sect Ophthalmol, Providence, RI USA. [Krzystolik, Magdalena G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4180 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102381 ER PT J AU Lippestad, M Hodges, RR Utheim, TP Li, DY Serhan, CN Dartt, DA AF Lippestad, Marit Hodges, Robin R. Utheim, Tor Paaske Li, Dayu Serhan, Charles N. Dartt, Darlene A. TI Differential Effects of Pro-resolution Mediators Resolvins RvD1 and RvE1 on Conjunctival Goblet Cell Function SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lippestad, Marit; Utheim, Tor Paaske] Univ Oslo, Dept Med Biochem, Oslo, Norway. [Lippestad, Marit; Hodges, Robin R.; Li, Dayu; Dartt, Darlene A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4425 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103207 ER PT J AU Liu, CL Vojnovic, D Kochevar, IE Jurkunas, UV AF Liu, Cailing Vojnovic, Dijana Kochevar, Irene E. Jurkunas, Ula V. TI UVA Irradiation Activates Nrf2-Regulated Antioxidant Defense and Induces p53/Caspase3 Dependent Apoptosis in Corneal Endothelial Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Liu, Cailing; Vojnovic, Dijana; Jurkunas, Ula V.] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst,Massachusetts Eye & Ear, Boston, MA USA. [Kochevar, Irene E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4897 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104255 ER PT J AU Liu, YN Simavli, H Que, C Akduman, M Rizzo, J Tsikata, E Maurer, R De Boer, JF Chen, TC AF Liu, Yingna Simavli, Huseyin Que, Christian Akduman, Mustafa Rizzo, Jennifer Tsikata, Edem Maurer, Rie De Boer, Johannes F. Chen, Teresa C. TI Comparison of peripapillary retinal thickness (RT) with retinal nerve fiber layer (RNFL) thickness measurements for diagnostic capability and artifact rates SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Liu, Yingna; Simavli, Huseyin; Que, Christian; Tsikata, Edem; Maurer, Rie; Chen, Teresa C.] Harvard Univ, Sch Med, Boston, MA USA. [Simavli, Huseyin; Que, Christian; Akduman, Mustafa; Rizzo, Jennifer; Tsikata, Edem; Chen, Teresa C.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Maurer, Rie] Brigham & Womens Hosp, Ctr Clin Invest, Boston, MA 02115 USA. [De Boer, Johannes F.] Vrije Univ Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands. RI Simavli, Huseyin/K-4404-2016 NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4561 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103342 ER PT J AU Lopez, MJ Jamali, A Harris, DL Hamrah, P AF Lopez, Maria J. Jamali, Arsia Harris, Deshea L. Hamrah, Pedram TI The Chemokine Receptor CXCR4 Mediates Recruitment of CD11c+Dendritic Cells into the Inflammed Murine Corneas SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lopez, Maria J.; Jamali, Arsia; Harris, Deshea L.; Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA. [Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea & Refract Surg Serv,Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4039 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102240 ER PT J AU Lu, Y Bernabeu, M Lammer, J Cai, CC Aiello, LP Sun, JK AF Lu, Yang Bernabeu, Miguel Lammer, Jan Cai, Charles Chen Aiello, Lloyd Paul Sun, Jennifer K. TI Perifoveal Capillary Perfusion Pressure and Wall Shear Stress Estimated by a Computational Model Based on Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lu, Yang; Lammer, Jan; Cai, Charles Chen; Aiello, Lloyd Paul; Sun, Jennifer K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Bernabeu, Miguel] UCL, Ctr Computat Sci, London, England. [Bernabeu, Miguel] UCL, CoMPLEX, London, England. [Lammer, Jan] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria. [Aiello, Lloyd Paul; Sun, Jennifer K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5665 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891106162 ER PT J AU Mackey, AM Aranda, J Gerhardinger, C Kazlauskas, A AF Mackey, Ashley Michael Aranda, Jorge Gerhardinger, Chiara Kazlauskas, Andrius TI Development and Characterization of a new Mouse Model of Proliferative Diabetic Retinopathy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Mackey, Ashley Michael; Aranda, Jorge; Gerhardinger, Chiara; Kazlauskas, Andrius] Harvard Univ, Sch Med, Mass Eye & Ear Infirm, Ophthalmol,Schepens Eye Res Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4676 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104040 ER PT J AU Maidana, DE Lin, HJ Dib, B Miller, JB Bouzika, P Tian, B Miller, JW Vavvas, D AF Maidana, Daniel E. Lin, Haijiang Dib, Bernard Miller, John B. Bouzika, Peggy Tian, Bo Miller, Joan W. Vavvas, Demetrios TI microRNA-192 Expression Induced by TGF-beta 1 Contributes to Epithelial-Mesenchymal Transition of RPE by activating AKT Kinases SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Maidana, Daniel E.; Lin, Haijiang; Dib, Bernard; Miller, John B.; Bouzika, Peggy; Tian, Bo; Miller, Joan W.; Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Ophthalmol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4231 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103021 ER PT J AU Moein, H Lopez, MJ Harris, DL Hamrah, P AF Moein, Hamidreza Lopez, Maria J. Harris, Deshea L. Hamrah, Pedram TI Mucosal Addressin Cell Adhesion Molecule (MAdCAM)-1 Mediate Dendritic Cell Trafficking In Vivo and is Up-Regulated after Corneal Graft Rejection SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Moein, Hamidreza; Lopez, Maria J.; Harris, Deshea L.; Hamrah, Pedram] Schepens Eye Res Inst, Ophthalmol, Boston, MA USA. [Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Ophthalomol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4033 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102234 ER PT J AU Murugesan, N Clermont, AC Sun, LL Feener, EP AF Murugesan, Nivetha Clermont, Allen C. Sun, LeiLei Feener, Edward P. TI Proteomic characterization of retinal edema in rats SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Murugesan, Nivetha; Clermont, Allen C.; Sun, LeiLei; Feener, Edward P.] Joslin Diabet Ctr, Vasc Cell Biol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4693 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104057 ER PT J AU Nakata, I Gaier, ED Navarro-Gomez, D Borchert, JS Gai, XW Pasquale, LR Lessell, S Cestari, DM Rizzo, JF Wiggs, JL AF Nakata, Isao Gaier, Eric D. Navarro-Gomez, Daniel Borchert, John Simmons Gai, Xiaowu Pasquale, Louis R. Lessell, Simmons Cestari, Dean M. Rizzo, Joseph F. Wiggs, Janey L. TI Mitochondria haplogroups in patients with dominant optic atrophy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Nakata, Isao; Gaier, Eric D.; Navarro-Gomez, Daniel; Borchert, John Simmons; Gai, Xiaowu; Pasquale, Louis R.; Lessell, Simmons; Cestari, Dean M.; Rizzo, Joseph F.; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3861 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102073 ER PT J AU Notomi, S Hisatomi, T Tachibana, T Murakami, Y Ikeda, Y Terasaki, H Sakamoto, T Miller, JW Ishibashi, T Vavvas, D AF Notomi, Shoji Hisatomi, Toshio Tachibana, Takashi Murakami, Yusuke Ikeda, Yasuhiro Terasaki, Hiroto Sakamoto, Taiji Miller, Joan W. Ishibashi, Tatsuro Vavvas, Demetrios TI Dysfunctional autophagosome and phagosome in age-related macular degeneration (AMD) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Notomi, Shoji; Miller, Joan W.; Vavvas, Demetrios] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA USA. [Notomi, Shoji; Hisatomi, Toshio; Tachibana, Takashi; Murakami, Yusuke; Ikeda, Yasuhiro; Ishibashi, Tatsuro] Kyushu Univ, Ophthalmol, Fukuoka 812, Japan. [Hisatomi, Toshio] Natl Hosp Org Kyushu Med Ctr, Ophthalmol, Fukuoka, Japan. [Terasaki, Hiroto; Sakamoto, Taiji] Kagoshima Univ, Ophthalmol, Kagoshima 890, Japan. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3537 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101168 ER PT J AU Papakostas, TD Nicolaou, F Al-Moujahed, A Miller, JB Lin, HJ Gragoudas, ES Vavvas, D AF Papakostas, Thanos D. Nicolaou, Fotini Al-Moujahed, Ahmad Miller, John B. Lin, Haijiang Gragoudas, Evangelos S. Vavvas, Demetrios TI Deferoxamine inhibits the growth of uveal melanoma cells in vitro SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Papakostas, Thanos D.; Al-Moujahed, Ahmad; Miller, John B.; Lin, Haijiang; Gragoudas, Evangelos S.; Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Nicolaou, Fotini] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5320 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105234 ER PT J AU Pervan, CL Lautz, JD Blitzer, AL Stubbs, EB AF Pervan, Cynthia Lynn Lautz, Jonathan D. Blitzer, Andrea L. Stubbs, Evan B. TI Constitutive Expression and Release of TGF-beta 2 by Human Trabecular Meshwork Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Pervan, Cynthia Lynn; Lautz, Jonathan D.; Blitzer, Andrea L.; Stubbs, Evan B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, Hines, IL 60141 USA. [Pervan, Cynthia Lynn; Stubbs, Evan B.] Loyola Univ Chicago, Ophthalmol, Maywood, IL USA. [Lautz, Jonathan D.] Loyola Univ Chicago, Program Neurosci, Maywood, IL USA. [Blitzer, Andrea L.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3295 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100166 ER PT J AU Qian, CXY Hasegawa, E Haddock, L Wu, DM Mukai, S AF Qian, Cynthia Xin-Ya Hasegawa, Eiichi Haddock, Luis Wu, David M. Mukai, Shizuo TI Smartphone fundus photography, in vivo retinal fluorescent photography and fluorescein angiography in mouse eyes SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Qian, Cynthia Xin-Ya; Hasegawa, Eiichi; Wu, David M.; Mukai, Shizuo] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Haddock, Luis] Bascom Palmer Eye Inst, Palm Beach Gardens, FL USA. [Wu, David M.] Harvard Univ, Sch Med, Genet, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4104 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102305 ER PT J AU Ramke, M Zhou, XH Chintakuntlawar, A Rajaiya, J Chodosh, J AF Ramke, Mirja Zhou, Xiaohong Chintakuntlawar, Ashish Rajaiya, Jaya Chodosh, James TI MyD88 Adaptor Protein is Required for Adenovirus Keratitis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ramke, Mirja; Zhou, Xiaohong; Chintakuntlawar, Ashish; Rajaiya, Jaya; Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4841 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104199 ER PT J AU Rao, R Choi, C Yoon, MK AF Rao, Rohini Choi, Catherine Yoon, Michael K. TI Google Glass in Oculoplastic Surgery: measurement of the margin reflex distance SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Rao, Rohini; Choi, Catherine; Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4738 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104102 ER PT J AU Roh, M Cho, H Yasa, C Nicholson, L Uchiyama, E Young, LH Durand, M Lobo, AM Papaliodis, G Sobrin, L AF Roh, Miin Cho, Heeyoon Yasa, Cagla Nicholson, Laura Uchiyama, Eduardo Young, Lucy H. Durand, Marlene Lobo, Ann-Marie Papaliodis, George Sobrin, Lucia TI Toxoplasmosis Antibody Titers as a Supportive Tool in the Diagnosis of Ocular Toxoplasmosis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Roh, Miin; Cho, Heeyoon; Yasa, Cagla; Nicholson, Laura; Uchiyama, Eduardo; Young, Lucy H.; Durand, Marlene; Lobo, Ann-Marie; Papaliodis, George; Sobrin, Lucia] Massachusettes Eye & Ear Infirm, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3133 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100008 ER PT J AU Schnabolk, G Bandyopadhyay, M Tomlinson, S Rohrer, B AF Schnabolk, Gloriane Bandyopadhyay, Mausumi Tomlinson, Stephen Rohrer, Baerbel TI New insights on complement inhibitor CD59 in mouse laser-induced choroidal neovascularization: reduced expression after injury and targeted delivery for protein replacement SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Schnabolk, Gloriane; Tomlinson, Stephen; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Med Univ S Carolina, Microbiol & Immunol, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5459 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105371 ER PT J AU Smith, K Castillejos, A Diaz-Aguilar, D Kim, C Sweigard, H Connor, KM AF Smith, Kaylee Castillejos, Alexandra Diaz-Aguilar, Daniel Kim, Clifford Sweigard, Harry Connor, Kip M. TI The role of the alternative complement pathway in vascular regression SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Smith, Kaylee; Castillejos, Alexandra; Diaz-Aguilar, Daniel; Kim, Clifford; Sweigard, Harry; Connor, Kip M.] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3406 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101046 ER PT J AU Sun, JK Wang, PW Fung, AE AF Sun, Jennifer K. Wang, Pin-wen Fung, Anne E. TI Durability of diabetic retinopathy improvement and impact of delayed therapy with ranibizumab (RBZ) during the RIDE/RISE open-label extension (OLE) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Sun, Jennifer K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Sun, Jennifer K.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Wang, Pin-wen; Fung, Anne E.] Genentech Inc, San Francisco, CA 94080 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3143 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100018 ER PT J AU Syed, ZA Sutula, F AF Syed, Zeba Almas Sutula, Francis TI Dynamic Intraductal Meibomian Probing (DIMP): A Novel Approach to the Treatment of Meibomian Gland Dysfunction SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Syed, Zeba Almas; Sutula, Francis] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4761 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891104125 ER PT J AU Tahvildari, M Emami-Naeini, P Omoto, M Saban, D Chauhan, S Dana, R AF Tahvildari, Maryam Emami-naeini, Parisa Omoto, Masahiro Saban, Daniel Chauhan, Sunil Dana, Reza TI Pretreatment of Donor Corneas with Anti-Inflammatory Cytokines Promotes Allograft Survival in High-Risk Corneal Transplantation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Tahvildari, Maryam; Omoto, Masahiro; Chauhan, Sunil; Dana, Reza] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA. [Emami-naeini, Parisa] Wayne State Univ, Kresge Eye Inst, Detroit, MI USA. [Saban, Daniel] Duke Eye Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4025 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102226 ER PT J AU van Zyl, T Papakostas, TD Lim, LS Miller, JB Husain, D Eliott, D Kim, LA AF van Zyl, Tave Papakostas, Thanos D. Lim, Laurence Shen Miller, John B. Husain, Deeba Eliott, Dean Kim, Leo A. TI Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion in Patients with Prior Treatment with Bevacizumab or Ranibizumab SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [van Zyl, Tave; Papakostas, Thanos D.; Lim, Laurence Shen; Miller, John B.; Husain, Deeba; Eliott, Dean; Kim, Leo A.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Lim, Laurence Shen] Singapore Natl Eye Ctr, Ophthalmol, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4623 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891103404 ER PT J AU Wu, DM Kirchner, R Soumillon, M Mikkelsen, T Cepko, CL AF Wu, David M. Kirchner, Rory Soumillon, Magali Mikkelsen, Tarej Cepko, Connie L. TI Transcriptome profiling of single rod photoreceptors in the Rd1 mouse SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Wu, David M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA USA. [Wu, David M.; Cepko, Connie L.] Harvard Univ, Sch Med, Dept Genet, HHMI, Boston, MA USA. [Kirchner, Rory] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Soumillon, Magali; Mikkelsen, Tarej] Broad Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5499 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105411 ER PT J AU Yamaguchi, T Harris, DL Higa, K Shimazaki, J von Andrian, U Hamrah, P AF Yamaguchi, Takefumi Harris, Deshea L. Higa, Kazunari Shimazaki, Jun von Andrian, Ulrich Hamrah, Pedram TI Neurogenic Immune Homeostasis: Peripheral Innervation Maintains Avascularity and Immune Privilege of the Cornea SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Yamaguchi, Takefumi; Harris, Deshea L.; Hamrah, Pedram] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA. [Yamaguchi, Takefumi; Harris, Deshea L.; Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea Serv,Dept Ophthalmol, Boston, MA USA. [Yamaguchi, Takefumi; Higa, Kazunari; Shimazaki, Jun] Tokyo Dent Coll, Ophthalmol, Chiba, Japan. [von Andrian, Ulrich; Hamrah, Pedram] Harvard Univ, Childrens Hosp, Sch Med, Immune Dis Inst,Program Cellular & Mol Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 4034 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891102235 ER PT J AU Martin, EC Dick, AM Scioli-Salter, ER Mitchell, KS AF Martin, Emily C. Dick, Alexandra M. Scioli-Salter, Erica R. Mitchell, Karen S. TI Impact of a Yoga Intervention on Physical Activity, Self-Efficacy, and Motivation in Women with PTSD Symptoms SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; HEALTH-PROMOTION; AEROBIC EXERCISE; DEPRESSION; BEHAVIOR; ANXIETY AB Background: Studies using yoga have demonstrated initial efficacy for treating symptoms across anxiety disorders, including posttraumatic stress disorder. Objective: Understanding how interventions influence participants' physical activity and what determinants affect continued physical activity behavior change is important because maintenance of the behavior may be critical to continued mental health gains and symptom reduction. Methods: This study investigated change in physical activity and possible psychological mechanisms of physical activity behavior change, including self-efficacy and regulatory motivation, in a randomized controlled trial of yoga for women with post-traumatic stress disorder symptoms (n=38). Results: Growth curve modeling results showed no significant changes in physical activity or self-efficacy for either group, whereas external motivation decreased significantly in the yoga group but not in the control group. Conclusions: Investigators of future yoga interventions may want to focus on increasing self-efficacy and internal regulatory motivation, so that physical activity and resultant symptom relief can be maintained. C1 [Martin, Emily C.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Dick, Alexandra M.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA. [Scioli-Salter, Erica R.; Mitchell, Karen S.] Vet Affairs Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA. [Scioli-Salter, Erica R.; Mitchell, Karen S.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Mitchell, KS (reprint author), Vet Affairs Boston Healthcare Syst 116B 3, Natl Ctr PTSD, Womens Hlth Sci Div, 150 South Huntington Ave, Boston, MA 02130 USA. EM Karen.Mitchell5@va.gov OI Cox-Martin, Emily/0000-0002-2011-3905 FU National Cancer Institute [R25T CA057730]; National Institutes of Health through Cancer Center Support grant [CA016672]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [1IK2RX000704-01A2] FX The first author is supported by National Cancer Institute grant R25T CA057730. The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support grant CA016672. The research described here was also supported in part by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service, award number 1IK2RX000704-01A2. NR 42 TC 1 Z9 1 U1 12 U2 30 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD JUN 1 PY 2015 VL 21 IS 6 BP 327 EP 332 DI 10.1089/acm.2014.0389 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA CU9NU UT WOS:000363872100003 PM 25973554 ER PT J AU Abdelaziz, M Dohlman, CH Sayegh, RR AF Abdelaziz, Musa Dohlman, Claes H. Sayegh, Rony R. TI Glare Reduction Strategies for Keratoprosthesis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Abdelaziz, Musa; Sayegh, Rony R.] Case Western Reserve Univ, Univ Hosp, Ophthalmol, Cleveland, OH 44106 USA. [Dohlman, Claes H.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1121 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203030 ER PT J AU Aggarwal, S Muller, R Pavan-Langston, D AF Aggarwal, Shruti Mueller, Rodrigo Pavan-Langston, Deborah TI Herpes Zoster Vaccination: Impact on the Incidence and Complications of Herpes Zoster Ophthalmicus. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Aggarwal, Shruti; Mueller, Rodrigo; Pavan-Langston, Deborah] Massachusetts Eye & Ear Infirm, Ophthalmol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 941 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202262 ER PT J AU Allen, K Wang, DY Janessian, M Navarro-Gomez, D White, J Choi, EY Pasquale, LR Consugar, M Gai, XW Wiggs, JL AF Allen, Keri Wang, DanYi Janessian, Maria Navarro-Gomez, Daniel White, Joseph Choi, Eun Young Pasquale, Louis R. Consugar, Mark Gai, Xiaowu Wiggs, Janey L. TI Panel-based genetic testing of Juvenile-Open Angle Glaucoma probands in the United States SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Allen, Keri; Wang, DanYi; Janessian, Maria; Navarro-Gomez, Daniel; White, Joseph; Choi, Eun Young; Pasquale, Louis R.; Consugar, Mark; Gai, Xiaowu; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2544 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206129 ER PT J AU Cakiner-Egilmez, T Payal, AR Gonzalez, LA Chomsky, A Baze, EF Vollman, D Lawrence, MG Daly, MK AF Cakiner-Egilmez, Tulay Payal, Abhishek R. Gonzalez, Luis A. Chomsky, Amy Baze, Elizabeth F. Vollman, David Lawrence, Mary Gilbert Daly, Mary K. TI The association of pseudo-exfoliation syndrome (PXF) with functional visual improvement after cataract surgery: Results of the Ophthalmic Surgical Outcomes Data (OSOD) Project SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Cakiner-Egilmez, Tulay; Payal, Abhishek R.; Gonzalez, Luis A.; Daly, Mary K.] Boston Healthcare Syst, Vet Affairs, Ophthalmol, Jamaica Plain, MA USA. [Payal, Abhishek R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Chomsky, Amy] VA Tennessee Valley Healthcare Syst, Ophthalmol, Nashville, TN USA. [Chomsky, Amy] Vanderbilt Univ, Sch Med, Vanderbilt Eye Inst, Nashville, TN 37212 USA. [Baze, Elizabeth F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Baze, Elizabeth F.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA. [Vollman, David] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA. [Vollman, David] St Louis VA Med Ctr, St Louis, MO USA. [Lawrence, Mary Gilbert] DoD VA Vis Ctr Excellence, Bethesda, MD USA. [Daly, Mary K.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 665 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202004 ER PT J AU Chang, VS Papavasileiou, E Ren, A Uchiyama, E Sullivan, L Lobo, AM Papaliodis, G Sobrin, L AF Chang, Victoria S. Papavasileiou, Evangelia Ren, Ai Uchiyama, Eduardo Sullivan, Lynn Lobo, Ann-Marie Papaliodis, George Sobrin, Lucia TI Gene Polymorphisms associated with Ocular involvement in Sarcoidosis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Chang, Victoria S.; Papavasileiou, Evangelia; Ren, Ai; Uchiyama, Eduardo; Sullivan, Lynn; Lobo, Ann-Marie; Papaliodis, George; Sobrin, Lucia] Massachusetts Eye & Ear Infimary, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1258 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203167 ER PT J AU Chen, XL Allen, K Linkroum, K Wang, DY Consugar, M DelBono, E Wiggs, JL AF Chen, Xueli Allen, Keri Linkroum, Kevin Wang, DanYi Consugar, Mark DelBono, Elizabeth Wiggs, Janey L. TI FOXF2 mutations in patients with early-onset glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Chen, Xueli; Allen, Keri; Linkroum, Kevin; Wang, DanYi; Consugar, Mark; DelBono, Elizabeth; Wiggs, Janey L.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2538 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206123 ER PT J AU Ciolino, JB Salvador, B Tulsan, R Ross, A Taghizadeh, K Kohane, D AF Ciolino, Joseph B. Salvador, Borja Tulsan, Rekha Ross, Amy Taghizadeh, Koli Kohane, Daniel TI Dexamethasone-Eluting Contact Lens Drug Delivery For The Ocular Inflammation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ciolino, Joseph B.; Salvador, Borja; Tulsan, Rekha; Ross, Amy] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Ciolino, Joseph B.; Salvador, Borja; Tulsan, Rekha; Ross, Amy; Kohane, Daniel] Boston Childrens Hosp, Anaesthesia, Boston, MA USA. [Taghizadeh, Koli] MIT, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 2 U2 5 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 148 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882200138 ER PT J AU Culla, BS Arzeno, L Kolovou, PE Martinez, S Dohlman, CH Lopez, MA AF Culla, Borja Salvador Arzeno, Linette Kolovou, Paraskevi Evi Martinez, Santiago Dohlman, Claes H. Angel Lopez, Miguel TI Anatomical and visual outcomes after Boston Keratoprosthesis type 1 in chemical burns: the Santo Domingo experience SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Culla, Borja Salvador; Kolovou, Paraskevi Evi; Dohlman, Claes H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. [Arzeno, Linette; Martinez, Santiago; Angel Lopez, Miguel] Hosp Elias Santana, Santo Domingo, Dominican Rep. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1116 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203025 ER PT J AU Davies, E Langston, D Chodosh, J AF Davies, Emma Langston, Deborah Chodosh, James TI Incidence of Herpes zoster ophthalmicus (HZO) at Massachusetts Eye and Ear Infirmary (MEEI) from 2007-2013 SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Davies, Emma; Langston, Deborah; Chodosh, James] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1863 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204310 ER PT J AU Dib, B Lin, HJ Maidana, DE Miller, JB Bouzika, P Tian, B Miller, JW Vavvas, D AF Dib, Bernard Lin, Haijiang Maidana, Daniel E. Miller, John B. Bouzika, Peggy Tian, Bo Miller, Joan W. Vavvas, Demetrios TI Mitochondrial DNA acts as pro-inflammatory in AMD SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Dib, Bernard; Lin, Haijiang; Maidana, Daniel E.; Miller, John B.; Bouzika, Peggy; Tian, Bo; Miller, Joan W.; Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Dib, Bernard; Lin, Haijiang; Maidana, Daniel E.; Miller, John B.; Bouzika, Peggy; Tian, Bo; Miller, Joan W.; Vavvas, Demetrios] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 799 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202136 ER PT J AU Fan, BJ Pasquale, LR Kang, JH Levkovitch-Verbin, H Haines, JL Wiggs, JL AF Fan, Baojian Pasquale, Louis R. Kang, Jae H. Levkovitch-Verbin, Hani Haines, Jonathan L. Wiggs, Janey L. TI Association of Clusterin Variants and Exfoliation Syndrome: An Analysis in Two Caucasian Datasets and A Summary Meta-analysis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Fan, Baojian; Pasquale, Louis R.; Wiggs, Janey L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Pasquale, Louis R.; Kang, Jae H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA. [Levkovitch-Verbin, Hani] Tel Aviv Univ, Chaim Sheba Med Ctr, Goldschleger Eye Inst, Tel Hashomer, Israel. [Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2549 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206134 ER PT J AU Haddad, NMN Cancino, R Silva, PS Okeke, E Tolson, A Aiello, LP Cavallerano, JD AF Haddad, Nour Maya N. Cancino, Ramon Silva, Paolo S. Okeke, Eyiuche Tolson, Ann Aiello, Lloyd Paul Cavallerano, Jerry D. TI Ultrawide Field Imaging (UWFI) for Diabetic Retinopathy in a Community-Based Teleophthalmology Program SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Haddad, Nour Maya N.; Silva, Paolo S.; Tolson, Ann; Aiello, Lloyd Paul; Cavallerano, Jerry D.] Joslin Diabet Ctr, Beetham Eye Inst, Retina, Boston, MA 02215 USA. [Cancino, Ramon; Okeke, Eyiuche] MCHC, Mattapan, MA USA. [Cancino, Ramon] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA. [Silva, Paolo S.; Aiello, Lloyd Paul; Cavallerano, Jerry D.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1425 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203316 ER PT J AU Hasegawa, E Yanai, R Muluki, L Husain, D Miller, JW Connor, KM AF Hasegawa, Eiichi Yanai, Ryoji Muluki, Lama Husain, Deeba Miller, Joan W. Connor, Kip M. TI The effect of Cytochrome P450 lipid metabolites on leukocyte recruitment in intraocular inflammation. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Hasegawa, Eiichi; Yanai, Ryoji; Muluki, Lama; Husain, Deeba; Miller, Joan W.; Connor, Kip M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Angiogenesis Lab, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 12 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882200002 ER PT J AU Horton, MB Silva, PS Lewis, D Cavallerano, JD Aiello, LP AF Horton, Mark B. Silva, Paolo S. Lewis, Drew Cavallerano, Jerry D. Aiello, Lloyd Paul TI Identification of Diabetic Retinopathy (DR) and Reduction in Ungradable Image Rate with Ultrawide Field Imaging (UWFI) within the Indian Health Service (IHS) Teleophthalmology Program SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Horton, Mark B.] Natl Reading Ctr, Joslin Vis Network, Indian Hlth Serv, Phoenix, AZ USA. [Silva, Paolo S.; Cavallerano, Jerry D.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Silva, Paolo S.; Cavallerano, Jerry D.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Lewis, Drew] Estenda Solut, Conshohocken, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1424 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203315 ER PT J AU Johnson, AJ Soeken, T Kim, M Wang, HCH DeMartelaere, S Kochevar, IE AF Johnson, Anthony James Soeken, Timothy Kim, Mirang Wang, Heuy-Ching Hetty DeMartelaere, Sheri Kochevar, Irene E. TI Sealing of Corneal and Scleral Lacerations Using Photo-Activated Rose Bengal Dye and Amniotic Membrane SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Johnson, Anthony James; Kim, Mirang; Wang, Heuy-Ching Hetty] USAISR, Res, San Antonio, TX USA. [Soeken, Timothy] Baylor Coll Med, Houston, TX 77030 USA. [DeMartelaere, Sheri] SAUSHEC, Ophthalmol, Ft Sam Houston, TX USA. [Kochevar, Irene E.] Mass Gen Hosp, Wellman Grp, Dermatol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1596 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204057 ER PT J AU Kheirkhah, A Saboo, U Dana, R AF Kheirkhah, Ahmad Saboo, Ujwala Dana, Reza TI Overestimation of Corneal Endothelial Cell Density by Selecting Smaller Areas to Count the Cells in Images of In Vivo Confocal Microscopy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kheirkhah, Ahmad; Saboo, Ujwala; Dana, Reza] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1148 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203057 ER PT J AU Kim, EL Toeteberg-Harms, M Tran, JS Chahal, JS Rhee, DJ Chopra, V Varma, R Francis, BA AF Kim, Esther Lee Toeteberg-Harms, Marc Tran, Jeffrey S. Chahal, Jasdeep S. Rhee, Douglas J. Chopra, Vikas Varma, Rohit Francis, Brian A. TI Vision Loss and Recovery after Baerveldt Glaucoma Implant Surgery SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kim, Esther Lee; Tran, Jeffrey S.; Chahal, Jasdeep S.; Varma, Rohit] Univ So Calif, Inst Eye, Ophthalmol, Los Angeles, CA USA. [Toeteberg-Harms, Marc] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Rhee, Douglas J.] Case Western Reserve Univ, Ophthalmol & Visual Sci, Cleveland, OH 44106 USA. [Chopra, Vikas; Francis, Brian A.] Doheny Eye Inst, Ophthalmol, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2710 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206279 ER PT J AU King, R Hauser, MA Pasquale, LR Wiggs, JL Ashley-Koch, AE Allingham, RR Geisert, EE AF King, Rebecca Hauser, Michael A. Pasquale, Louis R. Wiggs, Janey L. Ashley-Koch, Allison E. Allingham, R. Rand Geisert, Eldon E. TI Mouse Genomic Loci Modulating Corneal Thickness SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [King, Rebecca; Geisert, Eldon E.] Emory Sch Med, Ophthalmol, Atlanta, GA USA. [Hauser, Michael A.] Duke Univ, Med & Opthalmol, Durham, NC USA. [Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA. [Wiggs, Janey L.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Ashley-Koch, Allison E.] Duke Univ, Med, Durham, NC USA. [Allingham, R. Rand] Duke Univ, Opthalmol, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1645 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204105 ER PT J AU Kochevar, IE Zhu, H Alt, C Melki, S AF Kochevar, Irene E. Zhu, Hong Alt, Clemens Melki, Samir TI In Vivo Cornea Crosslinking with Rose Bengal and Green Light: 1-month results SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Kochevar, Irene E.; Zhu, Hong; Alt, Clemens] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Melki, Samir] Boston Eye Grp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3019 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882207183 ER PT J AU Konstantinou, E Saeij, JPJ Young, LH AF Konstantinou, Eleni Saeij, Jeroen P. J. Young, Lucy H. TI Cell death of gamma interferon (IFNg)-stimulated human macrophages upon Toxoplasma gondii infection limits parasite replication SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Konstantinou, Eleni; Young, Lucy H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. [Konstantinou, Eleni; Saeij, Jeroen P. J.] MIT, Biol, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1892 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204339 ER PT J AU Krishnan, A Fei, F Jones, A Ksander, BR Rothstein, AM Gregory-Ksander, MS AF Krishnan, Anitha Fei, Fei Jones, Alexander Ksander, Bruce R. Rothstein, Ann Marshak Gregory-Ksander, Meredith S. TI Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of Glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Krishnan, Anitha; Fei, Fei; Jones, Alexander; Ksander, Bruce R.; Gregory-Ksander, Meredith S.] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Rsrch Inst,Mass Eye & Ear Infirm, Boston, MA USA. [Rothstein, Ann Marshak] Univ Massachusetts, Sch Med, Med, Worcester, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2594 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206163 ER PT J AU Lains, I Bartosch, C Mondim, V Husain, D Miller, JW AF Lains, Ines Bartosch, Carla Mondim, Vera Husain, Deeba Miller, Joan W. TI Second primary cancers in uveal melanoma survivors and the role of radiotherapy: a long-term population-based study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lains, Ines; Husain, Deeba; Miller, Joan W.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Lains, Ines] Univ Coimbra, Fac Med, Coimbra, Portugal. [Bartosch, Carla] Inst Portugues Oncol Porto, Oporto, Portugal. [Mondim, Vera] Ctr Hosp Lisboa Cent, Lisbon, Portugal. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1293 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203195 ER PT J AU Lindsey, J Shekhawat, N Lawrence, MG Vollman, D Daly, MK Baze, EF Chomsky, A AF Lindsey, Jennifer Shekhawat, Nakul Lawrence, Mary Gilbert Vollman, David Daly, Mary K. Baze, Elizabeth F. Chomsky, Amy CA VA Ophdhalmic Surgical Outcomes TI Impact of Diabetes Mellitus on cataract surgery outcomes: results of the Ophthalmic Surgical Outcomes Data Project SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lindsey, Jennifer; Shekhawat, Nakul; Chomsky, Amy] Vanderbilt Univ Med, Vanderbilt Eye Inst, Nashville, TN USA. [Lindsey, Jennifer; Shekhawat, Nakul; Chomsky, Amy] VA Tennessee Valley Healthcare Syst Ctr, Nashville, TN USA. [Lawrence, Mary Gilbert] DoD Vis Ctr Excellence, Arlington, VA USA. [Vollman, David] St Louis VA Med Ctr, Ophthalmol, St Louis, MO USA. [Vollman, David] Washington Univ, Sch Med, Ophthalmol, St Louis, MO USA. [Daly, Mary K.] VA Boston Healthcare Syst, Ophthalmol, Boston, MA USA. [Daly, Mary K.] Boston Univ, Sch Med, Ophthalmol, Boston, MA 02118 USA. [Baze, Elizabeth F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Baze, Elizabeth F.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 674 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202013 ER PT J AU Ma, K Thanos, A Shah, A Mantagos, I AF Ma, Kelly Thanos, Aristomenis Shah, Ankoor Mantagos, Iason TI An acute damage score to guide surgical intervention in ocular Stevens-Johnson Syndrome SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ma, Kelly] Boston Med Ctr, Ophthalmol, Boston, MA USA. [Ma, Kelly; Thanos, Aristomenis; Shah, Ankoor; Mantagos, Iason] Boston Childrens Hosp, Ophthalmol, Boston, MA USA. [Thanos, Aristomenis] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1601 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204062 ER PT J AU Men, C Bujakowska, KM Place, E Liu, Q Pierce, EA AF Men, Clara Bujakowska, Kinga Maria Place, Emily Liu, Qin Pierce, Eric A. TI Sequence-specific suppression of alleles causing dominantly inherited retinal degenerations using the RNA-guided nuclease Cas9 SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Men, Clara; Bujakowska, Kinga Maria; Liu, Qin; Pierce, Eric A.] Harvard Univ, Sch Med, Boston, MA USA. [Men, Clara; Bujakowska, Kinga Maria; Place, Emily; Liu, Qin; Pierce, Eric A.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1086 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202407 ER PT J AU Muller, R Taniguchi, E Cruzat, A Cavalcanti, BM Dohlman, CH Hamrah, P AF Mueller, Rodrigo Taniguchi, Elise Cruzat, Andrea Cavalcanti, Bernardo M. Dohlman, Claes H. Hamrah, Pedram TI Longitudinal Assessment of Boston Type 1 Keratoprosthesis/Cornea Interface by Anterior Segment-OCT Allows Detection and Monitoring of Corneal Tissue Melts SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Mueller, Rodrigo; Taniguchi, Elise; Cruzat, Andrea; Cavalcanti, Bernardo M.; Dohlman, Claes H.; Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1123 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203032 ER PT J AU Obert, E Ghatnekar, G Rohrer, B AF Obert, Elisabeth Ghatnekar, Gautam Rohrer, Baerbel TI Effects of the Act-1 Peptide on Retinal Pigment Epithelial Cell Integrity in Two Mouse Models of Age-Related Macular Degeneration SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Obert, Elisabeth; Rohrer, Baerbel] Med Univ S Carolina, Charleston, SC 29425 USA. [Ghatnekar, Gautam] FirstString Res, Mt Pleasant, SC USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2341 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205342 ER PT J AU Okunuki, Y Hasegawa, E Yanai, R Smith, K Castillejos, A Connor, KM AF Okunuki, Yoko Hasegawa, Eiichi Yanai, Ryoji Smith, Kaylee Castillejos, Alexandra Connor, Kip M. TI The effect of dietary supplementation with omega-3 and omega-6 long-chain polyunsaturated fatty acids on retinal detachment SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Okunuki, Yoko; Hasegawa, Eiichi; Yanai, Ryoji; Smith, Kaylee; Castillejos, Alexandra; Connor, Kip M.] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 25 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882200015 ER PT J AU Payal, AR Sola-Del Valle, D Gonzalez, LA Cakiner-Egilmez, T Chomsky, A Baze, EF Vollman, D Lawrence, MG Daly, MK AF Payal, Abhishek R. Sola-Del Valle, David Gonzalez, Luis A. Cakiner-Egilmez, Tulay Chomsky, Amy Baze, Elizabeth F. Vollman, David Lawrence, Mary Gilbert Daly, Mary K. TI The association of American Society of Anesthesiologists (ASA) class with functional visual improvement after cataract surgery: Results of the Ophthalmic Surgical Outcomes Data (OSOD) Project SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Payal, Abhishek R.; Sola-Del Valle, David] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Payal, Abhishek R.; Sola-Del Valle, David; Gonzalez, Luis A.; Cakiner-Egilmez, Tulay; Daly, Mary K.] Vet Affairs Boston Healthcare Syst, Jamaica Plain, MA USA. [Chomsky, Amy] VA Tennessee Valley Healthcare Syst, Nashville, TN USA. [Chomsky, Amy] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA. [Baze, Elizabeth F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Baze, Elizabeth F.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA. [Vollman, David] St Louis VA Med Ctr, Ophthalmol, St Louis, MO USA. [Vollman, David] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA. [Lawrence, Mary Gilbert] DoD VA Vis Ctr Excellence, Bethesda, MD USA. [Daly, Mary K.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 668 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202007 ER PT J AU Qazi, Y Kheirkhah, A Dohlman, TH Cruzat, A Cavalcanti, B Colon, C Dana, R Hamrah, P AF Qazi, Yureeda Kheirkhah, Ahmad Dohlman, Thomas H. Cruzat, Andrea Cavalcanti, Bernardo Colon, Clara Dana, Reza Hamrah, Pedram TI Corneal Dendritic Cells as a Surrogate Biomarker of Therapeutic Efficacy in Dry Eye-Associated Corneal Inflammation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Qazi, Yureeda; Kheirkhah, Ahmad; Dohlman, Thomas H.; Cruzat, Andrea; Cavalcanti, Bernardo; Colon, Clara; Dana, Reza; Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 291 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882201050 ER PT J AU Rajaiya, J Lee, J Lee, JY Chodosh, J AF Rajaiya, Jaya Lee, JiSun Lee, Jeong Yoon Chodosh, James TI Dynamin-2 negatively regulates adenovirus trafficking in corneal cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Rajaiya, Jaya; Lee, JiSun; Lee, Jeong Yoon; Chodosh, James] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204317 ER PT J AU Reardon, W Sharpe, RA Sharpe, E AF Reardon, Wade Sharpe, Robert Allan Sharpe, Elizabeth TI Retrospective analysis of resident-performed microinvasive glaucoma surgery with the iStent SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Reardon, Wade; Sharpe, Robert Allan; Sharpe, Elizabeth] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Sharpe, Elizabeth] Ralph H Johnson VA Med Ctr, Ophthalmol, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2694 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206263 ER PT J AU Rohrer, B Woodell, A Casey, S Williamson, T Jones, BW Tomlinson, S Atkinson, C AF Rohrer, Baerbel Woodell, Alex Casey, Sarah Williamson, Tucker Jones, Bryan W. Tomlinson, Stephen Atkinson, Carl TI Inhibition of the alternative pathway of complement accelerates recovery from smoke-induced functional and morphological ocular injury SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Rohrer, Baerbel; Woodell, Alex] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel; Tomlinson, Stephen] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Casey, Sarah; Williamson, Tucker; Tomlinson, Stephen; Atkinson, Carl] Med Univ S Carolina, Immunol, Charleston, SC 29425 USA. [Jones, Bryan W.] Univ Utah, Ophthalmol, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205289 ER PT J AU Ruberti, J Zareian, R Karamichos, D Tambe, D Susilo, M Paten, J Saeidi, N Zieske, JD AF Ruberti, Jeffrey Zareian, Ramin Karamichos, Dimitrios Tambe, Dhananjay Susilo, Monica Paten, Jeffrey Saeidi, Nima Zieske, James D. TI Long-term, Live-Imaging of the Mechanodynamics of Primary Human Corneal Fibroblasts: From Initial Seeding to Matrix Production SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Ruberti, Jeffrey; Susilo, Monica] Northeastern Univ, Bioengn, Boston, MA 02115 USA. [Ruberti, Jeffrey; Zieske, James D.] Schepens Eye Res Inst, Boston, MA USA. [Zareian, Ramin] Univ Calif Berkeley, Bioengn, Berkeley, CA 94720 USA. [Karamichos, Dimitrios] Univ Oklahoma, Hlth Sci Ctr, Ophthalmol, Oklahoma City, OK USA. [Tambe, Dhananjay] Univ S Alabama, Mech Engn, Mobile, AL 36688 USA. [Paten, Jeffrey] Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA. [Saeidi, Nima] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI karamichos, dimitrios/D-9651-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1934 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204381 ER PT J AU Saboo, US Abud, T Amparo, F Ciolino, JB Hamrah, P Dana, R AF Saboo, Ujwala Sachin Abud, Tulio Amparo, Francisco Ciolino, Joseph B. Hamrah, Pedram Dana, Reza TI Prospective, Randomized, Double-Masked Clinical Trial Comparing Safety and Efficacy of Topical Tacrolimus vs. Methylprednisolone for Ocular Graft-Versus-Host Disease SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Saboo, Ujwala Sachin; Abud, Tulio; Amparo, Francisco; Ciolino, Joseph B.; Hamrah, Pedram; Dana, Reza] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 303 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882201062 ER PT J AU Scarcelli, G Besner, S Pineda, R Yun, SH AF Scarcelli, Giuliano Besner, Sebastien Pineda, Roberto Yun, Seok H. TI Observation of focal weakening in keratoconic corneas in vivo and ex vivo with Brillouin microscopy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Scarcelli, Giuliano; Besner, Sebastien; Yun, Seok H.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Cambridge, MA 02138 USA. [Pineda, Roberto] Massahusetts Eye & Ear Infirm, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2999 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882207163 ER PT J AU Sendra, V Jamali, A Harris, DL Hamrah, P AF Sendra, Victor Jamali, Arsia Harris, Deshea L. Hamrah, Pedram TI Plasmacytoid Dendritic Cells Mediate Adaptive Immunity in Acute Herpes Simplex Virus Keratitis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Sendra, Victor; Jamali, Arsia; Harris, Deshea L.; Hamrah, Pedram] Mass Eye & Ear, Schepens Eye Res Inst, Boston, MA USA. [Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Cornea & Refract Surg Serv, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1856 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882204304 ER PT J AU Seyed-Razavi, Y Hamrah, P AF Seyed-Razavi, Yashar Hamrah, Pedram TI CO2-Induced Corneal Nociceptor Stimulation Reveals Neuropeptide Changes in a Novel Murine Pain Model SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Seyed-Razavi, Yashar; Hamrah, Pedram] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst,Massachusetts Eye & Ear, Boston, MA USA. [Hamrah, Pedram] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea & Refract Surg Serv,Dept Ophthalmol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3074 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882207237 ER PT J AU Silva, PS Ledesma, M Cavallerano, JD Ajlan, R Sun, JK Aiello, LP AF Silva, Paolo S. Ledesma, Migil Cavallerano, Jerry D. Ajlan, Radwan Sun, Jennifer K. Aiello, Lloyd Paul TI Predominantly Peripheral Diabetic Retinopathy Lesions and Retinopathy Severity are Associated with Peripheral Nonperfusion on Ultrawide Field Fluorescein Angiography SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Silva, Paolo S.; Cavallerano, Jerry D.; Ajlan, Radwan; Sun, Jennifer K.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Silva, Paolo S.; Cavallerano, Jerry D.; Sun, Jennifer K.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Ledesma, Migil] Philippine Eye Res Inst, Manila, Philippines. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2018 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205035 ER PT J AU Smesseim, R Cao, JF Van Essen, TH Mulder, A van Zeeburg, E Ksander, BR Jager, MJ AF Smesseim, Rind Cao, Jinfeng Van Essen, T. Huibertus Mulder, Arend van Zeeburg, Elsbeth Ksander, Bruce R. Jager, Martine J. TI HLA class I expression in cell lines derived from conjunctival melanoma and retinoblastoma using allele-specific monoclonal antibodies and flow cytometry SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Smesseim, Rind; Cao, Jinfeng; Van Essen, T. Huibertus; Mulder, Arend; Jager, Martine J.] Leiden Univ, Med Ctr, Ophthalmol, Leiden, Netherlands. [van Zeeburg, Elsbeth] Rotterdam Ophthalm Inst, Rotterdam, Netherlands. [van Zeeburg, Elsbeth] Rotterdam Eye Hosp, Rotterdam, Netherlands. [Ksander, Bruce R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 68 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882200058 ER PT J AU Sola-Del Valle, D Payal, AR Gonzalez, LA Cakiner-Egilmez, T Chen, X Chomsky, A Baze, EF Vollman, D Lawrence, MG Daly, MK AF Sola-Del Valle, David Payal, Abhishek R. Gonzalez, Luis A. Cakiner-Egilmez, Tulay Chen, Xi Chomsky, Amy Baze, Elizabeth F. Vollman, David Lawrence, Mary Gilbert Daly, Mary K. TI The impact of glaucoma on functional visual improvement after cataract surgery: Results of the Veterans Affairs (VA) Ophthalmic Surgical Outcomes Data (OSOD) Project SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Sola-Del Valle, David; Payal, Abhishek R.; Gonzalez, Luis A.; Cakiner-Egilmez, Tulay; Chen, Xi; Daly, Mary K.] VA Boston Healthcare Syst, Dept Ophthalmol, Jamaica Plain, MA USA. [Sola-Del Valle, David; Payal, Abhishek R.; Chen, Xi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalmol, Boston, MA USA. [Chomsky, Amy] VA Tennesse Valley Healthcare Syst, Nashville, TN USA. [Chomsky, Amy] Vanderbilt Univ, Sch Med, Vanderbilt Eye Inst, Nashville, TN 37212 USA. [Baze, Elizabeth F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Baze, Elizabeth F.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA. [Vollman, David] St Louis VA Med Ctr, St Louis, MO USA. [Vollman, David] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA. [Lawrence, Mary Gilbert] DoD VA Vis Ctr Excellence, Bethesda, MD USA. [Daly, Mary K.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2110 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205113 ER PT J AU Song, BJ Pasquale, LR Aiello, LP Silva, PS AF Song, Brian J. Pasquale, Louis R. Aiello, Lloyd Paul Silva, Paolo S. TI Monoscopic vs. Stereoscopic Optic Nerve Evaluation for Glaucomatous Features: Comparison of Ultrawide-field Scanning Laser Ophthalmoscopy and 35 mm Slide Photographs in a Diabetes Ocular Telemedicine Program SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Song, Brian J.; Pasquale, Louis R.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Song, Brian J.; Pasquale, Louis R.; Aiello, Lloyd Paul; Silva, Paolo S.] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Aiello, Lloyd Paul; Silva, Paolo S.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1023 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202344 ER PT J AU Talcott, KE Mukai, S AF Talcott, Katherine Elizabeth Mukai, Shizuo TI Phenotypic variability and utility of red-free and wide-field autofluorescence imaging in incontinentia pigmenti patients SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Talcott, Katherine Elizabeth; Mukai, Shizuo] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 399 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882201158 ER PT J AU Taniguchi, E Paschalis, EI Li, DJ Wang, HB Brauner, SC Greenstein, SH Turalba, AV Pasquale, LR Shen, LQ AF Taniguchi, Elise Paschalis, Eleftherios I. Li, Dejiao Wang, Haobing Brauner, Stacey C. Greenstein, Scott H. Turalba, Angela V. Pasquale, Louis R. Shen, Lucy Q. TI Prelaminar and Lamina Cribrosa Defects Detected by Swept Source OCT in Glaucoma Stratified by Visual Field Loss Pattern SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Taniguchi, Elise; Paschalis, Eleftherios I.; Li, Dejiao; Wang, Haobing; Brauner, Stacey C.; Greenstein, Scott H.; Turalba, Angela V.; Pasquale, Louis R.; Shen, Lucy Q.] Massachusetts Eye & Ear Infirm, Ophthalmol, Boston, MA 02114 USA. [Wang, Haobing] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2056 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205072 ER PT J AU Tian, B Lin, HJ Maidana, DE Dib, B Miller, JB Bouzika, P Miller, JW Vavvas, D AF Tian, Bo Lin, Haijiang Maidana, Daniel E. Dib, Bernard Miller, John B. Bouzika, Peggy Miller, Joan W. Vavvas, Demetrios TI Effect of MiR-17(star) on oxidative damage in human retinal epithelial cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Tian, Bo; Lin, Haijiang; Maidana, Daniel E.; Dib, Bernard; Miller, John B.; Bouzika, Peggy; Miller, Joan W.; Vavvas, Demetrios] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Quincy, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 811 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202148 ER PT J AU Wahle, A Lee, KE Lee, K Zhang, L Bogunovic, H Harding, AT Scheetz, TE Sonka, M Klein, R Abramoff, MD AF Wahle, Andreas Lee, Kristine E. Lee, Kyungmoo Zhang, Li Bogunovic, Hrvoje Harding, Adam T. Scheetz, Todd E. Sonka, Milan Klein, Ronald Abramoff, Michael David TI Use of XNAT to generate phenotype data from OCT scans for use with genetic association analyses SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Wahle, Andreas; Lee, Kyungmoo; Zhang, Li; Bogunovic, Hrvoje; Sonka, Milan] Univ Iowa, Elect & Comp Engn, Iowa City, IA USA. [Lee, Kristine E.; Scheetz, Todd E.; Sonka, Milan; Klein, Ronald; Abramoff, Michael David] Univ Wisconsin, Ophthalmol & Visual Sci, Madison, WI USA. [Harding, Adam T.] Univ Iowa, Inst Clin & Translat Sci, Iowa City, IA USA. [Abramoff, Michael David] US Dept Vet Affairs, Iowa City, IA USA. RI Bogunovic, Hrvoje/J-3445-2014 OI Bogunovic, Hrvoje/0000-0002-9168-0894 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1261 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203170 ER PT J AU Wiecek, EK Jackson, ML Bex, PJ AF Wiecek, Emily K. Jackson, Mary Lou Bex, Peter J. TI Binocular Microperimetry with Simulated Asymmetric Bilateral Scotomas SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Wiecek, Emily K.] Univ Coll London, Ophthalmol, Boston, MA USA. [Wiecek, Emily K.; Bex, Peter J.] Northeastern Univ, Psychol, Boston, MA 02115 USA. [Jackson, Mary Lou] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 549 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882201307 ER PT J AU Yang, JL Saint-Geniez, M Ng, YSE Moses, MA D'Amore, PA AF Yang, Jinling Saint-Geniez, Magali Ng, Yin Shan Eric Moses, Marsha A. D'Amore, Patricia A. TI Shedding of Endomucin by Endothelial Cells under Inflammatory Conditions: Involvement of Matrix Metalloproteases SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Yang, Jinling; Saint-Geniez, Magali; Ng, Yin Shan Eric; D'Amore, Patricia A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Schepens Eye Res Inst, Boston, MA USA. [Moses, Marsha A.] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA. [Moses, Marsha A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [D'Amore, Patricia A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3104 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882207266 ER PT J AU Zeitz, C Bujakowska, KM Neidhardt, J El Shamieh, S Sahel, JA Audo, IS AF Zeitz, Christina Bujakowska, Kinga Maria Neidhardt, John El Shamieh, Said Sahel, Jose Alain Audo, Isabelle S. TI The importance of Sanger sequencing of exon ORF15 of RPGR at the time of next-generation sequencing SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Zeitz, Christina; El Shamieh, Said; Sahel, Jose Alain; Audo, Isabelle S.] Univ Paris 06, Sorbonne Univ, Inst Vis, INSERM,U968,CNRS,UMR 7210,UMR S 968, D-26111 Paris, France. [Bujakowska, Kinga Maria] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Genom Inst, Boston, MA USA. [Neidhardt, John] Carl von Ossietzky Univ Oldenburg, Fac Med & Hlth Sci, Human Genet, Oldenburg, Germany. [Sahel, Jose Alain; Audo, Isabelle S.] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM DHOS CIC 1423, Paris, France. RI Zeitz, Christina/F-2757-2017 NR 0 TC 0 Z9 0 U1 0 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2599 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206168 ER PT J AU Zhu, H Johnson, AJ Lewis, A DeMartelaere, S Cho, R Kim, M Wang, HC Kochevar, IE AF Zhu, Hong Johnson, Anthony J. Lewis, Andrew DeMartelaere, Sheri Cho, Raymond Kim, Mirang Wang, Heuy-Ching Kochevar, Irene E. TI Comparison of Chemical and Photo-Crosslinked Amniotic Membrane with Cryopreserved Amniotic Membrane for the Treatment of Severe Exposure Keratopathy in the New Zealand White Rabbit SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Zhu, Hong; Kochevar, Irene E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Johnson, Anthony J.; Kim, Mirang; Wang, Heuy-Ching] US Army Inst Surg Res, Res, Ft Sam Houston, TX USA. [Lewis, Andrew; DeMartelaere, Sheri; Cho, Raymond] San Antonio Mil Med Ctr, Res, Ft Sam Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 735 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882202073 ER PT J AU Bell, KJ Smart, CE Steil, GM Brand-Miller, JC King, B Wolpert, HA AF Bell, Kirstine J. Smart, Carmel E. Steil, Garry M. Brand-Miller, Jennie C. King, Bruce Wolpert, Howard A. TI Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era SO DIABETES CARE LA English DT Article ID SUBCUTANEOUS INSULIN INFUSION; BLOOD-GLUCOSE; PRANDIAL INSULIN; PUMP THERAPY; BOLUS; CHILDREN; MEALS; MELLITUS; FOODS; HYPERGLYCEMIA AB BACKGROUND Continuous glucose monitoring highlights the complexity of postprandial glucose patterns present in type 1 diabetes and points to the limitations of current approaches tomealtime insulin dosing based primarily on carbohydrate counting. METHODS A systematic review of all relevant biomedical databases, including MEDLINE, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials, was conducted to identify research on the effects of dietary fat, protein, and glycemic index (GI) on acute postprandial glucose control in type 1 diabetes and prandial insulin dosing strategies for these dietary factors. RESULTS All studies examining the effect of fat (n = 7), protein (n = 7), and GI (n = 7) indicated that these dietary factors modify postprandial glycemia. Late postprandial hyperglycemia was the predominant effect of dietary fat; however, in some studies, glucose concentrations were reduced in the first 2-3 h, possibly due to delayed gastric emptying. Ten studies examining insulin bolus dose and delivery patterns required for high-fat and/or high-protein meals were identified. Because of methodological differences and limitations in experimental design, study findings were inconsistent regarding optimal bolus delivery pattern; however, the studies indicated that high-fat/protein meals require more insulin than lower-fat/protein meals with identical carbohydrate content. CONCLUSIONS These studies have important implications for clinical practice and patient education and point to the need for research focused on the development of new insulin dosing algorithms based on meal composition rather than on carbohydrate content alone. C1 [Bell, Kirstine J.; Brand-Miller, Jennie C.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia. [Bell, Kirstine J.; Brand-Miller, Jennie C.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia. [Bell, Kirstine J.; Wolpert, Howard A.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Smart, Carmel E.; King, Bruce] John Hunter Childrens Hosp, Dept Paediat Endocrinol & Diabet, Newcastle, NSW, Australia. [Smart, Carmel E.; King, Bruce] Univ Newcastle, Hunter Med Res Inst, Sch Med & Publ Hlth, Rankin Pk, Australia. [Steil, Garry M.] Childrens Hosp, Boston, MA 02115 USA. [Steil, Garry M.; Wolpert, Howard A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Wolpert, HA (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA. EM howard.wolpert@joslin.harvard.edu RI Brand-Miller, Jennie/A-6835-2013 OI Brand-Miller, Jennie/0000-0002-6797-8754 NR 41 TC 24 Z9 24 U1 2 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2015 VL 38 IS 6 BP 1008 EP 1015 DI 10.2337/dc15-0100 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CT7BV UT WOS:000362969000019 PM 25998293 ER PT J AU Leiter, LA Teoh, H Braunwald, E Mosenzon, O Cahn, A Kumar, KMP Smahelova, A Hirshberg, B Stahre, C Frederich, R Bonnici, F Scirica, BM Bhatt, DL Raz, I AF Leiter, Lawrence A. Teoh, Hwee Braunwald, Eugene Mosenzon, Ofri Cahn, Avivit Kumar, K. M. Prasanna Smahelova, Alena Hirshberg, Boaz Stahre, Christina Frederich, Robert Bonnici, Francois Scirica, Benjamin M. Bhatt, Deepak L. Raz, Itamar CA SAVOR-TIMI 53 Steering Comm Invest TI Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial SO DIABETES CARE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; PLACEBO-CONTROLLED TRIAL; GLYCEMIC CONTROL; ELDERLY-PATIENTS; CLINICAL-TRIALS; CARDIOVASCULAR-DISEASE; PATIENT POPULATION; POOLED ANALYSIS; DOUBLE-BLIND AB OBJECTIVE To examine the safety and cardiovascular (CV) effects of saxagliptin in the pre-defined elderly (>= 65 years) and very elderly (>= 75 years) subpopulations of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. RESEARCH DESIGN AND METHODS Individuals >= 40 years (n = 16,492; elderly, n = 8,561; very elderly, n = 2,330) with HbA(1c) >= 6.5% (47.5 mmol/mol) and <= 12.0% (107.7 mmol/mol) were randomized (1: 1) to saxagliptin (5 or 2.5 mg daily) or placebo in a double-blind trial for a median follow-up of 2.1 years. RESULTS The hazard ratio (HR) for the comparison of saxagliptin versus placebo for the primary end point (composite of CV mortality, myocardial infarction, or ischemic stroke) was 0.92 for elderly patients vs. 1.15 for patients <65 years (P = 0.06) and 0.95 for very elderly patients. The HRs for the secondary composite end points in the entire cohort, elderly cohort, and very elderly cohort were similar. Although saxagliptin increased the risk of hospitalization for heart failure in the overall saxagliptin population, there was no age-based treatment interaction (P = 0.76 for elderly patients vs. those <65 years; P = 0.34 for very elderly patients vs. those <75 years). Among saxagliptin-treated individuals with baseline HbA(1c) >= 7.6% (59.6 mmol/mol), the mean change from baseline HbA(1c) at 2 years was 20.69%, 20.64%, 20.66%, and 20.66% for those >= 65, <65, >= 75, and <75 years old, respectively. The incidence of overall adverse events (AEs) and serious AEs was similar between saxagliptin and placebo in all cohorts; however, hypoglycemic events were higher for saxagliptin versus placebo regardless of age. CONCLUSIONS The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. AEs and serious AEs as well as glycemic efficacy of saxagliptin in elderly patients are similar to those found in younger patients. C1 [Leiter, Lawrence A.; Teoh, Hwee] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Endocrinol & Metab, Toronto, ON, Canada. [Leiter, Lawrence A.; Teoh, Hwee] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada. [Teoh, Hwee] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Cardiac Surg, Toronto, ON, Canada. [Braunwald, Eugene; Scirica, Benjamin M.; Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div, Boston, MA 02115 USA. [Mosenzon, Ofri; Cahn, Avivit; Raz, Itamar] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel. [Kumar, K. M. Prasanna] Bangalore Diabet Hosp, Bangalore, Karnataka, India. [Kumar, K. M. Prasanna] Bangalore Diabet Hosp, Ctr Diabet & Endocrine Care, Bangalore, Karnataka, India. [Smahelova, Alena] Charles Univ Prague, Dept Internal Gerontometabol Clin, Hradec Kralove, Czech Republic. [Hirshberg, Boaz] AstraZeneca, Wilmington, DE USA. [Stahre, Christina] AstraZeneca, Molndal, Sweden. [Frederich, Robert] Bristol Myers Squibb Co, Princeton, NJ USA. [Bonnici, Francois] UCT Private Acad Hosp, Cape Town, South Africa. RP Leiter, LA (reprint author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Endocrinol & Metab, Toronto, ON, Canada. EM leiterl@smh.ca FU AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; Eli Lilly; GlaxoSmithKline; Janssen; Merck; Novo Nordisk; Sanofi; Servier; Takeda; TIMI Study Group; Brigham and Women's Hospita from Abbott; Amgen; Bayer Healthcare; Daiichi Sankyo; Gilead; Merck (SPRI); Novartis; Pfizer; Johnson Johnson; Hadassah University Hospital from Novo Nordisk; TIMI Study Group and Brigham and Women's Hospital from AstraZeneca; Eisai; Arena; Boston Clinical Research Institute; Covance; Elsevier PracticeUpdate Cardiology; Forest Pharmaceuticals; Lexicon; St. Jude Medical; University of Calgary; Amarin; Ethicon; Forest Laboratories; Ischemix; Medtronic; Roche; Medicines Company FX The SAVORTIMI 53 RCT was sponsored by AstraZeneca and Bristol-Myers Squibb. It was designed by the TIMI Study Group and Hadassah Medical Organization in conjunction with the sponsors, who provided monitoring support and donated the saxagliptin used. L.A.L. has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Sanofi, Servier, and Takeda. E.B. has received research grants (through the TIMI Study Group and the Brigham and Women's Hospital) from Abbott, Amgen, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead, GlaxoSmithKline, Merck (SPRI), Novartis, Pfizer, Sanofi, and Johnson & Johnson. O.M. has received research grants (through Hadassah University Hospital) from Novo Nordisk; has served on the speaker's bureaus of AstraZeneca and Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Merck Sharp & Dohme, and Sanofi; has served on the advisory boards of AstraZeneca and Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, and Sanofi; and has received grants (through institution as study physician) from AstraZeneca and Bristol-Myers Squibb. A.C. has served on the advisory boards of AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Teva. R.F. owns Bristol-Myers Squibb stock and is a current employee of Pfizer (Collegeville, PA). F.B. has received research grant support and/or speaker/consulting honoraria from AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi. B.M.S. has received research grants (through the TIMI Study Group and Brigham and Women's Hospital) from AstraZeneca and Bristol-Myers Squibb, Bayer Healthcare, Daiichi Sankyo, Eisai, Gilead, GlaxoSmithKline, Johnson & Johnson, and Merck and consulting fees from Arena, AstraZeneca, Boston Clinical Research Institute, Bristol-Myers Squibb, Covance, Eisai, Elsevier PracticeUpdate Cardiology, Forest Pharmaceuticals, Gilead, Lexicon, St. Jude Medical, and the University of Calgary. D.L.B. has served on the advisory boards of Cardax, Elsevier PracticeUpdate Cardiology, Medscape Cardiology, and Regado Biosciences; has served on the board of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; has served as chair of the American Heart Association Get With The Guidelines Steering Committee; has served on data monitoring committees of the Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.; org), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (associate editor; section editor, pharmacology), Population Health Research Institute (clinical trial steering committee), Slack Incorporated (chief medical editor, Cardiology Today's Intervention), and WebMD (continuing medical education steering committees); has served as the deputy editor of Clinical Cardiology; has received research funding from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; and has done unfunded research for Flowco, PLx Pharma, and Takeda. I.R. has served on the advisory boards of AstraZeneca/Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; has served as a consultant for Andromeda Biotech Ltd, AstraZeneca and Bristol-Myers Squibb, and Insuline; and has served on the speaker's bureaus for AstraZeneca and Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. No other potential conflicts of interest relevant to this article were reported. NR 42 TC 17 Z9 19 U1 1 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2015 VL 38 IS 6 BP 1145 EP 1153 DI 10.2337/dc14-2868 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CT7BV UT WOS:000362969000036 PM 25758769 ER PT J AU Teo, AR AF Teo, A. R. TI Developing a mental health research career: A review of early career opportunities in the US SO ASIA-PACIFIC PSYCHIATRY LA English DT Meeting Abstract C1 [Teo, A. R.] Portland VA Med Ctr, Portland, OR USA. [Teo, A. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1758-5864 EI 1758-5872 J9 ASIA-PAC PSYCHIAT JI Asia-Pac. Psychiatry PD JUN PY 2015 VL 7 SU 1 SI SI MA 60 BP 18 EP 19 PG 2 WC Psychiatry SC Psychiatry GA CT0SD UT WOS:000362505800028 ER PT J AU Teo, AR Fetters, MD Stufflebam, K Tateno, M Balhara, Y Choi, TY Kanba, S Mathews, CA Kato, TA AF Teo, A. R. Fetters, M. D. Stufflebam, K. Tateno, M. Balhara, Y. Choi, T. Y. Kanba, S. Mathews, C. A. Kato, T. A. TI A cross-national study of social withdrawal: Identification, diagnosis and psychosocial features of hikikomori in four countries SO ASIA-PACIFIC PSYCHIATRY LA English DT Meeting Abstract C1 [Teo, A. R.] Portland VA Med Ctr, Portland, OR USA. [Teo, A. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Fetters, M. D.] Univ Michigan, Japanese Family Hlth Program, Ann Arbor, MI 48109 USA. [Fetters, M. D.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Stufflebam, K.] FreshStart ClubHouse, Ann Arbor, MI USA. [Tateno, M.] Sapporo Med Univ, Sapporo Hana Dev Psychiat Clin, Ch Ku, Sapporo, Hokkaid, Japan. [Tateno, M.] Sapporo Med Univ, Dept Neuropsychiat, Ch Ku, Sapporo, Hokkaid, Japan. [Balhara, Y.] All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, India. [Choi, T. Y.] Catholic Univ Daegu, Sch Med, Dept Psychiat, Daegu, South Korea. [Kanba, S.; Kato, T. A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan. [Mathews, C. A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kato, T. A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. NR 0 TC 0 Z9 0 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1758-5864 EI 1758-5872 J9 ASIA-PAC PSYCHIAT JI Asia-Pac. Psychiatry PD JUN PY 2015 VL 7 SU 1 SI SI MA 61 BP 19 EP 19 PG 1 WC Psychiatry SC Psychiatry GA CT0SD UT WOS:000362505800029 ER PT J AU Mifflin, J AF Mifflin, Jeffrey TI ALEXANDER GARDNER: The Western Photographs, 1867-1868 SO JOURNAL OF THE WEST LA English DT Book Review C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ABC-CLIO PI SANTA BARBARA PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA SN 0022-5169 EI 1930-0115 J9 J WEST JI J. West PD SUM PY 2015 VL 54 IS 3 BP 75 EP 76 PG 2 WC History SC History GA CT2FW UT WOS:000362618400013 ER PT J AU Olsen, C Fleming, K Prendergast, N Rubio, R Emmert-Streib, F Bontempi, G Quackenbush, J Haibe-Kains, B AF Olsen, Catharina Fleming, Kathleen Prendergast, Niall Rubio, Renee Emmert-Streib, Frank Bontempi, Gianluca Quackenbush, John Haibe-Kains, Benjamin TI Using shRNA experiments to validate gene regulatory networks SO GENOMICS DATA LA English DT Article DE Knock-down; Gene expression; Microarray; Colon cancer; shRNA ID INFERENCE AB Quantitative validation of gene regulatory networks (GRNs) inferred from observational expression data is a difficult task usually involving time intensive and costly laboratory experiments. We were able to show that gene knock-down experiments can be used to quantitatively assess the quality of large-scale GRNs via a purely data-driven approach (Olsen et al. 2014). Our new validation framework also enables the statistical comparison of multiple network inference techniques, which was a long-standing challenge in the field. In this Data in Brief we detail the contents and quality controls for the gene expression data (available from NCBI Gene Expression Omnibus repository with accession number GSE53091) associated with our study published in Genomics (Olsen et al. 2014). We also provide R code to access the data and reproduce the analysis presented in this article. (C) 2015 Published by Elsevier Inc. C1 [Olsen, Catharina; Bontempi, Gianluca] Univ Libre Bruxelles, Machine Learning Grp, Brussels, Belgium. [Olsen, Catharina; Bontempi, Gianluca] Interuniv Inst Bioinformat Brussels IB2, Brussels, Belgium. [Fleming, Kathleen; Prendergast, Niall; Rubio, Renee; Quackenbush, John; Haibe-Kains, Benjamin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Computat Biol & Funct Genom Lab, Boston, MA 02115 USA. [Emmert-Streib, Frank] Tampere Univ Technol, Dept Signal Proc, Computat Med & Stat Learning Lab, Tampere 33720, Finland. [Haibe-Kains, Benjamin] Univ Hlth Network, Princess Margaret Canc Ctr, Bioinformat & Computat Genom Lab, Toronto, ON M5G 1L7, Canada. [Haibe-Kains, Benjamin] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Emmert-Streib, Frank] Inst Biosci & Med Technol, Tampere 33520, Finland. RP Haibe-Kains, B (reprint author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto Med Discovery Tower,11th Floor,Room 310, Toronto, ON M5G 1L7, Canada. EM bhaibeka@uhnresearch.ca RI Emmert-Streib, Frank/G-8099-2011; Haibe-Kains, Benjamin/D-3702-2011 OI Emmert-Streib, Frank/0000-0003-0745-5641; Haibe-Kains, Benjamin/0000-0002-7684-0079 FU NLM NIH HHS [R01 LM010129] NR 8 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-5960 J9 GENOM DATA JI Genom. Data PD JUN PY 2015 VL 4 BP 123 EP 126 DI 10.1016/j.gdata.2015.03.011 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA CT2ZB UT WOS:000362674500032 PM 26484195 ER PT J AU Dominick, K Wink, LK McDougle, CJ Erickson, CA AF Dominick, Kelli Wink, Logan K. McDougle, Christopher J. Erickson, Craig A. TI A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Article ID BODY-MASS INDEX; ADOLESCENTS; BEHAVIOR; CHILDREN; POPULATION; ATTENTION AB Objective: The purpose of this study was to assess the impact of ziprasidone monoantipsychotic treatment targeting irritability in a naturalistic outpatient autism spectrum disorder (ASD) clinical setting. Methods: We examined the use of ziprasidone, predominantly in combination with other psychotropic agents, targeting irritability in 42 youth with ASD in a large ASD-specific treatment database. Mean age at start of treatment, treatment duration, final dose, body mass index (BMI), BMI Z score, and Clinical Global Impressions-Improvement Scale (CGI-I) score at final visit were determined, and changes with treatment were analyzed using paired t tests. Cardiac corrected QT (QTc) interval data were extracted from electrocardiograms when available. Results: Mean age at start of treatment was 11.8 years. And final mean dose of ziprasidone was 98.7mg/day or 1.7mg/kg/day. Seventeen (40%) participants were considered treatment responders based on the CGI-I. No changes in QTc (although only examined in nine participants), weight, BMI, or other vital signs were noted, with ziprasidone use. The rate of treatment response was less than what has been reported for the two atypical antipsychotics, risperidone and aripiprazole, approved by the Food and Drug Administration (FDA) for the treatment of irritability in autistic disorder. The response rate with ziprasidone may be more consistent with response rates for other atypical antipsychotics, although none of these agents has been studied in larger-scale double-blind, placebo-controlled trials. The lower rate of response to ziprasidone in this open-label trial is likely influenced by the treatment-refractory nature of the population studied. Conclusions: The weight neutrality of ziprasidone appears favorable compared with other second generation antipsychotics in this population. The response rate to ziprasidone targeting irritability may be lower than response rates associated with FDA-approved agents for this indication. Overall, ziprasidone use appeared well tolerated in youth with ASD. C1 [Dominick, Kelli; Wink, Logan K.; Erickson, Craig A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [McDougle, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [McDougle, Christopher J.] Lurie Ctr Autism, Lexington, MA USA. RP Erickson, CA (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA. EM craig.erickson@cchmc.org FU NCATS NIH HHS [UL1 TR001425] NR 14 TC 3 Z9 3 U1 1 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD JUN 1 PY 2015 VL 25 IS 5 BP 397 EP 401 DI 10.1089/cap.2014.0111 PG 5 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA CS4YB UT WOS:000362081100003 PM 26091194 ER PT J AU Sholl, LM Nishino, M Pokharel, S Mino-Kenudson, M French, CA Janne, PA Lathan, C AF Sholl, Lynette M. Nishino, Mizuki Pokharel, Saraswati Mino-Kenudson, Mari French, Christopher A. Janne, Pasi A. Lathan, Christopher TI Primary Pulmonary NUT Midline Carcinoma SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE NUT midline carcinoma; Pulmonary; Squamous cell carcinoma ID LUNG-CANCER; CLINICOPATHOLOGICAL FEATURES; BRAIN METASTASES; BRD-NUT; DIFFERENTIATION; REARRANGEMENT; MECHANISM; DIAGNOSIS; SERIES AB NUT midline carcinoma (NMC) is a poorly differentiated tumor typically driven by a t(15; 19) rearrangement leading to a NUT fusion event. This rare and uniformly fatal tumor arises in multiple organ sites; however the clinical, radiographic, and pathologic characteristics of primary pulmonary NMC are poorly defined. We identified eight cases of primary pulmonary NMC in our consult practice over 4 years and, using a NUT immunohistochemistry screen, retrospectively identified one additional case from 166 (0.6%) consecutive in-house biopsies of lung carcinomas lacking glandular differentiation. Eight cases had available clinical and radiographic data and shared a remarkable degree of similarity. The median age at presentation was 30 (range 21-68). Six patients had little or no smoking history. All complained of 1 to 3 months of cough at presentation. Computed tomography scans showed a large, centrally located primary mass with confluent involvement of mediastinal lymph nodes, pleural disease, and sparing of the contralateral lung. Lytic bone metastases were common but brain metastases were absent in all cases. Pathologically, all cases showed primitive-appearing round to epitheloid cells growing in nests and sheets. All tumors expressed keratin, p63 or p40, and NUT protein. Eight cases had a fluorescence in situ hybridization-proven BRD4-NUT or BRD3-NUT rearrangement; one case was presumed to have a NUT-variant fusion event. Median overall survival was 2.2 months. Despite the rarity of primary pulmonary NMC, it is important to recognize this entity to counsel patients regarding outcome and to identify candidates for targeted BRD inhibitors currently in clinical trials. C1 [Sholl, Lynette M.; French, Christopher A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Nishino, Mizuki] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Pokharel, Saraswati] Roswell Pk Canc Inst, Dept Pathol & Lab Med, Buffalo, NY 14263 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Janne, Pasi A.; Lathan, Christopher] Dana Farber Canc Inst, Thorac Oncol Program, Boston, MA 02115 USA. RP Sholl, LM (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM lmsholl@part-ners.org FU NCI NIH HHS [K23 CA157631, L40 CA108477, R01 CA124633] NR 28 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD JUN PY 2015 VL 10 IS 6 BP 951 EP 959 DI 10.1097/JTO.0000000000000545 PG 9 WC Oncology; Respiratory System SC Oncology; Respiratory System GA CS4UG UT WOS:000362070800022 PM 26001144 ER PT J AU McFarland, LV AF McFarland, Lynne V. TI Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review SO ANTIBIOTICS-BASEL LA English DT Review DE probiotics; clostridium difficile infections; diarrhea; meta-analysis ID ANTIBIOTIC-ASSOCIATED DIARRHEA; PLACEBO-CONTROLLED TRIAL; LACTOBACILLUS-ACIDOPHILUS CL1285; SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; HOSPITALIZED-PATIENTS; PUBLICATION BIAS; CLINICAL-TRIAL; ADULT PATIENTS; DISEASE AB Clostridium difficile infections are a global clinical concern and are one of the leading causes of nosocomial outbreaks. Preventing these infections has benefited from multidisciplinary infection control strategies and new antibiotics, but the problem persists. Probiotics are effective in preventing antibiotic-associated diarrhea and may also be a beneficial strategy for C. difficile infections, but randomized controlled trials are scarce. This meta-analysis pools 21 randomized, controlled trials for primary prevention of C. difficile infections (CDI) and four trials for secondary prevention of C. difficile recurrences and assesses the efficacy of specific probiotic strains. Four probiotics significantly improved primary CDI prevention: (Saccharomyces boulardii, Lactobacillus casei DN114001, a mixture of L. acidophilus and Bifidobacterium bifidum, and a mixture of L. acidophilus, L. casei and L. rhamnosus). None of the tested probiotics significantly improved secondary prevention of CDI. More confirmatory randomized trials are needed to establish if probiotics are useful for preventing C. difficile infections. C1 Univ Washington, Dept Med Chem, VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP McFarland, LV (reprint author), Univ Washington, Dept Med Chem, VA Puget Sound Healthcare Syst, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. EM lvmcfarl@u.washington.edu FU Biocodex, France; Lallemand, France FX Lynne McFarland has received fees as a speaker (Biocodex, France and Lallemand, France) and is on the scientific advisory board of BioK+, Canada. NR 59 TC 11 Z9 13 U1 0 U2 6 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2079-6382 J9 ANTIBIOTICS-BASEL JI Antibiotics-Basel PD JUN PY 2015 VL 4 IS 2 BP 160 EP 178 DI 10.3390/antibiotics4020160 PG 19 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CS4UQ UT WOS:000362071900002 PM 27025619 ER PT J AU Lindinger, NM Jacobson, JL Molteno, CD Warton, F Wintermark, P Warfield, S Dodge, N Taylor, P Hoyme, HE De Jong, G Warton, C Grant, E Zollei, L van der Kouwe, A Meintjes, EM Jacobson, SW AF Lindinger, N. M. Jacobson, J. L. Molteno, C. D. Warton, F. Wintermark, P. Warfield, S. Dodge, N. Taylor, P. Hoyme, H. E. De Jong, G. Warton, C. Grant, E. Zollei, L. van der Kouwe, A. Meintjes, E. M. Jacobson, S. W. TI SMALLER CORPUS CALLOSUMIN THE NEWBORN AS AN EARLY INDICATOR OF ADVERSE EFFECT IN FASD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Cape Town, ZA-7700 Rondebosch, South Africa. Wayne State Univ, Sch Med, Detroit, MI 48202 USA. Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 132 BP 44A EP 44A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100133 ER PT J AU Busch, AC Hetzel, S Brown, RT AF Busch, A. C. Hetzel, S. Brown, R. T. TI PHARMACOTHERAPEUTIC INTERVENTION TO IMPROVE TREATMENT ENGAGEMENT AMONG ALCOHOL DEPENDENT VETERANS AFTER HOSPITAL DISCHARGE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Busch, A. C.; Hetzel, S.; Brown, R. T.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 260 BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100261 ER PT J AU Schrodek, E Pennington, DL Lasher, B Herbst, E Yohannes, S McDonald, J Schmeling, BL Wong, T Batki, SL AF Schrodek, E. Pennington, D. L. Lasher, B. Herbst, E. Yohannes, S. McDonald, J. Schmeling, B. L. Wong, T. Batki, S. L. TI AN EVALUATION OF TOPIRAMATE TREATMENT: SECONDARY HEALTH OUTCOMES FOR VETERANS WITH ALCOHOL USE DISORDER AND COMORBID PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 258 BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100259 ER PT J AU Hutchison, D Possemato, K Lynch, KG Maisto, SA Oslin, DW AF Hutchison, D. Possemato, K. Lynch, K. G. Maisto, S. A. Oslin, D. W. TI CRAVINGS MEDIATE DECREASES IN DRINKING FOR VETERANS WHO USE NALTREXONE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Hutchison, D.; Possemato, K.; Lynch, K. G.; Maisto, S. A.; Oslin, D. W.] Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 261 BP 77A EP 77A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100262 ER PT J AU Yohannes, S Pennington, DL Lasher, B Schrodek, E McDonald, J Schmeling, BL Wong, T Lee, I Batki, SL AF Yohannes, S. Pennington, D. L. Lasher, B. Schrodek, E. McDonald, J. Schmeling, B. L. Wong, T. Lee, I. Batki, S. L. TI PHARMACOTHERAPY CLINICAL TRIAL RECRUITMENT OF VETERANS WITH ALCOHOL USE DISORDER AND COMORBID PTSD/MTBI SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 273 BP 80A EP 80A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100274 ER PT J AU Pennington, DL Meyerhoff, D Schmidt, T Schmeling, B Lasher, B Schrodek, E Yohannes, S McDonald, J Herbst, E Wong, T Batki, SL AF Pennington, D. L. Meyerhoff, D. Schmidt, T. Schmeling, B. Lasher, B. Schrodek, E. Yohannes, S. McDonald, J. Herbst, E. Wong, T. Batki, S. L. TI COGNITIVE FUNCTION IN PATIENTS WITH ALCOHOL USE DISORDER WITH AND WITHOUT PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 290 BP 84A EP 84A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100291 ER PT J AU Schmeling, B Heinz, AJ Pennington, DL Cohen, N Lasher, BA Schrodek, E Yohannes, S McDonald, J Wong, T Batki, SL AF Schmeling, B. Heinz, A. J. Pennington, D. L. Cohen, N. Lasher, B. A. Schrodek, E. Yohannes, S. McDonald, J. Wong, T. Batki, S. L. TI AN EXAMINATION OF RELATIONS BETWEEN COGNITIVE FUNCTIONING AND ALCOHOL USE AND CRAVING AMONG VETERANS WITH ALCOHOL USE DISORDER AND TRAUMA EXPOSURE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Schmeling, B.; Heinz, A. J.; Pennington, D. L.; Cohen, N.; Lasher, B. A.; Schrodek, E.; Yohannes, S.; McDonald, J.; Wong, T.; Batki, S. L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 293 BP 85A EP 85A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100294 ER PT J AU Buck, KJ Denmark, DL Walter, NAR AF Buck, K. J. Denmark, D. L. Walter, N. A. R. TI A SYSTEMS BIOLOGY APPROACH IMPLICATES OXIDATIVE HOMEOSTASIS IN ALCOHOL WITHDRAWAL VULNERABILITY SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland Alcohol Res Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 468 BP 128A EP 128A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100468 ER PT J AU Oslin, DW Polusny, M Kehle-Forbes, S Van Horn, D Yusko, D Drapkin, ML Foa, E Ingram, I AF Oslin, D. W. Polusny, M. Kehle-Forbes, S. Van Horn, D. Yusko, D. Drapkin, M. L. Foa, E. Ingram, I. TI INTEGRATED VERSUS SEQUENTIAL TREATMENT FOR COMORBID PTSD/ADDICTION AMONG VETERANS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Penn, Philadelphia, PA USA. Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 524 BP 142A EP 142A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101047 ER PT J AU Goeke, CM Zhang, X Bhattacharyya, S York, JM Tobacman, JK Guizzetti, M AF Goeke, C. M. Zhang, X. Bhattacharyya, S. York, J. M. Tobacman, J. K. Guizzetti, M. TI ROLE OF N-ACETYL-GALACTOSAMINE-6-SULFATASE IN ETHANOL-INDUCED INHIBITION OF ASTROCYTE-MEDIATED HIPPOCAMPAL PYRAMIDAL NEURON NEURITE OUTGROWTH SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Univ Illinois, Coll Med, Chicago, IL 60612 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] OHSU, Portland, OR 97239 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 839 BP 220A EP 220A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101361 ER PT J AU Dou, X Charness, ME AF Dou, X. Charness, M. E. TI ANKYRIN BINDING TO TYR1229 ON THE L1 CYTOPLASMIC DOMAIN IS REQUIRED FOR ETHANOL INHIBITION OF L1 ADHESION SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02132 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 844 BP 221A EP 221A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101366 ER PT J AU Rasmussen, DD Johanson, SS Kincaid, CL Froehlich, JC AF Rasmussen, D. D. Johanson, S. S. Kincaid, C. L. Froehlich, J. C. TI IN FEMALE P RATS, PRAZOSIN plus NALTREXONE DECREASES ALCOHOL DRINKING MORE EFFECTIVELY THAN EITHER DRUG ALONE, WITH MAXIMUM EFFECT ON INTERMITTENT DRINKING SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 905 BP 237A EP 237A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101427 ER PT J AU Rasmussen, DD Kincaid, CL Johanson, SS Froehlich, JC AF Rasmussen, D. D. Kincaid, C. L. Johanson, S. S. Froehlich, J. C. TI PRAZOSIN plus PROPRANOLOL plus NALTREXONE DECREASES ALCOHOL DRINKING IN FEMALE P RATS MORE EFFECTIVELY THAN THE INDIVIDUAL DRUGS OR TWO-DRUG COMBINATIONS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 906 BP 237A EP 237A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101428 ER PT J AU Simpson, TL Stappenbeck, CA Luterek, JA Rosenthal, CF Gurrad, B Kaysen, D AF Simpson, T. L. Stappenbeck, C. A. Luterek, J. A. Rosenthal, C. F. Gurrad, B. Kaysen, D. TI OUTCOMES OF AN RCT COMPARING TWO COPING SKILLS AMONG DUALLY DIAGNOSED INDIVIDUALS WITH ALCOHOL DEPENDENCE AND PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Simpson, T. L.; Stappenbeck, C. A.; Luterek, J. A.; Rosenthal, C. F.; Gurrad, B.; Kaysen, D.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 200 BP 299A EP 299A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637102084 ER PT J AU Einsele, H Richardson, P Hungria, V Yoon, SS Beksac, M Dimopoulos, M Elghandour, A Jedrzejczak, W Guenther, A Nakorn, TN Siritanaratkul, N Schlossman, R Hou, J Moreau, P Lonial, S Lee, JH Sopala, M Bengoudifa, BR Corrado, C San-Miguel, J AF Einsele, H. Richardson, P. Hungria, V. Yoon, S. S. Beksac, M. Dimopoulos, M. Elghandour, A. Jedrzejczak, W. Guenther, A. Nakorn, T. Na Siritanaratkul, N. Schlossman, R. Hou, J. Moreau, P. Lonial, S. Lee, J. H. Sopala, M. Bengoudifa, B. R. Corrado, C. San-Miguel, J. TI SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Einsele, H.] Univ Hosp Wurzburg, Wurzburg, Germany. [Richardson, P.; Schlossman, R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hungria, V.] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil. [Yoon, S. S.] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Beksac, M.] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey. [Dimopoulos, M.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Elghandour, A.] Univ Alexandria, Alexandria, Egypt. [Jedrzejczak, W.] Med Univ Warsaw, Warsaw, Poland. [Guenther, A.] Univ Hosp Schleswig Holstein, Kiel, Germany. [Guenther, A.] Univ Kiel, Kiel, Germany. [Nakorn, T. Na] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Nakorn, T. Na] Chulalongkorn Univ, Bangkok, Thailand. [Siritanaratkul, N.] Siriraj Hosp, Bangkok, Thailand. [Hou, J.] Chang Zheng Hosp, Shanghai, Peoples R China. [Moreau, P.] Univ Hosp Nantes, Nantes, France. [Lonial, S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Lee, J. H.] Gachon Univ, Gil Hosp, Inchon, South Korea. [Sopala, M.; Bengoudifa, B. R.; Corrado, C.] Novartis Pharma AG, Basel, Switzerland. [San-Miguel, J.] Univ Navarra Clin, Pamplona, Spain. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S102 BP 1 EP 1 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901002 ER PT J AU Jakubowiak, A Offidani, M Pegourie, B De La Rubia, J Garderet, L Laribi, K Bosi, A Marasca, R Laubach, J Mohrbacher, A Carella, AM Singhal, AK Tsao, LC Lynch, M Bleickardt, E Jou, YM Palumbo, A AF Jakubowiak, A. Offidani, M. Pegourie, B. De La Rubia, J. Garderet, L. Laribi, K. Bosi, A. Marasca, R. Laubach, J. Mohrbacher, A. Carella, A. M. Singhal, A. K. Tsao, L. C. Lynch, M. Bleickardt, E. Jou, Y. M. Palumbo, A. TI A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Jakubowiak, A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Offidani, M.] Osped Riuniti Ancona, Azienda Osped Univ, Ancona, Italy. [Pegourie, B.] Hop Albert Michallon, CHU Grenoble, Grenoble, France. [De La Rubia, J.] HUP La Fe, Valencia, Spain. [Garderet, L.] Hop St Antoine, F-75571 Paris, France. [Laribi, K.] Ctr Hosp, Le Mans, France. [Bosi, A.] Azienda Osped Univ Careggi, Florence, Italy. [Marasca, R.] Azienda Osped Univ, Policlin Modena, Modena, Italy. [Laubach, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mohrbacher, A.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Carella, A. M.] IRCCS San Martino IST, Genoa, Italy. [Singhal, A. K.; Tsao, L. C.] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. [Lynch, M.; Bleickardt, E.; Jou, Y. M.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [Palumbo, A.] Osped Molinette, Azienda Osped Univ San Giovanni Battista Torino, Turin, Italy. RI Marasca, Roberto/I-8072-2013 OI Marasca, Roberto/0000-0002-6431-6878 NR 2 TC 5 Z9 5 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S103 BP 2 EP 2 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901003 ER PT J AU Sportoletti, P Baldoni, S Del Papa, B Aureli, P Dorillo, E Varasano, E Cecchini, D Zei, T Di Tommaso, A De Falco, F Plebani, S Amico, V Roti, G Stegmaier, K Rosati, E Falini, B Di Ianni, M Falzetti, F AF Sportoletti, P. Baldoni, S. Del Papa, B. Aureli, P. Dorillo, E. Varasano, E. Cecchini, D. Zei, T. Di Tommaso, A. De Falco, F. Plebani, S. Amico, V. Roti, G. Stegmaier, K. Rosati, E. Falini, B. Di Ianni, M. Falzetti, F. TI IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Sportoletti, P.; Del Papa, B.; Aureli, P.; Dorillo, E.; Varasano, E.; Cecchini, D.; Zei, T.; Falini, B.; Falzetti, F.] Inst Hematol, Perugia, Italy. [Baldoni, S.; Di Tommaso, A.; Plebani, S.; Amico, V.; Di Ianni, M.] Inst Hematol, Laquila, Italy. [De Falco, F.; Rosati, E.] Biosci & Med Embryol Sect, Perugia, Italy. [Roti, G.; Stegmaier, K.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S122 BP 11 EP 11 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901022 ER PT J AU Caocci, G Voso, MT Angelucci, E Stauder, R Cottone, F Abel, G Nguyen, KTT Platzbecker, U Beyne-Rauzy, O Gaidano, G Invernizzi, R Molica, S Criscuolo, M Breccia, M Lubbert, M Sanpaolo, G Buccisano, F Ricco, A Palumbo, G Niscola, P Zhang, H Fenu, S La Nasa, G Mandelli, F Efficace, F AF Caocci, G. Voso, M. T. Angelucci, E. Stauder, R. Cottone, F. Abel, G. Nguyen, K. T. T. Platzbecker, U. Beyne-Rauzy, O. Gaidano, G. Invernizzi, R. Molica, S. Criscuolo, M. Breccia, M. Luebbert, M. Sanpaolo, G. Buccisano, F. Ricco, A. Palumbo, G. Niscola, P. Zhang, H. Fenu, S. La Nasa, G. Mandelli, F. Efficace, F. TI ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Caocci, G.; La Nasa, G.] Univ Cagliari, Dept Internal Med, Hematol Unit, Cagliari, Italy. [Voso, M. T.; Buccisano, F.] Univ Roma Tor Vergata, Dept Hematol, Rome, Italy. [Angelucci, E.] A Businco Hosp, Dept Hematol, Cagliari, Italy. [Stauder, R.] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, A-6020 Innsbruck, Austria. [Cottone, F.; Mandelli, F.; Efficace, F.] Italian Grp Adult Hematol Dis GIMEMA, Ctr Data, Rome, Italy. [Cottone, F.; Mandelli, F.; Efficace, F.] Italian Grp Adult Hematol Dis GIMEMA, Hlth Outcomes Res Unit, Rome, Italy. [Abel, G.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02115 USA. [Nguyen, K. T. T.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Platzbecker, U.] Univ Hosp Dresden Carl Gustav Carus, Dept Med 1, Dresden, Germany. [Beyne-Rauzy, O.] CHU Toulouse Purpan, Dept Internal Med, F-31059 Toulouse, France. [Gaidano, G.] Amedeo Avogadro Univ Eastern Piedmont, Div Hematol, Dept Translat Med, Novara, Italy. [Invernizzi, R.] Univ Pavia IRCCS, Policlin San Matteo Fdn, Dept Internal Med, Pavia, Italy. [Molica, S.] Pugliese Ciaccio Hosp Ctr, Dept Oncol Hematol, Catanzaro, Italy. [Criscuolo, M.] Univ Rome Cattolica S Cuore, Dept Hematol, Rome, Italy. [Breccia, M.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy. [Luebbert, M.] Univ Freiburg, Med Ctr, Freiburg, Germany. [Sanpaolo, G.] IRCCS Casa Sollievo della Sofferenza Hosp, Dept Hematol, San Giovanni Rotondo, Italy. [Sanpaolo, G.] IRCCS Casa Sollievo della Sofferenza Hosp, Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy. [Ricco, A.] Univ Bari, Univ Dept Emergency & Organ Transplantat, Hematol Sect, Dept Emergency & Organ Transplantat, Bari, Italy. [Palumbo, G.] AOU Policlin V Emanuele, UO Ematol, Catania, Italy. [Niscola, P.] S Eugenio Hosp, Dept Hematol, Rome, Italy. [Zhang, H.] Liaoning Univ Tradit Chinese Med, Dept Hematol, Affiliated Hosp, Shenyang, Peoples R China. [Fenu, S.] S Giovanni Addolorata Hosp, Dept Hematol, Rome, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S147 BP 23 EP 23 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901047 ER PT J AU Cella, D Moreau, P Kuter, D Goldschmidt, H Davis, C Oukessou, A Sy, O Joo, S Annemans, L AF Cella, D. Moreau, P. Kuter, D. Goldschmidt, H. Davis, C. Oukessou, A. Sy, O. Joo, S. Annemans, L. TI AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE MYELOMA (PREAMBLE): A PRELIMINARY REPORT OF DISEASE IMPACT ON QUALITY OF LIFE SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Cella, D.] Northwestern Univ, Evanston, IL USA. [Moreau, P.] Univ Hosp, Nantes, France. [Kuter, D.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Goldschmidt, H.] Univ Heidelberg Hosp, Heidelberg, Germany. [Davis, C.; Oukessou, A.; Sy, O.; Joo, S.] Bristol Myers Squibb Co, Princeton, NJ USA. [Annemans, L.] Univ Ghent, B-9000 Ghent, Belgium. [Annemans, L.] Univ Brussels, Ghent, Belgium. RI richard, chrystelle/K-8595-2015 NR 6 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S148 BP 23 EP 24 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901048 ER PT J AU Minden, MD Dombret, H Seymour, JF Stone, RM Alibhai, S Nixon, A Kudlac, A Songer, S Beach, C Bartiromo, C Dohner, H AF Minden, M. D. Dombret, H. Seymour, J. F. Stone, R. M. Alibhai, S. Nixon, A. Kudlac, A. Songer, S. Beach, C. Bartiromo, C. Doehner, H. TI THE EFFECT OF AZACITIDINE ON HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE AZA-AML-001 TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Minden, M. D.; Alibhai, S.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Dombret, H.] Univ Paris Diderot, Hop St Louis, Inst Univ Hematol, Paris, France. [Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nixon, A.; Kudlac, A.] PRMA Consulting Ltd, Fleet, Hants, England. [Songer, S.; Beach, C.; Bartiromo, C.] Celgene Corp, Summit, NJ USA. [Doehner, H.] Univ Ulm Klinikum, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P184 BP 40 EP 41 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901084 ER PT J AU Cortes, J Kim, DW Pinilla-Ibarz, J le Coutre, PD Paquette, R Chuah, C Nicolini, FE Apperley, JF Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Lustgarten, S Rivera, VM Clackson, T Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Shah, NP Kantarjian, HM AF Cortes, J. Kim, D. W. Pinilla-Ibarz, J. le Coutre, P. D. Paquette, R. Chuah, C. Nicolini, F. E. Apperley, J. F. Khoury, H. J. Talpaz, M. DiPersio, J. F. DeAngelo, D. J. Abruzzese, E. Rea, D. Baccarani, M. Mueller, M. C. Gambacorti-Passerini, C. Lustgarten, S. Rivera, V. M. Clackson, T. Haluska, F. G. Guilhot, F. Deininger, M. W. Hochhaus, A. Hughes, T. P. Shah, N. P. Kantarjian, H. M. TI PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Cortes, J.; Kantarjian, H. M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kim, D. W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, P. D.] Charite, D-13353 Berlin, Germany. [Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, C.] Singapore Gen Hosp, Singapore, Singapore. [Chuah, C.] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore. [Nicolini, F. E.] Ctr Hosp Lyon Sud, Lyon, France. [Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, J. F.] Washington Univ, Sch Med, St Louis, MO USA. [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Rea, D.] Hop St Louis, Paris, France. [Baccarani, M.] Univ Bologna, Bologna, Italy. [Mueller, M. C.] Univ Med Mannheim, Mannheim, Germany. [Gambacorti-Passerini, C.] Univ Milano Bicocca, Azienda Osped San Gerardo, Monza, Italy. [Lustgarten, S.; Rivera, V. M.; Clackson, T.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Guilhot, F.] CHU Poitiers, INSERM, CIC 1402, Poitiers, France. [Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, A.] Jena Univ Hosp, Jena, Germany. [Hughes, T. P.] Inst Med & Vet Sci, Adelaide, SA, Australia. [Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P234 BP 64 EP 64 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901136 ER PT J AU Gkotzamanidou, M Sanchez, JM Samur, MK Fulciniti, M Anderson, KC Munshi, NC AF Gkotzamanidou, M. Martin Sanchez, J. Samur, M. Kemal Fulciniti, M. Anderson, K. C. Munshi, N. C. TI LSD1 IMPAIRS OSTEOCLASTOGENESIS AND EPITHELIAL-MESENCHYMAL TRANSITION IN MM AND ENHANCES HDAC INHIBITORS ACTIVITY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Gkotzamanidou, M.] Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens 11528, Greece. [Gkotzamanidou, M.; Anderson, K. C.; Munshi, N. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Martin Sanchez, J.] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Hematol 2,Inst Biomed Sevilla IBIS, Seville, Spain. [Samur, M. Kemal] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Fulciniti, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Munshi, N. C.] Boston Healthcare Syst, West Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P260 BP 76 EP 77 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901162 ER PT J AU Fulciniti, MT Oliva, S Amodio, N Roccaro, A Bandi, RL Daisy, H Cagnetta, A Senapedis, W Baloglu, E Anderson, KC Ghobrial, I Munshi, NC AF Fulciniti, M. T. Oliva, S. Amodio, N. Roccaro, A. Bandi, R. L. Daisy, H. Cagnetta, A. Senapedis, W. Baloglu, E. Anderson, K. C. Ghobrial, I. Munshi, N. C. TI P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Fulciniti, M. T.; Oliva, S.; Roccaro, A.; Bandi, R. L.; Daisy, H.; Cagnetta, A.; Anderson, K. C.; Ghobrial, I.; Munshi, N. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. [Oliva, S.] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy. [Amodio, N.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Senapedis, W.; Baloglu, E.] Karyopharm Therapeut Inc, Newton, MA USA. RI Amodio, Nicola/K-7335-2016 OI Amodio, Nicola/0000-0002-1345-4410 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P265 BP 78 EP 79 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901167 ER PT J AU Moreau, P San-Miguel, J Hungria, V Yoon, SS Beksac, M Dimopoulos, M Elghandour, A Jedrzejczak, W Guenther, A Nakorn, TN Siritanaratkul, N Schlossman, R Hou, J Lonial, S Lee, JH Einsele, H Sopala, M Bengoudifa, BR Corrado, C Richardson, P AF Moreau, P. San-Miguel, J. Hungria, V. Yoon, S. S. Beksac, M. Dimopoulos, M. Elghandour, A. Jedrzejczak, W. Guenther, A. Nakorn, T. Na Siritanaratkul, N. Schlossman, R. Hou, J. Lonial, S. Lee, J. H. Einsele, H. Sopala, M. Bengoudifa, B. -R. Corrado, C. Richardson, P. TI ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Moreau, P.] Univ Hosp Nantes, Nantes, France. [San-Miguel, J.] Univ Navarra Clin, Pamplona, Spain. [Hungria, V.] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil. [Yoon, S. S.] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Beksac, M.] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey. [Dimopoulos, M.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Elghandour, A.] Univ Alexandria, Alexandria, Egypt. [Jedrzejczak, W.] Med Univ Warsaw, Warsaw, Poland. [Guenther, A.] Univ Hosp Schleswig Holstein, Kiel, Germany. [Guenther, A.] Univ Kiel, Kiel, Germany. [Nakorn, T. Na] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Nakorn, T. Na] Chulalongkorn Univ, Bangkok, Thailand. [Siritanaratkul, N.] Siriraj Hosp, Bangkok, Thailand. [Schlossman, R.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hou, J.] Chang Zheng Hosp, Shanghai, Peoples R China. [Lonial, S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Lee, J. H.] Gachon Univ, Gil Hosp, Inchon, South Korea. [Einsele, H.] Univ Wurzburg, D-97070 Wurzburg, Germany. [Sopala, M.; Bengoudifa, B. -R.; Corrado, C.] Novartis Pharma AG, Basel, Switzerland. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P268 BP 80 EP 81 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901170 ER PT J AU Raje, N Bensinger, W Lebovic, D Lonial, S Jagannath, S Acre-Lara, C Rosko, A Harb, W Bahlis, N Supko, J Tamang, D Jones, S Wheeler, C Richardson, P AF Raje, N. Bensinger, W. Lebovic, D. Lonial, S. Jagannath, S. Acre-Lara, C. Rosko, A. Harb, W. Bahlis, N. Supko, J. Tamang, D. Jones, S. Wheeler, C. Richardson, P. TI RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Raje, N.; Supko, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bensinger, W.] Univ Washington, Seattle, WA 98195 USA. [Lebovic, D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Lonial, S.] Emory Univ, Atlanta, GA 30322 USA. [Jagannath, S.] Mt Sinai Hosp, New York, NY 10029 USA. [Acre-Lara, C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Rosko, A.] Ohio State Univ, Columbus, OH 43210 USA. [Harb, W.] Horizon Oncol Ctr, Lafayette, IN USA. [Bahlis, N.] Tom Baker Canc Clin, Calgary, AB, Canada. [Tamang, D.; Jones, S.; Wheeler, C.] Acetylon Pharmaceut Inc, Boston, MA USA. [Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P279 BP 86 EP 86 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901181 ER PT J AU Magarotto, V Sonneveld, P Voorhees, P Paba-Prada, C Plesner, T Mellqvist, UH Byrne, C Harmenberg, J Nordstrom, E Palumbo, A Richardson, P AF Magarotto, V. Sonneveld, P. Voorhees, P. Paba-Prada, C. Plesner, T. Mellqvist, U. H. Byrne, C. Harmenberg, J. Nordstrom, E. Palumbo, A. Richardson, P. TI ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Magarotto, V.; Palumbo, A.] Turin Univ Hosp, Turin, Italy. [Sonneveld, P.] Erasmus, Rotterdam, Netherlands. [Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA. [Paba-Prada, C.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Plesner, T.] Vejle Hosp, Vejle, Denmark. [Mellqvist, U. H.] Sodra Alvsborgs Hosp, Boras, Sweden. [Byrne, C.] Oncopeptides AB, Miami, FL USA. [Harmenberg, J.; Nordstrom, E.] Oncopeptides AB, Stockholm, Sweden. NR 0 TC 1 Z9 1 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P285 BP 89 EP 89 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901187 ER PT J AU Munshi, N Avet-Loiseau, H Rawstron, A Owen, R Thakurta, A Sherrington, P Georgieva, A Anderson, K Gregory, W AF Munshi, N. Avet-Loiseau, H. Rawstron, A. Owen, R. Thakurta, A. Sherrington, P. Georgieva, A. Anderson, K. Gregory, W. TI SIGNIFICANT IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) STATUS ON SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA (MM) WHO ACHIEVE COMPLETE RESPONSE (CR): A META-ANALYSIS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Munshi, N.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Avet-Loiseau, H.] Inst Univ Canc, Unit Genom Myeloma, Toulouse, France. [Rawstron, A.; Owen, R.] St James Univ Hosp, Leeds, W Yorkshire, England. [Thakurta, A.] Celgene Corp, Summit, NJ USA. [Sherrington, P.] Celgene Int, Boudry, Switzerland. [Georgieva, A.] Excerpta Med, Amsterdam, Netherlands. [Gregory, W.] Univ Leeds, Leeds, W Yorkshire, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA LB297 BP 94 EP 95 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901199 ER PT J AU Emerson, R Nikiforow, S Milano, F Sherwood, A Papermaster, A Guthrie, K Carlson, C Warren, E Ritz, J Robins, H Cutler, C Delaney, C AF Emerson, R. Nikiforow, S. Milano, F. Sherwood, A. Papermaster, A. Guthrie, K. Carlson, C. Warren, E. Ritz, J. Robins, H. Cutler, C. Delaney, C. TI TCR REPERTOIRE DIVERSITY ASSESSED WITH IMMUNOSEQUENCING IS ASSOCIATED WITH PATIENT MORTALITY FOLLOWING CORD BLOOD TRANSPLANT SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Emerson, R.; Sherwood, A.] Adapt Biotechnol, Seattle, WA USA. [Nikiforow, S.; Ritz, J.; Cutler, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Milano, F.; Papermaster, A.; Guthrie, K.; Carlson, C.; Warren, E.; Robins, H.; Delaney, C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P349 BP 119 EP 119 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901253 ER PT J AU Roberts, AW Ma, S Brander, D Kipps, TJ Barrientos, JC Davids, MS Anderson, MA Choi, M Tam, C Magee, L Kreutzer, J Singh, R Kim, J Dimovski, B Mason-Bright, T Prine, B Zhu, M Humerickhouse, RA Seymour, JF AF Roberts, A. W. Ma, S. Brander, D. Kipps, T. J. Barrientos, J. C. Davids, M. S. Anderson, M. A. Choi, M. Tam, C. Magee, L. Kreutzer, J. Singh, R. Kim, J. Dimovski, B. Mason-Bright, T. Prine, B. Zhu, M. Humerickhouse, R. A. Seymour, J. F. TI VENETOCLAX (ABT-199/GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Roberts, A. W.; Anderson, M. A.; Magee, L.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia. [Roberts, A. W.; Anderson, M. A.; Magee, L.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia. [Ma, S.; Kreutzer, J.] Northwestern Univ, Chicago, IL 60611 USA. [Brander, D.; Singh, R.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Kipps, T. J.; Choi, M.; Kim, J.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Barrientos, J. C.] Hofstra North Shore LIJ Sch Med, Lake Success, NY USA. [Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tam, C.; Dimovski, B.; Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Mason-Bright, T.; Prine, B.; Zhu, M.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S431 BP 154 EP 154 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901337 ER PT J AU Jaeger, U Barr, PM Brown, JR Hillmen, P O'Brien, S Barrientos, JC Reddy, NM Coutre, S Mulligan, SP Furman, RR Cymbalista, F Montillo, M Dearden, C Robak, T Moreno, C Pagel, JM Burger, JA Suzuki, S Sukbuntherng, J Cole, G James, DF Byrd, JC AF Jaeger, U. Barr, P. M. Brown, J. R. Hillmen, P. O'Brien, S. Barrientos, J. C. Reddy, N. M. Coutre, S. Mulligan, S. P. Furman, R. R. Cymbalista, F. Montillo, M. Dearden, C. Robak, T. Moreno, C. Pagel, J. M. Burger, J. A. Suzuki, S. Sukbuntherng, J. Cole, G. James, D. F. Byrd, J. C. TI ADHERENCE AND DOSE INTENSITY FOLLOWING ADMINISTRATION OF THE IBRUTINIB 420 MG DOSE IN PATIENTS WITH PREVIOUSLY TREATED CLL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Jaeger, U.] Med Univ Vienna, Vienna, Austria. [Barr, P. M.] Univ Rochester, Wilmot Canc Inst, Rochester, NY 14627 USA. [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hillmen, P.] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. [O'Brien, S.; Burger, J. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Barrientos, J. C.] North Shore LIJ Canc Inst, Lake Success, NY USA. [Reddy, N. M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Coutre, S.] Stanford Univ, Sch Med, Stanford, CA USA. [Mulligan, S. P.] Royal N Shore Hosp, Sydney, NSW, Australia. [Furman, R. R.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Cymbalista, F.] Hop Avicenne, Paris, France. [Montillo, M.] Osped Niguarda Ca Granda, Milan, Italy. [Dearden, C.] Royal Marsden Hosp, London SW3 6JJ, England. [Robak, T.] Med Univ Lodz, Lodz, Poland. [Moreno, C.] Hosp Santa Creu St Pau, Barcelona, Spain. [Pagel, J. M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Suzuki, S.; Sukbuntherng, J.; Cole, G.; James, D. F.] Pharmacyclics Inc, Sunnyvale, CA USA. [Byrd, J. C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S435 BP 155 EP 155 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901340 ER PT J AU Davids, MS Kim, HT Costello, C Avigan, D Chen, YB Armand, P Alyea, EP Hedlund, J McSweeney, P Liguori, R Ritz, J Ball, ED Bashey, A Soiffer, RJ AF Davids, M. S. Kim, H. T. Costello, C. Avigan, D. Chen, Y. B. Armand, P. Alyea, E. P. Hedlund, J. McSweeney, P. Liguori, R. Ritz, J. Ball, E. D. Bashey, A. Soiffer, R. J. TI UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF CTLA4 BLOCKADE WITH IPILIMUMAB FOR RELAPSED HEMATOLOGIC MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Davids, M. S.; Kim, H. T.; Armand, P.; Alyea, E. P.; Liguori, R.; Ritz, J.; Soiffer, R. J.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Costello, C.; Ball, E. D.] Univ Calif San Diego, Moores Canc Ctr, Div BMT, La Jolla, CA 92093 USA. [Avigan, D.] Beth Israel Deaconess Med Ctr, BMT Program, Boston, MA 02215 USA. [Chen, Y. B.] Massachusetts Gen Hosp, BMT Program, Boston, MA 02114 USA. [Hedlund, J.] New England Canc Specialists, Scarborough, ME USA. [McSweeney, P.] Colorado Blood Canc Inst, Denver, CO USA. [Bashey, A.] Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA. NR 0 TC 2 Z9 2 U1 2 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S445 BP 159 EP 160 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901350 ER PT J AU Dimopoulos, M Lonial, S Palumbo, A White, D Grosicki, S Spicka, I Walter-Croneck, A Moreau, P Mateos, MV Magen, H Belch, A Reece, D Beksac, M Spencer, A Oakervee, H Taniwaki, M Rollig, C Wu, KL Singhal, A San Miguel, J Matsumoto, M Katz, J Bleickardt, E Poulart, V Richardson, P AF Dimopoulos, M. Lonial, S. Palumbo, A. White, D. Grosicki, S. Spicka, I. Walter-Croneck, A. Moreau, P. Mateos, M. -V. Magen, H. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Taniwaki, M. Roellig, C. Wu, K. L. Singhal, A. San Miguel, J. Matsumoto, M. Katz, J. Bleickardt, E. Poulart, V. Richardson, P. TI ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Dimopoulos, M.] Univ Athens, Athens 11528, Greece. [Lonial, S.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Palumbo, A.] AOU San Giovanni Battista Torino Osped Molinette, Turin, Italy. [White, D.] QEII Hlth Sci Ctr, Halifax, NS, Canada. [White, D.] Dalhousie Univ, Halifax, NS, Canada. [Grosicki, S.] Silesian Med Univ, Katowice, Poland. [Spicka, I.] Charles Univ Hosp, Prague, Czech Republic. [Walter-Croneck, A.] Med Univ Lublin, Lublin, Poland. [Moreau, P.] Univ Hosp, Nantes, France. [Mateos, M. -V.] Univ Hosp Salamanca IBSAL, Salamanca, Spain. [Magen, H.] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel. [Magen, H.] Tel Aviv Univ, Ramat Aviv, Israel. [Belch, A.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Belch, A.] Univ Alberta, Edmonton, AB, Canada. [Reece, D.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Beksac, M.] Ankara Univ, TR-06100 Ankara, Turkey. [Spencer, A.] Alfred Hlth Monash Univ, Melbourne, Vic, Australia. [Oakervee, H.] Barts & London NHS Trust, London, England. [Taniwaki, M.] Kyoto Prefectural Univ Med, Kyoto, Japan. [Roellig, C.] Univ Klinikum TU, Dresden, Germany. [Wu, K. L.] ZNA Stuivenberg, Antwerp, Belgium. [Singhal, A.] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. [San Miguel, J.] Univ Navarra Clin, Pamplona, Spain. [Matsumoto, M.] Nishigunma Natl Hosp, Shibukawa, Japan. [Katz, J.] Bristol Myers Squibb Co, Princeton, NJ USA. [Bleickardt, E.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. [Poulart, V.] Bristol Myers Squibb Co, Braine Lalleud, Belgium. [Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S471 BP 173 EP 173 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901376 ER PT J AU Roccaro, A Sacco, A Moschetta, M Shi, J Chiarini, M Pan, C Cardarelli, P Kuhne, M Ghobrial, I AF Roccaro, A. Sacco, A. Moschetta, M. Shi, J. Chiarini, M. Pan, C. Cardarelli, P. Kuhne, M. Ghobrial, I. TI TARGETING EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) THROUGH CXCR4 BLOCKADE IN MULTIPLE MYELOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Roccaro, A.; Sacco, A.; Moschetta, M.; Shi, J.; Ghobrial, I.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Chiarini, M.] Spedali Civil Brescia, Ctr Ric Oncoematol AIL CREA, I-25125 Brescia, Italy. [Pan, C.; Cardarelli, P.; Kuhne, M.] Bristol Myers Squibb, Redwood City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S479 BP 177 EP 177 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901384 ER PT J AU Kuruvilla, J Mau-Sorensen, M Stone, R Wagner-Johnston, N Garzon, R Savoie, L Flinn, I Baz, R Wang, M Martin, P Gabrail, N Brown, P Goy, A Rashal, T Carlson, R Landesman, Y Saint-Martin, JR Marshall, T Savona, M Norori, S Shacham, S Kauffman, M Gutierrez, M AF Kuruvilla, J. Mau-Sorensen, M. Stone, R. Wagner-Johnston, N. Garzon, R. Savoie, L. Flinn, I. Baz, R. Wang, M. Martin, P. Gabrail, N. Brown, P. Goy, A. Rashal, T. Carlson, R. Landesman, Y. Saint-Martin, J. -R. Marshall, T. Savona, M. Norori, S. Shacham, S. Kauffman, M. Gutierrez, M. TI PATIENTS WITH HEAVILY PRETREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WHO RESPOND TO ORAL SELINEXOR THERAPY SHOW PROLONGED SURVIVAL: UDPATED PHASE 1 RESULTS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Kuruvilla, J.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Mau-Sorensen, M.; Brown, P.] Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark. [Stone, R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wagner-Johnston, N.] Washington Univ, St Louis, MO USA. [Garzon, R.] Ohio State Univ, Columbus, OH 43210 USA. [Savoie, L.] Univ Calgary, Calgary, AB, Canada. [Flinn, I.] Sarah Cannon Res Inst, Nashville, TN USA. [Baz, R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Wang, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Martin, P.] Weill Cornell Med Coll, New York, NY USA. [Gabrail, N.] Gabrail Canc Ctr, Canton, OH USA. [Goy, A.; Gutierrez, M.] Hackensack Univ Hosp, Hackensack, NJ USA. [Rashal, T.; Carlson, R.; Landesman, Y.; Saint-Martin, J. -R.; Marshall, T.; Shacham, S.; Kauffman, M.] Karyopharm Therapeut, Newton, MA USA. [Savona, M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Norori, S.] Ozmosis Res, Toronto, ON, Canada. RI Garzon, Ramiro/E-3104-2011 NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S485 BP 180 EP 180 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204901390 ER PT J AU Komrokji, R Garcia-Manero, G Ades, L Laadem, A Vo, B Prebet, T Stamatoullas, A Boyd, T Delaunay, J Steensma, DP Sekeres, MA Beyne-Rauzy, O Zou, J Attie, KM Sherman, ML Fenaux, P List, AF AF Komrokji, R. Garcia-Manero, G. Ades, L. Laadem, A. Vo, B. Prebet, T. Stamatoullas, A. Boyd, T. Delaunay, J. Steensma, D. P. Sekeres, M. A. Beyne-Rauzy, O. Zou, J. Attie, K. M. Sherman, M. L. Fenaux, P. List, A. F. TI A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ANEMIA REQUIRING TRANSFUSION SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Komrokji, R.; List, A. F.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA. [Garcia-Manero, G.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Ades, L.; Fenaux, P.] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France. [Laadem, A.; Vo, B.; Zou, J.] Celgene Corp, Summit, NJ USA. [Prebet, T.] Inst J Paoli I Calmettes, Dept Oncohematol, F-13009 Marseille, France. [Stamatoullas, A.] Ctr Henri Becquerel, Serv Hematol, F-76038 Rouen, France. [Boyd, T.] Yakima Valley Mem Hosp, North Star Lodge Canc Ctr, Yakima, WA USA. [Delaunay, J.] Hop Hotel Dieu, CHU Nantes, Serv Hematol Clin, Nantes, France. [Steensma, D. P.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Sekeres, M. A.] Cleveland Clin, Taussig Canc Inst, Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA. [Beyne-Rauzy, O.] Ctr Hosp Univ Purpan, Dept Hematol Med Interne, Toulouse, France. [Attie, K. M.; Sherman, M. L.] Acceleron Pharma, Cambridge, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S510 BP 192 EP 192 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902015 ER PT J AU de Botton, S Pollyea, DA Stein, EM DiNardo, C Fathi, AT Roboz, GJ Collins, R Swords, RT Flinn, I Altman, JK Tallman, MS Kantarjian, H Colby, K Fan, B Goldwasser, M Prahl, M Agresta, S Stone, RM AF de Botton, S. Pollyea, D. A. Stein, E. M. DiNardo, C. Fathi, A. T. Roboz, G. J. Collins, R. Swords, R. T. Flinn, I. Altman, J. K. Tallman, M. S. Kantarjian, H. Colby, K. Fan, B. Goldwasser, M. Prahl, M. Agresta, S. Stone, R. M. TI CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [de Botton, S.] Inst Gustave Roussy, Villejuif, France. [Pollyea, D. A.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Stein, E. M.; Tallman, M. S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [DiNardo, C.; Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Fathi, A. T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Roboz, G. J.] Weill Cornell Med Coll, New York, NY USA. [Collins, R.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Swords, R. T.] Sylvester Comprehens Canc Ctr, Miami, FL USA. [Flinn, I.] Sarah Cannon Res Inst, Nashville, TN USA. [Altman, J. K.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA. [Colby, K.; Fan, B.; Goldwasser, M.; Prahl, M.; Agresta, S.] Agios Pharmaceut, Cambridge, MA 02139 USA. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 4 Z9 4 U1 1 U2 3 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P563 BP 214 EP 215 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902068 ER PT J AU DiNardo, C Stein, EM Altman, JK Collins, R DeAngelo, DJ Fathi, AT Flinn, I Frankel, A Levine, RL Medeiros, BC Patel, M Pollyea, DA Roboz, GJ Stone, RM Swords, RT Tallman, MS Almon, C Fan, B Goldwasser, M Yen, K Attar, E de Botton, S AF DiNardo, C. Stein, E. M. Altman, J. K. Collins, R. DeAngelo, D. J. Fathi, A. T. Flinn, I. Frankel, A. Levine, R. L. Medeiros, B. C. Patel, M. Pollyea, D. A. Roboz, G. J. Stone, R. M. Swords, R. T. Tallman, M. S. Almon, C. Fan, B. Goldwasser, M. Yen, K. Attar, E. de Botton, S. TI AG-221, AN ORAL, SELECTIVE, FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH2 MUTANT ENZYME, INDUCED DURABLE RESPONSES IN A PHASE 1 STUDY OF IDH2 MUTATION-POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIES SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [DiNardo, C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Stein, E. M.; Levine, R. L.; Tallman, M. S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Altman, J. K.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA. [Collins, R.; Frankel, A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [DeAngelo, D. J.; Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fathi, A. T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Flinn, I.] Sarah Cannon Res Inst, Nashville, TN USA. [Medeiros, B. C.] Stanford Comprehens Canc Ctr, Stanford, CA USA. [Patel, M.] Florida Canc Specialists SCRI, Sarasota, FL USA. [Pollyea, D. A.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Roboz, G. J.] Weill Cornell Med Coll, New York, NY USA. [Swords, R. T.] Sylvester Comprehens Canc Ctr, Miami, FL USA. [Almon, C.; Fan, B.; Goldwasser, M.; Yen, K.; Attar, E.] Agios Pharmaceut, Cambridge, MA USA. [de Botton, S.] Inst Gustave Roussy, Villejuif, France. NR 0 TC 4 Z9 4 U1 1 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P569 BP 216 EP 217 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902073 ER PT J AU Schuh, A Dombret, H Sandhu, I Seymour, JF Stone, RM Al-Ali, HK Alimena, G Lewis, I Kyun, SS Geddes, M Cilloni, D Je-Hwan, L Songer, S Lucy, LM Beach, C Dohner, H AF Schuh, A. Dombret, H. Sandhu, I. Seymour, J. F. Stone, R. M. Al-Ali, H. K. Alimena, G. Lewis, I. Kyun, S. Sang Geddes, M. Cilloni, D. Je-Hwan, L. Songer, S. Lucy, L. M. Beach, C. Doehner, H. TI OVERALL SURVIVAL (OS) WITHOUT COMPLETE REMISSION (CR) IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN THE AZA-AML-001 STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Schuh, A.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Dombret, H.] Univ Paris Diderot, Inst Univ Hernatol, Hop St Louis, Paris, France. [Sandhu, I.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada. [Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Al-Ali, H. K.] Univ Klinikum Leipzig, Leipzig, Germany. [Alimena, G.] Univ Roma La Sapienza, Policlin Umberto I, I-00185 Rome, Italy. [Lewis, I.] Royal Adelaide Hosp, Adelaide, SA 5000, Australia. [Kyun, S. Sang] Kyungpook Natl Univ Hosp, Daegu, South Korea. [Geddes, M.] Tom Baker Canc Clin, Calgary, AB, Canada. [Cilloni, D.] AOU San Luigi Gonzaga, Turin, Italy. [Je-Hwan, L.] Asan Med Ctr, Seoul, South Korea. [Songer, S.; Lucy, L. M.; Beach, C.] Celgene Corp, Summit, NJ USA. [Doehner, H.] Univ Ulm Klinikum, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P575 BP 219 EP 220 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902079 ER PT J AU Improgo, R Tesar, B Klitgaard, J Magori-Cohen, R Yu, L Fernandes, SM Chaudhary, D Miao, W Romero, DL Westlin, WF Kim, HT Brown, JR AF Improgo, R. Tesar, B. Klitgaard, J. Magori-Cohen, R. Yu, L. Fernandes, S. M. Chaudhary, D. Miao, W. Romero, D. L. Westlin, W. F. Kim, H. T. Brown, J. R. TI MYD88 L265P SOMATIC MUTATIONS INFLUENCE GENE EXPRESSION AND THERAPEUTIC RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Improgo, R.; Tesar, B.; Klitgaard, J.; Yu, L.; Fernandes, S. M.; Brown, J. R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Improgo, R.; Tesar, B.; Klitgaard, J.; Yu, L.; Brown, J. R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Magori-Cohen, R.; Kim, H. T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Magori-Cohen, R.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Chaudhary, D.; Miao, W.; Romero, D. L.; Westlin, W. F.] Nimbus Discovery Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P579 BP 221 EP 222 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902084 ER PT J AU Coutre, S Barrientos, J Brown, J De Vos, S Furman, R Keating, M O'Brien, S Pagel, J Sharman, J Zelenetz, A Newcomb, T Cho, Y Aguilar, C Dreiling, L AF Coutre, S. Barrientos, J. Brown, J. De Vos, S. Furman, R. Keating, M. O'Brien, S. Pagel, J. Sharman, J. Zelenetz, A. Newcomb, T. Cho, Y. Aguilar, C. Dreiling, L. TI SAFETY OF IDELALISIB IN B-CELL MALIGNANCIES: INTEGRATED ANALYSIS OF EIGHT CLINICAL TRIALS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Coutre, S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Barrientos, J.] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA. [Brown, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [De Vos, S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Furman, R.] Weill Cornell Med Coll, New York, NY USA. [Keating, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [O'Brien, S.] Chao Family Comprehens Canc Ctr, Orange, CA USA. [Pagel, J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Sharman, J.] US Oncol, Springfield, OR USA. [Sharman, J.] Willamette Valley Canc Inst, Springfield, OR USA. [Zelenetz, A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Newcomb, T.; Cho, Y.; Aguilar, C.; Dreiling, L.] Gilead Sci Inc, Foster City, CA 94404 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P588 BP 225 EP 225 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902092 ER PT J AU Robak, T Wach, M Jones, JA Owen, C Brown, JR Menter, AR Ysebaert, L Wagner-Johnston, N Awan, F Taylor, K Schuh, A Cannell, P Morris, K Larratt, L Skotnicki, A Loscertales, J Nathwani, A Badoux, X Hahn, U Pulczynski, EJ Feugier, P Zini, JM Dihuydy, MS Sanhes, L Garcia-Marco, JA Bosch, F Dreiling, L Peterman, S Cho, Y Dubowy, R Vandenberghe, E AF Robak, T. Wach, M. Jones, J. A. Owen, C. Brown, J. R. Menter, A. R. Ysebaert, L. Wagner-Johnston, N. Awan, F. Taylor, K. Schuh, A. Cannell, P. Morris, K. Larratt, L. Skotnicki, A. Loscertales, J. Nathwani, A. Badoux, X. Hahn, U. Pulczynski, E. Jacobsen Feugier, P. Zini, J. -M. Dihuydy, M. -S. Sanhes, L. Garcia-Marco, J. A. Bosch, F. Dreiling, L. Peterman, S. Cho, Y. Dubowy, R. Vandenberghe, E. TI RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Robak, T.] Med Univ Lodz, Lodz, Poland. [Wach, M.] Med Univ Lublin, Lublin, Poland. [Jones, J. A.; Awan, F.] Ohio State Univ, Columbus, OH 43210 USA. [Owen, C.] Tom Baker Canc Clin, Calgary, AB, Canada. [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Menter, A. R.] Kaiser Permanente Med Grp, Denver, CO USA. [Ysebaert, L.] Insi Univ Canc Toulouse Oncopole, Toulouse, France. [Wagner-Johnston, N.] Washington Univ, Med Ctr, St Louis, MO USA. [Taylor, K.] Mater, Haematol Clin Australia, South Brisbane, Australia. [Taylor, K.] Mater, Oncol Clin Australia, South Brisbane, Australia. [Schuh, A.] Churchill Hosp, Oxford OX3 7LJ, England. [Cannell, P.] Royal Perth Hosp, Perth, WA 6001, Australia. [Morris, K.] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia. [Larratt, L.] Cross Canc Inst, Edmonton, AB, Canada. [Skotnicki, A.] Uniwersytetu Jagiellonskiego Krakowie, Coll Med, Krakow, Poland. [Loscertales, J.] Hosp Univ La Princesa, Madrid, Spain. [Nathwani, A.] UCL, London, England. [Badoux, X.] St George Hosp, Kogarah, NSW, Australia. [Hahn, U.] Queen Elizabeth Hosp, Woodville South, Australia. [Pulczynski, E. Jacobsen] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark. [Feugier, P.] Ctr Hosp Univ Nancy, Vandoeuvre Les Nancy, France. [Zini, J. -M.] Hop St Louis, Paris, France. [Dihuydy, M. -S.] Ctr Hosp Univ Bordeaux, Pessac, France. [Sanhes, L.] Ctr Hosp Perpignan, Perpignan, France. [Garcia-Marco, J. A.] Hosp Puerta Hierro Majadahonda, Madrid, Spain. [Bosch, F.] Hosp Valle De Hebron, Barcelona, Spain. [Dreiling, L.; Peterman, S.; Cho, Y.; Dubowy, R.] Gilead Sci, Foster City, CA USA. [Vandenberghe, E.] St James Hosp, Dublin 8, Ireland. RI Awan, Farrukh/L-5642-2016 OI Awan, Farrukh/0000-0003-1813-9812 NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA LB598 BP 229 EP 229 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902102 ER PT J AU Garcia-Manero, G Fenaux, P Al-Kali, A Baer, M Sekeres, M Roboz, G Gaidano, G Scott, B Greenberg, P Platzbecker, U Steensma, D Kreuzer, KA Godley, L Collins, R Atallah, E Azarnia, N Silverman, L AF Garcia-Manero, G. Fenaux, P. Al-Kali, A. Baer, M. Sekeres, M. Roboz, G. Gaidano, G. Scott, B. Greenberg, P. Platzbecker, U. Steensma, D. Kreuzer, K. -A. Godley, L. Collins, R. Atallah, E. Azarnia, N. Silverman, L. TI OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Garcia-Manero, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Fenaux, P.] Hosp St Louis, Paris, France. [Al-Kali, A.] Mayo Clin, Rochester, MN USA. [Baer, M.] Univ Maryland, Baltimore, MD 21201 USA. [Sekeres, M.] Cleveland Clin, Cleveland, OH 44106 USA. [Roboz, G.] Weill Cornell Med Coll, New York, NY USA. [Gaidano, G.] Amedeo Avogadro Univ Eastern Piedmont, Novaro, Italy. [Scott, B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Greenberg, P.] Stanford Med Sch, Stanford, CA USA. [Platzbecker, U.] Univ Klinikum Dresden, Dresden, Germany. [Steensma, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kreuzer, K. -A.] Univ Klinikum Koln, Cologne, Germany. [Godley, L.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Collins, R.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Atallah, E.] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA. [Atallah, E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Azarnia, N.] Onconova Therapeut Inc, Newtown, PA USA. [Silverman, L.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P616 BP 238 EP 238 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902121 ER PT J AU Vij, R Savona, M Siegel, D Kaufman, JL Badros, A Ghobrial, I Paner, A Jagannath, S Jakubowiak, A Mikhael, J Kapoor, P Neuman, L Obreja, M Berdeja, J AF Vij, R. Savona, M. Siegel, D. Kaufman, J. L. Badros, A. Ghobrial, I. Paner, A. Jagannath, S. Jakubowiak, A. Mikhael, J. Kapoor, P. Neuman, L. Obreja, M. Berdeja, J. TI UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Vij, R.] Washington Univ, St Louis, MO 63130 USA. [Savona, M.] Vanderbilt Univ, Nashville, TN 37235 USA. [Siegel, D.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Kaufman, J. L.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Badros, A.] Univ Maryland, Baltimore, MD 21201 USA. [Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Paner, A.] Rush Univ, Chicago, IL 60612 USA. [Jagannath, S.] Mt Sinai Hosp, New York, NY 10029 USA. [Jakubowiak, A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Mikhael, J.] Mayo Clin, Scottsdale, AZ USA. [Kapoor, P.] Mayo Clin, Rochester, MN USA. [Neuman, L.; Obreja, M.] Onyx Pharmaceut, San Francisco, CA USA. [Berdeja, J.] Sarah Cannon Res Inst, Nashville, TN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P646 BP 251 EP 251 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902150 ER PT J AU Hari, P Shain, KH Voorhees, P Gabrail, N Abidi, M Zonder, J Boccia, R Richardson, PG Neuman, L Wong, H Dixon, S Prada, CP AF Hari, P. Shain, K. H. Voorhees, P. Gabrail, N. Abidi, M. Zonder, J. Boccia, R. Richardson, P. G. Neuman, L. Wong, H. Dixon, S. Prada, C. P. TI OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Hari, P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Shain, K. H.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA. [Gabrail, N.] Gabrail Canc Ctr, Canton, OH USA. [Abidi, M.] Spectrum Hlth, Grand Rapids, MI USA. [Zonder, J.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Boccia, R.] Ctr Canc & Blood Disorders, Bethesda, MD USA. [Richardson, P. G.; Prada, C. P.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Neuman, L.; Wong, H.; Dixon, S.] Onyx Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P653 BP 254 EP 255 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902157 ER PT J AU D'Souza, A Pasquini, M Logan, B Giralt, S Krishnan, A Antin, J Howard, A Horowitz, M Goodman, S Laport, G Qazilbash, M Mendizabal, A Sahebi, F Weisdorf, D Vesole, D Stadtmauer, E Maloney, D Hari, P AF D'Souza, A. Pasquini, M. Logan, B. Giralt, S. Krishnan, A. Antin, J. Howard, A. Horowitz, M. Goodman, S. Laport, G. Qazilbash, M. Mendizabal, A. Sahebi, F. Weisdorf, D. Vesole, D. Stadtmauer, E. Maloney, D. Hari, P. TI HEAVY LIGHT CHAIN RATIO NORMALIZATION ALLOWS IDENTIFICATION OF ELECTROPHORETIC NON-COMPLETE RESPONSE PATIENTS WITH IMPROVED OUTCOMES: A LONG TERM FOLLOW UP UPDATE FOR BMT CTN 0102 CORRELATIVE STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [D'Souza, A.; Pasquini, M.; Logan, B.; Horowitz, M.; Hari, P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Giralt, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Krishnan, A.; Sahebi, F.] City Hope Natl Med Ctr, Duarte, CA USA. [Antin, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Howard, A.] Natl Marrow Donor Program, Minneapolis, MN USA. [Goodman, S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Laport, G.] Stanford Univ, Palo Alto, CA 94304 USA. [Qazilbash, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Mendizabal, A.] EMMES Corp, Rockville, MD USA. [Weisdorf, D.] Univ Minnesota, Minneapolis, MN USA. [Vesole, D.] John Theurer Canc Ctr, Hackensack, NJ USA. [Stadtmauer, E.] Univ Penn, Philadelphia, PA 19104 USA. [Maloney, D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P664 BP 259 EP 259 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902168 ER PT J AU Trehu, E Pozdnyakova, O Hasserjian, R Salama, M Mesa, R Foltz, L Gupta, V Mascarenhas, J Ritchie, E Hoffman, R Silver, R Kremyanskaya, M Kantarjian, H Gotlib, J Verstovsek, S AF Trehu, E. Pozdnyakova, O. Hasserjian, R. Salama, M. Mesa, R. Foltz, L. Gupta, V. Mascarenhas, J. Ritchie, E. Hoffman, R. Silver, R. Kremyanskaya, M. Kantarjian, H. Gotlib, J. Verstovsek, S. TI BONE MARROW FIBROSIS BY WHO GRADE AND QUANTITATIVE IMAGE ANALYSIS IS REDUCED BY PRM-151 IN PATIENTS WITH MYELOFIBROSIS AND ASSOCIATED WITH IMPROVED BONE MARROW MORPHOLOGY AND INCREASED PLATELET COUNTS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Trehu, E.] Promedior Inc, Res & Dev, Lexington, MA USA. [Pozdnyakova, O.] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA. [Hasserjian, R.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. [Salama, M.] Univ Utah, Pathol, Salt Lake City, UT USA. [Mesa, R.] Mayo Clin, Hematol, Scottsdale, AZ USA. [Foltz, L.] St Pauls Hosp, Hematol, Vancouver, BC V6Z 1Y6, Canada. [Gupta, V.] Princess Margaret Hosp, Hematol, Toronto, ON M4X 1K9, Canada. [Mascarenhas, J.; Hoffman, R.; Kremyanskaya, M.] Mt Sinai Med Ctr, Hematol, New York, NY 10029 USA. [Ritchie, E.; Silver, R.] Weill Cornell Med Ctr, Hematol, New York, NY USA. [Kantarjian, H.; Verstovsek, S.] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA. [Gotlib, J.] Stanford Canc Inst, Hematol, Stanford, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA P677 BP 266 EP 266 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902181 ER PT J AU Treon, S Tripsas, C Meid, K Warren, D Varma, G Green, R Argyropoulos, K Yang, G Cao, Y Xu, L Patterson, C Rodig, S Zehnder, J Aster, J Harris, NL Kanan, S Ghobrial, I Laubach, J Hunter, Z Salman, Z Cheng, M Li, J Clow, F Graef, T Castillo, J Palomba, ML Advani, R AF Treon, S. Tripsas, C. Meid, K. Warren, D. Varma, G. Green, R. Argyropoulos, K. Yang, G. Cao, Y. Xu, L. Patterson, C. Rodig, S. Zehnder, J. Aster, J. Harris, N. L. Kanan, S. Ghobrial, I. Laubach, J. Hunter, Z. Salman, Z. Cheng, M. Li, J. Clow, F. Graef, T. Castillo, J. Palomba, M. L. Advani, R. TI IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Treon, S.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Tripsas, C.; Meid, K.; Warren, D.; Yang, G.; Cao, Y.; Xu, L.; Patterson, C.; Kanan, S.; Ghobrial, I.; Laubach, J.; Hunter, Z.; Castillo, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Varma, G.; Zehnder, J.; Advani, R.] Stanford Univ, Inst Canc, Stanford, CA 94305 USA. [Green, R.; Argyropoulos, K.; Palomba, M. L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Rodig, S.; Aster, J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Harris, N. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Salman, Z.; Cheng, M.; Li, J.; Clow, F.; Graef, T.] Pharmacyclics Inc, Sunnyvale, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S785 BP 311 EP 311 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902289 ER PT J AU Jakubowiak, A Griffith, K Jasielec, J Rosenbaum, C McDonnell, K Berdeja, J Vij, R Raje, N Reece, D Dytfeld, D Zimmerman, T AF Jakubowiak, A. Griffith, K. Jasielec, J. Rosenbaum, C. McDonnell, K. Berdeja, J. Vij, R. Raje, N. Reece, D. Dytfeld, D. Zimmerman, T. TI POST-TRANSPLANT CARFILZOMIB (KYPROLIS (R)), LENALIDOMIDE (REVLIMID (R)), AND DEXAMETHASONE (KRD) CONSOLIDATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): EFFICACY AND TOLERABILITY OF EXTENDED TREATMENT SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Jakubowiak, A.; Rosenbaum, C.; McDonnell, K.; Zimmerman, T.] Univ Chicago, Chicago, IL 60637 USA. [Griffith, K.] Univ Michigan, Ann Arbor, MI 48109 USA. [Jasielec, J.] Northshore Univ Hlth Syst, Evanston, IL USA. [Berdeja, J.] Sarah Cannon Canc Ctr, Nashville, TN USA. [Vij, R.] Washington Univ, St Louis, MO USA. [Raje, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Reece, D.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Dytfeld, D.] Poznan Univ Med Sci, Poznan, Poland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S787 BP 312 EP 312 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902291 ER PT J AU Bahlo, J Kutsch, N Bergmann, M Byrd, J Dohner, H Eichhorst, B Else, M Geisler, C Grever, M Lepretre, S Neuberg, D Oscier, D Robak, T Rosenquist, R Shanafelt, T Stilgenbauer, S Hallek, M AF Bahlo, J. Kutsch, N. Bergmann, M. Byrd, J. Doehner, H. Eichhorst, B. Else, M. Geisler, C. Grever, M. Lepretre, S. Neuberg, D. Oscier, D. Robak, T. Rosenquist, R. Shanafelt, T. Stilgenbauer, S. Hallek, M. TI THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Bahlo, J.; Kutsch, N.; Eichhorst, B.; Hallek, M.] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany. [Bergmann, M.] Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany. [Byrd, J.; Grever, M.] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA. [Doehner, H.; Stilgenbauer, S.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. [Else, M.] Inst Canc Res, Div Mol Pathol, London SW3 6JB, England. [Geisler, C.] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark. [Lepretre, S.] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France. [Neuberg, D.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Oscier, D.] Royal Bournemouth Hosp, Dept Hematol, Bournemouth, Dorset, England. [Robak, T.] Med Univ Lodz, Dept Hematol, Lodz, Poland. [Rosenquist, R.] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden. [Shanafelt, T.] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S791 BP 313 EP 314 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902295 ER PT J AU MacBeth, KJ Tang, L Seymour, JF Stone, RM Minden, MD Lucy, LM Beach, C Dohner, H AF MacBeth, K. J. Tang, L. Seymour, J. F. Stone, R. M. Minden, M. D. Lucy, L. M. Beach, C. Doehner, H. TI ASSOCIATION OF MIR29 RNA WITH RESPONSE AND SURVIVAL IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR CONVENTIONAL CARE REGIMENS (CCR) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [MacBeth, K. J.; Tang, L.; Lucy, L. M.; Beach, C.] Celgene Corp, Summit, NJ USA. [Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Minden, M. D.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Doehner, H.] Univ Ulm Klinikum, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S797 BP 317 EP 317 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902301 ER PT J AU Armand, P Timmerman, J Lesokhin, A Halwani, A Millenson, M Schuster, S Gutierrez, M Scott, E Cattry, D Freeman, G Chapuy, B Ligon, A Rodig, S Zhu, L Grosso, J Simon, J Shipp, M Cohen, A Lebovic, D Dhodapkar, M Avigan, D Ansell, S Borrello, I AF Armand, P. Timmerman, J. Lesokhin, A. Halwani, A. Millenson, M. Schuster, S. Gutierrez, M. Scott, E. Cattry, D. Freeman, G. Chapuy, B. Ligon, A. Rodig, S. Zhu, L. Grosso, J. Simon, J. Shipp, M. Cohen, A. Lebovic, D. Dhodapkar, M. Avigan, D. Ansell, S. Borrello, I. TI NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES AND CLASSICAL HODGKIN LYMPHOMA: UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY (CA209-039) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Armand, P.; Freeman, G.; Chapuy, B.; Shipp, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Timmerman, J.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Lesokhin, A.; Cattry, D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Halwani, A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Millenson, M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Schuster, S.; Cohen, A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Gutierrez, M.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Scott, E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Ligon, A.; Rodig, S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Zhu, L.; Grosso, J.; Simon, J.] Bristol Myers Squibb Co, Princeton, NJ USA. [Lebovic, D.] Univ Michigan, Hematol, Ann Arbor, MI 48109 USA. [Dhodapkar, M.] Yale Canc Ctr, New Haven, CT USA. [Avigan, D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Borrello, I.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Borrello, I.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. NR 0 TC 2 Z9 2 U1 2 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA S808 BP 323 EP 323 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902312 ER PT J AU Tausch, E Landau, D Taylor-Weiner, A Stewart, C Reiter, J Bahlo, J Kluth, S Bozic, I Lawrence, M Boettcher, S Cibulskis, K Mertens, D Sougnez, C Rosenberg, M Hess, J Carter, S Edelmann, J Kless, S Fink, A Fischer, K Ritgen, M Kneba, M Gabriel, S Lander, E Nowak, M Dohner, H Hallek, M Neuberg, D Getz, G Stilgenbauer, S Wu, C AF Tausch, E. Landau, D. Taylor-Weiner, A. Stewart, C. Reiter, J. Bahlo, J. Kluth, S. Bozic, I. Lawrence, M. Boettcher, S. Cibulskis, K. Mertens, D. Sougnez, C. Rosenberg, M. Hess, J. Carter, S. Edelmann, J. Kless, S. Fink, A. Fischer, K. Ritgen, M. Kneba, M. Gabriel, S. Lander, E. Nowak, M. Doehner, H. Hallek, M. Neuberg, D. Getz, G. Stilgenbauer, S. Wu, C. TI WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Tausch, E.; Mertens, D.; Edelmann, J.; Kless, S.; Doehner, H.; Stilgenbauer, S.] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany. [Landau, D.; Neuberg, D.; Wu, C.] Harvard Univ, Sch Med, Boston, MA USA. [Landau, D.; Wu, C.] Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA. [Landau, D.; Wu, C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Landau, D.; Taylor-Weiner, A.; Stewart, C.; Lawrence, M.; Cibulskis, K.; Sougnez, C.; Rosenberg, M.; Hess, J.; Carter, S.; Gabriel, S.; Lander, E.; Getz, G.; Wu, C.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Reiter, J.] IST Austria Inst Sci & Technol Austria, Klosterneuburg, Austria. [Bahlo, J.; Kluth, S.; Fink, A.; Fischer, K.; Hallek, M.] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany. [Bahlo, J.; Kluth, S.; Fink, A.; Fischer, K.; Hallek, M.] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany. [Bozic, I.; Nowak, M.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA. [Boettcher, S.; Ritgen, M.; Kneba, M.] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany. [Mertens, D.] German Canc Res Ctr, Cooperat Unit Mech Leukemogenesis, Heidelberg, Germany. [Fink, A.; Fischer, K.; Hallek, M.] Cent Off, German CLL Study Grp, Cologne, Germany. [Hallek, M.] Cologne Cluster Excellence Cellular Stress Respon, Cologne, Germany. [Neuberg, D.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Getz, G.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Getz, G.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA LB2070 BP 335 EP 336 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902337 ER PT J AU DeAngelo, DJ Stelljes, M Martinelli, G Kantarjian, H Liedtke, M Stock, W Goekbuget, N Wang, K Pacagnella, L Sleight, B Vandendries, E Advani, AS AF DeAngelo, D. J. Stelljes, M. Martinelli, G. Kantarjian, H. Liedtke, M. Stock, W. Goekbuget, N. Wang, K. Pacagnella, L. Sleight, B. Vandendries, E. Advani, A. S. TI EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN (INO) VS STANDARD OF CARE (SOC) IN SALVAGE 1 OR 2 PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): AN ONGOING GLOBAL PHASE 3 STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stelljes, M.] Univ Klinikum Munster, Munster, Germany. [Martinelli, G.] Univ Bologna, Inst Seragnoli, Bologna, Italy. [Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Liedtke, M.] Stanford Comprehens Canc Ctr, Stamford, CT USA. [Stock, W.] Univ Chicago, Chicago, IL 60637 USA. [Goekbuget, N.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany. [Wang, K.; Vandendries, E.] Pfizer Inc, Cambridge, MA USA. [Pacagnella, L.; Sleight, B.] Pfizer Inc, Groton, CT 06340 USA. [Advani, A. S.] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA LB2073 BP 337 EP 337 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902340 ER PT J AU Burrows, F Pallis, M Ryan, J Seedhouse, C Abdul-Aziz, A Montero, J Letai, A Russell, N AF Burrows, F. Pallis, M. Ryan, J. Seedhouse, C. Abdul-Aziz, A. Montero, J. Letai, A. Russell, N. TI COMPLEMENTARY DYNAMIC BH3 PROFILES PREDICT INDUCTION OF APOPTOSIS BY THE MULTI-KINASE INHIBITOR TG02 IN COMBINATION WITH THE BH3 MIMETIC ABT-199 IN AML CELLS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Burrows, F.] Tragara Pharma, Oncol Biol, Carlsbad, CA USA. [Pallis, M.; Seedhouse, C.; Abdul-Aziz, A.; Russell, N.] Univ Nottingham Hosp, Dept Haematol, Nottingham NG7 2UH, England. [Ryan, J.; Montero, J.; Letai, A.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E887 BP 354 EP 354 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902382 ER PT J AU Seymour, JF Dohner, H Kumar, R Stone, RM Wierzbowska, A del Castillo, TB Falantes, J Delaunay, J Sabloff, M Voso, MT Kim, I Ram, R Gau, JP Songer, S Lucy, LM Beach, C Dombret, H AF Seymour, J. F. Doehner, H. Kumar, R. Stone, R. M. Wierzbowska, A. Bernal del Castillo, T. Falantes, J. Delaunay, J. Sabloff, M. Voso, M. T. Kim, I. Ram, R. Gau, J. P. Songer, S. Lucy, L. M. Beach, C. Dombret, H. TI OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia. [Doehner, H.] Univ Ulm Klinikum, Ulm, Germany. [Kumar, R.] Canc Care Manitoba, Winnipeg, MB, Canada. [Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wierzbowska, A.] Med Univ Lodz, Lodz, Poland. [Bernal del Castillo, T.] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain. [Falantes, J.] Hosp Univ Virgen del Rocio, Inst BioMed Sevilla, Seville, Spain. [Delaunay, J.] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France. [Sabloff, M.] Univ Ottawa, Ottawa, ON, Canada. [Sabloff, M.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Voso, M. T.] Univ Roma Tor Vergata, Rome, Italy. [Kim, I.] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Ram, R.] Rabin Med Ctr, Petah Tiqwa, Israel. [Gau, J. P.] Taipei Vet Gen Hosp, Taipei, Taiwan. [Songer, S.; Lucy, L. M.; Beach, C.] Celgene Corp, Summit, NJ USA. [Dombret, H.] Univ Paris Diderot, Inst Univ Hematol, Hop St Louis, Paris, France. RI Wierzbowska, Agnieszka/S-9449-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E954 BP 381 EP 381 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204902449 ER PT J AU Nicolini, FE DeAngelo, DJ Abruzzese, E Apperley, JF Holyoake, TL Larson, RA Lustgarten, S Rivera, VM Clackson, T Conlan, MG Haluska, FG Talpaz, M Cortes, JE AF Nicolini, F. E. DeAngelo, D. J. Abruzzese, E. Apperley, J. F. Holyoake, T. L. Larson, R. A. Lustgarten, S. Rivera, V. M. Clackson, T. Conlan, M. G. Haluska, F. G. Talpaz, M. Cortes, J. E. TI PONATINIB EFFICACY AND SAFETY IN PATIENTS WITH A HISTORY OF STEM CELL TRANSPLANTATION (SCT) IN THE PACE TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Holyoake, T. L.] Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, Glasgow, Lanark, Scotland. [Larson, R. A.] Univ Chicago, Chicago, IL 60637 USA. [Lustgarten, S.; Rivera, V. M.; Clackson, T.; Conlan, M. G.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Cortes, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RI Holyoake, Tessa/M-3668-2015 OI Holyoake, Tessa/0000-0002-0608-6066 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E1104 BP 440 EP 440 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204903086 ER PT J AU Siegel, D Kaufman, JL Raje, N Mikhael, J Kapoor, P Treon, S Castillo, J Neuman, L Obreja, M Ghobrial, I AF Siegel, D. Kaufman, J. L. Raje, N. Mikhael, J. Kapoor, P. Treon, S. Castillo, J. Neuman, L. Obreja, M. Ghobrial, I. TI UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Siegel, D.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Kaufman, J. L.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Raje, N.] Harvard Univ, Sch Med, Boston, MA USA. [Mikhael, J.] Mayo Clin, Scottsdale, AZ USA. [Kapoor, P.] Mayo Clin, Rochester, MN USA. [Treon, S.; Castillo, J.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Neuman, L.; Obreja, M.] Onyx Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E1154 BP 461 EP 461 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204903134 ER PT J AU Silverman, L Fenaux, P Al-Kali, A Baer, M Sekeres, M Roboz, G Gaidano, G Scott, B Greenberg, P Platzbecker, U Steensma, D Kreuzer, KA Godley, L Collins, R Atallah, E Azarnia, N Garcia-Manero, G AF Silverman, L. Fenaux, P. Al-Kali, A. Baer, M. Sekeres, M. Roboz, G. Gaidano, G. Scott, B. Greenberg, P. Platzbecker, U. Steensma, D. Kreuzer, K. -A. Godley, L. Collins, R. Atallah, E. Azarnia, N. Garcia-Manero, G. TI PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Silverman, L.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Fenaux, P.] Hosp St Louis, Paris, France. [Al-Kali, A.] Mayo Clin, Rochester, MN USA. [Baer, M.] Univ Maryland, Baltimore, MD 21201 USA. [Sekeres, M.] Cleveland Clin, Cleveland, OH 44106 USA. [Roboz, G.] Weill Cornell Med Coll, New York, NY USA. [Gaidano, G.] Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy. [Scott, B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Greenberg, P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Platzbecker, U.] Univ Klinikum Dresden, Dresden, Germany. [Steensma, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kreuzer, K. -A.] Univ Klinikum Koln, Cologne, Germany. [Godley, L.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Collins, R.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Atallah, E.] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA. [Atallah, E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Azarnia, N.] Onconova Therapeut Inc, Newtown, PA USA. [Garcia-Manero, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E1227 BP 492 EP 492 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204903210 ER PT J AU Rozic, G Jakubikova, J Duek, A Avigdor, A Nagler, A Leiba, M AF Rozic, G. Jakubikova, J. Duek, A. Avigdor, A. Nagler, A. Leiba, M. TI THE NOVEL MOLECULE STK405759 HAS SELECTIVE CYTOTOXICITY AGAINST MULTIPLE MYELOMA IN VITRO AND IN VIVO SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Rozic, G.; Duek, A.; Avigdor, A.; Nagler, A.; Leiba, M.] Chaim Sheba Med Ctr, Div Hematol & BMT, Ramat Gan, Israel. [Jakubikova, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA E1246 BP 500 EP 500 PG 1 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204903229 ER PT J AU Uno, T Verstovsek, S Mesa, R Talpaz, M Ritchie, E Wadleigh, M Odenike, OM Jamieson, C Stein, B AF Uno, T. Verstovsek, S. Mesa, R. Talpaz, M. Ritchie, E. Wadleigh, M. Odenike, O. M. Jamieson, C. Stein, B. TI PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 20th Congress of European-Hematology-Association CY JUN 11-14, 2015 CL Vienna, AUSTRIA C1 [Verstovsek, S.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Mesa, R.] Mayo Clin, Scottsdale, AZ USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Ritchie, E.] Cornell Univ, New York, NY 10021 USA. [Wadleigh, M.] Dana Faber Canc Inst, Boston, MA USA. [Odenike, O. M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Jamieson, C.] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA. [Stein, B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD JUN PY 2015 VL 100 SU 1 MA LB2091 BP 542 EP 543 PG 2 WC Hematology SC Hematology GA CR3BJ UT WOS:000361204903336 ER PT J AU Greenberg, MS Wood, NE Spring, JD Gurvits, TV Nagurney, JT Zafonte, RD Pitman, RK AF Greenberg, Mark S. Wood, Nellie E. Spring, Justin D. Gurvits, Tamara V. Nagurney, John T. Zafonte, Ross D. Pitman, Roger K. TI Pilot Study of Neurological Soft Signs and Depressive and Postconcussive Symptoms During Recovery From Mild Traumatic Brain Injury (mTBI) SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; SPORT-RELATED CONCUSSION; MOTOR SPEED; HEAD-INJURY; RELIABILITY; INVENTORY; VALIDITY; PERFORMANCE; IMPAIRMENT AB Neurological soft signs (NSSs) tap into a variety of perceptual, motor, and cognitive functions. The authors administered a battery of NSSs serially to a group of 14 pilot patients recruited from an emergency room after they experienced a mild traumatic brain injury. Patients were seen within 96 hours after injury, and again 30 and 90 days later. Measures of balance, mood, and postconcussive symptoms and impairment were also obtained. NSSs and balance improved across visits. Across visits, NSSs and balance were not significantly associated with any postconcussive outcome measures, although depressive symptoms were. Initial neurological impairment appeared to predict subsequent residual postconcussive symptoms and impairment, but this result requires replication. C1 [Greenberg, Mark S.; Wood, Nellie E.; Spring, Justin D.; Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Greenberg, Mark S.; Nagurney, John T.; Zafonte, Ross D.; Pitman, Roger K.] Harvard Univ, Sch Med, Boston, MA USA. [Zafonte, Ross D.] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Greenberg, Mark S.; Zafonte, Ross D.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Greenberg, MS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM mark_greenberg@hms.harvard.edu FU United States Army Medical Research and Materiel Command (USAMRMC) Telemedicine and Technology Research Center (TATRC) [W81XWH-11-1-0408]; NIH/EKS-NICHD 1R24 [HD065688]; USDOE-NIDRR [H133A080035]; USAMRAA [W81XWH-11-2-0210]; USAMRMC [W81XWH-08-2-0159] FX This work was directly supported by a grant from the United States Army Medical Research and Materiel Command (USAMRMC) Telemedicine and Technology Research Center (TATRC), #W81XWH-11-1-0408 (MSG and RKP). Co-author RDZ is also supported by: NIH/EKS-NICHD 1 R24 #HD065688; USDOE-NIDRR #H133A080035; USAMRAA #W81XWH-11-2-0210; USAMRMC #W81XWH-08-2-0159. NR 47 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2015 VL 27 IS 3 BP 199 EP 205 DI 10.1176/appi.neuropsych.14050111 PG 7 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CR7LK UT WOS:000361531000014 PM 26222967 ER PT J AU Ohki, T Popma, JJ Angle, JF Jaff, MR Yokoi, H Piergari, GN AF Ohki, Takao Popma, Jeffrey J. Angle, John F. Jaff, Michael R. Yokoi, Hiroyoshi Piergari, Guy N. TI Durability of Secondary Outcome Measures in a Nitinol Superficial Femoral Artery Stent Trial SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Ohki, Takao] Jikei Univ, Sch Med, Minato Ku, Tokyo, Japan. [Popma, Jeffrey J.] Beth Israel Deaconess Med Ctr, Newton, MA USA. [Angle, John F.] Univ Virginia, Charlottesville, VA USA. [Jaff, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Yokoi, Hiroyoshi] Kokura Mem Hosp, Fukuoka, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA VESS17 BP 25S EP 25S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200044 ER PT J AU Suckow, BD Schanzer, A Hoel, AW Wyers, MC Marone, L Veeraswamy, RK Nolan, BW AF Suckow, Bjoern D. Schanzer, Andres Hoel, Andrew W. Wyers, Mark C. Marone, Luke Veeraswamy, Ravi K. Nolan, Brian W. TI A Novel Quality of Life Instrument for Patients with an Abdominal Aortic Aneurysm SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Suckow, Bjoern D.; Nolan, Brian W.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Lebanon, NH 03766 USA. [Schanzer, Andres] Univ Mass, Sch Med, Worcester, MA USA. [Hoel, Andrew W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Wyers, Mark C.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA. [Marone, Luke] Univ Pittsburgh, Pittsburgh, PA USA. [Veeraswamy, Ravi K.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA SS6 BP 43S EP 44S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200076 ER PT J AU Jones, DW Goodney, PP Conrad, MF Nolan, BW Rzucidlo, EM Powell, RJ Walsh, DB Cronenwett, JL Stone, DH AF Jones, Douglas W. Goodney, Philip P. Conrad, Mark F. Nolan, Brian W. Rzucidlo, Eva M. Powell, Richard J. Walsh, Daniel B. Cronenwett, Jack L. Stone, David H. TI Dual-Antiplatelet Therapy Reduces Stroke but Increases Bleeding at the Time of Carotid Endarterectomy SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Jones, Douglas W.] New York Presbyterian Hosp, New York, NY USA. [Goodney, Philip P.; Nolan, Brian W.; Rzucidlo, Eva M.; Powell, Richard J.; Walsh, Daniel B.; Cronenwett, Jack L.; Stone, David H.] Dartmouth Hitchcock, Sect Vasc Surg, Lebanon, NH USA. [Conrad, Mark F.] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA SS13 BP 48S EP 48S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200084 ER PT J AU Corey, MR Ergul, EA English, SJ Patel, VI Lancaster, RT Kwolek, CJ Cambria, RP Conrad, MF AF Corey, Michael R. Ergul, Emel A. English, Sean J. Patel, Virendra I. Lancaster, Robert T. Kwolek, Christopher J. Cambria, Richard P. Conrad, Mark F. TI The Natural History of Splanchnic Artery Aneurysms (SAAs) and Outcomes Following Operative Intervention SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Corey, Michael R.; Ergul, Emel A.; English, Sean J.; Patel, Virendra I.; Lancaster, Robert T.; Kwolek, Christopher J.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA SS24 BP 110S EP 111S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200210 ER PT J AU McGillicuddy, EA Ozaki, CK Shah, SK Belkin, M Hamdan, AH Barshes, NR Wyers, MC Nguyen, LL AF McGillicuddy, Edward A. Ozaki, C. Keith Shah, Samir K. Belkin, Michael Hamdan, Allen H. Barshes, Neal R. Wyers, Mark C. Nguyen, Louis L. TI The Impact of Vascular Surgery Wound Complications on Quality of Life SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [McGillicuddy, Edward A.; Ozaki, C. Keith; Shah, Samir K.; Belkin, Michael; Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Barshes, Neal R.] Baylor Coll Med, Missouri City, TX USA. [Hamdan, Allen H.; Wyers, Mark C.] Harvard Univ, Sch Med, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA PC56 BP 132S EP 132S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200247 ER PT J AU Judelson, DR Simons, JP Flahive, JM Patel, VI Nolan, BW Bachman, M Healey, CT Schanzer, A AF Judelson, Dejah R. Simons, Jessica P. Flahive, Julie M. Patel, Virendra I. Nolan, Brian W. Bachman, Marcos Healey, Christopher T. Schanzer, Andres TI Determinants of Follow-Up Failure in Patients Enrolled in the Vascular Study Group of New England (VSGNE) SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Judelson, Dejah R.; Simons, Jessica P.; Flahive, Julie M.; Bachman, Marcos; Schanzer, Andres] Univ Massachusetts, Sch Med, Worcester, MA USA. [Patel, Virendra I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Healey, Christopher T.] Maine Med Partners Surg Care, Portland, ME USA. [Nolan, Brian W.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA PC136 BP 154S EP 155S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200287 ER PT J AU Lau, MK Meier, JL Gasper, W Lovett, DH Velez, PM Owens, CD AF Lau, Marcos K. Meier, Joy L. Gasper, Warren Lovett, David H. Velez, Pauline M. Owens, Christopher D. TI Renal Progression in the Advanced Chronic Kidney Disease Populations: Creation of the ESRD Prediction Scorecard SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Meier, Joy L.] VA Northern Calif Hlth Care Syst, Martinez, CA USA. [Gasper, Warren; Lovett, David H.; Owens, Christopher D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Velez, Pauline M.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA RR15 BP 195S EP 195S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200360 ER PT J AU Krishnatry, R Zhukova, N Stucklin, AG Pole, J Mistry, M Ramaswamy, V Bartels, U Huang, AN Laperriere, N Dirks, P Zelcer, S Silva, M Johnston, DL Scheinemann, K Hawkins, C Bandopadhayay, P Kieran, MW Manley, PE Bouffet, E Tabori, U AF Krishnatry, Rahul Zhukova, Nataliya Stucklin, Ana Guerreiro Pole, Jason Mistry, Matthew Ramaswamy, Vijay Bartels, Ute Huang, Annie Laperriere, Normand Dirks, Peter Zelcer, Shayna Silva, Mariana Johnston, Donna L. Scheinemann, Katrin Hawkins, Cynthia Bandopadhayay, Pratiti Kieran, Mark W. Manley, Peter E. Bouffet, Eric Tabori, Uri TI RADIATION THERAPY IS ASSOCIATED WITH INCREASED LATE MORTALITY IN LONG-TERM ADULT SURVIVORS OF CHILDHOOD LOW GRADE GLIOMA: A POPULATION BASED STUDY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Krishnatry, Rahul; Zhukova, Nataliya; Stucklin, Ana Guerreiro; Mistry, Matthew; Ramaswamy, Vijay; Bartels, Ute; Huang, Annie; Laperriere, Normand; Dirks, Peter; Hawkins, Cynthia; Bouffet, Eric; Tabori, Uri] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Krishnatry, Rahul; Laperriere, Normand] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Zelcer, Shayna] London Hlth Sci Ctr, London, ON, Canada. [Silva, Mariana] Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada. [Johnston, Donna L.] CHEO Res Inst, Ottawa, ON, Canada. [Scheinemann, Katrin] McMaster Childrens Hosp, Hamilton, ON, Canada. [Bandopadhayay, Pratiti; Kieran, Mark W.; Manley, Peter E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pole, Jason] Pediat Oncol Grp Ontario, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA LG-03 BP 18 EP 19 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800073 ER PT J AU Leary, S Kilburn, L Geyer, JR Olson, JM MacDonald, T Ellison, D Kocak, M Onar, A Ermoian, R Poussaint, TY Boyett, JM Kun, L Fouladi, M AF Leary, Sarah Kilburn, Lindsay Geyer, J. Russell Olson, James M. MacDonald, Tobey Ellison, David Kocak, Mehmet Onar, Arzu Ermoian, Ralph Poussaint, Tina Young Boyett, James M. Kun, Larry Fouladi, Maryam TI FEASIBILITY OF VORINOSTAT COMBINED WITH ISOTRETINOIN AND CHEMOTHERAPY FOR YOUNG CHILDREN WITH NEWLY DIAGNOSED EMBRYONAL BRAIN TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Leary, Sarah; Geyer, J. Russell; Olson, James M.] Seattle Childrens, Seattle, WA USA. [Kilburn, Lindsay] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Ellison, David; Kocak, Mehmet; Onar, Arzu; Boyett, James M.; Kun, Larry; Fouladi, Maryam] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Leary, Sarah; Geyer, J. Russell; Olson, James M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Ermoian, Ralph] Univ Washington, Seattle, WA 98195 USA. [Poussaint, Tina Young] Dana Farber Canc Inst, Boston, MA 02115 USA. [MacDonald, Tobey] Childrens Healthcare Atlanta, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA MB-32 BP 27 EP 27 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800109 ER PT J AU Lafay-Cousin, L Chi, S Smith, A Wells, E Madden, J Margol, A Ramaswamy, V Owen, E Strother, D Dhall, G Foreman, N Packer, R Bouffet, E AF Lafay-Cousin, Lucie Chi, Susan Smith, Amy Wells, Elizabeth Madden, Jennifer Margol, Ashley Ramaswamy, Vijay Owen, Emily Strother, Douglas Dhall, Girish Foreman, Nicholas Packer, Roger Bouffet, Eric TI VERY ENCOURAGING LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOME OF YOUNG CHILDREN TREATED FOR MEDULLOBLASTOMA WITH SEQUENTIAL HIGH DOSE CHEMOTHERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Ramaswamy, Vijay; Strother, Douglas; Bouffet, Eric] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA. [Smith, Amy; Owen, Emily] Arnold Palmer Hosp Children, Orlando, FL USA. [Margol, Ashley; Dhall, Girish] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Madden, Jennifer; Foreman, Nicholas] Childrens Hosp Colorado, Denver, CO USA. [Lafay-Cousin, Lucie] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada. [Wells, Elizabeth; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA MB-35 BP 28 EP 28 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800112 ER PT J AU Vitte, J Chareyre, F Stemmer-Rachamimov, A Judkins, A Giovannini, M AF Vitte, Jeremie Chareyre, Fabrice Stemmer-Rachamimov, Anat Judkins, Alexander Giovannini, Marco TI CONDITIONAL INACTIVATION OF SMARCB1 IN P0 PERMISSIVE MOUSE CELLS GENERATES RHABDOID TUMORS IN THE PERIPHERAL NERVOUS SYSTEM AND IN THE BRAIN SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Vitte, Jeremie; Chareyre, Fabrice; Giovannini, Marco] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Mol Neurooncol & Pathol Dept, Boston, MA 02114 USA. [Stemmer-Rachamimov, Anat] Harvard Univ, Sch Med, Boston, MA USA. [Judkins, Alexander] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA. RI Vitte, Jeremie/B-9874-2017 OI Vitte, Jeremie/0000-0002-2567-7988 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA PM-02 BP 31 EP 31 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800126 ER PT J AU Hoffman, LM Geller, J Leach, J Boue, D Drissi, R Chen, L Krailo, M Panandiker, AP Chow, L Haas-Kogan, D Jogal, S Nelson, M Jakacki, R Kieran, M Cohen, K Pollack, I Gajjar, A Fouladi, M AF Hoffman, Lindsey M. Geller, James Leach, James Boue, Daniel Drissi, Rachid Chen, Lu Krailo, Mark Panandiker, Atmaram Pai Chow, Lionel Haas-Kogan, Daphne Jogal, Sachin Nelson, Marvin Jakacki, Reggie Kieran, Mark Cohen, Kenneth Pollack, Ian Gajjar, Amar Fouladi, Maryam TI A FEASIBILITY AND RANDOMIZED PHASE II STUDY OF VORINOSTAT, BEVACIZUMAB, OR TEMOZOLOMIDE DURING RADIATION FOLLOWED BY MAINTENANCE CHEMOTHERAPY IN NEWLY-DIAGNOSED PEDIATRIC HIGH-GRADE GLIOMA: CHILDREN'S ONCOLOGY GROUP STUDY ACNS0822 SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Hoffman, Lindsey M.; Geller, James; Leach, James; Drissi, Rachid; Chow, Lionel; Fouladi, Maryam] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Boue, Daniel] Dayton Childrens Hosp, Dayton, OH USA. [Chen, Lu; Krailo, Mark] Childrens Oncol Grp Stat & Data Ctr, Monrovia, CA USA. [Panandiker, Atmaram Pai; Gajjar, Amar] St Jude Childrens Hosp Med Ctr, Memphis, TN USA. [Haas-Kogan, Daphne] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jogal, Sachin] Midwest Childrens Canc Ctr, Milwaukee, WI USA. [Nelson, Marvin] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Kieran, Mark] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jakacki, Reggie; Pollack, Ian] Childrens Hosp Pittsburg, Pittsburgh, PA USA. [Cohen, Kenneth] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA TR-14 BP 39 EP 40 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800160 ER PT J AU Neuwelt, E Doolittle, N Knight, K Lindemulder, S AF Neuwelt, Edward Doolittle, Nancy Knight, Kristin Lindemulder, Susan TI USE OF IV N-ACETYLCYSTEINE IN COMBINATION WITH SODIUM THIOSULFATE FOR PREVENTION OF OTOTOXICITY IN PEDIATRIC PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Neuwelt, Edward; Doolittle, Nancy; Knight, Kristin; Lindemulder, Susan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Neuwelt, Edward] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA TR-15 BP 40 EP 40 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800161 ER PT J AU Luthra, S AF Luthra, Suvitesh TI The Scientific Foundation, Rationale and Argument for a Nonfrequentist Bayesian Analysis in Clinical Trials in Coronary Artery Disease SO HEART LUNG AND CIRCULATION LA English DT Article DE Bayesian analysis; Randomized control trials; Frequentist analysis; Coronary artery disease; Prior ID INTERNAL THORACIC ARTERY AB Randomised control trials (RCT) are considered the gold standard for the strength of evidence used in formulation of guidelines in the contemporary clinical practice. The analysis is based on the design of an experiment that analyses data collected in a future event space with no regard to past observations. It bases its conclusions on arbitrary values of significance that might not be clinically relevant or plausible. A Bayesian analysis looks at all the past evidence and observations to reach a conclusion and does not have the shortcomings of a RCT. C1 Massachusetts Gen Hosp, Cardiac Surg, Boston, MA 02114 USA. RP Luthra, S (reprint author), Massachusetts Gen Hosp, Cardiac Surg, Boston, MA 02114 USA. EM suviteshluthra@yahoo.com NR 7 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1443-9506 EI 1444-2892 J9 HEART LUNG CIRC JI Heart Lung Circ. PD JUN PY 2015 VL 24 IS 6 BP 614 EP 616 DI 10.1016/j.hlc.2014.12.002 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CR1CC UT WOS:000361059400020 PM 25648381 ER PT J AU Vaidya, A Curhan, GC Paik, JM Kronenberg, H Taylor, EN AF Vaidya, Anand Curhan, Gary C. Paik, Julie M. Kronenberg, Henry Taylor, Eric N. TI Hypertension, Antihypertensive Medications, and Risk of Incident Primary Hyperparathyroidism SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ANGIOTENSIN-ALDOSTERONE SYSTEM; CALCIUM-REGULATORY HORMONES; PLASMA PARATHYROID-HORMONE; INTIMA-MEDIA THICKNESS; LOOP DIURETIC USE; 25-HYDROXYVITAMIN D; PROSPECTIVE COHORT; BLOOD-PRESSURE; VITAMIN-D; CARDIOVASCULAR MORTALITY AB Context: Hypertension is associated with higher PTH levels, and specific antihypertensive medications may modulate PTH. Whether hypertension or the use of specific antihypertensive medications influences the risk of developing incident primary hyperparathyroidism (P-HPTH) is not known. Objective: The purpose of this study was to investigate whether a history of hypertension and the use of specific antihypertensive medications determine the risk for developing P-HPTH in a large prospective study. Design/Participants: A longitudinal prospective cohort of female nurses in the Nurses' Health Study I (n = 75 600), who did not have P-HPTH at baseline and completed a questionnaire assessment of lifetime history of P-HPTH were followed from 1986 to 2008. Most participants were white and postmenopausal. Setting: The study was a nationwide cohort study. Main Outcome Measure: Incident P-HPTH was assessed initially via questionnaire and then was confirmed by medical record review. Cox proportional hazards models were used to adjust for potential confounders. Results: We documented 347 incident cases of P-HPTH during 1 719 416 person-years of follow-up. The age-adjusted relative risk (RR) for incident P-HPTH associated with hypertension was 1.80 (95% confidence interval [CI], 1.43-2.26), and the multivariate-adjusted RR was 1.45 (95% CI, 1.10-1.91). Among participants with a history of hypertension, the use of furosemide, when compared with the use of other antihypertensive medications, was associated with increased risk for developing P-HPTH; age-adjusted RR for incident P-HPTH was 1.79 (95% CI, 1.15-2.79) and multivariate-adjusted RR was 1.71 (95% CI, 1.08-2.71). Conclusions: In a large longitudinal prospective cohort study of mostly older white women, a history of hypertension and use of furosemide were associated with a significantly higher risk of developing P-HPTH. C1 [Vaidya, Anand] Harvard Univ, Sch Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Curhan, Gary C.; Paik, Julie M.] Harvard Univ, Sch Med, Div Renal Med, Boston, MA 02115 USA. [Curhan, Gary C.; Paik, Julie M.; Taylor, Eric N.] Harvard Univ, Sch Med, Channing Div Network Med, Boston, MA 02115 USA. [Vaidya, Anand; Curhan, Gary C.; Paik, Julie M.; Taylor, Eric N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Vaidya, Anand; Curhan, Gary C.; Paik, Julie M.; Kronenberg, Henry] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA 02115 USA. [Taylor, Eric N.] Maine Med Ctr, Div Nephrol & Transplantat, Portland, ME 04102 USA. RP Vaidya, A (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. EM avaidya1@partners.org FU National Institutes of Health [UM1-CA186107, CA087969, DK099739]; National Heart, Lung, and Blood Institute of the National Institutes of Health [K23HL111771]; William Randolph Hearst Foundation; National Institute of Digestive and Diabetes and Kidney Diseases of the National Institutes of Health [K24DK091417, K23DK100447] FX This work was supported by the National Institutes of Health (Grants UM1-CA186107, CA087969, and DK099739). A.V. was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award K23HL111771) and by a William Randolph Hearst Foundation Young Investigator Award. The National Institute of Digestive and Diabetes and Kidney Diseases of the National Institutes of Health supported G.C.C. under Award K24DK091417 and J.M.P. under Award K23DK100447. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 56 TC 5 Z9 6 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2015 VL 100 IS 6 BP 2396 EP 2404 DI 10.1210/jc.2015-1619 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CQ8ET UT WOS:000360840000054 PM 25885946 ER PT J AU Caramori, ML Kim, Y Goldfine, AB Moore, JH Rich, SS Mychaleckyj, JC Kirkpatrick, D Nickerson, H Krolewski, AS Mauer, M AF Caramori, M. Luiza Kim, Youngki Goldfine, Allison B. Moore, Jason H. Rich, Stephen S. Mychaleckyj, Josyf C. Kirkpatrick, David Nickerson, Helen Krolewski, Andrzej S. Mauer, Michael TI Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CULTURED SKIN FIBROBLASTS; MESSENGER-RNA EXPRESSION; CELLULAR BASIS; SIBLING PAIRS; MEVALONATE PATHWAY; OXIDATIVE STRESS; RISK; SUSCEPTIBILITY; THERAPY; TOPHAT AB Context: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in the United States. Objective: The aim of this study was to determine whether there were skin fibroblast gene expression differences between subjects with type 1 diabetes (T1D) with or without DN. Setting: This was a cross-sectional study conducted in the University of Minnesota. Patients: Study volunteers were 100 former participants of Genetics of Kidneys in Diabetes: 40 were diabetic nephropathy (DN) Controls, normoalbuminuric after >= 15 years of T1D; and 60 were DN Cases, 25 with proteinuria and 35 with ESRD. Intervention(s): Skin fibroblasts were grown in high glucose (HG) for five passages (approximately 6 weeks). MainOutcomeMeasure(s): SF gene expression was assessed by transcriptome sequencing using the Illumina HiSeq 2000 platform. Pathway analyses tested directionally consistent group differences within the Kyoto Encyclopedia of Genes and Genomes pathways. Results: Eight pathways, all related to cell cycle and repair, were up-regulated in the DN Controls vs the DN Cases. These pathways markedly overlapped with the pathways up-regulated by HG in T1D monozygotic twins (MZT), but not in their non-T1D MZT. DN Cases showed statistical trends toward up-regulation of these pathways vs non-T1D MZT, but much less so than the DN Controls. Conclusions: Together, these data suggest that SF from T1D patients undergo epigenetic modifications resulting in increased expression of genes in healing and repair pathways. These responses, much more robust in patients protected from DN, suggest that epigenetic factors are important in DN risk. C1 [Caramori, M. Luiza; Mauer, Michael] Univ Minnesota, Dept Med & Pediat, Minneapolis, MN 55455 USA. [Kim, Youngki] Univ Minnesota, Dept Pediat & Lab Med & Pathol, Minneapolis, MN 55455 USA. [Goldfine, Allison B.; Krolewski, Andrzej S.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Moore, Jason H.] Dartmouth Coll, Perelman Sch Med, Dept Biostat & Epidemiol, Dept Genet,Inst Biomed Informat, Hanover, NH 03755 USA. [Rich, Stephen S.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA. [Mychaleckyj, Josyf C.] Univ Virginia, Dept Bioinformat & Genet, Charlottesville, VA 22908 USA. [Kirkpatrick, David] Univ Minnesota, Dept Genet, Cell Biol & Dev, Minneapolis, MN 55455 USA. [Nickerson, Helen] JDRF, New York, NY 10004 USA. RP Caramori, ML (reprint author), 420 Delaware St SE,Mayo Mail Code 101, Minneapolis, MN 55455 USA. EM caram001@umn.edu OI Nickerson, Helen/0000-0002-3382-6306 FU Juvenile Diabetes Research Foundation (JDRF) [JDRF-42-2009-755]; Pennock Professorship; JDRF Career Development Award FX This work was supported by a research grant from Juvenile Diabetes Research Foundation (JDRF) (JDRF-42-2009-755; Dr Caramori) and by funds from the Pennock Professorship (M.L.C.). M.L.C. was a recipient of a JDRF Career Development Award. NR 39 TC 5 Z9 5 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2015 VL 100 IS 6 BP E876 EP E882 DI 10.1210/jc.2014-4465 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CQ8ET UT WOS:000360840000007 PM 25871838 ER PT J AU Middelbeek, RJ Veuger, SA AF Middelbeek, Roeland J. Veuger, Stan A. TI Letter to the Editor: Re: Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Letter ID BURDEN C1 [Middelbeek, Roeland J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Middelbeek, Roeland J.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Middelbeek, Roeland J.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Veuger, Stan A.] Amer Enterprise Inst Publ Policy Res, Washington, DC 20036 USA. RP Middelbeek, RJ (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM roeland.middelbeek@joslin.harvard.edu FU NIDDK NIH HHS [T32-DK07260-038] NR 5 TC 1 Z9 1 U1 1 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2015 VL 100 IS 6 BP L52 EP L53 DI 10.1210/jc.2015-2010 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CQ8ET UT WOS:000360840000022 PM 26047084 ER PT J AU Deipolyi, AR Bailin, A Wicky, S Alansari, S Oklu, R AF Deipolyi, Amy R. Y. Bailin, Alexander Wicky, Stephan Alansari, Shehab Oklu, Rahmi TI Adrenal Vein Sampling for Conn's Syndrome: Diagnosis and Clinical Outcomes SO DIAGNOSTICS LA English DT Article DE adrenal vein sampling; primary aldosteronism; Conn's syndrome; endocrinology ID ALDOSTERONE-PRODUCING ADENOMAS; PRIMARY HYPERALDOSTERONISM; COMPUTED-TOMOGRAPHY; PREVALENCE; HYPERTENSION AB Adrenal vein sampling (AVS) is the gold standard test to determine unilateral causes of primary aldosteronism (PA). We have retrospectively characterized our experience with AVS including concordance of AVS results and imaging, and describe the approach for the PA patient in whom bilateral AVS is unsuccessful. We reviewed the medical records of 85 patients with PA and compared patients who were treated medically and surgically on pre-procedure presentation and post-treatment outcomes, and evaluated how technically unsuccessful AVS results were used in further patient management. Out of the 92 AVS performed in 85 patients, AVS was technically successful bilaterally in 58 (63%) of cases. Either unsuccessful AVS prompted a repeat AVS, or results from the contralateral side and from CT imaging were used to guide further therapy. Patients who were managed surgically with adrenalectomy had higher initial blood pressure and lower potassium levels compared with patients who were managed medically. Adrenalectomy results in significantly decreased blood pressure and normalization of potassium levels. AVS can identify surgically curable causes of PA, but can be technically challenging. When one adrenal vein fails to be cannulated, results from the contralateral vein can be useful in conjunction with imaging and clinical findings to suggest further management. C1 [Deipolyi, Amy R. Y.] NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, New York, NY 10016 USA. [Bailin, Alexander; Wicky, Stephan; Alansari, Shehab; Oklu, Rahmi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol, Boston, MA 02114 USA. RP Oklu, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Radiol, 55 Fruit St,GRB-290A, Boston, MA 02114 USA. EM amy.deipolyi@nyumc.org; bhartealex@gmail.com; stephan.wickyvandoyer@umassmemorial.org; drshehabalansari@gmail.com; roklu@mgh.harvard.edu OI Deipolyi, Amy/0000-0003-3144-386X NR 31 TC 0 Z9 0 U1 1 U2 5 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2075-4418 J9 DIAGNOSTICS JI Diagnostics PD JUN PY 2015 VL 5 IS 2 BP 254 EP 271 DI 10.3390/diagnostics5020254 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA CR1VY UT WOS:000361114500009 PM 26854152 ER PT J AU Dwojak, S Deschler, D Sargent, M Emerick, K Guadagnolo, BA Petereit, D AF Dwojak, Sunshine Deschler, Daniel Sargent, Michele Emerick, Kevin Guadagnolo, B. Ashleigh Petereit, Daniel TI Knowledge and Screening of Head and Neck Cancer Among American Indians in South Dakota SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; NORTHERN-PLAINS; ALASKA-NATIVES; THROAT CANCER; RISK; PREVALENCE; INFECTION; SURVIVAL; MOUTH AB Objectives. We established the level of awareness of risk factors and early symptoms of head and neck cancer among American Indians in South Dakota and determined whether head and neck cancer screening detected clinical findings in this population. Methods. We used the European About Face survey. We added questions about human papillomavirus, a risk factor for head and neck cancer, and demographics. Surveys were administered at 2 public events in 2011. Participants could partake in a head and neck cancer screening at the time of survey administration. Results. Of the 205 American Indians who completed the survey, 114 participated in the screening. Mean head and neck cancer knowledge scores were 26 out of 44. Level of education was the only factor that predicted higher head and neck cancer knowledge (b = 0.90; P =.01). Nine (8%) people had positive head and neck cancer screening examination results. All abnormal clinical findings were in current or past smokers (P = .06). Conclusions. There are gaps in American Indian knowledge of head and neck cancer risk factors and symptoms. Community-based head and neck cancer screening in this population is feasible and may be a way to identify early abnormal clinical findings in smokers. C1 [Dwojak, Sunshine; Deschler, Daniel; Emerick, Kevin] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Sargent, Michele; Petereit, Daniel] Rapid City Reg Hosp, John T Vucurevich Canc Care Inst, Rapid City, SD USA. [Guadagnolo, B. Ashleigh] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Dwojak, S (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM sunshine_dwojak@meei.harvard.edu FU National Institutes of Health [T32DC000020]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources) [8UL1TR000170-05]; Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [8UL1TR000170-05]; Harvard University; Native People for Cancer Control FX This work was conducted with support from National Institutes of Health (award T32DC000020); Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, award 8UL1TR000170-05); financial contributions from Harvard University and its affiliated academic health care centers; and a Native People for Cancer Control community grant. NR 27 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1155 EP 1160 DI 10.2105/AJPH.2014.302177 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800031 PM 25320895 ER PT J AU Baggett, TP Chang, YC Singer, DE Porneala, BC Gaeta, JM O'Connell, JJ Rigotti, NA AF Baggett, Travis P. Chang, Yuchiao Singer, Daniel E. Porneala, Bianca C. Gaeta, Jessie M. O'Connell, James J. Rigotti, Nancy A. TI Tobacco-, Alcohol-, and Drug-Attributable Deaths and Their Contribution to Mortality Disparities in a Cohort of Homeless Adults in Boston SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SUBSTANCE-ABUSING HOMELESS; SMOKING-CESSATION; RISK-FACTORS; CONTROLLED-TRIAL; GLOBAL BURDEN; MENTAL-HEALTH; USE DISORDERS; DISEASE; CANADA; POPULATION AB Objectives. We quantified tobacco-, alcohol-, and drug-attributable deaths and their contribution to mortality disparities among homeless adults. Methods. We ascertained causes of death among 28 033 adults seen at the Boston Health Care for the Homeless Program in 2003 to 2008. We calculated population-attributable fractions to estimate the proportion of deaths attributable to tobacco, alcohol, or drug use. We compared attributable mortality rates with those for Massachusetts adults using rate ratios and differences. Results. Of 1302 deaths, 236 were tobacco-attributable, 215 were alcohol-attributable, and 286 were drug-attributable. Fifty-two percent of deaths were attributable to any of these substances. In comparison with Massachusetts adults, tobacco-attributable mortality rates were 3 to 5 times higher, alcohol-attributable mortality rates were 6 to 10 times higher, and drug-attributable mortality rates were 8 to 17 times higher. Disparities in substance-attributable deaths accounted for 57% of the all-cause mortality gap between the homeless cohort and Massachusetts adults. Conclusions. In this clinic-based cohort of homeless adults, over half of all deaths were substance-attributable, but this did not fully explain the mortality disparity with the general population. Interventions should address both addiction and non-addiction sources of excess mortality. C1 [Baggett, Travis P.; Chang, Yuchiao; Singer, Daniel E.; Porneala, Bianca C.; O'Connell, James J.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Baggett, Travis P.; Chang, Yuchiao; Singer, Daniel E.; O'Connell, James J.; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Baggett, Travis P.; Gaeta, Jessie M.; O'Connell, James J.] Boston Hlth Care Homeless Program, Boston, MA USA. [Gaeta, Jessie M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA. RP Baggett, TP (reprint author), 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM tbaggett@mgh.harvard.edu FU National Institute on Drug Abuse at the National Institutes of Health [K23DA034008]; American Cancer Society [122269-IRG-12-070-01-IRG] FX This study was supported by the National Institute on Drug Abuse at the National Institutes of Health (award K23DA034008; to T. P. B.), and the American Cancer Society (award 122269-IRG-12-070-01-IRG; to T. P. B.). NR 91 TC 10 Z9 10 U1 7 U2 14 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1189 EP 1197 DI 10.2105/AJPH.2014.302248 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800036 PM 25521869 ER PT J AU Boyko, EJ Trone, DW Peterson, AV Jacobson, IG Littman, AJ Maynard, C Seelig, AD Crum-Cianflone, NF Bricker, JB AF Boyko, Edward J. Trone, Daniel W. Peterson, Arthur V. Jacobson, Isabel G. Littman, Alyson J. Maynard, Charles Seelig, Amber D. Crum-Cianflone, Nancy F. Bricker, Jonathan B. TI Longitudinal Investigation of Smoking Initiation and Relapse Among Younger and Older US Military Personnel SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; READJUSTMENT RATING-SCALE; DEPARTMENT-OF-DEFENSE; TOBACCO USE; CIGARETTE-SMOKING; UNITED-STATES; PROSPECTIVE COHORT; MILLENNIUM COHORT; SERVICE MEMBERS; BODY-WEIGHT AB Objectives. We examined whether military service, including deployment and combat experience, were related to smoking initiation and relapse. Methods. We included older (panel 1) and younger (panel 2) participants in the Millennium Cohort Study. Never smokers were followed for 3 to 6 years for smoking initiation, and former smokers were followed for relapse. Complementary log-log regression models estimated the relative risk (RR) of initiation and relapse by military exposure while adjusting for demographic, health, and lifestyle factors. Results. Deployment with combat experience predicted higher initiation rate (panel 1: RR = 1.44; 95% confidence interval [CI] = 1.28, 1.62; panel 2: RR = 1.26; 95% CI = 1.04, 1.54) and relapse rate (panel 1 only: RR = 1.48; 95% CI = 1.36, 1.62). Depending on the panel, previous mental health disorders, life stressors, and other military and nonmilitary characteristics independently predicted initiation and relapse. Conclusions. Deployment with combat experience and previous mental disorder may identify military service members in need of intervention to prevent smoking initiation and relapse. C1 [Boyko, Edward J.; Littman, Alyson J.; Seelig, Amber D.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Maynard, Charles] VA Eastern Colorado, VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev,VA Puget Sound Hlth Care Syst, Denver, CO USA. [Trone, Daniel W.; Jacobson, Isabel G.] Naval Hlth Res Ctr, Dept Def Ctr Deployment Hlth Res, San Diego, CA USA. [Crum-Cianflone, Nancy F.] Naval Med Ctr, San Diego, CA USA. [Peterson, Arthur V.; Bricker, Jonathan B.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,MS-152E, Seattle, WA 98108 USA. EM Edward.Boyko@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU Department of Veterans Affairs Clinical Science Research and Development Program; Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command (Fort Detrick, MD); Career Development Award from the VA Rehabilitation Research and Development Program [CDA 6982]; VA Puget Sound Health Care System FX This study was funded by a Merit Review Award from the Department of Veterans Affairs Clinical Science Research and Development Program. The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command (Fort Detrick, MD). A. J. Littman is supported by a Career Development Award from the VA Rehabilitation Research and Development Program (CDA 6982). The VA Puget Sound Health Care System provided support for C. Maynard's participation in this research. NR 38 TC 6 Z9 6 U1 2 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1220 EP 1229 DI 10.2105/AJPH.2014.302538 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800040 PM 25880953 ER PT J AU Gaskins, AJ Chiu, Y Williams, PL Toth, TL Hauser, R Chavarro, JE AF Gaskins, A. J. Chiu, Y. Williams, P. L. Toth, T. L. Hauser, R. Chavarro, J. E. TI Association between serum folate and vitamin B12 and success of assisted reproductive technologies SO HUMAN REPRODUCTION LA English DT Meeting Abstract CT 31st Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology (ESHRE) CY JUN 14-17, 2015 CL Lisbon, PORTUGAL SP European Soc Human Reprod & Embryol DE folate; ART; vitamin B12; IVF C1 [Gaskins, A. J.; Chiu, Y.; Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Williams, P. L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Toth, T. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Toth, T. L.] Harvard Univ, Sch Med, Vincent Obstet & Gynecol, Boston, MA USA. [Hauser, R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2015 VL 30 SU 1 MA P-420 BP 300 EP 300 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CP2XF UT WOS:000359740302086 ER PT J AU Abadia, L Gaskins, AJ Chiu, YH Wright, DL Hauser, R Chavarro, JE Souter, I Vanegas, J AF Abadia, L. Gaskins, A. J. Chiu, Y. H. Wright, D. L. Hauser, R. Chavarro, J. E. Souter, I. Vanegas, J. TI Pre-treatment serum vitamin D levels and fertilization rates among women undergoing assisted reproduction SO HUMAN REPRODUCTION LA English DT Meeting Abstract CT 31st Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology (ESHRE) CY JUN 14-17, 2015 CL Lisbon, PORTUGAL SP European Soc Human Reprod & Embryol DE vitamin D; reproductive techniques; assisted C1 [Abadia, L.; Chiu, Y. H.; Vanegas, J.] Harvard Univ, Sch Publ Hlth, Nutr, Boston, MA 02115 USA. [Gaskins, A. J.; Chavarro, J. E.] Harvard Univ, Sch Publ Hlth, Nutr & Epidemiol, Boston, MA 02115 USA. [Wright, D. L.; Souter, I.] Massachusetts Gen Hosp, Obstet & Gynecol, Boston, MA 02114 USA. [Hauser, R.] Harvard Univ, Sch Publ Hlth, Epidemiol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2015 VL 30 SU 1 MA P-751 BP 443 EP 443 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CP2XF UT WOS:000359740303121 ER PT J AU Keiser, NW Birket, SE Evans, IA Tyler, SR Crooke, AK Sun, XS Zhou, WH Nellis, JR Stroebele, EK Chu, KK Tearney, GJ Stevens, MJ Harris, JK Rowe, SM Engelhardt, JF AF Keiser, Nicholas W. Birket, Susan E. Evans, Idil A. Tyler, Scott R. Crooke, Adrianne K. Sun, Xingshen Zhou, Weihong Nellis, Joseph R. Stroebele, Elizabeth K. Chu, Kengyeh K. Tearney, Guillermo J. Stevens, Mark J. Harris, J. Kirk Rowe, Steven M. Engelhardt, John F. TI Defective Innate Immunity and Hyperinflammation in Newborn Cystic Fibrosis Transmembrane Conductance Regulator-Knockout Ferret Lungs SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE cystic fibrosis; cystic fibrosis transmembrane conductance regulator; animal model; innate immunity; inflammation ID AIRWAY SURFACE DEHYDRATION; PSEUDOMONAS-AERUGINOSA; SUBMUCOSAL GLANDS; PULMONARY INFLAMMATION; YOUNG-CHILDREN; HOST-DEFENSE; NITRIC-OXIDE; DISEASE; EPITHELIA; EXPRESSION AB Mucociliary clearance (MCC) and submucosal glands are major components of airway innate immunity that have impaired function in cystic fibrosis (CF). Although both of these defense systems develop postnatally in the ferret, the lungs of newborn ferrets remain sterile in the presence of a functioning cystic fibrosis transmembrane conductance regulator gene. We evaluated several components of airway innate immunity and inflammation in the early CF ferret lung. At birth, the rates of MCC did not differ between CF and non-CF animals, but the height of the airway surface liquid was significantly reduced in CF newborn ferrets. CF ferrets had impaired MCC after 7 days of age, despite normal rates of ciliogenesis. Only non-CF ferrets eradicated Pseudomonas directly introduced into the lung after birth, whereas both genotypes could eradicate Staphylococcus. CF bronchoalveolar lavage fluid (BALF) had significantly lower antimicrobial activity selectively against Pseudomonas than non-CF BALF, which was insensitive to changes in pH and bicarbonate. Liquid chromatography-tandem mass spectrometry and cytokine analysis of BALF from sterile Caesarean-sectioned and nonsterile naturally born animals demonstrated CF-associated disturbances in IL-8, TNF-alpha, and IL-beta, and pathways that control immunity and inflammation, including the complement system, macrophage functions, mammalian target of rapamycin signaling, and eukaryotic initiation factor 2 signaling. Interestingly, during the birth transition, IL-8 was selectively induced in CF BALF, despite no genotypic difference in bacterial load shortly after birth. These results suggest that newborn CF ferrets have defects in both innate immunity and inflammatory signaling that may be important in the early onset and progression of lung disease in these animals. C1 [Keiser, Nicholas W.; Evans, Idil A.; Tyler, Scott R.; Crooke, Adrianne K.; Sun, Xingshen; Zhou, Weihong; Nellis, Joseph R.; Stroebele, Elizabeth K.; Engelhardt, John F.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, Iowa City, IA 52242 USA. [Birket, Susan E.; Rowe, Steven M.] Univ Alabama Birmingham, Sch Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Chu, Kengyeh K.; Tearney, Guillermo J.; Stevens, Mark J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Stevens, Mark J.; Harris, J. Kirk] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO USA. RP Engelhardt, JF (reprint author), Univ Iowa, Dept Anat & Cell Biol, Ctr Gene Therapy, Roy J Carver Chair Mol Med, Room 1-111 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA. EM john-engelhardt@uiowa.edu FU National Institutes of Health [DK047967, HL108902, HL1116213]; University of Iowa Center for Gene Therapy grant [DK054759]; University of Alabama Cystic Fibrosis Translational Core Center grant [DK072482]; Roy J Carver Chair in Molecular Medicine; Cystic Fibrosis Foundation [ROWE10XX0, TEARNE12XX0] FX This work was supported by National Institutes of Health grants DK047967 and HL108902 (J.F.E.) and HL1116213 (S.M.R. and G.J.T.), University of Iowa Center for Gene Therapy grant DK054759, University of Alabama Cystic Fibrosis Translational Core Center grant DK072482, the Roy J Carver Chair in Molecular Medicine (J.F.E.), and Cystic Fibrosis Foundation grants ROWE10XX0 (S.M.R.) and TEARNE12XX0 (G.J.T.). Mass spectrometry analysis was performed in the Roy J. Carver Charitable Trust-supported CCOM Proteomics Facility at the University of Iowa. NR 50 TC 15 Z9 15 U1 1 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD JUN PY 2015 VL 52 IS 6 BP 683 EP 694 DI 10.1165/rcmb.2014-0250OC PG 12 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA CQ2YI UT WOS:000360468100004 PM 25317669 ER PT J AU Rosenkrantz, AB Harisinghani, M AF Rosenkrantz, Andrew B. Harisinghani, Mukesh TI Metrics for Original Research Articles in the AJR: From First Submission to Final Publication SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE journalism; publication; radiology research ID 10 PRINCIPLES; MANUSCRIPT; JOURNALS; MEDIA AB OBJECTIVE. The objective of our study was to evaluate manuscript metrics pertaining to AJR submissions, assessing the pathway from manuscript submission to publication, including the reviewer allocation time, decisions rendered, timing of decisions rendered, and time to publication. MATERIALS AND METHODS. Six hundred ninety-six unsolicited Original Research manuscripts submitted to the AJR between July 1, 2012, and December 21, 2012, were included in this retrospective analysis. Metrics pertaining to manuscripts' decision status and associated timelines were extracted by journal editorial staff and assessed using standard summary statistics. RESULTS. For new submissions, decisions rendered were as follows: Accept, 0.3%; Minor Revision, 8.5%; Major Revision, 19.7%; Reject, 65.1%; and Reject Without Review, 6.5%. For first and second resubmissions, 40.0-55.2% of manuscripts representing a Major Revision and 91.5-94.7% of manuscripts representing a Minor Revision were accepted; 100% of manuscripts undergoing a third resubmission were accepted; 98.3% and 84.7% of manuscripts receiving at first submission a decision of Minor Revision and Major Revision, respectively, ultimately achieved acceptance. The time (mean +/- SD) to review a new submission was 30.5 +/- 43.1 days (Accept), 42.7 +/- 27.4 days (Minor Revision), 39.4 +/- 17.6 days (Major Revision), and 40.2 +/- 20.3 days (Reject) and decreased with each subsequent resubmission to 6.3 +/- 6.3 days (Accept) for third resubmissions. The mean days for authors to submit a first resubmission was 21.1 +/- 15.3 days (Minor Revision) and 73.7 +/- 65.1 days (Major Revision) and decreased with each subsequent resubmission to 9.8 +/- 11.3 days (Minor Revision) and 27.0 +/- 0.0 days (Major Revision) for third resubmissions. The mean time from acceptance to publication was 242.5 +/- 47.5 days. CONCLUSION. The observed metrics may provide valuable insights for authors and for AJR editorial staff in ongoing efforts to shorten turnaround times from manuscript submission to publication. C1 [Rosenkrantz, Andrew B.] NYU Langone, Med Ctr, Dept Radiol, Ctr Biomed Imaging,Sch Med, New York, NY 10016 USA. [Harisinghani, Mukesh] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Rosenkrantz, AB (reprint author), NYU Langone, Med Ctr, Dept Radiol, Ctr Biomed Imaging,Sch Med, 660 First Ave,3rd Fl, New York, NY 10016 USA. EM andrew.rosenkrantz@nyumc.org NR 21 TC 5 Z9 5 U1 0 U2 2 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP 1152 EP 1156 DI 10.2214/AJR.14.13944 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100024 PM 26001223 ER PT J AU Godwin, BD Drake, FT Simianu, VV Shriki, JE Hippe, DS Dighe, M Bastawrous, S Cuevas, C Flum, D Bhargava, P AF Godwin, Benjamin D. Drake, Frederick T. Simianu, Vlad V. Shriki, Jabi E. Hippe, Daniel S. Dighe, Manjiri Bastawrous, Sarah Cuevas, Carlos Flum, David Bhargava, Puneet TI A Novel Reporting System to Improve Accuracy in Appendicitis Imaging SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE appendectomy; appendicitis; CT; standardized reporting ID LOWER QUADRANT PAIN; SUSPECTED ACUTE APPENDICITIS; COMPUTED-TOMOGRAPHY; HELICAL CT; NEGATIVE APPENDECTOMY; CLINICAL-OUTCOMES; DIAGNOSIS; CONTRAST; PERFORMANCE; PATIENT AB OBJECTIVE. The purpose of this study was to ascertain if standardized radiologic reporting for appendicitis imaging increases diagnostic accuracy. MATERIALS AND METHODS. We developed a standardized appendicitis reporting system that includes objective imaging findings common in appendicitis and a certainty score ranging from 1 (definitely not appendicitis) through 5 (definitely appendicitis). Four radiologists retrospectively reviewed the preoperative CT scans of 96 appendectomy patients using our reporting system. The presence of appendicitis-specific imaging findings and certainty scores were compared with final pathology. These comparisons were summarized using odds ratios (ORs) and the AUC. RESULTS. The appendix was visualized on CT in 89 patients, of whom 71 (80%) had pathologically proven appendicitis. Imaging findings associated with appendicitis included appendiceal diameter (odds ratio [OR] = 14 [> 10 vs < 6 mm]; p = 0.002), periappendiceal fat stranding (OR = 8.9; p < 0.001), and appendiceal mucosal hyperenhancement (OR = 8.7; p < 0.001). Of 35 patients whose initial clinical findings were reported as indeterminate, 28 (80%) had appendicitis. In this initially indeterminate group, using the standardized reporting system, radiologists assigned higher certainty scores (4 or 5) in 21 of the 28 patients with appendicitis (75%) and lower scores (1 or 2) in five of the seven patients without appendicitis (71%) (AUC = 0.90; p = 0.001). CONCLUSION. Standardized reporting and grading of objective imaging findings correlated well with postoperative pathology and may decrease the number of CT findings reported as indeterminate for appendicitis. Prospective evaluation of this reporting system on a cohort of patients with clinically suspected appendicitis is currently under way. C1 [Godwin, Benjamin D.; Shriki, Jabi E.; Hippe, Daniel S.; Dighe, Manjiri; Bastawrous, Sarah; Cuevas, Carlos; Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Drake, Frederick T.; Simianu, Vlad V.; Flum, David] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Shriki, Jabi E.; Bastawrous, Sarah] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,UW Mailbox 357115, Seattle, WA 98195 USA. EM bhargp@uw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases training grant [5T32DK070555] FX V. V. Simianu and F. T. Drake are supported by a National Institute of Diabetes and Digestive and Kidney Diseases training grant (5T32DK070555). The Surgical Care and Outcomes Assessment Program (SCOAP) is a Coordinated Quality Improvement Program of the Foundation for Health Care Quality (FHCQ). NR 38 TC 1 Z9 1 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP 1212 EP 1219 DI 10.2214/AJR.14.13512 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100033 PM 26001230 ER PT J AU Lowry, KP Turan, EA Eisenberg, J Kong, CY Barnes, JA Pandharipande, PV AF Lowry, Kathryn P. Turan, Ekin A. Eisenberg, Jonathan Kong, Chung Y. Barnes, Jeffrey A. Pandharipande, Pari Vijay TI Projected Effects of Radiation-Induced Cancers on Life Expectancy in Patients Undergoing CT Surveillance for Limited-Stage Hodgkin Lymphoma: A Markov Model SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE CT; decision analysis; Hodgkin lymphoma; population surveillance; radiation-induced neoplasms ID AGGRESSIVE NON-HODGKIN; ROUTINE FOLLOW-UP; CONVENIENT APPROXIMATION; RISK; TOMOGRAPHY; RELAPSE; CHILDHOOD; ONCOLOGY; DISEASE; UPDATE AB OBJECTIVE. Patients with limited-stage Hodgkin lymphoma (HL) undergo frequent posttreatment surveillance CT examinations, raising concerns about the cumulative magnitude of radiation exposure. The purpose of this study was to project radiation-induced cancer risks relative to competing risks of HL and account for the differential timing of each. MATERIALS AND METHODS. We adapted a previously developed Markov model to project lifetime mortality risks and life expectancy losses due to HL versus radiation-induced cancers in HL patients undergoing surveillance CT. In the base case, we modeled 35-year-old men and women undergoing seven CT examinations of the chest, abdomen, and pelvis over 5 years. Radiation-induced cancer risks and deaths for 17 organ systems were modeled using an organ-specific approach, accounting for specific anatomy exposed at CT. Cohorts of 20-, 50-, and 65-year-old men and women were evaluated in secondary analyses. Markov chain Monte Carlo methods were used to estimate the uncertainty of radiation risk projections. RESULTS. For 35-year-old adults, we projected 3324/100,000 (men) and 3345/100,000 (women) deaths from recurrent lymphoma and 245/100,000 (men, 95% uncertainty interval [UI]: 121-369) and 317/100,000 (women, 95% UI: 202-432) radiation-induced cancer deaths. Discrepancies in life expectancy losses between HL (428 days in men, 482 days in women) and radiation-induced cancers (11.6 days in men, [95% UI: 5.7-17.5], 15.6 days in women [95% UI: 9.8-21.4]) were proportionately greater because of the delayed timing of radiation-induced cancers relative to recurrent HL. Deaths and life expectancy losses from radiation-induced cancers were highest in the youngest cohorts. CONCLUSION. Given the low rate of radiation-induced cancer deaths associated with CT surveillance, modest CT benefits would justify its use in patients with limited-stage HL. C1 [Lowry, Kathryn P.; Turan, Ekin A.; Eisenberg, Jonathan; Kong, Chung Y.; Pandharipande, Pari Vijay] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Lowry, Kathryn P.; Pandharipande, Pari Vijay] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Barnes, Jeffrey A.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. RP Pandharipande, PV (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Fl, Boston, MA 02114 USA. EM pari@mgh-ita.org FU Medical Imaging and Technology Alliance; National Cancer Institute [K07CA133097, K25CA133141] FX P. V. Pandharipande receives research funding from the Medical Imaging and Technology Alliance for unrelated research. This research was supported in part by awards to C. Y. Kong (K25CA133141) and P. V. Pandharipande (K07CA133097) from the National Cancer Institute. The research content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. NR 33 TC 1 Z9 1 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP 1228 EP 1233 DI 10.2214/AJR.14.13287 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100035 PM 26001232 ER PT J AU Jaramillo, D Bedoya, MA Wang, DJ Pena, AH Delgado, J Jaimes, C Ho-Fung, V Kaplan, P AF Jaramillo, Diego Bedoya, Maria A. Wang, Dah-Jyuu Pena, Andres H. Delgado, Jorge Jaimes, Camilo Ho-Fung, Victor Kaplan, Paige TI Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE bone marrow; Gaucher disease; MRI; MR spectroscopy ID LOCALIZED H-1 SPECTROSCOPY; ENZYME REPLACEMENT THERAPY; SKELETAL INVOLVEMENT; FAT FRACTION; BURDEN SCORE; EXPERIENCE; CHILDREN AB OBJECTIVE. The objective of our study was to use proton MR spectroscopy (MRS) to quantitatively evaluate bone marrow infiltration by measuring the fat fraction (FF) and to compare the FF with semiquantitative bone marrow MRI scores and clinical status in children treated for type 1 Gaucher disease (GD). SUBJECTS AND METHODS. Over a 2-year period, we prospectively evaluated 10 treated GD patients (six males, four females; median age, 15.1 years) and 10 healthy agematched control subjects (five males, five females; median age, 15.3 years) using 3-T proton MRS of L5 and the femoral neck. Water and lipid AUCs were measured to calculate the FF. Two blinded pediatric musculoskeletal radiologists performed a semiquantitative analysis of the conventional MR images using the bone marrow burden score and modified Spanish MRI score. We evaluated symptoms, spleen and liver volumes, platelet levels, hemoglobin levels, and bone complications. RESULTS. In the femur, the FF was higher in the control subjects (median, 0.71) than the GD patients (0.54) (p = 0.02). In L5, the difference in FF-higher FF in control subjects (0.37) than in GD patients (0.26)-was not significant (p = 0.16). In both groups and both regions, the FF increased with patient age (p < 0.02). Semiquantitative scores showed no differences between control subjects and treated GD patients (p > 0.11). Eight of 10 GD patients were asymptomatic and two had chronic bone pain. The median age of patients at symptom onset was 4.0 years, the median age of patients at the initiation of enzyme replacement therapy was 4.3 years, and the median treatment duration was 10.2 years. Hemoglobin level, platelet count, and liver volume at MRI were normal. Mean pretreatment spleen volume (15.4-fold above normal) decreased to 2.8-fold above normal at the time of MRI (p = 0.01). CONCLUSION. Proton MRS detected FF differences that were undetectable using conventional MRI; for that reason, proton MRS can be used to optimize treatment of GD patients. C1 [Jaramillo, Diego; Bedoya, Maria A.; Wang, Dah-Jyuu; Delgado, Jorge; Ho-Fung, Victor] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA. [Jaramillo, Diego; Ho-Fung, Victor] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Pena, Andres H.] SUNY Stony Brook, Univ Hosp, Dept Radiol, Stony Brook, NY 11794 USA. [Jaimes, Camilo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Kaplan, Paige] Childrens Hosp Philadelphia, Sect Metab Dis, Philadelphia, PA 19104 USA. [Kaplan, Paige] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Jaramillo, D (reprint author), Childrens Hosp Philadelphia, Dept Radiol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA. EM jaramillo@email.chop.edu FU Genzyme Corporation, Sanofi Company; Genzyme FX D. Jaramillo has received a research grant from Genzyme Corporation, a Sanofi Company, to enable this pilot study to be done. P. Kaplan is a member of the Advisory Board for Gaucher Disease and Mucopolysaccharidosis, which is supported by Genzyme; she has received honoraria in this capacity and for giving lectures, which have been independently prepared. NR 22 TC 2 Z9 2 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP 1296 EP 1302 DI 10.2214/AJR.14.13563 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100044 PM 26001241 ER PT J AU Fairchild, A Tirumani, SH Rosenthal, MH Howard, SA Krajewski, KM Nishino, M Shinagare, AB Jagannathan, JP Ramaiya, NH AF Fairchild, Alexandra Tirumani, Sree Harsha Rosenthal, Michael H. Howard, Stephanie A. Krajewski, Katherine M. Nishino, Mizuki Shinagare, Atul B. Jagannathan, Jyothi P. Ramaiya, Nikhil H. TI Hormonal Therapy in Oncology: A Primer for the Radiologist SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Review DE aromatase inhibitors; corticosteroids; hormonal therapy; imaging; somatostatin; tamoxifen ID GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RECEIVING ADJUVANT LETROZOLE; ANDROGEN DEPRIVATION THERAPY; RESISTANT PROSTATE-CANCER; METASTATIC BREAST-CANCER; POSTMENOPAUSAL WOMEN; PHASE-II; PNEUMATOSIS-INTESTINALIS; AGGRESSIVE ANGIOMYXOMA; NEUROENDOCRINE TUMORS AB OBJECTIVE. The purpose of this article is to provide a comprehensive imaging review of the common hormonal therapies used in oncology and the side effects associated with them. CONCLUSION. Commonly used hormones in oncology include corticosteroids, somatostatin analogues, progestins, gonadotropin-releasing hormone agonists and antagonists, antiandrogens, aromatase inhibitors, and selective estrogen receptor modulators. Familiarity with these hormones and their side effects can help radiologists to be vigilant for the side effects and complications of these agents. C1 [Fairchild, Alexandra; Tirumani, Sree Harsha; Rosenthal, Michael H.; Howard, Stephanie A.; Krajewski, Katherine M.; Nishino, Mizuki; Shinagare, Atul B.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA. [Tirumani, Sree Harsha; Rosenthal, Michael H.; Howard, Stephanie A.; Krajewski, Katherine M.; Nishino, Mizuki; Shinagare, Atul B.; Jagannathan, Jyothi P.; Ramaiya, Nikhil H.] Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, Boston, MA 02215 USA. RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Sreeharsha_Tirumani@dfci.harvard.edu NR 64 TC 0 Z9 0 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP W620 EP W630 DI 10.2214/AJR.14.13604 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100002 PM 26001251 ER PT J AU Ho, ML Juliano, A Eisenberg, RL Moonis, G AF Ho, Mai-Lan Juliano, Amy Eisenberg, Ronald L. Moonis, Gul TI Anatomy and Pathology of the Facial Nerve SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Editorial Material DE cranial nerve VII; facial nerve C1 [Ho, Mai-Lan; Eisenberg, Ronald L.] Harvard Univ, Sch Med, Dept Radiol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Juliano, Amy] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02215 USA. [Moonis, Gul] Columbia Univ, Med Ctr, Dept Radiol, Boston, MA USA. RP Eisenberg, RL (reprint author), Harvard Univ, Sch Med, Dept Radiol, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA. EM rleisenb@bidmc.harvard.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP W612 EP W619 DI 10.2214/AJR.14.13444 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100001 PM 26001250 ER PT J AU Niell, BL Kattapuram, T Halpern, EF Salazar, GM Penzias, A Bonk, SS Forde, JC Hayden, E Sande, M Minehart, RD Gordon, JA AF Niell, Bethany L. Kattapuram, Taj Halpern, Elkan F. Salazar, Gloria M. Penzias, Alexandra Bonk, Shawn S. Forde, Joanne C. Hayden, Emily Sande, Margaret Minehart, Rebecca D. Gordon, James A. TI Prospective Analysis of an Interprofessional Team Training Program Using High-Fidelity Simulation of Contrast Reactions SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE contrast reactions; education; interprofessional; simulation; team training ID CRISIS RESOURCE-MANAGEMENT; OPERATING-ROOM; RADIOLOGY RESIDENTS; MEDICAL-EDUCATION; CARDIAC-SURGERY; PATIENT-CARE; RESUSCITATION; EMERGENCIES; COMMUNICATION; PERFORMANCE AB OBJECTIVE. Successful management of a contrast reaction requires prompt recognition and treatment and effective team dynamics among radiologists, technologists, and nurses. A radiology department implemented a simulation program in which teams of nurses, technologists, and physicians managed simulated contrast reactions. The purpose of this study was to evaluate whether simulation improved the participants' abilities to manage a contrast reaction and work in a team during an emergency. SUBJECTS AND METHODS. Physicians, nurses, and technologists worked in interprofessional teams to manage two high-fidelity simulated adverse contrast reactions. Participants completed surveys before and after the simulation that included knowledge-based questions about the appropriate management of contrast reactions. Surveys also included questions for assessing participants' perceptions of their ability to manage adverse contrast reactions, measured with a 6-point Likert scale. Before and after comparisons were made with the McNemar test with a Bonferroni correction requiring p <= 0.003 for significance. For the other analyses, p <= 0.05 was considered significant. RESULTS. After completion of the simulation exercises, participants had significant improvement in knowledge (p < 0.001). After the simulation, participants reported significant improvement in their ability to manage an anaphylactoid reaction and their ability to work in a team (p < 0.00001). Participants requested repeat simulation exercises every 6-12 months. CONCLUSION. Simulation exercises improved the self-reported ability of radiology personnel to manage contrast reactions and work in a team during an emergency. Simulation should be incorporated into future educational initiatives to improve patient safety in radiology practices. C1 [Niell, Bethany L.; Kattapuram, Taj; Halpern, Elkan F.; Salazar, Gloria M.; Penzias, Alexandra; Bonk, Shawn S.; Forde, Joanne C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Niell, Bethany L.; Hayden, Emily; Sande, Margaret; Minehart, Rebecca D.; Gordon, James A.] Massachusetts Gen Hosp, MGH Learning Lab, Boston, MA 02114 USA. [Niell, Bethany L.] Massachusetts Gen Hosp, Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA. [Halpern, Elkan F.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Hayden, Emily; Sande, Margaret; Gordon, James A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med,Div Med Simulat, Boston, MA USA. [Minehart, Rebecca D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Niell, BL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. EM bniell@partners.org NR 32 TC 4 Z9 4 U1 3 U2 4 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP W670 EP W676 DI 10.2214/AJR.14.13778 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100007 PM 26001255 ER PT J AU Rivera-Barrios, AE Brown, S Reid, CM Hassanein, AH Coimbra, R Dobke, M Herrera, FA AF Rivera-Barrios, Angel E. Brown, Satara Reid, Christopher M. Hassanein, Aladdin H. Coimbra, Raul Dobke, Marek Herrera, Fernando A., Jr. TI Craniofacial Fracture Patterns in All Terrain Vehicle Injuries SO ANNALS OF PLASTIC SURGERY LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the South6eastern-Society-of-Plastic-and-Reconstructive-Surgeons CY JUN 08-12, 2014 CL Nassau, BAHAMAS SP SE Soc Plast & Reconstruct Surg ID ACCIDENTS; CHILDREN AB Background A multicenter, retrospective study was conducted to determine the frequency and distribution of craniofacial fractures sustained from all terrain vehicle (ATV) accidents. Methods Medical records of all patients presenting to 2 trauma centers with ATV-related craniofacial trauma from 2001 to 2013 were reviewed. Patient notes and radiographic images were analyzed for detailed craniofacial injury data. The identified fractures were classified as: frontal/skullbase, naso-orbital, maxilla/zygoma, and mandible. In addition, patient demographic information, length of stay, airway status, intensive care unit stay, Glasgow coma scale, use of safety equipment, associated traumatic brain injury, and surgical intervention were compiled. Results One hundred fifty-six patients with craniofacial fractures secondary to ATV accidents presented from 2001 to 2013. The incidence of craniofacial fractures found in patients with ATV injuries was 12.2%. Sixty-one patients (39.1%) suffered frontal/skullbase fractures, 98 (62.8%) naso-orbital fractures, 62 (39.7%) maxillary/zygoma fractures, and 35 (22.4%) mandibular fractures. Forty-one patients (26.3%) required surgical intervention to correct their craniofacial injuries. Conclusions The most common craniofacial fractures experienced in ATV injuries are naso-orbital fractures. The correlation of nonuse of safety equipment and associated traumatic brain injuries displays the importance of using helmets when operating ATVs. Future studies can be conducted examining ATV-related upper extremity injuries, among others. C1 [Rivera-Barrios, Angel E.; Brown, Satara; Reid, Christopher M.; Hassanein, Aladdin H.; Coimbra, Raul; Dobke, Marek; Herrera, Fernando A., Jr.] Med Univ S Carolina, Ralph Johnson VA Med Ctr, Charleston, SC 29425 USA. [Rivera-Barrios, Angel E.; Brown, Satara; Reid, Christopher M.; Hassanein, Aladdin H.; Coimbra, Raul; Dobke, Marek; Herrera, Fernando A., Jr.] Univ Calif San Diego, San Diego, CA 92103 USA. RP Herrera, FA (reprint author), Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. EM herreraf@musc.edu NR 10 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-7043 EI 1536-3708 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD JUN PY 2015 VL 74 SU 4 BP S229 EP S230 DI 10.1097/SAP.0000000000000445 PG 2 WC Surgery SC Surgery GA CQ4IC UT WOS:000360567200011 PM 25695451 ER PT J AU Cadavid, D Auwaerter, P Rumbaugh, J Gelderblom, H AF Cadavid, D. Auwaerter, P. Rumbaugh, J. Gelderblom, H. TI TREATMENT FOR THE NEUROLOGICAL COMPLICATIONS OF LYME DISEASE - A COCHRANE DATABASE SYSTEMATIC REVIEW SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Biennial Meeting of the Peripheral-Nerve-Society CY JUN 27-JUL 02, 2015 CL Quebec, CANADA SP Peripheral Nerve Soc C1 [Cadavid, D.] Biogen Idec Inc, Neurol Clin Dev, Cambridge, MA USA. [Cadavid, D.] Massachusetts Gen Hosp, Charlestown, MA USA. [Auwaerter, P.; Rumbaugh, J.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Gelderblom, H.] Natl Assoc Statutory Hlth Insurance Funds, Dept Med, Berlin, Germany. NR 0 TC 0 Z9 0 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 EI 1529-8027 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD JUN PY 2015 VL 20 IS 2 BP 110 EP 111 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CP9LC UT WOS:000360214600064 ER PT J AU Fridman, V Sadjadi, R Bundy, B Sillau, S Bacon, C Burns, J Day, J Feely, S Finkel, RS Grider, T Kirk, V Herrmann, DN Laura, M Li, J Lloyd, T Muntoni, F Pareyson, D Ramchandren, S Reilly, MM Scherer, S Shy, R Sumner, C Yum, S Zuchner, S Shy, ME AF Fridman, V Sadjadi, R. Bundy, B. Sillau, S. Bacon, C. Burns, J. Day, J. Feely, S. Finkel, R. S. Grider, T. Kirk, V Herrmann, D. N. Laura, M. Li, J. Lloyd, T. Muntoni, F. Pareyson, D. Ramchandren, S. Reilly, M. M. Scherer, S. Shy, R. Sumner, C. Yum, S. Zuchner, S. Shy, M. E. CA Inherited Neuropathies Consortium TI DISEASE PROGRESSION IN HEREDITARY NEUROPATHY: A LONGITUDINAL ANALYSIS OF DATA CONTAINED WITH THE INHERITED NEUROPATHIES CONSORTIUM NATURAL HISTORY STUDY SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Biennial Meeting of the Peripheral-Nerve-Society CY JUN 27-JUL 02, 2015 CL Quebec, CANADA SP Peripheral Nerve Soc C1 [Fridman, V] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Sadjadi, R.] Univ Virginia Hosp, Dept Neurol, Charlottesville, VA USA. [Bundy, B.; Kirk, V] Univ S Florida, Epidemiol Ctr, Tampa, FL USA. [Sillau, S.] Univ Colorado Hosp, Dept Neurol, Denver, CO USA. [Bacon, C.; Feely, S.; Grider, T.; Shy, R.; Shy, M. E.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA. [Burns, J.] Univ Sydney, Sydney, NSW 2006, Australia. [Burns, J.] Childrens Hosp, Sydney, NSW, Australia. [Day, J.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA. [Finkel, R. S.] Nemours Childrens Hosp, Div Neurol, Orlando, FL USA. [Herrmann, D. N.] Univ Rochester, Dept Neurol, Rochester, NY USA. [Laura, M.; Reilly, M. M.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England. [Li, J.] Vanderbilt Univ, Dept Neurol, Nashville, TN 37235 USA. [Lloyd, T.; Sumner, C.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD USA. [Muntoni, F.] UCL Inst Child Hlth, London, England. [Muntoni, F.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Pareyson, D.] IRCCS Fdn, Carlo Besta Neurol Inst, Milan, Italy. [Ramchandren, S.; Shy, R.; Shy, M. E.] Wayne State Univ, Dept Neurol, Detroit, MI USA. [Scherer, S.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Yum, S.] Childrens Hosp Philadelphia, Neuromuscular Program, Philadelphia, PA 19104 USA. [Zuchner, S.] Univ Miami, Ctr Human Mol Genom, Miami, FL USA. [Ramchandren, S.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 EI 1529-8027 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD JUN PY 2015 VL 20 IS 2 BP 143 EP 144 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CP9LC UT WOS:000360214600146 ER PT J AU Lang, M Treister, R Oaklander, AL AF Lang, M. Treister, R. Oaklander, A. L. TI COST/BENEFIT ANALYSIS OF BLOOD TESTS FOR CAUSES OF "IDIOPATHIC" SMALL-FIBER POLYNEUROPATHY (SFPN) SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Biennial Meeting of the Peripheral-Nerve-Society CY JUN 27-JUL 02, 2015 CL Quebec, CANADA SP Peripheral Nerve Soc C1 [Lang, M.; Treister, R.; Oaklander, A. L.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Oaklander, A. L.] Massachusetts Gen Hosp, Dept Pathol Neuropathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 EI 1529-8027 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD JUN PY 2015 VL 20 IS 2 BP 178 EP 178 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CP9LC UT WOS:000360214600237 ER PT J AU Treister, R O'Neil, K Liu, X Lang, M Oaklander, AL AF Treister, R. O'Neil, K. Liu, X. Lang, M. Oaklander, A. L. TI FIRST EVALUATION OF EFFICACY AND SAFETY OF IMMUNOGLOBULIN TREATMENT OF DYSIMMUNE SMALL-FIBER PREDOMINANT POLYNEUROPATHY (SFPN) SO JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM LA English DT Meeting Abstract CT Biennial Meeting of the Peripheral-Nerve-Society CY JUN 27-JUL 02, 2015 CL Quebec, CANADA SP Peripheral Nerve Soc C1 [Treister, R.; O'Neil, K.; Liu, X.; Lang, M.; Oaklander, A. L.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Liu, X.] Shanxi Med Univ, Dayi Hosp, Dept Neurol, Taiyuan, Shanxi, Peoples R China. [Oaklander, A. L.] Massachusetts Gen Hosp, Dept Pathol Neuropathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1085-9489 EI 1529-8027 J9 J PERIPHER NERV SYST JI J. Peripher. Nerv. Syst. PD JUN PY 2015 VL 20 IS 2 BP 239 EP 239 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CP9LC UT WOS:000360214600393 ER PT J AU Rohatgi, S Ramaiya, NH Jagannathan, JP Howard, SA Shinagare, AB Krajewski, KM AF Rohatgi, Saurabh Ramaiya, Nikhil H. Jagannathan, Jyothi P. Howard, Stephanie A. Shinagare, Atul B. Krajewski, Katherine M. TI Metastatic Chordoma: Report of the Two Cases and Review of the Literature SO EURASIAN JOURNAL OF MEDICINE LA English DT Review DE Chordoma; metastasis; imatinib; positron emission tomography ID NOTOCHORDAL CELL TUMORS; SACROCOCCYGEAL CHORDOMA; MOBILE SPINE; BENIGN; EXPERIENCE; MIMICKING; DISEASE; LESION AB Chordomas are rare malignant bone tumours with a predilection for the axial skeleton, especially the sacrum and skull base. Median survival in patients with metastatic disease is usually dismal. Treatment is challenging due to the propensity for local recurrence, metastatic disease as well as lack of clear consensus regarding the optimal management. Our case report highlights two cases of sacral chordoma with locally recurrent and widespread metastatic disease, stable on molecular targeted therapy. C1 [Rohatgi, Saurabh; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.; Howard, Stephanie A.; Shinagare, Atul B.; Krajewski, Katherine M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Radiol, Boston, MA 02115 USA. RP Rohatgi, S (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA. EM sarohatgi@gmail.com NR 26 TC 1 Z9 1 U1 0 U2 1 PU AVES YAYINCILIK, IBRAHIM KARA PI ISTANBUL PA KIZILELMA CAD 5-3, FINDIKZADE, ISTANBUL, 34096, TURKEY SN 1308-8734 EI 1308-8742 J9 EURASIAN J MED JI Eurasian J. Med. PD JUN PY 2015 VL 47 IS 2 BP 151 EP 154 DI 10.5152/eurasianjmed.2015.52 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CQ1OC UT WOS:000360366100013 PM 26180502 ER PT J AU Yeo, KK Armstrong, EJ Soni, K Waldo, SW Patel, M Reeves, R MacGregor, JS Low, RI Shunk, KA Mahmud, E Rogers, JH AF Yeo, Khung Keong Armstrong, Ehrin J. Soni, Krishan Waldo, Stephen W. Patel, Mitul Reeves, Ryan MacGregor, John S. Low, Reginald I. Shunk, Kendrick A. Mahmud, Ehtisham Rogers, Jason H. TI Long-term outcomes of angiographically confirmed coronary stent thrombosis: results from a multicentre California registry SO EUROINTERVENTION LA English DT Article DE coronary artery disease; risk factors; stent thrombosis ID INTRAVASCULAR ULTRASOUND; CLINICAL PRESENTATION; ELUTING STENTS; CLOPIDOGREL AB Aims: Limited data exist on long-term outcomes of patients with stent thrombosis (ST). Our aim was to describe the long-term outcomes after angiographically confirmed ST. Methods and results: In this multicentre registry, consecutive cases of definite ST were identified between 2005 and 2013. Clinical and procedural characteristics, in-hospital outcomes and long-term survival up to five years were compared between those with and those without adverse cardiovascular and cerebrovascular events (MACCE), defined as all-cause mortality, myocardial infarction and stroke. Two hundred and twenty-one patients with 239 stent thrombosis events were identified. Patients who developed MACCE were older, less likely to be men, and less likely to have hypertension. Angiographic characteristics were similar. Patients who had a MACCE event showed a trend towards a lower likelihood of procedural success (86% vs. 91%, p=0.05). MACCE rates were 22% at one year and 41% at five years. All-cause mortality was 13% at one year and 24% at five years. On multivariable analysis, age, diabetes mellitus, active smoking and ST at a bifurcation were independently associated with the occurrence of MACCE up to five years. Conclusions: Age, active smoking, diabetes mellitus and bifurcation disease are independently associated with long-term MACCE over a five-year follow-up period. C1 [Yeo, Khung Keong; Low, Reginald I.; Rogers, Jason H.] Univ Calif Davis, Dept Med, Div Cardiovasc Med, Davis Med Ctr, Sacramento, CA 95817 USA. [Yeo, Khung Keong] Natl Heart Ctr Singapore, Dept Cardiol, Singapore, Singapore. [Armstrong, Ehrin J.] Univ Colorado, Dept Med, Div Cardiol, Denver, CO USA. [Soni, Krishan; Shunk, Kendrick A.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Waldo, Stephen W.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Patel, Mitul; Reeves, Ryan; Mahmud, Ehtisham] Univ Calif San Diego, Dept Med, Div Cardiovasc Med, San Diego, CA 92103 USA. [Shunk, Kendrick A.] Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA. RP Rogers, JH (reprint author), Univ Calif Davis, Dept Med, Div Cardiovasc Med, Davis Med Ctr, Sacramento, CA 95817 USA. EM jason.rogers@ucdmc.ucdavis.edu FU Medtronic; Boston Scientific; Abbott Vascular; Accumetrics; Sanofi Aventis FX K.K. Yeo has received research support from Medtronic and is on the speakers bureau for Abbott Vascular. R. Low is on the advisory board of Abbott Vascular and Boston Scientific. K. Shunk receives institutional research support from Abbott Vascular, Gilead, InfraRedx, and Siemens Medical Systems. E. Mahmud is on the speakers bureau for Medtronic and Eli Lilly, is a consultant for Eli Lilly, and has received research support from Boston Scientific, Abbott Vascular, Accumetrics and Sanofi Aventis. J. Rogers is a consultant for Volcano, Medtronic, and Boston Scientific. The other authors have no conflicts of interest to declare. NR 16 TC 2 Z9 2 U1 0 U2 0 PU EUROPA EDITION PI TOULOUSE CEDEX 6 PA 19 ALLEES JEAN JAURES B P 61508, TOULOUSE CEDEX 6, 31015, FRANCE SN 1774-024X EI 1969-6213 J9 EUROINTERVENTION JI EuroIntervention PD JUN PY 2015 VL 11 IS 2 BP 188 EP 195 DI 10.4244/EIJV11I2A33 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CO9QQ UT WOS:000359510800010 PM 26093838 ER PT J AU Gatz, M Harris, JR Kaprio, J McGue, M Smith, NL Snieder, H Spiro, A Butler, DA AF Gatz, Margaret Harris, Jennifer R. Kaprio, Jaakko McGue, Matt Smith, Nicholas L. Snieder, Harold Spiro, Avron, III Butler, David A. CA Inst Med Comm Twins Studies TI Cohort Profile: The National Academy of Sciences-National Research Council Twin Registry (NAS-NRC Twin Registry) SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article ID PARKINSON DISEASE; VETERAN TWINS; RISK; PAIRS; SCHIZOPHRENIA; DEMENTIA; SMOKING AB The National Academy of Sciences-National Research Council Twin Registry (NAS-NRC Twin Registry) is a comprehensive registry of White male twin pairs born in the USA between 1917 and 1927, both of the twins having served in the military. The purpose was medical research and ultimately improved clinical care. The cohort was assembled in the early 1960s with identification of approximately 16 000 twin pairs, review of service records, a brief mailed questionnaire assessing zygosity, and a health survey largely comparable to questionnaires used at that time with Scandinavian twin registries. Subsequent large-scale data collection occurred in 1974, 1985 and 1998, repeating the health survey and including information on education, employment history and earnings. Self-reported data have been supplemented with mortality, disability and medical data through record linkage. Potential collaborators should access the study website [http://www.iom.edu/Activities/Veterans/TwinsStudy.aspx] or e-mail the Medical Follow-up Agency at [Twins@nas.edu]. Questionnaire data are being prepared for future archiving with the National Archive of Computerized Data on Aging (NACDA) at the Inter-University Consortium for Political and Social Research (ICPSR), University of Michigan, MI. C1 [Gatz, Margaret] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. [Gatz, Margaret] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Harris, Jennifer R.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway. [Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland. [Kaprio, Jaakko] Univ Helsinki, Inst Mol Med, Helsinki, Finland. [Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth & Subst Abuse Serv, Helsinki, Finland. [McGue, Matt] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Smith, Nicholas L.] Puget Sound Hlth Care Syst, VA Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Spiro, Avron, III] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Jamaica Plain, MA USA. [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Spiro, Avron, III] Boston Univ, Sch Med, Boston, MA 02118 USA. [Butler, David A.] Natl Acad Sci, Inst Med, Med Follow Up Agcy, Washington, DC 20418 USA. RP Gatz, M (reprint author), Univ So Calif, Dept Psychol, 3620 McClintock Ave, Los Angeles, CA 90089 USA. EM gatz@usc.edu OI Kaprio, Jaakko/0000-0002-3716-2455 FU National Institutes of Health [R21 AG039572] FX The authors acknowledge financial support from the National Institutes of Health: R21 AG039572. NR 31 TC 1 Z9 1 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD JUN PY 2015 VL 44 IS 3 BP 819 EP 825 DI 10.1093/ije/dyu181 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CP2JB UT WOS:000359702200015 PM 25183748 ER PT J AU Jackevicius, CA Co, MJ Warner, AL AF Jackevicius, Cynthia A. Co, Mary Joana Warner, Alberta L. TI Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome SO INTERNATIONAL JOURNAL OF PHARMACY PRACTICE LA English DT Article DE anaemia; anaemia of chronic kidney disease; congestive heart failure; CRAS; kidney failure ID CONGESTIVE-HEART-FAILURE; CHRONIC-RENAL-FAILURE; SUBCUTANEOUS ERYTHROPOIETIN; INTRAVENOUS IRON; UNITED-STATES; PATTERNS; DISEASE; HOSPITALIZATIONS; MEDICATIONS; MANAGEMENT AB Objectives Chronic kidney disease (CKD) and anemia are common in patients with heart failure (HF) - these 3 conditions have been coined the Cardiorenal Anemia Sydrome (CRAS). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines do not specifically address patients with CRAS, creating uncertainty in erythropoietin (EPO) prescribing. We sought to determine predictors of EPO use in patients with CRAS. Methods We conducted a retrospective cohort study at the Veteran's Affairs Greater Los Angeles Healthcare System (VAGLAHS), a 300+ bed facility that provides primary and tertiary inpatient, and ambulatory care services, between January 1, 2003 to December 31, 2006. A multiple logistic regression model was constructed to identify predictors of EPO use among CRAS patients. Key findings Of 2058 patients with CRAS, 213 (10.3%) were prescribed EPO. There were significant differences in baseline characteristics between the EPO and non-EPO groups. The following predictors were found to be associated with EPO prescription: iron supplementation (odds ratio [OR] 52.70, 95% confidence interval [CI] 11.70-237.46), renal clinic appointment (OR 2.60, 95% CI 1.79-3.76), malignancy (OR 1.52, 95% CI 1.07-2.16) and use of hydralazine/nitrates (OR 1.41, 95% CI 1.03-1.92). There was an inverse association found between EPO prescription and baseline hemoglobin (OR 0.61, 95% CI 0.53-0.70) and eGFR (OR 0.96, 95% CI 0.94-0.97). Conclusion A small proportion of patients eligible for EPO therapy according to guidelines at the time of the study were prescribed the indicated therapy. Markers of declining renal function or those suggesting need for anemia therapy were identified as EPO predictors. C1 [Jackevicius, Cynthia A.; Co, Mary Joana] Western Univ Hlth Sci, Pharm Practice & Adm Dept, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.; Warner, Alberta L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Warner, Alberta L.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Co, Mary Joana] Providence St Joseph Med Ctr, Dept Pharm, Burbank, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 28 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0961-7671 EI 2042-7174 J9 INT J PHARM PRACT JI Int. J. Pharm. Pract. PD JUN PY 2015 VL 23 IS 3 BP 199 EP 204 DI 10.1111/ijpp.12133 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CP2OS UT WOS:000359717300006 PM 24990704 ER PT J AU Abedalthagafi, MS Bi, WL Merrill, PH Gibson, WJ Rose, MF Du, ZM Francis, JM Du, R Dunn, IF Ligon, AH Beroukhim, R Santagata, S AF Abedalthagafi, Malak S. Bi, Wenya Linda Merrill, Parker H. Gibson, William J. Rose, Matthew F. Du, Ziming Francis, Joshua M. Du, Rose Dunn, Ian F. Ligon, Azra H. Beroukhim, Rameen Santagata, Sandro TI ARID1A and TERT promoter mutations in dedifferentiated meningioma SO CANCER GENETICS LA English DT Article DE Meningioma; anaplastic; intratumoral heterogeneity; SWI/SNF complex; chromatin remodeling ID DNA-SEQUENCING DATA; TUMOR-SUPPRESSOR; ANAPLASTIC MENINGIOMAS; MALIGNANT PROGRESSION; MOLECULAR-GENETICS; CANCER; EXPRESSION; FRAMEWORK; TRAF7; CELLS AB Unlike patients with World Health Organization (WHO) grade I meningiomas, which are considered benign, patients with WHO grade III meningiomas have very high mortality rates. The principles underlying tumor progression in meningioma are largely unknown, yet a detailed understanding of these mechanisms will be required for effective management of patients with these high grade lethal tumors. We present a case of an intraventricular meningioma that at first presentation displayed remarkable morphologic heterogeneity composed of distinct regions independently fulfilling histopathologic criteria for WHO grade I, II, and III designations. The lowest grade regions had classic meningothelial features, while the highest grade regions were markedly dedifferentiated. Whereas progression in meningiomas is generally observed during recurrence following radiation and systemic medical therapies, the current case offers us a snapshot of histologic progression and intratumoral heterogeneity in a native pretreatment context. Using whole exome sequencing and high resolution array-based comparative genomic hybridization, we observed marked genetic heterogeneity between the various areas. Notably, in the higher grade regions we found increased aneuploidy with progressive loss of heterozygosity, the emergence of mutations in the TEAT promoter, and compromise of ARID1A. These findings provide new insights into intratumoral heterogeneity in the evolution of malignant phenotypes in anaplastic meningiomas and potential pathways of malignant progression. C1 [Abedalthagafi, Malak S.; Merrill, Parker H.; Rose, Matthew F.; Du, Ziming; Santagata, Sandro] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp,Div Neuropathol, Boston, MA 02115 USA. [Bi, Wenya Linda; Du, Rose; Dunn, Ian F.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Gibson, William J.; Beroukhim, Rameen; Santagata, Sandro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Francis, Joshua M.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Francis, Joshua M.; Beroukhim, Rameen] Broad Inst MIT & Harvard, Cambridge, MA USA. [Ligon, Azra H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Ctr Adv Mol Diagnost,Clin Cytogenet L, Boston, MA 02115 USA. RP Santagata, S (reprint author), Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp,Div Neuropathol, Boston, MA 02115 USA. EM ssantagata@partners.org OI Rose, Matthew/0000-0002-1148-4130; Du, Rose/0000-0003-2641-6496 FU King Abdulaziz City for Science and Technology (KACST), Saudi Arabia [35-1041, 110968]; National Institute of General Medical Sciences [T32GM007753]; Brain Science Foundation; Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research FX We are grateful to Marian Slaney and Sebastian Valentino for assistance with histology, Terri Woo for assistance with immunohistochemistry, and Marc L. Listewnik for cytogenetic data support for technical assistance. The work is supported by 35-1041 grant from King Abdulaziz City for Science and Technology (KACST) no. 110968, Saudi Arabia (M.A.A.), T32GM007753 from the National Institute of General Medical Sciences (W.J.G), the Brain Science Foundation (S.S.), and the Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research (S.S.). NR 31 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2210-7762 EI 2210-7770 J9 CANCER GENET-NY JI Cancer Genet. PD JUN PY 2015 VL 208 IS 6 BP 345 EP 350 DI 10.1016/j.cancergen.2015.03.005 PG 6 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA CO0DV UT WOS:000358821200008 PM 25963524 ER PT J AU Lee, JM Trepel, JB Choyke, P Cao, L Sissung, T Houston, N Yu, MS Figg, WD Turkbey, IB Steinberg, SM Lee, MJ Ivy, SP Liu, JF Matulonis, UA Kohn, EC AF Lee, Jung-Min Trepel, Jane B. Choyke, Peter Cao, Liang Sissung, Tristan Houston, Nicole Yu, Minshu Figg, William D. Turkbey, Ismail Baris Steinberg, Seth M. Lee, Min-Jung Ivy, S. Percy Liu, Joyce F. Matulonis, Ursula A. Kohn, Elise C. TI CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer SO FRONTIERS IN ONCOLOGY LA English DT Article DE CEC; IL-8; biomarkers; olaparib; cediranib; ovarian cancer ID CIRCULATING ENDOTHELIAL-CELLS; RESISTANT PROSTATE-CANCER; ADP-RIBOSE POLYMERASE; 0 CLINICAL-TRIAL; POLY(ADP-RIBOSE) POLYMERASE; RETROSPECTIVE ANALYSIS; MAINTENANCE THERAPY; MICROVESSEL DENSITY; PARP INHIBITORS; BREAST-CANCER AB Objective: Olaparib (O), a polyADPribose polymerase (PARP) inhibitor, and cediranib (C), a VEGF receptor (VEGFR)1-3 inhibitor together had greater activity than 0 alone in women with recurrent platinum-sensitive ovarian cancer (OvCa). The objective of this study is to identify potential lead biomarker candidates for response to O+C in the setting of a multi-institutional phase II study of 0 with and without C in recurrent platinum-sensitive OvCa. Methods: A self-selected group of patients participated in a prospectively planned exploratory biomarker substudy of the randomized phase II study of 0 versus O+C. Whole blood for peripheral blood mononuclear cell (PBMC) and plasma isolation was collected prior to and on day 3 of treatment. Quantitation of circulating endothelial cells (CEC), IL-6, IL-8, VEGF, and soluble VEGFR-2 plasma concentrations, and polyADPribose (PAR) incorporation were performed. Single nucleotide polymorphism analysis of XF?CC1 280H, R194W, and Q399R was done. Dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI) was performed at baseline and day 3 of treatment. Parameter changes were compared between the two arms using an exact Wilcoxon rank sum test. Kaplan Meier and log-rank tests were used to examine survival outcome. Results: Thirteen patients elected to participate in the translational substudy, seven patients on 0 and six patients on O+C. Patients on O+C had a greater decrease in IL-8 concentration and larger CEC fold increase compared with those on 0 alone (p = 0.026, p = 0.032). The fold increase in CEC on day 3 was associated with duration of progression-free survival (PFS) (R-2 = 0.77, 95% Cl 0.55-0.97, p < 0.001). IL-8 post-pretreatment changes correlate with PFS (p = 0.028). XF?CC1 DNA polymorphisms were not related to PFS. All patients had reduction in PAR incorporation, and all except one had reduction in vascular flow on DCE-MRI. Conclusion: Our exploratory correlative studies indicate that CEC and IL-8 changes may be predictive for response to 0+ C and prognostic in recurrent platinum-sensitive OvCa, requiring prospective validation. C1 [Lee, Jung-Min; Trepel, Jane B.; Choyke, Peter; Cao, Liang; Sissung, Tristan; Houston, Nicole; Yu, Minshu; Figg, William D.; Turkbey, Ismail Baris; Steinberg, Seth M.; Lee, Min-Jung; Kohn, Elise C.] Ctr Canc Res, Bethesda, MD USA. [Ivy, S. Percy] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Liu, Joyce F.; Matulonis, Ursula A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Lee, JM (reprint author), 10 Ctr Dr MSC1906,Bldg 10,Room 12N-226, Bethesda, MD 20892 USA. EM leej6@mail.nih.gov RI Figg Sr, William/M-2411-2016 FU Intramural Program of the Center for Cancer Research, National Cancer Institute, NIH; Cancer Therapy Evaluation Program of the NCI FX This correlative project was funded by the Intramural Program of the Center for Cancer Research, National Cancer Institute, NIH. The randomized phase-2 study was funded by the Cancer Therapy Evaluation Program of the NCI. Olaparib and cediranib were supplied under a Cooperative Research and Development Agreement between the NCI, NIH, Bethesda, MD, USA and AstraZeneca. The corresponding and senior authors had access to all the data and made the final decision to submit for publication. NR 52 TC 5 Z9 6 U1 0 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD JUN 1 PY 2015 VL 5 AR 123 DI 10.3389/fonc.2015.00123 PG 8 WC Oncology SC Oncology GA CO4OP UT WOS:000359140600001 PM 26082895 ER PT J AU Moucheraud, C Gass, J Lipsitz, S Spector, J Agrawal, P Hirschhorn, LR Gawande, A Kodkany, B AF Moucheraud, Corrina Gass, Jonathon Lipsitz, Stuart Spector, Jonathan Agrawal, Priya Hirschhorn, Lisa R. Gawande, Atul Kodkany, Bhala TI Bedside Availability of Prepared Oxytocin and Rapid Administration After Delivery to Prevent Postpartum Hemorrhage: An Observational Study in Karnataka, India SO GLOBAL HEALTH-SCIENCE AND PRACTICE LA English DT Article ID 3RD STAGE; ACTIVE MANAGEMENT; LABOR; IMPLEMENTATION; BIRTH AB Postpartum hemorrhage is a leading cause of maternal death worldwide. Rapid provision of uterotonics after childbirth is recommended to reduce the incidence and severity of postpartum hemorrhage. Data obtained through direct observation of childbirth practices, collected in a study of the World Health Organization's Safe Childbirth Checklist in Karnataka, India, were used to measure if oxytocin prepared for administration and available at the bedside before birth was associated with decreased time to administration after birth. This was an observational study of provider behavior: data were obtained during a baseline assessment of health worker practices prior to introduction of the Safe Childbirth Checklist, representing behavior in the absence of any intervention. Analysis was based on 330 vaginal deliveries receiving oxytocin at any point postpartum. Oxytocin was prepared and available at bedside for approximately 39% of deliveries. We found that advance preparation and bedside availability of oxytocin was associated with increased likelihood of oxytocin administration within 1 minute after delivery (adjusted risk ratio = 4.89, 95% CI = 2.61, 9.16), as well as with decreased overall time to oxytocin administration after delivery (2.9 minutes sooner in adjusted models, 95% CI = -5.0, -0.9). Efforts to reduce postpartum hemorrhage should include recommendations and interventions to ensure advance preparation and bedside availability of oxytocin to facilitate prompt administration of the medicine after birth. C1 [Moucheraud, Corrina; Agrawal, Priya] Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Gass, Jonathon; Lipsitz, Stuart; Hirschhorn, Lisa R.; Gawande, Atul] Brigham & Womens Hosp, Ariadne Labs, Boston, MA 02115 USA. [Gass, Jonathon; Lipsitz, Stuart; Hirschhorn, Lisa R.; Gawande, Atul] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Lipsitz, Stuart; Gawande, Atul] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Spector, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Agrawal, Priya] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England. [Hirschhorn, Lisa R.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA. [Kodkany, Bhala] Jawaharlal Nehru Med Coll, Womens & Childrens Hlth Res Unit, Belagavi, Karnataka, India. RP Moucheraud, C (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. EM cmoucheraud@mail.harvard.edu NR 20 TC 1 Z9 1 U1 0 U2 0 PU US AGENCY INT DEVELOPMENT-USAID PI BALTIMORE PA US AGENCY INT DEVELOPMENT-USAID, BALTIMORE, MD 00000 USA SN 2169-575X J9 GLOB HEALTH-SCI PRAC JI Glob. Health PD JUN PY 2015 VL 3 IS 2 BP 300 EP 304 DI 10.9745/GHSP-D-14-00239 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2SR UT WOS:000359007400014 PM 26085025 ER PT J AU Morain, SR Joffe, S Campbell, EG Mello, MM AF Morain, Stephanie R. Joffe, Steven Campbell, Eric G. Mello, Michelle M. TI Institutional Oversight of Faculty-Industry Consulting Relationships in US Medical Schools: A Delphi Study SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID CONFLICTS-OF-INTEREST; ROFECOXIB LITIGATION; DOCUMENTS; TRIALS; INVESTIGATORS; AUTHORSHIP; PRIORITIES; STANDARDS; CONSENSUS; REVIEWS AB The conflicts of interest that may arise in relationships between academic researchers and industry continue to prompt controversy. The bulk of attention has focused on financial aspects of these relationships, but conflicts may also arise in the legal obligations that faculty acquire through consulting contracts. However, oversight of faculty members' consulting agreements is far less vigorous than for financial conflicts, creating the potential for faculty to knowingly or unwittingly contract away important rights and freedoms. Increased regulation could prevent this, but it is unclear what forms of oversight universities view as feasible and effective. In this article, we report on a Delphi study to evaluate several approaches for oversight of consulting agreements by medical schools. The panel was comprised of 11 senior administrators with responsibility for oversight of faculty consulting relationships. We found broad agreement among panelists regarding the importance of institutional oversight to protect universities' interests. There was strong support for two specific approaches: providing educational resources to faculty and submitting consulting agreements for institutional review. Notwithstanding the complexities of asserting authority to regulate private consulting agreements between faculty members and companies, medical school administrators reached consensus that several approaches to improving institutional oversight are feasible and useful. C1 [Morain, Stephanie R.] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21218 USA. [Joffe, Steven] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Campbell, Eric G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mongan Inst Hlth Policy, Cambridge, MA 02138 USA. [Mello, Michelle M.] Univ N Carolina, Hlth Policy & Adm, Chapel Hill, NC USA. RP Morain, SR (reprint author), Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD 21218 USA. OI Joffe, Steven/0000-0002-0667-7384 FU National Center For Research Resources [1R21RR031916-01] FX The project described was supported by grant number 1R21RR031916-01 from the National Center For Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health. The authors gratefully acknowledge the contributions of our panel members, Kelly Curran, Laurel Fleming, Lois Geist, Julie Gottlieb, Joseph Jankowski, Jim Kiriakis, Helen McLaughlin, Gail Norris, Jeff Seo, Lee Taylor, and David Wehrle, as well as three anonymous senior administrative officials who pilot-tested our survey instrument. Survey responses do not necessarily represent the official views of panelists' respective academic institutions. We also thank Yelena Greenberg for assistance in defining the sampling frame, and Norman Daniels for helpful comments on an earlier draft of this manuscript. NR 45 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1073-1105 EI 1748-720X J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SUM PY 2015 VL 43 IS 2 SI SI BP 383 EP 396 DI 10.1111/jlme.12255 PG 14 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA CO3UZ UT WOS:000359087400026 PM 26242961 ER PT J AU Chirindel, A Adebahr, S Schuster, D Schimek-Jasch, T Schanne, DH Nemer, U Mix, M Meyer, P Grosu, AL Brunner, T Nestle, U AF Chirindel, Alin Adebahr, Sonja Schuster, Daniel Schimek-Jasch, Tanja Schanne, Daniel H. Nemer, Ursula Mix, Michael Meyer, Philipp Grosu, Anca-Ligia Brunner, Thomas Nestle, Ursula TI Impact of 4D-(18)FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE 4DPET/CT; SBRT; Central lung tumors; Target volume delineation ID STEREOTACTIC ABLATIVE RADIOTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; EARLY-STAGE; COMPUTED-TOMOGRAPHY; CANCER NSCLC; CT SCANS; PET; RADIATION; MOTION; PHANTOM AB Purpose: Evaluation of the effect of co-registered 4D-(18)FDG-PET/CT for SBRT target delineation in patients with central versus peripheral lung tumors. Methods: Analysis of internal target volume (ITV) delineation of central and peripheral lung lesions in 21 SBRT-patients. Manual delineation was performed by 4 observers in 2 contouring phases: on respiratory gated 4DCT with diagnostic 3DPET available aside (CT-ITV) and on co-registered 4DPET/CT (PET/CT-ITV). Comparative analysis of volumes and inter-reader agreement. Results: 11 cases of peripheral and 10 central lesions were evaluated. In peripheral lesions, average CT-ITV was 6.2 cm(3) and PET/CT-ITV 8.6 cm(3), resembling a mean change in hypothetical radius of 2 mm. For both CT-ITVs and PET/CT-ITVs inter reader agreement was good and unchanged (0.733 and 0.716; p = 0.58). All PET/CT-ITVs stayed within the PTVs derived from CT-ITVs. In central lesions, average CT-ITVs were 42.1 cm(3), PET/CT-ITVs 44.2 cm(3), without significant overall volume changes. Inter-reader agreement improved significantly (0.665 and 0.750; p < 0.05). 2/10 PET/CT-ITVs exceeded the PTVs derived from CT-ITVs by >1 ml in average for all observers. Conclusion: The addition of co-registered 4DPET data to 4DCT based target volume delineation for SBRT of centrally located lung tumors increases the inter-observer agreement and may help to avoid geographic misses. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Chirindel, Alin; Adebahr, Sonja; Schuster, Daniel; Schimek-Jasch, Tanja; Grosu, Anca-Ligia; Brunner, Thomas; Nestle, Ursula] Univ Med Ctr Freiburg, Dept Radiat Oncol, D-79106 Freiburg, Germany. [Chirindel, Alin; Adebahr, Sonja; Grosu, Anca-Ligia; Brunner, Thomas; Nestle, Ursula] German Canc Consortium DKTK, Heidelberg, Germany. [Schanne, Daniel H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Nemer, Ursula; Mix, Michael; Meyer, Philipp] Univ Med Ctr Freiburg, Dept Nucl Med, Freiburg, Germany. RP Nestle, U (reprint author), Univ Med Ctr Freiburg, Dept Radiat Oncol, Robert Koch Str 3, D-79106 Freiburg, Germany. EM ursula.nestle@uniklinik-freiburg.de NR 29 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JUN PY 2015 VL 115 IS 3 BP 335 EP 341 DI 10.1016/j.radonc.2015.05.019 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CN9XO UT WOS:000358804600008 PM 26116339 ER PT J AU Klein, E AF Klein, Eran TI Eloquent Brain, Ethical Challenges: Functional Brain Mapping in Neurosurgery SO SEMINARS IN ULTRASOUND CT AND MRI LA English DT Article ID LOW-GRADE GLIOMAS; SURGERY; AREAS AB Functional brain mapping is an increasingly relied upon tool in presurgical planning and intraoperative decision making. Mapping allows personalization of structure-function relationships when surgical or other treatment of pathology puts eloquent functioning like language or vision at risk As an innovative technology, functional brain mapping holds great promise but also raises important ethical questions. In this article, recent work in neuroethics on functional imaging and functional neurosurgery is explored and applied to functional brain mapping. Specific topics discussed in this article are incidental findings, responsible innovation, and informed consent. (C) 2015 Elsevier Inc. All rights reserved. C1 [Klein, Eran] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. [Klein, Eran] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Klein, Eran] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA. RP Klein, E (reprint author), Dept Vet Affairs, Med Ctr, Portland Div, 3710 SW US Vet Hosp Rd,POB 1034,P3 Neuro, Portland, OR 97207 USA. EM kleine@ohsu.edu NR 28 TC 1 Z9 1 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0887-2171 EI 1558-5034 J9 SEMIN ULTRASOUND CT JI Semin. Ultrasound CT MRI PD JUN PY 2015 VL 36 IS 3 BP 291 EP 295 DI 10.1053/j.sult.2015.05.009 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CO7IL UT WOS:000359332700008 PM 26233862 ER PT J AU Leung, Y Fikry, K Shah, B Madapu, M Gaz, RD Leffert, LR Jiang, YD AF Leung, Yiuka Fikry, Karim Shah, Bhavika Madapu, Manokanth Gaz, Randall D. Leffert, Lisa R. Jiang, Yandong TI Continuous Positive Airway Pressure with Pressure Support Ventilation Is Effective in Treating Acute-Onset Bilateral Recurrent Laryngeal Nerve Palsy SO A & A CASE REPORTS LA English DT Article ID VOCAL CORD PARALYSIS; IDENTIFICATION; THYROIDECTOMY; OBSTRUCTION AB Acute bilateral recurrent laryngeal nerve injury leading to acute vocal cord paralysis (VCP) is a serious complication of head and neck surgery, often requiring emergent surgical intervention. Although well documented, its presentation may be sudden and unexpected, occurring despite lack of obvious intraoperative nerve injury. There is limited literature on airway management strategies for patients with acute bilateral VCP before attaining a secure airway. We report a case of acute VCP that was successfully treated with continuous positive airway pressure via facemask ventilation. This effective temporizing strategy allowed clinicians to plan and prepare for tracheostomy, minimizing potential complications. C1 [Leung, Yiuka; Fikry, Karim; Shah, Bhavika; Madapu, Manokanth; Leffert, Lisa R.; Jiang, Yandong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Gaz, Randall D.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Jiang, YD (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM yjiang@partners.org NR 19 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2325-7237 J9 A A CASE REP JI A A Case Rep. PD JUN 1 PY 2015 VL 4 IS 11 BP 155 EP 157 DI 10.1213/XAA.0000000000000150 PG 3 WC Anesthesiology SC Anesthesiology GA CM3HO UT WOS:000357572900004 PM 26035222 ER PT J AU Zwaan, L Singh, H AF Zwaan, Laura Singh, Hardeep TI The challenges in defining and measuring diagnostic error SO DIAGNOSIS LA English DT Article DE clinical decision-making; cognitive errors; diagnostic error; judgment; patient safety ID ADVERSE EVENTS; CELIAC-DISEASE; HEALTH-CARE; OVERDIAGNOSIS; MEDICINE; HINDSIGHT; RESPECT; TRENDS; CLAIMS; TIME AB Diagnostic errors have emerged as a serious patient safety problem but they are hard to detect and complex to define. At the research summit of the 2013 Diagnostic Error in Medicine 6th International Conference, we convened a multidisciplinary expert panel to discuss challenges in defining and measuring diagnostic errors in real-world settings. In this paper, we synthesize these discussions and outline key research challenges in operationalizing the definition and measurement of diagnostic error. Some of these challenges include 1) difficulties in determining error when the disease or diagnosis is evolving over time and in different care settings, 2) accounting for a balance between underdiagnosis and overaggressive diagnostic pursuits, and 3) determining disease diagnosis likelihood and severity in hindsight. We also build on these discussions to describe how some of these challenges can be addressed while conducting research on measuring diagnostic error. C1 [Zwaan, Laura] Erasmus MC, Inst Med Educ Res Rotterdam, Rotterdam, Netherlands. [Zwaan, Laura] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Singh, Hardeep] Baylor Coll Med, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Zwaan, L (reprint author), Erasmus MC, Inst Med Educ Res Rotterdam, Rotterdam, Netherlands. EM L.zwaan@erasmusmc.nl RI Zwaan, Laura/I-6473-2015 FU AHRQ HHS [R01 HS022087, R13 HS021774]; NCI NIH HHS [K23 CA125585] NR 41 TC 13 Z9 13 U1 3 U2 8 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD JUN PY 2015 VL 2 IS 2 BP 97 EP 103 DI 10.1515/dx-2014-0069 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CL9FD UT WOS:000357280400004 PM 26955512 ER PT J AU Kopacz, MS Hoffmire, CA Morley, SW Vance, CG AF Kopacz, Marek S. Hoffmire, Claire A. Morley, Sybil W. Vance, C. Garland TI Using a Spiritual Distress Scale to Assess Suicide Risk in Veterans: An Exploratory Study SO PASTORAL PSYCHOLOGY LA English DT Article DE Veterans; Chaplaincy services; Moral injury; Suicide ID INTERVENTION; COMBAT AB This exploratory study (1) examined the ability of a spiritual distress scale used by chaplains to identify Veterans with certain suicide risk factors and (2) provided an initial assessment of the reliability and validity of this scale to screen for Veterans at increased risk of suicide based on the presence of these risk factors. The scale consisted of five questions examining the presence or absence of guilt, sadness or grief, anger or resentment, despair or hopelessness, and feeling that life has no meaning or purpose. The scale was analyzed using Chronbach's alpha-coefficient, factor analysis, Student's t-tests, and logistic regression. Cut-off values were determined using the maximum Youden statistic. The five questions had a high level of internal consistency(alpha =0.88). Factor analysis suggested the presence of a common underlying factor, with correlations ranging from 0.42 to 0.78. Those identified with a suicide risk factor had significantly higher mean composite scores on this scale. Further, scores were significantly associated with increased odds of being identified with a suicide risk factor. A score >= 10 may be best suited for differentiating between individuals with and without certain suicide risk factors. This scale shows promise for identifying Veterans who may be at increased risk of suicide. C1 [Kopacz, Marek S.; Hoffmire, Claire A.; Morley, Sybil W.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Vance, C. Garland] US Dept Vet Affairs, Charles George VA Med Ctr, Asheville, NC 28805 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 28 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-2789 EI 1573-6679 J9 PASTOR PSYCHOL JI Pastor. Psychol. PD JUN PY 2015 VL 64 IS 3 BP 381 EP 390 DI 10.1007/s11089-014-0633-1 PG 10 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA CH8VV UT WOS:000354315100007 ER PT J AU Ricci, KA Griffin, AR Heslin, KC Kranke, D Dobalian, A AF Ricci, Karen A. Griffin, Anne R. Heslin, Kevin C. Kranke, Derrick Dobalian, Aram TI Evacuate or Shelter-in-place? The Role of Corporate Memory and Political Environment in Hospital-evacuation Decision Making SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE disasters; hospital evacuation; organizational culture; organizational decision making ID PUBLIC-HEALTH; DISASTERS; LESSONS; SANDY; CARE AB Problem: Hospital-evacuation decisions are rarely straightforward in protracted advance-warning events. Previous work provides little insight into the decision-making process around evacuation. This study was conducted to identify factors that most heavily influenced the decisions to evacuate the US Department of Veterans Affairs (VA) New York Harbor Healthcare System's (NYHHS; New York USA) Manhattan Campus before Hurricane Irene in 2011 and before Superstorm Sandy in 2012. Methods: Semi-structured interviews with 11 senior leaders were conducted on the processes and factors that influenced the evacuation decisions prior to each event. Results: The most influential factor in the decision to evacuate the Manhattan Campus before Hurricane Irene was New York City's (NYC's) hospital-evacuation mandate. As a federal facility, the Manhattan VA medical center (VAMC) was exempt from the city's order, but decision makers felt compelled to comply. In the case of Superstorm Sandy, corporate memory of a similar 1992 storm that crippled the Manhattan facility drove the decision to evacuate before the storm hit. Conclusions: Results suggest that hospital-evacuation decisions are confounded by political considerations and are influenced by past disaster experience. Greater shared situational awareness among at-risk hospitals, along with a more coordinated approach to evacuation decision making, could reduce pressure on hospitals to make these high-stakes decisions. Systematic mechanisms for collecting, documenting, and sharing lessons learned from past disasters are sorely needed at the institutional, local, and national levels. Ricci KA, Griffin AR, Heslin KC, Kranke D, Dobalian A. Evacuate or shelter-in-place? The role of corporate memory and political environment in hospital-evacuation decision making. C1 [Ricci, Karen A.; Griffin, Anne R.; Kranke, Derrick; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr VEMEC, North Hills, CA USA. [Ricci, Karen A.] RAND Corp, Santa Monica, CA USA. [Heslin, Kevin C.] US Dept HHS, Ctr Delivery Org & Markets CDOM, Agcy Healthcare Res & Qual, Rockville, MD USA. [Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Dobalian, A (reprint author), Vet Emergency Management Evaluat Ctr VEMEC, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. EM Aram.Dobalian@va.gov NR 27 TC 2 Z9 2 U1 7 U2 10 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD JUN PY 2015 VL 30 IS 3 BP 233 EP 238 DI 10.1017/S1049023X15000229 PG 6 WC Emergency Medicine SC Emergency Medicine GA CN4OP UT WOS:000358410000004 PM 25783663 ER PT J AU Reddy, A Canamucio, A Werner, RM AF Reddy, Ashok Canamucio, Anne Werner, Rachel M. TI Impact of the Patient-Centered Medical Home on Veterans' Experience of Care SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID QUALITY-OF-CARE; HEALTH-CARE; OUTCOMES; TRANSFORMATION; COMMUNICATION; SATISFACTION; SYSTEMS; COSTS AB Objectives: A core tenet of the patient-centered medical home is improving patient experiences of care, but evidence is limited on the impact of medical home adoption on patient experiences of care. Study Design: We conducted a repeated cross-sectional, patient-level analysis in 1 region of the Veterans Health Administration (VHA), which includes 56 primary care sites. Methods: Our primary outcomes include 5 domains of patient care experience from the Survey of Healthcare Experiences of Patients (SHEP). We used a linear probability model to test whether changes in medical home implementation are associated with changes in patient experience of care. Results: During the study period, 30,849 SHEP respondents received care. We observed significant increase in medical home implementation: a 10-fold increase in percentage of primary care providers who were part of a medical home, a 7-fold increase in 8 out of 9 structural measures of the medical home, and an increase in overall quality of medical home implementation. Yet, we found no association between medical home adoption and 5 domains of patient experience of care. For example, patients assigned to a medical home provider had a 0.51 percentage point (95% CI, -1.8 to 2.8) higher response in how well they communicate with their provider compared with patients not assigned to a medical provider and with patients in the pre-medical home period. Conclusions: Despite wide implementation of the medical home, we did not see an improvement in patient experiences of care in the VHA. As we focus on primary care transformation, we need to find ways to incorporate the patient's voice and input into these transitions. C1 [Reddy, Ashok; Canamucio, Anne; Werner, Rachel M.] Philadelphia VA Med Ctr, PACT, VISN Ctr Evaluat 4, Philadelphia, PA USA. [Reddy, Ashok; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Reddy, Ashok; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Reddy, Ashok] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. RP Reddy, A (reprint author), Univ Penn, Perelman Sch Med, Blockley Hall 1303,423 Guardian Dr, Philadelphia, PA 19104 USA. EM ashokr@upenn.edu FU Robert Wood Johnson Foundation Clinical Scholars Program; VA Office of Patient Care Services FX This work was supported by the Robert Wood Johnson Foundation Clinical Scholars Program. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. NR 30 TC 2 Z9 2 U1 5 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUN PY 2015 VL 21 IS 6 BP 413 EP + PG 19 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN8BS UT WOS:000358662700008 PM 26168062 ER PT J AU Kobraei, EM Eberlin, KR Ricci, JA Reish, RG Winograd, JM Cetrulo, CL AF Kobraei, Edward M. Eberlin, Kyle R. Ricci, Joseph A. Reish, Richard G. Winograd, Jonathan M. Cetrulo, Curtis L., Jr. TI GHOST Protocol: Greatest Healing Opportunity for Soft Tissue, a Treatment Paradigm for Complex Sarcoma Reconstruction SO AMERICAN SURGEON LA English DT Article ID CLEFT-LIP; MANAGEMENT; RADIATION; CANCER; PALATE; TRIAL; STAGE; TEAM; FLAP; CARE AB Modern sarcoma treatment has created new challenges for plastic surgeons. This study was designed to review the recent experience and practice patterns following complex sarcoma resection at a large sarcoma center. All cases from October 2013 to October 2014 involving rare nonepithelial tumors, a multidisciplinary surgical team, radiation and/or chemotherapy treatments, and plastic surgical reconstruction were included in the analysis. In addition to evaluating clinical outcomes, cases were reviewed to identify factors associated with excellent or poor patient care. Review of these cases formed the basis of the greatest healing opportunity for soft tissue (GHOST) protocol. Our patient population included seven males (64%) and four females (36%). All except one patient was exposed to radiotherapy, chemotherapy, or some combination. Diverse procedures were used for reconstruction. Early complications occurred in two patients (18%), and late complications in four patients (36%). Sarcoma resection was found to be highly morbid in our series. Patients with poor preoperative nutritional status were more likely to experience complications postoperatively. The decision to stage a reconstruction was complex and influenced by several factors. Multimodal sarcoma treatments may involve highly morbid procedures and create complex wounds. The GHOST protocol is a useful reference for plastic surgeons. C1 [Kobraei, Edward M.; Eberlin, Kyle R.; Ricci, Joseph A.; Reish, Richard G.; Winograd, Jonathan M.; Cetrulo, Curtis L., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA USA. RP Kobraei, EM (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, 148 Newton St,Unit 3, Brighton, MA 02135 USA. EM eddiekobra@gmail.com NR 22 TC 0 Z9 1 U1 1 U2 1 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD JUN PY 2015 VL 81 IS 6 BP 557 EP 563 PG 7 WC Surgery SC Surgery GA CN2EM UT WOS:000358233400017 PM 26031266 ER PT J AU Yin, SY Jin, WP De Salles, A AF Yin, Shaoya Jin, Weipeng De Salles, Antonio TI Occipital-device-related pain as a complication of deep brain stimulation SO BRITISH JOURNAL OF NEUROSURGERY LA English DT Article DE complication; deep brain stimulation; essential tremor; occipital pain; Parkinson's disease; reposition ID HARDWARE COMPLICATIONS; SURGERY; IMPLANTATION AB Deep brain stimulation is an established treatment for movement disorders. We reported 4 patients (1.3%) of postoperative occipital headache related to the placement of the connection among 309 patients from 1998 to 2008. The patients were treated successfully by repositioning the connector into a groove created in the bone. C1 [Yin, Shaoya; De Salles, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA. [Yin, Shaoya; De Salles, Antonio] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yin, Shaoya] Tianjin Huanhu Hosp, Neurol Cent Hosp Tianjin, Dept Neurosurg, Tianjin, Peoples R China. [Jin, Weipeng] Tianjin Med Univ, Hosp 2, Dept Neurosurg, Tianjin, Peoples R China. RP Yin, SY (reprint author), Dept Neurosurg, Neurosurg, 122 Qixiangtai Rd, Tianjin 300060, Peoples R China. EM yinsy@163.com NR 14 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0268-8697 EI 1360-046X J9 BRIT J NEUROSURG JI Br. J. Neurosurg. PD JUN PY 2015 VL 29 IS 3 BP 340 EP 342 DI 10.3109/02688697.2014.1003031 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CN7OY UT WOS:000358625100007 PM 25659960 ER PT J AU Dick, AW Pacula, RL Gordon, AJ Sorbero, M Burns, RM Leslie, D Stein, BD AF Dick, Andrew W. Pacula, Rosalie L. Gordon, Adam J. Sorbero, Mark Burns, Rachel M. Leslie, Douglas Stein, Bradley D. TI Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11 SO HEALTH AFFAIRS LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; OFFICE-BASED TREATMENT; UNITED-STATES; USE DISORDER; ADDICTION TREATMENT; DEPENDENT PATIENTS; COST-EFFECTIVENESS; OPIATE ADDICTION; RISK BEHAVIORS; NONMEDICAL USE AB Opioid use disorders are a significant public health problem, affecting two million people in the United States. Treatment with buprenorphine, methadone, or both is predominantly offered in methadone clinics, yet many people do not receive the treatment they need. In 2002 the Food and Drug Administration approved buprenorphine for prescription by physicians who completed a course and received a waiver from the Drug Enforcement Administration, exempting them from requirements in the Controlled Substances Act. To determine the waiver program's impact on the availability of opioid agonist treatment, we analyzed data for the period 2002-11 to identify counties with opioid treatment shortages. We found that the percentage of counties with a shortage of waivered physicians fell sharply, from 98.9 percent in 2002 to 46.8 percent in 2011. As a result, the percentage of the US population residing in what we classified as opioid treatment shortage counties declined from 48.6 percent in 2002 to 10.4 percent in 2011. These findings suggest that the increase in waivered physicians has dramatically increased potential access to opioid agonist treatment. Policy makers should focus their efforts on further increasing the number and geographical distribution of physicians, particularly in more rural counties, where prescription opioid misuse is rapidly growing. C1 [Dick, Andrew W.] RAND Corp, Boston, MA 02116 USA. [Pacula, Rosalie L.] RAND, Santa Monica, CA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Med, Pittsburgh, PA 15260 USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sorbero, Mark; Burns, Rachel M.; Stein, Bradley D.] RAND, Pittsburgh, PA USA. [Leslie, Douglas] Penn State Coll Med, Publ Hlth Sci & Psychiat, Pittsburgh, PA USA. [Stein, Bradley D.] Univ Pittsburgh, Sch Med, Psychiat, Pittsburgh, PA 15260 USA. RP Dick, AW (reprint author), RAND Corp, Boston, MA 02116 USA. EM stein@rand.org FU National Institute on Drug Abuse of the National Institutes of Health [1R01DA032881-01A1] FX An earlier version on this article was presented at the Addiction Health Services Research conference in Portland, Oregon, October 23-25, 2013. Bradley Stein was previously an employee of Community Care Behavioral Health Organization, a nonprofit organization that manages behavioral health services for Medicaid enrollees in Pennsylvania. Stein has also served on an advisory board for Otsuka Pharmaceuticals. Adam Gordon receives royalties from Cambridge University Press and UptoDate for work unrelated to the topic of this article. The authors are indebted to Steve Mason of the Substance Abuse and Mental Health Services Administration for assistance with the Buprenorphine Waiver Notification System data; Mary Vaiana, Sebastian Bauhoff, Carrie Farmer, and Todd Mandell for review and Feedback on earlier versions of the manuscript; and Gina Boyd for research assistance The National Institute on Drug Abuse of the National Institutes of Health supported this study (Grant No 1R01DA032881-01A1). NR 57 TC 9 Z9 9 U1 5 U2 8 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUN PY 2015 VL 34 IS 6 BP 1028 EP 1034 DI 10.1377/hlthaff.2014.1205 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CN5EY UT WOS:000358453800018 PM 26056209 ER PT J AU El-Far, M Ancuta, P Routy, JP Zhang, YW Bakeman, W Bordi, R DaFonseca, S Said, EA Gosselin, A Tep, TS Eichbaum, Q van Grevenynghe, J Schwartz, O Freeman, GJ Haddad, EK Chomont, N Sekaly, RP AF El-Far, Mohamed Ancuta, Petronela Routy, Jean-Pierre Zhang, Yuwei Bakeman, Wendy Bordi, Rebeka DaFonseca, Sandrina Said, Elias A. Gosselin, Annie Tep, Tevy-Suzy Eichbaum, Quentin van Grevenynghe, Julien Schwartz, Olivier Freeman, Gordon J. Haddad, Elias K. Chomont, Nicolas Sekaly, Rafick-Pierre TI Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID INDUCED CD4 DEGRADATION; HIV-1 NEF; DOWN-REGULATION; IMMUNOLOGICAL SYNAPSE; UP-REGULATION; INFECTION; CTLA-4; LYMPHOCYTES; BINDING; PROTEIN AB CTLA-4 is a negative regulator of 1-cell receptor-mediated CD4(+) T-cell activation and function. Upregulation of CTLA-4 during human immunodeficiency virus type 1 (HIV-1) infection on activated T cells, particularly on HIV-specific CD4(+) T cells, correlates with immune dysfunction and disease progression. As HIV-1 infects and replicates in activated CD4(+) T cells, we investigated mechanisms by which HIV-1 modulates CTLA-4 expression to establish productive viral infection in these cells. Here, we demonstrate that HIV-1 infection in activated CD4(+) T cells was followed by Nef-mediated downregulation of CTLA-4. This was associated with a decreased 1-cell activation threshold and significant resistance to CTLA-4 triggering. In line with these in vitro results, quantification of pro-viral HIV DNA from treatment-naive HIV-infected subjects demonstrated a preferential infection of memory CD4(+)CTLA-4(+) T cells, thus identifying CTLA-4 as a biomarker for HIV-infected cells in vivo. As transcriptionally active HIV-1 and Nef expression in vivo were previously shown to take place mainly in the CD3(+)CD4(-)CD8(-) [double-negative (DN)] cells, we further quantified HIV DNA in the CTLA-4(+) and CTLA-4(-) subpopulations of these cells. Our results showed that DN T cells lacking CTLA-4 expression were enriched in HIV DNA compared with DN CTLA-4(+) cells. Together, these results suggested that HIV-1 preferential infection of CD4(+)CTLA-4(+) T cells in vivo was followed by Nef-mediated concomitant downregulation of both CD4 and CTLA-4 upon transition to productive infection. This also highlights the propensity of HIV-1 to evade restriction of the key negative immune regulator CTLA-4 on cell activation and viral replication, and therefore contributes to the overall HIV-1 pathogenesis. C1 [El-Far, Mohamed; Ancuta, Petronela; Zhang, Yuwei; Bordi, Rebeka; DaFonseca, Sandrina; Said, Elias A.; Gosselin, Annie; Tep, Tevy-Suzy; van Grevenynghe, Julien; Haddad, Elias K.; Chomont, Nicolas; Sekaly, Rafick-Pierre] CHU Montreal, Ctr Rech, Montreal, PQ, Canada. [El-Far, Mohamed; Ancuta, Petronela; Zhang, Yuwei; DaFonseca, Sandrina; Said, Elias A.; Tep, Tevy-Suzy; van Grevenynghe, Julien; Chomont, Nicolas; Sekaly, Rafick-Pierre] Univ Montreal, Dept Microbiol lnfectiol & Immunol, Quebec City, PQ, Canada. [Routy, Jean-Pierre] McGill Univ, Ctr Hlth, Div Hematol & Chron Viral Illness Serv, Montreal, PQ, Canada. [Zhang, Yuwei; Bakeman, Wendy; Bordi, Rebeka; DaFonseca, Sandrina; van Grevenynghe, Julien; Haddad, Elias K.; Chomont, Nicolas; Sekaly, Rafick-Pierre] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA. [Eichbaum, Quentin] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Schwartz, Olivier] Inst Pasteur, Dept Virol, Virus & Immun Grp, Paris, France. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Sekaly, Rafick-Pierre] Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Chomont, N (reprint author), CHU Montreal, Ctr Rech, Montreal, PQ, Canada. EM nchomont@vgtifl.org; rafick.sekaly@gmail.com FU Canadian Institutes of Health Research; US National Institutes of Health [NIH U19 AI096109-03, IDPIDA028871-01]; Canadian Institutes of Health Research [103230]; Canadian Institutes of Health Research Canadian HIV Trials Network [CTN 257]; Fonds de la Recherche Quebec-Sante: Reseau SIDA/Maladies infectieuses FX We are grateful to J. D. Schatzle, N. Casartelli, S. Deschenes and M. R. Boulassel for fruitful discussions and reading the manuscript. We extend our thanks to S. Gimmig, L. Lejeune and D. Gauchat for technical expertise with cell sorting, as well as to A. Filali-Mouhim and J.-P. Goulet for helping with the statistical analysis. M. E., E. A. S. and J. V. G. are funded by the Canadian Institutes of Health Research. J-P. R. holds the Louis Lowenstein Chair in Haematology & Oncology at McGill University. This study was supported by funds from the US National Institutes of Health (NIH U19 AI096109-03 and IDPIDA028871-01), Canadian Institutes of Health Research (103230), Canadian Institutes of Health Research Canadian HIV Trials Network (CTN 257) and Fonds de la Recherche Quebec-Sante: Reseau SIDA/Maladies infectieuses. NR 50 TC 1 Z9 1 U1 0 U2 7 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD JUN PY 2015 VL 96 BP 1463 EP 1477 DI 10.1099/vir.0.000065 PN 6 PG 15 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA CN1OJ UT WOS:000358189000027 PM 25626682 ER PT J AU Psaros, C Kagan, L Shifren, JL Willett, J Jacquart, J Alert, MD Macklin, EA Styer, AK Denninger, JW LaRoche, KL Park, ER AF Psaros, Christina Kagan, Leslee Shifren, Jan L. Willett, Jessica Jacquart, Jolene Alert, Marissa D. Macklin, Eric A. Styer, Aaron K. Denninger, John W. LaRoche, Katie L. Park, Elyse R. TI Mind-body group treatment for women coping with infertility: a pilot study SO JOURNAL OF PSYCHOSOMATIC OBSTETRICS AND GYNECOLOGY LA English DT Article DE Adherence; infertility; mental health; mind-body; relaxation response; stress ID IN-VITRO FERTILIZATION; LIFE ORIENTATION TEST; RELAXATION RESPONSE; PSYCHOLOGICAL INTERVENTIONS; SALIVARY CORTISOL; PERCEIVED STRESS; PRIMATE MODELS; ANXIETY; IMPACT; YOGA AB Objectives: To evaluate the feasibility of a 10-week mind-body intervention (MBI) for women coping with fertility challenges, examine the impact of an MBI on psychological distress and cortisol levels, and assess adherence to MBI skills 12-months after completion of the intervention. Design: Prospective open pilot study of 51 women with infertility enrolled in a group MBI. Psychological variables and salivary cortisol levels were obtained pre- and post-intervention; a 12-month follow-up survey assessed MBI skill adherence. Participants completed practice logs throughout the intervention. Results: Participants attended an average of eight sessions (SD = 2.0), and practiced mind-body techniques which elicited the relaxation response (RR) an average of 5.9 (SD = 0.8) days/week and 20.1 (SD = 9.9) min/day; 80% completed the post-treatment assessment. The intervention resulted in a significant increase in perceived social support and a decrease in depressive symptoms and perceived stress; however, there were no significant changes in cortisol levels. Sixty-eight percent of the participants completed the 12-month follow-up, with 51% reporting continuation of RR-eliciting practice. Conclusion: This group of women with infertility provided with an MBI showed decreased symptoms of depression and stress and increased perceived social support. The protocol was feasible and participants reported a high degree of adherence and maintenance to the skills taught during the intervention. The findings indicate the value of appropriate evaluation against a control group. C1 [Psaros, Christina; Kagan, Leslee; Willett, Jessica; Jacquart, Jolene; Alert, Marissa D.; Denninger, John W.; LaRoche, Katie L.; Park, Elyse R.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Psaros, Christina; Denninger, John W.; Park, Elyse R.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Shifren, Jan L.; Styer, Aaron K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Fertil Ctr,Vincent Dept Obstet & Gynecol, Boston, MA USA. [Macklin, Eric A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Macklin, Eric A.] Harvard Univ, Sch Med, Boston, MA USA. RP Psaros, C (reprint author), Massachusetts Gen Hosp, Dept Psychiat, One Bowdoin Sq, Boston, MA 02114 USA. EM cpsaros@partners.org OI Macklin, Eric/0000-0003-1618-3502 FU Centers for Disease Control and Prevention [5R01DP000339] FX The study was funded by Centers for Disease Control and Prevention, grant number 5R01DP000339. NR 62 TC 3 Z9 3 U1 5 U2 13 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0167-482X EI 1743-8942 J9 J PSYCHOSOM OBST GYN JI J. Psychosomat. Obstet. Gynecol. PD JUN PY 2015 VL 36 IS 2 BP 75 EP 83 DI 10.3109/0167482X.2014.989983 PG 9 WC Psychology, Clinical; Obstetrics & Gynecology; Psychiatry SC Psychology; Obstetrics & Gynecology; Psychiatry GA CN6BF UT WOS:000358517700006 PM 25541217 ER PT J AU McCormack, S Johnson, B Saunders, RH Jacobsen, PL Siegel, MA Friedlander, AH DeLuke, DM AF McCormack, Steve Johnson, Bart Saunders, Ralph H. Jacobsen, Peter L. Siegel, Michael A. Friedlander, Arthur H. DeLuke, Dean M. TI PROPHYLACTIC ANTIBIOTICS SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Editorial Material C1 [Johnson, Bart] Swedish Gen Practice Residency, Seattle, WA USA. [Saunders, Ralph H.] Univ Rochester, Eastman Inst Oral Hlth, Rochester, NY USA. [Jacobsen, Peter L.] Univ Pacific, San Francisco, CA USA. [Siegel, Michael A.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [DeLuke, Dean M.] Virginia Commonwealth Univ, Sch Dent, Richmond, VA USA. [DeLuke, Dean M.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JUN PY 2015 VL 146 IS 6 BP 357 EP 358 DI 10.1016/j.adaj.2015.04.019 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CN6CZ UT WOS:000358522500002 ER PT J AU Wilson, PC Fitzgibbon, WR Garrett, SM Jaffa, AA Luttrell, LM Brands, MW El-Shewy, HM AF Wilson, Parker C. Fitzgibbon, Wayne R. Garrett, Sara M. Jaffa, Ayad A. Luttrell, Louis M. Brands, Michael W. El-Shewy, Hesham M. TI Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; CA2+ ENTRY; CELL-PROLIFERATION; SIGNALING PATHWAYS; BASILAR ARTERIES; VASCULAR-TONE; IN-VITRO; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; 1-PHOSPHATE AB Angiotensin II (AngII) plays a critical role in the regulation of vascular tone and blood pressure mainly via regulation of Ca2+ mobilization. Several reports have implicated sphingosine kinase 1 (SK1)/sphingosine 1-phosphate (S1P) in the mobilization of intracellular Ca2+ through a yet-undefined mechanism. Here we demonstrate that AngII-induces biphasic calcium entry in vascular smooth muscle cells, consisting of an immediate peak due to inositol tris-phosphate-dependent release of intracellular calcium, followed by a sustained transmembrane Ca2+ influx through store-operated calcium channels (SOCs). Inhibition of SK1 attenuates the second phase of transmembrane Ca2+ influx, suggesting a role for SK1 in AngII-dependent activation of SOC. Intracellular S1P triggers SOC-dependent Ca2+ influx independent of S1P receptors, whereas external application of S1P stimulated S1P receptor-dependent Ca2+ influx that is insensitive to inhibitors of SOCs, suggesting that the SK1/S1P axis regulates store-operated calcium entry via intracellular rather than extracellular actions. Genetic deletion of SK1 significantly inhibits both the acute hypertensive response to AngII in anaesthetized SK1 knockout mice and the sustained hypertensive response to continuous infusion of AngII in conscious animals. Collectively these data implicate SK1 as the missing link that connects the angiotensin AT1A receptor to transmembrane Ca2+ influx and identify SOCs as a potential intracellular target for SK1. C1 [Wilson, Parker C.] Yale New Haven Med Ctr, Dept Pathol, New Haven, CT 06510 USA. [Fitzgibbon, Wayne R.; Garrett, Sara M.; Jaffa, Ayad A.; Luttrell, Louis M.; El-Shewy, Hesham M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Dept Res Serv, Charleston, SC 29401 USA. [Brands, Michael W.] Georgia Hlth Sci Univ, Dept Physiol, Med Coll Georgia, Augusta, GA 30912 USA. [Jaffa, Ayad A.] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut 1136044, Lebanon. RP El-Shewy, HM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St,MSC 776, Charleston, SC 29425 USA. EM elshewy@musc.edu FU National Institutes of Health COBRE in Lipidomics and Pathobiology at Medical University of South Carolina; National Institutes of Health [DK55524, S10 RR027777, HL077192, HL087986]; Dialysis Clinics Inc Grant FX This work was supported by National Institutes of Health COBRE in Lipidomics and Pathobiology at Medical University of South Carolina (to H.M.E.), National Institutes of Health Grants DK55524, S10 RR027777 (to L.M.L.), HL077192, and HL087986 (to A.A.J.), and Dialysis Clinics Inc Grant (to W.R.F.). NR 49 TC 4 Z9 4 U1 0 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JUN PY 2015 VL 29 IS 6 BP 896 EP 908 DI 10.1210/me.2014-1388 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN6HA UT WOS:000358534000010 PM 25871850 ER PT J AU Hariri, LP AF Hariri, Lida P. TI In Vivo Microscopy Will the Microscope Move From Our Desk Into the Patient? SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Editorial Material ID OPTICAL COHERENCE TOMOGRAPHY C1 [Hariri, Lida P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Hariri, Lida P.] Harvard Univ, Sch Med, Boston, MA USA. RP Hariri, LP (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren Bldg 219, Boston, MA 02114 USA. EM LHARIRI@mgh.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD JUN PY 2015 VL 139 IS 6 BP 719 EP 720 DI 10.5858/arpa.2014-0549-ED PG 2 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA CN3BR UT WOS:000358298900008 PM 26030239 ER PT J AU Deshpande, V AF Deshpande, Vikram TI IgG4-Related Disease of the Gastrointestinal Tract A 21st Century Chameleon SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID PRIMARY SCLEROSING CHOLANGITIS; IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; HEPATIC INFLAMMATORY PSEUDOTUMOR; AUTOIMMUNE PANCREATITIS; DIAGNOSTIC-CRITERIA; PLASMA-CELLS; EXTRAHEPATIC CHOLANGIOCARCINOMA; SYSTEMIC-DISEASE; BILE-DUCT; FEATURES AB Context.-Immunoglobulin G4 (IgG4)-related disease is a systemic fibroinflammatory disease capable of affecting virtually any organ. Although the pancreas and hepatobiliary system are commonly affected, involvement of the tubular gut is unusual. The pancreatic manifestations of this disease (autoimmune pancreatitis) often mimic pancreatic carcinoma, whereas the hepatobiliary manifestations are mistaken for cholangiocarcinoma or primary sclerosing cholangitis. The characteristic histologic features include a dense lymphoplasmacytic infiltrate, storiform-type fibrosis, and obliterative phlebitis. An increase in IgG4(+) plasma cells and an IgG4 to IgG ratio of more than 40% are considered obligatory components of the diagnostic algorithm. Objective.-To review the challenges associated with the diagnosis of IgG4-related disease of the gastrointestinal tract. Data Sources.-A review of pertinent literature, along with the author's personal experience, based on institutional and consultation materials. Conclusion.-The complete spectrum of histologic changes is seldom captured in a biopsy specimen, and thus, the histopathology findings are best interpreted within the overall clinical context. Increased IgG4(+) plasma cells are identified in a variety of benign and malignant diseases of the gastrointestinal tract. C1 [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Deshpande, Vikram] Harvard Univ, Sch Med, Boston, MA USA. RP Deshpande, V (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 2, Boston, MA 02114 USA. EM Vikramdirdeshpande@gmail.com NR 48 TC 5 Z9 5 U1 0 U2 0 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD JUN PY 2015 VL 139 IS 6 BP 742 EP 749 DI 10.5858/arpa.2014-0181-RA PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA CN3BR UT WOS:000358298900012 PM 26030243 ER PT J AU Zhao, CQ Moriarty, AT Ghofrani, M Husain, M Tambouret, RH Laucirica, R Laser, A Fischer, A Ocal, IT Souers, RJ Russell, DK Fan, F Crothers, BA AF Zhao, Chengquan Moriarty, Ann T. Ghofrani, Mohiedean Husain, Mujtaba Tambouret, Rosemary H. Laucirica, Rodolfo Laser, Alice Fischer, Andrew Ocal, Idris T. Souers, Rhona J. Russell, Donna K. Fan, Fang Crothers, Barbara A. TI Human Papillomavirus Testing and Reporting Rates in 2012 Results of a College of American Pathologists National Survey SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID INTERLABORATORY COMPARISON PROGRAM; CURRENT LABORATORY PRACTICES; ATYPICAL SQUAMOUS CELLS; CERVICOVAGINAL CYTOLOGY; CERVICAL-CANCER; UNDETERMINED SIGNIFICANCE; CONSENSUS GUIDELINES; SPECIMEN ADEQUACY; PARTICIPANTS; MANAGEMENT AB Context.-College of American Pathologists (CAP) surveys are used to establish national benchmarks for laboratory parameters. Objective.-To evaluate changes in laboratory human papillomavirus (HPV) testing patterns in laboratories incorporating HPV testing with Papanicolaou tests in 2012. Design.-Data were analyzed from the CAP HPV Supplemental Questionnaire distributed to 1771 laboratories participating in either CAP HPV or CAP Papanicolaou proficiency testing in 2013. Results.-A total of 1022 laboratories (58%) responded. There were more high-risk (HR) HPV tests performed per institution as compared to previous surveys. There were more HPV tests performed within an institution as compared to previous surveys. Hybrid Capture 2 (HC2) remains the most common method (42.4%, 239 of 564); Cervista and cobas methods are used in 37.2% (210 of 564) and 14.9% (84 of 564) of laboratories, respectively. Human papillomavirus testing is offered as a reflex test after a Papanicolaou test result of atypical squamous cells of undetermined significance (ASC-US) in 89.6% of laboratories (476 of 531); as a cotest for women aged 30 years and older in 60.3% (404 of 531); as reflex testing after atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) in 42.7% (320 of 531); and as reflex testing after atypical glandular cells (AGC) in 27.3% (145 of 531). The HPV-positive rates for ASC-US and ASC-H were similar in 2012 and 2006. Cervista (49.2%, 88 of 179) and Roche cobas (27.4%, 49 of 179) are the most common methods used for genotyping. Most laboratories use the CAP Human Papillomavirus for Cytology Program for proficiency testing. Conclusions.-There was an increase in annual volume of HR-HPV testing with a shift toward in-house HR-HPV testing. Genotyping volumes also increased. HC2 and Cervista are most commonly used, with an increasing volume of Roche cobas testing. The most common indication for HPV testing among all laboratories was ASC-US reflex testing, but an increase in HPV cotesting was observed. The data provide an update into persisting and newer trends in HPV testing practices. C1 [Zhao, Chengquan] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. [Moriarty, Ann T.] AmeriPath Indiana, Dept Esoter Testing, Indianapolis, IN USA. [Ghofrani, Mohiedean] PeaceHlth Labs, Dept Pathol, Vancouver, WA USA. [Husain, Mujtaba] Univ Cent Florida, Clin Sci, Orlando, FL 32816 USA. [Tambouret, Rosemary H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Laucirica, Rodolfo] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Laser, Alice] North Shore LIJ Hlth Syst, Dept Pathol, New Hyde Pk, NY USA. [Fischer, Andrew] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA. [Ocal, Idris T.] Mayo Clin, Dept Pathol, Scottsdale, AZ USA. [Souers, Rhona J.] Coll Amer Pathologists, Biostat, Northfield, IL USA. [Russell, Donna K.] Univ Rochester, Dept Pathol, Med Ctr, Rochester, NY 14627 USA. [Fan, Fang] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS USA. [Crothers, Barbara A.] Walter Reed Natl Mil Med Ctr, Dept Pathol, Bethesda, MD USA. RP Zhao, CQ (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, 300 Halket St, Pittsburgh, PA 15213 USA. EM zhaoc@upmc.edu FU College of American Pathologists (CAP) FX The study was supported by the College of American Pathologists (CAP), but conceptualized by members of the CAP Cytopathology Committee. NR 14 TC 6 Z9 6 U1 0 U2 1 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD JUN PY 2015 VL 139 IS 6 BP 757 EP 761 DI 10.5858/arpa.2014-0393-CP PG 5 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA CN3BR UT WOS:000358298900014 PM 25436905 ER PT J AU Demirjian, A Lucas, CE Garrison, LE Kozak-Muiznieks, NA States, S Brown, EW Wortham, JM Beaudoin, A Casey, ML Marriott, C Ludwig, AM Sonel, AF Muder, RR Hicks, LA AF Demirjian, Alicia Lucas, Claressa E. Garrison, Laurel E. Kozak-Muiznieks, Natalia A. States, Stanley Brown, Ellen W. Wortham, Jonathan M. Beaudoin, Amanda Casey, Megan L. Marriott, Chandra Ludwig, Alison M. Sonel, Ali F. Muder, Robert R. Hicks, Lauri A. TI The Importance of Clinical Surveillance in Detecting Legionnaires' Disease Outbreaks: A Large Outbreak in a Hospital With a Legionella Disinfection System-Pennsylvania, 2011-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Legionnaires' disease; Legionella pneumophila; healthcare-acquired infection; disinfectants; infection control ID COPPER-SILVER IONIZATION; SEQUENCE-BASED SCHEME; WATER; PNEUMOPHILA; CONSTRUCTION; EXPERIENCE; PNEUMONIA; FOUNTAIN; IONS; GENE AB Background. Healthcare-associated Legionnaires' disease (LD) is a preventable pneumonia with a 30% case fatality rate. The Centers for Disease Control and Prevention guidelines recommend a high index of suspicion for the diagnosis of healthcare-associated LD. We characterized an outbreak and evaluated contributing factors in a hospital using copper-silver ionization for prevention of Legionella growth in water. Methods. Through medical records review at a large, urban tertiary care hospital in November 2012, we identified patients diagnosed with LD during 2011-2012. Laboratory-confirmed cases were categorized as definite, probable, and not healthcare associated based on time spent in the hospital during the incubation period. We performed an environmental assessment of the hospital, including collection of samples for Legionella culture. Clinical and environmental isolates were compared by genotyping. Copper and silver ion concentrations were measured in 11 water samples. Results. We identified 5 definite and 17 probable healthcare-associated LD cases; 6 case patients died. Of 25 locations (mostly potable water) where environmental samples were obtained for Legionella-specific culture, all but 2 showed Legionella growth; 11 isolates were identical to 3 clinical isolates by sequence-based typing. Mean copper and silver concentrations were at or above the manufacturer's recommended target for Legionella control. Despite this, all samples where copper and silver concentrations were tested showed Legionella growth. Conclusions. This outbreak was linked to the hospital's potable water system and highlights the importance of maintaining a high index of suspicion for healthcare-associated LD, even in the setting of a long-term disinfection program. C1 [Demirjian, Alicia; Wortham, Jonathan M.; Beaudoin, Amanda; Ludwig, Alison M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30309 USA. [Demirjian, Alicia; Lucas, Claressa E.; Garrison, Laurel E.; Kozak-Muiznieks, Natalia A.; Brown, Ellen W.; Wortham, Jonathan M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30309 USA. [States, Stanley] Pittsburgh Water & Sewer Author, Pittsburgh, PA USA. [Beaudoin, Amanda] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Casey, Megan L.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA. [Marriott, Chandra] Penn Dept Hlth, Pittsburgh, PA USA. [Ludwig, Alison M.] VA Off Publ Hlth Surveillance & Res, Palo Alto, CA USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Demirjian, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30309 USA. EM alicia.demirjian@post.harvard.edu NR 32 TC 16 Z9 16 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1596 EP 1602 DI 10.1093/cid/civ153 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500007 PM 25722201 ER PT J AU Calderwood, SB AF Calderwood, Stephen B. TI IDSA Response to Factors Contributing to the Decline of Medical Residents Choosing the Field of Infectious Diseases SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Calderwood, Stephen B.] Infect Dis Soc Amer, Arlington, VA USA. RP Calderwood, SB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM calderwood.stephen@mgh.harvard.edu NR 3 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1724 EP 1724 DI 10.1093/cid/civ149 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500027 PM 25713184 ER PT J AU Yamada, T Cavelti-Weder, C Caballero, F Lysy, PA Guo, LL Sharma, A Li, WD Zhou, Q Bonner-Weir, S Weir, GC AF Yamada, Takatsugu Cavelti-Weder, Claudia Caballero, Francisco Lysy, Philippe A. Guo, Lili Sharma, Arun Li, Weida Zhou, Qiao Bonner-Weir, Susan Weir, Gordon C. TI Reprogramming Mouse Cells With a Pancreatic Duct Phenotype to Insulin-Producing beta-Like Cells SO ENDOCRINOLOGY LA English DT Article ID PROGENITOR CELLS; EXOCRINE CELLS; ACINAR-CELLS; ISLET CELLS; IN-VIVO; REGENERATION; DIFFERENTIATION; MATURATION; GENERATION; GROWTH AB Reprogramming technology has opened the possibility of converting one cell type into another by forced expression of transgenes. Transduction of adenoviral vectors encoding 3 pancreatic transcription factors, Pdx1, Ngn3, and MafA, into mouse pancreas results in direct reprogramming of exocrine cells to insulin-producing beta-like cells. We hypothesized that cultured adult pancreatic duct cells could be reprogrammed to become insulin- producing beta-cells by adenoviral-mediated expression of this same combination of factors. Exocrine were isolated from adult mouse insulin 1 promoter (MIP)-green fluorescent protein (GFP) transgenic mice to allow new insulin- expressing cells tobedetected by GFP fluorescence. Cultured cells were transduced by an adenoviral vector carrying a polycistronic construct Ngn3/Pdx1/MafA/mCherry (Ad-M3C) or mCherry sequence alone as a control vector. In addition, the effects of glucagon-like peptide-1 (GLP-1) receptor agonist, exendin-4 (Ex-4) on the reprogramming process were examined. GFP(+) cells appeared 2 days after Ad-M3C transduction; the reprogramming efficiency was 8.6 +/- 2.6% by day 4 after transduction. Ad-M3C also resulted in increased expression of beta-cell markers insulin 1 and 2, with enhancement by Ex-4. Expression of other beta-cell markers, neuroD and GLP-1 receptor, were also significantly up-regulated. The amount of insulin release into the media and insulin content of the cells were significantly higher in the Ad-M3C-transduced cells; this too was enhanced by Ex-4. The transduced cells did not secrete insulin in response to increased glucose, indicating incomplete differentiation to beta-cells. Thus, cultured murine adult pancreatic cells with a duct phenotype can be directly reprogrammed to insulin- producing beta-like cells by adenoviral delivery of 3 pancreatic transcription factors. C1 [Yamada, Takatsugu; Cavelti-Weder, Claudia; Caballero, Francisco; Lysy, Philippe A.; Guo, Lili; Sharma, Arun; Bonner-Weir, Susan; Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol,Res Div, Boston, MA 02215 USA. [Li, Weida; Zhou, Qiao] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. RP Weir, GC (reprint author), Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, One Joslin Pl, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu FU Juvenile Diabetes Research Foundation; Hahnemann Hospital Foundation; National Institutes of Health [R01 DK066056, DK093909, P30 DK036836]; Diabetes Research and Wellness Foundation FX This work was supported by grants from the Juvenile Diabetes Research Foundation and the Hahnemann Hospital Foundation (G.C.W.), by National Institutes of Health Grants R01 DK066056 and DK093909 (to S.B.-W.) and P30 DK036836 (Joslin Diabetes Research Center and its Advanced Microscopy Core), and by the Diabetes Research and Wellness Foundation. NR 40 TC 6 Z9 6 U1 1 U2 8 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2015 VL 156 IS 6 BP 2029 EP 2038 DI 10.1210/en.2014-1987 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN4YB UT WOS:000358435400013 PM 25836667 ER PT J AU Balhara, B Burkart, A Topcu, V Lee, YK Cowan, C Kahn, CR Patti, ME AF Balhara, Bharti Burkart, Alison Topcu, Vehap Lee, Youn-Kyoung Cowan, Chad Kahn, C. Ronald Patti, Mary-Elizabeth TI Severe Insulin Resistance Alters Metabolism in Mesenchymal Progenitor Cells SO ENDOCRINOLOGY LA English DT Article ID EPIDERMAL-GROWTH-FACTOR; RECEPTOR GENE-EXPRESSION; PLURIPOTENT STEM-CELLS; SKELETAL-MUSCLE; MITOCHONDRIAL DYSFUNCTION; MUTANT ALLELES; WEIGHT-LOSS; LEPRECHAUNISM; DEFECTS; PATIENT AB Donohue syndrome (DS) is characterized by severe insulin resistance due to mutations in the insulin receptor (INSR) gene. To identify molecular defects contributing to metabolic dysregulation in DS in the undifferentiated state, we generated mesenchymal progenitor cells (MPCs) from induced pluripotent stem cells derived from a 4-week-old female with DS and a healthy newborn male (control). INSR mRNA and protein were significantly reduced in DS MPC (for beta-subunit, 64% and 89% reduction, respectively, P < .05), but IGF1R mRNA and protein did not differ vs control. Insulin-stimulated phosphorylation of INSR or the downstream substrates insulin receptor substrate 1 and protein kinase B did not differ, but ERK phosphorylation tended to be reduced in DS (32% decrease, P = .07). By contrast, IGF-1 and insulin-stimulated insulin-like growth factor 1 (IGF-1) receptor phosphorylation were increased in DS (IGF-1, 8.5-vs 4.5-fold increase; INS, 11-vs 6-fold; P = .05). DS MPC tended to have higher oxygen consumption in both the basal state (87% higher, P = .09) and in response to the uncoupler carbonyl cyanide-p-triflouromethoxyphenylhydrazone (2-fold increase, P = .06). Although mitochondrial DNA or mass did not differ, oxidative phosphorylation protein complexes III and V were increased in DS (by 37% and 6%, respectively; P < .05). Extracellular acidification also tended to increase in DS (91% increase, P = .07), with parallel significant increases in lactate secretion (34% higher at 4 h, P < .05). In summary, DS MPC maintain signaling downstream of the INSR, suggesting that IGF-1R signaling may partly compensate for INSR mutations. However, alterations in receptor expression and pathway-specific defects in insulin signaling, even in undifferentiated cells, can alter cellular oxidative metabolism, potentially via transcriptional mechanisms. C1 [Balhara, Bharti; Burkart, Alison; Topcu, Vehap; Kahn, C. Ronald; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Lee, Youn-Kyoung; Cowan, Chad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Lee, Youn-Kyoung; Cowan, Chad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Lee, Youn-Kyoung; Cowan, Chad] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Patti, ME (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM mary.elizabeth.patti@joslin.harvard.edu RI Topcu, Vehap/E-5545-2015 OI Topcu, Vehap/0000-0001-7224-5697 FU Pediatric Endocrine Society grant; National Institutes of Health [T32DK007260]; Harold Whitworth Pierce Charitable Trust postdoctoral fellowship; Scientific and Technological Research Council of Turkey; American Diabetes Association; Novo Foundation FX This work was supported in part by a Pediatric Endocrine Society grant (B.B.), the National Institutes of Health Grant T32DK007260 (to A.B.), the Harold Whitworth Pierce Charitable Trust postdoctoral fellowship (A.B.), The Scientific and Technological Research Council of Turkey (V.T.), the American Diabetes Association (M.-E.P.), and the Novo Foundation (M.E.P. and C.R.K.). NR 44 TC 3 Z9 3 U1 1 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2015 VL 156 IS 6 BP 2039 EP 2048 DI 10.1210/en.2014-1403 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN4YB UT WOS:000358435400014 PM 25811318 ER PT J AU Seremwe, M Schnellmann, RG Bollag, WB AF Seremwe, Mutsa Schnellmann, Rick G. Bollag, Wendy B. TI Calpain-10 Activity Underlies Angiotensin II-Induced Aldosterone Production in an Adrenal Glomerulosa Cell Model SO ENDOCRINOLOGY LA English DT Article ID SKELETAL-MUSCLE; SECRETION; CALCIUM; INHIBITOR; SYSTEM; DYSFUNCTION; EXPRESSION; INFLUX; LINES AB Aldosterone is a steroid hormone important in the regulation of blood pressure. Aberrant production of aldosterone results in the development and progression of diseases including hypertension and congestive heart failure; therefore, a complete understanding of aldosterone production is important for developing more effective treatments. Angiotensin II (AngII) regulates steroidogenesis, in part through its ability to increase intracellular calcium levels. Calcium can activate calpains, proteases classified as typical or atypical based on the presence or absence of penta-EF-hands, which are involved in various cellular responses. We hypothesized that calpain, in particular calpain-10, is activated by AngII in adrenal glomerulosa cells and underlies aldosterone production. Our studies showed that pan-calpain inhibitors reduced AngII-induced aldosterone production in 2 adrenal glomerulosa cell models, primary bovine zona glomerulosa and human adrenocortical carcinoma (HAC15) cells, as well as CYP11B2 expression in the HAC15 cells. Although AngII induced calpain activation in these cells, typical calpain inhibitors had no effect on AngII-elicited aldosterone production, suggesting a lack of involvement of classical calpains in this process. However, an inhibitor of the atypical calpain, calpain-10, decreased AngII-induced aldosterone production. Consistent with this result, small interfering RNA (siRNA)-mediated knockdown of calpain-10 inhibited aldosterone production and CYP11B2 expression, whereas adenovirus-mediated overexpression of calpain-10 resulted in increased AngII-induced aldosterone production. Our results indicate that AngII-induced activation of calpain-10 in glomerulosa cells underlies aldosterone production and identify calpain-10 or its downstream pathways as potential targets for the development of drug therapies for the treatment of hypertension. C1 [Bollag, Wendy B.] Charlie Norwood Vet Adm Med Ctr, Augusta, GA 30904 USA. [Seremwe, Mutsa; Bollag, Wendy B.] Georgia Regents Univ, Dept Physiol, Augusta, GA 30912 USA. [Bollag, Wendy B.] Georgia Regents Univ, Dermatol Sect, Dept Med, Augusta, GA 30912 USA. [Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Bollag, WB (reprint author), Georgia Regents Univ, Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA. EM WB@gru.edu FU National Institutes of Health [HL070046, GM084147, ES012239]; Veterans Affairs Merit Review Award [BX001344, BX000851] FX This work was supported in part by the National Institutes of Health Grant HL070046 and Veterans Affairs Merit Review Award BX001344 (to W.B.B.) and by National Institutes of Health Grants GM084147 and ES012239 and Veterans Affairs Merit Review Award BX000851 (to R.G.S.). W.B.B. is also supported by a Veterans Affairs Research Career Scientist award. NR 34 TC 0 Z9 0 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2015 VL 156 IS 6 BP 2138 EP 2149 DI 10.1210/en.2014-1866 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN4YB UT WOS:000358435400022 PM 25836666 ER PT J AU Hayes, MA Gallagher, MW Gilbert, KS Creech, SK DeCandia, CJ Beach, CA Taft, CT AF Hayes, Maureen A. Gallagher, Matthew W. Gilbert, Karina Stavitsky Creech, Suzannah K. DeCandia, Carmela J. Beach, Corey A. Taft, Casey T. TI Targeting Relational Aggression in Veterans: The Strength at Home Friends and Family Intervention SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Psychotherapies; Veterans and Military Issues; Violence/Aggression ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; PSYCHOLOGICAL AGGRESSION; PHYSICAL AGGRESSION; SOCIAL SUPPORT; EARLY MARRIAGE; ALCOHOL-USE; METAANALYSIS; DEPRESSION; SEVERITY AB Objective: We evaluated the effectiveness of Strength at Home Friends and Families (SAH-F), a dyadic group intervention to prevent relational aggression and its negative consequences, in a community-based sample of service members/veterans and significant others who reported relational difficulties. Method: Participants included 70 veterans and their loved ones. Recruitment was conducted from October 2010 through March 2012. Participants completed an initial assessment that included measures of relational aggression and functioning, depressive symptoms, and posttraumatic stress disorder (PTSD) symptoms. Participants were enrolled in the 10-week SAH-F targeting social information-processing mechanisms hypothesized to underlie the relationship between trauma and aggression and were reassessed at program completion and 3 months after intervention. Results: Significant reductions in psychological aggression were seen both at program completion and at 3-month follow-up for both veterans (standardized mean gain effect size [ESsg] = -0.45, P <.05) and significant others (ESsg = -0.30, P <.05). Perpetration of physical aggression remained low after pretreatment and did not increase. Relationship adjustment reported by significant others, but not veterans, indicated a significant improvement from pretreatment to program completion (ESsg = 0.33, P <.05). Significant (P <.05) decreases in depressive symptoms were observed from pretreatment to program completion for veterans (ESsg = -0.30, P <.05) and significant others (ESsg = -0.55, P <.05), and significant decreases in PTSD symptoms were observed from pretreatment to follow-up for veterans and significant others (ESsg = -0.52, P <.05). Conclusions: Results provide support for the effectiveness of SAH-F in reducing relational aggression in military member/significant other dyads and enhancing relationship quality and mental health. (c) Copyright 2015 Physicians Postgraduate Press, Inc. C1 [Hayes, Maureen A.; DeCandia, Carmela J.; Beach, Corey A.] Amer Inst Res, Natl Ctr Family Homelessness, Waltham, MA USA. [Gallagher, Matthew W.; Gilbert, Karina Stavitsky; Creech, Suzannah K.; Taft, Casey T.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Gallagher, Matthew W.; Gilbert, Karina Stavitsky; Taft, Casey T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Creech, Suzannah K.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. RP Taft, CT (reprint author), VA Boston Healthcare Syst, 116B-2,150 South Huntington Ave, Boston, MA 02130 USA. EM casey.taft@va.gov OI Creech, Suzannah/0000-0002-6582-1673 FU Blue Shield of California Foundation FX Supported by a Blue Shield of California Foundation grant to The National Center on Family Homelessness at the American Institutes for Research. NR 25 TC 5 Z9 5 U1 2 U2 16 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2015 VL 76 IS 6 BP E774 EP E778 DI 10.4088/JCP.14m09155 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CN3WH UT WOS:000358358300009 PM 26132685 ER PT J AU Mischoulon, D AF Mischoulon, David TI Novel Approaches to Study Design and Intervention for Residual Symptoms of MDD SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Editorial Material DE Depression; Research Methods and Statistics ID RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; CLINICAL-TRIALS; PLACEBO NEEDLE; DOUBLE-BLIND; DE-QI; ACUPUNCTURE; MANAGEMENT; BELIEFS C1 [Mischoulon, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA. RP Mischoulon, D (reprint author), 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM dmischoulon@partners.org FU Bowman Family Foundation; FisherWallace; Nordic Naturals; Methylation Sciences; PharmoRx Therapeutics FX Dr Mischoulon has received research support from the Bowman Family Foundation, FisherWallace, Nordic Naturals, Methylation Sciences, and PharmoRx Therapeutics; has received honoraria for consulting, speaking, and writing from Pamlab and the Massachusetts General Hospital Psychiatry Academy; and has received royalties from Lippincott Williams & Wilkins for the published book Natural Medications for Psychiatric Disorders: Considering the Alternatives. NR 30 TC 1 Z9 1 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2015 VL 76 IS 6 BP E815 EP E817 DI 10.4088/JCP.14com09451 PG 3 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CN3WH UT WOS:000358358300015 PM 26132691 ER PT J AU Levey, EJ AF Levey, Elizabeth J. TI The Power of Intentionality in the Psychoanalytic Understanding of Development SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION LA English DT Article DE attachment; autism; development; intersubjectivity ID ATTACHMENT; ORIGINS; SELF C1 Massachusetts Gen Hosp, Child & Adolescent Psychiat, Boston, MA 02114 USA. RP Levey, EJ (reprint author), Massachusetts Gen Hosp, Child & Adolescent Psychiat, Yawkey 6A,32 Fruit St, Boston, MA 02114 USA. EM ejlevey@gmail.com NR 23 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-0651 EI 1941-2460 J9 J AM PSYCHOANAL ASS JI J. Am. Psychoanal. Assoc. PD JUN PY 2015 VL 63 IS 3 BP 529 EP 539 DI 10.1177/0003065115589743 PG 11 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA CN0QN UT WOS:000358118500016 PM 26185291 ER PT J AU Distel, LML Shepard, J Malone, J Waldinger, RJ AF Distel, Laura M. L. Shepard, John Malone, Johanna Waldinger, Robert J. TI LIFE SPAN TRAJECTORIES OF DEPRESSIVE SYMPTOMATOLOGY AND PERSONALITY FUNCTIONING SO JOURNAL OF THE AMERICAN PSYCHOANALYTIC ASSOCIATION LA English DT Article ID 5-FACTOR MODEL; DEFENSE-MECHANISMS; DISORDERS; ANXIETY C1 [Distel, Laura M. L.; Shepard, John; Malone, Johanna; Waldinger, Robert J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Malone, Johanna; Waldinger, Robert J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Distel, LML (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM lmldistel@gmail.com; jmalone4@mgh.harvard.edu NR 11 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-0651 EI 1941-2460 J9 J AM PSYCHOANAL ASS JI J. Am. Psychoanal. Assoc. PD JUN PY 2015 VL 63 IS 3 BP NP10 EP NP14 DI 10.1177/0003065115594185 PG 5 WC Psychiatry; Psychology, Psychoanalysis SC Psychiatry; Psychology GA CN0QN UT WOS:000358118500003 PM 26185296 ER PT J AU Movassaghian, M Brunner, AM Blonquist, TM Sadrzadeh, H Bhatia, A Perry, AM Attar, EC Amrein, PC Ballen, KK Neuberg, DS Fathi, AT AF Movassaghian, Maryam Brunner, Andrew M. Blonquist, Traci M. Sadrzadeh, Hossein Bhatia, Ashmeet Perry, Ashley M. Attar, Eyal C. Amrein, Philip C. Ballen, Karen K. Neuberg, Donna S. Fathi, Amir T. TI Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis SO LEUKEMIA & LYMPHOMA LA English DT Article DE Myeloid sarcoma; acute myeloid leukemia; granulocytic sarcoma; survival ID ACUTE MYELOBLASTIC-LEUKEMIA; NONLEUKEMIC-GRANULOCYTIC-SARCOMA; STEM-CELL TRANSPLANTATION; MYELODYSPLASTIC SYNDROME; MARROW-TRANSPLANTATION; CHLOROMA; SURVIVAL; T(8/21)(Q22,Q22); THERAPY AB Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diagnosed with isolated MS between 1973 and 2010. Overall survival (OS) was calculated and compared between MS and non-MS AML using the log-rank test. Survival was also evaluated based upon the primary site of disease presentation. The 3-year survival rate for MS (0.319; 95% confidence interval [CI]: 0.267-0.371) was greater than for non-MS AML (0.172; 95% CI: 0.168-0.175). There was variation in survival based on the site of involvement. The survival rates for isolated MS involving the pelvis/genitourinary organs, eyes/gonads and gastrointestinal mucosa appeared to be slightly improved when compared to primary sites of soft tissues, lymphatic/hematopoietic tissues or nervous system. C1 [Movassaghian, Maryam; Brunner, Andrew M.; Sadrzadeh, Hossein; Bhatia, Ashmeet; Perry, Ashley M.; Attar, Eyal C.; Amrein, Philip C.; Ballen, Karen K.; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Brunner, Andrew M.; Blonquist, Traci M.; Neuberg, Donna S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Fathi, AT (reprint author), Massachusetts Gen Hosp, Zero Emerson Pl,Suite 118, Boston, MA 02114 USA. EM afathi@partners.org NR 34 TC 4 Z9 4 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JUN PY 2015 VL 56 IS 6 BP 1698 EP 1703 DI 10.3109/10428194.2014.963080 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA CN2RP UT WOS:000358269900022 PM 25213180 ER PT J AU Strati, P Tong, WG Vitale, C Wierda, WG O'Brien, S Brown, JR Weng, WK Kipps, T Keating, MJ Ferrajoli, A AF Strati, Paolo Tong, Wei-Gang Vitale, Candida Wierda, William G. O'Brien, Susan Brown, Jennifer R. Weng, Wen-Kai Kipps, Thomas Keating, Michael J. Ferrajoli, Alessandra TI A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia SO LEUKEMIA & LYMPHOMA LA English DT Letter ID CD20 ANTIGEN-EXPRESSION; GM-CSF; MAINTENANCE TREATMENT; LYMPHOMA; THERAPY; IMMUNOTHERAPY; POLYMORPHISMS; MECHANISMS; CELLS C1 [Strati, Paolo; Tong, Wei-Gang; Vitale, Candida; Wierda, William G.; O'Brien, Susan; Keating, Michael J.; Ferrajoli, Alessandra] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weng, Wen-Kai] Stanford Univ, Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Kipps, Thomas] Univ Calif San Diego, San Diego, CA 92103 USA. RP Ferrajoli, A (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM aferrajo@mdanderson.org FU NCATS NIH HHS [UL1 TR000371]; NCI NIH HHS [P30 CA016672, P01 CA081534] NR 12 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD JUN PY 2015 VL 56 IS 6 BP 1878 EP 1880 DI 10.3109/10428194.2014.974049 PG 3 WC Oncology; Hematology SC Oncology; Hematology GA CN2RP UT WOS:000358269900049 PM 25311497 ER PT J AU Sheikh, Z Sima, C Glogauer, M AF Sheikh, Zeeshan Sima, Corneliu Glogauer, Michael TI Bone Replacement Materials and Techniques Used for Achieving Vertical Alveolar Bone Augmentation SO MATERIALS LA English DT Article DE vertical bone augmentation; alveolar ridge augmentation; biomaterials; bone graft materials; bone replacement; osteoconduction; osteoinduction; creeping substitution ID FREEZE-DRIED BONE; PLATELET-RICH PLASMA; PERIODONTAL OSSEOUS DEFECTS; MAXILLARY SINUS AUGMENTATION; CONTROLLED CLINICAL-TRIAL; AUTOGENOUS BLOCK GRAFTS; MESENCHYMAL STEM-CELLS; ANORGANIC BOVINE BONE; LOCALIZED RIDGE AUGMENTATION; DEFICIENT EDENTULOUS RIDGES AB Alveolar bone augmentation in vertical dimension remains the holy grail of periodontal tissue engineering. Successful dental implant placement for restoration of edentulous sites depends on the quality and quantity of alveolar bone available in all spatial dimensions. There are several surgical techniques used alone or in combination with natural or synthetic graft materials to achieve vertical alveolar bone augmentation. While continuously improving surgical techniques combined with the use of auto- or allografts provide the most predictable clinical outcomes, their success often depends on the status of recipient tissues. The morbidity associated with donor sites for auto-grafts makes these techniques less appealing to both patients and clinicians. New developments in material sciences offer a range of synthetic replacements for natural grafts to address the shortcoming of a second surgical site and relatively high resorption rates. This narrative review focuses on existing techniques, natural tissues and synthetic biomaterials commonly used to achieve vertical bone height gain in order to successfully restore edentulous ridges with implant-supported prostheses. C1 [Sheikh, Zeeshan; Glogauer, Michael] Univ Toronto, Matrix Dynam Grp, Fac Dent, Toronto, ON M5S 3E2, Canada. [Sima, Corneliu] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA 02142 USA. RP Sheikh, Z (reprint author), Univ Toronto, Matrix Dynam Grp, Fac Dent, Room 221,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada. EM zeeshan.sheikh@utoronto.ca; csima@forsyth.org; michael.glogauer@utoronto.ca OI Sima, Corneliu/0000-0003-3526-4850 NR 382 TC 10 Z9 10 U1 3 U2 14 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1996-1944 J9 MATERIALS JI Materials PD JUN PY 2015 VL 8 IS 6 BP 2953 EP 2993 DI 10.3390/ma8062953 PG 41 WC Materials Science, Multidisciplinary SC Materials Science GA CM3NK UT WOS:000357588900008 ER PT J AU Li, XH Zhang, D Liu, B AF Li, Xinhua Zhang, Da Liu, Bob TI CT dose equilibration and energy absorption in polyethylene cylinders with diameters from 6 to 55 cm SO MEDICAL PHYSICS LA English DT Article DE computed tomography (CT); dosimetry; ratio; equilibration; energy absorption ID COMPUTED-TOMOGRAPHY; MONTE-CARLO; PRACTICAL APPROACH; DOSIMETRY; EQUATIONS; PROFILES AB Purpose: ICRU Report No. 87 Committee and AAPM Task Group 200 designed a three-sectional polyethylene phantom of 30 cm in diameter and 60 cm in length for evaluating the midpoint dose D-L(0) and its rise-to-the-equilibrium curve MI). D L(0)1 D-eq from computed tomography (CT) scanning, where Deg is the equilibrium dose. To aid the use of the phantom in radiation dose assessment and to gain an understanding of dose equilibration and energy absorption in polyethylene, the authors evaluated the short (20 cm) to long (60 cm) phantorn dose ratio with a polyethylene diameter of 30 cm, assessed H(L) in polyethylene cylinders of 6-55 cm in diameters, and examined energy absorption in these cylinders. Methods: A GEANT4-based Monte Carlo program was used to simulate the single axial scans of polyethylene cylinders (diameters 6-55 cm and length 90 cm, as well as diameter 30 cm and lengths 20 and 60 cm) on a clinical CT scanner (Somatom Definition dual source CT, Siemens Healthcare). Axial dose distributions were computed on the phantom central and peripheral axes. An average dose over the central 23 or 100 mm region was evaluated for modeling dose measurement using a 0.6 cm(3) thimble chamber or a 10 cm long pencil ion chamber, respectively. The short (20 cm) to long (90 cm) phantom dose ratios were calculated for the 30 cm diameter polyethylene phantoms scanned at four tube voltages (80-140 kV) and a range of beam apertures (1-25 cm). H(L) was evaluated using the dose integrals computed with the 90 cm long phantoms. The resultant H(L) data were subsequently used to compute the fraction of the total energy absorbed inside or outside the scan range (E-in/E or E-out/E) on the phantom central and peripheral axes, where E = LDeq was the total energy absorbed along the z axis. Results: The midpoint dose in the 60 cm long polyethylene phantom was equal to that in the 90 cm long polyethylene phantom. The short-to-long phantom dose ratios changed with beam aperture and phantom axis but were insensitive to tube voltage. H(L) was insensitive to tube voltage and CT scanner model. As phantom diameter increased from 6 to 55 cm, E-in/E generally decreased but asymptotically approached constant levels on the peripheral axes of large phantoms. The curve of Ein/E versus scan length was almost identical to that of H(L) Similarly, E-out/E increased with scan length and asymptotically approached the equilibrium for large scan lengths. E-out/D-eq was much less than the equilibrium length L-eq where H(L) = 0.98, even with scan lengths much larger than L-eq. Conclusions: The polyethylene phantom designed by ICRU Report No. 87 Committee and AAPM Task Group 200 is adequately long for assessing the midpoint dose and its equilibration in CT scanning. The short-to-long phantom dose ratios and the H(L) data provided in this paper allow easy evaluations of the midpoint dose, longitudinal dose distribution, and energy absorption in polyethylene phantoms. The results of dose equilibration and energy absorption presented herein may be insightful for the clinical CT scans with various subject sizes and scan lengths. (C) 2015 American Association of Physicists in Medicine. C1 [Liu, Bob] Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Radiol, Webster Ctr Adv Res & Educ Radiat, Boston, MA 02114 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Diagnost Imaging Phys, Boston, MA 02114 USA. EM bliu7@mgh.harvard.edu NR 20 TC 1 Z9 1 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 2882 EP 2891 DI 10.1118/1.4919848 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998300015 PM 26127041 ER PT J AU Cai, WX Hurwitz, MH Williams, CL Dhou, S Berbeco, RI Seco, J Mishra, P Lewis, JH AF Cai, Weixing Hurwitz, Martina H. Williams, Christopher L. Dhou, Salam Berbeco, Ross I. Seco, Joao Mishra, Pankaj Lewis, John H. TI 3D delivered dose assessment using a 4DCT-based motion model SO MEDICAL PHYSICS LA English DT Article DE SBRT; 4DCT; respiratory motion; treatment verification ID STEREOTACTIC BODY RADIOTHERAPY; CONE-BEAM CT; LUNG-CANCER RADIOTHERAPY; TUMOR-LOCALIZATION; RESPIRATORY MOTION; EPID DOSIMETRY; MONTE-CARLO; VERIFICATION; IMAGE; FEASIBILITY AB Purpose: The purpose of this work is to develop a clinically feasible method of calculating actual delivered dose distributions for patients who have significant respiratory motion during the course of stereotactic body radiation therapy (SBRT). Methods: A novel approach was proposed to calculate the actual delivered dose distribution for SBRT lung treatment. This approach can be specified in three steps. (1) At the treatment planning stage, a patient-specific motion model is created from planning 4DCT data. This model assumes that the displacement vector field (DVF) of any respiratory motion deformation can be described as a linear combination of some basis DVFs. (2) During the treatment procedure, 2D time-varying projection images (either kV or MV projections) are acquired, from which time-varying "fluoroscopic" 3D images of the patient are reconstructed using the motion model. The DVF of each timepoint in the time-varying reconstruction is an optimized linear combination of basis DVFs such that the 2D projection of the 3D volume at this timepoint matches the projection image. (3) 3D dose distribution is computed for each timepoint in the set of 3D reconstructed fluoroscopic images, from which the total effective 3D delivered dose is calculated by accumulating deformed dose distributions. This approach was first validated using two modified digital extended cardio-torso (XCAT) phantoms with lung tumors and different respiratory motions. The estimated doses were compared to the dose that would be calculated for routine 4DCT-based planning and to the actual delivered dose that was calculated using "ground truth" XCAT phantoms at all timepoints. The approach was also tested using one set of patient data, which demonstrated the application of our method in a clinical scenario. Results: For the first XCAT phantom that has a mostly regular breathing pattern, the errors in 95% volume dose (D95) are 0.11% and 0.83%, respectively for 3D fluoroscopic images reconstructed from kV and MV projections compared to the ground truth, which is clinically comparable to 4DCT (0.093%). For the second XCAT phantom that has an irregular breathing pattern, the errors are 0.81% and 1.75% for kV and MV reconstructions, both of which are better than that of 4DCT (4.01%). In the case of real patient, although it is impossible to obtain the actual delivered dose, the dose estimation is clinically reasonable and demonstrates differences between 4DCT and MV reconstruction-based dose estimates. Conclusions: With the availability of kV or MV projection images, the proposed approach is able to assess delivered doses for all respiratory phases during treatment. Compared to the planning dose based on 4DCT, the dose estimation using reconstructed 3D fluoroscopic images was as good as 4DCT for regular respiratory pattern and was a better dose estimation for the irregular respiratory pattern. (C) 2015 American Association of Physicists in Medicine. C1 [Cai, Weixing; Hurwitz, Martina H.; Williams, Christopher L.; Dhou, Salam; Berbeco, Ross I.; Mishra, Pankaj; Lewis, John H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Cai, Weixing; Hurwitz, Martina H.; Williams, Christopher L.; Dhou, Salam; Berbeco, Ross I.; Mishra, Pankaj; Lewis, John H.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Seco, Joao] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Francis H Burr Proton Therapy Ctr,Dept Radiat Onc, Boston, MA 02115 USA. RP Cai, WX (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. EM wcai@lroc.harvard.edu; jhlewis@lroc.harvard.edu FU NCI NIH HHS [K99 CA166186, NIH/NCI1K99CA166186] NR 29 TC 5 Z9 6 U1 1 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 2897 EP 2907 DI 10.1118/1.4921041 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998300017 PM 26127043 ER PT J AU Collins-Fekete, CA Brousmiche, S Hansen, D Beaulieu, L Seco, J AF Collins-Fekete, C. A. Brousmiche, S. Hansen, D. Beaulieu, L. Seco, J. TI Patient Specific Proton Stopping Powers Estimation by Combining Proton Radiography and Prior-Knowledge X-Ray CT Information SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Collins-Fekete, C. A.] Massachussetts Gen Hosp, Quebec City, PQ, Canada. [Collins-Fekete, C. A.; Brousmiche, S.] Ion Beam Applicat, Louvain, Belgium. [Collins-Fekete, C. A.; Hansen, D.] Aarhus Univ, Aarhus, Denmark. [Collins-Fekete, C. A.; Beaulieu, L.] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada. [Seco, J.] Massachusetts Gen Hosp, Boston, MA USA. [Seco, J.] Harvard Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3199 EP 3200 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301050 PM 26127131 ER PT J AU Batin, E Depauw, N MacDonald, S Lu, H AF Batin, E. Depauw, N. MacDonald, S. Lu, H. TI Surface Imaging for the Set-Up of Proton Post-Mastectomy Chestwall Irradiation: Gated Images Vs Non Gated Images SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Batin, E.; Depauw, N.; MacDonald, S.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3200 EP 3200 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301052 PM 26127138 ER PT J AU Park, YK Sharp, GC Gierga, DP Ye, SJ Winey, BA AF Park, Yang-Kyun Sharp, Gregory C. Gierga, David P. Ye, Sung-Joon Winey, Brian A. TI Real-Time Intrafractional Motion Tracking During VMAT Delivery Using a Conventional Elekta CBCT System SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Park, Yang-Kyun; Sharp, Gregory C.; Gierga, David P.; Winey, Brian A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ye, Sung-Joon] Seoul Natl Univ, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3219 EP 3219 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301128 PM 26127211 ER PT J AU Altundal, Y Sajo, E Ngwa, W AF Altundal, Y. Sajo, E. Ngwa, W. TI Using Radiotherapy Biomaterials to Brand and Track Deadly Cancer Cells SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Altundal, Y.; Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA. [Ngwa, W.] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3222 EP 3222 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301141 PM 26127225 ER PT J AU Matuszak, M Moran, J Xiao, Y Mayo, C Bosch, W Popple, R Marks, L Wu, Q Molineu, A Miller, R Yock, T McNutt, T Brown, N Purdie, T Yorke, E Santanam, L Gabriel, P Michalski, J Moore, J Richardson, S Siochi, R Napalitano, M Ulin, K Fitzgerald, T Feng, M Verbakel, W Siddiqui, S Morgas, T Martel, M Archambault, Y Ladra, M Lansing, B Ruo, R Fogliata-Cozzi, A Hurkmans, C AF Matuszak, M. Moran, J. Xiao, Y. Mayo, C. Bosch, W. Popple, R. Marks, L. Wu, Q. Molineu, A. Miller, R. Yock, T. McNutt, T. Brown, N. Purdie, T. Yorke, E. Santanam, L. Gabriel, P. Michalski, J. Moore, J. Richardson, S. Siochi, R. Napalitano, M. Ulin, K. Fitzgerald, T. Feng, M. Verbakel, W. Siddiqui, S. Morgas, T. Martel, M. Archambault, Y. Ladra, M. Lansing, B. Ruo, R. Fogliata-Cozzi, A. Hurkmans, C. TI AAPM Task Group 263 Tackling Standardization of Nomenclature for Radiation Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Matuszak, M.; Feng, M.] Univ Michigan, Ann Arbor, MI 48109 USA. [Moran, J.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Xiao, Y.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Mayo, C.; Miller, R.] Mayo Clin, Rochester, MN USA. [Bosch, W.; Michalski, J.] Washington Univ, St Louis, MO USA. [Popple, R.] Univ Alabama Birmingham, Birmingham, AL USA. [Marks, L.] UNC Sch Med, Chapel Hill, NC USA. [Wu, Q.] Duke Univ, Med Ctr, Durham, NC USA. [Molineu, A.; Martel, M.] UT MD Anderson Canc Ctr, Houston, TX USA. [Yock, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McNutt, T.] Johns Hopkins Univ, Severna Pk, MD USA. [Brown, N.] Baptist Med Ctr, Jacksonville, FL USA. [Purdie, T.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Yorke, E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Santanam, L.] Washington Univ, Sch Med, St Louis, MO USA. [Gabriel, P.] Univ Penn, Philadelphia, PA 19104 USA. [Moore, J.] Johns Hopkins Univ, Baltimore, MD USA. [Richardson, S.] Swedish Med Ctr, Tumor Inst, Seattle, WA USA. [Ulin, K.] UMass Med Ctr, Lincoln, RI USA. [Fitzgerald, T.] Univ Massachusetts, Worcester, MA 01605 USA. [Verbakel, W.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Siddiqui, S.] Henry Ford Hlth Syst, Detroit, MI USA. [Morgas, T.; Archambault, Y.] Varian Med Syst, Palo Alto, CA USA. [Lansing, B.] Elekta Inc, Atlanta, GA USA. [Ruo, R.] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada. [Fogliata-Cozzi, A.] Osped San Giovanni Bellinzona, Porto Valtravaglia, Italy. [Hurkmans, C.] Catharina Hosp, Eindhoven, Netherlands. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3231 EP 3231 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301178 ER PT J AU Yang, K Gazi, P Boone, J AF Yang, K. Gazi, P. Boone, J. TI The Impact of X-Ray Scattering On Image Noise for Dedicated Breast CT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Yang, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gazi, P.] Univ Calif Davis, Sacramento, CA 95817 USA. [Boone, J.] UC Davis Med Ctr, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3243 EP 3243 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301228 PM 26127312 ER PT J AU Lau, A Ren, L Liu, H Yang, K Ahmad, S Chen, Y AF Lau, A. Ren, L. Liu, H. Yang, K. Ahmad, S. Chen, Y. TI Absorbed Dose Estimation for a Commercially Available MicroCT Scanner SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Lau, A.; Ahmad, S.; Chen, Y.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Ren, L.; Liu, H.] Univ Oklahoma, Norman, OK 73019 USA. [Yang, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3261 EP 3261 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301304 PM 26127387 ER PT J AU Han, Z Yip, S Lewis, J Mannarino, E Friesen, S Wagar, M Hacker, F AF Han, Z. Yip, S. Lewis, J. Mannarino, E. Friesen, S. Wagar, M. Hacker, F. TI Setup Accuracy in Spine SBRT Using CBCT 6D Image Guidance in Comparison with 6D ExacTrac SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3271 EP 3271 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301343 PM 26127427 ER PT J AU Saleh, Z Thor, M Sharp, G Tang, X Volpe, T Margiasso, R Veeraraghavan, H Muren, L Deasy, J AF Saleh, Z. Thor, M. Sharp, G. Tang, X. Volpe, T. Margiasso, R. Veeraraghavan, H. Muren, L. Deasy, J. TI A Novel Objective Approach to Identify Scan Outliers in Deformable Image Registration for Longitudinal Datasets SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Saleh, Z.; Volpe, T.; Margiasso, R.] Mem Sloan Kettering West Harrison, West Harrison, NY USA. [Thor, M.; Veeraraghavan, H.; Deasy, J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tang, X.] Mem Sloan Kettering Canc Ctr, West Harrison, NY USA. [Muren, L.] Aarhus Univ, Aarhus, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3286 EP 3286 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301404 PM 26127490 ER PT J AU Shusharina, N Khan, F Sharp, G Choi, N AF Shusharina, N. Khan, F. Sharp, G. Choi, N. TI 18F-FDG PET Imaging to Improve RT Treatment Outcome for Locally Advanced Lung Cancer SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Shusharina, N.; Khan, F.; Sharp, G.; Choi, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3293 EP 3293 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301432 PM 26127519 ER PT J AU Ren, X Sharp, G Gao, H AF Ren, X. Sharp, G. Gao, H. TI Automated Segmentation with Post-Registration Atlas Selection Based On Mutual Information SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Ren, X.; Gao, H.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China. [Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3295 EP 3295 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301440 PM 26127524 ER PT J AU Ruiz, B Feng, Y Shores, R Fung, C AF Ruiz, B. Feng, Y. Shores, R. Fung, C. TI A Novel Expansion Method for MRI Based Target Delineation in Prostate Radiotherapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Ruiz, B.] Alliance Oncol, Newburyport, MA USA. [Ruiz, B.; Feng, Y.] E Carolina Univ, Greenville, NC USA. [Shores, R.] Alliance Oncol, Greenville, MS USA. [Fung, C.] Beth Isreal Deaconess Med Ctr, Radiat Oncol, Newburyport, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3316 EP 3316 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301528 PM 26127613 ER PT J AU Spadea, M Izquierdo, D Catana, C Collins-Fekete, C Bortfeld, T Seco, J AF Spadea, M. Izquierdo, D. Catana, C. Collins-Fekete, C. Bortfeld, T. Seco, J. TI Feasibility Study of MRI-Only Proton Therapy Planning SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Spadea, M.] Magna Graecia Univ Catanzaro, ImagEngLab, Catanzaro, Italy. [Izquierdo, D.; Catana, C.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Collins-Fekete, C.; Bortfeld, T.; Seco, J.] Massachusetts Gen Hosp, Harvard Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3316 EP 3317 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301529 PM 26127611 ER PT J AU Coroller, T Grossmann, P Hou, Y Lee, S Mak, R Aerts, H AF Coroller, T. Grossmann, P. Hou, Y. Lee, S. Mak, R. Aerts, H. TI CT-Based Volumetric Features Are Associated with Somatic Mutations in Lung Cancer SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Coroller, T.; Grossmann, P.; Hou, Y.; Lee, S.; Mak, R.; Aerts, H.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3322 EP 3323 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301553 ER PT J AU Grassberger, C Sharp, G Fintelmann, F Paganetti, H Willers, H AF Grassberger, C. Sharp, G. Fintelmann, F. Paganetti, H. Willers, H. TI Time Evolution of Radiation-Induced Lung Injury After Stereotactic Proton Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Grassberger, C.; Sharp, G.; Fintelmann, F.; Paganetti, H.; Willers, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3323 EP 3323 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301554 PM 26127638 ER PT J AU Hong, X Paganetti, H Gao, H AF Hong, X. Paganetti, H. Gao, H. TI A Deterministic Solver of the Boltzmann-Fokker-Planck Equation for Dose Calculation SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Hong, X.; Gao, H.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China. [Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3335 EP 3335 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301604 PM 26127688 ER PT J AU Yan, S Lu, H Flanz, J Depauw, N Adams, J Gorissen, BL Wang, Y Daartz, J Bortfeld, T AF Yan, S. Lu, H. Flanz, J. Depauw, N. Adams, J. Gorissen, B. L. Wang, Y. Daartz, J. Bortfeld, T. TI Are Proton Gantries Needed? An Analysis of 4332 Patient Proton Gantry Treatment Plans From the Past 10 Years SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Yan, S.; Lu, H.; Flanz, J.; Depauw, N.; Adams, J.; Gorissen, B. L.; Wang, Y.; Daartz, J.; Bortfeld, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3361 EP 3361 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301712 PM 26127794 ER PT J AU Schuemann, J Giantsoudi, D Grassberger, C Paganetti, H AF Schuemann, J. Giantsoudi, D. Grassberger, C. Paganetti, H. TI Assessing the Clinical Impact of Approximations in Analytical Dose Calculations for Proton Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Schuemann, J.; Giantsoudi, D.; Grassberger, C.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3362 EP 3362 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301717 PM 26127799 ER PT J AU Buzurovic, I Hansen, J Bhagwat, M O'Farrell, D Damato, A Friesen, S Devlin, P Cormack, R AF Buzurovic, I. Hansen, J. Bhagwat, M. O'Farrell, D. Damato, A. Friesen, S. Devlin, P. Cormack, R. TI Characterization of Dose Distributions in High-Dose-Rate Surface Brachytherapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Buzurovic, I.; Hansen, J.; Bhagwat, M.; O'Farrell, D.; Damato, A.; Friesen, S.; Devlin, P.; Cormack, R.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3369 EP 3370 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301747 ER PT J AU Wang, Y Park, YK Doppke, KP AF Wang, Yi Park, Yang-Kyun Doppke, Karen P. TI Comprehensive Validation of the Electron Monte Carlo Dose Calculation Algorithm in RayStation Treatment Planning System for An Elekta Linear Accelerator with AgilityTM Treatment Head SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Wang, Yi; Park, Yang-Kyun; Doppke, Karen P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 1 Z9 1 U1 2 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3382 EP 3382 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301800 PM 26127884 ER PT J AU Ouyang, Z Altundal, Y Sajo, E Ngwa, W AF Ouyang, Z. Altundal, Y. Sajo, E. Ngwa, W. TI Dose Enhancement Effect Due to Cerium Oxide Nanoparticles Employed as Radiation Protectants SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Ouyang, Z.; Altundal, Y.; Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA. [Ngwa, W.] Harvard Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 MA SU-E-T-279 BP 3397 EP 3397 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998301860 PM 26127943 ER PT J AU Seco, J Giantsoudi, D Eaton, BR Adams, JA Paganetti, H MacDonald, S AF Seco, J. Giantsoudi, D. Eaton, B. R. Adams, J. A. Paganetti, H. MacDonald, S. TI Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in CSI of Pediatric Patients SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3418 EP 3418 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302075 PM 26128033 ER PT J AU Depauw, N Patel, S MacDonald, S Lu, H AF Depauw, N. Patel, S. MacDonald, S. Lu, H. TI Evaluation of Deep Inspiration Breath-Hold Technique for Post-Mastectomy Proton Pencil Beam Scanning Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Depauw, N.; Patel, S.; MacDonald, S.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3421 EP 3422 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302089 PM 26128044 ER PT J AU Wagar, M Bhagwat, M O'Farrell, D Friesen, S Buzurovic, I Damato, A Devlin, P Cormack, R AF Wagar, M. Bhagwat, M. O'Farrell, D. Friesen, S. Buzurovic, I. Damato, A. Devlin, P. Cormack, R. TI Examining Acquisition Rate for Using MatriXX Ion Chamber Array to Measure HDR Brachytherapy Treatments SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Wagar, M.; Bhagwat, M.; O'Farrell, D.; Friesen, S.; Buzurovic, I.; Damato, A.; Devlin, P.; Cormack, R.] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3429 EP 3429 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302119 PM 26128080 ER PT J AU Moteabbed, M Trofimov, A Sharp, GC Wang, Y Zietman, AL Efstathiou, JA Lu, H AF Moteabbed, M. Trofimov, A. Sharp, G. C. Wang, Y. Zietman, A. L. Efstathiou, J. A. Lu, H. TI Impact of Interfractional Variations On Anterior Vs. Lateral-Field Proton Therapy of Prostate Cancer SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Moteabbed, M.; Trofimov, A.; Sharp, G. C.; Wang, Y.; Zietman, A. L.; Efstathiou, J. A.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3439 EP 3439 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302163 PM 26128119 ER PT J AU Ramos-Mendez, J Perl, J Schuemann, J Shin, J Paganetti, H Faddegon, B AF Ramos-Mendez, J. Perl, J. Schuemann, J. Shin, J. Paganetti, H. Faddegon, B. TI Implementation of An Extension Module for Dose Response Models in the TOPAS Monte Carlo Toolkit SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Ramos-Mendez, J.; Faddegon, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Perl, J.] Stanford Linear Accelerator Ctr, Menlo Pk, CA USA. [Schuemann, J.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shin, J.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3441 EP 3442 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302172 PM 26128130 ER PT J AU Lin, Y Held, K McMahon, S Paganetti, H Schuemann, J AF Lin, Y. Held, K. McMahon, S. Paganetti, H. Schuemann, J. TI Investigation of Gold Nanoparticle Radiosensitization for Carbon Ion Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Lin, Y.; Held, K.; McMahon, S.; Paganetti, H.; Schuemann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, Y.; Held, K.; McMahon, S.; Paganetti, H.; Schuemann, J.] Harvard Univ, Sch Med, Boston, MA USA. [McMahon, S.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT7 1NN, Antrim, North Ireland. NR 0 TC 1 Z9 1 U1 1 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3454 EP 3454 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302224 ER PT J AU Toltz, A Hoesl, M Schuemann, J Seuntjens, J Lu, H Paganetti, H AF Toltz, A. Hoesl, M. Schuemann, J. Seuntjens, J. Lu, H. Paganetti, H. TI In-Vivo Diode Dosimetry Proton Therapy Range Verification Validation Study for Pediatric CSI SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Toltz, A.; Seuntjens, J.] McGill Univ, Montreal, PQ, Canada. [Hoesl, M.; Schuemann, J.; Lu, H.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3455 EP 3456 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302230 PM 26128185 ER PT J AU Lin, Y La Tessa, C Rusek, A Held, K AF Lin, Y. La Tessa, C. Rusek, A. Held, K. TI Irradiation of Human Cell Lines Using Carbon Ions: Real Time Dosimetry Using Gaf-Chromic Film SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Lin, Y.; Held, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, Y.; Held, K.] Harvard Univ, Sch Med, Boston, MA USA. [La Tessa, C.; Rusek, A.] NASA Space Radiat Lab, Brookhaven Natl Lab, Upton, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3456 EP 3456 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302232 PM 26128191 ER PT J AU Xiang, H Li, B Russo, G Behrman, R Lu, H Fernando, H Kachnic, L AF Xiang, H. Li, B. Russo, G. Behrman, R. Lu, H. Fernando, H. Kachnic, L. TI Measurement of CT Density Model Variations and the Impact On the Accuracy of Monte Carlo (MC) Dose Calculation in Stereotactic Body Radiation Therapy for Lung Cancer SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Xiang, H.; Kachnic, L.] Boston Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02118 USA. [Xiang, H.; Fernando, H.; Kachnic, L.] Boston Med Ctr, Boston, MA USA. [Li, B.; Behrman, R.] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA. [Fernando, H.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA. [Russo, G.; Lu, H.; Kachnic, L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Russo, G.; Lu, H.; Kachnic, L.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3460 EP 3460 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302247 PM 26128206 ER PT J AU Ramos-Mendez, J Paganetti, H Faddegon, B AF Ramos-Mendez, J. Paganetti, H. Faddegon, B. TI Monte Carlo Calculation of Source Terms and Attenuation Lengths for Neutrons Produced by 50-200 MeV Protons On Brass SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Ramos-Mendez, J.; Faddegon, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3463 EP 3463 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302260 PM 26128219 ER PT J AU Geng, C Schuemann, J Moteabbed, M Paganetti, H AF Geng, C. Schuemann, J. Moteabbed, M. Paganetti, H. TI Neutron Dose Equivalent Evaluation for Pencil Beam Scanning Proton Therapy with Apertures SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Geng, C.; Schuemann, J.; Moteabbed, M.; Paganetti, H.] Massachusetts Gen Hospotal, Boston, MA USA. [Geng, C.; Schuemann, J.; Moteabbed, M.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA USA. [Geng, C.] Nanjing Univ Aeronaut & Astronaut, Nanjing 210016, Jiangsu, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3466 EP 3466 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302273 PM 26128233 ER PT J AU Guo, M Craft, D Gao, H AF Guo, M. Craft, D. Gao, H. TI Plan Averaging for Multi-Criteria Navigation of Step-And-Shoot IMRT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Guo, M.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China. [Craft, D.] Massachusetts Gen Hosp, Cambridge, MA USA. [Gao, H.] Shanghai Jiao Tong Univ, Shanghai 200030, Shanghai, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3477 EP 3477 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302320 PM 26128277 ER PT J AU Phillips, J Gueorguiev, G Grassberger, C Paganetti, H Sharp, G AF Phillips, J. Gueorguiev, G. Grassberger, C. Paganetti, H. Sharp, G. TI Proton Dose Calculation for Irregular Motion Using a Sliding Interface SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Phillips, J.; Gueorguiev, G.; Grassberger, C.; Paganetti, H.; Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3483 EP 3483 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302345 PM 26128302 ER PT J AU Arjomandy, B Klein, E Taylor, P Ainsley, C Safai, S Sahoo, N Pankuch, M Park, S Farr, J Kase, Y Flanz, J Yorke, E Followill, D AF Arjomandy, B. Klein, E. Taylor, P. Ainsley, C. Safai, S. Sahoo, N. Pankuch, M. Park, S. Farr, J. Kase, Y. Flanz, J. Yorke, E. Followill, D. TI Quality Assurances for Proton Therapy Delivery Equipment SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Arjomandy, B.] McLaren Canc Inst, Flint, MI USA. [Klein, E.] Washington Univ, St Louis, MO USA. [Taylor, P.; Followill, D.] UT MD Anderson Canc Ctr, Houston, TX USA. [Ainsley, C.] Univ Penn, Philadelphia, PA 19104 USA. [Safai, S.] Paul Scherrer Inst, Villigen, Switzerland. [Sahoo, N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Pankuch, M.] CDH Proton Ctr, Warrenville, IL USA. [Park, S.] McLaren Flint, Flint, MI USA. [Farr, J.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Kase, Y.] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan. [Flanz, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yorke, E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3485 EP 3486 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302355 PM 26128310 ER PT J AU Qin, N Giantsoudi, D Tian, Z Schuemann, J Pompos, A Paganetti, H Jiang, S Jia, X AF Qin, N. Giantsoudi, D. Tian, Z. Schuemann, J. Pompos, A. Paganetti, H. Jiang, S. Jia, X. TI Recent Developments and Comprehensive Validations of a GPU-Based Proton Monte Carlo Simulation Package, GPMC SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Qin, N.; Tian, Z.; Pompos, A.; Jiang, S.; Jia, X.] UT Southwestern Med Ctr, Dallas, TX USA. [Giantsoudi, D.; Schuemann, J.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3491 EP 3491 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302379 PM 26128337 ER PT J AU Gorissen, BL Depauw, N Unkelbach, J AF Gorissen, B. L. Depauw, N. Unkelbach, J. TI Robustness Versus Plan Quality for IMPT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3494 EP 3494 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302390 PM 26128350 ER PT J AU Sinha, N Cifter, G Ngwa, W AF Sinha, N. Cifter, G. Ngwa, W. TI Three Dimensional in Silico Study of Brachytherapy Application with In-Situ Dose-Painting Administered Via Gold-Nanoparticle Eluters SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Sinha, N.] Wentworth Inst Technol, Boston, MA USA. [Cifter, G.; Ngwa, W.] Harvard Univ, Sch Med, Boston, MA USA. [Cifter, G.; Ngwa, W.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3509 EP 3509 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302456 PM 26128413 ER PT J AU Manem, V Paganetti, H AF Manem, V. Paganetti, H. TI Three-Dimensional Carcinogenic Maps Induced by Photons and Protons SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Manem, V.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3510 EP 3510 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302458 PM 26128418 ER PT J AU Hong, X Gao, H Schuemann, J Paganette, H AF Hong, X. Gao, H. Schuemann, J. Paganette, H. TI T-Test Based Prior Error Estimate and Stopping Criterion for Monte Carlo Dose Calculation in Proton Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Hong, X.; Gao, H.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China. [Schuemann, J.; Paganette, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3514 EP 3514 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302475 PM 26128432 ER PT J AU McNamara, A Schuemann, J Paganetti, H AF McNamara, A. Schuemann, J. Paganetti, H. TI A Phenomenological Relative Biological Effectiveness (RBE) Model for Proton Therapy Based On All Published in Vitro Cell Survival Data SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [McNamara, A.; Schuemann, J.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI McNamara, Aimee/C-9432-2009 OI McNamara, Aimee/0000-0001-8792-0464 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3528 EP 3528 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302534 ER PT J AU Moteabbed, M Depauw, N Kooy, H Yock, T Paganetti, H AF Moteabbed, M. Depauw, N. Kooy, H. Yock, T. Paganetti, H. TI When Does Pencil Beam Scanning Become Superior to Passive Scattered Proton Therapy for Pediatric Head and Neck Cancers? SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Moteabbed, M.; Depauw, N.; Kooy, H.; Yock, T.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3528 EP 3528 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302533 ER PT J AU Sorriaux, J Testa, M Paganetti, H Bertrand, D de Xivry, JO Lee, J Palmans, H Vynckier, S Sterpin, E AF Sorriaux, J. Testa, M. Paganetti, H. Bertrand, D. de Xivry, J. Orban Lee, J. Palmans, H. Vynckier, S. Sterpin, E. TI Quality Correction Factors in Scanned Or Broad Proton Therapy Beams Are Indistinguishable SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Sorriaux, J.; Lee, J.; Sterpin, E.] Catholic Univ Louvain, Mol Imaging Radiotherapy & Oncol, B-1200 Brussels, Belgium. [Sorriaux, J.; Lee, J.] Catholic Univ Louvain, ICTEAM Inst, Louvain La Neuve, Belgium. [Testa, M.; Paganetti, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Testa, M.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Bertrand, D.; de Xivry, J. Orban] Ion Beam Applicat, Louvain, Brabant Wallon, Belgium. [Palmans, H.] EBG MedAustron GmbH, Wiener Neustadt, Austria. [Palmans, H.] Natl Phys Lab, Teddington TW11 0LW, Middx, England. [Vynckier, S.] Clin Univ St Luc, B-1200 Brussels, Belgium. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3529 EP 3529 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302536 ER PT J AU Gao, Y Lin, H Liu, T Li, X Liu, B Khawaja, R Kalra, M Caracappa, P Xu, X AF Gao, Y. Lin, H. Liu, T. Li, X. Liu, B. Khawaja, R. Kalra, M. Caracappa, P. Xu, X. TI Simulation Study of Patient Off-Centering Effect On Organ Dose in Chest CT Scan SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Gao, Y.; Lin, H.; Liu, B.; Khawaja, R.; Kalra, M.; Caracappa, P.; Xu, X.] Rensselaer Polytech Inst, Troy, NY USA. [Liu, T.; Li, X.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3544 EP 3544 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302596 PM 26128554 ER PT J AU Verburg, J Bortfeld, T Seco, J AF Verburg, J. Bortfeld, T. Seco, J. TI Prompt Gamma-Ray Spectroscopy for Range Verification of Clinical Proton Beams SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3548 EP 3548 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302612 PM 26128576 ER PT J AU DeLorenzo, M Wu, D Rutel, I Yang, K AF DeLorenzo, M. Wu, D. Rutel, I. Yang, K. TI Shield: Semi-Automated Calculation of Air Kerma Rate and Barrier Thickness SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [DeLorenzo, M.; Wu, D.; Rutel, I.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Yang, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3555 EP 3555 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302630 PM 26128624 ER PT J AU Rehani, M Seibert, J Clements, J AF Rehani, M. Seibert, J. Clements, J. TI What Is Medical Physics Without Radiation Safety? SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Rehani, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Seibert, J.] UC Davis Med Ctr, Davis, CA USA. [Clements, J.] Kaiser Permanente, Oakland, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3561 EP 3561 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302650 ER PT J AU Cifter, G Sajo, E Korideck, H Kumar, R Sridhar, S Cormack, R Makrigiorgos, G Ngwa, W AF Cifter, G. Sajo, E. Korideck, H. Kumar, R. Sridhar, S. Cormack, R. Makrigiorgos, G. Ngwa, W. TI Next Generation Radiotherapy Biomaterials Loaded With Gold Nanoparticles SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Cifter, G.; Korideck, H.; Kumar, R.; Cormack, R.; Makrigiorgos, G.; Ngwa, W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. [Cifter, G.; Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3565 EP 3565 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302660 PM 26128708 ER PT J AU Hao, Y Cifter, G Altundal, Y Sinha, N Moreau, M Sajo, E Makrigiorgos, G Ngwa, W AF Hao, Y. Cifter, G. Altundal, Y. Sinha, N. Moreau, M. Sajo, E. Makrigiorgos, G. Ngwa, W. TI Leveraging the Abscopal Effect Via New Design Radiotherapy Biomaterials Loaded with Immune Checkpoint Inhibitors SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Hao, Y.; Cifter, G.; Altundal, Y.; Moreau, M.; Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA. [Sinha, N.] Wentworth Inst Technol, Boston, MA USA. [Makrigiorgos, G.; Ngwa, W.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Makrigiorgos, G.; Ngwa, W.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3565 EP 3565 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302659 PM 26128710 ER PT J AU McMahon, S Paganetti, H Prise, K AF McMahon, S. Paganetti, H. Prise, K. TI Material Optimisation for Nanoparticle-Sensitized Radiotherapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [McMahon, S.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Prise, K.] Queens Univ Belfast, Belfast, Antrim, North Ireland. RI Prise, Kevin/N-7872-2015 OI Prise, Kevin/0000-0001-6134-7946 NR 0 TC 0 Z9 0 U1 0 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3565 EP 3566 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302661 ER PT J AU Detappe, A Rottmann, J Kunjachan, S Tillement, O Berbeco, R AF Detappe, A. Rottmann, J. Kunjachan, S. Tillement, O. Berbeco, R. TI Theranostic Gadolinium-Based AGuIX Nanoparticles for MRI-Guided Radiation Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Detappe, A.; Rottmann, J.; Kunjachan, S.; Berbeco, R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. [Detappe, A.; Tillement, O.] Inst Lumiere Mat, Villeurbanne, France. [Detappe, A.] Nano H, St Quentin Fallavier, France. NR 0 TC 2 Z9 2 U1 2 U2 8 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3566 EP 3566 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998302662 ER PT J AU Siebers, J Unkelbach, J Xu, H AF Siebers, J. Unkelbach, J. Xu, H. TI New methods to ensure target coverage SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Siebers, J.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Unkelbach, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Xu, H.] Univ Maryland, College Pk, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3586 EP 3586 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303004 PM 26128804 ER PT J AU Velazquez, ER Meier, R Dunn, W Alexander, B Wiest, R Bauer, S Gutman, D Reyes, M Aerts, H AF Velazquez, E. Rios Meier, R. Dunn, W. Alexander, B. Wiest, R. Bauer, S. Gutman, D. Reyes, M. Aerts, H. TI Evaluation of Fully Automatic Volumetric GBM Segmentation in the TCGA-GBM Dataset: Prognosis and Correlation with VASARI Features SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Velazquez, E. Rios] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Meier, R.] Inst Surg Technol & Biomech, Bern, Switzerland. [Dunn, W.; Gutman, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Alexander, B.] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Med, Boston, MA 02115 USA. [Wiest, R.; Reyes, M.] Univ Bern, Inst Surg Technol & Biomech, Bern, Switzerland. [Bauer, S.] Inst Surg Technol & Biomech, Support Ctr Adva, Bern, Switzerland. [Aerts, H.] Dana Farber Brigham Womens Canc Ctr, Boston, MA USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3589 EP 3589 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303015 ER PT J AU Don, S Cormack, R Viswanathan, A Damato, A AF Don, S. Cormack, R. Viswanathan, A. Damato, A. TI A Robot for the Automated Delivery of An Electromagnetic Tracking Sensor for the Localization of Brachytherapy Catheters SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Don, S.; Cormack, R.; Viswanathan, A.; Damato, A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3594 EP 3594 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303033 PM 26128840 ER PT J AU Grossmann, P Grove, O El-Hachem, N Velazquez, ER Parmar, C Leijenaar, R Haibe-Kains, B Lambin, P Gillies, R Aerts, H AF Grossmann, P. Grove, O. El-Hachem, N. Velazquez, E. Rios Parmar, C. Leijenaar, R. Haibe-Kains, B. Lambin, P. Gillies, R. Aerts, H. TI BEST IN PHYSICS (JOINT IMAGING-THERAPY): Identification of Molecular Phenotypes by Integrating Radiomics and Genomics SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Grossmann, P.; Velazquez, E. Rios; Parmar, C.; Aerts, H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Grove, O.; Gillies, R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [El-Hachem, N.] Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada. [Leijenaar, R.] Res Inst GROW, Maastricht, Netherlands. [Haibe-Kains, B.] Univ Hlth Network, Toronto, ON, Canada. RI Aerts, Hugo/P-6350-2015; Haibe-Kains, Benjamin/D-3702-2011 OI Aerts, Hugo/0000-0002-2122-2003; Haibe-Kains, Benjamin/0000-0002-7684-0079 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3602 EP 3602 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303061 ER PT J AU Velazquez, ER Narayan, V Grossmann, P Dunn, W Gutman, D Aerts, H AF Velazquez, E. Rios Narayan, V. Grossmann, P. Dunn, W. Gutman, D. Aerts, H. TI Automated Radiomic Features Complement the Prognostic Value of VASARI in the TCGA-GBM Dataset SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Velazquez, E. Rios; Grossmann, P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Narayan, V.] Brigham & Womens Hosp, Harvard Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Dunn, W.; Gutman, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Aerts, H.] Dana Farber Brigham Womens Canc Ctr, Boston, MA USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 1 Z9 1 U1 0 U2 4 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3603 EP 3603 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303063 ER PT J AU Gertsenshteyn, I Tyagi, N Farjam, R Apte, A Sharp, G AF Gertsenshteyn, I. Tyagi, N. Farjam, R. Apte, A. Sharp, G. TI Comparing Mutual Information and Gradient Magnitude Metrics for Deformable Image Registration SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Gertsenshteyn, I.; Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tyagi, N.; Farjam, R.; Apte, A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3606 EP 3606 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303073 PM 26128902 ER PT J AU Underwood, T Giantsoudi, D Moteabbed, M Zietman, A Efstathiou, J Paganetti, H Lu, HM AF Underwood, T. Giantsoudi, D. Moteabbed, M. Zietman, A. Efstathiou, J. Paganetti, H. Lu, H. M. TI Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE-Weighted Rectal Dose SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Underwood, T.; Giantsoudi, D.; Moteabbed, M.; Zietman, A.; Efstathiou, J.; Paganetti, H.; Lu, H. M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Underwood, T.; Giantsoudi, D.; Moteabbed, M.; Zietman, A.; Efstathiou, J.; Paganetti, H.; Lu, H. M.] Harvard Univ, Sch Med, Boston, MA USA. [Underwood, T.] UCL, Dept Med Phys & Bioengn, London WC1E 6BT, England. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3615 EP 3616 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303107 PM 26128957 ER PT J AU Gorissen, BL Giantsoudi, D Unkelbach, J Paganetti, H AF Gorissen, B. L. Giantsoudi, D. Unkelbach, J. Paganetti, H. TI LET-Based Inverse Planning for IMPT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3616 EP 3616 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303110 PM 26128963 ER PT J AU Giantsoudi, D Jee, K Rose, B MacDonald, S Paganetti, H AF Giantsoudi, D. Jee, K. Rose, B. MacDonald, S. Paganetti, H. TI Proton Radiation Therapy for Left-Sided Breast Cancer: LET and RBE Considerations for Cardiac Toxicity SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Giantsoudi, D.; Jee, K.; Rose, B.; MacDonald, S.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rose, B.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3617 EP 3617 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303114 PM 26128972 ER PT J AU Gao, Y Liu, T Li, X Liu, B Kalra, M Caracappa, P Xu, X AF Gao, Y. Liu, T. Li, X. Liu, B. Kalra, M. Caracappa, P. Xu, X. TI A Preliminary Method of Risk-Informed Optimization of Tube Current Modulation for Dose Reduction in CT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Gao, Y.; Liu, B.; Kalra, M.; Caracappa, P.; Xu, X.] Rensselaer Polytech Inst, Troy, NY USA. [Liu, T.; Li, X.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3622 EP 3622 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303127 PM 26128995 ER PT J AU Rehani, M Zhang, D Park, J Rehani, MM AF Rehani, M. Zhang, D. Park, J. Rehani, Madan M. TI Eye Lens Dosimetty for Patients and Staff SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Rehani, M.; Rehani, Madan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, D.] Toshiba Amer Med Syst, Monroe, CT USA. [Park, J.] Seoul Natl Univ Hosp, Seoul, South Korea. [Rehani, Madan M.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3623 EP 3624 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303132 PM 26129003 ER PT J AU Deasy, J Aerts, H Veeraraghavan, H El Naqa, I AF Deasy, J. Aerts, H. Veeraraghavan, H. El Naqa, I. TI Radiomics: Advances in the Use of Quantitative Imaging Used for Predictive Modeling SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Deasy, J.; Veeraraghavan, H.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Aerts, H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Aerts, H.] Dana Farber Canc Inst, Boston, MA USA. [El Naqa, I.] Univ Michigan, Ann Arbor, MI 48109 USA. RI Aerts, Hugo/P-6350-2015 OI Aerts, Hugo/0000-0002-2122-2003 NR 0 TC 0 Z9 0 U1 1 U2 10 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3632 EP 3632 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303158 ER PT J AU Geng, C Moteabbed, M Xu, X Paganetti, H AF Geng, C. Moteabbed, M. Xu, X. Paganetti, H. TI Risk Assessment of Scattered Neutrons for a Fetus From Proton Therapy of a Brain Tumor During Pregnancy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Geng, C.; Moteabbed, M.; Paganetti, H.] Massachusetts Gen Hospotal, Boston, MA USA. [Geng, C.; Moteabbed, M.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA USA. [Geng, C.] Nanjing Univ Aeronaut & Astronaut, Nanjing, Jiangsu, Peoples R China. [Xu, X.] Rensselaer Polytech Inst, Troy, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3636 EP 3636 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303172 PM 26129088 ER PT J AU Mainali, M Ngwa, W Cifter, G Celli, J AF Mainali, M. Ngwa, W. Cifter, G. Celli, J. TI Potential of Using Cerium Oxide Nanoparticles (CONP) for Protecting Healthy Tissue During Accelerated Partial Breast Irradiation (APBI) SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Mainali, M.] Univ Massachusetts Boston, Dana Farber Canc Inst, Boston, MA USA. [Ngwa, W.] Harvard Univ, Sch Med, Boston, MA USA. [Cifter, G.] Univ Massachusetts Lowell, Dana Farber Canc Inst, Boston, MA USA. [Celli, J.] Univ Massachusetts Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3643 EP 3643 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303201 PM 26129114 ER PT J AU Brivio, D Zygmanski, P Sajo, E Makrigiorgos, G Ngwa, W AF Brivio, D. Zygmanski, P. Sajo, E. Makrigiorgos, G. Ngwa, W. TI Monte Carlo Evaluation of Kilovoltage Radiosurgery with AuNPs for Age Related Macular Degeneration (AMD) SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Brivio, D.; Zygmanski, P.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Sajo, E.] Univ Massachusetts Lowell, Lowell, MA USA. [Makrigiorgos, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ngwa, W.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3644 EP 3644 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303202 PM 26129120 ER PT J AU McNamara, A McMahon, S Lin, Y Paganetti, H Kuncic, Z Schuemann, J AF McNamara, A. McMahon, S. Lin, Y. Paganetti, H. Kuncic, Z. Schuemann, J. TI Using Gold Nanoparticles to Target Mitochondria in Radiation Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [McNamara, A.; McMahon, S.; Lin, Y.; Paganetti, H.; Schuemann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McNamara, A.; Lin, Y.] Harvard Univ, Sch Med, Boston, MA USA. [Kuncic, Z.] Univ Sydney, Sydney, NSW 2006, Australia. NR 0 TC 0 Z9 0 U1 0 U2 7 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3644 EP 3644 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303204 PM 26129118 ER PT J AU Collins-Fekete, CA Doolan, P Dias, M Beaulieu, L Seco, J AF Collins-Fekete, C. A. Doolan, P. Dias, M. Beaulieu, L. Seco, J. TI Developing a Phenomenological Model of the Proton Trajectory Within a Heterogeneous Medium Required for Proton Imaging SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Collins-Fekete, C. A.] Massachussetts Gen Hosp, Quebec City, PQ, Canada. [Collins-Fekete, C. A.; Doolan, P.] Univ Coll London Hosp, London, England. [Collins-Fekete, C. A.; Dias, M.] Politecn Milan, Milan, Lombardia, Italy. [Collins-Fekete, C. A.; Beaulieu, L.] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada. [Seco, J.] Harvard Med, Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3645 EP 3645 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303207 PM 26129124 ER PT J AU Baillie, D Cormack, R Stanescu, T AF Baillie, D. Cormack, R. Stanescu, T. TI New Developments in Hybrid MR-Treatment: Technology (Session 3 of the MRgRT Certificate Course series) SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Cormack, R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Cormack, R.] Dana Farber Canc Inst, Boston, MA USA. [Stanescu, T.] Princess Margaret Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3666 EP 3666 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303275 PM 26129223 ER PT J AU Cai, W Hurwitz, M Williams, C Dhou, S Berbeco, R Seco, J Cifter, F Myronakis, M Lewis, J AF Cai, W. Hurwitz, M. Williams, C. Dhou, S. Berbeco, R. Seco, J. Cifter, F. Myronakis, M. Lewis, J. TI 4DCBCT-Based Dose Assessment for SBRT Lung Cancer Treatment SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Cai, W.; Hurwitz, M.; Williams, C.; Dhou, S.; Berbeco, R.; Cifter, F.; Myronakis, M.; Lewis, J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Seco, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cai, W.; Hurwitz, M.; Williams, C.; Dhou, S.; Berbeco, R.; Seco, J.; Cifter, F.; Myronakis, M.; Lewis, J.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3669 EP 3669 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303287 ER PT J AU Cai, W Hurwitz, M Williams, C Dhou, S Berbeco, R Seco, J Cifter, F Myronakis, M Mishra, P Lewis, J AF Cai, W. Hurwitz, M. Williams, C. Dhou, S. Berbeco, R. Seco, J. Cifter, F. Myronakis, M. Mishra, P. Lewis, J. TI 3D Delivered Dose Assessment Using a 4DCT-Based Motion Model SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Cai, W.; Hurwitz, M.; Williams, C.; Dhou, S.; Berbeco, R.; Cifter, F.; Myronakis, M.; Lewis, J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Seco, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cai, W.; Hurwitz, M.; Williams, C.; Dhou, S.; Berbeco, R.; Seco, J.; Cifter, F.; Myronakis, M.; Lewis, J.] Harvard Univ, Sch Med, Boston, MA USA. [Mishra, P.] Varian Med Syst, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3669 EP 3669 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303286 ER PT J AU Sharp, G Apte, A Schreibmann, E AF Sharp, G. Apte, A. Schreibmann, E. TI Software Libraries for your Research Projects - Don't Start From Scratch! SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Sharp, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Apte, A.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Schreibmann, E.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3672 EP 3672 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303297 PM 26129259 ER PT J AU Doolan, P Bentefour, E Testa, M Cascio, E Royle, G Gottschalk, B Lu, H AF Doolan, P. Bentefour, E. Testa, M. Cascio, E. Royle, G. Gottschalk, B. Lu, H. TI Single-Detector Proton Radiography as a Portal Imaging Equivalent for Proton Therapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Doolan, P.] Univ Coll London Hosp, London, England. [Bentefour, E.] Ion Beam Applicat, Louvain La Neuve, Belgium. [Testa, M.; Cascio, E.; Lu, H.] Massachussetts Gen Hosp, Boston, MA USA. [Royle, G.] UCL, London, England. [Gottschalk, B.] Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3680 EP 3680 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303322 PM 26129306 ER PT J AU Deye, J Fraass, B Bortfeld, T Michalski, J AF Deye, J. Fraass, B. Bortfeld, T. Michalski, J. TI NIH-Funded Research, Clinical Trials and Program Projects SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Deye, J.] NCI, Bethesda, MD 20892 USA. [Fraass, B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Bortfeld, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Michalski, J.] Washington Univ, St Louis, MO 63130 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3690 EP 3691 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303357 PM 26129369 ER PT J AU Tang, A Samost, A Viswanathan, A Cormack, R Damato, A AF Tang, A. Samost, A. Viswanathan, A. Cormack, R. Damato, A. TI Analyzing the Safety Implications of a Brachytherapy Process Improvement Project Utilizing a Novel System-Theory-Based Hazard-Analysis Technique SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Tang, A.; Samost, A.] MIT, Cambridge, MA 02139 USA. [Viswanathan, A.; Cormack, R.; Damato, A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3692 EP 3692 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303364 PM 26129375 ER PT J AU Manem, V Grassberger, C Paganetti, H AF Manem, V. Grassberger, C. Paganetti, H. TI Modeling Organ Specific Mechanistic Interactions Between Radiation and Chemotherapy SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Manem, V.; Grassberger, C.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3703 EP 3703 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303398 PM 26129428 ER PT J AU Craft, D AF Craft, D. TI Accelerating Sliding Window VMAT by Open-Out/close-in Field Delivery Techniques SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Craft, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3705 EP 3705 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303407 PM 26129436 ER PT J AU DeLorenzo, M Wu, D Yang, K Rutel, I AF DeLorenzo, M. Wu, D. Yang, K. Rutel, I. TI RadShield: Semi-Automated Calculation of Air Kerma Rate and Barrier Thickness SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [DeLorenzo, M.; Wu, D.; Rutel, I.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Yang, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3719 EP 3719 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303456 PM 26129491 ER PT J AU Winey, B Ma, L AF Winey, B. Ma, L. TI Spine SBRT SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Winey, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ma, L.] UCSF Comprehens Canc Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3721 EP 3721 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303464 PM 26129506 ER PT J AU Brousmiche, S Souris, K de Xivry, JO Lee, J Macq, B Seco, J AF Brousmiche, S. Souris, K. de Xivry, J. Orban Lee, J. Macq, B. Seco, J. TI Assessing How Stochastic CT Noise Can Lead to Systematic Proton Range Errors SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Brousmiche, S.; de Xivry, J. Orban] Ion Beam Applicat, Louvain La Neuve, Belgium. [Souris, K.; Lee, J.] UCL, Mol Imaging Radiotherapy & Oncol, Brussels, Belgium. [Macq, B.] UCL, ICTEAM Inst, Louvain La Neuve, Belgium. [Seco, J.] Mass Gen Hosp, Harvard Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3726 EP 3726 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303481 PM 26129529 ER PT J AU Hoesl, M Deepak, S Moteabbed, M Park, Y Orbain, J Bentefour, E Lu, H AF Hoesl, M. Deepak, S. Moteabbed, M. Park, Y. Orbain, J. Bentefour, E. Lu, H. TI Clinical Commissioning of An In-Vivo Range Verification System for Prostate Cancer Treatment with Anterior and Anterior Oblique Proton Beams SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Hoesl, M.; Moteabbed, M.; Park, Y.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hoesl, M.] Univ Munich, D-81377 Munich, Germany. [Deepak, S.; Orbain, J.] Catholic Univ Louvain, ICTEAM Inst, Louvain La Neuve, Belgium. [Bentefour, E.] IBA, B-1348 Louvain La Neuve, Belgium. RI Samuel, Deepak/B-6482-2017 OI Samuel, Deepak/0000-0002-4560-5957 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3726 EP 3726 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303479 ER PT J AU Unkelbach, J Bussiere, M Shih, H Chapman, P Loeffler, J AF Unkelbach, J. Bussiere, M. Shih, H. Chapman, P. Loeffler, J. TI Spatiotemporal Dose Shaping to Achieve Uniform Fractionation in Healthy Tissues Along with Hypo-Fractionation in Targets SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Unkelbach, J.; Bussiere, M.; Shih, H.; Chapman, P.; Loeffler, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3741 EP 3742 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303536 PM 26129596 ER PT J AU Rottmann, J Morf, D Fueglistaller, R Chen, H Yip, S Star-Lack, J Zentai, G Berbeco, R AF Rottmann, J. Morf, D. Fueglistaller, R. Chen, H. Yip, S. Star-Lack, J. Zentai, G. Berbeco, R. TI JUNIOR INVESTIGATOR WINNER - Novel EPID for Enhanced Contrast and Detective Quantum Efficiency SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Rottmann, J.; Chen, H.; Yip, S.; Berbeco, R.] Brigham & Womans Hosp, Dana Farber Canc Inst, Boston, MA USA. [Rottmann, J.; Chen, H.; Yip, S.; Berbeco, R.] Harvard Univ, Sch Med, Boston, MA USA. [Morf, D.; Fueglistaller, R.; Star-Lack, J.; Zentai, G.] Varian Med Syst Inc, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3742 EP 3742 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303538 PM 26129598 ER PT J AU Yip, S Rottmann, I Chen, H Morf, D Fueglistaller, R Star-Lack, J Zentai, G Berbeco, R AF Yip, S. Rottmann, I. Chen, H. Morf, D. Fueglistaller, R. Star-Lack, J. Zentai, G. Berbeco, R. TI Combination of Multiple EPID Imager Layers Improves Image Quality and Tracking Performance of Low Contrast Objects SO MEDICAL PHYSICS LA English DT Meeting Abstract CT 57th Annual Meeting and Exhibition of the American-Association-of-Physicists-in-Medicine (AAPM) CY JUL 12-16, 2015 CL Anaheim, CA SP Amer Assoc Physicists Med C1 [Yip, S.; Rottmann, I.; Chen, H.; Berbeco, R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Yip, S.; Rottmann, I.; Chen, H.; Berbeco, R.] Harvard Univ, Sch Med, Boston, MA USA. [Morf, D.; Fueglistaller, R.; Star-Lack, J.; Zentai, G.] Varian Med Syst, Palo Alto, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD JUN PY 2015 VL 42 IS 6 BP 3742 EP 3742 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5KH UT WOS:000356998303539 PM 26129599 ER PT J AU Eilers, G Czaplinski, JT Mayeda, M Bahri, N Tao, D Zhu, MJ Hornick, JL Lindeman, NI Sicinska, E Wagner, AJ Fletcher, JA Marino-Enriquez, A AF Eilers, Grant Czaplinski, Jeffrey T. Mayeda, Mark Bahri, Nacef Tao, Derrick Zhu, Meijun Hornick, Jason L. Lindeman, Neal I. Sicinska, Ewa Wagner, Andrew J. Fletcher, Jonathan A. Marino-Enriquez, Adrian TI CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID MULTICENTER PHASE-II; DEPENDENT KINASE 4/6; FIBROSARCOMATOUS TRANSFORMATION; PROGNOSTIC-SIGNIFICANCE; RING CHROMOSOMES; MESYLATE; INHIBITION; SEQUENCES; TUMORS; TRIAL AB Dermatofibrosarcoma protuberans (DFSP) is an aggressive PDGFB-dependent cutaneous sarcoma characterized by infiltrative growth and frequent local recurrences. Some DFSP progress to a higher-grade fibrosarcomatous form, with rapid growth and increased risk of metastasis. Imatinib provides clinical benefit in approximately 50% of patients with unresectable or metastatic DFSP. However, efficacious medical therapies have not been developed for imatinib-resistant DFSP. We established a model of imatinib-resistant DFSP and evaluated CDK4/6 inhibition as a genomically credentialed targeted therapy. DFSP105, an imatinib-resistant human cell line, was established from a fibrosarcomatous DFSP (FS-DFSP), and was studied by SNP arrays and sequencing to identify targetable genomic alterations. Findings were validated in vitro and in vivo, and confirmed in a series including 12 DFSP and 6 FS-DFSP. SNP analysis of DFSP105 revealed a homozygous deletion encompassing CDKN2A and CDKN2B. The resultant p16 loss implicated CDK4/6 as a potential therapeutic target in DFSP. We further demonstrated CDKN2A homozygous deletion in 1 of 12 conventional DFSP and 2 of 6 FS-DFSP, whereas p16 expression was lost in 4 of 18 DFSP. In vitro treatment of DFSP105 with two structurally distinct selective CDK4/6 inhibitors, PD-0332991 and LEE011, led to inhibition of RB1 phosphorylation and inhibition of proliferation (GI(50) 160 nmol/L and 276 nmol/L, respectively). In vivo treatment of DFSP105 with PD-0332991 (150 mg/kg) inhibited xenograft growth in mice, in comparison with imatinib-treated or -untreated tumors. In conclusion, CDKN2A deletion can contribute to DFSP progression. CDK4/6 inhibition is a preclinically effective treatment against p16-negative, imatinib-resistant FS-DFSP, and should be evaluated as a therapeutic strategy in patients with unresectable or metastatic imatinib-resistant DFSP. (C)2015 AACR. C1 [Eilers, Grant; Mayeda, Mark; Bahri, Nacef; Tao, Derrick; Zhu, Meijun; Hornick, Jason L.; Lindeman, Neal I.; Fletcher, Jonathan A.; Marino-Enriquez, Adrian] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Czaplinski, Jeffrey T.; Sicinska, Ewa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol,Dept Med Oncol, Boston, MA 02115 USA. [Wagner, Andrew J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol,Dept Med Oncol, Boston, MA 02115 USA. RP Marino-Enriquez, A (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM jfletcher@partners.org; admarino@partners.org FU US NIH [1P50CA168512, 1P50CA127003]; Sarcoma Alliance for Research through Collaboration FX This work was supported by grants from the US NIH, including 1P50CA168512 (to J.A. Fletcher and A. Marino-Enriquez) and 1P50CA127003 (to J.A. Fletcher), and from The Sarcoma Alliance for Research through Collaboration (to A. Marino-Enriquez). NR 37 TC 12 Z9 13 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD JUN PY 2015 VL 14 IS 6 BP 1346 EP 1353 DI 10.1158/1535-7163.MCT-14-0793 PG 8 WC Oncology SC Oncology GA CM9UK UT WOS:000358054300009 PM 25852058 ER PT J AU Rotstein, BH Liang, SH Belov, VV Livni, E Levine, DB Bonab, AA Papisov, MI Perlis, RH Vasdev, N AF Rotstein, Benjamin H. Liang, Steven H. Belov, Vasily V. Livni, Eli Levine, Dylan B. Bonab, Ali A. Papisov, Mikhail I. Perlis, Roy H. Vasdev, Neil TI Practical Radiosynthesis and Preclinical Neuroimaging of [C-11] isradipine, a Calcium Channel Antagonist SO MOLECULES LA English DT Article DE carbon-11; radiosynthesis; isradipine; positron emission tomography; neuroimaging; calcium channel blocker ID GENOME-WIDE ASSOCIATION; IN-VIVO; DIHYDROPYRIDINE BINDING; PARKINSONS-DISEASE; PET RADIOLIGANDS; RECEPTORS; NEURONS; 1,4-DIHYDROPYRIDINES; RADIOTRACERS; NIMODIPINE AB In the interest of developing in vivo positron emission tomography (PET) probes for neuroimaging of calcium channels, we have prepared a carbon-11 isotopologue of a dihydropyridine Ca2+-channel antagonist, isradipine. Desmethyl isradipine (4-(benzo[c][1,2,5]oxadiazol-4-yl)-5-(isopropoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid) was reacted with [C-11]CH3I in the presence of tetrabutylammonium hydroxide in DMF in an HPLC injector loop to produce the radiotracer in a good yield (6 +/- 3% uncorrected radiochemical yield) and high specific activity (143 +/- 90 GBq mu mol(-1) at end-of-synthesis). PET imaging of normal rats revealed rapid brain uptake at baseline (0.37 +/- 0.08% ID/cc (percent of injected dose per cubic centimeter) at peak, 15-60 s), which was followed by fast washout. After pretreatment with isradipine (2 mgkg(-1), i.p.), whole brain radioactivity uptake was diminished by 25%-40%. This preliminary study confirms that [C-11]isradipine can be synthesized routinely for research studies and is brain penetrating. Further work on Ca2+-channel radiotracer development is planned. C1 [Rotstein, Benjamin H.; Liang, Steven H.; Belov, Vasily V.; Livni, Eli; Levine, Dylan B.; Bonab, Ali A.; Papisov, Mikhail I.; Vasdev, Neil] Harvard Univ, Sch Med, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Liang, Steven H.; Belov, Vasily V.; Livni, Eli; Levine, Dylan B.; Bonab, Ali A.; Papisov, Mikhail I.; Vasdev, Neil] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Belov, Vasily V.; Levine, Dylan B.; Bonab, Ali A.; Papisov, Mikhail I.] Shriners Hosp Children Boston, Dept Res, Boston, MA 02114 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA. RP Vasdev, N (reprint author), Harvard Univ, Sch Med, Dept Radiol, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA. EM rotstein.benjamin@mgh.harvard.edu; liang.steven@mgh.harvard.edu; vbelov@mgh.harvard.edu; elivni@mgh.harvard.edu; dblevine@mgh.harvard.edu; bonab@pet.mgh.harvard.edu; papisov@helix.mgh.harvard.edu; rperlis@mgh.harvard.edu; vasdev.neil@mgh.harvard.edu OI Papisov, Mikhail/0000-0003-4716-2122; Rotstein, Benjamin/0000-0001-9707-9357 FU Natural Sciences and Engineering Research Council of Canada (NSERC); Stanley Center for Psychiatric Research FX B.H.R. was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Postdoctoral Fellowship. R.H.P. and E.L. were supported in part by the Stanley Center for Psychiatric Research. We thank Edward Soares for helpful discussions. NR 41 TC 1 Z9 1 U1 0 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1420-3049 J9 MOLECULES JI Molecules PD JUN PY 2015 VL 20 IS 6 BP 9550 EP 9559 DI 10.3390/molecules20069550 PG 10 WC Chemistry, Organic SC Chemistry GA CM8ZE UT WOS:000357992700006 PM 26016546 ER PT J AU Chiorean, EG Hurwitz, HI Cohen, RB Schwartz, JD Dalal, RP Fox, FE Gao, L Sweeney, CJ AF Chiorean, E. G. Hurwitz, H. I. Cohen, R. B. Schwartz, J. D. Dalal, R. P. Fox, F. E. Gao, L. Sweeney, C. J. TI Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors SO ANNALS OF ONCOLOGY LA English DT Article DE ramucirumab; phase I study; VEGFR-2; solid tumors; vascular endothelial growth factor ID VEGF-C; LYMPHANGIOGENESIS; ANGIOGENESIS; METASTASIS; TRIAL AB Background: Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2). An initial phase I study evaluated ramucirumab administered weekly in advanced cancer patients. This phase I study of ramucirumab [ administered every 2 or 3 weeks (Q2W or Q3W)] examined safety, maximum tolerated dose, pharmacokinetics, immunogenicity, antitumor activity, and pharmacodynamics. Patients and methods: Patients with advanced solid malignancies were treated with escalating doses of ramucirumab i.v. over 1 h. Blood was sampled for pharmacokinetics studies throughout treatment; levels of circulating vascular endothelial growth factor-A (VEGF-A) and soluble VEGF receptors (R)-1 and -2 were assessed. Results: Twenty-five patients were treated with ramucirumab: 13 with 6, 8, or 10 mg/kg Q2W, and 12 with 15 or 20 mg/kg Q3W. The median treatment duration was 12 weeks (range 2-81). No dose-limiting toxicities were observed. The most frequently reported adverse events (AEs) included proteinuria and hypertension (n = 6 each), and diarrhea, fatigue and headache (n = 4 each). Treatment-related grade 3/4 AEs were: two grade 3 hypertension (10 and 20 mg/kg), one each grade 3 vomiting, fatigue (20 mg/kg), atrial flutter (15 mg/kg), and one each grade 4 duodenal ulcer hemorrhage (6 mg/kg) and grade 4 pneumothorax (20 mg/kg). Pharmacokinetic analysis revealed low clearance and half-life of similar to 110-160 h. Analysis of serum biomarkers indicated considerable patient-to-patient variability, but trends toward elevated VEGF-A and a transient decline in soluble VEGFR-2. Fifteen patients (60%) had best response of stable disease, with a median duration of 13 months (range 2-18 months) in tumor types including colorectal, renal, liver, and neuroendocrine cancers. Conclusion: Ramucirumab was well tolerated. Study results led to recommended phase II doses of 8 mg/kg Q2W and 10 mg/kg Q3W. Prolonged stable disease was observed, suggesting ramucirumab efficacy in various solid tumors. C1 [Chiorean, E. G.] Univ Washington, Dept Med, Div Med Oncol, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Hurwitz, H. I.] Duke Univ, Sch Med, GI Oncol Unit, Durham, NC 27706 USA. [Cohen, R. B.] Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Schwartz, J. D.; Dalal, R. P.; Fox, F. E.; Gao, L.] Eli Lilly & Co, Clin Dev, Bridgewater, MA USA. [Sweeney, C. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Chiorean, EG (reprint author), Univ Washington, Dept Med, Div Med Oncol, Fred Hutchinson Canc Res Ctr, 825 Eastlake Ave East,G4830, Seattle, WA 98109 USA. EM gchiorea@uw.edu NR 20 TC 17 Z9 17 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD JUN PY 2015 VL 26 IS 6 BP 1230 EP 1237 DI 10.1093/annonc/mdv144 PG 8 WC Oncology SC Oncology GA CM9AO UT WOS:000357997500028 PM 25787923 ER PT J AU Bagci-Onder, T Du, WL Figueiredo, JL Martinez-Quintanilla, J Shah, K AF Bagci-Onder, Tugba Du, Wanlu Figueiredo, Jose-Luiz Martinez-Quintanilla, Jordi Shah, Khalid TI Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells SO BRAIN LA English DT Article DE breast to brain metastasis; stem cell; death receptor; TRAIL ID CANCER-TREATMENT; TRAIL; THERAPIES; EFFICACY; FATE; REGRESSION; MIGRATION; TROPISM; GENE AB Characterizing clinically relevant brain metastasis models and assessing the therapeutic efficacy in such models are fundamental for the development of novel therapies for metastatic brain cancers. In this study, we have developed an in vivo imageable breast-to-brain metastasis mouse model. Using real time in vivo imaging and subsequent composite fluorescence imaging, we show a widespread distribution of micro-and macro-metastasis in different stages of metastatic progression. We also show extravasation of tumour cells and the close association of tumour cells with blood vessels in the brain thus mimicking the multi-foci metastases observed in the clinics. Next, we explored the ability of engineered adult stem cells to track metastatic deposits in this model and show that engineered stem cells either implanted or injected via circulation efficiently home to metastatic tumour deposits in the brain. Based on the recent findings that metastatic tumour cells adopt unique mechanisms of evading apoptosis to successfully colonize in the brain, we reasoned that TNF receptor superfamily member 10A/10B apoptosis-inducing ligand (TRAIL) based proapoptotic therapies that induce death receptor signalling within the metastatic tumour cells might be a favourable therapeutic approach. We engineered stem cells to express a tumour selective, potent and secretable variant of a TRAIL, S-TRAIL, and show that these cells significantly suppressed metastatic tumour growth and prolonged the survival of mice bearing metastatic breast tumours. Furthermore, the incorporation of pro-drug converting enzyme, herpes simplex virus thymidine kinase, into therapeutic S-TRAIL secreting stem cells allowed their eradication post-tumour treatment. These studies are the first of their kind that provide insight into targeting brain metastasis with stem-cell mediated delivery of pro-apoptotic ligands and have important clinical implications. C1 [Bagci-Onder, Tugba; Du, Wanlu; Figueiredo, Jose-Luiz; Martinez-Quintanilla, Jordi; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA. [Bagci-Onder, Tugba; Du, Wanlu; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. EM kshah@mgh.harvard.edu FU James McDonnell Foundation; [RO1 CA138922] FX This work was supported RO1 CA138922 (K.S.), James McDonnell Foundation (K.S.). NR 34 TC 9 Z9 9 U1 1 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD JUN 1 PY 2015 VL 138 BP 1710 EP 1721 DI 10.1093/brain/awv094 PN 6 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CM9BD UT WOS:000357999300032 PM 25910782 ER PT J AU Blashill, AJ Ehlinger, PP Mayer, KH Safren, SA AF Blashill, Aaron J. Ehlinger, Peter P. Mayer, Kenneth H. Safren, Steven A. TI Optimizing Adherence to Preexposure and Postexposure Prophylaxis: The Need for an Integrated Biobehavioral Approach SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE PrEP; PEP; adherence; HIV; mental health ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; MEDICATION ADHERENCE; ANTIRETROVIRAL PROPHYLAXIS; HIV PREVENTION; USE DRUGS; INFECTION; EXPOSURE; INDIVIDUALS; DEPRESSION AB Preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) has been shown to be effective in preventing transmission of human immunodeficiency virus (HIV). A dose-response relationship between adherence and HIV transmission is illustrated in the current PrEP literature, and adherence interventions for PrEP may be useful, although currently few effective programs have been developed and tested. There is a paucity of randomized controlled trials testing PEP adherence interventions, and further research is needed. We conclude by proposing the importance of tailoring adherence counseling to address psychosocial factors and mental health stressors that may negatively affect adherence. C1 [Blashill, Aaron J.; Ehlinger, Peter P.; Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blashill, Aaron J.; Mayer, Kenneth H.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA. [Blashill, Aaron J.; Mayer, Kenneth H.; Safren, Steven A.] Fenway Hlth, Boston, MA USA. [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Blashill, AJ (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,7th Flr, Boston, MA 02114 USA. EM ablashill@mgh.harvard.edu FU National Institute of Mental Health [K23MH096647, K24MH094214] FX Some of the author time was supported by the National Institute of Mental Health (grant numbers K23MH096647 to A. J. B. and K24MH094214 awarded to S. A. S.). NR 35 TC 2 Z9 2 U1 3 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 SU 3 BP S187 EP S190 DI 10.1093/cid/civ111 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZZ UT WOS:000358072500007 PM 25972502 ER PT J AU Stack, BC Bimston, DN Bodenner, DL Brett, EM Dralle, H Orloff, LA Pallota, J Snyder, SK Wong, RJ Randolph, GW AF Stack, Brendan C., Jr. Bimston, David N. Bodenner, Donald L. Brett, Elise M. Dralle, Henning Orloff, Lisa A. Pallota, Johanna Snyder, Samuel K. Wong, Richard J. Randolph, Gregory W. CA AACE Endocrine Surg Sci Comm TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: POSTOPERATIVE HYPOPARATHYRODISM - DEFINITIONS AND MANAGEMENT SO ENDOCRINE PRACTICE LA English DT Review ID PARATHYROID-HORMONE ASSAY; TOTAL THYROIDECTOMY; RECALCITRANT HYPOCALCEMIA; DOUBLE-BLIND; VITAMIN-D; AUTOTRANSPLANTATION; SURGERY; GLANDS; RISK; COMPLICATIONS C1 [Stack, Brendan C., Jr.] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA. [Stack, Brendan C., Jr.; Bodenner, Donald L.] Univ Arkansas Med Sci, UAMS Thyroid Ctr, Little Rock, AR 72205 USA. [Bimston, David N.] Mem Ctr Integrat Endocrine Surg, Hollywood, FL USA. [Bodenner, Donald L.] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA. [Brett, Elise M.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Dralle, Henning] Univ Halle Wittenberg, Univ Hosp, Fac Med, Dept Gen Visceral & Vasc Surg, D-06108 Halle, Germany. [Orloff, Lisa A.] Stanford Univ, Dept Otolaryngol Head & Neck Surg Head & Neck End, Palo Alto, CA 94304 USA. [Pallota, Johanna] Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Snyder, Samuel K.] Scott & White Clin Texas A&M HSC, Temple, TX USA. [Wong, Richard J.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA. Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Gen & Thyroid Div,Endocrine Surg Serv,Massachuset, Boston, MA USA. [AACE Endocrine Surg Sci Comm] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med,Massachusetts Gen Hosp, Parathyroid Endocrine Surg Div,Endocrine Surg Ser, Boston, MA USA. RP Stack, BC (reprint author), 4301 W Markham St,543, Little Rock, AR 72205 USA. EM bstack@uams.edu NR 52 TC 9 Z9 9 U1 1 U2 11 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUN PY 2015 VL 21 IS 6 BP 674 EP 685 DI 10.4158/EP14462.DSC PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CM5ML UT WOS:000357732000014 PM 26135962 ER PT J AU Davies, L Morris, LGT Haymart, M Chen, AY Goldenberg, D Morris, J Ogilvie, JB Terris, DJ Netterville, J Wong, RJ Randolph, G AF Davies, Louise Morris, Luc G. T. Haymart, Megan Chen, Amy Y. Goldenberg, David Morris, John Ogilvie, Jennifer B. Terris, David J. Netterville, James Wong, Richard J. Randolph, Gregory CA AACE Endocrine Surg Sci Comm TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYRIOD CANCER SO ENDOCRINE PRACTICE LA English DT Review ID PAPILLARY THYROID-CANCER; UNITED-STATES; RADIATION-EXPOSURE; SYSTEMATIC AUTOPSY; IODINE INTAKE; RISK; CARCINOMA; HEALTH; ESTROGEN; OBESITY AB Objective: (1) Describe current epidemiology of thyroid cancer in the United States; (2) evaluate hypothesized causes of the increased incidence of thyroid cancer; and (3) suggest next steps in research and clinical action. Methods: Analysis of data from Surveillance, Epidemiology and End Results System and the National Center for Vital Statistics. Literature review of published English-language articles through December 31, 2013. Results: The incidence of thyroid cancer has tripled over the past 30 years, whereas mortality is stable. The increase is mainly comprised of smaller tumors. These facts together suggest the major reason for the increased incidence is detection of subclinical, nonlethal disease. This has likely occurred through: health care system access, incidental detection on imaging, more frequent biopsy, greater volumes of and extent of surgery, and changes in pathology practices. Because larger-size tumors have increased in incidence also, it is possible that there is a concomitant true rise in thyroid cancer incidence. The only clearly identifiable contributor is radiation exposure, which has likely resulted in a few additional cases annually. The contribution of the following causes to the increasing incidence is unclear: iodine excess or insufficiency, diabetes and obesity, and molecular disruptions. The following mechanisms do not currently have strong evidence to support a link with the development of thyroid cancer: estrogen, dietary nitrate, and autoimmune thyroid disease. Conclusion: Research should focus on illuminating which thyroid cancers need treatment. Patients should be advised of the benefits as well as harms that can occur with treatment of incidentally identified, small, asymptomatic thyroid cancers. C1 [Davies, Louise] VA Outcomes Grp, Dept Vet Affairs, Med Ctr, White River Jct, VT 05009 USA. [Davies, Louise] Geisel Sch Med, Otolaryngol Sect, Dartmouth, NS, Canada. [Davies, Louise] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Morris, Luc G. T.; Wong, Richard J.] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA. [Haymart, Megan] Univ Michigan, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA. [Chen, Amy Y.] Emory Univ, Sch Med, Dept Otolaryngol, Atlanta, GA USA. [Goldenberg, David] Penn State Coll Med, Div Otolaryngol Head & Neck Surg, State Coll, PA USA. [Morris, John] Mayo Clin, Div Endocrinol, Rochester, MN USA. [Ogilvie, Jennifer B.] NYU, Sch Med, Div Endocrine Surg, New York, NY USA. [Terris, David J.] Georgia Regents Univ, Dept Otolaryngol, Augusta, GA USA. [Netterville, James] Vanderbilt Univ Sch Med, Vanderbilt Bill Wilkerson Ctr Otolaryngol Head &, Head & Neck Oncol Serv, Nashville, TN USA. [Randolph, Gregory] Harvard Univ, Massachusetts Eye & Ear Infirm,Sch Med, Massachusetts Gen Hosp,Otolaryngol Head & Neck Su, Div Thyroid & Parathyroid Endocrine Surg,Div Surg, Boston, MA 02114 USA. RP Davies, L (reprint author), VA Outcomes Grp, 111B,215 North Main St, White River Jct, VT 05009 USA. EM louise.davies@dartmouth.edu FU Department of Veterans Affairs; National Institutes of Health [1K07CA154595-02] FX Dr. Davies received support from the Department of Veterans Affairs; Dr. Haymart received support from the National Institutes of Health (1K07CA154595-02). NR 64 TC 28 Z9 28 U1 1 U2 5 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUN PY 2015 VL 21 IS 6 BP 686 EP 696 DI 10.4158/EP14466.DSCR PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CM5ML UT WOS:000357732000015 PM 26135963 ER PT J AU Salem, KZ Ghobrial, IM AF Salem, Karma Z. Ghobrial, Irene M. TI The road to cure in multiple myeloma starts with smoldering disease SO EXPERT OPINION ON ORPHAN DRUGS LA English DT Review DE early treatment; multiple myeloma; precursor disease; prevention of progression; prognosis; risk factors of progression; smoldering myeloma ID UNDETERMINED SIGNIFICANCE MGUS; MONOCLONAL GAMMOPATHY; MELPHALAN-PREDNISONE; UNTREATED MYELOMA; RANDOMIZED-TRIAL; ZOLEDRONIC ACID; EARLY-STAGE; PROGRESSION; RISK; THALIDOMIDE AB Introduction: Smoldering multiple myeloma (SMM) is a heterogeneous clinical entity that defines patients in the spectrum of disease progression from monoclonal gammopathy of undetermined significance to multiple myeloma (MM). Current standard of care is observation until end organ damage occurs. In spite of this, the scientific community has begun to question whether the strategy of watchful waiting should be replaced with earlier therapeutic intervention with the ultimate goal of preventing clonal heterogeneity and end organ damage. Areas covered: In this review, we challenge the concept of observation as the best option of therapy in SMM. We present current data on diagnosis, prognostic factors of disease progression and studies that have been conducted to date to determine whether earlier therapeutic interventions will lead to an improvement in overall survival of patients with MM. Expert opinion: If the recommendations of treatment of SMM were to change, the scientific body of evidence would have to overcome four major hurdles: to demonstrate that early intervention leads to prolonged survival and delay in development of end organ damage, that it does not have long-term toxicities, that it is implemented in patients with a high-likelihood of developing myeloma and that it does not lead to the outgrowth of more resistant clones. Only well-designed clinical trials will determine whether cure can be achieved with earlier interventions. C1 [Salem, Karma Z.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ghobrial, IM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM Irene_ghobrial@dfci.harvard.edu FU NIH [R01CA-181683-01]; Leukemia and Lymphoma Society FX This work was supported by NIH R01CA-181683-01 and the Leukemia and Lymphoma Society. IMG is on the advisory board of Celgene, Millennium, Onyx, BMS and Noxxon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. NR 51 TC 0 Z9 0 U1 1 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2167-8707 J9 EXPERT OPIN ORPHAN D JI Exp. Opin. Orphan Drugs PD JUN PY 2015 VL 3 IS 6 BP 653 EP 661 DI 10.1517/21678707.2015.1036740 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CN0CE UT WOS:000358079100003 ER PT J AU Chiu, YH Afeiche, MC Gaskins, AJ Williams, PL Petrozza, JC Tanrikut, C Hauser, R Chavarro, JE AF Chiu, Y. H. Afeiche, M. C. Gaskins, A. J. Williams, P. L. Petrozza, J. C. Tanrikut, C. Hauser, R. Chavarro, J. E. TI Fruit and vegetable intake and their pesticide residues in relation to semen quality among men from a fertility clinic SO HUMAN REPRODUCTION LA English DT Article DE fruits and vegetables; pesticide; semen quality ID FOOD FREQUENCY QUESTIONNAIRE; UNITED-STATES; SPERM PARAMETERS; EXPOSURE; INFERTILITY; REPRODUCIBILITY; PREVALENCE; TOXICITY; VALIDITY; WORKERS AB STUDY QUESTION: Is consumption of fruits and vegetables with high levels of pesticide residues associated with lower semen quality? SUMMARY ANSWER: Consumption of fruits and vegetables with high levels of pesticide residues was associated with a lower total sperm count and a lower percentage of morphologically normal sperm among men presenting to a fertility clinic. WHAT IS KNOWN ALREADY: Occupational and environmental exposure to pesticides is associated with lower semen quality. Whether the same is true for exposure through diet is unknown. STUDY DESIGN, SIZE, DURATION: Men enrolled in the Environment and Reproductive Health (EARTH) Study, an ongoing prospective cohort at an academic medical fertility center. Male partners (n = 155) in subfertile couples provided 338 semen samples during 2007-2012. PARTICIPANTS/MATERIALS, SETTING, METHODS: Semen samples were collected over an 18-month period following diet assessment. Sperm concentration and motility were evaluated by computer-aided semen analysis (CASA). Fruits and vegetables were categorized as containing high or low-to-moderate pesticide residues based on data from the annual United States Department of Agriculture Pesticide Data Program. Linear mixed models were used to analyze the association of fruit and vegetable intake with sperm parameters accounting for within-person correlations across repeat samples while adjusting for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: Total fruit and vegetable intake was unrelated to semen quality parameters. High pesticide residue fruit and vegetable intake, however, was associated with poorer semen quality. On average, men in highest quartile of high pesticide residue fruit and vegetable intake (>= 1.5 servings/day) had 49% (95% confidence interval (CI): 31%, 63%) lower total sperm count and 32% (95% CI: 7%, 58%) lower percentage of morphologically normal sperm than men in the lowest quartile of intake (<0.5 servings/day) (P, trend = 0.003 and 0.02, respectively). Low-to-moderate pesticide residue fruit and vegetable intake was associated with a higher percentage of morphologically normal sperm (P, trend = 0.04). LIMITATIONS, REASONS FOR CAUTION: Surveillance data, rather than individual pesticide assessment, was used to assess the pesticide residue status of fruits and vegetables. CASA is a useful method for clinical evaluation but may be considered less favorable for accurate semen analysis in the research setting. Owing to the observational nature of the study, confirmation is required by interventional studies as well. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this is the first report on the consumption of fruits and vegetables with high levels of pesticide residue in relation to semen quality. Further confirmation of these findings is warranted. C1 [Chiu, Y. H.; Gaskins, A. J.; Chavarro, J. E.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Afeiche, M. C.; Hauser, R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Gaskins, A. J.; Williams, P. L.; Hauser, R.; Chavarro, J. E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Williams, P. L.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Petrozza, J. C.] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA. [Tanrikut, C.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Chavarro, J. E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Chavarro, J. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Chavarro, JE (reprint author), 665 Huntington Ave, Boston, MA 02115 USA. EM jchavarr@hsph.harvard.edu FU National Institute for Environmental Health Sciences (NIEHS) [ES009718, ES022955, ES000002]; National Institutes of Health [P30 DK046200]; Ruth L. Kirschstein, National Research Service [T32 DK007703-16] FX This study was supported by grants ES009718, ES022955 and ES000002 from the National Institute for Environmental Health Sciences (NIEHS), grants P30 DK046200 from the National Institutes of Health and Ruth L. Kirschstein, National Research Service Award T32 DK007703-16. NR 37 TC 12 Z9 12 U1 2 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2015 VL 30 IS 6 BP 1342 EP 1351 DI 10.1093/humrep/dev064 PG 10 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CM9GJ UT WOS:000358015200009 PM 25824023 ER PT J AU Saxena, R Georgopoulos, NA Braaten, TJ Bjonnes, AC Koika, V Panidis, D Welt, CK AF Saxena, R. Georgopoulos, N. A. Braaten, T. J. Bjonnes, A. C. Koika, V. Panidis, D. Welt, C. K. TI Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance SO HUMAN REPRODUCTION LA English DT Article DE genome-wide association; single-nucleotide polymorphism; follicle-stimulating hormone receptor; polycystic ovary syndrome ID GENOME-WIDE ASSOCIATION; CHROMOSOME 2P16.3; POLYMORPHISMS; METAANALYSIS; ALA307THR; SECRETION; DENND1A; LOCI AB STUDY QUESTION: ArePCOS risk variants identified in women of Han Chinese ethnicity also associated with risk of PCOS or the phenotypic features of PCOS in European women? SUMMARY ANSWER: One variant, rs2268361-T, in the intron of FSHR was associated with PCOS and lower FSH levels, while another variant rs705702-G near the RAB5B and SUOX genes was associated with insulin and glucose levels after oral glucose testing in women with PCOS of European ethnicity. WHAT IS KNOWN ALREADY: Three of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1). However, additional replication is needed to establish the importance of these variants in European women and to determine the relationship to PCOS phenotypic traits. STUDY DESIGN, SIZE, DURATION: The study was a case-control examination in a discovery cohort of women with PCOS(n = 485) and controls (n = 407) from Boston (Boston 1). Replication was performed in women from Greece (cases n = 884 and controls n = 311) and an additional cohort from Boston (Boston electronic medical record (EMR); n = 350 cases and n = 1258 controls). PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Women had PCOS defined by the National Institutes of Health criteria in Boston 1 and Greece (n = 783), with additional subjects fulfilling the Rotterdam criteria (hyperandrogenism, polycystic ovary morphology and regular menses) in Greece (n = 101). Controls in Boston and Greece had regular menstrual cycles and no hyperandrogenism. The second cohort from Boston was defined using the EMR and natural language processing. Allele frequencies for variants associated with PCOS in Han Chinese women were examined in PCOS cases and controls, along with the relationship to quantitative traits. MAIN RESULTS AND THE ROLE OF CHANCE: A variant rs2268361-T in an intron of FSHR was associated with PCOS (0.84 [0.76-0.93], OR [95% CI]; P = 0.002). The rs2268361-T was associated with lower FSH levels (-0.15 +/- 0.05; P = 0.0029). A variant rs705702-G near RAB5B and SUOX was associated with insulin (-0.16 +/- 0.05, P = 0.0029) and glucose levels (-0.20 +/- 0.05, P = 0.0002) 120 min after an oral glucose test. LIMITATIONS, REASONS FOR CAUTION: The study was large and contained replication cohorts, but was limited by a small number of controls in the Greek cohort and a small number of cases in the second Boston cohort. The second Boston group was identified using electronic medical record review, but was validated for the cardinal features of PCOS. WIDER IMPLICATIONS OF THE FINDINGS: This study demonstrates a cross-ethnic PCOS risk locus in FSHR in women of European ancestry with PCOS. The variant may influence FSH receptor responsiveness as suggested by the associated change in FSH levels. The relationship between a variant near RAB5B and SUOX and glucose stimulated insulin and glucose levels suggests an influence of one of these genes on glucose tolerance, but the absence of a relationship with PCOS points to potential differences in the international PCOS patient populations. C1 [Saxena, R.; Bjonnes, A. C.] Massachusetts Gen Hosp, Dept Anaesthesia, Boston, MA 02114 USA. [Saxena, R.; Bjonnes, A. C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Georgopoulos, N. A.; Koika, V.; Panidis, D.] Univ Patras, Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol, GR-26110 Patras, Greece. [Braaten, T. J.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA. [Panidis, D.] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 2, Div Endocrinol & Human Reprod, GR-54006 Thessaloniki, Greece. [Welt, C. K.] Univ Utah, Div Endocrinol Metab & Diabet, Salt Lake City, UT USA. RP Welt, CK (reprint author), Univ Utah, EIHG, Div Endocrinol Metab & Diabet, 15 N 2030 E, Salt Lake City, UT 84112 USA. EM cwelt@genetics.utah.edu OI Welt, Corrine/0000-0002-8219-5504 FU Eunice Kennedy Shriver National Institute Of Child Health & Human Development [R01HD065029]; Harvard Clinical and Translational Science Center, from the National Center for Research Resources [1 UL1 RR025758]; American Diabetes Association [1-10-CT-57]; Partners Healthcare Center for Personalized Genetics Project Grant FX The project was supported by Award Number R01HD065029 from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development, Award Number 1 UL1 RR025758, Harvard Clinical and Translational Science Center, from the National Center for Research Resources, award 1-10-CT-57 from the American Diabetes Association and the Partners Healthcare Center for Personalized Genetics Project Grant. NR 26 TC 11 Z9 11 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2015 VL 30 IS 6 BP 1454 EP 1459 DI 10.1093/humrep/dev085 PG 6 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CM9GJ UT WOS:000358015200020 PM 25904635 ER PT J AU Tellechea, A Silva, EA Min, JH Leal, EC Auster, ME Pradhan-Nabzdyk, L Shih, W Mooney, DJ Veves, A AF Tellechea, Ana Silva, Eduardo A. Min, Jianghong Leal, Ermelindo C. Auster, Michael E. Pradhan-Nabzdyk, Leena Shih, William Mooney, David J. Veves, Aristidis TI Alginate and DNA Gels Are Suitable Delivery Systems for Diabetic Wound Healing SO INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS LA English DT Article DE biomaterials; diabetic foot ulcers; wound healing; neuropeptides; endothelial precursor cells ID TISSUE REGENERATION; FOOT ULCERS; CELLS; ANGIOGENESIS; EFFICACY; INFLAMMATION; PAYLOADS; SAFETY; TRIAL AB Diabetic foot ulcers (DFU) represent a severe health problem and an unmet clinical challenge. In this study, we tested the efficacy of novel biomaterials in improving wound healing in mouse models of diabetes mellitus (DM). The biomaterials are composed of alginate- and deoxyribonucleic acid (DNA)-based gels that allow incorporation of effector cells, such as outgrowth endothelial cells (OEC), and provide sustained release of bioactive factors, such as neuropeptides and growth factors, which have been previously validated in experimental models of DM wound healing or hind limb ischemia. We tested these biomaterials in mice and demonstrate that they are biocompatible and can be injected into the wound margins without major adverse effects. In addition, we show that the combination of OEC and the neuropeptide Substance P has a better healing outcome than the delivery of OEC alone, while subtherapeutic doses of vascular endothelial growth factor (VEGF) are required for the transplanted cells to exert their beneficial effects in wound healing. In summary, alginate and DNA scaffolds could serve as potential delivery systems for the next-generation DFU therapies. C1 [Tellechea, Ana; Leal, Ermelindo C.; Auster, Michael E.; Pradhan-Nabzdyk, Leena; Veves, Aristidis] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Tellechea, Ana; Leal, Ermelindo C.] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal. [Silva, Eduardo A.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA. [Min, Jianghong; Shih, William] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Min, Jianghong; Shih, William; Mooney, David J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Mooney, David J.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. RP Veves, A (reprint author), Beth Israel Deaconess Med Ctr, Palmer 321A,One Deaconess Rd, Boston, MA 02215 USA. EM aveves@bidmc.harvard.edu RI Silva, Eduardo/M-2711-2015 OI Silva, Eduardo/0000-0003-3173-7622 FU National Institutes of Health (NIH) [1R24DK091210-01]; Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BD/48624/2008] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Institutes of Health (NIH) Grant 1R24DK091210-01 to WS, DJM, and AV, and by Fundacao para a Ciencia e Tecnologia (FCT) Fellowship SFRH/BD/48624/2008 to AT. NR 30 TC 3 Z9 3 U1 1 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-7346 EI 1552-6941 J9 INT J LOW EXTR WOUND JI Int. J. Low. Extrem. Wounds PD JUN PY 2015 VL 14 IS 2 BP 146 EP 153 DI 10.1177/1534734615580018 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA CN0QP UT WOS:000358118700007 PM 26032947 ER PT J AU Eberlin, KR Del Frari, B Dai, XY Austen, WG AF Eberlin, Kyle R. Del Frari, Barbara Dai, Xinyi Austen, William G., Jr. TI The John D. Constable International Traveling Fellowship: A Reciprocal Education in Plastic Surgery SO JOURNAL OF CRANIOFACIAL SURGERY LA English DT Article DE Constable fellowship; international exchange; traveling fellowship ID MISSIONS AB The John D. Constable International Traveling Fellowship has been an integral part of the American Association of Plastic Surgeons since 2006 and has provided an opportunity for international plastic surgeons to work with leaders in American plastic surgery. C1 [Eberlin, Kyle R.; Austen, William G., Jr.] Harvard Univ, Massachusetts Gen Hosp, Div Plast Surg, Sch Med, Boston, MA 02114 USA. [Del Frari, Barbara] Med Univ Innsbruck, Dept Plast Reconstruct & Aesthet Surg, A-6020 Innsbruck, Austria. [Dai, Xinyi] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Plast & Hand Surg, Shanghai 200030, Peoples R China. RP Austen, WG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Plast & Reconstruct Surg, Med Sch,Wang Ambulatory Care Ctr 435, 55 Fruit St, Boston, MA 02114 USA. EM wausten@mgh.harvard.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1049-2275 EI 1536-3732 J9 J CRANIOFAC SURG JI J. Craniofac. Surg. PD JUN PY 2015 VL 26 IS 4 BP 1050 EP 1052 DI 10.1097/SCS.0000000000001680 PG 3 WC Surgery SC Surgery GA CM3GH UT WOS:000357569600056 PM 26080120 ER PT J AU Restrepo, MI Keyt, H Reyes, LF AF Restrepo, Marcos I. Keyt, Holly Reyes, Luis F. TI Aerosolized Antibiotics SO RESPIRATORY CARE LA English DT Article DE aerosols; antibacterial agents; cystic fibrosis (CF); bronchiectasis; ventilator-associated pneumonia (VAP) ID VENTILATOR-ASSOCIATED PNEUMONIA; CYSTIC FIBROSIS BRONCHIECTASIS; INHALED AZTREONAM LYSINE; TOBRAMYCIN INHALATION POWDER; CHRONIC BRONCHIAL INFECTION; INTENSIVE-CARE-UNIT; PSEUDOMONAS-AERUGINOSA; ACQUIRED PNEUMONIA; RESPIRATORY-TRACT; NEBULIZED CEFTAZIDIME AB Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensures high concentrations of the medication in the targeted tissues, the airways, with generally lower systemic absorption and systemic adverse effects. Aerosolized antibiotics have been tested as treatment for bacterial infections in patients with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and ventilator-associated pneumonia (VAP). The most successful application of this to date is treatment of infections in patients with CF. It has been hypothesized that similar success would be seen in NCFB and in difficult-to-treat hospital-acquired infections such as VAP. This review summarizes the available evidence supporting the use of aerosolized antibiotics and addresses the specific considerations that clinicians should recognize when prescribing an aerosolized antibiotic for patients with CF, NCFB, and VAP. C1 [Restrepo, Marcos I.; Keyt, Holly; Reyes, Luis F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Reyes, Luis F.] Univ La Sabana, Bogota, Colombia. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu FU National Institutes of Health Grant from the National Heart, Lung, and Blood Institute [K23HL096054] FX Dr Restrepo was partially supported by National Institutes of Health Grant K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The funding agencies had no role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 72 TC 2 Z9 3 U1 2 U2 8 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUN PY 2015 VL 60 IS 6 BP 762 EP 771 DI 10.4187/respcare.04208 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CM8IY UT WOS:000357944400002 PM 26070573 ER PT J AU Hess, DR AF Hess, Dean R. TI Aerosol Therapy During Noninvasive Ventilation or High-Flow Nasal Cannula SO RESPIRATORY CARE LA English DT Article DE aerosol; high-flow nasal cannula; inhaler; nebulizer; noninvasive ventilation ID POSITIVE-PRESSURE VENTILATION; EXCIPIENT SUBMICROMETER PARTICLES; PULMONARY RADIOAEROSOL DEPOSITION; ENHANCED CONDENSATIONAL GROWTH; RANDOMIZED CONTROLLED-TRIAL; AIRWAY PRESSURE; IN-VITRO; MECHANICAL VENTILATION; COMBINATION-DRUG; ACUTE ASTHMA AB Noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) are increasingly used for patients with acute respiratory failure. Some patients receiving these therapies might also benefit from inhaled drug delivery. Thus, it is attractive to combine aerosol therapy with NIV or HFNC. The purpose of this paper is to review the available evidence related to the use of inhaled aerosols with NIV or HFNC. Available evidence supports the delivery of aerosols during NIV. Inhaled bronchodilator response might be improved with the use of NIV in acute asthma, but the evidence is not sufficiently mature to recommend this as standard therapy. Evidence does support aerosol delivery without discontinuation of NIV. Clinical studies on aerosol delivery during HFNC are needed, and based on the available in vitro evidence, it is not possible to make a recommendation for or against aerosol delivery during HFNC. C1 [Hess, Dean R.] Massachusetts Gen Hosp, Resp Care Dept, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. RP Hess, DR (reprint author), Massachusetts Gen Hosp, Resp Care Dept, Ellison 401,55 Fruit St, Boston, MA 02114 USA. EM dhess@mgh.harvard.edu NR 46 TC 6 Z9 6 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUN PY 2015 VL 60 IS 6 BP 880 EP 891 DI 10.4187/respcare.04042 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CM8IY UT WOS:000357944400018 PM 26070581 ER PT J AU Jones, L Lambert, JC Wang, LS Choi, SH Harold, D Vedernikov, A Escott-Price, V Stone, T Richards, A Bellenguez, C Ibrahim-Verbaas, CA Naj, AC Sims, R Gerrish, A Jun, G DeStefano, AL Bis, JC Beecham, GW Grenier-Boley, B Russo, G Thornton-Wells, TA Jones, N Smith, AV Chouraki, V Thomas, C Ikram, MA Zelenika, D Vardarajan, BN Kamatani, Y Lin, CF Schmidt, H Kunkle, BW Dunstan, ML Ruiz, A Bihoreau, MT Reitz, C Pasquier, F Hollingworth, P Hanon, O Fitzpatrick, AL Buxbaum, JD Campion, D Crane, PK Becker, T Gudnason, V Cruchaga, C Craig, D Amin, N Berr, C Lopez, OL De Jager, PL Deramecourt, V Johnston, JA Evans, D Lovestone, S Letteneur, L Kornhuber, J Tarraga, L Rubinsztein, DC Eiriksdottir, G Sleegers, K Goate, AM Fievet, N Huentelman, MJ Gill, M Emilsson, V Brown, K Kamboh, MI Keller, L Barberger-Gateau, P McGuinness, B Larson, EB Myers, AJ Dufouil, C Todd, S Wallon, D Love, S Kehoe, P Rogaeva, E Gallacher, J St George-Hyslop, P Clarimon, J Lleo, A Bayer, A Tsuang, DW Yu, L Tsolaki, M Bossu, P Spalletta, G Proitsi, P Collinge, J Sorbi, S Garcia, FS Fox, N Hardy, J Naranjo, MCD Razquin, C Bosco, P Clarke, R Brayne, C Galimberti, D Mancuso, M Moebus, S Mecocci, P del Zompo, M Maier, W Hampel, H Pilotto, A Bullido, M Panza, F Caffarra, P Nacmias, B Gilbert, JR Mayhaus, M Jessen, F Dichgans, M Lannfelt, L Hakon, H Pichler, S Carrasquillo, MM Ingelsson, M Beekly, D Alavarez, V Zou, FG Valladares, O Younkin, SG Coto, E Hamilton-Nelson, KL Mateo, I Owen, MJ Faber, KM Jonsson, PV Combarros, O O'Donovan, MC Cantwell, LB Soininen, H Blacker, D Mead, S Mosley, TH Bennett, DA Harris, TB Fratiglioni, L Holmes, C de Bruijn, RFAG Passmore, P Montine, TJ Bettens, K Rotter, JI Brice, A Morgan, K Foroud, TM Kukull, WA Hannequin, D Powell, JF Nails, MA Ritchie, K Lunetta, KL Kauwe, JSK Boerwinkle, E Riemenschneider, M Boada, M Hiltunen, M Martin, ER Pastor, P Schmidt, R Rujescu, D Dartigues, JF Mayeux, R Tzourio, C Hofman, A Nothen, MM Graff, C Psaty, BM Haines, JL Lathrop, M Pericak-Vance, MA Launer, LJ Farrer, LA van Duijn, CM Van Broeckhoven, C Ramirez, A Schellenberg, GD Seshadri, S Amouyel, P Williams, J Holmans, PA AF Jones, Lesley Lambert, Jean-Charles Wang, Li-San Choi, Seung-Hoan Harold, Denise Vedernikov, Alexey Escott-Price, Valentina Stone, Timothy Richards, Alexander Bellenguez, Celine Ibrahim-Verbaas, Carla A. Naj, Adam C. Sims, Rebecca Gerrish, Amy Jun, Gyungah DeStefano, Anita L. Bis, Joshua C. Beecham, Gary W. Grenier-Boley, Benjamin Russo, Giancarlo Thornton-Wells, Tricia A. Jones, Nicola Smith, Albert V. Chouraki, Vincent Thomas, Charlene Ikram, M. Arfan Zelenika, Diana Vardarajan, Badri N. Kamatani, Yoichiro Lin, Chiao-Feng Schmidt, Helena Kunkle, Brian W. Dunstan, Melanie L. Ruiz, Agustin Bihoreau, Marie-Therese Reitz, Christiane Pasquier, Florence Hollingworth, Paul Hanon, Olivier Fitzpatrick, Annette L. Buxbaum, Joseph D. Campion, Dominique Crane, Paul K. Becker, Tim Gudnason, Vilmundur Cruchaga, Carlos Craig, David Amin, Najaf Berr, Claudine Lopez, Oscar L. De Jager, Philip L. Deramecourt, Vincent Johnston, Janet A. Evans, Denis Lovestone, Simon Letteneur, Luc Kornhuber, Johanes Tarraga, Lluis Rubinsztein, David C. Eiriksdottir, Gudny Sleegers, Kristel Goate, Alison M. Fievet, Nathalie Huentelman, Matthew J. Gill, Michael Emilsson, Valur Brown, Kristelle Kamboh, M. Ilyas Keller, Lina Barberger-Gateau, Pascale McGuinness, Bernadette Larson, Eric B. Myers, Amanda J. Dufouil, Carole Todd, Stephen Wallon, David Love, Seth Kehoe, Pat Rogaeva, Ekaterina Gallacher, John St George-Hyslop, Peter Clarimon, Jordi Lleo, Alberti Bayer, Anthony Tsuang, Debby W. Yu, Lei Tsolaki, Magda Bossu, Paola Spalletta, Gianfranco Proitsi, Petra Collinge, John Sorbi, Sandro Garcia, Fiorentino Sanchez Fox, Nick Hardy, John Deniz Naranjo, Maria Candida Razquin, Cristina Bosco, Paola Clarke, Robert Brayne, Carol Galimberti, Daniela Mancuso, Michelangelo Moebus, Susanne Mecocci, Patrizia del Zompo, Maria Maier, Wolfgang Hampel, Harald Pilotto, Alberto Bullido, Maria Panza, Francesco Caffarra, Paolo Nacmias, Benedetta Gilbert, John R. Mayhaus, Manuel Jessen, Frank Dichgans, Martin Lannfelt, Lars Hakonarson, Hakon Pichler, Sabrina Carrasquillo, Minerva M. Ingelsson, Martin Beekly, Duane Alavarez, Victoria Zou, Fanggeng Valladares, Otto Younkin, Steven G. Coto, Eliecer Hamilton-Nelson, Kara L. Mateo, Ignacio Owen, Michael J. Faber, Kelley M. Jonsson, Palmi V. Combarros, Onofre O'Donovan, Michael C. Cantwell, Laura B. Soininen, Hilkka Blacker, Deborah Mead, Simon Mosley, Thomas H., Jr. Bennett, David A. Harris, Tamara B. Fratiglioni, Laura Holmes, Clive de Bruijn, Renee F. A. G. Passmore, Peter Montine, Thomas J. Bettens, Karolien Rotter, Jerome I. Brice, Alexis Morgan, Kevin Foroud, Tatiana M. Kukull, Walter A. Hannequin, Didier Powell, John F. Nails, Michael A. Ritchie, Karen Lunetta, Kathryn L. Kauwe, John S. K. Boerwinkle, Eric Riemenschneider, Matthias Boada, Merce Hiltunen, Mikko Martin, Eden R. Pastor, Pau Schmidt, Reinhold Rujescu, Dan Dartigues, Jean-Francois Mayeux, Richard Tzourio, Christophe Hofman, Albert Noethen, Markus M. Graff, Caroline Psaty, Bruce M. Haines, Jonathan L. Lathrop, Mark Pericak-Vance, Margaret A. Launer, Lenore J. Farrer, Lindsay A. van Duijn, Cornelia M. Van Broeckhoven, Christine Ramirez, Alfredo Schellenberg, Gerard D. Seshadri, Sudha Amouyel, Philippe Williams, Julie Holmans, Peter A. CA Int Genomics Alzheimer's Dis Conso MRC CFAS TI Convergent genetic and expression data implicate immunity in Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Dementia; Neurodegeneration; Immune response; Endocytosis; Cholesterol metabolism; Ubiquitination; Pathway analysis; ALIGATOR; Weighted gene co-expression network analysis ID GENOME-WIDE ASSOCIATION; NETWORK ANALYSIS; UNITED-STATES; PREVALENCE; VARIANTS; POPULATION; BRAIN; LISTS AB Background: Late-onset Alzheimer's disease (AD) is heritable with 20 genes showing genome-wide association in the International Genomics of Alzheimer's Project (IGAP). To identify the biology underlying the disease, we extended these genetic data in a pathway analysis. Methods: The ALIGATOR and GSEA algorithms were used in the IGAP data to identify associated functional pathways and correlated gene expression networks in human brain. Results: ALIGATOR identified an excess of curated biological pathways showing enrichment of association. Enriched areas of biology included the immune response (P = 3.27 X 10(-12) after multiple testing correction for pathways), regulation of endocytosis (P = 1.31 X 10(-11)), cholesterol transport (P = 2.96 X 10(-9)), and proteasome-ubiquitin activity (P = 1.34 X 10(-6)). Correlated gene expression analysis identified four significant network modules, all related to the immune response (corrected P = .002-.05). Conclusions: The immime response, regulation of endocytosis, cholesterol transport, and protein ubiquitination represent prime targets for AD therapeutics. (C) 2015 Published by Elsevier Inc. on behalf of The Alzheimer's Association. C1 [Jones, Lesley; Vedernikov, Alexey; Escott-Price, Valentina; Stone, Timothy; Richards, Alexander; Sims, Rebecca; Gerrish, Amy; Jones, Nicola; Thomas, Charlene; Dunstan, Melanie L.; Hollingworth, Paul; Owen, Michael J.; O'Donovan, Michael C.; Williams, Julie; Holmans, Peter A.] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Cardiff CF24 4HQ, S Glam, Wales. [Lambert, Jean-Charles; Bellenguez, Celine; Grenier-Boley, Benjamin; Chouraki, Vincent; Deramecourt, Vincent; Fievet, Nathalie; Amouyel, Philippe] Inserm U744, F-59000 Lille, France. [Lambert, Jean-Charles; Bellenguez, Celine; Grenier-Boley, Benjamin; Chouraki, Vincent; Pasquier, Florence; Amouyel, Philippe] Univ Lille 2, F-59000 Lille, France. [Lambert, Jean-Charles; Bellenguez, Celine; Grenier-Boley, Benjamin; Chouraki, Vincent; Fievet, Nathalie; Amouyel, Philippe] Inst Pasteur, F-59000 Lille, France. [Ibrahim-Verbaas, Carla A.] Erasmus MC Univ Med Ctr, Dept Epidemiol Clin Genet & Neurol, NL-3015 CE Rotterdam, Netherlands. [Naj, Adam C.; Beecham, Gary W.; Kunkle, Brian W.; Gilbert, John R.; Hamilton-Nelson, Kara L.; Martin, Eden R.; Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Coral Gables, FL 33124 USA. [Jun, Gyungah; Vardarajan, Badri N.; Farrer, Lindsay A.] Boston Univ Sch Med, Dept Med Biomed Genet, Boston, MA 02218 USA. [Jun, Gyungah; Farrer, Lindsay A.] Boston Univ Sch Med, Dept Ophthalmol, Boston, MA 02215 USA. [Choi, Seung-Hoan; Jun, Gyungah; DeStefano, Anita L.; Lunetta, Kathryn L.; Farrer, Lindsay A.] Boston Univ Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Bis, Joshua C.; Fitzpatrick, Annette L.; Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA. [Beecham, Gary W.; Martin, Eden R.; Pericak-Vance, Margaret A.] Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33124 USA. [Russo, Giancarlo; Amouyel, Philippe] Funct Genom Ctr, CH-8038 Zurich, Switzerland. [Thornton-Wells, Tricia A.; Haines, Jonathan L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA. [Smith, Albert V.; Gudnason, Vilmundur; Emilsson, Valur] Univ Iceland, Fac Pharmaceut Sci, IS-5254000 Reykjavik, Iceland. [Smith, Albert V.; Gudnason, Vilmundur; Eiriksdottir, Gudny; Emilsson, Valur] Iceland Heart Assoc, IS-5254000 Kopavogur, Iceland. [Ikram, M. Arfan; Hofman, Albert] Erasmus MC Univ Med Ctr, Dept Epidemiol, NL-3015 CE Rotterdam, Netherlands. [Ikram, M. Arfan; Hofman, Albert] Erasmus MC Univ Med Ctr, Dept Neurol, NL-3015 CE Rotterdam, Netherlands. [Ikram, M. Arfan; Hofman, Albert] Erasmus MC Univ Med Ctr, Dept Radiol, NL-3015 CE Rotterdam, Netherlands. [Ikram, M. Arfan; Hofman, Albert] Netherlands Consortium Hlth Aging, Leiden, Netherlands. [Zelenika, Diana; Bihoreau, Marie-Therese; Lathrop, Mark] CEA, Inst Genom, Ctr Natl Genotypage, F-91300 Evry, France. [Kamatani, Yoichiro; Lathrop, Mark] Fdn Jean Dausset CEPH, F-75010 Paris, France. [Wang, Li-San; Lin, Chiao-Feng; Valladares, Otto; Cantwell, Laura B.; Schellenberg, Gerard D.] Univ Penn Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Schmidt, Helena] Med Univ Graz, Inst Mol Biol & Biochem, A-8010 Graz, Austria. [Ruiz, Agustin; Tarraga, Lluis] Fundacio ACE, Memory Clin, Inst Catala Neurociencies Aplicades, Barcelona 8029, Spain. [Reitz, Christiane; Mayeux, Richard] Columbia Univ, Dept Neurol, Taub Inst Alzheimers Dis & Aging Brain, New York, NY 10027 USA. [Reitz, Christiane; Mayeux, Richard] Columbia Univ, Dept Neurol, Gertrude H Sergievsky Ctr, New York, NY 10027 USA. [Pasquier, Florence; Deramecourt, Vincent; Amouyel, Philippe] CHRU Lille, F-59037 Lille, France. [Ramirez, Alfredo] Univ Bonn, Dept Psychiat & Psychotherapy, D-53113 Bonn, Germany. [Ramirez, Alfredo] Univ Bonn, Inst Human Genet, D-53113 Bonn, Germany. [Hanon, Olivier] Univ Paris 05, Fac Med, UMR Inserm 894, F-75014 Paris, France. [Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA. [Fitzpatrick, Annette L.] Univ Washington, Dept Global Hlth, Seattle, WA 98101 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10027 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10027 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet, New York, NY 10027 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genom Sci, New York, NY 10027 USA. [Campion, Dominique; Wallon, David; Hannequin, Didier] Ctr Hosp Rouvray, Fac Med, INSERM U614, F-76000 Rouen, France. [Crane, Paul K.; Larson, Eric B.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Becker, Tim] Univ Bonn, German Ctr Neurodegenerat Dis DZNE, D-53113 Bonn, Germany. [Becker, Tim] Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-53113 Bonn, Germany. [Cruchaga, Carlos; Goate, Alison M.] Washington Univ Sch Med, Dept Psychiat, St Louis, MO USA. [Cruchaga, Carlos; Goate, Alison M.] Washington Univ Sch Med, Hope Ctr Program Prot Aggregat & Neurodegenerat, St Louis, MO USA. [Craig, David; Johnston, Janet A.; McGuinness, Bernadette; Todd, Stephen; Passmore, Peter] Queens Univ Belfast, Ageing Grp, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT7 1NN, Antrim, North Ireland. [Amin, Najaf; van Duijn, Cornelia M.] Erasmus MC Univ Med Ctr, Dept Epidemiol, NL-3015 CE Rotterdam, Netherlands. [Berr, Claudine; Ritchie, Karen] Hop La Colombiere, INSERM U888, F-34000 Montpellier, France. [Lopez, Oscar L.] Univ Pittsburgh Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [De Jager, Philip L.] Brigham & Womens Hosp, Program Translat NeuroPsychiat Genom, Inst Neurosci, Dept Neurol & Psychiat, Boston, MA 02215 USA. [De Jager, Philip L.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [De Jager, Philip L.] Broad Inst, Program Med & Populat Genet, Boston, MA 02215 USA. [Evans, Denis] Rush Univ Med Ctr, Dept Internal Med, Rush Inst Hlth Aging, Chicago, IL 60612 USA. [Lovestone, Simon; Proitsi, Petra; Powell, John F.] Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5, England. [Letteneur, Luc; Barberger-Gateau, Pascale; Dufouil, Carole; Dartigues, Jean-Francois] Victor Segalen Univ, Inserm U897, F-33076 Bordeaux, France. [Kornhuber, Johanes] Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Erlangen, Germany. [Rubinsztein, David C.; Kauwe, John S. K.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 OXY, England. [Sleegers, Kristel; Bettens, Karolien; Van Broeckhoven, Christine] VIB, Dept Mol Genet, Neurodegenerat Brain Dis Grp, B-2000 Antwerp, Belgium. [Sleegers, Kristel; Bettens, Karolien; Van Broeckhoven, Christine] Univ Antwerp, Inst Born Bunge, Neurogenet Lab, B-2000 Antwerp, Belgium. [Huentelman, Matthew J.] Translat Genom Res Inst, Neurogen Div, Phoenix, AZ 85004 USA. [Gill, Michael] St James Hosp, Mercers Inst Res Aging, Dublin 8, Ireland. [Gill, Michael] Univ Ireland Trinity Coll, Dublin 8, Ireland. [Brown, Kristelle; Morgan, Kevin] Univ Nottingham, Inst Genet, Queens Med Ctr, Nottingham NG7 2UH, England. [Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15213 USA. [Kamboh, M. Ilyas] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15213 USA. [Keller, Lina] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Aging Reasearch Ctr, S-17177 Stockholm, Sweden. [Keller, Lina] Stockholm Univ, S-17177 Stockholm, Sweden. [Larson, Eric B.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA 98195 USA. [Myers, Amanda J.] Univ Miami, Dept Psychiat & Behav Sci, Miller Sch Med, Miami, FL 33124 USA. [Love, Seth; Kehoe, Pat] Univ Bristol, Clin Neurosci, Bristol BS10 5NB, Avon, England. [Rogaeva, Ekaterina; St George-Hyslop, Peter] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 1A1, Canada. [Gallacher, John; Bayer, Anthony] Cardiff Univ, Inst Primary Care & Publ Hlth, Univ Wales Hosp, Cardiff CF14 4XN, S Glam, Wales. [St George-Hyslop, Peter] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 1TN, England. [St George-Hyslop, Peter] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 1TN, England. [Clarimon, Jordi; Lleo, Alberti] Univ Autonoma Barcelona, Neurol Dept, IIB St Pau, St Pau Hosp, Barcelona 08026, Spain. [Clarimon, Jordi; Lleo, Alberti] Ctr Networker Biomed Res Neurodegenerat Dis CIBER, Barcelona, Spain. [Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Yu, Lei; Bennett, David A.] Rush Univ Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Tsolaki, Magda] Aristotle Univ Thessaloniki, Thessaloniki 54621, Greece. [Bossu, Paola; Spalletta, Gianfranco] Fdn Santa Lucia, Clin & Behav Neurol, I-00142 Rome, Italy. [Collinge, John; Mead, Simon] UCL Inst Neurol, Dept Neurodegenerat Dis, MRC Prion Unit, London WC1N 3BG, England. [Nacmias, Benedetta] Univ Florence, Dept Neurol & Psychiat Sci, I-50121 Florence, Italy. [Sorbi, Sandro; Nacmias, Benedetta] Univ Florence, Ctr Ric Trasferimento & Alta Formaz DENOTHE, Florence, Italy. [Garcia, Fiorentino Sanchez; Deniz Naranjo, Maria Candida] Hosp Univ Dr Negrin, Dept Immunol, Las Palmas Gran Canaria 35012, Spain. [Fox, Nick] UCL Inst Neurol, Dept Neurodegenerat Dis, Dementia Res Ctr, London WC1N 3BG, England. [Hardy, John] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England. [Hardy, John] Inst Neurol, Reta Lilla Weston Labs, London WC1N 3BG, England. [Bosco, Paola] IRCCS Assoc Oasi Maria SS, I-94018 Troina, Italy. [Clarke, Robert] Univ Oxford, Clin Trial Serv Unit, OHAP, Oxford OX1 2JD, England. [Brayne, Carol; MRC CFAS] Univ Cambridge, Inst Publ Hlth, CFAS, Cambridge CB2 1TN, England. [Galimberti, Daniela] Univ Milan, Fdn Ca Granda, IRCCS Osped Policlin, I-20122 Milan, Italy. [Mancuso, Michelangelo] Univ Pisa, Neurol Clin, I-56126 Pisa, Italy. [Moebus, Susanne] Univ Duisburg Essen, Inst Med Informat Biometry & Epidemiol, Urban Epidemiol, Univ Hosp Essen, D-45141 Essen, Germany. [Mecocci, Patrizia] Univ Perugia, Sect Gerontol & Geriatr, Dept Clin & Expt Med, I-06100 Perugia, Italy. [del Zompo, Maria] Univ Cagliari, Dept Biomed Sci, Sect Neurosci & Clin Pharmacol, I-09123 Cagliari, Italy. [Maier, Wolfgang; Jessen, Frank] Univ Bonn, Dept Psychiat & Psychotherapy, Bonn, Germany. [Maier, Wolfgang; Jessen, Frank] German Ctr Neurodegenerat Dis DZNE, D-53113 Bonn, Germany. [Hampel, Harald] Univ Paris 06, Dept Neurol, Inst Memoire & Malad Alzheimer, Paris, France. [Pilotto, Alberto] IRCCS Casa Sollievo Sofferenza, Gerontol & Geriatr Res Lab, I-71013 San Giovanni Rotondo, FG, Italy. [Bullido, Maria] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid 28046, Spain. [Bullido, Maria] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Bullido, Maria] Inst Invest Sanitaria Hosp la Paz IdIPaz, Madrid, Spain. [Panza, Francesco] Univ Bari, Ctr Aging Brain, Dept Geriatr, I-70121 Bari, Italy. [Caffarra, Paolo] Univ Parma, Dept Neurosci, I-43100 Parma, Italy. [Caffarra, Paolo] Ctr Cognit Disorders AUSL, Parma, Italy. [Gilbert, John R.] Univ Miami, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33124 USA. [Mayhaus, Manuel] Univ Hosp, Dept Psychiat, D-66424 Saarland, Germany. [Lannfelt, Lars; Ingelsson, Martin] Uppsala Univ, Dept Publ Hlth Geriatr, S-75312 Uppsala, Sweden. [Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Carrasquillo, Minerva M.; Zou, Fanggeng; Younkin, Steven G.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Beekly, Duane] Univ Washington, Natl Alzheimers Coordinating Ctr, Seattle, WA 98195 USA. [Alavarez, Victoria; Coto, Eliecer] Genet Mol Huca Oviedo, Oviedo 33006, Spain. [Mateo, Ignacio; Combarros, Onofre] Univ Cantabria, Marques de Valdecilla Univ Hosp, Neurol Serv, E-39005 Santander, Spain. [Mateo, Ignacio; Combarros, Onofre] Univ Cantabria, Marques de Valdecilla Univ Hosp, CIBERNED, E-39005 Santander, Spain. [Mateo, Ignacio; Combarros, Onofre] IFIMAV, Santander 39005, Spain. [Faber, Kelley M.; Foroud, Tatiana M.] Indiana Univ, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Jonsson, Palmi V.] Landspitali Univ Hosp, IS-5431000 Reykjavik, Iceland. [Soininen, Hilkka; Hiltunen, Mikko] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio 70211, Finland. [Soininen, Hilkka; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland. [Blacker, Deborah] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Farrer, Lindsay A.] Boston Univ Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA. [Blacker, Deborah] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. Univ Mississippi Med Ctr, Dept Geriatr Med, Jackson, MS 39216 USA. [Mosley, Thomas H., Jr.; Bennett, David A.] Rush Univ Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Harris, Tamara B.] NIH, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Fratiglioni, Laura] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Aging Reasearch Ctr, S-11418 Stockholm, Sweden. [Fratiglioni, Laura] Stockholm Univ, S-11418 Stockholm, Sweden. [Fratiglioni, Laura; Graff, Caroline; Launer, Lenore J.] Karolinska Univ Hosp Huddinge, Dept Geriatr Med, Genet Unit, S-14186 Stockholm, Sweden. [Holmes, Clive] Univ Southampton, Sch Med, Div Clin Neurosci, Southampton SO17 1BJ, Hants, England. [de Bruijn, Renee F. A. G.] Erasmus MC Univ Med Ctr, Dept Neurol, NL-3015 CE Rotterdam, Netherlands. [de Bruijn, Renee F. A. G.] Erasmus MC Univ Med Ctr, Dept Epidemiol, NL-3015 CE Rotterdam, Netherlands. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Brice, Alexis] CRicm UMRS975, Paris, France. [Brice, Alexis] Hop La Pitie Salpetriere, AP HP, F-75013 Paris, France. [Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Nails, Michael A.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA. [Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA. [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Houston, TX 77030 USA. [Riemenschneider, Matthias] Univ Hosp, Dept Psychiat, Saarland 66424, Germany. [Boada, Merce] Fundacio ACE, Memory Clin, Inst Catala Neurociencies Aplicades, Barcelona 8029, Spain. [Schmidt, Reinhold] Med Univ Graz, Dept Neurol, A-8010 Graz, Austria. [Rujescu, Dan] Univ Munich, Dept Psychiat, D-80539 Munich, Germany. [Rujescu, Dan] Univ Halle, D-80336 Halle, Germany. [Dartigues, Jean-Francois] CHU Bordeaux, Ctr Memoire Ressources & Rech Bordeaux, Bordeaux, France. [Tzourio, Christophe] Victor Segalen Univ, Inserm U708, F-33076 Bordeaux, France. [Noethen, Markus M.] Univ Bonn, Inst Human Genet, Dept Genom, Life & Brain Ctr, D-53113 Bonn, Germany. [Noethen, Markus M.] German Ctr Neurodegenerat Dis DZNE, D-53113 Bonn, Germany. [Graff, Caroline] Karolinska Inst, Dept Neurobiol Care Sci & Soc, KIADRC, S-17177 Stockholm, Sweden. [Haines, Jonathan L.] Vanderbilt Univ, Vanderbilt Ctr Human Genet Res, Nashville, TN 37212 USA. [Lathrop, Mark] McGill Univ, Montreal, PQ, Canada. [Lathrop, Mark] Genome Quebec Innovat Ctr, Montreal, PQ, Canada. [Farrer, Lindsay A.; Seshadri, Sudha] Boston Univ Sch Med, Dept Neurol, Boston, MA 02215 USA. [Razquin, Cristina; Pastor, Pau] Univ Navarra Sch Med, Div Neurosci, Ctr Appl Med Res, Neurogenet Lab, Pamplona 28023, Spain. [Pastor, Pau] Univ Navarra Sch Med, Dept Neurol, Univ Navarra Clin, Pamplona, Spain. [Pastor, Pau] Inst Salud Carlos III, CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Dichgans, Martin] Klinikum Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany. [Dichgans, Martin] German Ctr Neurodegenerat Dis DZNE, D-80336 Munich, Germany. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Harold, Denise] St James Hosp, Neuropsychiat Genet Grp, Dept Psychiat, Trinity Ctr Hlth Sci, Dublin 8, Ireland. RP Williams, J (reprint author), Cardiff Univ, Inst Psychol Med & Clin Neurosci, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales. EM philippe.amouyel@pasteur-lille.fr; williamsj@cardiff.ac.uk RI Caffarra, Paolo/K-6567-2016; Tsuang, Debby/L-7234-2016; Tzourio, christophe/B-4015-2009; Hardy, John/C-2451-2009; Gudnason, Vilmundur/K-6885-2015; Bosso, Paola/E-4832-2014; Kamatani, Yoichiro/N-5513-2015; Pastor, Pau/C-9834-2009; Bullido, Maria/C-8509-2014; Lambert, jean-charles/A-9553-2014; Smith, Albert/K-5150-2015; Ritchie, Karen/G-3571-2013; OI Denning, Nicola/0000-0001-8467-7382; Bayer, Antony/0000-0002-7514-248X; Farrer, Lindsay/0000-0001-5533-4225; Seshadri, Sudha/0000-0001-6135-2622; galimberti, daniela/0000-0002-9284-5953; Kukull, Walter/0000-0001-8761-9014; NACMIAS, Benedetta/0000-0001-9338-9040; sorbi, sandro/0000-0002-0380-6670; Kamboh, M. Ilyas/0000-0002-3453-1438; Caffarra, Paolo/0000-0003-2246-5223; Tsuang, Debby/0000-0002-4716-1894; Tzourio, christophe/0000-0002-6517-2984; Gudnason, Vilmundur/0000-0001-5696-0084; Bosso, Paola/0000-0002-1432-0078; Pastor, Pau/0000-0002-7493-8777; Bullido, Maria/0000-0002-6477-1117; Lambert, jean-charles/0000-0003-0829-7817; Smith, Albert/0000-0003-1942-5845; Gill, Michael/0000-0003-0206-5337; Escott-Price, Valentina/0000-0003-1784-5483; Harold, Denise/0000-0001-5195-0143; Holmans, Peter/0000-0003-0870-9412; Buxbaum, Joseph/0000-0001-8898-8313; Panza, Francesco/0000-0002-7220-0656; Nothen, Markus/0000-0002-8770-2464; Todd, Stephen/0000-0002-2312-9195 FU Wellcome Trust; Medical Research Council; Alzheimer's Research UK; Welsh Assembly Government; National Institutes of Health, National Institute on Aging (NIH-NIA); Erasmus Medical Center; Erasmus University; French National Foundation on Alzheimer's Disease and Related Disorders; Centre National de Genotypage; Institut Pasteur de Lille; Inserm; FRC (Fondation pour la Recherche sur le Cerveau); Rotary; LABEX (Laboratory of Excellence Program Investment for the Future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease); Alzheimer's Association FX This work was made possible by the generous participation of the control subjects, the patients, and their families. GERAD was supported by the Wellcome Trust, Medical Research Council, Alzheimer's Research UK, and the Welsh Assembly Government. ADGC and CHARGE were supported by the National Institutes of Health, National Institute on Aging (NIH-NIA). CHARGE was also supported by Erasmus Medical Center and Erasmus University. IGAP was funded by the French National Foundation on Alzheimer's Disease and Related Disorders, the Centre National de Genotypage and the Institut Pasteur de Lille, Inserm, FRC (Fondation pour la Recherche sur le Cerveau), and Rotary. This work has been developed and supported by the LABEX (Laboratory of Excellence Program Investment for the Future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease). The French National Foundation on Alzheimer's Disease and Related Disorders and the Alzheimer's Association provided support for I-GAP meetings, communication and some funds to each consortium to support analyses. NR 36 TC 20 Z9 20 U1 7 U2 37 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUN PY 2015 VL 11 IS 6 BP 658 EP 671 DI 10.1016/j.jalz.2014.05.1757 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA CL8NR UT WOS:000357231900008 ER PT J AU Snyder, HM Corriveau, RA Craft, S Faber, JE Greenberg, SM Knopman, D Lamb, BT Montine, TJ Nedergaard, M Schaffer, CB Schneider, JA Wellington, C Wilcock, DM Zipfel, GJ Zlokovic, B Bain, LJ Bosetti, F Galis, ZS Koroshetz, W Carrillo, MC AF Snyder, Heather M. Corriveau, Roderick A. Craft, Suzanne Faber, James E. Greenberg, Steven M. Knopman, David Lamb, Bruce T. Montine, Thomas J. Nedergaard, Maiken Schaffer, Chris B. Schneider, Julie A. Wellington, Cheryl Wilcock, Donna M. Zipfel, Gregory J. Zlokovic, Berislav Bain, Lisa J. Bosetti, Francesca Galis, Zorina S. Koroshetz, Walter Carrillo, Maria C. TI Vascular contributions to cognitive impairment and dementia including Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Review DE Alzheimer's disease; Dementia; Biomarkers; Animal models; Vascular dementia; Small vessel disease ID CEREBRAL AMYLOID ANGIOPATHY; HIGH-DENSITY-LIPOPROTEIN; BLOOD-BRAIN-BARRIER; NATIVE COLLATERAL CIRCULATION; CARDIOVASCULAR RISK-FACTORS; ISCHEMIC-STROKE; MOUSE MODEL; A-BETA; CEREBROVASCULAR INTEGRITY; PRECURSOR PROTEIN AB Scientific evidence continues to demonstrate the linkage of vascular contributions to cognitive impairment and dementia such as Alzheimer's disease. In December, 2013, the Alzheimer's Association, with scientific input from the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute from the National Institutes of Health, convened scientific experts to discuss the research gaps in our understanding of how vascular factors contribute to Alzheimer's disease and related dementia. This manuscript summarizes the meeting and the resultant discussion, including an outline of next steps needed to move this area of research forward. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Snyder, Heather M.; Carrillo, Maria C.] Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA. [Corriveau, Roderick A.; Bosetti, Francesca; Koroshetz, Walter] NINDS, NIH, Bethesda, MD 20892 USA. [Craft, Suzanne] Wake Forest Univ Sch Med, Dept Gerontol & Geriatr Med, Winston Salem, NC USA. [Faber, James E.] Univ North Carolina Sch Med, Dept Cell Biol & Physiol, Chapel Hill, NC USA. [Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Greenberg, Steven M.] Harvard Univ, Sch Med, Boston, MA USA. [Knopman, David] Mayo Clin, Dept Neurol, Rochester, MN USA. [Lamb, Bruce T.] Cleveland Clin, Dept Neurosci, Cleveland, OH 44106 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Nedergaard, Maiken] Univ Rochester Med Ctr, Div Glial Dis & Therapeut, Rochester, NY USA. [Schaffer, Chris B.] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA. [Schneider, Julie A.] Rush Univ Med Ctr, Dept Pathol, Chicago, IL USA. [Schneider, Julie A.] Rush Univ Med Ctr, Dept Neurol Sci, Chicago, IL USA. [Wellington, Cheryl] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada. [Wilcock, Donna M.] Univ Kentucky, Dept Physiol, Lexington, KY USA. [Zipfel, Gregory J.] Washington Univ, Dept Neurol Surg, St Louis, MO USA. [Zipfel, Gregory J.] Washington Univ, Dept Neurol, St Louis, MO USA. [Zlokovic, Berislav] Univ So Calif, Dept Physiol, Los Angeles, CA USA. [Galis, Zorina S.] NHLBI, NIH, Bethesda, MD 20892 USA. RP Snyder, HM (reprint author), Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA. EM hsnyder@alz.org RI Schaffer, Chris/A-7409-2008; Wilcock, Donna/J-7517-2016 OI Schaffer, Chris/0000-0002-7800-9596; FU NIA NIH HHS [R01 AG048769]; NIDCR NIH HHS [R01 DE022743]; NINDS NIH HHS [R01 NS078167, R01 NS078304, R01 NS079637] NR 80 TC 64 Z9 64 U1 18 U2 52 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUN PY 2015 VL 11 IS 6 BP 710 EP 717 DI 10.1016/j.jalz.2014.10.008 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CL8NR UT WOS:000357231900013 PM 25510382 ER PT J AU Eluri, S Brugge, WR Daglilar, ES Jackson, SA Styn, MA Callenberg, KM Welch, DC Barr, TM Duits, LC Bergman, JJ Shaheen, NJ AF Eluri, Swathi Brugge, William R. Daglilar, Ebubekir S. Jackson, Sara A. Styn, Mindi A. Callenberg, Keith M. Welch, Derek C. Barr, Todd M. Duits, Lucas C. Bergman, Jacques J. Shaheen, Nicholas J. TI The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID HIGH-GRADE DYSPLASIA; OPERATING CHARACTERISTIC CURVES; TUMOR-SUPPRESSOR GENES; TERM-FOLLOW-UP; ENDOSCOPIC SURVEILLANCE; NEOPLASTIC PROGRESSION; CLONAL EXPANSION; RISK; HETEROZYGOSITY; CANCER AB OBJECTIVES: Risk stratification in Barrett's esophagus (BE) is challenging. We evaluated the ability of a panel of genetic markers to predict progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). METHODS: In this case-control study, we assessed a measure of genetic instability, the mutational load (ML), in predicting progression to HGD or EAC. Cases had nondysplastic BE or low-grade dysplasia (LGD) at baseline and developed HGD/EAC >= 1 year later. Controls were matched 2: 1, had nondysplastic BE or LGD, and no progression at follow-up. Formalin-fixed, paraffin-embedded tissue was microdissected for the epithelium. Loss of heterozygosity (LOH) and microsatellite instability (MSI) were assessed. ML was calculated from derangements in 10 genomic loci. High-clonality LOH mutations were assigned a value of 1, low-clonality mutations were assigned a value of 0.5, and MSI 0.75 at the first loci, and 0.5 for additional loci. These values were summed to the ML. Receiver operator characteristic (ROC) curves were created. RESULTS: There were 69 patients (46 controls and 23 cases). Groups were similar in age, follow-up time, baseline histology, and the number of microdissected targets. Mean ML in pre-progression biopsies was higher in cases (2.21) than in controls (0.42; P < 0.0001). Sensitivity was 100% at ML >= 0.5 and specificity was 96% at ML >= 1.5. Accuracy was highest at 89.9% for ML >= 1. ROC curves for ML >= 1 demonstrated an area under the curve (AUC) of 0.95. CONCLUSIONS: ML in pre-progression BE tissue predicts progression to HGD or EAC. Although further validation is necessary, ML may have utility as a biomarker in endoscopic surveillance of BE. C1 [Eluri, Swathi; Shaheen, Nicholas J.] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA. [Brugge, William R.; Daglilar, Ebubekir S.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Jackson, Sara A.; Styn, Mindi A.; Callenberg, Keith M.] Interpace Diagnost Corp, Pittsburgh, PA USA. [Welch, Derek C.] Pathgroup, Brentwood, TN USA. [Barr, Todd M.] Allegheny Gen Hosp, Dept Pathol & Lab Med, Pittsburgh, PA 15212 USA. [Duits, Lucas C.; Bergman, Jacques J.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands. RP Shaheen, NJ (reprint author), Univ N Carolina, Sch Med, Ctr Esophageal Dis & Swallowing, Med & Epidemiol,Div Gastroenterol & Hepatol, 130 Mason Farm Rd CB 7080, Chapel Hill, NC 27599 USA. EM nicholas_shaheen@med.unc.edu FU Interpace Diagnostics FX Interpace Diagnostics in part funded efforts to obtain archived pathology specimens, and performed the ML analysis. NR 51 TC 6 Z9 6 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUN PY 2015 VL 110 IS 6 BP 828 EP 834 DI 10.1038/ajg.2015.152 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CL6MS UT WOS:000357081800010 PM 26010308 ER PT J AU Dossett, ML Davis, RB Lembo, AJ Yeh, GY AF Dossett, Michelle L. Davis, Roger B. Lembo, Anthony J. Yeh, Gloria Y. TI Herbal Medicines, a Prominent Component in Complementary and Alternative Medicine Use in Gastrointestinal Field Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Dossett, Michelle L.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Davis, Roger B.; Yeh, Gloria Y.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Davis, Roger B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA. RP Dossett, ML (reprint author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, 151 Merrimac St,4th Floor, Boston, MA 02114 USA. EM mdossett@mgh.harvard.edu FU NCATS NIH HHS [1UL1TR001102-01]; NCCIH NIH HHS [T32AT000051] NR 3 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUN PY 2015 VL 110 IS 6 BP 936 EP 936 DI 10.1038/ajg.2015.111 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CL6MS UT WOS:000357081800026 PM 26052775 ER PT J AU Stoppel, WL Hu, DJ Domian, IJ Kaplan, DL Black, LD AF Stoppel, Whitney L. Hu, Dongjian Domian, Ibrahim J. Kaplan, David L. Black, Lauren D., III TI Anisotropic silk biomaterials containing cardiac extracellular matrix for cardiac tissue engineering SO BIOMEDICAL MATERIALS LA English DT Article DE cardiomyocytes; integrins; cell infiltration; acellular scaffold ID AMERICAN-HEART-ASSOCIATION; RANDOMIZED PHASE-1 TRIAL; PLURIPOTENT STEM-CELL; MYOCARDIAL-INFARCTION; SKELETAL MYOBLASTS; IN-VITRO; CARDIOMYOCYTES; REPAIR; REGENERATION; SCAFFOLDS AB Cardiac malformations and disease are the leading causes of death in the United States in live-born infants and adults, respectively. In both of these cases, a decrease in the number of functional cardiomyocytes often results in improper growth of heart tissue, wound healing complications, and poor tissue repair. The field of cardiac tissue engineering seeks to address these concerns by developing cardiac patches created from a variety of biomaterial scaffolds to be used in surgical repair of the heart. These scaffolds should be fully degradable biomaterial systems with tunable properties such that the materials can be altered to meet the needs of both in vitro culture (e.g. disease modeling) and in vivo application (e.g. cardiac patch). Current platforms do not utilize both structural anisotropy and proper cell-matrix contacts to promote functional cardiac phenotypes and thus there is still a need for critically sized scaffolds that mimic both the structural and adhesive properties of native tissue. To address this need, we have developed a silk-based scaffold platform containing cardiac tissue-derived extracellular matrix (cECM). These silk-cECM composite scaffolds have tunable architectures, degradation rates, and mechanical properties. Subcutaneous implantation in rats demonstrated that addition of the cECM to aligned silk scaffold led to 99% endogenous cell infiltration and promoted vascularization of a critically sized scaffold (10 x 5 x 2.5 mm) after 4 weeks in vivo. In vitro, silk-cECM scaffolds maintained the HL-1 atrial cardiomyocytes and human embryonic stem cell-derived cardiomyocytes and promoted a more functional phenotype in both cell types. This class of hybrid silk-cECM anisotropic scaffolds offers new opportunities for developing more physiologically relevant tissues for cardiac repair and disease modeling. C1 [Stoppel, Whitney L.; Kaplan, David L.; Black, Lauren D., III] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA. [Hu, Dongjian; Domian, Ibrahim J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Domian, Ibrahim J.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Black, Lauren D., III] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Cellular Mol & Dev Biol Program, Boston, MA 02111 USA. RP Stoppel, WL (reprint author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA. EM lauren.black@tufts.edu OI Black, Lauren/0000-0002-7486-5811 FU National Institutes of Health Institutional Research and Academic Career Development Awards program at Tufts University [K12GM074869]; NIH [EB002520] FX The authors would like to acknowledge Dr William Claycomb, professor in the Department of Biochemistry and Molecular Biology at the Louisiana State University School of Medicine for his kind donation of HL-1 cells for use in this work. In addition, WLS would like to acknowledge funding from the National Institutes of Health Institutional Research and Academic Career Development Awards program at Tufts University (K12GM074869, Training in Education and Critical Research Skills (TEACRS)). We also thank the NIH P41 (EB002520) for support of this work. NR 57 TC 8 Z9 8 U1 4 U2 52 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1748-6041 EI 1748-605X J9 BIOMED MATER JI Biomed. Mater. PD JUN PY 2015 VL 10 IS 3 AR 034105 DI 10.1088/1748-6041/10/3/034105 PG 13 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA CL6QV UT WOS:000357093000013 PM 25826196 ER PT J AU Menatti, AR DeBoer, LBH Weeks, JW Heimberg, RG AF Menatti, Andrew R. DeBoer, Lindsey B. Hopkins Weeks, Justin W. Heimberg, Richard G. TI Social anxiety and associations with eating psychopathology: Mediating effects of fears of evaluation SO BODY IMAGE LA English DT Article DE Social anxiety; Eating disorders; Fear of negative evaluation; Fear of positive evaluation; Social-evaluative concerns; Body image ID NEGATIVE-EVALUATION-SCALE; POSITIVE EVALUATION SCALE; PSYCHOMETRIC EVALUATION; BULIMIA-NERVOSA; PHOBIA SCALE; DISORDERS; COMORBIDITY; VALIDATION; PREVALENCE; ANOREXIA AB Recent work suggests unique relations among features of social anxiety disorder and eating disorder pathology. Thus, it may be important to determine specific facets of social anxiety that account for the relation between it and eating disorders. Given the similarities in social-evaluative concerns in both sets of symptoms, we hypothesized that fears of both positive and negative evaluation would each independently account for the relationship between social anxiety symptoms and eating pathology among college females (N=167). Results were partially supportive of hypotheses. Fear of negative evaluation independently accounted for a significant portion of the relationship between social anxiety and each domain of eating pathology that was tested, which included Drive for Thinness, Body Dissatisfaction, and Bulimic Symptoms. Body mass index appeared to play a moderating role on the relationship between fear of negative evaluation and body dissatisfaction, but not drive for thinness or bulimia symptoms. Clinical implications including diagnostic and treatment considerations will be discussed. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Menatti, Andrew R.; Weeks, Justin W.] Ohio Univ, Ctr Evaluat & Treatment Anxiety, Athens, OH 45701 USA. [DeBoer, Lindsey B. Hopkins] San Francisco VA Med Ctr, San Francisco, CA USA. [Heimberg, Richard G.] Temple Univ, Philadelphia, PA 19122 USA. RP Weeks, JW (reprint author), 200 Porter Hall, Athens, OH USA. EM weeksj@ohio.edu RI Hopkins, Lindsey/D-4408-2015 OI Hopkins, Lindsey/0000-0002-0577-2961 NR 56 TC 5 Z9 5 U1 5 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1740-1445 EI 1873-6807 J9 BODY IMAGE JI Body Image PD JUN PY 2015 VL 14 BP 20 EP 28 DI 10.1016/j.bodyim.2015.02.003 PG 9 WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary SC Psychology; Psychiatry GA CL8MJ UT WOS:000357228500004 PM 25867525 ER PT J AU Hartmann, AS Thomas, JJ Greenberg, JL Elliott, CM Matheny, NL Wilhelm, S AF Hartmann, A. S. Thomas, J. J. Greenberg, J. L. Elliott, C. M. Matheny, N. L. Wilhelm, S. TI Anorexia nervosa and body dysmorphic disorder: A comparison of body image concerns and explicit and implicit attractiveness beliefs SO BODY IMAGE LA English DT Article DE Body image disturbance; Coping strategies; Attractiveness beliefs; Anorexia nervosa; Body dysmorphic disorder ID COGNITIVE-BEHAVIORAL THERAPY; GO ASSOCIATION TASK; EATING-DISORDERS; TRANSDIAGNOSTIC TREATMENT; EMOTIONAL DISORDERS; UNIFIED PROTOCOL; FOLLOW-UP; QUESTIONNAIRE; RELIABILITY; ANXIETY AB Although body image is central to the etiological models of anorexia nervosa and body dysmorphic disorder, studies comparing body image and beliefs about attractiveness between the disorders are rare. Sixty-nine individuals (anorexia nervosa: n=24, body dysmorphic disorder: n=23, healthy controls: n=22) completed self-report measures (body image and general psychopathology), diagnostic interviews, and Go/No-Go Association tasks measuring implicit associations. Compared to controls, both clinical groups exhibited greater negative body image, a more negative attitude toward their physical selves, and more dysfunctional coping strategies (ps < .001). Also, both clinical groups shared greater explicit beliefs about the importance of attractiveness (ps < .001). In addition to supporting previous research with regard to comparable body image disturbance, this study also showed that beliefs regarding the importance of appearance (e.g., "one must be attractive to be successful") might be a fruitful target for therapy across both disorders. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Hartmann, A. S.; Thomas, J. J.; Greenberg, J. L.; Elliott, C. M.; Matheny, N. L.; Wilhelm, S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hartmann, A. S.; Thomas, J. J.; Greenberg, J. L.; Elliott, C. M.; Wilhelm, S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Hartmann, AS (reprint author), Univ Osnabruck, Dept Human Sci, Inst Psychol, Knollstr 15, D-49069 Osnabruck, Germany. EM andrea.hartmann@uos.de; jjthomas@mgh.harvard.edu; jlgreenberg@mgh.harvard.edu; celliott1@mgh.harvard.edu; matheny@psy.fsu.edu; swilhelm@mgh.harvard.edu OI Hartmann, Andrea/0000-0002-6251-3763 FU Swiss National Science Foundation [PBSKP1_134330/1, PBSKP1_140040] FX The present study was supported by a post-doctoral fellowship awarded to the first author by the Swiss National Science Foundation (PBSKP1_134330/1 and PBSKP1_140040). NR 61 TC 2 Z9 2 U1 8 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1740-1445 EI 1873-6807 J9 BODY IMAGE JI Body Image PD JUN PY 2015 VL 14 BP 77 EP 84 DI 10.1016/j.bodyim.2015.03.013 PG 8 WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary SC Psychology; Psychiatry GA CL8MJ UT WOS:000357228500012 PM 25920044 ER PT J AU Cox, AG Goessling, W AF Cox, Andrew G. Goessling, Wolfram TI The lure of zebrafish in liver research: regulation of hepatic growth in development and regeneration SO CURRENT OPINION IN GENETICS & DEVELOPMENT LA English DT Article ID ADENOMATOUS POLYPOSIS-COLI; INTRAHEPATIC BILIARY DEVELOPMENT; L-FABP GENE; TRANSGENIC ZEBRAFISH; TRANSCRIPTION FACTOR; RETINOIC ACID; ENDOPLASMIC-RETICULUM; PANCREAS DEVELOPMENT; ENDODERM FORMATION; DIGESTIVE-SYSTEM AB The liver is an essential organ that plays a pivotal role in metabolism, digestion and nutrient storage. Major efforts have been made to develop zebrafish (Danio rerio) as a model system to study the pathways regulating hepatic growth during liver development and 'regeneration. Zebrafish offer unique advantages over other vertebrates including in vivo imaging at cellular resolution and the capacity for large-scale chemical and genetic screens. Here, we review the cellular and molecular mechanisms that regulate hepatic growth during liver development in zebrafish. We also highlight emerging evidence that developmental pathways are reactivated following liver injury to facilitate regeneration. Finally, we discuss how zebrafish have transformed drug discovery efforts and enabled the identification of drugs that stimulate hepatic growth and provide hepatoprotection in pre-clinical models of liver injury, with the ultimate goal of identifying novel therapeutic approaches to treat liver disease. C1 [Cox, Andrew G.; Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Goessling, Wolfram] Dana Farber Canc Inst, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Stem Cell Inst, Cambridge, MA USA. [Goessling, Wolfram] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Goessling, W (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. EM wgoessling@partners.org OI Goessling, Wolfram/0000-0001-9972-1569 FU American Liver Foundation; Harvard Digestive Diseases Center Pilot Feasibility Grant; NIH/NIDDK [R01DK090311, R01DK095721] FX AGC was the recipient of an Irwin Arias Postdoctoral Fellowship by the American Liver Foundation and a Harvard Digestive Diseases Center Pilot Feasibility Grant. He is currently an American Liver Foundation Liver Scholar. WG is supported by NIH/NIDDK Grants R01DK090311 and R01DK095721. WG is a Pew Scholar in the Biomedical Sciences. NR 97 TC 5 Z9 6 U1 3 U2 12 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-437X EI 1879-0380 J9 CURR OPIN GENET DEV JI Curr. Opin. Genet. Dev. PD JUN PY 2015 VL 32 BP 153 EP 161 DI 10.1016/j.gde.2015.03.002 PG 9 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA CM5CQ UT WOS:000357704800022 PM 25863341 ER PT J AU Duany, YD Wu, B Hur, S AF Duany, Yoandris del Toro Wu, Bin Hur, Sun TI MDA5-filament, dynamics and disease SO CURRENT OPINION IN VIROLOGY LA English DT Article ID DOUBLE-STRANDED-RNA; OF-FUNCTION MUTATIONS; RECEPTOR RIG-I; ANTIVIRAL RESPONSES; STRUCTURAL BASIS; DSRNA RECOGNITION; MDA5 FILAMENTS; IFIH1; INTERFERON; ACTIVATION AB Melanoma Differentiation-Associated gene 5 (MDA5), encoded by the gene IFIH1, is a cytoplasmic sensor for viral double-stranded RNAs (dsRNAs). MDA5 activates the type I interferon signaling pathway upon detection of long viral dsRNA generated during replication of picornaviruses. Studies have shown that MDA5 forms a filament along the length of dsRNA and utilizes ATP-dependent filament dynamics to discriminate between self versus non-self on the basis of dsRNA length. This review summarizes our current understanding of how the MDA5 filament assembles and disassembles, how this filament dynamics are utilized in dsRNA length-dependent signaling, and how dysregulated filament dynamics lead to pathogenesis of immune disorders. C1 [Duany, Yoandris del Toro; Wu, Bin; Hur, Sun] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA. [Duany, Yoandris del Toro; Wu, Bin; Hur, Sun] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. RP Hur, S (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA. EM Sun.Hur@childrens.harvard.edu RI Wu, Bin/C-4715-2015 FU Novartis Foundation; Swiss National Science Foundation; Charles A. King Trust; NIH [AI106912, AI111784] FX YdTD was supported by fellowships from Novartis Foundation and Swiss National Science Foundation. BW was supported by Charles A. King Trust Fellowship. SH was a Pew Scholar and was funded by NIH R01 grant (AI106912 and AI111784). NR 48 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD JUN PY 2015 VL 12 BP 20 EP 25 DI 10.1016/j.coviro.2015.01.011 PG 6 WC Virology SC Virology GA CM1KK UT WOS:000357439600006 ER PT J AU Wu, B Hur, S AF Wu, Bin Hur, Sun TI How RIG-I like receptors activate MAVS SO CURRENT OPINION IN VIROLOGY LA English DT Article ID ANTIVIRAL SIGNAL ACTIVATION; INNATE IMMUNE-RESPONSE; DOUBLE-STRANDED-RNA; NF-KAPPA-B; STRUCTURAL BASIS; DSRNA RECOGNITION; ADAPTER PROTEIN; VIRAL-RNA; MDA5; FILAMENTS AB RIG-I and MDA5 are well-conserved cytoplasmic pattern recognition receptors that detect viral RNAs during infection and activate the type I interferon (IFN)-mediated antiviral immune response. While much is known about how these receptors recognize viral RNAs, how they interact with their common signaling adaptor molecule MAVS and activate the downstream signaling pathway had been less clear. Previous studies have shown that the signaling domains (tandem CARDs or 2CARDs) of RIG-I and MDA5 must form homo-oligomers in order to interact with MAVS, and that their interactions lead to filament formation of MAVS, a pre-requisite for downstream signal activation. More recent data suggest that multiple mechanisms synergistically promote tetramer formation of RIG-I 2CARD, and that this tetramer resembles a lock-washer, which serves as a helical template to nucleate the MAVS filament. We here summarize these recent findings and discuss the current understanding of the signal activation mechanisms of RIG-I and MDA5. C1 [Wu, Bin; Hur, Sun] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA. [Wu, Bin; Hur, Sun] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. RP Hur, S (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA. EM Sun.Hur@childrens.harvard.edu RI Wu, Bin/C-4715-2015 FU Charles A. King Trust; NIH [AI106912, AI111784] FX B.W. was supported by Charles A. King Trust Fellowship. S.H. was a Pew Scholar and was funded by NIH R01 grants (AI106912 and AI111784). NR 43 TC 20 Z9 20 U1 1 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD JUN PY 2015 VL 12 BP 91 EP 98 DI 10.1016/j.coviro.2015.04.004 PG 8 WC Virology SC Virology GA CM1KK UT WOS:000357439600015 PM 25942693 ER PT J AU Bariteau, JT Hsu, RY Mor, V Lee, Y DiGiovanni, CW Hayda, R AF Bariteau, Jason T. Hsu, Raymond Y. Mor, Vincent Lee, Yoojin DiGiovanni, Christopher W. Hayda, Roman TI Operative Versus Nonoperative Treatment of Geriatric Ankle Fractures: A Medicare Part A Claims Database Analysis SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE trauma; outcome studies ID ADMINISTRATIVE DATA; ELDERLY-PATIENTS; POPULATION; FIXATION; AGE AB Background: The incidence of ankle fractures is increasing in the geriatric population, and several studies suggest them to be the third most common extremity fracture in this age group. Previous work has reflected relatively low complication rates during operative treatment. Little is known, however, about the association between these injuries and overall mortality, nor whether operative intervention has any effect on mortality. We hypothesized that geriatric ankle fractures would be correlated with an elevated mortality rate and that operative intervention would be associated with a reduced mortality when compared to nonoperative management. Methods: Following Institutional Review Board approval we retrospectively assessed all relevant 2008 part A inpatient claims from the Medicare database. We queried diagnosis codes for ankle fractures, and then excluded any patients whose age was less then 65 or had an admission related to an ankle fracture during the previous year. Operative patients were then identified by their ICD-9 procedure codes occurring within 30 days of their initial diagnosis code; all other patients were presumed to be treated without operative intervention, thereby creating 2 groups for comparison. We then analyzed this database for specific variables including overall mortality, length of stay, age distribution, and other demographical characteristics. Groups were compared with Elixhauser and Deyo-Charlson scores to determine the level of comorbidities in each group. Multivariate logistic regression analysis was used to determine if operative intervention had a protective effect. Results: In all, 19 648 patients with an ankle fracture were identified. Of those, 15 193 underwent operative intervention (77.3%) and 4455 were treated nonoperatively (22.7%). The mean ages for nonoperative and operative intervention were 80.9 and 76.5, respectively (P < .0001). The average length of stay for nonoperative management was 4.5 days, while operative intervention resulted in a length of stay of 4.6 days (P = .43). One-year mortality was 21.5% for the nonoperative group and 9.1% for the operative group (P < .0001). The mean Elixhauser score for the nonoperative group was 2.5 and 2.2 for the operative group (P < .0001). The mean Deyo-Charlson score was 1.3 and 1.0 for the nonoperative and operative groups, respectively (P < .0001). Multivariate logistic regression analysis demonstrated an odds ratio of 0.534 of death within 1 year for patients undergoing operative intervention as compared to nonoperative intervention (95% CI 0.483-0.591, P < .0001). Conclusion: The incidence of geriatric ankle fractures continue to increase as our population continues to grow older. A significantly larger number of those patients were treated with operative intervention, at a ratio of approximately 3: 1 versus nonoperative management. Despite a relatively low overall reported complication rate with treatment of these injuries, they are associated with substantially increased 1-year mortality in both patient groups. Compared to the operative group, the nonoperative cohort demonstrated a 2-fold elevated mortality rate, although this may be related to them being an arguably more frail population as suggested by both comorbidity indexes. In spite of the difference in comorbidities, logistic regression analysis demonstrated operative intervention to have a protective effect. C1 [Bariteau, Jason T.] Emory Univ, Sch Med, Dept Orthopaed Surg, Atlanta, GA 30329 USA. [Hsu, Raymond Y.; Hayda, Roman] Brown Univ, Dept Orthopaed Surg, Providence, RI 02912 USA. [Mor, Vincent; Lee, Yoojin] Brown Univ, Ctr Gerontol & Hlth Care Res, Sch Publ Hlth, Providence, RI 02912 USA. [Mor, Vincent; Lee, Yoojin] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [DiGiovanni, Christopher W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA. RP Bariteau, JT (reprint author), Emory Univ, Sch Med, Dept Orthopaed Surg, 59 Execut Pk S,Ste 2000, Atlanta, GA 30329 USA. EM jason.bariteau@gmail.com NR 19 TC 4 Z9 4 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD JUN PY 2015 VL 36 IS 6 BP 648 EP 655 DI 10.1177/1071100715573707 PG 8 WC Orthopedics SC Orthopedics GA CL9KH UT WOS:000357296600006 PM 25712117 ER PT J AU McAlvin, JB Zhan, CY Dohlman, JC Kolovou, PE Salvador-Culla, B Kohane, DS AF McAlvin, James Brian Zhan, Changyou Dohlman, Jenny C. Kolovou, Paraskevi E. Salvador-Culla, Borja Kohane, Daniel S. TI Corneal Anesthesia With Site 1 Sodium Channel Blockers and Dexmedetomidine SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE tetrodotoxin; saxitoxin; dexmedetomidine; clonidine; corneal anesthesia ID SCIATIC-NERVE BLOCK; DURATION LOCAL-ANESTHESIA; ACTIVATED CATION CURRENT; PERINEURAL DEXMEDETOMIDINE; TETRODOTOXIN; BUPIVACAINE; CLONIDINE; ROPIVACAINE; ANALGESIA; RATS AB PURPOSE. Amino-amide or amino-ester local anesthetics, which are currently used for topical ocular anesthesia, are short acting and may delay corneal healing with long-term use. In contrast, site 1 sodium channel blockers (S1SCBs) are potent local anesthetics with minimal adverse tissue reaction. In this study, we examined topical local anesthesia with two S1SCBs, tetrodotoxin (TTX) or saxitoxin (STX) individually or in combination with alpha(2)-adrenergic receptor agonists (dexmedetomidine or clonidine), and compared them with the amino-ester ocular anesthetic proparacaine. The effect of test solutions on corneal healing was also studied. METHODS. Solutions of TTX +/- dexmedetomidine, TTX +/- clonidine, STX +/- dexmedetomidine, dexmedetomidine, or proparacaine were applied to the rat cornea. Tactile sensitivity was measured by recording the blink response to probing of the cornea with a Cochet-Bonnet esthesiometer. The duration of corneal anesthesia was calculated. Cytotoxicity from anesthetic solutions was measured in vitro. The effect on corneal healing was measured in vivo after corneal debridement followed by repeated drug administration. RESULTS. Addition of dexmedetomidine to TTX or STX significantly prolonged corneal anesthesia beyond that of either drug alone, whereas clonidine did not. Tetrodotoxin or STX coadministered with dexmedetomidine resulted in two to three times longer corneal anesthesia than did proparacaine. S1SCB-dexmedetomidine formulations were not cytotoxic. Corneal healing was not delayed significantly by any of the test solutions. CONCLUSIONS. Coadministration of S1SCBs with dexmedetomidine provided prolonged corneal anesthesia without delaying corneal wound healing. Such formulations may be useful for the management of acute surgical and nonsurgical corneal pain. C1 [McAlvin, James Brian] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Med,Div Med Crit Care, Boston, MA 02115 USA. [McAlvin, James Brian; Zhan, Changyou; Dohlman, Jenny C.; Salvador-Culla, Borja; Kohane, Daniel S.] Harvard Univ, Sch Med, Boston Childrens Hosp, Lab Biomat & Drug Delivery,Dept Anesthesiol,Div C, Boston, MA 02115 USA. [Kolovou, Paraskevi E.; Salvador-Culla, Borja] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Schepens Eye Res Inst, Boston, MA 02115 USA. RP Kohane, DS (reprint author), Harvard Univ, Sch Med, Lab Biomat & Drug Delivery, Dept Anesthesia,Div Crit Care Med,Childrens Hosp, 61 Binney St,Room 361, Boston, MA 02115 USA. EM daniel.kohane@childrens.harvard.edu FU National Institutes of Health Grant (Bethesda, MD, USA) [GM073626] FX Supported by a National Institutes of Health Grant GM073626 (Bethesda, MD, USA). NR 40 TC 3 Z9 3 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 6 BP 3820 EP 3826 DI 10.1167/iovs.15-16591 PG 7 WC Ophthalmology SC Ophthalmology GA CM5PJ UT WOS:000357740200041 PM 26066750 ER PT J AU Tandon, A Chen, CJ Penman, A Hancock, H James, M Husain, D Andreoli, C Li, XH Kuo, JZ Idowu, O Riche, D Papavasilieou, E Brauner, S Smith, SO Hoadley, S Richardson, C Kieser, T Vazquez, V Chi, C Fernandez, M Harden, M Cotch, MF Siscovick, D Taylor, HA Wilson, JG Reich, D Wong, TY Klein, R Klein, BEK Rotter, JI Patterson, N Sobrin, L AF Tandon, Arti Chen, Ching J. Penman, Alan Hancock, Heather James, Maurice Husain, Deeba Andreoli, Christopher Li, Xiaohui Kuo, Jane Z. Idowu, Omolola Riche, Daniel Papavasilieou, Evangelia Brauner, Stacey Smith, Sataria O. Hoadley, Suzanne Richardson, Cole Kieser, Troy Vazquez, Vanessa Chi, Cheryl Fernandez, Marlene Harden, Maegan Cotch, Mary Frances Siscovick, David Taylor, Herman A. Wilson, James G. Reich, David Wong, Tien Y. Klein, Ronald Klein, Barbara E. K. Rotter, Jerome I. Patterson, Nick Sobrin, Lucia TI African Ancestry Analysis and Admixture Genetic Mapping for Proliferative Diabetic Retinopathy in African Americans SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE genetics; diabetic retinopathy; proliferative diabetic retinopathy; African Americans; admixture; ancestry ID ASSOCIATION RESOURCE CARE; RISK-FACTORS; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; UNITED-STATES; METAANALYSIS; DISEASE; PROGRESSION; POPULATION; DESIGN AB PURPOSE. To examine the relationship between proportion of African ancestry (PAA) and proliferative diabetic retinopathy (PDR) and to identify genetic loci associated with PDR using admixture mapping in African Americans with type 2 diabetes (T2D). METHODS. Between 1993 and 2013, 1440 participants enrolled in four different studies had fundus photographs graded using the Early Treatment Diabetic Retinopathy Study scale. Cases (n = 305) had PDR while controls (n = 1135) had nonproliferative diabetic retinopathy (DR) or no DR. Covariates included diabetes duration, hemoglobin A(1C), systolic blood pressure, income, and education. Genotyping was performed on the Affymetrix platform. The association between PAA and PDR was evaluated using logistic regression. Genome-wide admixture scanning was performed using ANCESTRYMAP software. RESULTS. In the univariate analysis, PDR was associated with increased PAA (odds ratio [OR] = 1.36, 95% confidence interval [CI] = 1.16-1.59, P = 0.0002). In multivariate regression adjusting for traditional DR risk factors, income and education, the association between PAA and PDR was attenuated and no longer significant (OR = 1.21, 95% CI = 0.59-2.47, P = 0.61). For the admixture analyses, the maximum genome-wide score was 1.44 on chromosome 1. CONCLUSIONS. In this largest study of PDR in African Americans with T2D to date, an association between PAA and PDR is not present after adjustment for clinical, demographic, and socioeconomic factors. No genome-wide significant locus (defined as having a locus-genome statistic > 5) was identified with admixture analysis. Further analyses with even larger sample sizes are needed to definitively assess if any admixture signal for DR is present. C1 [Tandon, Arti; Reich, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Tandon, Arti; Reich, David; Patterson, Nick] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Chen, Ching J.; Hancock, Heather; Idowu, Omolola; Smith, Sataria O.; Hoadley, Suzanne; Richardson, Cole] Univ Mississippi, Med Ctr, Dept Ophthalmol, Jackson, MS 39216 USA. [Penman, Alan; Riche, Daniel; Taylor, Herman A.; Wilson, James G.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Penman, Alan] Univ Mississippi, Med Ctr, Dept Biostat, Jackson, MS 39216 USA. [James, Maurice] St Dominics Hosp, Ophthalmol, Jackson, MS USA. [Husain, Deeba; Papavasilieou, Evangelia; Brauner, Stacey; Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. [Andreoli, Christopher; Kieser, Troy] Harvard Vanguard Med Associates, Visual Serv Dept, Boston, MA USA. [Li, Xiaohui; Kuo, Jane Z.; Rotter, Jerome I.] LABiomed, Inst Translat Genom & Populat Sci, Torrance, CA USA. [Li, Xiaohui; Kuo, Jane Z.; Rotter, Jerome I.] Harbor UCLA, Dept Pediat, Torrance, CA USA. [Kuo, Jane Z.] Pathway Genom Corp, San Diego, CA USA. [Vazquez, Vanessa; Chi, Cheryl] Boston Med Ctr, Dept Ophthalmol, Boston, MA USA. [Fernandez, Marlene] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Harden, Maegan] Broad Inst, Genom Platform, Cambridge, MA USA. [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bethesda, MD 20892 USA. [Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Wong, Tien Y.] Natl Univ Singapore, Off Clin Sci, Duke NUS Grad Med Sch, Singapore 117548, Singapore. [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore. [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA. RP Sobrin, L (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St,12th Floor, Boston, MA 02114 USA. EM lucia_sobrin@meei.harvard.edu OI Cotch, Mary Frances/0000-0002-2046-4350 FU American Diabetes Association Clinical Translational Research Award (Alexandria, VA, USA) [1-11-CT-51]; National Eye Institute (Bethesda, MD, USA) [K12-EY16335]; Research to Prevent Blindness Career Development Award (New York City, NY, USA); Harvard Catalyst \ The Harvard Clinical and Translations Science Center Faculty Fellowship (Boston, MA, USA); Massachusetts Lions Eye Research Fund (Abington, MA, USA); Eleanor and Miles Shore Fellowship (Boston, MA, USA); Sara Elizabeth O'Brien Trust (Boston, MA, USA); National Heart, Lung Blood Institute (NHLBI) (Bethesda, MD, USA) [N01-HC-65226]; Atherosclerosis Risk in Communities (ARIC) Study; Jackson Heart Study (JHS); Multi-Ethnic Study of Atherosclerosis (MESA) FX Supported by grants from the American Diabetes Association Clinical Translational Research Award 1-11-CT-51 (Alexandria, VA, USA), National Eye Institute Grant K12-EY16335 (Bethesda, MD, USA), Research to Prevent Blindness Career Development Award (New York City, NY, USA), Harvard Catalyst vertical bar The Harvard Clinical and Translations Science Center Faculty Fellowship (Boston, MA, USA), Massachusetts Lions Eye Research Fund (Abington, MA, USA), Eleanor and Miles Shore Fellowship (Boston, MA, USA), Sara Elizabeth O'Brien Trust (Boston, MA, USA). The National Heart, Lung Blood Institute (NHLBI) Grant N01-HC-65226 (Bethesda, MD, USA) has supported genotyping and has created a genotype-phenotype database with data and samples from nine cohorts as part of Candidate Gene Association Resource (CARe). Please see the Supplementary Material for detailed information about the grants supporting three cohorts that were part of this study: Atherosclerosis Risk in Communities (ARIC) Study, Jackson Heart Study (JHS) and Multi-Ethnic Study of Atherosclerosis (MESA). NR 50 TC 0 Z9 0 U1 1 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 6 BP 3999 EP 4005 DI 10.1167/iovs.15-16674 PG 7 WC Ophthalmology SC Ophthalmology GA CM5PJ UT WOS:000357740200065 PM 26098467 ER PT J AU Muir, ER Chandra, SB De La Garza, BH Velagapudi, C Abboud, HE Duong, TQ AF Muir, Eric R. Chandra, Saurav B. De La Garza, Bryan H. Velagapudi, Chakradhar Abboud, Hanna E. Duong, Timothy Q. TI Layer-Specific Manganese-Enhanced MRI of the Diabetic Rat Retina in Light and Dark Adaptation at 11.7 Tesla SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE ultra high-resolution MRI; high field; MRI contrast agents; light and dark adaptation; visual stimulation; manganese; MEMRI; photoreceptors; diabetic retinopathy ID CHOROIDAL BLOOD-FLOW; MOUSE MODEL; OXYGEN-CONSUMPTION; FUNCTIONAL MRI; OUTER RETINA; CAT RETINA; RETINOPATHY; DYSFUNCTION; METABOLISM; RESOLUTION AB PURPOSE. To employ high-resolution manganese-enhanced MRI (MEMRI) to study abnormal calcium activity in different cell layers in streptozotocin-induced diabetic rat retinas, and to determine whether MEMRI detects changes at earlier time points than previously reported. METHODS. Sprague-Dawley rats were studied 14 days (n = 8) and 30 days (n = 5) after streptozotocin (STZ) or vehicle (n = 7) injection. Manganese-enhanced MRI at 20 x 20 x 700 mu m, in which contrast is based on manganese as a calcium analogue and an MRI contrast agent, was obtained in light and dark adaptation of the retina in the same animals in which one eye was covered and the fellow eye was not. The MEMRI activity encoding of the light and dark adaptation was achieved in awake conditions and imaged under anesthesia. RESULTS. Manganese-enhanced MRI showed three layers, corresponding to the inner retina, outer retina, and the choroid. In normal animals, the outer retina showed higher MEMRI activity in dark compared to light; the inner retina displayed lower activity in dark compared to light; and the choroid showed no difference in activity. Manganese-enhanced MRI activity changed as early as 14 days after hyperglycemia and decreased with duration of hyperglycemia in the outer retina in dark relative to light adaptation. The choroid also had altered MEMRI activity at 14 days, which returned to normal by 30 days. No differences in MEMRI activity were detected in the inner retina. CONCLUSIONS. Manganese-enhanced MRI detects progressive reduction in calcium activity with duration of hyperglycemia in the outer retina as early as 14 days after hyperglycemia, earlier than any other time point reported in the literature. C1 [Muir, Eric R.; Chandra, Saurav B.; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Velagapudi, Chakradhar; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu FU National Institutes of Health/National Eye Institute [R01 EY014211, EY018855, EY021173]; MERIT Award from the Department of Veterans Affairs; Clinical Translational Science Award (CTSA) [UL1 TR001120] FX Supported in part by the National Institutes of Health/National Eye Institute (R01 EY014211, EY018855, and EY021173), a MERIT Award from the Department of Veterans Affairs, and a Pilot Award, Translational Technology Research Award from the Clinical Translational Science Award (CTSA, Parent Grant UL1 TR001120). NR 34 TC 3 Z9 3 U1 0 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 6 BP 4006 EP 4012 DI 10.1167/iovs.14-16128 PG 7 WC Ophthalmology SC Ophthalmology GA CM5PJ UT WOS:000357740200066 PM 26098468 ER PT J AU Kramer, DB Hatfield, LA McGriff, D Ellis, CR Gura, MT Samuel, M Retel, LK Hauser, RG AF Kramer, Daniel B. Hatfield, Laura A. McGriff, Deepa Ellis, Christopher R. Gura, Melanie T. Samuel, Michelle Retel, Linda Kallinen Hauser, Robert G. TI Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE ICD leads; implantable cardioverter-defibrillators; postmarket surveillance ID UNIQUE DEVICE IDENTIFICATION; MEDICAL DEVICES; ICD LEADS; RIATA; PERFORMANCE; FAILURE; EXPERIENCE; MANAGEMENT; COMMITTEE; FIDELIS AB Background-As implantable cardioverter-defibrillator technology evolves, clinicians and patients need reliable performance data on current transvenous implantable cardioverter-defibrillator systems. In addition, real-world reliability data could inform postmarket surveillance strategies directed by regulators and manufacturers. Methods and Results-We evaluated Medtronic Sprint Quattro, Boston Scientific Endotak, and St Jude Medical Durata and Riata ST Optim leads implanted by participating center physicians between January 1, 2006 and September 1, 2012. Our analytic sample of 2653 patients (median age 65, male 73%) included 445 St Jude, 1819 Medtronic, and 389 Boston Scientific leads. After a median of 3.2 years, lead failure was 0.28% per year (95% CI, 0.19 to 0.43), with no statistically significant difference among manufacturers. Simulations based on these results suggest that detecting performance differences among generally safe leads would require nearly 10 000 patients or very long follow-up. Conclusions-Currently marketed implantable cardioverter-defibrillator leads rarely fail, which may be reassuring to clinicians advising patients about risks and benefits of transvenous implantable cardioverter-defibrillator systems. Regulators should consider the sample size implications when designing comparative effectiveness studies and evaluating new technology for preventing sudden cardiac death. C1 [Kramer, Daniel B.; Samuel, Michelle] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Kramer, Daniel B.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Kramer, Daniel B.; Hatfield, Laura A.] Harvard Univ, Sch Med, Boston, MA USA. [McGriff, Deepa; Retel, Linda Kallinen; Hauser, Robert G.] Minneapolis Heart Inst Fdn, Minneapolis, MN USA. [Ellis, Christopher R.] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA. [Gura, Melanie T.] Northeast Ohio Cardiovasc Specialists, Akron, OH USA. RP Kramer, DB (reprint author), BIDMC West Campus,185 Pilgrim Rd, Boston, MA 02215 USA. EM dkramer@bidmc.harvard.edu FU Minneapolis Heart Institute Foundation; Paul B. Beeson Career Development Award [K23AG045963]; US Food & Drug Administration [U01 FD004493-01] FX This work was supported by the Minneapolis Heart Institute Foundation. Dr Kramer is supported in part by a Paul B. Beeson Career Development Award (K23AG045963). Dr Hatfield is supported in part by a US Food & Drug Administration Contract (U01 FD004493-01). NR 30 TC 2 Z9 2 U1 11 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD JUN PY 2015 VL 4 IS 6 AR e001672 DI 10.1161/JAHA.114.001672 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CL5TV UT WOS:000357025100010 PM 26025935 ER PT J AU Cancedda, C Farmer, PE Kerry, V Nuthulaganti, T Scott, KW Goosby, E Binagwaho, A AF Cancedda, Corrado Farmer, Paul E. Kerry, Vanessa Nuthulaganti, Tej Scott, Kirstin W. Goosby, Eric Binagwaho, Agnes TI Maximizing the Impact of Training Initiatives for Health Professionals in Low-Income Countries: Frameworks, Challenges, and Best Practices SO PLOS MEDICINE LA English DT Article ID MEDICAL-EDUCATION; HUMAN-RESOURCES; GLOBAL HEALTH; PARTNERSHIP; PROGRAM; UNIVERSITY; AFRICA; RWANDA; COLLABORATION; SUPPORT C1 [Cancedda, Corrado; Farmer, Paul E.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Cancedda, Corrado; Farmer, Paul E.; Kerry, Vanessa; Binagwaho, Agnes] Harvard Univ, Sch Med, Boston, MA USA. [Cancedda, Corrado; Farmer, Paul E.] Partners Hlth, Boston, MA USA. [Kerry, Vanessa] Seed Global Hlth, Boston, MA USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nuthulaganti, Tej] Clinton Hlth Access Initiat, Clinton, MA USA. [Nuthulaganti, Tej; Scott, Kirstin W.] Harvard Univ, Cambridge, MA 02138 USA. [Goosby, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Binagwaho, Agnes] Minist Hlth Rwanda, Kigali, Rwanda. [Binagwaho, Agnes] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Cancedda, C (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM ccancedd@gmail.com NR 41 TC 8 Z9 8 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JUN PY 2015 VL 12 IS 6 AR e1001840 DI 10.1371/journal.pmed.1001840 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CM0UY UT WOS:000357395500008 PM 26079377 ER PT J AU Gleason, CE Dowling, NM Wharton, W Manson, JE Miller, VM Atwood, CS Brinton, EA Cedars, MI Lobo, RA Merriam, GR Neal-Perry, G Santoro, NF Taylor, HS Black, DM Budoff, MJ Hodis, HN Naftolin, F Harman, SM Asthana, S AF Gleason, Carey E. Dowling, N. Maritza Wharton, Whitney Manson, JoAnn E. Miller, Virginia M. Atwood, Craig S. Brinton, Eliot A. Cedars, Marcelle I. Lobo, Rogerio A. Merriam, George R. Neal-Perry, Genevieve Santoro, Nanette F. Taylor, Hugh S. Black, Dennis M. Budoff, Matthew J. Hodis, Howard N. Naftolin, Frederick Harman, S. Mitchell Asthana, Sanjay TI Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study SO PLOS MEDICINE LA English DT Article ID CONJUGATED EQUINE ESTROGENS; MINI-MENTAL-STATE; HEALTH INITIATIVE MEMORY; PROGESTERONE-INDUCED NEUROPROTECTION; ANDROGEN REPLACEMENT THERAPY; SURGICALLY MENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; PLUS PROGESTIN; MEDROXYPROGESTERONE ACETATE AB Background Menopausal hormone therapy (MHT) reportedly increases the risk of cognitive decline in women over age 65 y. It is unknown whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in younger women. The ancillary Cognitive and Affective Study (KEEPS-Cog) of the Kronos Early Estrogen Prevention Study (KEEPS) examined the effects of up to 4 y of MHT on cognition and mood in recently postmenopausal women. Methods and Findings KEEPS, a randomized, double-blinded, placebo-controlled clinical trial, was conducted at nine US academic centers. Of the 727 women enrolled in KEEPS, 693 (95.3%) participated in the ancillary KEEPS-Cog, with 220 women randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micronized progesterone (m-P) for the first 12 d of each month, 211 women randomized to receive 50 mu g/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the first 12 d of each month, and 262 women randomized to receive placebo pills and patches. Primary outcomes included the Modified Mini-Mental State examination; four cognitive factors: verbal learning/memory, auditory attention/working memory, visual attention/executive function, and speeded language/mental flexibility; and a mood measure, the Profile of Mood States (POMS). MHT effects were analyzed using linear mixed-effects (LME) models, which make full use of all available data from each participant, including those with missing data. Data from those with and without full data were compared to assess for potential biases resulting from missing observations. For statistically significant results, we calculated effect sizes (ESs) to evaluate the magnitude of changes. On average, participants were 52.6 y old, and 1.4 y past their last menstrual period. By month 48, 169 (24.4%) and 158 (22.8%) of the 693 women who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cognitive factors) and mood evaluations (POMS), respectively. However, because LME models make full use all available data, including data from women with missing data, 95.5% of participants were included in the final analysis (n = 662 in cognitive analyses, and n = 661 in mood analyses). To be included in analyses, women must have provided baseline data, and data from at least one post-baseline visit. The mean length of follow-up was 2.85 y (standard deviation [SD] = 0.49) for cognitive outcomes and 2.76 (SD = 0.57) for mood outcomes. No treatment-related benefits were found on cognitive outcomes. For mood, model estimates indicated that women treated with o-CEE showed improvements in depression and anxiety symptoms over the 48 mo of treatment, compared to women on placebo. The model estimate for the depression subscale was -5.36 x 10(-2) (95% CI, -8.27 x 10(-2) to -2.44 x 10(-2); ES = 0.49, p < 0.001) and for the anxiety subscale was -3.01 x 10(-2) (95% CI, -5.09 x 10(-2) to -9.34 x 10(-3); ES = 0.26, p < 0.001). Mood outcomes for women randomized to t-E2 were similar to those for women on placebo. Importantly, the KEEPS-Cog results cannot be extrapolated to treatment longer than 4 y. Conclusions The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. However, beneficial mood effects with small to medium ESs were noted with 4 y of o-CEE, but not with 4 y of t-E2. The generalizability of these findings is limited to recently postmenopausal women with low cardiovascular risk profiles. C1 [Gleason, Carey E.; Dowling, N. Maritza; Wharton, Whitney; Atwood, Craig S.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Gleason, Carey E.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Gleason, Carey E.; Dowling, N. Maritza; Atwood, Craig S.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Wharton, Whitney] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Wharton, Whitney] Emory Alzheimers Dis Res Ctr, Atlanta, GA USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Prevent Med, Sch Med, Boston, MA 02115 USA. [Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA. [Brinton, Eliot A.] Utah Fdn Biomed Res, Salt Lake City, UT USA. [Cedars, Marcelle I.] Univ Calif San Francisco, Obstet & Gynecol, San Francisco, CA 94143 USA. [Lobo, Rogerio A.] Columbia Univ Coll Phys & Surg, Obstet & Gynecol, New York, NY 10032 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Merriam, George R.] Univ Washington, Div Metab Endocrinol & Nutr, Tacoma, WA USA. [Neal-Perry, Genevieve] Albert Einstein Coll Med, Neurosci & Obstet & Gynecol, Bronx, NY 10467 USA. [Santoro, Nanette F.] Univ Colorado, Sch Med, Obstet & Gynecol, Aurora, CO USA. [Taylor, Hugh S.] Yale Univ, Sch Med, Obstet & Gynecol, New Haven, CT USA. [Black, Dennis M.] Univ Calif San Francisco, Epidemiol & Biostat, San Francisco, CA 94143 USA. [Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Cardiol, Torrance, CA 90509 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Naftolin, Frederick] NYU, Sch Med, Obstet & Gynecol, New York, NY USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ USA. [Harman, S. Mitchell] Phoenix VA Med Ctr, Div Endocrinol, Phoenix, AZ USA. RP Gleason, CE (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM ceg@medicine.wisc.edu FU National Institutes of Health (NIH) from the Clinical and Translational Science Award (CTSA) program of the NIH National Center for Research Resources [R01 AG029624, P50AG033514, R01AG031790, 1UL1RR025011]; Wisconsin National Primate Research Center base grant, NIH [NCRR000167]; Aurora Foundation; National Institutes of Health (NIH) [HL90639]; Einstein College of Medicine; CTSA [UL1 RR025750, KL2 RR025749, TL1 RR025748, UL1 RR024139]; Mayo CTSA [1 UL1 RR024150]; Mayo Foundation; Brigham and Women's Hospital/Harvard Medical School CTSA; UCSF CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024131]; NIH Roadmap for Medical Research; Madison VA; VA Puget Sound Health Care System FX The KEEPS-Cog project was supported by grants from the National Institutes of Health (NIH) R01 AG029624, P50AG033514, R01AG031790, grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the NIH National Center for Research Resources and the Wisconsin National Primate Research Center base grant, NIH NCRR000167. The Parent KEEPS trial was funded by grants from the Aurora Foundation to the Kronos Longevity Research Institute, National Institutes of Health (NIH) HL90639 to VMM, Einstein College of Medicine, CTSA UL1 RR025750, KL2 RR025749 and TL1 RR025748, Mayo CTSA 1 UL1 RR024150, the Mayo Foundation, Brigham and Women's Hospital/Harvard Medical School CTSA, CTSA UL1 RR024139 and UCSF CTSA UL1 RR024131 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Additional support provided by resources and facilities of the Madison VA, and the VA Puget Sound Health Care System. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov. Bayer HealthCare Pharmaceuticals, Inc. supplied the CLIMARA estradiol and placebo patches and Abbott Laboratories (formerly Solvay Pharmaceuticals) provided the micronized progesterone (PROMETRIUM) and placebo capsules. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 38 Z9 39 U1 3 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JUN PY 2015 VL 12 IS 6 AR e1001833 DI 10.1371/journal.pmed.1001833 PG 25 WC Medicine, General & Internal SC General & Internal Medicine GA CM0UY UT WOS:000357395500002 PM 26035291 ER PT J AU Tsai, AC Tomlinson, M AF Tsai, Alexander C. Tomlinson, Mark TI Inequitable and Ineffective: Exclusion of Mental Health from the Post-2015 Development Agenda SO PLOS MEDICINE LA English DT Editorial Material ID SUSTAINABLE DEVELOPMENT; GLOBAL HEALTH; MORTALITY; DISORDERS; SURVIVAL C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Tsai, Alexander C.] Harvard Ctr Populat & Dev Studies, Cambridge, MA USA. [Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Tomlinson, Mark] Univ Stellenbosch, Dept Psychol, ZA-7600 Stellenbosch, South Africa. RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. EM actsai@partners.org OI Tsai, Alexander/0000-0001-6397-7917 FU NIAAA NIH HHS [R24 AA022919]; NIMH NIH HHS [K23MH096620, K23 MH096620] NR 31 TC 5 Z9 5 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JUN PY 2015 VL 12 IS 6 AR e1001846 DI 10.1371/journal.pmed.1001846 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CM0UY UT WOS:000357395500012 PM 26125938 ER PT J AU Kieser, KJ Boutte, CC Kester, JC Baer, CE Barczak, AK Meniche, X Chao, MC Rego, EH Sassetti, CM Fortune, SM Rubin, EJ AF Kieser, Karen J. Boutte, Cara C. Kester, Jemila C. Baer, Christina E. Barczak, Amy K. Meniche, Xavier Chao, Michael C. Rego, E. Hesper Sassetti, Christopher M. Fortune, Sarah M. Rubin, Eric J. TI Phosphorylation of the Peptidoglycan Synthase PonA1 Governs the Rate of Polar Elongation in Mycobacteria SO PLOS PATHOGENS LA English DT Article ID PENICILLIN-BINDING PROTEINS; CELL-WALL SYNTHESIS; ESCHERICHIA-COLI; TUBERCULOSIS; VIRULENCE; GROWTH; BIOSYNTHESIS; MORPHOLOGY; DIVISION; PLATFORM AB Cell growth and division are required for the progression of bacterial infections. Most rod-shaped bacteria grow by inserting new cell wall along their mid-section. However, mycobacteria, including the human pathogen Mycobacterium tuberculosis, produce new cell wall material at their poles. How mycobacteria control this different mode of growth is incompletely understood. Here we find that PonA1, a penicillin binding protein (PBP) capable of transglycosylation and transpeptidation of cell wall peptidoglycan (PG), is a major governor of polar growth in mycobacteria. PonA1 is required for growth of Mycobacterium smegmatis and is critical for M. tuberculosis during infection. In both cases, PonA1's catalytic activities are both required for normal cell length, though loss of transglycosylase activity has a more pronounced effect than transpeptidation. Mutations that alter the amount or the activity of PonA1 result in abnormal formation of cell poles and changes in cell length. Moreover, altered PonA1 activity results in dramatic differences in antibiotic susceptibility, suggesting that a balance between the two enzymatic activities of PonA1 is critical for survival. We also find that phosphorylation of a cytoplasmic region of PonA1 is required for normal activity. Mutations in a critical phosphorylated residue affect transglycosylase activity and result in abnormal rates of cell elongation. Together, our data indicate that PonA1 is a central determinant of polar growth in mycobacteria, and its governance of cell elongation is required for robust cell fitness during both host-induced and antibiotic stress. C1 [Kieser, Karen J.; Boutte, Cara C.; Kester, Jemila C.; Chao, Michael C.; Rego, E. Hesper; Fortune, Sarah M.; Rubin, Eric J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Baer, Christina E.; Meniche, Xavier; Sassetti, Christopher M.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA. [Barczak, Amy K.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Rubin, Eric J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. RP Kieser, KJ (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. EM erubin@hsph.harvard.edu OI Chao, Michael/0000-0002-6046-585X FU US National Institutes of Health [U01-GM094568]; National Institute of Allergy and Infectious Disease [AI095208, AI064282, R01 AI09719101A3]; Howard Hughes Medical Institute; National Institutes of Health; National Science Foundation [DGE0946799, DGE-1144152] FX This work was supported by the US National Institutes of Health grant U01-GM094568 (to EJR), National Institute of Allergy and Infectious Disease grants AI095208 and AI064282 and the Howard Hughes Medical Institute (to CMS), National Institutes of Health and National Institute of Allergy and Infectious Disease grant R01 AI09719101A3 (to SMF), and National Science Foundation Graduate Research Fellowships DGE0946799 and DGE-1144152 (to KJK) and DGE-1144152 (to JCK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 10 Z9 10 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD JUN PY 2015 VL 11 IS 6 AR e1005010 DI 10.1371/journal.ppat.1005010 PG 28 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CM0WW UT WOS:000357400900063 PM 26114871 ER PT J AU Martin-Gayo, E Buzon, MJ Ouyang, ZY Hickman, T Cronin, J Pimenova, D Walker, BD Lichterfeld, M Yu, XG AF Martin-Gayo, Enrique Buzon, Maria Jose Ouyang, Zhengyu Hickman, Taylor Cronin, Jacqueline Pimenova, Dina Walker, Bruce D. Lichterfeld, Mathias Yu, Xu G. TI Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers SO PLOS PATHOGENS LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; RESTRICTION FACTOR SAMHD1; CYTOSOLIC DNA; CYCLIC DINUCLEOTIDE; INNATE IMMUNITY; SENSOR CGAS; EX-VIVO; IN-VIVO; INFECTION; RECOGNITION AB The majority of HIV-1 elite controllers (EC) restrict HIV-1 replication through highly functional HIV-1-specific T cell responses, but mechanisms supporting the evolution of effective HIV-1-specific T cell immunity in these patients remain undefined. Cytosolic immune recognition of HIV-1 in conventional dendritic cells (cDC) can facilitate priming and expansion of HIV-1-specific T cells; however, HIV-1 seems to be able to avoid intracellular immune recognition in cDCs in most infected individuals. Here, we show that exposure of cDCs from EC to HIV-1 leads to a rapid and sustained production of type I interferons and upregulation of several interferon-stimulated effector genes. Emergence of these cell-intrinsic immune responses was associated with a reduced induction of SAMHD1 and LEDGF/p75, and an accumulation of viral reverse transcripts, but inhibited by pharmacological blockade of viral reverse transcription or siRNA-mediated silencing of the cytosolic DNA sensor cGAS. Importantly, improved cell-intrinsic immune recognition of HIV-1 in cDCs from elite controllers translated into stronger abilities to stimulate and expand HIV-1-specific CD8 T cell responses. These data suggest an important role of cell-intrinsic type I interferon secretion in dendritic cells for the induction of effective HIV-1-specific CD8 T cells, and may be helpful for eliciting functional T cell immunity against HIV-1 for preventative or therapeutic clinical purposes. C1 [Martin-Gayo, Enrique; Buzon, Maria Jose; Ouyang, Zhengyu; Hickman, Taylor; Cronin, Jacqueline; Pimenova, Dina; Walker, Bruce D.; Lichterfeld, Mathias; Yu, Xu G.] MIT, Ragon Inst MGH, Boston, MA USA. [Martin-Gayo, Enrique; Buzon, Maria Jose; Ouyang, Zhengyu; Hickman, Taylor; Cronin, Jacqueline; Pimenova, Dina; Walker, Bruce D.; Lichterfeld, Mathias; Yu, Xu G.] Harvard, Boston, MA USA. [Buzon, Maria Jose; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Lichterfeld, Mathias] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. RP Martin-Gayo, E (reprint author), MIT, Ragon Inst MGH, Boston, MA USA. EM xyu@partners.org RI Buzon, Maria J/G-8286-2015 OI Buzon, Maria J/0000-0003-4427-9413 FU US National Institutes of Health [AI078799, AI089339, HL121890, AI098484, HL126554, AI116228, AI087452, AI098487, AI106468]; Harvard University Center of AIDS research (HU CFAR NIH/NIAID) [5P30AI060354-10]; Bill and Melinda Gates Foundation [OPP 1066973]; Mark and Lisa Swartz Foundation; Ragon Institute of MGH, MIT and Harvard; International HIV Controller Consortium FX This work was supported for the US National Institutes of Health (grants AI078799, AI089339, HL121890, AI098484, HL126554, AI116228 and AI087452 to XGY; AI098487 and AI106468 to ML). EMG is supported by the Harvard University Center of AIDS research (HU CFAR NIH/NIAID fund 5P30AI060354-10). PBMC sample collection was supported by the Bill and Melinda Gates Foundation (OPP 1066973), the Mark and Lisa Swartz Foundation, the Ragon Institute of MGH, MIT and Harvard, and the International HIV Controller Consortium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 69 TC 23 Z9 23 U1 4 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD JUN PY 2015 VL 11 IS 6 AR e1004930 DI 10.1371/journal.ppat.1004930 PG 22 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CM0WW UT WOS:000357400900023 PM 26067651 ER PT J AU Calhoun, AW Pian-Smith, MCM Truog, RD Gaba, DM Meyer, EC AF Calhoun, Aaron W. Pian-Smith, May C. M. Truog, Robert D. Gaba, David M. Meyer, Elaine C. TI Deception and Simulation Education Issues, Concepts, and Commentary SO SIMULATION IN HEALTHCARE-JOURNAL OF THE SOCIETY FOR SIMULATION IN HEALTHCARE LA English DT Article ID APPRAISING QUALITATIVE RESEARCH; PSYCHOLOGICAL EXPERIMENTS; MEDICAL-EDUCATION; DEATH; CURRICULUM; OBEDIENCE AB Summary Statement The use of deceptive methodology in simulation education is an emerging ethical controversy. At the 2014 International Meeting on Simulation in Healthcare, arguments for and against its use were debated by simulation experts. What emerged from this discussion was an apparent disconnect between current practice and existing empiric research on this subject. At present, no framework exists to guide the simulation community's exploration of this issue of deception. After reviewing the relevant psychological literature, we propose a framework delineating discrete elements and important relationships, which enables a comprehensive view of the factors germane to simulations that use deception. We further comment on key pedagogical and psychological issues in the context of this framework and define an agenda for further research. Educators are encouraged to use this framework when determining whether, when, and how deception might be used and, if used, how it can be ethically justified and carefully implemented. C1 [Calhoun, Aaron W.] Univ Louisville, Sch Med, Dept Pediat, Louisville, KY 40202 USA. [Pian-Smith, May C. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA USA. [Meyer, Elaine C.] Inst Professionalism & Eth Practice, Boston, MA USA. Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA. [Truog, Robert D.] Harvard Univ, Sch Med, Div Med Eth, Dept Social Med & Global Hlth, Boston, MA USA. [Gaba, David M.] Stanford Univ, Sch Med, Ctr Immers & Simulat Based Learning, Stanford, CA 94305 USA. [Gaba, David M.] VA Palo Alto HCS, Simulat Ctr, Palo Alto, CA USA. [Meyer, Elaine C.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA. [Meyer, Elaine C.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Calhoun, AW (reprint author), Univ Louisville, Pediat Div Pediat Crit Care Med, 571 S Floyd St,STE 332, Louisville, KY 40202 USA. EM aaron.calhoun@louisville.edu NR 38 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1559-2332 EI 1559-713X J9 SIMUL HEALTHC JI Simul. Healthc. PD JUN PY 2015 VL 10 IS 3 BP 163 EP 169 DI 10.1097/SIH.0000000000000086 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CK5BM UT WOS:000356237100005 PM 25932710 ER PT J AU Falcone, A Laurent, S Gravalos, C Benavides, M Munoz, FL Ychou, M Ciardiello, F Siena, S Yamaguchi, K Muro, K Denda, T Tsuji, Y Tebbutt, N Loehrer, PJ Lenz, HJ Mayer, RJ Ohtsu, A Van Cutsem, E AF Falcone, A. Laurent, S. Gravalos, C. Benavides, M. Munoz, F. Longo Ychou, M. Ciardiello, F. Siena, S. Yamaguchi, K. Muro, K. Denda, T. Tsuji, Y. Tebbutt, N. Loehrer, P. J. Lenz, H. -J. Mayer, R. J. Ohtsu, A. Van Cutsem, E. CA RECOURSE Study Grp TI Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT ESMO 17th World Congress on Gastrointestinal Cancer CY JUL 01-04, 2015 CL Barcelona, SPAIN SP ESMO C1 [Falcone, A.] Univ Pisa, Dept Translat Res & New Technol Med, Pisa, Italy. [Laurent, S.] Univ Hosp Ghent, Ghent, Belgium. [Gravalos, C.] Hosp Univ 12 Octubre, Madrid, Spain. [Benavides, M.] Hosp Reg Univ Carlos Haya, Malaga, Spain. [Munoz, F. Longo] Ramon y Cajal Univ Hosp, Madrid, Spain. [Ychou, M.] Inst Reg Canc Montpellier, Montpellier, France. [Ciardiello, F.] Univ Naples 2, Naples, Italy. [Siena, S.] Osped Niguarda Ca Granda, Milan, Italy. [Yamaguchi, K.] Saitama Canc Ctr, Inamachi, Japan. [Muro, K.] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan. [Denda, T.] Chiba Canc Ctr, Chiba 2608717, Japan. [Tsuji, Y.] Tonan Hosp, Sapporo, Hokkaido, Japan. [Tebbutt, N.] Austin Hosp, Melbourne, Vic 3084, Australia. [Loehrer, P. J.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. [Lenz, H. -J.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Mayer, R. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ohtsu, A.] Natl Canc Ctr, Kashiwashi, Japan. [Van Cutsem, E.] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD JUN PY 2015 VL 26 SU 4 MA P-284 DI 10.1093/annonc/mdv233.281 PG 1 WC Oncology SC Oncology GA CL6AL UT WOS:000357047400137 ER PT J AU Ohtsu, A Tabernero, J Bang, YJ Fuchs, C Sun, L Wang, Z Csiki, I Koshiji, M Van Cutsem, E AF Ohtsu, A. Tabernero, J. Bang, Y. -J. Fuchs, C. Sun, L. Wang, Z. Csiki, I. Koshiji, M. Van Cutsem, E. TI Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT ESMO 17th World Congress on Gastrointestinal Cancer CY JUL 01-04, 2015 CL Barcelona, SPAIN SP ESMO C1 [Ohtsu, A.] Natl Canc Ctr, Kashiwashi, Japan. [Tabernero, J.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain. [Bang, Y. -J.] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Fuchs, C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Sun, L.; Wang, Z.; Csiki, I.; Koshiji, M.] Merck & Co Inc, Kenilworth, NJ USA. [Van Cutsem, E.] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium. NR 0 TC 1 Z9 1 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD JUN PY 2015 VL 26 SU 4 MA P-106 DI 10.1093/annonc/mdv233.106 PG 1 WC Oncology SC Oncology GA CL6AL UT WOS:000357047400051 ER PT J AU Ren, BH Azzegagh, Z Jaramillo, AM Zhu, YX Pardo-Saganta, A Bagirzadeh, R Flores, JR Han, W Tang, YJ Tu, J Alanis, DM Evans, CM Guindani, M Roche, PA Rajagopal, J Chen, JC Davis, CW Tuvim, MJ Dickey, BF AF Ren, Binhui Azzegagh, Zoulikha Jaramillo, Ana M. Zhu, Yunxiang Pardo-Saganta, Ana Bagirzadeh, Rustam Flores, Jose R. Han, Wei Tang, Yong-Jun Tu, Jing Alanis, Denise M. Evans, Christopher M. Guindani, Michele Roche, Paul A. Rajagopal, Jayaraj Chen, Jichao Davis, C. William Tuvim, Michael J. Dickey, Burton F. TI SNAP23 is selectively expressed in airway secretory cells and mediates baseline and stimulated mucin secretion SO BIOSCIENCE REPORTS LA English DT Article DE 23-kDa paralogue of synaptosome-associated protein of 25 kDa (SNAP23); exocytosis; mucin; mucus; secretion ID MAST-CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; GOBLET CELLS; MUCUS HYPERSECRETION; GRANULE EXOCYTOSIS; MOUSE MODEL; IN-VIVO; SNAP-23; SNARE AB Airway mucin secretion is important pathophysiologically and as a model of polarized epithelial regulated exocytosis. We find the trafficking protein, SNAP23 (23-kDa paralogue of synaptosome-associated protein of 25 kDa), selectively expressed in secretory cells compared with ciliated and basal cells of airway epithelium by immunohistochemistry and FACS, suggesting that SNAP23 functions in regulated but not constitutive epithelial secretion. Heterozygous SNAP23 deletant mutant mice show spontaneous accumulation of intracellular mucin, indicating a defect in baseline secretion. However mucins are released from perfused tracheas of mutant and wild-type (WT) mice at the same rate, suggesting that increased intracellular stores balance reduced release efficiency to yield a fully compensated baseline steady state. In contrast, acute stimulated release of intracellular mucin from mutant mice is impaired whether measured by a static imaging assay 5 min after exposure to the secretagogue ATP or by kinetic analysis of mucins released from perfused tracheas during the first 10 min of ATP exposure. Together, these data indicate that increased intracellular stores cannot fully compensate for the defect in release efficiency during intense stimulation. The lungs of mutant mice develop normally and clear bacteria and instilled polystyrene beads comparable to WT mice, consistent with these functions depending on baseline secretion that is fully compensated. C1 [Ren, Binhui; Azzegagh, Zoulikha; Jaramillo, Ana M.; Bagirzadeh, Rustam; Flores, Jose R.; Han, Wei; Tang, Yong-Jun; Tu, Jing; Alanis, Denise M.; Chen, Jichao; Tuvim, Michael J.; Dickey, Burton F.] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA. [Zhu, Yunxiang; Davis, C. William] Univ N Carolina, Cyst Fibrosis Res & Treatment Ctr, Chapel Hill, NC 27599 USA. [Pardo-Saganta, Ana; Rajagopal, Jayaraj] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Evans, Christopher M.] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA. [Guindani, Michele] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. [Roche, Paul A.] NCI, Expt Immunol Branch, Bethesda, MD 20892 USA. RP Dickey, BF (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA. EM bdickey@mdanderson.org RI Guindani, Michele/F-1301-2017 OI Guindani, Michele/0000-0002-6363-9907 FU National Institutes of Health [R01HL097000, R01 HL080396, R21 ES023384]; MD Anderson Cancer Center Support Grant [CA16672]; Cystic Fibrosis Foundation [DICKE08G0, DAVIS08G0]; National Natural Science Foundation of China [81302013]; Intramural Research Program of the National Cancer Institute FX This study was supported by the National Institutes of Health [grant numbers R01HL097000 (to Y.X., M.J.T., C.W.D. and B.F.D.), R01 HL080396 and R21 ES023384 (to C.M.E.)] the MD Anderson Cancer Center Support Grant [grant number CA16672]; the Cystic Fibrosis Foundation [grant number DICKE08G0 (to M.J.T. and B.F.D.) and DAVIS08G0 (to C.W.D.)]; the National Natural Science Foundation of China [grant number 81302013 (to B.R.)]; and the Intramural Research Program of the National Cancer Institute (P.A.R.). NR 51 TC 0 Z9 0 U1 2 U2 4 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0144-8463 EI 1573-4935 J9 BIOSCIENCE REP JI Biosci. Rep. PD JUN 1 PY 2015 VL 35 AR e00220 DI 10.1042/BSR20150004 PN 3 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CL6VM UT WOS:000357105800029 ER PT J AU Kerlikowske, K Gard, CC Sprague, BL Tice, JA Miglioretti, DL AF Kerlikowske, Karla Gard, Charlotte C. Sprague, Brian L. Tice, Jeffrey A. Miglioretti, Diana L. CA Breast Canc Surveillance Consortiu TI One versus Two Breast Density Measures to Predict 5-and 10-Year Breast Cancer Risk SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID MAMMOGRAPHIC DENSITY; SCREENING MAMMOGRAPHY; WOMEN; MODEL; RECLASSIFICATION; REPRODUCIBILITY; VALIDATION; REDUCTION; CHOICE; MARKER AB Background: One measure of Breast Imaging Reporting and Data System (BI-RADS) breast density improves 5-year breast cancer risk prediction, but the value of sequential measures is unknown. We determined whether two BI-RADS density measures improve the predictive accuracy of the Breast Cancer Surveillance Consortium 5-year risk model compared with one measure. Methods: We included 722,654 women of ages 35 to 74 years with two mammograms with BI-RADS density measures on average 1.8 years apart; 13,715 developed invasive breast cancer. We used Cox regression to estimate the relative hazards of breast cancer for age, race/ethnicity, family history of breast cancer, history of breast biopsy, and one or two density measures. We developed a risk prediction model by combining these estimates with 2000-2010 Surveillance, Epidemiology, and End Results incidence and 2010 vital statistics for competing risk of death. Results: The two-measure density model had marginally greater discriminatory accuracy than the one-measure model (AUC, 0.640 vs. 0.635). Of 18.6% of women (134,404 of 722,654) who decreased density categories, 15.4% (20,741 of 134,404) of women whose density decreased from heterogeneously or extremely dense to a lower density category with one other risk factor had a clinically meaningful increase in 5-year risk from <1.67% with the one-density model to >= 1.67% with the two-density model. Conclusion: The two-density model has similar overall discrimination to the one-density model for predicting 5-year breast cancer risk and improves risk classification for women with risk factors and a decrease in density. Impact: A two-density model should be considered for women whose density decreases when calculating breast cancer risk. (C)2015 AACR. C1 [Kerlikowske, Karla; Tice, Jeffrey A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla; Tice, Jeffrey A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Gard, Charlotte C.] New Mexico State Univ, Dept Econ Appl Stat & Int Business, Las Cruces, NM 88003 USA. [Sprague, Brian L.] Univ Vermont, Dept Surg, Burlington, VT 05405 USA. [Sprague, Brian L.] Univ Vermont, Vermont Canc Ctr, Burlington, VT USA. [Miglioretti, Diana L.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Miglioretti, Diana L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Karla.Kerlikowske@ucsf.edu FU National Cancer Institute [P01 CA154292, HHSN261201100031C, U54 CA163303] FX This work was supported by the National Cancer Institute-funded Breast Cancer Surveillance Consortium (P01 CA154292 and HHSN261201100031C to K. Kerlikowske, B.L. Sprague, and D.L. Miglioretti) and U54 CA163303 to B.L. Sprague. The collection of cancer data used in this study was supported, in part, by several state public health departments and cancer registries throughout the U.S. For a full description of these sources, please see: http://breastscreening.cancer.gov/work/acknowledgement.html. NR 37 TC 1 Z9 1 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2015 VL 24 IS 6 BP 889 EP 897 DI 10.1158/1055-9965.EPI-15-0035 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CM1FB UT WOS:000357425200001 PM 25824444 ER PT J AU Jie, HB Schuler, PJ Lee, SC Srivastava, RM Argiris, A Ferrone, S Whiteside, TL Ferris, RL AF Jie, Hyun-Bae Schuler, Patrick J. Lee, Steve C. Srivastava, Raghvendra M. Argiris, Athanassios Ferrone, Soldano Whiteside, Theresa L. Ferris, Robert L. TI CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis SO CANCER RESEARCH LA English DT Article ID NATURAL-KILLER; CYTOLYTIC ACTIVITY; COLORECTAL-CANCER; PERIPHERAL-BLOOD; CROSS-TALK; IN-VIVO; IMMUNITY; RESISTANCE; CARCINOMA; MELANOMA AB The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of patients, and the variability and extent of cetuximab-mediated cellular immunity is not fully understood. We hypothesized that regulatory T cells (Treg) may exert a functional and clinical impact on antitumor immunity in cetuximab-treated individuals. The frequency, immunosuppressive phenotype, and activation status of Treg and natural killer (NK) cells were analyzed in the circulation and tumor microenvironment of cetuximab-treated patients with HNSCC enrolled in a novel neoadjuvant, single-agent cetuximab clinical trial. Notably, cetuximab treatment increased the frequency of CD4(+)FOXP3(+) intratumoral Treg expressing CTLA-4, CD39, and TGF beta. These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and their presence correlated with poor clinical outcome in two prospective clinical trial cohorts. Cetuximab expanded CTLA-4(+)FOXP3(+) Treg in vitro, in part, by inducing dendritic cell maturation, in combination with TGF beta and T-cell receptor triggering. Importantly, cetuximab-activated NK cells selectively eliminated intratumoral Treg but preserved effector T cells. In ex vivo assays, ipilimumab targeted CTLA4(+) Treg and restored cytolytic functions of NK cells mediating ADCC. Taken together, our results argue that differences in Treg-mediated suppression contribute to the clinical response to cetuximab treatment, suggesting its improvement by adding ipilimumab or other strategies of Treg ablation to promote antitumor immunity. (C) 2015 AACR. C1 [Jie, Hyun-Bae; Schuler, Patrick J.; Lee, Steve C.; Srivastava, Raghvendra M.; Whiteside, Theresa L.; Ferris, Robert L.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Schuler, Patrick J.] Univ Duisburg Essen, Dept Otorhinolaryngol, Essen, Germany. [Argiris, Athanassios] UT Hlth Sci Ctr San Antonio, Dept Med, Div Hematol Oncol, Canc Therapy & Res Ctr, San Antonio, TX USA. [Ferrone, Soldano] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Whiteside, Theresa L.; Ferris, Robert L.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA. [Whiteside, Theresa L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Whiteside, Theresa L.; Ferris, Robert L.] Univ Pittsburgh, Inst Canc, Canc Immunol Program, Pittsburgh, PA USA. RP Ferris, RL (reprint author), Hillman Canc Ctr Res Pavil, 5117 Ctr Ave,Room 2-26b, Pittsburgh, PA 15213 USA. EM ferrisrl@upmc.edu FU NIH [R01 DE19727, P50 CA097190, CA110249]; University of Pittsburgh Cancer Institute [P30CA047904] FX This work was supported by NIH grants R01 DE19727, P50 CA097190, CA110249, and University of Pittsburgh Cancer Institute grant P30CA047904. NR 47 TC 28 Z9 30 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JUN 1 PY 2015 VL 75 IS 11 BP 2200 EP 2210 DI 10.1158/0008-5472.CAN-14-2788 PG 11 WC Oncology SC Oncology GA CL9XX UT WOS:000357333500009 PM 25832655 ER PT J AU Tesfay, L Clausen, KA Kim, JW Hegde, P Wang, XH Miller, LD Deng, ZY Blanchette, N Arvedson, T Miranti, CK Babitt, JL Lin, HY Peehl, DM Torti, FM Torti, SV AF Tesfay, Lia Clausen, Kathryn A. Kim, Jin Woo Hegde, Poornima Wang, Xiaohong Miller, Lance D. Deng, Zhiyong Blanchette, Nicole Arvedson, Tara Miranti, Cindy K. Babitt, Jodie L. Lin, Herbert Y. Peehl, Donna M. Torti, Frank M. Torti, Suzy V. TI Hepcidin Regulation in Prostate and Its Disruption in Prostate Cancer SO CANCER RESEARCH LA English DT Article ID BONE MORPHOGENETIC PROTEIN; EXPRESSION; IRON; METHYLATION; PROGRESSION; ANTAGONIST; ACTIVATION; ANEMIA; TUMORIGENESIS; INFLAMMATION AB Hepcidin is a circulating peptide hormone made by the liver that is a central regulator of systemic iron uptake and recycling. Here, we report that prostate epithelial cells also synthesize hepcidin, and that synthesis and secretion of hepcidin are markedly increased in prostate cancer cells and tissue. Prostatic hepcidin functions as an autocrine hormone, decreasing cell surface ferroportin, an iron exporter, increasing intracellular iron retention, and promoting prostate cancer cell survival. Synthesis of hepcidin in prostate cancer is controlled by a unique intersection of pathways that involves BMP4/7, IL6, Wnt, and the dual BMP and Wnt antagonist, SOSTDC1. Epigenetic silencing of SOSTDC1 through methylation is increased in prostate cancer and is associated with accelerated disease progression in patients with prostate cancer. These results establish a new connection between iron metabolism and prostate cancer, and suggest that prostatic dysregulation of hepcidin contributes to prostate cancer growth and progression. (C) 2015 AACR. C1 [Tesfay, Lia; Deng, Zhiyong; Blanchette, Nicole; Torti, Suzy V.] Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, Farmington, CT 06030 USA. [Clausen, Kathryn A.] JK Associates, Conshohocken, PA USA. [Kim, Jin Woo] Panagene Inc, Taejon, South Korea. [Hegde, Poornima; Wang, Xiaohong] Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06030 USA. [Miller, Lance D.] Wake Forest Sch Med, Dept Canc Biol, Winston Salem, NC USA. [Arvedson, Tara] Amgen Inc, Dept Inflammat, Seattle, WA USA. [Miranti, Cindy K.] Van Andel Res Inst, Ctr Canc & Cell Biol, Lab Integrin Signaling, Program Skeletal Dis & Tumor Microenvironm, Grand Rapids, MI USA. [Babitt, Jodie L.; Lin, Herbert Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Anemia Signaling Res,Div Nephrol,Program, Boston, MA USA. [Peehl, Donna M.] Stanford Univ, Sch Med, Dept Urol, Stanford, CA USA. [Torti, Frank M.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA. RP Torti, SV (reprint author), Univ Connecticut, Ctr Hlth, Dept Mol Biol & Biophys, 263 Farmington Ave, Farmington, CT 06030 USA. EM storti@uchc.edu FU NIH [R01 CA-171101, R01 CA188025, RO1 DK-069533, RO1 DK-071837, RO1-DK087727]; Howard Goodman Fellowship Award from the Massachusetts General Hospital FX F.M. Torti and S.V. Torti were supported in part by NIH R01 CA-171101 and R01 CA188025. H.Y. Lin was supported by NIH grants RO1 DK-069533 and RO1 DK-071837. J.L. Babitt was supported in part by NIH grant RO1-DK087727 and a Howard Goodman Fellowship Award from the Massachusetts General Hospital. NR 44 TC 8 Z9 9 U1 1 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JUN 1 PY 2015 VL 75 IS 11 BP 2254 EP 2263 DI 10.1158/0008-5472.CAN-14-2465 PG 10 WC Oncology SC Oncology GA CL9XX UT WOS:000357333500014 PM 25858146 ER PT J AU Sullivan, RJ Flaherty, KT AF Sullivan, Ryan J. Flaherty, Keith T. TI New Strategies in Melanoma: Entering the Era of Combinatorial Therapy SO CLINICAL CANCER RESEARCH LA English DT Article ID STAGE-IV MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; T-CELL-ACTIVATION; BRAF-MUTATED MELANOMA; PHASE-III TRIAL; METASTATIC MELANOMA; MEK INHIBITION; INTERFERON-ALPHA; CONCURRENT BIOCHEMOTHERAPY; MONOCLONAL-ANTIBODIES AB The treatment of metastatic melanoma has been revolutionized over the past decade as effective molecularly targeted therapies and immunotherapies entered the clinic. It is hoped that deeper insights into the characteristics of patients and tumors that are most responsive will allow more precise patient selection for these therapies while understanding mechanisms of resistance will facilitate the develop of rational combinations or next-generation agents aimed at novel targets. (C) 2015 AACR. C1 [Sullivan, Ryan J.; Flaherty, Keith T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM kflaherty@partners.org NR 103 TC 2 Z9 2 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2015 VL 21 IS 11 BP 2424 EP 2435 DI 10.1158/1078-0432.CCR-14-1650 PG 12 WC Oncology SC Oncology GA CL9YT UT WOS:000357335800004 PM 26034218 ER PT J AU Juric, D Dienstmann, R Cervantes, A Hidalgo, M Messersmith, W Blumenschein, GR Tabernero, J Roda, D Calles, A Jimeno, A Wang, XD Bohorquez, SS Leddy, C Littman, C Kapp, AV Shames, DS Penuel, E Amler, LC Pirzkall, A Baselga, J AF Juric, Dejan Dienstmann, Rodrigo Cervantes, Andres Hidalgo, Manuel Messersmith, Wells Blumenschein, George R., Jr. Tabernero, Josep Roda, Desamparados Calles, Antonio Jimeno, Antonio Wang, Xiaodong Bohorquez, Sandra Sanabria Leddy, Cecilia Littman, Catherine Kapp, Amy V. Shames, David S. Penuel, Elicia Amler, Lukas C. Pirzkall, Andrea Baselga, Jose TI Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors SO CLINICAL CANCER RESEARCH LA English DT Article ID ACQUIRED-RESISTANCE; SIGNALING NETWORK; BREAST-CANCER; RECEPTOR; HER3; FAMILY; ERBB3; MECHANISMS; INHIBITORS; THERAPY AB Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A. Experimental Design: Patients with locally advanced or metastatic epithelial tumors received escalating doses of MEHD7945A (1-30 mg/kg) every 2 weeks (q2w) until disease progression or intolerable toxicity. An expansion cohort was enrolled at the recommended phase II dose (14 mg/kg, q2w). Plasma samples, tumor biopsies, FDG-PET were obtained for assessment of pharmacokinetics, and pharmacodynamic modulation downstream of EGFR and HER3. Results: No dose-limiting toxicities or MEHD7945A-related grade >= 4 adverse events (AE) were reported in dose-escalation (n = 30) or expansion (n = 36) cohorts. Related grade 3 AEs were limited to diarrhea and nausea in the same patient (30 mg/kg). Related AEs in >= 20% of patients <= 24 hours after the first infusion included grade 1/2 headache, fever, and chills, which were managed with premedication and/or symptomatic treatment. Pharmacodynamic data indicated target inhibition in 25% of evaluable patients. Best response by RECIST included 2 confirmed partial responses in squamous cell carcinomas of head and neck (SCCHN) patients with high tumor tissue levels of the HER3 ligand heregulin; 14 patients had stable disease >= 8 weeks, including SCCHN (n = 3), colorectal cancer (n = 6), and non-small cell lung cancer (n = 3). Conclusions: MEHD7945A was well-tolerated as single agent with evidence of tumor pharmacodynamic modulation and antitumor activity in SCCHN. Phase II studies were initiated with flat (nonweight-based) dosing at 1,100 mg q2w in SCCHN and colorectal cancer. (C) 2015 AACR. C1 [Juric, Dejan; Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Dienstmann, Rodrigo; Tabernero, Josep] Univ Autonoma Barcelona, Vall DHebron Univ Hosp, E-08193 Barcelona, Spain. [Dienstmann, Rodrigo; Tabernero, Josep] Univ Autonoma Barcelona, Inst Oncol VHIO, E-08193 Barcelona, Spain. [Cervantes, Andres; Roda, Desamparados] Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain. [Hidalgo, Manuel; Calles, Antonio] Spanish Natl Canc Res Ctr, Madrid, Spain. [Messersmith, Wells; Jimeno, Antonio] Univ Colorado, Ctr Canc, Denver, CO 80262 USA. [Blumenschein, George R., Jr.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Wang, Xiaodong; Bohorquez, Sandra Sanabria; Leddy, Cecilia; Littman, Catherine; Kapp, Amy V.; Shames, David S.; Penuel, Elicia; Amler, Lukas C.; Pirzkall, Andrea] Genentech Inc, San Francisco, CA 94080 USA. RP Baselga, J (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA. EM baselgaj@mskcc.org RI Hidalgo, Manuel/I-4995-2015; OI Hidalgo, Manuel/0000-0002-3765-3318; Calles, Antonio/0000-0002-2547-1947 FU Genentech FX This work was supported by Genentech. Genentech was involved in the study design, data interpretation, and the decision to submit for publication in conjunction with the authors. NR 19 TC 8 Z9 8 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2015 VL 21 IS 11 BP 2462 EP 2470 DI 10.1158/1078-0432.CCR-14-2412 PG 9 WC Oncology SC Oncology GA CL9YT UT WOS:000357335800009 PM 26034219 ER PT J AU McKay, RR Rodriguez, GE Lin, X Kaymakcalan, MD Hamnvik, OPR Sabbisetti, VS Bhatt, RS Simantov, R Choueiri, TK AF McKay, Rana R. Rodriguez, Gustavo E. Lin, Xun Kaymakcalan, Marina D. Hamnvik, Ole-Petter R. Sabbisetti, Venkata S. Bhatt, Rupal S. Simantov, Ronit Choueiri, Toni K. TI Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma SO CLINICAL CANCER RESEARCH LA English DT Article ID CONVERTING ENZYME-INHIBITORS; II TYPE-1 RECEPTOR; INTERFERON-ALPHA; PHASE-II; TUMOR ANGIOGENESIS; 1ST-LINE THERAPY; GROWTH-FACTOR; CANCER CELLS; SOLID TUMORS; SUNITINIB AB Purpose: The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era. Experimental Design: We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan-Meier method. Results: A total of 4,736 patients were included, of whom 1,487 received ASIs and 783 received other antihypertensive agents. Overall, ASI users demonstrated improved overall survival (OS) compared with users of other antihypertensive agents (adjusted HR, 0.838, P = 0.0105, 26.68 vs. 18.07 months) and individuals receiving no antihypertensive therapy (adjusted HR, 0.810, P = 0.0026, 26.68 vs. 16.72 months). When stratified by therapy type, a benefit in OS was demonstrated in ASI users compared with nonusers in individuals receiving VEGF therapy (adjusted HR, 0.737, P < 0.0001, 31.12 vs. 21.94 months) but not temsirolimus or IFN alpha. An in vitro cell viability assay demonstrated that sunitinib in combination with an ASI significantly decreased RCC cell viability compared with control at physiologically relevant doses. This effect was not observed with either agent alone or with other non-ASI antihypertensives or temsirolimus. Conclusions: In the largest analysis to date, we demonstrate that ASI use improved survival in mRCC patients treated in the targeted therapy era. Further studies are warranted to investigate the mechanism underlying this interaction and verify our observations to inform clinical practice. (C) 2015 AACR. C1 [McKay, Rana R.; Choueiri, Toni K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Rodriguez, Gustavo E.; Simantov, Ronit] Pfizer Inc, Pfizer Oncol, New York, NY USA. [Lin, Xun; Hamnvik, Ole-Petter R.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Kaymakcalan, Marina D.] Dana Farber Canc Inst, Dept Pharm & Clin Support, Boston, MA 02115 USA. [Sabbisetti, Venkata S.] Brigham & Womans Hosp, Dept Nephrol, Boston, MA USA. [Bhatt, Rupal S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol & Canc Biol, Boston, MA 02215 USA. RP Choueiri, TK (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM toni_choueiri@DFCI.harvard.edu FU Pfizer, Inc.; Dana-Farber/Harvard Cancer Center Kidney SPORE; Trust Family Fund for Kidney Cancer Research at Dana-Farber Cancer Institute; Michael Brigham Fund for Kidney Cancer Research at Dana-Farber Cancer Institute; Loker Pinard Fund for Kidney Cancer Research at Dana-Farber Cancer Institute FX This work was funded by Pfizer, Inc. In addition, this research was funded in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE, and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute (to T.K. Choueiri). NR 42 TC 14 Z9 14 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2015 VL 21 IS 11 BP 2471 EP 2479 DI 10.1158/1078-0432.CCR-14-2332 PG 9 WC Oncology SC Oncology GA CL9YT UT WOS:000357335800010 PM 25724518 ER PT J AU Blume-Jensen, P Berman, DM Rimm, DL Shipitsin, M Putzi, M Nifong, TP Small, C Choudhury, S Capela, T Coupal, L Ernst, C Hurley, A Kaprelyants, A Chang, H Giladi, E Nardone, J Dunyak, J Loda, M Klein, EA Magi-Galluzzi, C Latour, M Epstein, JI Kantoff, P Saad, F AF Blume-Jensen, Peter Berman, David M. Rimm, David L. Shipitsin, Michail Putzi, Mathew Nifong, Thomas P. Small, Clayton Choudhury, Sibgat Capela, Teresa Coupal, Louis Ernst, Christina Hurley, Aeron Kaprelyants, Alex Chang, Hua Giladi, Eldar Nardone, Julie Dunyak, James Loda, Massimo Klein, Eric A. Magi-Galluzzi, Cristina Latour, Mathieu Epstein, Jonathan I. Kantoff, Philip Saad, Fred TI Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer SO CLINICAL CANCER RESEARCH LA English DT Article ID RADICAL PROSTATECTOMY; GLEASON SCORE; PROGRESSION; PREDICTION; GRADE; AGGRESSIVENESS; OVERDIAGNOSIS; SURVEILLANCE; RECURRENCE; BIOMARKERS AB Purpose: Prostate cancer aggressiveness and appropriate therapy are routinely determined following biopsy sampling. Current clinical and pathologic parameters are insufficient for accurate risk prediction leading primarily to overtreatment and also missed opportunities for curative therapy. Experimental Design: An 8-biomarker proteomic assay for intact tissue biopsies predictive of prostate pathology was defined in a study of 381 patient biopsies with matched prostatectomy specimens. A second blinded study of 276 cases validated this assay's ability to distinguish "favorable" versus "nonfavorable" pathology independently and relative to current risk classification systems National Comprehensive Cancer Network (NCCN and D'Amico). Results: A favorable biomarker risk score of <= 0.33, and a nonfavorable risk score of >0.80 (possible range between 0 and 1) were defined on "false-negative" and "false-positive" rates of 10% and 5%, respectively. At a risk score <= 0.33, predictive values for favorable pathology in very low-risk and low-risk NCCN and low-risk D'Amico groups were 95%, 81.5%, and 87.2%, respectively, higher than for these current risk classification groups themselves (80.3%, 63.8%, and 70.6%, respectively). The predictive value for nonfavorable pathology was 76.9% at biomarker risk scores >0.8 across all risk groups. Increased biomarker risk scores correlated with decreased frequency of favorable cases across all risk groups. The validation study met its two coprimary endpoints, separating favorable from nonfavorable pathology (AUC, 0.68; P < 0.0001; OR, 20.9) and GS-6 versus non-GS-6 pathology (AUC, 0.65; P < 0.0001; OR, 12.95). Conclusions: The 8-biomarker assay provided individualized, independent prognostic information relative to current risk stratification systems, and may improve the precision of clinical decision making following prostate biopsy. (C)2015 AACR. C1 [Blume-Jensen, Peter; Shipitsin, Michail; Nifong, Thomas P.; Small, Clayton; Choudhury, Sibgat; Capela, Teresa; Ernst, Christina; Hurley, Aeron; Kaprelyants, Alex; Chang, Hua; Giladi, Eldar; Nardone, Julie; Dunyak, James] Metamark Genet Inc, Cambridge, MA USA. [Berman, David M.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada. [Rimm, David L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Putzi, Mathew] Urol Austin, Austin, TX USA. [Coupal, Louis] Impacts Inc, Montreal, PQ, Canada. [Loda, Massimo; Kantoff, Philip] Dana Farber Canc Inst, Boston, MA 02115 USA. [Klein, Eric A.] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA. [Magi-Galluzzi, Cristina] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA. [Latour, Mathieu; Saad, Fred] Univ Montreal, Ctr Hosp, Montreal, PQ H2X 0A9, Canada. [Epstein, Jonathan I.] Johns Hopkins Univ Hosp, Dept Pathol Urol & Oncol, Baltimore, MD 21287 USA. RP Saad, F (reprint author), Univ Montreal, Ctr Hosp, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada. EM fred.saad@umontreal.ca FU Metamark Genetics, Inc. FX This project was funded by Metamark Genetics, Inc. NR 34 TC 19 Z9 19 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JUN 1 PY 2015 VL 21 IS 11 BP 2591 EP 2600 DI 10.1158/1078-0432.CCR-14-2603 PG 10 WC Oncology SC Oncology GA CL9YT UT WOS:000357335800023 PM 25733599 ER PT J AU Lu, CY Zhang, F Lakoma, MD Butler, MG Fung, V Larkin, EK Kharbanda, EO Vollmer, WM Lieu, T Soumerai, SB Wu, AC AF Lu, Christine Y. Zhang, Fang Lakoma, Matthew D. Butler, Melissa G. Fung, Vicki Larkin, Emma K. Kharbanda, Elyse O. Vollmer, William M. Lieu, Tracy Soumerai, Stephen B. Wu, Ann Chen TI Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors SO CLINICAL THERAPEUTICS LA English DT Article DE asthma; drug tolerability; FDA; leukotriene inhibitors; montelukast; risk communication ID INTERRUPTED TIME-SERIES; PRIOR AUTHORIZATION; SUICIDAL-BEHAVIOR; DUAL-ENROLLEES; E-CODES; MEDICATIONS; MEDICAID; RISK; FDA; WARNINGS AB Purpose: In 2009, the US Food and Drug Administration (FDA) mandated a label change for leukotriene inhibitors (LTIs) to include neuropsychiatric adverse events (eg, depression and suicidality) as a precaution. This study investigated how this label change affected the use of LTIs and other asthma controller medications, mental health visits, and suicide attempts. Methods: We analyzed data (2005-2010) from 5 large health plans in the US Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network. The study cohort included children and adolescents (n = 30,000), young adults (n = 20,000), and adults (n = 90,000) with asthma. We used interrupted time series to examine changes in rates of LTI dispensings, non-LTI dispensings, mental health visits, and suicide attempts (using a validated algorithm based on a combination of diagnoses of injury or poisoning and psychiatric conditions). Findings: The label change was associated with abrupt reductions in LTI use among all age groups (relative reductions of 8.3%, 15.1%, and 6.0% among adolescents, young adults, and adults, respectively, compared with expected rates at 1 year after the warnings). Although we detected immediate offset increases in non-LTI asthma medication use, these increases were not sustained among adolescents and young adults. There were small increases in mental health visits among LTI users. Implications: The FDA label change for LTIs communicated possible risk of neuropsychiatric events. Communication and enhanced awareness may have increased reporting of mental health symptoms among young adults and adults. It is important to assess intended and unintended consequences of FDA warnings and label changes. (C) 2015 Elsevier HS Journals, Inc. All rights reserved. C1 [Lu, Christine Y.; Zhang, Fang; Lakoma, Matthew D.; Soumerai, Stephen B.; Wu, Ann Chen] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Lu, Christine Y.; Zhang, Fang; Lakoma, Matthew D.; Soumerai, Stephen B.; Wu, Ann Chen] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Butler, Melissa G.] Populat Hlth, Argus Grp, Hamilton, Bermuda. [Fung, Vicki] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Fung, Vicki] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Larkin, Emma K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Vollmer, William M.] Kaiser Permanente Northwest, Ctr Hlth Res Northwest, Portland, OR USA. [Lieu, Tracy] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Wu, Ann Chen] Childrens Hosp, Dept Pediat, Div Gen Pediat, Boston, MA 02115 USA. RP Lu, CY (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,Sixth Floor, Boston, MA 02215 USA. EM christine_lu@harvardpilgrim.org FU Agency for Healthcare Research and Quality [1R01HS019669]; National Institute of Diabetes and Digestive and Kidney Diseases from the Health Delivery Systems Center for Diabetes Translational Research [1P30-DK092924]; US National Institute of Mental Health [U19MH092201] FX The PEAL Network is supported by Agency for Healthcare Research and Quality grant 1R01HS019669 (principal investigator: S.B. Soumerai). S.B. Soumerai was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases grant 1P30-DK092924 from the Health Delivery Systems Center for Diabetes Translational Research. C.Y. Lu, F. Zhang, and S.B. Soumerai were supported in part by cooperative agreement U19MH092201 with the US National Institute of Mental Health. The sponsor had no role in the design and conduct of the study; analysis, and interpretation of the data; the preparation of the manuscript; or decision to submit the manuscript for publication. This paper is subject to the National Institutes of Health Public Access Policy (http://publicaccess.nih.gov/). NR 25 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD JUN PY 2015 VL 37 IS 6 BP 1280 EP 1291 DI 10.1016/j.clinthera.2015.03.027 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CL7HS UT WOS:000357143700014 PM 25920571 ER PT J AU Guerin, C Thompson, T Brower, R AF Guerin, Claude Thompson, Taylor Brower, Roy TI The ten diseases that look like ARDS SO INTENSIVE CARE MEDICINE LA English DT Editorial Material ID ACUTE RESPIRATORY-DISTRESS; BERLIN DEFINITION; CORTICOSTEROIDS; DIAGNOSIS; AUTOPSY; ADULTS C1 [Guerin, Claude] Hop Croix Rousse, Reanimat Med, F-69317 Lyon, France. [Thompson, Taylor] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA. [Thompson, Taylor] Harvard Univ, Sch Med, Boston, MA USA. [Brower, Roy] Johns Hopkins Univ, Sch Med, Pulm & Crit Care Med, Baltimore, MD USA. RP Guerin, C (reprint author), Hop Croix Rousse, Reanimat Med, F-69317 Lyon, France. EM claude.guerin@chu-lyon.fr NR 14 TC 8 Z9 8 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 EI 1432-1238 J9 INTENS CARE MED JI Intensive Care Med. PD JUN PY 2015 VL 41 IS 6 BP 1099 EP 1102 DI 10.1007/s00134-014-3608-x PG 4 WC Critical Care Medicine SC General & Internal Medicine GA CL2UO UT WOS:000356801200014 PM 25527375 ER PT J AU Deforche, L Feys, HB Ceunynck, KD Vandenbulcke, A Vandeputte, N Roose, E Fujimura, Y Soejima, K Lane, DA Luken, B Sadler, JE Deckmyn, H De Meyer, SF Vanhoorelbeke, K AF Deforche, L. Feys, H. B. Ceunynck, K. D. Vandenbulcke, A. Vandeputte, N. Roose, E. Fujimura, Y. Soejima, K. Lane, D. A. Luken, B. Sadler, Evan J. Deckmyn, H. De Meyer, S. F. Vanhoorelbeke, K. TI ADAMTS13-induced unfolding of the von Willebrand factor A2 domain SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Deforche, L.; Vandenbulcke, A.; Vandeputte, N.; Roose, E.; Deckmyn, H.; De Meyer, S. F.; Vanhoorelbeke, K.] KU Leuven Kulak, IRF Life Sci, Lab Thrombosis Res, Kortrijk, Belgium. [Feys, H. B.] Belgian Red Cross Flanders, Transfus Res Ctr, Ghent, Belgium. [Ceunynck, K. D.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr BIDMC, Boston, MA USA. [Fujimura, Y.] Nara Med Univ, Dept Blood Transfus Med, Kashihara, Nara 634, Japan. [Soejima, K.] Chemo Sero Therapeut Res Inst, Res Dept 1, Kikuchi, Japan. [Lane, D. A.; Luken, B.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Sadler, Evan J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Sadler, Evan J.] Washington Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA. [Sadler, Evan J.] Washington Univ, Sch Med, Dept Mol Biophys, St Louis, MO 63110 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA AS178 BP 64 EP 64 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901174 ER PT J AU Douketis, J Spyropoulos, A Kaatz, S Caprini, J Dunn, A Garcia, D Jacobson, A Jaffer, A Kindzelski, A Schulman, S Turpie, AG Becker, R Clark, NP Conti, B Ellsworth, S Harrison, RW Kong, D Johnson, G Krishnamoorthy, A Palmeri, S Parker, W Saucedo, J Schoch, P Tallman, D Witt, D Hasselblad, V Ortel, TL AF Douketis, J. Spyropoulos, A. Kaatz, S. Caprini, J. Dunn, A. Garcia, D. Jacobson, A. Jaffer, A. Kindzelski, A. Schulman, S. Turpie, A. G. Becker, R. Clark, N. P. Conti, B. Ellsworth, S. Harrison, R. W. Kong, D. Johnson, G. Krishnamoorthy, A. Palmeri, S. Parker, W. Saucedo, J. Schoch, P. Tallman, D. Witt, D. Hasselblad, V Ortel, T. L. CA BRIDGE Study Investigators TI Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial) SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Douketis, J.] St Josephs Healthcare, Hamilton, ON, Canada. [Douketis, J.; Turpie, A. G.] McMaster Univ, Hamilton, ON, Canada. [Spyropoulos, A.; Ortel, T. L.] Lenox Hill Hosp, North Shore LIJ Hlth Syst, Hofstra North Shore LIJ Sch Med, New York, NY 10021 USA. [Kaatz, S.; Ortel, T. L.] Hurley Med Ctr, Flint, MI USA. [Caprini, J.] North Shore Univ Hlth Syst, New York, NY USA. [Dunn, A.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Garcia, D.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Jacobson, A.] VA Loma Linda Healthcare Syst, Loma Linda, CA USA. [Jaffer, A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Kindzelski, A.] NHLBI, Bethesda, MD 20892 USA. [Schulman, S.] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada. [Becker, R.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Clark, N. P.] Kaiser Permanente Colorado, Lafayette, CO USA. [Conti, B.] Owen Sound Family Hlth Team, Owen Sound, ON, Canada. [Ellsworth, S.] Henry Ford Hosp, Detroit, MI 48202 USA. [Harrison, R. W.; Kong, D.; Krishnamoorthy, A.; Parker, W.; Hasselblad, V] Duke Univ, Durham, NC USA. [Johnson, G.] Univ Minnesota, Minneapolis, MN USA. [Palmeri, S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Saucedo, J.] NorthShore Univ HealthSyst, New York, NY USA. [Schoch, P.] US Dept Vet Affairs, Washington, DC USA. [Witt, D.] Univ Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA LB002 BP 83 EP 84 PG 2 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901228 ER PT J AU Hu, Z Huarng, M Menegatti, M Reyon, D Liu, Y Richter, C Joung, JK Peyvandi, F Shavit, J AF Hu, Z. Huarng, M. Menegatti, M. Reyon, D. Liu, Y. Richter, C. Joung, Keith J. Peyvandi, F. Shavit, J. TI Genome editing of factor X in zebrafish reveals unexpected early survival and late onset hemorrhage SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Hu, Z.; Huarng, M.; Liu, Y.; Richter, C.; Shavit, J.] Univ Michigan, Pediat, Ann Arbor, MI 48109 USA. [Menegatti, M.] Univ Milan, Pathophysiol & Transplantat, Milan, Italy. [Reyon, D.; Joung, Keith J.] Massachusetts Gen Hosp, Pathol, Charlestown, MA USA. [Peyvandi, F.] Fdn IRCCS Ca Granda, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA OR039 BP 108 EP 108 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901289 ER PT J AU Morange, PE Germain, M Tang, W Kabrhel, C Reitsma, P Heit, J Chasman, D Tregouet, D Rosendaal, F Smith, N AF Morange, P-E Germain, M. Tang, W. Kabrhel, C. Reitsma, P. Heit, J. Chasman, D. Tregouet, D. Rosendaal, F. Smith, N. CA INVENT Consortium TI Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two new susceptibility loci for venous thromboembolism SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Morange, P-E] Aix Marseille Univ, INSERM, Nutr Obes & Risk Thrombosis, UMR S 1062, Marseille, 02115, France. [Morange, P-E] La Timone Hosp, Haematol Lab, Marseille, France. [Germain, M.; Tregouet, D.] Inst Cardiometab & Nutr ICAN, Paris, France. [Germain, M.; Tregouet, D.] Univ Paris 06, Sorbonne Univ, Team Genom & Pathophysiol Cardiovasc Dis, UMR S 1166, Paris, France. [Germain, M.] INSERM, UMR S 1166, Paris, 98195, France. [Tang, W.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 98195 USA. [Kabrhel, C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med,Channing Network Med, Boston, MA 98195 USA. [Reitsma, P.] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Einthoven Lab Expt Vasc Med, Leiden, Netherlands. [Heit, J.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [Chasman, D.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA. [Chasman, D.] Harvard Univ, Sch Med, Boston, MA USA. [Tregouet, D.] UMR S 1166, Paris, France. [Rosendaal, F.] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Leiden, Netherlands. [Smith, N.] Univ Washington, Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA. [Smith, N.] Univ Washington, Seattle Epidemiol Res & Informat Ctr, VA Off Res & Dev, Seattle, WA USA. [Smith, N.] Univ Washington, Dept Epidemiol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA OR266 BP 197 EP 197 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901515 ER PT J AU Goldhaber, SZ Ageno, W Casella, I Han, CK Raskob, G Schellong, S Singer, DE Shash, D Desch, M Schulman, S AF Goldhaber, S. Z. Ageno, W. Casella, I Han, Kok C. Raskob, G. Schellong, S. Singer, D. E. Shash, D. Desch, M. Schulman, S. TI A global prospective cohort study of dabigatran for the treatment of venous thromboembolism (re-covery) SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Goldhaber, S. Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiovasc Div, Boston, MA 02115 USA. [Ageno, W.] Univ Insubria, Dept Clin Med, Varese, Italy. [Casella, I] Univ Sao Paulo, Dept Cirurgia, Sao Paulo, Brazil. [Han, Kok C.] Univ Malaya, Dept Med, Kuala Lumpur, Malaysia. [Raskob, G.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Norman, OK 73019 USA. [Schellong, S.] Municipal Hosp Friedrichstadt, Internal Med Dept 2, Dresden, Germany. [Singer, D. E.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Shash, D.; Desch, M.] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. [Schulman, S.] McMaster Univ, Dept Med, Hamilton, ON, Canada. NR 0 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO613-TUE BP 729 EP 729 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426904329 ER PT J AU Thalin, C Demers, M Blomgren, B Laska, AC von Arbin, M Wallen, H Wagner, D Aspberg, S AF Thalin, C. Demers, M. Blomgren, B. Laska, A. C. von Arbin, M. Wallen, H. Wagner, D. Aspberg, S. TI Cancer inducing netosis promotes widespread arterial thrombosis presenting as ischemic stroke with troponin elevation SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Thalin, C.; Laska, A. C.; von Arbin, M.; Wallen, H.; Aspberg, S.] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden. [Demers, M.; Wagner, D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Demers, M.; Wagner, D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Blomgren, B.] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden. [Wagner, D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO171-WED BP 814 EP 814 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426905010 ER PT J AU Liu, B Grabowski, EF Grabowski, PE Gunnarsson, P Ezban, M AF Liu, B. Grabowski, E. F. Grabowski, P. E. Gunnarsson, P. Ezban, M. TI Recombinant FVIII and FVIIA co-localize with platelet aggregates adherent to a collagen surface exposed for flowing normal or hemophiliac blood, and promote local fibrin deposition SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Liu, B.; Grabowski, E. F.] Massachusetts Gen Hosp, Pediat Hematol Oncol, Boston, MA 02114 USA. [Grabowski, P. E.] Univ Calif Irvine, Phys, Irvine, CA USA. [Gunnarsson, P.; Ezban, M.] Novo Nordisk, Copenhagen, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO463-WED BP 919 EP 919 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426905301 ER PT J AU Marshall, A Levine, M Howell, M Chang, Y Riklin, E Parry, BA Callahan, RT Okechukwu, I Ayres, AM Nahed, BV Dzik, W Goldstein, J AF Marshall, A. Levine, M. Howell, M. Chang, Y. Riklin, E. Parry, B. A. Callahan, R. T. Okechukwu, I Ayres, A. M. Nahed, B., V Dzik, W. Goldstein, J. TI Dose-related pulmonary complication rates after fresh frozen plasma administration for warfarin reversal SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Marshall, A.; Dzik, W.] Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA. [Marshall, A.] Dana Farber Canc Inst, Dept Hematol & Med Oncol, Boston, MA 02115 USA. [Levine, M.] Univ So Calif, Dept Emergency Med, Los Angeles, CA USA. [Howell, M.; Chang, Y.; Riklin, E.; Parry, B. A.; Callahan, R. T.; Okechukwu, I; Ayres, A. M.; Goldstein, J.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Nahed, B., V] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO601-WED BP 969 EP 969 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426905439 ER PT J AU Dzik, WH AF Dzik, W. H. TI Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Review DE Beriplex PN; factor Xa inhibitors; PER977; prothrombin complex concentrates; rivaroxaban ID PLACEBO-CONTROLLED TRIAL; IN-VITRO; INDUCED ANTICOAGULATION; THROMBIN GENERATION; UNIVERSAL ANTIDOTE; DOUBLE-BLIND; RIVAROXABAN; MANAGEMENT; DABIGATRAN; AGENTS AB Oral factor Xa inhibitors are an attractive class of anticoagulants expected to have broad application. Rapid and reliable reversal of the anticoagulant effect is important for patients with bleeding complications or those in need of urgent reversal for procedures. While no specific reversal agent is yet available, multiple published clinical guidelines suggest that four-factor prothrombin complex concentrates (PCC) should be considered when urgent reversal is desired. This presentation updates prior reviews on this topic (Crit Care, 17, 2013, 230; Thromb Haemost, 111, 2014, 189; J Thromb Thrombolysis, 2015, 39, 395); and summarizes more recent evidence in human studies indicating that four-factor PCCs available in North America do not reverse oral factor Xa-inhibitor anticoagulants. New agents on the horizon appear to be far more promising as therapies for reversal or oral factor Xa inhibitors. C1 Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA. RP Dzik, WH (reprint author), Massachusetts Gen Hosp, Blood Transfus Serv, Room J-224,55 Fruit St, Boston, MA 02114 USA. EM sdzik@partners.org NR 29 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 1 SI SI BP S187 EP S194 DI 10.1111/jth.12949 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CL1BN UT WOS:000356677500025 PM 26149022 ER PT J AU Pereira, SDA Santo, MPD Lauer, GM Lampe, E Ximenez, LLL AF Pereira, S. D. A. do Espirito Santo, M. P. Lauer, G. M. Lampe, E. Ximenez, L. L. L. TI An evolutionary approach of interspousal transmission of Hepatitis C Virus infection SO JOURNAL OF VIRAL HEPATITIS LA English DT Meeting Abstract CT 15th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) CY JUN 26-28, 2015 CL Berlin, GERMANY C1 [Pereira, S. D. A.; do Espirito Santo, M. P.; Lampe, E.; Ximenez, L. L. L.] Inst Oswaldo Cruz, Viral Hepatitis, BR-20001 Rio De Janeiro, Brazil. [Lauer, G. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lauer, G. M.] Harvard Univ, Sch Med, Gastrointestinal Unit, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JUN PY 2015 VL 22 SU 2 SI SI MA P123 BP 83 EP 83 DI 10.1111/jvh.117_12425 PG 1 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA CL3XB UT WOS:000356884200149 ER PT J AU Adoro, S Cubillos-Ruiz, JR Chen, X Deruaz, M Vrbanac, VD Song, M Park, S Murooka, TT Dudek, TE Luster, AD Tager, AM Streeck, H Bowman, B Walker, BD Kwon, DS Lazarevic, V Glimcher, LH AF Adoro, Stanley Cubillos-Ruiz, Juan R. Chen, Xi Deruaz, Maud Vrbanac, Vladimir D. Song, Minkyung Park, Suna Murooka, Thomas T. Dudek, Timothy E. Luster, Andrew D. Tager, Andrew M. Streeck, Hendrik Bowman, Brittany Walker, Bruce D. Kwon, Douglas S. Lazarevic, Vanja Glimcher, Laurie H. TI IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection SO NATURE COMMUNICATIONS LA English DT Article ID CHRONIC VIRAL-INFECTION; IN-VIVO; TRANSCRIPTION FACTORS; REPLICATION CAPACITY; CELLULAR MICRORNA; HUMANIZED MICE; EXPRESSION; DEPLETION; TRANSMISSION; RESPONSES AB Initial events after exposure determine HIV-1 disease progression, underscoring a critical need to understand host mechanisms that interfere with initial viral replication. Although associated with chronic HIV-1 control, it is not known whether interleukin-21 (IL-21) contributes to early HIV-1 immunity. Here we take advantage of tractable primary human lymphoid organ aggregate cultures to show that IL-21 directly suppresses HIV-1 replication, and identify microRNA-29 (miR-29) as an antiviral factor induced by IL-21 in CD4 T cells. IL-21 promotes transcription of all miR-29 species through STAT3, whose binding to putative regulatory regions within the MIR29 gene is enriched by IL-21 signalling. Notably, exogenous IL-21 limits early HIV-1 infection in humanized mice, and lower viremia in vivo is associated with higher miR-29 expression. Together, these findings reveal a novel antiviral IL-21-miR-29 axis that promotes CD4 T-cell-intrinsic resistance to HIV-1 infection, and suggest a role for IL-21 in initial HIV-1 control in vivo. C1 [Adoro, Stanley; Cubillos-Ruiz, Juan R.; Chen, Xi; Song, Minkyung; Park, Suna; Glimcher, Laurie H.] Cornell Univ, Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA. [Adoro, Stanley; Cubillos-Ruiz, Juan R.; Vrbanac, Vladimir D.; Dudek, Timothy E.; Tager, Andrew M.; Bowman, Brittany; Walker, Bruce D.; Kwon, Douglas S.; Glimcher, Laurie H.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA. [Deruaz, Maud; Vrbanac, Vladimir D.; Murooka, Thomas T.; Luster, Andrew D.; Tager, Andrew M.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. [Streeck, Hendrik] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Biol, D-45147 Essen, Germany. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20814 USA. [Lazarevic, Vanja] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA. RP Glimcher, LH (reprint author), Cornell Univ, Weill Cornell Med Coll, Dept Med, 1300 York Ave, New York, NY 10065 USA. EM lglimche@med.cornell.edu OI Chen, Xi/0000-0002-7995-6202 FU Ragon Institute of MGH, MIT and Harvard; CFAR Scholar Award; Ragon Institute; Harvard University Center for AIDS Research [NIAID P30AI060354]; National Institutes of Allergy and Infectious Disease [1R21AI087475-01] FX We thank Fabio Martinon, Matthew Greenblatt and Sarah Bettigole for critical reading of the manuscript and helpful discussions; John Moore and Thomas Ketas (Weill Cornell Medical College) for providing primary HIV-1 isolates, HIV-1NL4-3 and HIV-1NL4-3-luciferase virus supernatants. S.A., J.R.C-R. and M.D. were supported by Postdoctoral Fellowship Awards from the Ragon Institute of MGH, MIT and Harvard. T.T.M. was supported by the CFAR Scholar Award. The MGH Humanized Mouse Program (V.D.V., A.D.L. and A.M.T.) was supported by a Platform Award from the Ragon Institute and the Harvard University Center for AIDS Research grant NIAID P30AI060354. This study was supported by grants from the National Institutes of Allergy and Infectious Disease (1R21AI087475-01) and the Ragon Institute of MGH, MIT and Harvard to L.H.G. NR 67 TC 6 Z9 6 U1 3 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2015 VL 6 AR 7562 DI 10.1038/ncomms8562 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL7VS UT WOS:000357180800001 PM 26108174 ER PT J AU Mikucki, ME Fisher, DT Matsuzaki, J Skitzki, JJ Gaulin, NB Muhitch, JB Ku, AW Frelinger, JG Odunsi, K Gajewski, TF Luster, AD Evans, SS AF Mikucki, M. E. Fisher, D. T. Matsuzaki, J. Skitzki, J. J. Gaulin, N. B. Muhitch, J. B. Ku, A. W. Frelinger, J. G. Odunsi, K. Gajewski, T. F. Luster, A. D. Evans, S. S. TI Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints SO NATURE COMMUNICATIONS LA English DT Article ID INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; INDUCIBLE PROTEIN-10; CHEMOKINE GRADIENTS; ANTITUMOR IMMUNITY; MELANOMA PATIENTS; DENDRITIC CELLS; EFFECTOR-CELLS; CANCER MODEL; LYMPH-NODE AB T-cell trafficking at vascular sites has emerged as a key step in antitumour immunity. Chemokines are credited with guiding the multistep recruitment of CD8(+) T cells across tumour vessels. However, the multiplicity of chemokines within tumours has obscured the contributions of individual chemokine receptor/chemokine pairs to this process. Moreover, recent studies have challenged whether T cells require chemokine receptor signalling at effector sites. Here we investigate the hierarchy of chemokine receptor requirements during T-cell trafficking to murine and human melanoma. These studies reveal a non-redundant role for G(alpha i)-coupled CXCR3 in stabilizing intravascular adhesion and extravasation of adoptively transferred CD8(+) effectors that is indispensable for therapeutic efficacy. In contrast, functional CCR2 and CCR5 on CD8(+) effectors fail to support trafficking despite the presence of intratumoral cognate chemokines. Taken together, these studies identify CXCR3-mediated trafficking at the tumour vascular interface as a critical checkpoint to effective T-cell-based cancer immunotherapy. C1 [Mikucki, M. E.; Fisher, D. T.; Skitzki, J. J.; Gaulin, N. B.; Muhitch, J. B.; Ku, A. W.; Evans, S. S.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA. [Matsuzaki, J.; Odunsi, K.] Roswell Pk Canc Inst, Ctr Immunotherapy, Buffalo, NY 14263 USA. [Skitzki, J. J.] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA. [Frelinger, J. G.] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Frelinger, J. G.] Wilmot Canc Ctr, Rochester, NY 14642 USA. [Odunsi, K.] Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA. [Gajewski, T. F.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Gajewski, T. F.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Gajewski, T. F.] Univ Chicago, Comprehens Canc Ctr & Comm Immunol, Chicago, IL 60637 USA. [Luster, A. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02114 USA. RP Evans, SS (reprint author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton Str, Buffalo, NY 14263 USA. EM sharon.evans@roswellpark.org FU NIH [CA79765, AI082039, T32 CA085183, 1F30 CA177210, CA069212, CA127475, CA158318-01A1]; RPCI-UPCI Ovarian Cancer [SPORE P50CA159981-01A1]; Joanna M. Nicolay Foundation; University at Buffalo Mark Diamond Research Fund; Jennifer Linscott Tietgen Family Foundation; Roswell Park/Wilmot Collaborative Grant FX We thank K. Curry for technical assistance on transwell assays; S. Kaufman for isolating peripheral blood-derived mononuclear cell from normal human donors; R. Dolnick, K. de Jong and J. Tario, Jr. for assistance with flow cytometry and Luminex assays; M. Appenheimer for critical reading of the manuscript; and D. Mullins (Geisel School of Medicine at Dartmouth) for guidance on CXCR3-blocking Ab and helpful discussion. This work was supported by the NIH (CA79765 and AI082039 to S.S.E., T32 CA085183 and 1F30 CA177210 to M.E.M., CA069212 to A.D.L., CA127475 to T.G., CA158318-01A1 to K.O. and the RPCI-UPCI Ovarian Cancer SPORE P50CA159981-01A1 to K.O. and J.M.), the Joanna M. Nicolay Foundation and the University at Buffalo Mark Diamond Research Fund to M.E.M, the Jennifer Linscott Tietgen Family Foundation to S.S.E. and J.J.S., and the Roswell Park/Wilmot Collaborative Grant to S.S.E. and J.F. NR 70 TC 19 Z9 19 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2015 VL 6 AR 7458 DI 10.1038/ncomms8458 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL7UO UT WOS:000357177400002 PM 26109379 ER PT J AU Rogers, JM Barrera, LA Reyon, D Sander, JD Kellis, M Joung, JK Bulyk, ML AF Rogers, Julia M. Barrera, Luis A. Reyon, Deepak Sander, Jeffry D. Kellis, Manolis Joung, J. Keith Bulyk, Martha L. TI Context influences on TALE-DNA binding revealed by quantitative profiling SO NATURE COMMUNICATIONS LA English DT Article ID TRANSCRIPTION FACTORS; TARGET SPECIFICITY; EFFECTORS; MICROARRAYS; RECOGNITION; EXPRESSION; NUCLEASES; ACTIVATION; CLEAVAGE; COMPLEX AB Transcription activator-like effector (TALE) proteins recognize DNA using a seemingly simple DNA-binding code, which makes them attractive for use in genome engineering technologies that require precise targeting. Although this code is used successfully to design TALEs to target specific sequences, off-target binding has been observed and is difficult to predict. Here we explore TALE-DNA interactions comprehensively by quantitatively assaying the DNA-binding specificities of 21 representative TALEs to similar to 5,000-20,000 unique DNA sequences per protein using custom-designed protein-binding microarrays (PBMs). We find that protein context features exert significant influences on binding. Thus, the canonical recognition code does not fully capture the complexity of TALE-DNA binding. We used the PBM data to develop a computational model, Specificity Inference For TAL-Effector Design (SIFTED), to predict the DNA-binding specificity of any TALE. We provide SIFTED as a publicly available web tool that predicts potential genomic off-target sites for improved TALE design. C1 [Rogers, Julia M.; Barrera, Luis A.; Bulyk, Martha L.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA. [Rogers, Julia M.; Barrera, Luis A.; Bulyk, Martha L.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rogers, Julia M.; Barrera, Luis A.; Bulyk, Martha L.] Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA. [Barrera, Luis A.; Bulyk, Martha L.] Harvard Univ, Harvard MIT Div Hlth Sci & Technol HST, Sch Med, Boston, MA 02115 USA. [Barrera, Luis A.; Kellis, Manolis] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Reyon, Deepak; Sander, Jeffry D.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Reyon, Deepak; Sander, Jeffry D.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA. [Reyon, Deepak; Sander, Jeffry D.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Reyon, Deepak; Sander, Jeffry D.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Bulyk, Martha L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Bulyk, ML (reprint author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA. EM mlbulyk@receptor.med.harvard.edu FU NCCDPHP CDC HHS [DP1 GM105378]; NHGRI NIH HHS [R01 HG004037, T32 HG002295, R21 HG007573]; NIGMS NIH HHS [R01 GM113708, DP1 GM105378] NR 47 TC 2 Z9 2 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2015 VL 6 AR 7440 DI 10.1038/ncomms8440 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL7UH UT WOS:000357176700006 PM 26067805 ER PT J AU Sedic, M Skibinski, A Brown, N Gallardo, M Mulligan, P Martinez, P Keller, PJ Glover, E Richardson, AL Cowan, J Toland, AE Ravichandran, K Riethman, H Naber, SP Naar, AM Blasco, MA Hinds, PW Kuperwasser, C AF Sedic, Maja Skibinski, Adam Brown, Nelson Gallardo, Mercedes Mulligan, Peter Martinez, Paula Keller, Patricia J. Glover, Eugene Richardson, Andrea L. Cowan, Janet Toland, Amanda E. Ravichandran, Krithika Riethman, Harold Naber, Stephen P. Naeaer, Anders M. Blasco, Maria A. Hinds, Philip W. Kuperwasser, Charlotte TI Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence SO NATURE COMMUNICATIONS LA English DT Article ID MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; DNA-DAMAGE; TELOMERE DYSFUNCTION; TUMOR-SUPPRESSOR; DEPENDENT SENESCENCE; RETINOBLASTOMA GENE; MUTATION CARRIERS; LIFE-SPAN; EXPRESSION AB Although BRCA1 function is essential for maintaining genomic integrity in all cell types, it is unclear why increased risk of cancer in individuals harbouring deleterious mutations in BRCA1 is restricted to only a select few tissues. Here we show that human mammary epithelial cells (HMECs) from BRCA1-mutation carriers (BRCA1(mut/+)) exhibit increased genomic instability and rapid telomere erosion in the absence of tumour-suppressor loss. Furthermore, we uncover a novel form of haploinsufficiency-induced senescence (HIS) specific to epithelial cells, which is triggered by pRb pathway activation rather than p53 induction. HIS and telomere erosion in HMECs correlate with misregulation of SIRT1 leading to increased levels of acetylated pRb as well as acetylated H4K16 both globally and at telomeric regions. These results identify a novel form of cellular senescence and provide a potential molecular basis for the rapid cell- and tissue- specific predisposition of breast cancer development associated with BRCA1 haploinsufficiency. C1 [Sedic, Maja; Skibinski, Adam; Glover, Eugene; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA. [Sedic, Maja; Skibinski, Adam; Brown, Nelson; Keller, Patricia J.; Glover, Eugene; Hinds, Philip W.; Kuperwasser, Charlotte] Mol Oncol Res Inst, Tufts Med Ctr, Boston, MA 02111 USA. [Gallardo, Mercedes; Martinez, Paula; Blasco, Maria A.] Spanish Natl Canc Ctr, Telomeres & Telomerase Grp, E-28029 Madrid, Spain. [Mulligan, Peter; Naeaer, Anders M.] Harvard Univ, Sch Med, Dept Cell Biol, Charlestown, MA 02129 USA. [Mulligan, Peter; Naeaer, Anders M.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Richardson, Andrea L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Cowan, Janet; Naber, Stephen P.] Tufts Med Ctr, Dept Pathol, Boston, MA 02111 USA. [Toland, Amanda E.] Ohio State Univ, Dept Internal Med, Dept Mol Virol Immunol & Med Genet, Div Human Genet, Columbus, OH 43210 USA. [Ravichandran, Krithika; Riethman, Harold] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA. RP Kuperwasser, C (reprint author), Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Program Cell Mol & Dev Biol, 136 Harrison Ave, Boston, MA 02111 USA. EM Charlotte.Kuperwasser@tufts.edu OI Blasco, Maria A./0000-0002-4211-233X FU Raymond and Beverly Sackler Foundation; Breast Cancer Research Foundation; Silvian Foundation; NIH/NCI [CA125554, CA092644]; ERC Project Project TEL STEM CELL; FP7 Projects MARK-AGE; EuroBATS; Spanish Ministry of Economy and Competitiveness [SAF2008-05384, CSD2007-00017]; Regional of Government of Madrid Project [S2010/BMD-2303]; AXA Research Fund; Fundacion Botin (Spain); Fundacion Lilly (Spain) FX This work was supported by grants from the Raymond and Beverly Sackler Foundation (M.S.), the Breast Cancer Research Foundation (B.K. and C.K.), the Silvian Foundation (C.K. and A.S.) and the NIH/NCI CA125554 (C.K.), CA092644 (C.K.). Research in the Blasco laboratory was funded by ERC Project Project TEL STEM CELL, FP7 Projects MARK-AGE and EuroBATS, Spanish Ministry of Economy and Competitiveness Projects SAF2008-05384 and CSD2007-00017, Regional of Government of Madrid Project S2010/BMD-2303, AXA Research Fund, Fundacion Botin (Spain) and Fundacion Lilly (Spain). We thank members of the Kuperwasser laboratory for valuable discussions as well as Benjamin Dake, Sarah Phillips and Agueda Tejera for their help with experiments. NR 70 TC 17 Z9 18 U1 4 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2015 VL 6 AR 7505 DI 10.1038/ncomms8505 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL7UZ UT WOS:000357178600003 PM 26106036 ER PT J AU Miravitlles, M Anzueto, A AF Miravitlles, Marc Anzueto, Antonio TI Antibiotic prophylaxis in COPD: Why, when, and for whom? SO PULMONARY PHARMACOLOGY & THERAPEUTICS LA English DT Article DE COPD; Bronchial colonization; Antibiotics; Prophylaxis; macrolides; Quinolones ID OBSTRUCTIVE PULMONARY-DISEASE; CONTROLLED-TRIAL; EXACERBATIONS; PREVENTION; INFECTION; AIRWAY; AZITHROMYCIN; ERYTHROMYCIN; THERAPY; MOXIFLOXACIN AB One of the main goals of treatment of chronic obstructive pulmonary disease (COPD) is the prevention of exacerbations. Bronchodilators and anti-inflammatories are the first line therapy for treatment of COPD; however, these drugs are not effective in suppressing all infective exacerbations. In fact, the use of inhaled corticosteroids in patients with COPD and chronic bronchial infection may even increase the bacterial load in the airways and increase the risk of pneumonia. In this context, the use of long-term or intermittent antibiotic treatment has shown to prevent COPD exacerbations and hospitalizations. These effects may be achieved by reducing bacterial load in the airways in stable state and/or bronchial inflammation. The drugs more extensively studied are macrolides, followed by quinolones. The long-term use of antibiotics is associated with an increased risk of potentially serious adverse events and development of bacterial resistance. Therefore, the indication of long-term antibiotic therapy must be determined on a case by case basis taking into account the potential risks and benefits. In general, this treatment may be indicated in patients with severe or very severe COPD with frequent or severe exacerbations despite optimal pharmacological and non pharmacological treatment. These patients should be carefully monitored based on clinical and microbiological assessments. The most appropriate drug and regime administration, as well as the optimal duration of therapy are issues that still require further investigation. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Miravitlles, Marc] Hosp Univ Vall dHebron, Dept Pneumol, ES-08035 Barcelona, Spain. [Miravitlles, Marc] Ciber Enfermedades Resp CIBERES, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, San Antonio, TX USA. RP Miravitlles, M (reprint author), Hosp Univ Vall dHebron, Dept Pneumol, P Vall dHebron 119-129, ES-08035 Barcelona, Spain. EM mmiravitlles@vhebron.net OI Miravitlles, Marc/0000-0002-9850-9520 NR 42 TC 3 Z9 3 U1 1 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1094-5539 J9 PULM PHARMACOL THER JI Pulm. Pharmacol. Ther. PD JUN PY 2015 VL 32 BP 119 EP 123 DI 10.1016/j.pupt.2014.05.002 PG 5 WC Pharmacology & Pharmacy; Respiratory System SC Pharmacology & Pharmacy; Respiratory System GA CL5HL UT WOS:000356990300015 PM 24825753 ER PT J AU Zhang, TJ Walensky, LD Saghatelian, A AF Zhang, Tejia Walensky, Loren D. Saghatelian, Alan TI A Nonapoptotic Role for BAX and BAK in Eicosanoid Metabolism SO ACS CHEMICAL BIOLOGY LA English DT Article ID PROSTACYCLIN; APOPTOSIS; BCL-2; MITOCHONDRIA; INFLAMMATION; FIBROBLASTS; RECEPTORS; PROTEINS; KINETICS; BIOLOGY AB BCL-2 proteins are key regulators of programmed cell death. The interplay between pro and antiapoptotic BCL-2 members has important roles in many cancers. In addition to their apoptotic function, recent evidence supports key, nonapoptotic roles for several BCL-2 proteins: We used an unbiased lipidomics strategy to reveal that the proapoptotic proteins BAX, and to a lesser extent BAK, regulate the cellular inflammatory response by mediating COX-2 expression and prostaglandin biosynthesis: COX-2 upregulation in response to the bacterial endotoxin lipopolysaccharide is blunted in the absence of BAX, and Bax(-/-) Mouse embryonic fibroblasts display altered kinetics of NF kappa B and MAPK. signaling following: endotoxin treatment.; Our approach uncovers a novel, nonapoptotic function for BAX in regulation of the cellular inflammatory response and suggests that inflammation and apoptosis are more tightly connected than previously anticipated. C1 [Zhang, Tejia; Saghatelian, Alan] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA. [Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Walensky, Loren D.] Harvard Univ, Boston Childrens Hosp, Sch Med, Boston, MA 02215 USA. [Walensky, Loren D.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Linde Program Canc Chem Biol, Boston, MA 02215 USA. RP Saghatelian, A (reprint author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM asaghatelian@salk.edu FU Burroughs Wellcome Fund Award; Harvard Startup Fund; Searle Scholars Award; Lilly Fellowship; NIH [5R01CA050239] FX We thank members of the Saghatelian and Walensky research groups for general technical guidance and fruitful discussions. This research is supported by a Burroughs Wellcome Fund Award, Harvard Startup Fund, Searle Scholars Award and Lilly Fellowship (A.S.), and NIH Grant 5R01CA050239 (L.D.W.). NR 28 TC 1 Z9 1 U1 4 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD JUN PY 2015 VL 10 IS 6 BP 1398 EP 1403 DI 10.1021/acschembio.5b00168 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CL3JE UT WOS:000356845400006 PM 25815636 ER PT J AU Blashill, AJ Bedoya, CA Mayer, KH O'Cleirigh, C Pinkston, MM Remmert, JE Mimiaga, MJ Safren, SA AF Blashill, Aaron J. Bedoya, C. Andres Mayer, Kenneth H. O'Cleirigh, Conall Pinkston, Megan M. Remmert, Jocelyn E. Mimiaga, Matthew J. Safren, Steven A. TI Psychosocial Syndemics are Additively Associated with Worse ART Adherence in HIV-Infected Individuals SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Adherence; Syndemics; Comorbidity; ART; Antiretroviral therapy ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; DEPRESSION CBT-AD; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; HEALTH-PROBLEMS; MENTAL-HEALTH; DSM-IV; MINI AB Adherence to antiretroviral therapy (ART) among HIV-infected individuals is necessary to both individual and public health, and psychosocial problems have independently been associated with poor adherence. To date, studies have not systematically examined the effect of multiple, co-occurring psychosocial problems (i.e., "syndemics'') on ART adherence. Participants included 333 HIV-infected individuals who completed a comprehensive baseline evaluation, as part of a clinical trial to evaluate an intervention to treat depression and optimize medication adherence. Participants completed self-report questionnaires, and trained clinicians completed semi-structured diagnostic interviews. ART non-adherence was objectively measured via an electronic pill cap (i.e., MEMS). As individuals reported a greater number of syndemic indicators, their odds of non-adherence increased. Co-occurring psychosocial problems have an additive effect on the risk for poor ART adherence. Future behavioral medicine interventions are needed that address these problems comprehensively, and/or the core mechanisms that they share. C1 [Blashill, Aaron J.; Bedoya, C. Andres; O'Cleirigh, Conall; Remmert, Jocelyn E.; Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Blashill, Aaron J.; Bedoya, C. Andres; Mayer, Kenneth H.; O'Cleirigh, Conall; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA. [Blashill, Aaron J.; Mayer, Kenneth H.; O'Cleirigh, Conall; Mimiaga, Matthew J.; Safren, Steven A.] Fenway Inst, Boston, MA USA. [Mayer, Kenneth H.; Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Pinkston, Megan M.] Brown Med Sch, Providence, RI USA. [Pinkston, Megan M.] Miriam Hosp, Providence, RI 02906 USA. RP Blashill, AJ (reprint author), One Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM Ablashill@mgh.harvard.edu RI Bedoya, Cristina/K-8066-2014 OI Bedoya, Cristina/0000-0001-8057-9152 FU National Institute of Mental Health [R01MH084757]; NIMH [K24MH094214, K23MH096647] FX This research was supported by the National Institute of Mental Health, Grant R01MH084757, awarded to Dr. Steven A. Safren, NIMH K24MH094214 awarded to Dr. Safren, and NIMH K23MH096647 awarded to Dr. Aaron Blashill. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 32 TC 7 Z9 7 U1 3 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2015 VL 19 IS 6 BP 981 EP 986 DI 10.1007/s10461-014-0925-6 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CK8WF UT WOS:000356519600005 PM 25331267 ER PT J AU Jotwani, V Shlipak, MG Scherzer, R Parekh, RS Kao, WHL Bennett, M Cohen, MH Nowicki, M Sharma, A Young, M Tien, PC Parikh, CR Estrella, MM AF Jotwani, Vasantha Shlipak, Michael G. Scherzer, Rebecca Parekh, Rulan S. Kao, W. H. Linda Bennett, Michael Cohen, Mardge H. Nowicki, Marek Sharma, Anjali Young, Mary Tien, Phyllis C. Parikh, Chirag R. Estrella, Michelle M. TI APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE APOL1 genotype; risk variant; risk allele; G1 allele; G2 allele; single-nucleotide polymorphism (SNP); albumin-creatinine ratio (ACR); proteinuria; tubular injury biomarker; apolipoprotein L1; kidney disease; renal function; glomerular injury; African American; Women's Interagency HIV Study (WIHS) ID STAGE RENAL-DISEASE; GENOME-WIDE ASSOCIATION; ALL-CAUSE MORTALITY; L1 GENE VARIANTS; AFRICAN-AMERICANS; APOLIPOPROTEIN L1; INTERAGENCY HIV; RISK VARIANTS; CARDIOVASCULAR-DISEASE; INFECTED INDIVIDUALS AB Background: APOL1 genotype is associated with advanced kidney disease in African Americans, but the pathogenic mechanisms are unclear. Here, associations of APOL1 genotype with urine biomarkers of glomerular and tubular injury and kidney function decline were evaluated. Study Design: Observational study. Setting & Participants: 431 human immunodeficiency virus (HIV)-infected African American women enrolled in Women's Interagency HIV Study (WIHS). Predictor: APOL1 genotype. Outcomes: Albumin-creatinine ratio (ACR), 4 tubular injury biomarkers (interleukin 18 [IL-18], kidney injury molecule 1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL], and alpha(1)-microglobulin [A1M]), and kidney function estimated using the CKD-EPI cystatin C equation. Measurements: Participants were genotyped for APOL1 single-nucleotide polymorphisms rs73885319 (G1 allele) and rs71785313 (G2 allele). Urine biomarkers were measured using stored samples from 1999-2000. Cystatin C was measured using serum collected at baseline and 4- and 8-year follow-ups. Results: At baseline, ACRs were higher among 47 women with 2 APOL1 risk alleles versus 384 women with 0/1 risk allele (median, 24 vs 11 mg/g; P < 0.001). Compared with women with 0/1 risk allele, women with 2 risk alleles had 104% higher ACRs (95% CI, 29-223 mg/g) and 2-fold greater risk of ACR. 30 (95% CI, 1.17-3.44) mg/g after multivariable adjustment. APOL1 genotype showed little association with urine IL-18: Cr ratio, KIM-1: Cr ratio, and NGAL: Cr ratio (estimates of -5% [95% CI, -24% to 18%], -20% [95% CI, -36% to -1%], and 10% [95% CI, -26% to 64%], respectively) or detectable urine A1M (prevalence ratio, 1.13; 95% CI, 0.65-1.97) in adjusted analyses. Compared with women with 0/1 allele, women with 2 risk alleles had faster eGFR decline, by 1.2 (95% CI, 0.2 to 2.2) mL/min/1.73 m(2) per year, and 1.7- and 3.4-fold greater rates of incident chronic kidney disease (95% CI, 1.1 to 2.5) and 10% annual eGFR decline (95% CI, 1.7 to 6.7), respectively, with minimal attenuation after adjustment for glomerular and tubular injury biomarker levels. Limitations: Results may not be generalizable to men. Conclusions: Among HIV-infected African American women, APOL1-associated kidney injury appears to localize to the glomerulus, rather than the tubules. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Jotwani, Vasantha; Shlipak, Michael G.; Scherzer, Rebecca; Tien, Phyllis C.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Jotwani, Vasantha; Shlipak, Michael G.; Scherzer, Rebecca] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Parekh, Rulan S.] Hosp Sick Children, Univ Healthy Network, Toronto, ON M5G 1X8, Canada. [Parekh, Rulan S.] Univ Toronto, Toronto, ON, Canada. [Parekh, Rulan S.; Kao, W. H. Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Bennett, Michael] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Nowicki, Marek] Univ So Calif, Dept Med, Los Angeles, CA USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis & Travel Med, Washington, DC 20007 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Sect Nephrol, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. RP Jotwani, V (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM vasantha.jotwani@ucsf.edu FU NCATS NIH HHS [UL1 TR000004, UL1 TR000454, UL1-TR000004, UL1-TR000454]; NIA NIH HHS [R01 AG034853]; NIAID NIH HHS [P30 AI027763, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI042590, U01 AI103390, U01 AI103397, U01 AI103401, U01 AI103408, U01-AI-031834, U01-AI-034989, U01-AI-034993, U01-AI-034994, U01-AI-035004, U01-AI-042590, U01-AI-103390, U01-AI-103397, U01-AI-103401, U01-AI-103408]; NICHD NIH HHS [U01 HD032632, U01-HD-032632]; NIDDK NIH HHS [1 K23DK08131, F32 DK103451, K23 DK081317] NR 51 TC 3 Z9 3 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUN PY 2015 VL 65 IS 6 BP 889 EP 898 DI 10.1053/j.ajkd.2015.02.329 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CL1TP UT WOS:000356728000013 PM 25921719 ER PT J AU Lionetti, E Gatti, S Pulvirenti, A Catassi, C AF Lionetti, Elena Gatti, Simona Pulvirenti, Alfredo Catassi, Carlo TI Celiac disease from a global perspective SO BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY LA English DT Article DE Coeliac disease; Epidemiology; Incidence; Prevalence; Screening ID PROSPECTIVE BIRTH COHORT; POPULATION-BASED COHORT; NON-HODGKIN-LYMPHOMA; TRANSGLUTAMINASE ANTIBODY; HIGH PREVALENCE; ADULT-POPULATION; NATURAL-HISTORY; SCHOOL-CHILDREN; BLOOD-DONORS; NORTH-INDIA AB Celiac disease (CD) is one of the commonest lifelong disorders in countries populated by individuals of European origin, affecting approximately 1% of the general population. This is a common disease also in North Africa, Middle East and India. The widespread diffusion of CD is not surprising given that its causal factors (HLA predisposing genotypes and consumption of gluten-containing cereals) show a worldwide distribution. Further studies are needed to quantify the incidence of CD in apparently "celiac-free" areas such as Sub-Saharan Africa and Far East. Several reports have shown that CD is increasing in frequency in different geographic areas. Genetic factors do not explain the rising incidence during the last decades; environmental or lifestyle factors may be responsible for these changes over time. The majority of patients with CD are still undiagnosed all over the world, leading to debate about the need of screening program. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Lionetti, Elena] Univ Catania, Dept Paediat, I-95124 Catania, Italy. [Gatti, Simona; Catassi, Carlo] Marche Polytechn Univ, Dept Paediat, I-60123 Ancona, Italy. [Pulvirenti, Alfredo] Univ Catania, Dept Clin & Mol Biomed, I-95124 Catania, Italy. [Catassi, Carlo] MassGen Hosp Children, Ctr Celiac Res, Div Paediat Gastroenterol & Nutr, Boston, MA 02114 USA. RP Catassi, C (reprint author), Univ Politecn Marche, Dept Pediat, Via F Corridoni 11, I-60123 Ancona, Italy. EM elenalionetti@inwind.it; simona.gatti@hotmail.it; apulvirenti@dmi.unict.it; c.catassi@univpm.it NR 81 TC 18 Z9 18 U1 6 U2 23 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6918 EI 1532-1916 J9 BEST PRACT RES CL GA JI Best Pract. Res. Clin. Gastroenterol. PD JUN PY 2015 VL 29 IS 3 BP 365 EP 379 DI 10.1016/j.bpg.2015.05.004 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CL2BL UT WOS:000356748500002 PM 26060103 ER PT J AU Wilks, MQ Normandin, MD Yuan, HS Cho, H Guo, YY Herisson, F Ayata, C Wooten, DW El Fakhri, G Josephson, L AF Wilks, Moses Q. Normandin, Marc D. Yuan, Hushan Cho, Hoonsung Guo, Yanyan Herisson, Fanny Ayata, Cenk Wooten, Dustin W. El Fakhri, Georges Josephson, Lee TI Imaging PEG-Like Nanoprobes in Tumor, Transient Ischemia, and Inflammatory Disease Models SO BIOCONJUGATE CHEMISTRY LA English DT Article ID IRON CHELATORS; RHEUMATOID-ARTHRITIS; DEFEROXAMINE; CANCER; STROKE; RAT; THIOSEMICARBAZONES; DESFERRIOXAMINE; DEFERASIROX; XENOGRAFTS AB The iron chelator deferoxamine (DFO), approved for the treatment of iron overload, has been examined as a therapeutic in a variety of conditions which iron may exacerbate. To evaluate the potential of DFO-bearing PEG-like nanoprobes (DFO-PNs) as therapeutics, we determined their pharmacokinetics (PK) in normal mice, and imaged their accumulation in a tumor model and in models of transient brain ischemia and inflammation. DFO-PNs consist of a DFO, a Cy5.5, and PEG (5 kDa or 30 kDa) attached to Lys-Cys scaffold. Tumor uptake of a [Zr-89]:DFO-PN(10) (30 kDa PEG, diameter 10 nm) was imaged by PET, surface fluorescence, and fluorescence microscopy. DFO-PN(10) was internalized by tumor cells (fluorescence microscopy) and by cultured cells (by FACS). [Zr-89]:DFO-PN(4.3) (5 kDa PEG, diameter 4.3 nm) concentrated at incision generated inflammations but not at sites of transient brain ischemia. DFO-PNs are fluorescent, PK tunable forms of DFO that might be investigated as antitumor or anti-inflammatory agents. C1 [Wilks, Moses Q.; Normandin, Marc D.; Yuan, Hushan; Guo, Yanyan; Wooten, Dustin W.; El Fakhri, Georges; Josephson, Lee] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Dept Radiol, Charlestown, MA 02129 USA. [Herisson, Fanny; Ayata, Cenk] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Josephson, Lee] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Cho, Hoonsung] Chonnam Natl Univ, Sch Mat Sci & Engn, Kwangju 500757, South Korea. RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Dept Radiol, Charlestown, MA 02129 USA. EM ljosephson@mgh.harvard.edu FU [R01 EB 117699]; [R01 EB 009691]; [T32 EB013180] FX This work was supported by R01 EB 117699 (L.J.), R01 EB 009691(L.J.), and T32 EB013180 (support for M.Q.W. and D.W.W.). NR 44 TC 1 Z9 1 U1 1 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD JUN PY 2015 VL 26 IS 6 BP 1061 EP 1069 DI 10.1021/acs.bioconjchem.5b00213 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA CL2DS UT WOS:000356754400013 PM 25971846 ER PT J AU Dauriz, M Porneala, BC Guo, XQ Bielak, LF Peyser, PA Durant, NH Carnethon, MR Bonadonna, RC Bonora, E Bowden, DW Florez, JC Fornage, M Hivert, MF Jacobs, DR Kabagambe, EK Lewis, CE Murabito, JM Rasmussen-Torvik, LJ Rich, SS Vassy, JL Yao, J Carr, JJ Kardia, SLR Siscovick, D O'Donnell, CJ Rotter, JI Dupuis, J Meigs, JB AF Dauriz, Marco Porneala, Bianca C. Guo, Xiuqing Bielak, Lawrence F. Peyser, Patricia A. Durant, Nefertiti H. Carnethon, Mercedes R. Bonadonna, Riccardo C. Bonora, Enzo Bowden, Donald W. Florez, Jose C. Fornage, Myriam Hivert, Marie-France Jacobs, David R., Jr. Kabagambe, Edmond K. Lewis, Cora E. Murabito, Joanne M. Rasmussen-Torvik, Laura J. Rich, Stephen S. Vassy, Jason L. Yao, Jie Carr, Jeffrey J. Kardia, Sharon L. R. Siscovick, David O'Donnell, Christopher J. Rotter, Jerome I. Dupuis, Josee Meigs, James B. TI Association of a 62 Variants Type 2 Diabetes Genetic Risk Score With Markers of Subclinical Atherosclerosis A Transethnic, Multicenter Study SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE cardiovascular disease; genetic association; risk assessment; type 2 diabetes mellitus ID CORONARY-ARTERY CALCIUM; GENOME-WIDE ASSOCIATION; CARDIOVASCULAR-DISEASE; YOUNG-ADULTS; SUSCEPTIBILITY LOCI; MEDIA THICKNESS; PREVALENCE; MESA; HYPERTENSION; PROGRESSION AB Background Type 2 diabetes mellitus (T2D) and cardiovascular disease share risk factors and subclinical atherosclerosis (SCA) predicts events in those with and without diabetes mellitus. T2D genetic risk may predict both T2D and SCA. We hypothesized that greater T2D genetic risk is associated with higher extent of SCA. Methods and Results In a cross-sectional analysis, including 9210 European Americans, 3773 African Americans, 1446 Hispanic Americans, and 773 Chinese Americans without known cardiovascular disease and enrolled in the Framingham Heart Study, Coronary Artery Risk Development in Young Adults, Multi-Ethnic Study of Atherosclerosis, and Genetic Epidemiology Network of Arteriopathy studies, we tested a 62 T2D-loci genetic risk score for association with measures of SCA, including coronary artery or abdominal aortic calcium score, common and internal carotid artery intima-media thickness, and ankle-brachial index. We used ancestry-stratified linear regression models, with random effects accounting for family relatedness when appropriate, applying a genetic-only (adjusted for sex) and a full SCA risk factors-adjusted model (significance, P<0.01=0.05/5, number of traits analyzed). An inverse association with coronary artery calcium score in Multi-Ethnic Study of Atherosclerosis Europeans (fully-adjusted P=0.004) and with common carotid artery intima-media thickness in the Framingham Heart Study (P=0.009) was not confirmed in other study cohorts, either separately or in meta-analysis. Secondary analyses showed no consistent associations with -cell and insulin resistance genetic risk sub-scores in the Framingham Heart Study and in the Coronary Artery Risk Development in Young Adults. Conclusions SCA does not have a major genetic component linked to a burden of 62 T2D loci identified by large genome-wide association studies. A shared T2D-SCA genetic basis, if any, might become apparent from better functional information about both T2D and cardiovascular disease risk loci. C1 [Dauriz, Marco; Porneala, Bianca C.; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA. [Florez, Jose C.; Hivert, Marie-France] Massachusetts Gen Hosp, Diabet Unit, Dept Med, Boston, MA 02114 USA. [Dauriz, Marco; Porneala, Bianca C.; Florez, Jose C.; Vassy, Jason L.; O'Donnell, Christopher J.; Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Hivert, Marie-France] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Dauriz, Marco; Bonora, Enzo] Univ Verona, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, I-37100 Verona, Italy. [Dauriz, Marco; Bonora, Enzo] Hosp Trust Verona, Verona, Italy. [Guo, Xiuqing; Yao, Jie; Carr, Jeffrey J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Bielak, Lawrence F.; Peyser, Patricia A.; Kardia, Sharon L. R.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Durant, Nefertiti H.] Univ Alabama Birmingham, Sch Med, Dept Pediat, Div Pediat & Adolescent Med, Birmingham, AL USA. [Carnethon, Mercedes R.; Rasmussen-Torvik, Laura J.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Bonadonna, Riccardo C.] Univ Parma, Sch Med, Div Endocrinol, Dept Clin & Expt Med, I-43100 Parma, Italy. [Bonadonna, Riccardo C.] AOI Parma, Parma, Italy. [Bowden, Donald W.] Wake Forest Sch Med, Ctr Diabet Res & Human Genom, Winston Salem, NC USA. [Bowden, Donald W.] Wake Forest Sch Med, Dept Biochem & Internal Med, Winston Salem, NC USA. [Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Hivert, Marie-France] Univ Sherbrooke, Dept Med, Div Endocrinol & Metab, Sherbrooke, PQ J1K 2R1, Canada. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Kabagambe, Edmond K.] Vanderbilt Univ, Dept Med, Div Epidemiol, Nashville, TN USA. [Lewis, Cora E.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA. [Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02215 USA. [Murabito, Joanne M.; O'Donnell, Christopher J.; Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA. [Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA. [Vassy, Jason L.] VA Boston Healthcare Syst, Gen Internal Med Sect, Boston, MA USA. [Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Carr, Jeffrey J.] Wake Forest Univ Hlth Sci, Dept Radiol Sci, Winston Salem, NC USA. [Siscovick, David] New York Acad Med, New York, NY USA. [O'Donnell, Christopher J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [O'Donnell, Christopher J.] Harvard Univ, Sch Med, Boston, MA USA. [Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St 9th Floor, Boston, MA 02114 USA. EM jmeigs@partners.org RI Dauriz, Marco/S-5843-2016; OI Dauriz, Marco/0000-0002-5542-5941; BONORA, Enzo/0000-0003-1074-5164; Bonadonna, Riccardo/0000-0002-9809-1005 FU University of Verona; Massachusetts General Hospital-Harvard Medical School; National Institute of Health [U01 HG006500, L30 DK089597]; National Heart, Lung and Blood Institute's (NHLBI) [N01-HC-25195]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) [R01 DK078616]; NIDDK [K24 DK080140]; NIDDK Research Career Award [K23 DK65978]; Massachusetts General Hospital Physician Scientist Development Award; Doris Duke Charitable Foundation Clinical Scientist Development Award; NHLBI; University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging; MESA; NHLBI [N01-HC-65226]; National Center for Advancing Translational Sciences, CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; National Institutes of Health from National Heart, Lung, Blood Institute [HL087660, HL100245]; [N01 HC-95159]; [N01-HC-95160]; [N01-HC-95161]; [N01-HC-95162]; [N01-HC-95163]; [N01-HC-95164]; [N01-HC-95165]; [N01-HC-95166]; [N01-HC-95167]; [N01-HC-95168]; [N01-HC-95169]; [N02-HL-64278]; [RR-024156] FX M. Dauriz was supported by research grants of the University of Verona and Massachusetts General Hospital-Harvard Medical School. J.L. Vassy was supported by U01 HG006500 and L30 DK089597 from National Institute of Health. The Framingham Heart Study: This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's (NHLBI) Framingham Heart Study (Contract No. N01-HC-25195). A portion of this research used the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Also supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to J.B. Meigs, NIDDK K24 DK080140 to J.B. Meigs, and NIDDK Research Career Award K23 DK65978, a Massachusetts General Hospital Physician Scientist Development Award, and a Doris Duke Charitable Foundation Clinical Scientist Development Award to J.C. Florez. The CARDIA Study: The CARDIA Study is conducted and supported by the NHLBI in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging. This article has been reviewed and approved by CARDIA for scientific content. The MESA Study: MESA and the MESA SHARe project are conducted and supported by the NHLBI in collaboration with MESA investigators. Support is provided by grants and contracts N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, N02-HL-64278, and RR-024156. Funding for CARe genotyping was provided by NHLBI Contract N01-HC-65226. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. We thank the participants of the MESA study, the Coordinating Center, MESA investigators, and study staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. The GENOA Study: Genetic Epidemiology Network of Arteriopathy (GENOA) study is supported by the National Institutes of Health, grant numbers HL087660 and HL100245 from National Heart, Lung, Blood Institute. We thank Eric Boerwinkle, PhD, and Megan L. Grove from the Human Genetics Center and Institute of Molecular Medicine and Division of Epidemiology, University of Texas Health Science Center, Houston, Texas, USA, and Julie Cunningham, PhD, from the Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA, for their help with genotyping.; No additional external funding was received for this study. The funders had no role in the design or preparation of the article. NR 55 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD JUN PY 2015 VL 8 IS 3 BP 507 EP 515 DI 10.1161/CIRCGENETICS.114.000740 PG 9 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA CK7NI UT WOS:000356418800011 PM 25805414 ER PT J AU Braden, GC Arbona, RR Lepherd, M Monette, S Toma, A Fox, JG Dewhirst, FE Lipman, NS AF Braden, Gillian C. Arbona, Rodolfo Ricart Lepherd, Michelle Monette, Sebastien Toma, Aziz Fox, James G. Dewhirst, Floyd E. Lipman, Neil S. TI A Novel alpha-Hemolytic Streptococcus Species (Streptococcus azizii sp nov.) Associated with Meningoencephalitis in Naive Weanling C57BL/6 Mice SO COMPARATIVE MEDICINE LA English DT Article ID IN-HOUSE TRANSPORT; RIBOSOMAL-RNA GENE; MACROPHAGE ACTIVITY; LATEST DEVELOPMENTS; CYNOMOLGUS MONKEYS; PRENATAL STRESS; SUIS; IDENTIFICATION; PATHOGENESIS; MENINGITIS AB During 1 year, experimentally naive C57BL/6NCrl weanlings born to timed-pregnant dams from a single vendor demonstrated markedly increased mortality associated with runting, abnormal gait, and decreased activity. Gram-positive, aerobic, a-hemolytic, coccoid bacteria were isolated from the meninges (n = 16), blood (n = 1), and kidneys (n = 1) of clinically affected weanlings (n = 15); from the uterus (n = 1), meninges (n = 1), and oral cavity (n = 2) of 3 dams; and from the meninges and oral cavity of a clinically affected 86-d-old mouse in the same colony. Multifocal, necrosuppurative meningoencephalitis and ventriculitis with intralesional gram-positive coccoid bacteria were present in all but 2 affected animals. The bacterium also was isolated from the oral cavity of an asymptomatic timed-pregnant dam (1 of 23) from the same vendor and from 8 mice at the vendor's facility. All isolates (n = 25) were identified by using 2 semiautomated rapid-identification systems, one of which consistently identified the causative bacterium as Aerococcus viridans 2 (n = 12) or 3 (n = 13), with probabilities of 55.7% to 98.3%. The bacterium did not grow in 6.5% NaCl at 10 degrees C, thus suggesting a Streptococcus species. Partial 16S rRNA sequencing of 4 isolates suggested S. hyointestinalis (probability, 93.4%) and S. gallinaceus (99.5%). Full 16S rRNA sequences for 3 isolates identified the bacterium as a novel Streptococcus species most closely related to S. acidominimus strain LGM (96.5%) and Streptococcus species strain Smarlab 3301444 (96.3%) and for which we propose the name S. azizii. C1 [Braden, Gillian C.; Arbona, Rodolfo Ricart; Lepherd, Michelle; Monette, Sebastien; Lipman, Neil S.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Triinst Training Program Lab Anim Med & Sci, New York, NY 10021 USA. [Braden, Gillian C.; Arbona, Rodolfo Ricart; Lepherd, Michelle; Monette, Sebastien; Toma, Aziz; Lipman, Neil S.] Rockefeller Univ, New York, NY 10021 USA. [Arbona, Rodolfo Ricart; Lepherd, Michelle; Monette, Sebastien; Toma, Aziz; Lipman, Neil S.] Mem Sloan Kettering Canc Ctr, Ctr Comparat Med & Pathol, New York, NY 10021 USA. [Arbona, Rodolfo Ricart; Lepherd, Michelle; Monette, Sebastien; Toma, Aziz; Lipman, Neil S.] Weill Cornell Med Coll, New York, NY USA. [Lepherd, Michelle; Monette, Sebastien; Toma, Aziz] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Lab Comparat Pathol, New York, NY USA. [Fox, James G.] MIT, Div Comparat Med, Cambridge, MA 02139 USA. [Dewhirst, Floyd E.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. [Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. RP Lipman, NS (reprint author), Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Triinst Training Program Lab Anim Med & Sci, New York, NY 10021 USA. EM lipmann@mskcc.org FU National Cancer Institute [P30 CA 008748] FX We thank Dr Charles Clifford (Charles River Laboratories), Drs Jeffery Lohmiller and Paula Roesch (Taconic), and Dr Robert Livingston (IDEXX RADIL) for their input. In addition, we are grateful to Weill Comell's animal care and veterinary technical staff for providing excellent care to our animals. This work was supported in part by a Core Grant from the National Cancer Institute (P30 CA 008748) to MSKCC. NR 39 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1532-0820 J9 COMPARATIVE MED JI Comparative Med. PD JUN PY 2015 VL 65 IS 3 BP 186 EP 195 PG 10 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CL7JA UT WOS:000357147100004 PM 26141443 ER PT J AU Su, ZB Oto, J Wang, JW Kimball, WR Chenelle, CT Kacmarek, RM King, DR Jiang, YD Duggans, MJ AF Su, Zhenbo Oto, Jun Wang, Jingwen Kimball, William R. Chenelle, Christopher T. Kacmarek, Robert M. King, David R. Jiang, Yandong Duggans, Michael J. TI Validation of Respiratory Inductance Plethysmography for Measuring Tidal Volume in Swine SO COMPARATIVE MEDICINE LA English DT Article ID INDUCTIVE PLETHYSMOGRAPHY; RIB CAGE; PRESSURE; VENTILATION; EFFICIENCY; INFANTS; ABDOMEN; PATTERN; SLEEP; MASK AB Measuring tidal volume (V-T) in nonintubated swine or swine with leaking breathing circuits is challenging. The aim of this study was to validate respiratory inductance plethysmography (RIP) for measuring V-T in swine that are comparable in size to adult humans. To determine calibration curves, V-T and RIP readings were obtained from anesthetized swine (n = 8; weight, 46-50 kg) during positive-pressure (mechanical) ventilation and spontaneous breathing. For positive-pressure ventilation, 6 pigs were mechanically ventilated by using the pressure-control mode. The 2 pigs in the spontaneously breathing cohort each received a single intravenous bolus dose of propofol to abolish spontaneous breathing; V-T was measured during gradual return of their respiratory drive. A flow volume sensor was placed between the proximal end of the endotracheal tube and breathing circuit for the recording of inspiratory and expiratory V-T. RIP readings were recorded by using 2 bands, which simultaneously measured ribcage and abdominal excursions. The data revealed that V-T was linearly correlated with the movements of both ribcage and abdomen as measured by using plethysmography over a large range of tidal volume (44 to 1065 mL). In addition, the intercept of the linear equation was small or even negative during spontaneous breathing but increased significantly (maximum, 145 mL, 59.2 +/- 35.1 mL) during positive pressure ventilation. Our results indicate that V-T in swine can be calculated by using a simple univariate linear regression equation with RIP readings obtained during either mechanical ventilation or spontaneous breathing. C1 [Su, Zhenbo] Jilin Univ, China Japan Union Hosp, Dept Anesthesia, Changchun 130023, Peoples R China. [Su, Zhenbo; Oto, Jun; Wang, Jingwen; Kimball, William R.; Kacmarek, Robert M.; Jiang, Yandong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Su, Zhenbo; Oto, Jun; Wang, Jingwen; Chenelle, Christopher T.; Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care Serv, Boston, MA 02114 USA. [Wang, Jingwen] Jining Med Univ, Affiliated Hosp, Dept Obstet & Gynecol, Jining, Peoples R China. [King, David R.; Duggans, Michael J.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Knight Surg Res Lab, Operat, Boston, MA 02114 USA. RP Duggans, MJ (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Knight Surg Res Lab, Operat, Boston, MA 02114 USA. EM mduggan2@partners.org FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital FX This project is funded by the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital. NR 24 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1532-0820 J9 COMPARATIVE MED JI Comparative Med. PD JUN PY 2015 VL 65 IS 3 BP 225 EP 231 PG 7 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA CL7JA UT WOS:000357147100008 PM 26141447 ER PT J AU de Boer, RA Daniels, LB Maisel, AS Januzzi, JL AF de Boer, Rudolf A. Daniels, Lori B. Maisel, Alan S. Januzzi, James L., Jr. TI State of the Art: Newer biomarkers in heart failure SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Review DE Biomarkers; Heart failure; Diagnosis; Prognosis; Monitoring ID FAMILY-MEMBER ST2; CARDIAC TROPONIN-I; GELATINASE-ASSOCIATED LIPOCALIN; ACUTE MYOCARDIAL-INFARCTION; LONG-TERM MORTALITY; RESPIRATORY-TRACT INFECTIONS; LEFT-VENTRICULAR DYSFUNCTION; HIGH-SENSITIVITY ASSAY; DWELLING OLDER-ADULTS; NATRIURETIC PEPTIDE AB Since natriuretic peptides were successfully integrated into the clinical practice of heart failure (HF), the possibility of using new biomarkers to advance the management of affected patients has been explored. While a huge number of candidate HF biomarkers have been described recently, very few have made the difficult translation from initial promise to clinical application. These markers mirror the complex pathophysiology of heart failure at various levels: cell loss (troponin), fibrosis (ST2 and galectin-3), infection (procalcitonin), and renal disease (several renal markers). In this review, we examine the best emerging candidates for clinical assessment and management of patients with HF. C1 [de Boer, Rudolf A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Daniels, Lori B.; Maisel, Alan S.] Univ Calif San Diego, Div Cardiol, La Jolla, CA 92093 USA. [Maisel, Alan S.] Vet Affairs San Diego Med Ctr, Div Cardiol, La Jolla, CA USA. [Januzzi, James L., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA. RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA. EM jjanuzzi@partners.org FU DeSanctis Clinical Scholar Endowment; Netherlands Organization for Scientific Research VIDI grant [917.13.350] FX J.L.J. is supported in part by the DeSanctis Clinical Scholar Endowment, and R.A.d.B. by a Netherlands Organization for Scientific Research VIDI grant (917.13.350). NR 109 TC 21 Z9 21 U1 5 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JUN PY 2015 VL 17 IS 6 BP 559 EP 569 DI 10.1002/ejhf.273 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CL2UC UT WOS:000356799600006 PM 25880523 ER PT J AU Kaz, AM Grady, WM Stachler, MD Bass, AJ AF Kaz, Andrew M. Grady, William M. Stachler, Matthew D. Bass, Adam J. TI Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Barrett's esophagus; Esophageal adenocarcinoma; Cancer genomics; LOH; Aneuploidy; Genomic instability; DNA methylation ID METHYLATION INHIBITS BINDING; CPG ISLAND SHORES; DNA METHYLATION; NEOPLASTIC PROGRESSION; PROMOTER HYPERMETHYLATION; EARLY EVENT; POTENTIAL BIOMARKER; CLONAL EXPANSION; POOR-PROGNOSIS; E-CADHERIN AB Esophageal adenocarcinoma (EAC) develops from Barrett's esophagus (BE), wherein normal squamous epithelia is replaced by specialized intestinal metaplasia in response to chronic gastroesophageal acid reflux. BE can progress to low- and high-grade dysplasia, intramucosal, and invasive carcinoma. Both BE and EAC are characterized by loss of heterozygosity, aneuploidy, specific genetic mutations, and clonal diversity. Given the limitations of histopathology, genomic and epigenomic analyses may improve the precision of risk stratification. Assays to detect molecular alterations associated with neoplastic progression could be used to improve the pathologic assessment of BE/EAC and to select high-risk patients for more intensive surveillance. C1 [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, R&D Dept, Seattle, WA 98109 USA. [Kaz, Andrew M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Internal Med, Seattle, WA 98195 USA. [Stachler, Matthew D.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Bass, Adam J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North,D4-100, Seattle, WA 98109 USA. EM wgrady@fhcrc.org FU National Institutes of Health (NIH) National Cancer Institute (NCI) [RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, P01CA077852, PO1CA098101]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist FX Grant Support: Support for this work was provided by National Institutes of Health (NIH) National Cancer Institute (NCI) RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, and P01CA077852 (W. M. Grady) and PO1CA098101 (A. J. Bass); and a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (W. M. Grady). NR 89 TC 3 Z9 3 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8553 EI 1558-1942 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD JUN PY 2015 VL 44 IS 2 BP 473 EP + DI 10.1016/j.gtc.2015.02.015 PG 18 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CL5KZ UT WOS:000357000100018 PM 26021206 ER PT J AU Hirschfeld, J Dommisch, H Skora, P Horvath, G Latz, E Hoerauf, A Waller, T Kawai, T Jepsen, S Deschner, J Bekeredjian-Ding, I AF Hirschfeld, Josefine Dommisch, Henrik Skora, Philipp Horvath, Gabor Latz, Eicke Hoerauf, Achim Waller, Tobias Kawai, Toshihisa Jepsen, Soren Deschner, James Bekeredjian-Ding, Isabelle TI Neutrophil extracellular trap formation in supragingival biofilms SO INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article DE Oral biofilm; Neutrophils; NET; Bacteria; Interleukin-8 ID STAPHYLOCOCCUS-AUREUS BIOFILMS; GINGIVAL CREVICULAR FLUID; HOST-DEFENSE; CATHEPSIN-G; ANTIMICROBIAL PEPTIDES; INNATE IMMUNITY; CHRONIC PERIODONTITIS; CATHELICIDIN LL-37; SALIVARY LEVELS; DISEASE AB Background: Oral biofilms are the causative agents of the highly prevalent oral diseases periodontitis and caries. Additionally, the host immune response is thought to play a critical role in disease onset. Neutrophils are known to be a key host response factor to bacterial challenge on host surfaces. Release of neutrophil extracellular traps (NETs) as a novel antimicrobial defense strategy has gained increasing attention in the past years. Here, we investigated the influx of neutrophils into the dental plaque and the ability of oral bacteria to trigger intra-biofilm release of NETs and intracellular proteins. Methods: Supragingival biofilms and whole saliva were sampled from systemically healthy subjects participating in an experimental gingivitis study. Biofilms were analysed by immunofluorescence followed by confocal and fluorescence microscopy. Moreover, concentrations of cytokines and immune-associated proteins in biofilm suspensions and saliva were assessed by ELISA. Neutrophils obtained from blood were stimulated with twelve bacterial species isolated from cultured biofilms or with lipopolysaccharide to monitor NET formation. Results: Neutrophils, NETs, neutrophil-associated proteins (myeloperoxidase, elastase-2, cathepsin G, cathelicidin LL-37), interleukin-8, interleukin-1 beta and tumor necrosis factor were detected within plaque samples and saliva. All tested bacterial species as well as the polymicrobial samples isolated from the plaque of each donor induced release of NETs and interleukin-8. The degree of NET formation varied among different subjects and did not correlate with plaque scores or clinical signs of local inflammation. Conclusions: Our findings indicate that neutrophils are attracted towards dental biofilms, in which they become incorporated and where they are stimulated by microbes to release NETs and immunostimulatory proteins. Thus, neutrophils and NETs may be involved in host biofilm control, although their specific role needs to be further elucidated. Moreover, inter-patient variability suggests NET formation as a potential factor influencing the individual course of disease. (C) 2015 Elsevier GmbH. All rights reserved. C1 [Hirschfeld, Josefine; Skora, Philipp; Waller, Tobias; Jepsen, Soren] Univ Hosp Bonn, Ctr Dent & Oral Med, Dept Periodontol Operat & Prevent Dent, D-53111 Bonn, Germany. [Dommisch, Henrik] Charite, Dept Periodontol & Synopt Dent, Inst Dent & Oral Med, D-14197 Berlin, Germany. [Dommisch, Henrik] Univ Washington, Dept Oral Hlth Sci, Seattle, WA 98195 USA. [Horvath, Gabor; Latz, Eicke] Univ Hosp Bonn, Biomed Ctr, Inst Innate Immun, D-53127 Bonn, Germany. [Hoerauf, Achim; Bekeredjian-Ding, Isabelle] Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, D-53127 Bonn, Germany. [Kawai, Toshihisa] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA. [Deschner, James] Univ Hosp Bonn, Dept Expt Dentomaxillofacial Med, Ctr Dent & Oral Med, D-53111 Bonn, Germany. [Bekeredjian-Ding, Isabelle] Paul Ehrlich Inst, Div EU Cooperat Microbiol, D-63225 Langen, Germany. RP Hirschfeld, J (reprint author), Univ Hosp Bonn, Ctr Dent & Oral Med, Dept Periodontol Operat & Prevent Dent, Welschnonnenstr 17, D-53111 Bonn, Germany. EM josefine.hirschfeld@ukb.uni-bonn.de RI Bekeredjian-Ding, Isabelle/I-6197-2013 OI Bekeredjian-Ding, Isabelle/0000-0001-6646-5888 FU German Society of Periodontology [2-RST-2013]; German Research Foundation [KFO 208/TP2/TP9]; University Hospital of Bonn; German Society of Dental and Oral Medicine FX The authors wish to thank the following contributors: all study subjects for their participation, Dr. Hatice Hasturk and Melissa Martins at the Forsyth Institute Center for Clinical and Translational Research, Cambridge, MA, USA, for their help with recruiting and taking samples from the pilot study group, the staff of the periodontal clinic of the University Hospital of Bonn for their help with implementing the experimental gingivitis study as well as Diana Lalaouni and Jutta Eich for their help collecting and processing clinical samples. Dr. Andreas Limmer for providing technical equipment and Dr. Jun-o Jin for helping to aquire and analyse confocal microscopy data. This project was funded by the German Society of Dental and Oral Medicine, German Society of Periodontology (2-RST-2013), German Research Foundation (KFO 208/TP2/TP9) and the University Hospital of Bonn. Achim Hoerauf is a member of the Excellence Cluster Immunosensation (DFG, EXC1023) and of the German Center for Infectious Diseases. NR 83 TC 4 Z9 4 U1 0 U2 15 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4221 EI 1618-0607 J9 INT J MED MICROBIOL JI Int. J. Med. Microbiol. PD JUN-AUG PY 2015 VL 305 IS 4-5 BP 453 EP 463 DI 10.1016/j.ijmm.2015.04.002 PG 11 WC Microbiology; Virology SC Microbiology; Virology GA CL1WF UT WOS:000356734900003 PM 25959370 ER PT J AU Berry, DL Blonquist, TM Patel, RA Halpenny, B McReynolds, J AF Berry, Donna L. Blonquist, Traci M. Patel, Rupa A. Halpenny, Barbara McReynolds, Justin TI Exposure to a Patient-Centered, Web-Based Intervention for Managing Cancer Symptom and Quality of Life Issues: Impact on Symptom Distress SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE patient-centered technology; cancer; symptoms; quality of life; eHealth; Internet ID RANDOMIZED CONTROLLED-TRIAL; SELF-REPORT ASSESSMENT; PROPENSITY SCORE; SUPPORT; SYSTEM; ENGAGEMENT; DEPRESSION; ADHERENCE; ONCOLOGY; CARE AB Background: Effective eHealth interventions can benefit a large number of patients with content intended to support self-care and management of both chronic and acute conditions. Even though usage statistics are easily logged in most eHealth interventions, usage or exposure has rarely been reported in trials, let alone studied in relationship to effectiveness. Objective: The intent of the study was to evaluate use of a fully automated, Web-based program, the Electronic Self Report Assessment-Cancer (ESRA-C), and how delivery and total use of the intervention may have affected cancer symptom distress. Methods: Patients at two cancer centers used ESRA-C to self-report symptom and quality of life (SxQOL) issues during therapy. Participants were randomized to ESRA-C assessment only (control) or the ESRA-C intervention delivered via the Internet to patients' homes or to a tablet at the clinic. The intervention enabled participants to self-monitor SxQOL and receive self-care education and customized coaching on how to report concerns to clinicians. Overall and voluntary intervention use were defined as having >= 2 exposures, and one non-prompted exposure to the intervention, respectively. Factors associated with intervention use were explored with Fisher's exact test. Propensity score matching was used to select a sample of control participants similar to intervention participants who used the intervention. Analysis of covariance (ANCOVA) was used to compare change in Symptom Distress Scale (SDS-15) scores from pre-treatment to end-of-study by groups in the matched sample. Results: Radiation oncology participants used the intervention, overall and voluntarily, more than medical oncology and transplant participants. Participants who were working and had more than a high school education voluntarily used the intervention more. The SDS-15 score was reduced by an estimated 1.53 points (P=.01) in the intervention group users compared to the matched control group. Conclusions: The intended effects of a Web-based, patient-centered intervention on cancer symptom distress were modified by intervention use frequency. Clinical and personal demographics influenced voluntary use. C1 [Berry, Donna L.; McReynolds, Justin] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02215 USA. [Berry, Donna L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Blonquist, Traci M.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02215 USA. [Patel, Rupa A.] GoDaddy Grp, Usabil Engn, Kirkland, WA USA. [Halpenny, Barbara] Univ Washington, Biomed & Hlth Informat, Seattle, WA 98195 USA. RP Berry, DL (reprint author), Dana Farber Canc Inst, Phyllis F Cantor Ctr, 450 Brookline Ave LW 518, Boston, MA 02215 USA. EM donna_berry@dfci.harvard.edu FU National Institute of Nursing Research (NINR), National Institutes of Health [R01 NR008726] FX All authors were funded by a grant (R01 NR008726) from the National Institute of Nursing Research (NINR), National Institutes of Health, for contributions to the study. No author was paid specifically for manuscript preparation. The NINR did not make any publication decisions. The authors are grateful to the patients, family members, and clinicians who gave time and effort to participate in this trial. The work of many talented research staff and students in collecting and coding data is greatly appreciated. NR 32 TC 3 Z9 3 U1 2 U2 10 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD JUN PY 2015 VL 17 IS 6 AR e136 DI 10.2196/jmir.4190 PG 11 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA CL3AF UT WOS:000356819800003 PM 26041682 ER PT J AU Smith, JG Newton-Cheh, C AF Smith, J. Gustav Newton-Cheh, Christopher TI Genome-wide association studies of late-onset cardiovascular disease SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Review DE Genome-wide association study; Cardiovascular disease; Aging ID CORONARY-ARTERY-DISEASE; ABDOMINAL AORTIC-ANEURYSM; MENDELIAN RANDOMIZATION ANALYSIS; ATRIAL-FIBRILLATION RECURRENCE; ISCHEMIC-HEART-DISEASE; COMMON GENETIC VARIANT; INTIMA-MEDIA THICKNESS; MYOCARDIAL-INFARCTION; SEQUENCE VARIANT; CHROMOSOME 9P21 AB Human genetics is a powerful tool for discovering causal mediators of human disease and physiology. Cardiovascular diseases with late onset in the lifecourse have historically not been considered genetic diseases, but in recent years the contribution of a heritable factor has been established. More importantly, over the last decade genome-wide association studies (GWASs) have identified many loci associated with late-onset cardiovascular diseases including coronary artery disease, carotid artery disease, ischemic stroke, aortic aneurysm, peripheral vascular disease, atrial fibrillation, valvular disease and correlates of vascular and myocardial function. Here we review findings from GWASs considered statistically robust with regard to multiple testing (p < 5 x 10(-8)) for late-onset cardiovascular diseases and traits. Although for only a handful of the 92 genetic loci described here have the mechanisms underlying disease association been established, new and previously unsuspected pathways have been implicated for several conditions. Examples include a role for NO signaling in myocardial repolarization and sudden cardiac death and a role for the protein sortilin in lipid metabolism and coronary artery disease. Genetic loci with multiple trait associations have also provided novel biological insights. For example, of the 46 genetic loci associated with coronary artery disease, only 16 are also associated with conventional risk factors for cardiovascular disease whereas the remaining two thirds may reflect novel pathway. Much work remains to functionally characterize genetic loci and for clinical utility, but accruing insights into the biological basis of cardiovascular aging in human populations promise to point to novel therapeutic and preventive strategies. This article is part of a Special Issue entitled 'SI:CV Aging'. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Smith, J. Gustav; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Harvard Univ, Sch Med, Boston, MA USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Smith, J. Gustav; Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA. [Smith, J. Gustav] Lund Univ, Dept Cardiol, Clin Sci, SE-22185 Lund, Sweden. [Smith, J. Gustav] Shane Univ Hosp, SE-22185 Lund, Sweden. RP Smith, JG (reprint author), Lund Univ, Dept Cardiol, Skane Univ Hosp, Clin Sci, SE-22185 Lund, Sweden. EM gustav.smith@med.lu.se; cnewtoncheh@mgh.harvard.edu FU Swedish Research Council [2014-2469]; Swedish Heart-Lung Foundation [20130534]; Crafoord Foundation; Swedish Heart Association; Marta Winkler Foundation; Skane University Hospital; Swedish National Health Service; National Institute of Health [R01HL113933, R01HL124262] FX J.G.S. was supported by the Swedish Research Council (2014-2469), the Swedish Heart-Lung Foundation (20130534), the Crafoord Foundation, the Swedish Heart Association, the Marta Winkler Foundation, Skane University Hospital and the Swedish National Health Service. C.N.-C. was supported by the National Institute of Health (R01HL113933, R01HL124262). NR 152 TC 8 Z9 8 U1 0 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JUN PY 2015 VL 83 BP 131 EP 141 DI 10.1016/j.yjmcc.2015.04.004 PG 11 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA CL3GT UT WOS:000356839100014 PM 25870159 ER PT J AU Bangen, KJ Gu, YA Gross, AL Schneider, BC Skinner, JC Benitez, A Sachs, BC Shih, R Sisco, S Schupf, N Mayeux, R Manly, JJ Luchsinger, JA AF Bangen, Katherine J. Gu, Yian Gross, Alden L. Schneider, Brooke C. Skinner, Jeannine C. Benitez, Andreana Sachs, Bonnie C. Shih, Regina Sisco, Shannon Schupf, Nicole Mayeux, Richard Manly, Jennifer J. Luchsinger, Jose A. TI Relationship Between Type 2 Diabetes Mellitus and Cognitive Change in a Multiethnic Elderly Cohort SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; cognition; aging; vascular risk factors ID VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE NEUROPATHOLOGY; OLDER-ADULTS; DEMENTIA; IMPAIRMENT; DECLINE; POPULATION; ASSOCIATION; CHOLESTEROL; DYSFUNCTION AB ObjectivesTo examine the association between diabetes mellitus and cognitive functioning at baseline and cognitive change over time in a large, ethnically diverse sample of older adults. DesignProspective cohort study. SettingWashington Heights-Inwood Columbia Aging Project, a community-based, prospective study of risk factors for dementia in northern Manhattan, New York City. ParticipantsHispanic, non-Hispanic black, and non-Hispanic white men and women aged 65 and older without dementia at baseline (N=1,493). MeasurementsParticipants underwent baseline and follow-up cognitive and health assessments approximately every 18months. Generalized estimating equations were used to examine the longitudinal association between diabetes mellitus and cognition. ResultsDiabetes mellitus was associated with poorer baseline cognitive performance in memory, language, processing speed and executive functioning, and visuospatial abilities. After adjusting for age, education, sex, race and ethnicity, and apolipoprotein-epsilon 4, participants with diabetes mellitus performed significantly worse at baseline than those without in language and visuospatial abilities. There were no differences between those with and without diabetes mellitus in terms of rate of cognitive change over a mean follow-up time of 6years. ConclusionThe rate of cognitive change in elderly persons with and without diabetes mellitus is similar, although cognitive performance is poorer in persons with diabetes mellitus. These findings suggest that cognitive changes may occur early during the diabetes mellitus process and highlight the need for studies to follow participants beginning at least in midlife, before the typical later-life onset of dementia. C1 [Bangen, Katherine J.] Vet Affairs San Diego Healthcare Syst, Res Serv, San Diego, CA USA. [Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Gu, Yian; Schupf, Nicole; Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Gross, Alden L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Schneider, Brooke C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Skinner, Jeannine C.] Vanderbilt Univ, Med Ctr, Vanderbilt Memory & Alzheimers Ctr, Dept Neurol, Nashville, TN USA. [Benitez, Andreana] Med Univ S Carolina, Dept Radiol & Radiol Sci, Ctr Biomed Imaging, Charleston, SC 29425 USA. [Sachs, Bonnie C.] Virginia Commonwealth Univ, Dept Neurol, Sch Med, Richmond, VA 23284 USA. [Shih, Regina] RAND Corp, Arlington, VA USA. [Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Schupf, Nicole; Mayeux, Richard; Luchsinger, Jose A.] Columbia Univ, Dept Epidemiol, Joseph P Mailman Sch Publ Hlth, New York, NY USA. [Schupf, Nicole; Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA. [Mayeux, Richard] Columbia Univ, Dept Psychiat, New York, NY USA. [Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Dept Neurol, New York, NY USA. [Luchsinger, Jose A.] Columbia Univ, Coll Phys & Surg, Coll Med, New York, NY USA. RP Luchsinger, JA (reprint author), Columbia Univ, Med Ctr, 630 West 168th St, New York, NY 10032 USA. EM jal94@cumc.columbia.edu FU National Institute on Aging [AG026413, AG037212, AG030995, K99AG042483]; National Institute on Mental Health [T32 MH 19934-17]; National Institute on Minority Health and Health Disparities [P60 MD000206] FX K. Bangen, Y. Gu, N. Schupf, R. Mayeux, J. Manly, and J. Luchsinger receive funding from the National Institutes of Health. This study was funded by grants from the National Institute on Aging (AG026413, AG037212, AG030995, K99AG042483), National Institute on Mental Health (T32 MH 19934-17), and National Institute on Minority Health and Health Disparities (P60 MD000206). J. Luchsinger has been a consultant to Nutricia, Inc. and has received royalties from Springer Publishing for a book he edited entitled Diabetes and the Brain. NR 50 TC 7 Z9 7 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1075 EP 1083 DI 10.1111/jgs.13441 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500003 PM 26096383 ER PT J AU Genther, DJ Betz, J Pratt, S Martin, KR Harris, TB Satterfield, S Bauer, DC Newman, AB Simonsick, EM Lin, FR AF Genther, Dane J. Betz, Joshua Pratt, Sheila Martin, Kathryn R. Harris, Tamara B. Satterfield, Suzanne Bauer, Douglas C. Newman, Anne B. Simonsick, Eleanor M. Lin, Frank R. CA Hlth Aging Body Composition Study TI Association Between Hearing Impairment and Risk of Hospitalization in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hearing impairment; hospitalization; older adults; epidemiology ID QUICK DIAGNOSIS UNITS; ELDER LIFE PROGRAM; HEALTH-CARE USE; INCIDENT DEMENTIA; BODY-COMPOSITION; SOCIAL-ISOLATION; AGE; STATES; DISEASE; ADMISSION AB ObjectivesTo determine the association between hearing impairment (HI) and risk and duration of hospitalization in community-dwelling older adults in the United States. DesignProspective observational study. SettingHealth, Aging and Body Composition Study. ParticipantsWell-functioning community-dwelling white and black Medicare beneficiaries aged 70 to 79 at study enrollment in 1997-98 were followed for a median of 12years. MeasurementsIncidence, annual rate, and duration of hospitalization were the primary outcomes. Hearing was defined as the pure-tone average (PTA) of hearing thresholds in decibels re: hearing level (dB HL) at octave frequencies from 0.5 to 4.0kHz. Mild HI was defined as a PTA from 25 to 40dB HL, and moderate or greater HI was defined as a PTA greater than 40dB HL. ResultsOf the 2,148 participants included in the analysis, 1,801 (83.5%) experienced one or more hospitalizations, with 7,007 adjudicated hospitalization events occurring during the study period. Eight hundred eighty-two (41.1%) participants had normal hearing, 818 (38.1%) had mild HI, and 448 (20.9%) had moderate or greater HI. After adjusting for demographic characteristics and cardiovascular comorbidities, persons with mild HI experienced a 16% (hazard ratio (HR)=1.16, 95% confidence interval (CI) =1.04-1.29) greater risk of incident hospitalization and a 17% (incidence rate ratio (IRR)=1.17, 95% CI=1.04-1.32) greater annual rate of hospitalization, and those with moderate or greater HI experienced a 21% (HR=1.21, 95% CI=1.06-1.38) greater risk of incident hospitalization and a 19% (IRR=1.19, 95% CI=1.04-1.38) greater annual rate of hospitalization than persons with normal hearing. There was no significant association between HI and mean duration of hospitalization. ConclusionHearing-impaired older adults experience a greater incidence and annual rate of hospitalization than those with normal hearing. Investigating whether rehabilitative therapies could affect the risk of hospitalization in older adults requires further study. C1 [Genther, Dane J.; Lin, Frank R.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA. [Genther, Dane J.; Betz, Joshua; Lin, Frank R.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21287 USA. [Betz, Joshua] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21287 USA. [Pratt, Sheila] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Pratt, Sheila] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Martin, Kathryn R.; Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Martin, Kathryn R.] Univ Aberdeen, Sch Med & Dent, Epidemiol Grp, Aberdeen, Scotland. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Bauer, Douglas C.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Simonsick, Eleanor M.; Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. [Simonsick, Eleanor M.] Johns Hopkins Univ, NIA, Intramural Res Program, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. RP Genther, DJ (reprint author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St,Suite 6210, Baltimore, MD 21287 USA. EM dgenthe2@jhmi.edu RI Newman, Anne/C-6408-2013; OI Newman, Anne/0000-0002-0106-1150; Genther, Dane/0000-0002-7925-012X; Betz, Joshua/0000-0003-4488-9799 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050, K24AG031155]; National Institute of Nursing Research [R01-NR012459]; National Institutes of Health [T32DC000027]; National Institute on Deafness and Other Communication Disorders [K23DC011279]; Intramural Research Program of the NIA; Triological Society and American College of Surgeons through the Clinician Scientist Award; Eleanor Schwartz Charitable Foundation FX This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106; NIA Grant R01-AG028050; and National Institute of Nursing Research Grant R01-NR012459. This study was further supported in part by National Institutes of Health Grant T32DC000027, NIA grant K24AG031155, National Institute on Deafness and Other Communication Disorders Grant K23DC011279, Intramural Research Program of the NIA, Triological Society and American College of Surgeons through the Clinician Scientist Award, and Eleanor Schwartz Charitable Foundation. Dr. Pratt was supported in part with resources and the use of facilities at the Department of Veterans Affairs Pittsburgh Healthcare System, although the contents do not represent the views of the Department of Veterans Affairs or the U.S. government. This work was presented as a poster display as part of the American Auditory Society Scientific and Technology Meeting, March 6-8, 2014, Scottsdale, Arizona. NR 42 TC 3 Z9 3 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1146 EP 1152 DI 10.1111/jgs.13456 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500012 PM 26096388 ER PT J AU Dougherty, M Harris, PS Teno, J Corcoran, AM Douglas, C Nelson, J Way, D Harrold, JE Casarett, DJ AF Dougherty, Meredith Harris, Pamela S. Teno, Joan Corcoran, Amy M. Douglas, Cindy Nelson, Jackie Way, Deborah Harrold, Joan E. Casarett, David J. TI Hospice Care in Assisted Living Facilities Versus at Home: Results of a Multisite Cohort Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE assisted living; hospice; palliative care ID LIFE; END AB ObjectivesTo compare residents of assisted living facilities receiving hospice with people receiving hospice care at home. DesignElectronic health record-based retrospective cohort study. SettingNonprofit hospices in the Coalition of Hospices Organized to Investigate Comparative Effectiveness network. ParticipantsIndividuals admitted to hospice between January 1, 2008, and May 15, 2012 (N=85,581; 7,451 (8.7%) assisted living facility, 78,130 (91.3%) home). MeasurementsHospice length of stay, use of opioids for pain, and site of death. ResultsThe assisted living population was more likely than the home hospice population to have a diagnosis of dementia (23.5% vs 4.7%; odds ratio (OR)=13.3, 95% confidence interval (CI) =12.3-14.4; P<.001) and enroll in hospice closer to death (median length of stay 24 vs 29days). Assisted living residents were less likely to receive opioids for pain (18.1% vs 39.7%; OR=0.33, 95% CI=0.29-0.39, P<.001) and less likely to die in an inpatient hospice unit (9.3% vs 16.1%; OR=0.53, 95% CI=0.49-0.58, P<.001) or a hospital (1.3% vs 7.6%; OR=0.16, 95% CI=0.13-0.19, P<.001). ConclusionThree are several differences between residents of assisted living receiving hospice care and individuals living at home receiving hospice care. A better understanding of these differences could allow hospices to develop guidelines for better coordination of end-of-life care for the assisted living population. C1 [Dougherty, Meredith; Casarett, David J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Harris, Pamela S.] Kansas City Hospice & Palliat Care, Kansas City, MO USA. [Teno, Joan] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA. [Corcoran, Amy M.] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA. [Douglas, Cindy] Faith Presbyterian Hospice, Dallas, TX USA. [Nelson, Jackie] Arbor Hospice, Ann Arbor, MI USA. [Way, Deborah] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Harrold, Joan E.] Hospice & Community Care, Lancaster, PA USA. RP Casarett, DJ (reprint author), Univ Penn, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 13 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1153 EP 1157 DI 10.1111/jgs.13429 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500013 PM 26096389 ER PT J AU Benson, AB Venook, AP Bekaii-Saab, T Chan, E Chen, YJ Cooper, HS Engstrom, PF Enzinger, PC Fenton, MJ Fuchs, CS Grem, JL Grothey, A Hochster, HS Hunt, S Kamel, A Kirilcuk, N Leong, LA Lin, E Messersmith, WA Mulcahy, MF Murphy, JD Nurkin, S Rohren, E Ryan, DP Saltz, L Sharma, S Shibata, D Skibber, JM Sofocleous, CT Stoffel, EM Stotsky-Himelfarb, E Willett, CG Gregory, KM Freedman-Cass, D AF Benson, Al B., III Venook, Alan P. Bekaii-Saab, Tanios Chan, Emily Chen, Yi-Jen Cooper, Harry S. Engstrom, Paul F. Enzinger, Peter C. Fenton, Moon J. Fuchs, Charles S. Grem, Jean L. Grothey, Axel Hochster, Howard S. Hunt, Steven Kamel, Ahmed Kirilcuk, Natalie Leong, Lucille A. Lin, Edward Messersmith, Wells A. Mulcahy, Mary F. Murphy, James D. Nurkin, Steven Rohren, Eric Ryan, David P. Saltz, Leonard Sharma, Sunil Shibata, David Skibber, John M. Sofocleous, Constantinos T. Stoffel, Elena M. Stotsky-Himelfarb, Eden Willett, Christopher G. Gregory, Kristina M. Freedman-Cass, Deborah TI Rectal Cancer, Version 2.2015 Featured Updates to the NCCN Guidelines SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID III COLON-CANCER; PREOPERATIVE CHEMORADIOTHERAPY; CONCOMITANT CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIATION; NONOPERATIVE TREATMENT; ADJUVANT TREATMENT; COLORECTAL-CANCER; LOCAL RECURRENCE; FOLLOW-UP; PHASE-II AB The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship. The NCCN Rectal Cancer Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize major discussion points from the 2015 NCCN Rectal Cancer Panel meeting. Major discussion topics this year were perioperative therapy options and surveillance for patients with stage I through III disease. C1 [Benson, Al B., III; Mulcahy, Mary F.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Venook, Alan P.] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Bekaii-Saab, Tanios] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [Bekaii-Saab, Tanios] Solove Res Inst, Columbus, OH USA. [Chan, Emily] Vanderbilt Ingram Canc Ctr, Springfield, TN USA. [Chen, Yi-Jen] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Cooper, Harry S.; Engstrom, Paul F.] Fox Chase Canc Ctr, Philadelphia, PA USA. [Enzinger, Peter C.; Fuchs, Charles S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Fenton, Moon J.] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Grem, Jean L.] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Grothey, Axel] Mayo Clin, Ctr Canc, Rochester, MN USA. [Hochster, Howard S.] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA. [Hunt, Steven] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Hunt, Steven] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Kamel, Ahmed] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA. [Kirilcuk, Natalie] Stanford Canc Inst, Stanford, CA USA. [Lin, Edward] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA. [Messersmith, Wells A.] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Murphy, James D.] UC San Diego Moores Canc Ctr, San Diego, CA USA. [Nurkin, Steven] Roswell Pk Canc Inst, Buffalo, NY USA. [Rohren, Eric; Skibber, John M.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Saltz, Leonard; Sofocleous, Constantinos T.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Sharma, Sunil] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Shibata, David] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Stoffel, Elena M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Stotsky-Himelfarb, Eden] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Willett, Christopher G.] Duke Canc Inst, Durham, NC USA. [Gregory, Kristina M.; Freedman-Cass, Deborah] Natl Comprehens Canc Network, Ft Washington, PA USA. RP Benson, AB (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. OI Saltz, Leonard/0000-0001-8353-4670 FU Eisai; Bristol-Myers Squibb; Genentech BioOncology; Merck; Novartis Oncology; Novocure; Boehringer Ingelheim Pharmaceuticals, Inc. FX Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. NR 40 TC 20 Z9 23 U1 2 U2 4 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2015 VL 13 IS 6 BP 719 EP 728 PG 10 WC Oncology SC Oncology GA CL3IK UT WOS:000356843400005 PM 26085388 ER PT J AU Motzer, RJ Jonasch, E Agarwal, N Beard, C Bhayani, S Bolger, GB Chang, SS Choueiri, TK Costello, BA Derweesh, IH Gupta, S Hancock, SL Kim, JJ Kuzel, TM Lam, ET Lau, C Levine, EG Lin, DW Michaelson, MD Olencki, T Pili, R Plimack, ER Rampersaud, EN Redman, BG Ryan, CJ Sheinfeld, J Shuch, B Sircar, K Somer, B Wilder, RB Dwyer, M Kumar, R AF Motzer, Robert J. Jonasch, Eric Agarwal, Neeraj Beard, Clair Bhayani, Sam Bolger, Graeme B. Chang, Sam S. Choueiri, Toni K. Costello, Brian A. Derweesh, Ithaar H. Gupta, Shilpa Hancock, Steven L. Kim, Jenny J. Kuzel, Timothy M. Lam, Elaine T. Lau, Clayton Levine, Ellis G. Lin, Daniel W. Michaelson, M. Dror Olencki, Thomas Pili, Roberto Plimack, Elizabeth R. Rampersaud, Edward N. Redman, Bruce G. Ryan, Charles J. Sheinfeld, Joel Shuch, Brian Sircar, Kanishka Somer, Brad Wilder, Richard B. Dwyer, Mary Kumar, Rashmi TI Testicular Cancer, Version 2.2015 SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID GERM-CELL TUMORS; CLINICAL STAGE-I; LYMPH-NODE DISSECTION; POSITRON-EMISSION-TOMOGRAPHY; MEDICAL-RESEARCH-COUNCIL; HIGH-DOSE CHEMOTHERAPY; INDIANA-UNIVERSITY EXPERIENCE; TERM-FOLLOW-UP; CISPLATIN-BASED CHEMOTHERAPY; GEMCITABINE SALVAGE CHEMOTHERAPY AB Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups-pure seminoma and nonseminoma-which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma. C1 [Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, Med Oncol, New York, NY USA. [Motzer, Robert J.] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX USA. [Jonasch, Eric] Mem Sloan Kettering Canc Ctr, Internal Med, New York, NY USA. [Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Hematol Hematol Oncol, Salt Lake City, UT 84112 USA. [Beard, Clair] Dana Farber Brigham & Womens Canc Ctr, Radiat Oncol, Boston, MA USA. [Beard, Clair] Barnes Jewish Hosp, Siteman Canc Ctr, Urol, St Louis, MO USA. [Bhayani, Sam] Washington Univ, Sch Med, Urol, St Louis, MO 63130 USA. [Bolger, Graeme B.] Univ Alabama Birmingham, Ctr Comprehens Canc, Med Oncol, Birmingham, AL USA. [Chang, Sam S.] Vanderbilt Ingram Canc Ctr, Urol, Nashville, TN USA. [Chang, Sam S.] Dana Farber Brigham & Womens Canc Ctr, Med Oncol, Boston, MA USA. [Choueiri, Toni K.] Dana Farber Brigham & Womens Canc Ctr, Internal Med, Boston, MA USA. [Costello, Brian A.] Mayo Clin, Ctr Canc, Med Oncol, Rochester, MN USA. [Derweesh, Ithaar H.] UC San Diego Moores Canc Ctr, Urol, San Diego, CA USA. [Gupta, Shilpa] H Lee Moffitt Canc Ctr & Res Inst, Med Oncol, Tampa, FL USA. [Gupta, Shilpa] Stanford Canc Inst, Radiat Oncol, Stanford, CA USA. [Hancock, Steven L.] Stanford Canc Inst, Internal Med, Stanford, CA USA. [Kim, Jenny J.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Med Oncol, Baltimore, MD USA. [Kuzel, Timothy M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Hematol Hematol Oncol, Evanston, IL 60208 USA. [Lam, Elaine T.] Univ Colorado, Ctr Canc, Med Oncol, Boulder, CO 80309 USA. [Lau, Clayton] City Hope Comprehens Canc Ctr, Urol, Duarte, CA USA. [Levine, Ellis G.; Pili, Roberto] Roswell Pk Canc Inst, Med Oncol, Buffalo, NY USA. [Lin, Daniel W.] Univ Washington, Seattle Canc Care Alliance, Urol, Seattle, WA 98195 USA. [Michaelson, M. Dror] Massachusetts Gen Hosp, Ctr Canc, Med Oncol, Boston, MA 02114 USA. [Olencki, Thomas] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA. [Olencki, Thomas] Solove Res Inst, Med Oncol, Columbus, OH USA. [Plimack, Elizabeth R.] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA. [Rampersaud, Edward N.] Duke Canc Inst, Urol, Durham, NC USA. [Redman, Bruce G.] Univ Michigan, Ctr Comprehens Canc, Med Oncol, Ann Arbor, MI 48109 USA. [Ryan, Charles J.] UCSF Helen Diller Family Comprehens Canc Ctr, Med Oncol, San Francisco, CA USA. [Ryan, Charles J.] UCSF Helen Diller Family Comprehens Canc Ctr, Urol, San Francisco, CA USA. [Sheinfeld, Joel] Mem Sloan Kettering Canc Ctr, Urol, New York, NY USA. [Shuch, Brian] Smilow Canc Hosp, Yale Canc Ctr, Urol, New Haven, CT USA. [Sircar, Kanishka] Univ Texas MD Anderson Canc Ctr, Pathol, Houston, TX USA. [Somer, Brad] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Med Oncol, Knoxville, TN 37996 USA. [Wilder, Richard B.] H Lee Moffitt Canc Ctr & Res Inst, Radiat Oncol, Tampa, FL USA. RP Motzer, RJ (reprint author), Mem Sloan Kettering Canc Ctr, Med Oncol, New York, NY USA. NR 171 TC 16 Z9 16 U1 1 U2 9 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2015 VL 13 IS 6 BP 772 EP 798 PG 27 WC Oncology SC Oncology GA CL3IK UT WOS:000356843400010 PM 26085393 ER PT J AU Beard, CJ Gupta, S Motzer, RJ O'Donnell, EK Plimack, ER Margolin, KA Ryan, CJ Sheinfeld, J Feldman, DR AF Beard, Clair J. Gupta, Shilpa Motzer, Robert J. O'Donnell, Elizabeth K. Plimack, Elizabeth R. Margolin, Kim A. Ryan, Charles J. Sheinfeld, Joel Feldman, Darren R. TI Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID GERM-CELL TUMORS; LYMPH-NODE DISSECTION; RISK-ADAPTED TREATMENT; STAGE-I NONSEMINOMA; POSTCHEMOTHERAPY RESIDUAL MASS; PROGNOSTIC-FACTORS; PRIMARY CHEMOTHERAPY; RANDOMIZED-TRIAL; TESTIS CANCER; RETROPERITONEAL LYMPHADENECTOMY AB Testicular cancer is the most common cancer in men aged 15 to 40 years in the United States, Canada, and many European countries. Given the excellent prognosis of most men with testicular cancer, updates in care after treatment have become very important. This article provides a review of the available evidence, integrated with expert medical judgment, in the area of testicular cancer follow-up. C1 [Beard, Clair J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Gupta, Shilpa] Univ S Florida, H Lee Moffitt Canc Ctr, Div Med Oncol, Tampa, FL 33682 USA. [Motzer, Robert J.; Feldman, Darren R.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [O'Donnell, Elizabeth K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA. [Plimack, Elizabeth R.] Fox Chase Canc Ctr, Dept Hematol Oncol, Philadelphia, PA 19111 USA. [Margolin, Kim A.] Stanford Univ, Med Ctr, Div Oncol, Palo Alto, CA 94304 USA. [Ryan, Charles J.] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA. [Sheinfeld, Joel] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA. RP Beard, CJ (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St,ASB 1,Level 2, Boston, MA 02115 USA. EM cbeard@lroc.harvard.edu OI Feldman, Darren/0000-0003-2424-4635 FU Bayer FX Dr. Feldman has disclosed that he is a consultant and/or advisory role for Gilead, research support from Bayer, and consultant for Seattle Genetics. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. NR 80 TC 2 Z9 2 U1 0 U2 3 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JUN PY 2015 VL 13 IS 6 BP 811 EP 822 PG 12 WC Oncology SC Oncology GA CL3IK UT WOS:000356843400012 PM 26085395 ER PT J AU Lu, FL Zhang, Y AF Lu, Falong Zhang, Yi TI Cell totipotency: molecular features, induction, and maintenance SO NATIONAL SCIENCE REVIEW LA English DT Review DE totipotency; pluripotency; epigenetics; embryonic stem cell; reprogramming; somatic cell nuclear transfer (SCNT) ID EMBRYONIC STEM-CELLS; MOUSE PREIMPLANTATION DEVELOPMENT; EARLY MAMMALIAN EMBRYO; TRANSCRIPTION FACTOR; NUCLEAR TRANSFER; PATERNAL GENOME; ES CELLS; IN-VIVO; ENDOGENOUS RETROVIRUSES; DEVELOPMENTAL CAPACITY AB In mammals, pluripotent stem cells can give rise to every cell type of embryonic lineage, and hold great potential in regenerative medicine and disease modeling. Guided by the mechanism underlying pluripotency, pluripotent stem cells have been successfully induced through manipulating the transcriptional and epigenetic networks of various differentiated cell types. However, the factors that confer totipotency, the ability to give rise to cells in both embryonic and extra-embryonic lineages still remain poorly understood. It is currently unknown whether totipotency can be induced and maintained in vitro. In this review, we summarize the current progress in the field, with the aim of providing a foundation for understanding the mechanisms that regulate totipotency. C1 [Lu, Falong; Zhang, Yi] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Lu, Falong; Zhang, Yi] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Lu, Falong; Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Zhang, Yi] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Zhang, Y (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. EM yzhang@genetics.med.harvard.edu RI Lu, Falong/Q-3013-2016 FU National Institutes of Health; Howard Hughes Medical Institute FX Work in the Zhang lab is supported by National Institutes of Health and Howard Hughes Medical Institute. YZ is an Investigator of the Howard Hughes Medical Institute. NR 96 TC 3 Z9 3 U1 3 U2 22 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2095-5138 EI 2053-714X J9 NATL SCI REV JI Natl. Sci. Rev. PD JUN PY 2015 VL 2 IS 2 BP 217 EP 225 DI 10.1093/nsr/nwv009 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL3OZ UT WOS:000356861100017 PM 26114010 ER PT J AU Ince, TA Sousa, AD Jones, MA Harrell, JC Agoston, ES Krohn, M Selfors, LM Liu, WB Chen, K Yong, M Buchwald, P Wang, B Hale, KS Cohick, E Sergent, P Witt, A Kozhekbaeva, Z Gao, SZ Agoston, AT Merritt, MA Foster, R Rueda, BR Crum, CP Brugge, JS Mills, GB AF Ince, Tan A. Sousa, Aurea D. Jones, Michelle A. Harrell, J. Chuck Agoston, Elin S. Krohn, Marit Selfors, Laura M. Liu, Wenbin Chen, Ken Yong, Mao Buchwald, Peter Wang, Bin Hale, Katherine S. Cohick, Evan Sergent, Petra Witt, Abigail Kozhekbaeva, Zhanna Gao, Sizhen Agoston, Agoston T. Merritt, Melissa A. Foster, Rosemary Rueda, Bo R. Crum, Christopher P. Brugge, Joan S. Mills, Gordon B. TI Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours SO NATURE COMMUNICATIONS LA English DT Article ID HUMAN BREAST-CARCINOMA; GENE-EXPRESSION; EPITHELIAL-CELLS; CANCER SUBTYPES; ROCK INHIBITOR; CLAUDIN-LOW; STEM-CELLS; CLEAR-CELL; PROTEIN; BIM AB Currently available human tumour cell line panels consist of a small number of lines in each lineage that generally fail to retain the phenotype of the original patient tumour. Here we develop a cell culture medium that enables us to routinely establish cell lines from diverse subtypes of human ovarian cancers with >95% efficiency. Importantly, the 25 new ovarian tumour cell lines described here retain the genomic landscape, histopathology and molecular features of the original tumours. Furthermore, the molecular profile and drug response of these cell lines correlate with distinct groups of primary tumours with different outcomes. Thus, tumour cell lines derived using this methodology represent a significantly improved platform to study human tumour pathophysiology and response to therapy. C1 [Ince, Tan A.; Sousa, Aurea D.; Jones, Michelle A.; Wang, Bin; Witt, Abigail; Kozhekbaeva, Zhanna] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Interdisciplinary Stem Cell Inst,Dept Pathol, Miami, FL 33136 USA. [Ince, Tan A.; Sousa, Aurea D.; Jones, Michelle A.; Wang, Bin; Witt, Abigail; Kozhekbaeva, Zhanna] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. [Harrell, J. Chuck] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27514 USA. [Agoston, Elin S.; Cohick, Evan; Agoston, Agoston T.; Merritt, Melissa A.; Crum, Christopher P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Krohn, Marit; Hale, Katherine S.; Mills, Gordon B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Selfors, Laura M.; Gao, Sizhen; Brugge, Joan S.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Liu, Wenbin; Chen, Ken; Yong, Mao] Univ Texas Houston, MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA. [Buchwald, Peter] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA. [Sergent, Petra; Foster, Rosemary; Rueda, Bo R.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Div Gynecol Oncol, Boston, MA 02114 USA. [Sergent, Petra; Foster, Rosemary; Rueda, Bo R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Ince, TA (reprint author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Interdisciplinary Stem Cell Inst,Dept Pathol, Miami, FL 33136 USA. EM TInce@med.miami.edu OI Sousa, Aurea/0000-0002-9153-7414; Buchwald, Peter/0000-0003-2732-8180 FU Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; DoD-CDMRP Ovarian Cancer Research Program Resource Development Grant [W81XWH-14-1-0160, OC130649]; National Cancer Institute, Roadmap Epigenomics project [R01-CA146445-01]; Advanced Medical Research Foundation; Dr Miriam and Sheldon D. Adelson Medical Research Foundation; CCSG grant [P30 CA016672, R01CA123219] FX We would like to acknowledge Ferenc Reinhardt and Terri Woo for their technical assistance with mouse xenograft experiments and immunohistochemistry, respectively. We would like to thank Benjamin G. Neel, Christopher J. Kemp, Carla Grandori and Ulker Ince for critical comments, reading and edits of the manuscript. This work was funded by grants to T.A.I. from Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; DoD-CDMRP Ovarian Cancer Research Program (W81XWH-14-1-0160) Resource Development Grant (OC130649); and National Cancer Institute, Roadmap Epigenomics project (R01-CA146445-01). Additional funding from Advanced Medical Research Foundation (B.R.R.), the Dr Miriam and Sheldon D. Adelson Medical Research Foundation (J.S.B.), CCSG grant P30 CA016672 (G.B.M.) and R01CA123219 to G.B.M., J.S.B. and T.A.I. NR 70 TC 23 Z9 24 U1 4 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2015 VL 6 AR 7419 DI 10.1038/ncomms8419 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL7UC UT WOS:000357176200001 PM 26080861 ER PT J AU Moy, B AF Moy, Beverly TI Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene SO ONCOLOGIST LA English DT Editorial Material ID CANCER-PATIENTS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Moy, B (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 9A, Boston, MA 02114 USA. EM bmoy@partners.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 571 EP 571 DI 10.1634/theoncologist.2015-0137 PG 1 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400001 PM 25986242 ER PT J AU Nipp, RD Powell, E Chabner, B Moy, B AF Nipp, Ryan D. Powell, Elizabeth Chabner, Bruce Moy, Beverly TI Recognizing the Financial Burden of Cancer Patients in Clinical Trials SO ONCOLOGIST LA English DT Editorial Material DE Cost of illness; Health care costs; Clinical trial; Financial support; Quality of life ID QUALITY-OF-LIFE; BARRIERS; PARTICIPATION; ENROLLMENT; ONCOLOGY; COSTS; DISPARITIES; EXPERIENCE; TOXICITY; IMPACT C1 [Nipp, Ryan D.; Powell, Elizabeth; Chabner, Bruce; Moy, Beverly] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Nipp, RD (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM rnipp@mgh.harvard.edu NR 28 TC 2 Z9 2 U1 1 U2 5 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 572 EP 575 DI 10.1634/theoncologist.2015-0068 PG 4 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400002 PM 25986245 ER PT J AU Rosenberg, SM Stanton, AL Petrie, KJ Partridge, AH AF Rosenberg, Shoshana M. Stanton, Annette L. Petrie, Keith J. Partridge, Ann H. TI Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer SO ONCOLOGIST LA English DT Article DE Tamoxifen; Aromatase inhibitors; Breast cancer; Symptoms ID RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; HOT FLASHES; CLINICAL-PRACTICE; FOLLOW-UP; AMERICAN SOCIETY; TAMOXIFEN; MANAGEMENT; ADHERENCE AB Background. Adherence to adjuvant endocrine therapy (ET) influences breast cancer survival. Because ET side effects are frequently cited as reasons for nonadherence, understanding how perceptions and motivations in relation to ET are associated with symptom attribution can help promote timely symptom management. Materials and Methods. Participants were 2,086 breast cancer survivors recruited through the Army of Women registry who were current tamoxifen or aromatase inhibitor (AI) users. Participants reported whether they were bothered by each of 47 symptoms during the past month and whether they thought each symptom was related to taking ET. Frequencies of overall symptoms and symptoms attributed and misattributed to ET were calculated, and linear regression was used to assess sociodemographics, emotions, and illness perceptions as predictors of symptoms attributed to ET. Results. Women attributed a mean of 8.9 symptoms and misattributed a mean of 1.5 symptoms to ET. In the multivariable analysis, younger age, a more recent diagnosis, AI use (vs. tamoxifen), anxiety, depressive symptoms, more ET-related negative emotions, more concern about long-term ET use, and greater perceived ET necessity were independently associated with attribution of more symptoms to ET. More perceived ET necessity was associated with correctly attributing symptoms to ET, whereas higher depressive symptoms and more concern about ET use were associated with misattribution of symptoms to ET. Conclusion. Given that many women perceive a range of symptoms as a consequence of ET, attention to these symptoms may reduce symptom burden and improve quality of life, potentially improving ET adherence and optimizing survival. C1 [Rosenberg, Shoshana M.; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Rosenberg, Shoshana M.; Partridge, Ann H.] Harvard Univ, Sch Med, Boston, MA USA. [Stanton, Annette L.] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Stanton, Annette L.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Stanton, Annette L.] Univ Calif Los Angeles, Dept Psychiat Biobehav Sci, Los Angeles, CA USA. [Petrie, Keith J.] Univ Auckland, Dept Psychol Med, Auckland 1, New Zealand. RP Partridge, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM ahpartridge@partners.org FU NIH [5 R25 CA057711]; Breast Cancer Research Foundation FX This work was supported by NIH Grant 5 R25 CA057711 (to S.M.R.) and by the Breast Cancer Research Foundation (to A.L.S.). NR 41 TC 2 Z9 2 U1 1 U2 4 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 598 EP 604 DI 10.1634/theoncologist.2015-0007 PG 7 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400007 PM 25933930 ER PT J AU Landry, JC Feng, Y Prabhu, RS Cohen, SJ Staley, CA Whittington, R Sigurdson, ER Nimeiri, H Verma, U Benson, A AF Landry, Jerome C. Feng, Yang Prabhu, Roshan S. Cohen, Steven J. Staley, Charles A. Whittington, Richard Sigurdson, Elin Ruth Nimeiri, Halla Verma, Udit Benson, Al Bowen TI Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 SO ONCOLOGIST LA English DT Article ID PATHOLOGICAL COMPLETE RESPONSE; EARLY BREAST-CANCER; NEOADJUVANT CHEMORADIOTHERAPY; CHEMOTHERAPY; THERAPY AB Background. The addition of bevacizumab to chemotherapy improves overall survival for metastatic colorectal cancer. We initiated a phase II trial to evaluate preoperative capecitabine, oxaliplatin, and bevacizumab with radiation therapy (RT) followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab for locally advanced rectal cancer. The purpose of this report is to describe the 5-year oncologic outcomes of this regimen. Methods. In a phase II Simon two-stage design study, we evaluated preoperative treatment with capecitabine (825 mg/m(2) b.i.d. Monday-Friday), oxaliplatin (50 mg/m(2) weekly), bevacizumab (5 mg/kg on days 1, 15, and 29), and RT (50.4 Gy). Surgery was performed by 8 weeks after RT. Beginning 8-12 weeks after surgery, patients received FOLFOX plus bevacizumab (5mg/kg) every 2 weeks for 12 cycles (oxaliplatin stopped after 9 cycles). The primary endpoint was a pathologic complete response (path-CR) rate of 30%. Fifty-seven patients with resectable T3/T4 rectal adenocarcinoma were enrolled between 2006 and 2010. Results. Of 57 enrolled patients, 53 were eligible and included in the analysis. Forty-eight (91%) patients completed preoperative therapy, all of whom underwent curative surgical resection. Nine patients (17%) achieved path-CR. There were 29 worst grade 3 events, 8 worst grade 4 events, and 2 patient deaths, 1 of which was attributed to study therapy. Twenty-six patients (54%) began adjuvant chemotherapy. After a median follow-up period of 41 months, the 5-year overall survival (OS) rate for all patients was 80%. Only 2 patients experienced cancer recurrence: 1 distant (liver) and 1 loco-regional (pelvic lymph nodes), respectively. Both of these patients are still alive. The 5-year relapse-free survival rate was 81%. Conclusion. Despite the path-CR primary endpoint of this trial not being reached, the 5-year OS and recurrence-free survival rates were excellent. However, the neoadjuvant and surgical toxicity of this regimen was significant and was the primary reason for the low compliance with adjuvant systemic therapy. Because of the lack of an improvement in the path-CR rate, the substantial associated toxicity, and the negative phase III trials of adjuvant bevacizumab in colon cancer, this regimen will not be pursued for further study. C1 [Landry, Jerome C.; Staley, Charles A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Feng, Yang] Dana Farber Canc Inst, Boston, MA 02115 USA. [Prabhu, Roshan S.] Levine Canc Inst, Southeast Radiat Oncol Grp, Charlotte, NC USA. [Cohen, Steven J.; Sigurdson, Elin Ruth] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Whittington, Richard] Vet Affairs New Jersey Healthcare Syst, E Orange, NJ USA. [Nimeiri, Halla; Benson, Al Bowen] Northwestern Univ, Chicago, IL 60611 USA. [Verma, Udit] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Landry, JC (reprint author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd Northeast, Atlanta, GA 30322 USA. EM jland01@emory.edu FU NCI NIH HHS [U10 CA066636, P30 CA060553, U10 CA021115, U10 CA023318, U10 CA180794, U10 CA180820, U10 CA180864] NR 18 TC 8 Z9 8 U1 0 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 615 EP 616 DI 10.1634/theoncologist.2015-0106 PG 2 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400009 PM 25926352 ER PT J AU Sullivan, RJ Ibrahim, N Lawrence, DP Aldridge, J Giobbie-Hurder, A Hodi, FS Flaherty, KT Conley, C Mier, JW Atkins, MB McDermott, DF AF Sullivan, Ryan J. Ibrahim, Nageatte Lawrence, Donald P. Aldridge, Julie Giobbie-Hurder, Anita Hodi, F. Stephen Flaherty, Keith T. Conley, Christine Mier, James W. Atkins, Michael B. McDermott, David F. TI A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma SO ONCOLOGIST LA English DT Article ID METASTATIC MELANOMA; IMPROVED SURVIVAL; MULTIPLE-MYELOMA; MEK INHIBITION; BRAF; IPILIMUMAB; VEMURAFENIB; DABRAFENIB AB Background. Sorafenib and bortezomib affect BCL family member expression. We previously demonstrated that bortezomib augmented sorafenib-mediated cytotoxicity in melanoma cell lines in vitro. We aimed to combine sorafenib 400 mg b.i.d. with increasing doses of weekly bortezomib. Methods. Patients with metastatic melanoma were enrolled in dose-escalation cohorts to determine the maximum tolerated dose (MTD) of sorafenib (twice daily) in combination with bortezomib (weekly for 3 of 4 weeks). The MTD was defined as the highest dose level at which less than 33% of patients exhibited a dose-limiting toxicity (DLT). Efficacy, as measured by 6-month progression-free survival and response rate per RECIST, was documented. Results. Eleven patients were enrolled at three dose levels. DLTs (fatigue and rash) were seen in two of three patients at the highest dose level. Five patients were enrolled for sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m(2) weekly for 3 of every 4 weeks; none had DLTs, and this dose level was defined as the MTD. Of 10 evaluable patients, no responses were seen. Two of 11 patients (18%) remained progression free for longer than 6 months. Conclusion. The combination of sorafenib and bortezomib is safe but not active in patients with melanoma. C1 [Sullivan, Ryan J.; Lawrence, Donald P.; Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Ibrahim, Nageatte; Aldridge, Julie; Giobbie-Hurder, Anita; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Flaherty, Keith T.; Conley, Christine; Mier, James W.; McDermott, David F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. RP Sullivan, RJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA. EM rsullivan7@partners.org NR 13 TC 3 Z9 3 U1 0 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 617 EP 618 DI 10.1634/theoncologist.2015-0105 PG 2 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400010 PM 25986244 ER PT J AU Graff, JN Beer, TM AF Graff, Julie N. Beer, Tomasz M. TI Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer SO ONCOLOGY-NEW YORK LA English DT Review ID PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; ZOLEDRONIC ACID; INCREASED SURVIVAL; MULTIPLE-MYELOMA; BONE METASTASES; ENZALUTAMIDE; MEN; BISPHOSPHONATES; CHEMOTHERAPY AB Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid. C1 [Graff, Julie N.; Beer, Tomasz M.] Portland VA Med Ctr, Portland, OR USA. [Graff, Julie N.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. RP Graff, JN (reprint author), Knight Canc Inst, 3303 SW Bond Ave,MC CH14R, Portland, OR 97239 USA. EM graffj@ohsu.edu FU Astellas Pharma Global; Bayer; Medivation; Janssen FX Dr. Graff receives research funding from Astellas Pharma Global, Bayer, and Medivation. Dr. Beer receives research funding from Astellas Pharma Global, Janssen, and Medivation; he receives consulting fees from Astellas Pharma Global and Bayer. NR 41 TC 3 Z9 3 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JUN PY 2015 VL 29 IS 6 BP 416 EP 423 PG 8 WC Oncology SC Oncology GA CL3HY UT WOS:000356842200002 PM 26091674 ER PT J AU Chan, AT AF Chan, Andrew T. TI OTC Secondary Prevention of Metastatic Colorectal Cancer Moves Closer to Clinical Reality SO ONCOLOGY-NEW YORK LA English DT Editorial Material C1 [Chan, Andrew T.] Massachusetts Gen Hosp, Gastroenterol Training Program, Boston, MA 02114 USA. [Chan, Andrew T.] Harvard Univ, Sch Med, Med, Cambridge, MA 02138 USA. RP Chan, AT (reprint author), Massachusetts Gen Hosp, Gastroenterol Training Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JUN PY 2015 VL 29 IS 6 BP 429 EP 430 PG 2 WC Oncology SC Oncology GA CL3HY UT WOS:000356842200005 PM 26126295 ER PT J AU Brown, JR AF Brown, Jennifer R. TI Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID OPEN-LABEL; IBRUTINIB; RITUXIMAB; FLUDARABINE; TRIAL; CYCLOPHOSPHAMIDE; IDELALISIB; LYMPHOMA; CLL C1 [Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Brown, Jennifer R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Brown, JR (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 21 TC 0 Z9 0 U1 0 U2 2 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JUN PY 2015 VL 29 IS 6 BP 442 EP + PG 2 WC Oncology SC Oncology GA CL3HY UT WOS:000356842200008 PM 26091679 ER PT J AU Frank, JW Carey, EP Fagan, KM Aron, DC Todd-Stenberg, J Moore, BA Kerns, RD Au, DH Ho, PM Kirsh, SR AF Frank, Joseph W. Carey, Evan P. Fagan, Katherine M. Aron, David C. Todd-Stenberg, Jeff Moore, Brent A. Kerns, Robert D. Au, David H. Ho, P. Michael Kirsh, Susan R. TI Evaluation of a Telementoring Intervention for Pain Management in the Veterans Health Administration SO PAIN MEDICINE LA English DT Article DE Telehealth; Pain Management; Primary Care; Anticonvulsants; Antidepressants; Opioids and Physical Therapy ID CHRONIC OPIOID THERAPY; CHRONIC NONCANCER PAIN; PRIMARY-CARE CLINICIAN; PROJECT ECHO; UNITED-STATES; MEDICAL-CENTERS; SPECIALTY CARE; MENTAL-HEALTH; HEPATITIS-C; ACCESS AB ObjectiveHalf of all Veterans experience chronic pain yet many face geographical barriers to specialty pain care. In 2011, the Veterans Health Administration (VHA) launched the Specialty Care Access Network-ECHO (SCAN-ECHO), which uses telehealth technology to provide primary care providers with case-based specialist consultation and pain management education. Our objective was to evaluate the pilot SCAN-ECHO pain management program (SCAN-ECHO-PM). Design and SettingThis was a longitudinal observational evaluation of SCAN-ECHO-PM in seven regional VHA healthcare networks. MethodsWe identified the patient panels of primary care providers who submitted a consultation to one or more SCAN-ECHO-PM sessions. We constructed multivariable Cox proportional hazards models to assess the association between provider SCAN-ECHO-PM consultation and 1) delivery of outpatient care (physical medicine, mental health, substance use disorder, and pain medicine) and 2) medication initiation (antidepressants, anticonvulsants, and opioid analgesics). ResultsPrimary care providers (N = 159) who presented one or more SCAN-ECHO-PM sessions had patient panels of 22,454 patients with chronic noncancer pain (CNCP). Provider consultation to SCAN-ECHO-PM was associated with utilization of physical medicine [hazard ratio (HR) 1.10, 95% confidence interval (CI) 1.05-1.14] but not mental health (HR 0.99, 95% CI 0.93-1.05), substance use disorder (HR 0.93, 95% CI 0.84-1.03) or specialty pain clinics (HR 1.01, 95% CI 0.94-1.08). SCAN-ECHO-PM consultation was associated with initiation of an antidepressant (HR 1.09, 95% CI 1.02-1.15) or anticonvulsant medication (HR 1.13, 95% CI 1.06-1.19) but not an opioid analgesic (HR 1.05, 0.99-1.10). ConclusionsSCAN-ECHO-PM was associated with increased utilization of physical medicine services and initiation of nonopioid medications among patients with CNCP. SCAN-ECHO-PM may provide a novel means of building pain management competency among primary care providers. C1 [Frank, Joseph W.; Carey, Evan P.; Fagan, Katherine M.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Frank, Joseph W.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Aron, David C.; Kirsh, Susan R.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Aron, David C.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA. [Todd-Stenberg, Jeff; Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Moore, Brent A.; Kerns, Robert D.] Yale Univ, Sch Med, New Haven, CT USA. [Moore, Brent A.; Kerns, Robert D.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Ho, P. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Kirsh, Susan R.] Vet Hlth Adm, Off Specialty Care, Washington, DC USA. RP Frank, JW (reprint author), VA Eastern Colorado Hlth Care Syst, Ambulatory Care, 1055 Clermont St, Denver, CO 80220 USA. EM joseph.frank@va.gov RI Moore, Brent/O-4867-2015 OI Moore, Brent/0000-0003-0123-6616 NR 40 TC 8 Z9 8 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUN PY 2015 VL 16 IS 6 BP 1090 EP 1100 DI 10.1111/pme.12715 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CL1SG UT WOS:000356724000008 PM 25716075 ER PT J AU Driscoll, MA Higgins, DM Seng, EK Buta, E Goulet, JL Heapy, AA Kerns, RD Brandt, CA Haskell, SG AF Driscoll, Mary A. Higgins, Diana M. Seng, Elizabeth K. Buta, Eugenia Goulet, Joseph L. Heapy, Alicia A. Kerns, Robert D. Brandt, Cynthia A. Haskell, Sally G. TI Trauma, Social Support, Family Conflict, and Chronic Pain in Recent Service Veterans: Does Gender Matter? SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Gender; Trauma; Support; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; RECEIVING PRIMARY-CARE; WOMEN VETERANS; PERSIAN-GULF; RHEUMATOID-ARTHRITIS; OEF/OIF VETERANS; PHYSICAL ABUSE; IRAQI FREEDOM; WAR VETERANS AB ObjectiveWomen veterans have a higher prevalence of chronic pain relative to men. One hypothesis is that differential combat and traumatic sexual experiences and attenuated levels of social support between men and women may differentially contribute to the development and perpetuation of pain. This investigation examined [1] gender differences in trauma, social support, and family conflict among veterans with chronic pain, and [2] whether trauma, social support, and family conflict were differentially associated with pain severity, pain interference, and depressive symptom severity as a function of gender. MethodsParticipants included 460 veterans (56% female) who served in support of recent conflicts, and who endorsed pain lasting 3 months or longer. Participants completed a baseline survey during participation in a longitudinal investigation. Self-report measures included pain severity, pain interference, depressive symptom severity, exposure to traumatic life events, emotional and tangible support, and family conflict. ResultsRelative to men, women veterans reporting chronic pain evidenced higher rates of childhood interpersonal trauma (51% vs 34%; P<0.001) and military sexual trauma (54% vs 3%; P<0.001), along with lower levels of combat exposure (10.00 vs 16.85, P<0.001). Gender was found to be a moderator of the association of marital status, combat exposure, childhood interpersonal trauma, and family conflict with pain interference. It also moderated family conflict in the prediction of depressive symptoms. ConclusionsResults underscore the potential importance of developing and testing gender specific models of chronic pain that consider the relative roles of trauma, social support, and family conflict. C1 [Driscoll, Mary A.; Heapy, Alicia A.; Kerns, Robert D.] VA Connecticut Healthcare Syst, Dept Psychol, West Haven, CT 06516 USA. [Driscoll, Mary A.; Heapy, Alicia A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Higgins, Diana M.] VA Boston Healthcare Syst, Anesthesiol Crit Care & Pain Med Serv, Jamaica Plain, MA 02130 USA. [Higgins, Diana M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Seng, Elizabeth K.] Yeshiva Univ, Ferkauf Grad Sch Psychol, New York, NY 10033 USA. [Seng, Elizabeth K.] Yeshiva Univ, Albert Einstein Coll Med, Saul R Korey Dept Neurol, Bronx, NY 10461 USA. [Buta, Eugenia; Brandt, Cynthia A.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Buta, Eugenia] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat, New Haven, CT 06510 USA. [Kerns, Robert D.] Yale Univ, Dept Psychol, New Haven, CT 06510 USA. [Kerns, Robert D.] Yale Univ, Dept Neurol, New Haven, CT 06510 USA. [Brandt, Cynthia A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06510 USA. [Haskell, Sally G.] VA Connecticut Healthcare Syst, Dept Gen Internal Med, West Haven, CT 06516 USA. [Haskell, Sally G.] Yale Univ, Sch Med, Dept Gen Internal Med, New Haven, CT 06510 USA. RP Driscoll, MA (reprint author), VA Connecticut Healthcare Syst, PRIME Ctr 11ACSLG,950 Campbell Ave, West Haven, CT 06516 USA. EM madriscoll77@gmail.com OI Higgins, Diana/0000-0002-6885-266X; Goulet, Joseph/0000-0002-0842-804X FU VA Health Services Research and Development award [DHI07-065]; VA Health Services Research and Development Service Center of Innovation [CIN 13-407] FX This research was supported by a VA Health Services Research and Development award (PI: SH & CB), #DHI07-065 and the VA Health Services Research and Development Service Center of Innovation (CIN 13-407). NR 54 TC 2 Z9 2 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUN PY 2015 VL 16 IS 6 BP 1101 EP 1111 DI 10.1111/pme.12744 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CL1SG UT WOS:000356724000009 PM 25930005 ER PT J AU Chapuy, CI Nicholson, RT Aguad, MD Chapuy, B Laubach, JP Richardson, PG Doshi, P Kaufman, RM AF Chapuy, Claudia I. Nicholson, Rachel T. Aguad, Maria D. Chapuy, Bjoern Laubach, Jacob P. Richardson, Paul G. Doshi, Parul Kaufman, Richard M. TI Resolving the daratumumab interference with blood compatibility testing SO TRANSFUSION LA English DT Article ID HUMAN CD38; SURFACE; GLYCOHYDROLASE; PROTEIN; CELLS AB BACKGROUNDDaratumumab (DARA), a promising novel therapy for multiple myeloma, is an IgG1 monoclonal antibody that recognizes CD38 on myeloma cells. During routine compatibility testing, we observed that the plasma of five of five DARA-treated patients demonstrated a positive antibody screen and panreactivity on red blood cell (RBC) panel testing. We hypothesized that the observed panreactivity reflected DARA binding to CD38 on reagent RBCs, and we investigated methods to prevent this binding. STUDY DESIGN AND METHODSDARA binding to CD38+ or CD38- HL60 cells was assessed by flow cytometry. To remove cell surface CD38, cells were incubated with dithiothreitol (DTT) or trypsin. Soluble CD38 or anti-DARA was used to neutralize DARA in solution. Routine blood bank serologic methods were used to test samples from DARA-treated patients and normal plasma samples spiked with DARA and/or alloantibodies. RESULTSNormal plasma samples spiked with DARA (0.1-10 mu g/mL) and incubated with reagent RBCs recapitulated the interference observed with samples from DARA-treated patients. Flow cytometry experiments confirmed DARA binding to CD38+ HL60 cells, but not to CD38- controls. DTT treatment of CD38+ HL60 cells reduced DARA binding by 92% by denaturing cell surface CD38. Treating DARA-containing plasma with soluble CD38 or anti-DARA idiotype also inhibited DARA binding. CONCLUSIONDARA causes panreactivity in vitro by binding to CD38 on reagent RBCs. Treating reagent RBCs with DTT is a robust method to negate the DARA interference, enabling the safe provision of blood to DARA-treated patients. Because DTT denatures Kell antigens, K- units are provided to these patients. C1 [Chapuy, Claudia I.; Nicholson, Rachel T.; Aguad, Maria D.; Kaufman, Richard M.] Brigham & Womens Hosp, Blood Bank, Dept Pathol, Boston, MA 02115 USA. [Chapuy, Bjoern; Laubach, Jacob P.; Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Doshi, Parul] Janssen R&D, Spring House, PA USA. RP Kaufman, RM (reprint author), Brigham & Womens Hosp, Blood Bank, Amory 260,75 Francis St, Boston, MA 02115 USA. EM rmkaufman@partners.org NR 15 TC 27 Z9 28 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD JUN PY 2015 VL 55 IS 6 SI SI BP 1545 EP 1554 DI 10.1111/trf.13069 PN 2 PG 10 WC Hematology SC Hematology GA CL1AI UT WOS:000356674000026 PM 25764134 ER PT J AU Michalek, AK Kan, D Prochaska, J AF Michalek, Anne Kathryn Kan, David Prochaska, Judith TI Engaging veterans with substance abuse disorders into a research trial: success with study branding, networking, and presence SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Veteran health administration; Recruitment; Retention; Multiple-risk behavior change; Methods research ID CLINICAL-TRIALS; SUCCESSFUL RECRUITMENT; RETENTION STRATEGIES; PARTICIPANTS; SMOKERS; INTERVENTION; INFORMATION; PREVALENCE; QUALITY; PEOPLE AB Recruiting and retaining clients in health interventions can be challenging especially when targeting multiple behavior change in high-risk populations. To inform the methods of trials working with similarly complex clinical populations, we describe multi-pronged efforts to recruit and retain a representative sample. In a two-group RCT, veterans were recruited from a Veteran Affairs Medical Center. The goal was to enroll 200 participants over a 25-month period, and to exceed 70 % follow-up for all treatment arms. To meet these goals, a four-pronged strategy was developed: branding, outreach/networking, onsite presence, and incentives. In month 1, 32 % of the proposed sample size was met (n=64), and by month 2, 45 % (n=90); the recruitment goal (n=200) was achieved 13 months ahead of schedule. Retention exceeds 90% at all time points out to 18 months. The multipronged recruitment and retention plan was efficient, cost effective, and may generalize to other health promotion initiatives. C1 [Michalek, Anne Kathryn] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kan, David] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Prochaska, Judith] Stanford Prevent Res Ctr, Stanford, CA 94305 USA. RP Prochaska, J (reprint author), Stanford Prevent Res Ctr, Med Sch Off Bldg,X316,1265 Welch Rd, Stanford, CA 94305 USA. EM jpro@stanford.edu FU National Institutes of Health [P50DA09253] FX We wish to acknowledge the clinical team that provided valuable treatment referrals and support throughout the duration of the trial, including Peter Banys, MD; Steven Batki, MD; Ricky Chen, RN; William Clift, AT; Ellen Herbst, MD; Patricia Lane, RN; and Rebecca Young, RN. We acknowledge Pro-Change Behavior Systems Inc., which developed the multiple risk behavior change intervention evaluated in this trial. We also acknowledge the contributions of research staff Carson Benowitz-Fredericks and Erin Dougherty who worked with participants in this trial. Study supported by the National Institutes of Health grant #P50DA09253 NR 37 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD JUN PY 2015 VL 5 IS 2 BP 167 EP 176 DI 10.1007/s13142-014-0302-z PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2QI UT WOS:000356788700006 PM 26029279 ER PT J AU Mani, SK Kern, CB Kimbrough, D Addy, B Kasiganesan, H Rivers, WT Patel, RK Chou, JC Spinale, FG Mukherjee, R Menick, DR AF Mani, Santhosh K. Kern, Christine B. Kimbrough, Denise Addy, Benjamin Kasiganesan, Harinath Rivers, William T. Patel, Risha K. Chou, James C. Spinale, Francis G. Mukherjee, Rupak Menick, Donald R. TI Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and-9 expression and preserves LV function postmyocardial infarction SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE myocardial infarction; histone deacetylase; matrix metalloproteinases; transcriptional regulation; macrophages; LV remodeling ID NF-KAPPA-B; EXPERIMENTAL MYOCARDIAL-INFARCTION; CARDIAC-HYPERTROPHY; TARGETED DELETION; MATRIX-METALLOPROTEINASE-9 EXPRESSION; GENE-EXPRESSION; CARDIOMYOCYTE HYPERTROPHY; ISCHEMIA-REPERFUSION; HYPERTENSIVE-RATS; TRANSCRIPTION AB Left ventricular (LV) remodeling, after myocardial infarction (MI), can result in LV dilation and LV pump dysfunction. Post-MI induction of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been implicated as causing deleterious effects on LV and extracellular matrix remodeling in the MI region and within the initially unaffected remote zone. Histone deacetylases (HDACs) are a class of enzymes that affect the transcriptional regulation of genes during pathological conditions. We assessed the efficacy of both class I/IIb- and class I-selective HDAC inhibitors on MMP-2 and MMP-9 abundance and determined if treatment resulted in the attenuation of adverse LV and extracellular matrix remodeling and improved LV pump function post-MI. MI was surgically induced in MMP-9 promoter reporter mice and randomized for treatment with a class I/IIb HDAC inhibitor for 7 days post-MI. After MI, LV dilation, LV pump dysfunction, and activation of the MMP-9 gene promoter were significantly attenuated in mice treated with either the class I/IIb HDAC inhibitor tichostatin A or suberanilohydroxamic acid (voronistat) compared with MI-only mice. Immunohistological staining and zymographic levels of MMP-2 and MMP-9 were reduced with either tichostatin A or suberanilohydroxamic acid treatment. Class I HDAC activity was dramatically increased post-MI. Treatment with the selective class I HDAC inhibitor PD-106 reduced post-MI levels of both MMP-2 and MMP-9 and attenuated LV dilation and LV pump dysfunction post-MI, similar to class I/IIb HDAC inhibition. Taken together, these unique findings demonstrate that selective inhibition of class I HDACs may provide a novel therapeutic means to attenuate adverse LV remodeling post-MI. C1 [Mani, Santhosh K.; Kimbrough, Denise; Addy, Benjamin; Kasiganesan, Harinath; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Kern, Christine B.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Rivers, William T.; Patel, Risha K.; Mukherjee, Rupak] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Chou, James C.] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA. [Menick, Donald R.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC USA. RP Menick, DR (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM menickd@musc.edu FU American Heart Association (AHA); National Institutes of Health (NIH) [R01-HL-095696, UL1-TR-000062]; Veterans Affairs Health Administration; NIH [R01-HL-121382, 5-P20-RR-016434, HL-057952, HL-059165]; AHA Scientist Development Grant; NIH Postdoctoral Fellowship Grant [T32-HL-07260]; AHA Predoctoral Fellowship FX This work was supported by an American Heart Association (AHA) grant-in-aid, National Institutes of Health (NIH) Grants R01-HL-095696 and UL1-TR-000062, a merit award from the Veterans Affairs Health Administration, and a gift from Mr. and Mrs. Robert Tarr (to D.R. Menick). C.B. Kern was supported by NIH Grants R01-HL-121382 and 5-P20-RR-016434 and an AHA Scientist Development Grant. F.G. Spinale was supported by NIH Grants HL-057952 and HL-059165 and a merit award from the Veterans Affairs Health Administration. D. Kimbrough was supported by NIH Postdoctoral Fellowship Grant T32-HL-07260 and an AHA Predoctoral Fellowship. NR 61 TC 8 Z9 8 U1 2 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUN 1 PY 2015 VL 308 IS 11 BP H1391 EP H1401 DI 10.1152/ajpheart.00390.2014 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA CK5MS UT WOS:000356269600010 PM 25795711 ER PT J AU Meterko, M Marfeo, EE McDonough, CM Jette, AM Ni, PS Bogusz, K Rasch, EK Brandt, DE Chan, L AF Meterko, Mark Marfeo, Elizabeth E. McDonough, Christine M. Jette, Alan M. Ni, Pengsheng Bogusz, Kara Rasch, Elizabeth K. Brandt, Diane E. Chan, Leighton TI Work Disability Functional Assessment Battery: Feasibility and Psychometric Properties SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Disability evaluation; Outcomes assessment (health care); Psychometrics; Rehabilitation; United States Social Security Administration; Validation studies ID BEHAVIORAL HEALTH FUNCTION; QUALITY-OF-LIFE; PHYSICAL FUNCTION INSTRUMENT; ITEM POOL CONSTRUCTION; SELF-REPORT; APPROPRIATENESS MEASUREMENT; VALIDITY; RELIABILITY; DISEASE; PAIN AB Objective: To assess the feasibility and psychometric properties of 8 scales covering 2 domains of the newly developed Work Disability Functional Assessment Battery (WD-FAB): physical function (PF) and behavioral health (BH) function. Design: Cross-sectional study. Setting: Community. Participants: Adults (N=973) unable to work because of a physical (n=497) or a mental (n=476) disability. Interventions: Not applicable. Main Outcome Measures: Each disability group responded to a survey consisting of the relevant WD-FAB scales and existing measures of established validity. The WD-FAB scales were evaluated with regard to data quality (score distribution, percentage of "I don't know" responses), efficiency of administration (number of items required to achieve reliability criterion, time required to complete the scale) by computerized adaptive testing (CAT), and measurement accuracy as tested by person fit. Construct validity was assessed by examining both convergent and discriminant correlations between the WD-FAB scales and scores on same-domain and cross-domain established measures. Results: Data quality was good, and CAT efficiency was high across both WD-FAB domains. Measurement accuracy was very good for PP scales; BH scales demonstrated more variability. Construct validity correlations, both convergent and divergent, between all WD-FAB scales and established measures were in the expected direction and range of magnitude. Conclusions: The data quality, CAT efficiency, person fit, and construct validity of the WD-FAB scales were well supported and suggest that the WD-FAB could be used to assess PP and BH function related to work disability. Variation in scale performance suggests the need for future work on item replenishment and refinement, particularly with regard to the Self-Efficacy scale. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Meterko, Mark; Marfeo, Elizabeth E.; McDonough, Christine M.; Jette, Alan M.; Ni, Pengsheng; Bogusz, Kara] Boston Univ, Hlth & Disabil Res Inst, Sch Publ Hlth, Boston, MA 02118 USA. [Meterko, Mark] Ctr Healthcare Org & Implementat Res, VA Boston Healthcare Syst, Boston, MA USA. [Rasch, Elizabeth K.; Brandt, Diane E.; Chan, Leighton] Mark O Hatfield Clin Res Ctr, NIH, Rehabil Med Dept, Bethesda, MD 20892 USA. RP Meterko, M (reprint author), Boston Univ, Hlth & Disabil Res Inst, Sch Publ Hlth, 715 Albany St T5W, Boston, MA 02118 USA. EM Meterkom@bu.edu FU Social Security Administration-National Institutes of Health Interagency Agreements under the National Institutes of Health [HHSN269200900004C, HHSN269201000011C, HHSN2692011000091]; National Institutes of Health Intramural Research Program FX Supported by Social Security Administration-National Institutes of Health Interagency Agreements under the National Institutes of Health (contract nos. HHSN269200900004C, HHSN269201000011C, and HHSN2692011000091) and by the National Institutes of Health Intramural Research Program. NR 26 TC 2 Z9 2 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2015 VL 96 IS 6 BP 1028 EP 1035 DI 10.1016/j.apmr.2014.11.025 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK7FM UT WOS:000356398200009 PM 25528263 ER PT J AU Wecht, JM Weir, JP Galea, M Martinez, S Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Galea, Marinella Martinez, Stephanie Bauman, William A. TI Prevalence of Abnormal Systemic Hemodynamics in Veterans With and Without Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Hypertension; Hypotension; Orthostatic hypotension; Rehabilitation; Tachycardia ID HYPOTENSION PREDICTS MORTALITY; ELEVATED HEART-RATE; REMAINING AUTONOMIC FUNCTION; POPULATION HEALTH SURVEY; PULSE-WAVE VELOCITY; LOW BLOOD-PRESSURE; MIDDLE-AGED MEN; ORTHOSTATIC HYPOTENSION; INTERNATIONAL STANDARDS; CARDIOVASCULAR-DISEASE AB Objective: Increased prevalence of heart rate and blood pressure abnormalities are evident in persons with spinal cord injury (SCI), but age, comorbid medical conditions, and prescription medication use may contribute. To determine differences in the prevalence of cardiac acceleration (heart rate >= 80 beats per minute), hypotension (blood pressure <= 110/70mmHg), orthostatic hypotension (OH) (-20/-10mmHg with upright positioning), and hypertension (HTN) (blood pressure >= 140/90mmHg) in veterans with and without SCI. Design: Observational trial. Setting: Medical center. Participants: Subjects included veterans with SCI (n=62; cervical: tetraplegia, C3-8; high thoracic, T1-5; low thoracic, T7-L2) and veterans without SCI (n=160). Interventions: None. Main Outcome Measures: We assessed medical history, prescription medication use, and heart rate and blood pressure during a routine clinical visit. Prevalence rates of cardiac acceleration, hypotension, OH, and HTN were calculated using binary logistic regression analysis with 95% confidence intervals. The influence of SCI status, age, smoking status, cardiovascular diagnoses, and use of prescribed antihypertensive medications on the prevalence of abnormal heart rate and blood pressure recordings was determined. Results: The diagnosis of HTN was reduced in the high thoracic and tetraplegia groups compared with the non-SCI and low thoracic groups. Use of antihypertensive medications was increased in the low thoracic group compared with the other 3 groups and was increased in the non-SCI group compared with the tetraplegia group. The prevalence of cardiac acceleration was reduced, and the prevalence of systolic hypotension was increased in the tetraplegia group. The prevalence of diastolic hypotension was increased in all SCI groups compared with the non-SCI group. For all analyses, increased prevalence of abnormal heart rate and blood pressure recordings was not further explained by the covariates, with the exception of age, cardiovascular diagnoses, and antihypertensive medications in the cardiac acceleration model; however, SCI status remained significant and was the dominant predictor variable. Conclusions: Our data suggest that SCI status contributes to the prevalence of cardiac acceleration and systolic and diastolic hypotension regardless of cardiovascular medical conditions or prescription antihypertensive medication use. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Wecht, Jill M.; Martinez, Stephanie; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Galea, Marinella; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. [Galea, Marinella; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY USA. RP Wecht, JM (reprint author), James J Peters Vet Affairs Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Room 7A-13,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B9212C, B6999R] FX Supported by the Veterans Affairs Rehabilitation Research and Development Service (grants nos. B9212C and B6999R). NR 62 TC 0 Z9 0 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2015 VL 96 IS 6 BP 1071 EP 1079 DI 10.1016/j.apmr.2015.01.018 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK7FM UT WOS:000356398200014 PM 25660005 ER PT J AU Rodriguez, D Cornejo, KM Sadow, PM Santiago-Lastra, Y Feldman, AS AF Rodriguez, Dayron Cornejo, Kristine M. Sadow, Peter M. Santiago-Lastra, Yahir Feldman, Adam S. TI Myopeficytoma tumor of the glans penis SO CANADIAN JOURNAL OF UROLOGY LA English DT Article DE cancer; penile; myopericytoma; pathology; immunohistology ID MYOPERICYTOMA; SPECTRUM; DIFFERENTIATION; TERM AB Myopericytoma is a low grade spindle cell neoplasm largely occurring in skin. We describe the first reported case of a penile myopericytoma. Histologically, the penile tumor was composed of a perivascular proliferation of tumor cells with ovoid shaped nuclei and abundant eosinophilic cytoplasm. Immunohistochemically, the tumor was reactive for markers of smooth muscle differentiation and vascular differentiation. The tumor was noted to be negative for BRAF by immunohistochemistry and wild-type upon gene sequencing using SnaPshot. Our finding serves to expand the anatomical distribution of myopericytoma and broadens the spectrum of primary mesenchymal neoplasms that may be encountered in the penis. C1 [Rodriguez, Dayron; Santiago-Lastra, Yahir; Feldman, Adam S.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Feldman, AS (reprint author), Massachusetts Gen Hosp, Dept Urol, 55 Fruit St,Yawkey Ctr 7E, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 2 PU CANADIAN J UROLOGY PI ST LAURENT PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA SN 1195-9479 J9 CAN J UROL JI Can. J. Urol. PD JUN PY 2015 VL 22 IS 3 BP 7830 EP 7833 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA CK9LZ UT WOS:000356562900013 PM 26068635 ER PT J AU Maneta, EK Cohen, S Schulz, MS Waldinger, RJ AF Maneta, E. K. Cohen, S. Schulz, M. S. Waldinger, R. J. TI Linkages between childhood emotional abuse and marital satisfaction: The mediating role of empathic accuracy for hostile emotions SO CHILD ABUSE & NEGLECT LA English DT Article DE Child victimization; Emotional abuse; Relationship satisfaction; Empathic accuracy; Couples ID NEWLYWED COUPLES; PHYSICAL ABUSE; SEXUAL-ABUSE; MALTREATMENT; ADJUSTMENT; AGGRESSION; VICTIMIZATION; RELIABILITY; STABILITY; VALIDITY AB Research linking childhood emotional abuse (CEA) and adult marital satisfaction has focused on individuals without sufficient attention to couple processes. Less attention has also been paid to the effects of CEA on the ability to read other's emotions, and how this may be related to satisfaction in intimate relationships. In this study, 156 couples reported on histories of CEA, marital satisfaction and empathic accuracy of their partners' positive and hostile emotions during discussion of conflicts in their relationships. Actor-Partner Interdependence Modeling was used to examine links between CEA and marital satisfaction, with empathic accuracy as a potential mediator. Both men's and women's CEA histories were linked not only with their own lower marital satisfaction but also with their partners' lower satisfaction. Empathic accuracy for hostile emotions mediated the link between women's CEA and their satisfaction and their partners' satisfaction in the relationship. Findings suggest that a history of CEA is associated with difficulties with empathic accuracy, and that empathic inaccuracy in part mediates the association between CEA and adult marital dissatisfaction. (c) 2014 Elsevier Ltd. All rights reserved. C1 [Maneta, E. K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA 02115 USA. [Cohen, S.; Waldinger, R. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schulz, M. S.] Bryn Mawr Coll, Bryn Mawr, PA 19010 USA. RP Maneta, EK (reprint author), Boston Childrens Hosp, Dept Psychiat, BCH 3051,300 Longwood Ave, Boston, MA 02115 USA. FU National Institute of Mental Health [K08 MH01555] FX Funded by a grant from the National Institute of Mental Health (K08 MH01555). NR 46 TC 2 Z9 2 U1 1 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 EI 1873-7757 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD JUN PY 2015 VL 44 BP 8 EP 17 DI 10.1016/j.chiabu.2014.07.017 PG 10 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA CL0PK UT WOS:000356644400003 PM 25151303 ER PT J AU Pham, PMT Pham, PAT Pham, SV Pham, PTT Pham, PTT Pham, PCT AF Pham, Phuong-Mai T. Pham, Phuong-Anh T. Pham, Son V. Pham, Phuong-Truc T. Pham, Phuong-Thu T. Pham, Phuong-Chi T. TI Correction of hyponatremia and osmotic demyelinating syndrome: have we neglected to think intracellularly? SO CLINICAL AND EXPERIMENTAL NEPHROLOGY LA English DT Article DE Hypophosphatemia; Hypokalemia; Hypomagnesemia; Hypoglycemia; Thiamine; Folate ID CENTRAL PONTINE MYELINOLYSIS; CELL-VOLUME REGULATION; EXTRAPONTINE MYELINOLYSIS; HYPOGLYCEMIA; ENCEPHALOPATHY; HYPERNATREMIA; POTASSIUM; DISEASE; OSMOLES; WATER AB Osmotic demyelination syndrome (ODS) is a complication generally associated with overly rapid correction of hyponatremia. Traditionally, nephrologists have been trained to focus solely on limiting the correction rate. However, there is accumulating evidence to suggest that the prevention of ODS is beyond achieving slow correction rates. We (1) reviewed the literature for glial intracellular protective alterations during hyperosmolar stress, a state presumed equivalent to the rapid correction of hyponatremia, and (2) analyzed all available hyponatremia-associated ODS cases from PubMed for possible contributing factors including correction rates and concurrent metabolic disturbances involving hypokalemia, hypophosphatemia, hypomagnesemia, and/or hypoglycemia. In response to acute hyperosmolar stress, glial cells undergo immediate extracellular free water shift, followed by active intracellular Na+, K+ and amino acid uptake, and eventual idiogenic osmoles synthesis. At minimum, protective mechanisms require K+, Mg2+, phosphate, amino acids, and glucose. There were 158 cases of hyponatremia-associated ODS where both correction rates and other metabolic factors were documented. Compared with the rapid correction group (> 0.5 mmol/L/h), the slow correction group (a parts per thousand currency sign0.5 mmol/L/h) had a greater number of cases with concurrent hypokalemia (49.4 vs. 33.3 %, p = 0.04), and a greater number of cases with any concurrent metabolic derangements (55.8 vs. 38.3 %, p = 0.03). Glial cell minimizes volume changes and injury in response to hyperosmolar stress via mobilization and/or utilization of various electrolytes and metabolic factors. The prevention of ODS likely requires both minimization of correction rate and optimization of intracellular response during the correction phase when a sufficient supply of various factors is necessary. C1 [Pham, Phuong-Mai T.] Greater Los Angeles Vet Adm, Sepulveda, CA 91343 USA. [Pham, Phuong-Anh T.] Vet Affairs Cent Calif Hlth Care Syst, Fresno, CA 93703 USA. [Pham, Son V.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pham, Son V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Pham, Phuong-Truc T.] Penn State Worthington Scranton, Dunmore, PA 18512 USA. [Pham, Phuong-Thu T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Pham, Phuong-Chi T.] Olive View UCLA Med Ctr, Div Nephrol & Hypertens, Sylmar, CA 91342 USA. RP Pham, PCT (reprint author), Olive View UCLA Med Ctr, Div Nephrol & Hypertens, 14445 Olive View Dr,2B-182, Sylmar, CA 91342 USA. EM Phuong-Mai.Pham@va.gov; Phuong-Anh.Pham@va.gov; PhamS@uthscsa.edu; PTP2@psu.edu; PPham@mednet.ucla.edu; Pham.PChi@ucla.edu NR 39 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1342-1751 EI 1437-7799 J9 CLIN EXP NEPHROL JI Clin. Exp. Nephrol. PD JUN PY 2015 VL 19 IS 3 BP 489 EP 495 DI 10.1007/s10157-014-1021-y PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CK5FZ UT WOS:000356249700022 PM 25150510 ER PT J AU Shipherd, JC AF Shipherd, Jillian C. TI Defining Competence when Working with Sexual and Gender Minority Populations: Training Models for Professional Development SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Editorial Material DE cultural competence; diversity; education; gender minority; Lesbian; gay; bisexual and transgender (LGBT); LGBT health; sexual minority; training C1 [Shipherd, Jillian C.] VHA Patient Care Serv, LGBT Program, Washington, DC USA. [Shipherd, Jillian C.] VA Boston Healthcare Syst, Boston, MA USA. [Shipherd, Jillian C.] Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA. [Shipherd, Jillian C.] Boston Univ, Sch Med, Boston, MA 02130 USA. RP Shipherd, JC (reprint author), Boston Univ, Sch Med, Womens Hlth Sci Div 116B 3, Natl Ctr PTSD,VA Cent Off, 150 South Huntington Ave, Boston, MA 02130 USA. EM jillian.shipherd@va.gov NR 8 TC 4 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0969-5893 EI 1468-2850 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD JUN PY 2015 VL 22 IS 2 BP 101 EP 104 DI 10.1111/cpsp.12100 PG 4 WC Psychology, Clinical SC Psychology GA CK7ZM UT WOS:000356456600001 ER PT J AU Matza, AR Sloan, CA Kauth, MR AF Matza, Alexis R. Sloan, Colleen A. Kauth, Michael R. TI Quality LGBT Health Education: A Review of Key Reports and Webinars SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Review DE education; LGBT health; psychology ID GENDER MINORITY VETERANS; SYSTEMATIC REVIEWS; GRADUATE-STUDENTS; BISEXUAL CLIENTS; MENTAL-HEALTH; GAY; RECOMMENDATIONS; COMMUNICATION; POPULATIONS; STRESS AB An identified gap in training in the field of psychology is training on lesbian, gay, bisexual, and transgender (LGBT) health. Through a systematic review, we identified excellent LGBT health key reports and webinars that are in English, up-to-date, and easily accessible for free on the Internet. This article reviews 26 LGBT health key reports to identify core content themes (terminology, differences within LGBT populations, health and health disparities, transgender-specific content, and diversity). A summary table is provided for each of these 26 key reports with regard to how well they capture the core themes and what strengths they offer clinical psychologists. The authors used these themes to evaluate the quality of LGBT health education webinars. Webinars were also evaluated to see whether they employed material intended to promote transfer and retention of knowledge and improve learner's clinical practice. The criteria we identified to evaluate the LGBT health webinars may also serve as a guide to content experts interested in creating new webinars or other educational programs on LGBT health care. C1 [Matza, Alexis R.] VA Boston Healthcare Syst, VA Patient Care Serv LGBT Program 10P4Y, Boston, MA 02130 USA. [Matza, Alexis R.; Sloan, Colleen A.] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Kauth, Michael R.] Baylor Coll Med, VA South Cent Mental Illness Res Educ & Clin Ctr, VA Patient Care Serv LGBT Program 10P4Y, Houston VA HSR&D Ctr Excellence,Michael E DeBakey, Houston, TX 77030 USA. RP Matza, AR (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA. EM alexis.matza@va.gov NR 79 TC 4 Z9 4 U1 6 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0969-5893 EI 1468-2850 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD JUN PY 2015 VL 22 IS 2 BP 127 EP 144 DI 10.1111/cpsp.12096 PG 18 WC Psychology, Clinical SC Psychology GA CK7ZM UT WOS:000356456600004 ER PT J AU Boroughs, MS Bedoya, CA O'Cleirigh, C Safren, SA AF Boroughs, Michael S. Bedoya, C. Andres O'Cleirigh, Conall Safren, Steven A. TI Toward Defining, Measuring, and Evaluating LGBT Cultural Competence for Psychologists SO CLINICAL PSYCHOLOGY-SCIENCE AND PRACTICE LA English DT Review DE competence; LGBT; special populations; sexual minorities; gender minorities; training ID HOMOSEXUAL IDENTITY FORMATION; COGNITIVE-BEHAVIORAL THERAPY; CHILDHOOD SEXUAL-ABUSE; BISEXUAL CLIENTS; SUBSTANCE USE; MENTAL-HEALTH; GAY MEN; THEORETICAL-MODEL; ORIENTATION; INTERSECTIONALITY AB A central part of providing evidence-based practice is appropriate cultural competence to facilitate psychological assessment and intervention with diverse clients. At a minimum, cultural competence with lesbian, gay, bisexual, and transgender (LGBT) people involves adequate scientific and supervised practical training, with increasing depth and complexity across training levels. To further this goal, we offer 28 recommendations of minimum standards moving toward ideal training for LGBT-specific cultural competence. We review and synthesize the relevant literature to achieve and assess competence across the various levels of training (doctoral, internship, postdoctoral, and beyond) in order to guide the field toward best practices. These recommendations are aligned with educational and practice guidelines set forth by the field and informed by other allied professions in order to provide a road map for programs, faculty, and trainees in improving the training of psychologists to work with LGBT individuals. C1 [Boroughs, Michael S.; Bedoya, C. Andres] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [O'Cleirigh, Conall; Safren, Steven A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Fenway Inst Fenway Hlth, Cambridge, MA 02138 USA. RP Boroughs, MS (reprint author), Massachusetts Gen Hosp, Behav Med Serv, One Bowdoin Sq, Boston, MA 02114 USA. EM mboroughs@mgh.harvard.edu RI Bedoya, Cristina/K-8066-2014 OI Bedoya, Cristina/0000-0001-8057-9152 FU National Institute of Mental Health [K24MH094214-01, R01MH095624-01] FX Some of the author time (SAS) was supported by the National Institute of Mental Health grant K24MH094214-01 and (CO) by the National Institute of Mental Health grant R01MH095624-01. NR 107 TC 6 Z9 6 U1 6 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0969-5893 EI 1468-2850 J9 CLIN PSYCHOL-SCI PR JI Clin. Psychol.-Sci. Pract. PD JUN PY 2015 VL 22 IS 2 BP 151 EP 171 DI 10.1111/cpsp.12098 PG 21 WC Psychology, Clinical SC Psychology GA CK7ZM UT WOS:000356456600006 PM 26279609 ER PT J AU Pinter, SF Colognori, D Beliveau, BJ Sadreyev, RI Payer, B Yildirim, E Wu, CT Lee, JT AF Pinter, Stefan F. Colognori, David Beliveau, Brian J. Sadreyev, Ruslan I. Payer, Bernhard Yildirim, Eda Wu, Chao-ting Lee, Jeannie T. TI Allelic Imbalance Is a Prevalent and Tissue-Specific Feature of the Mouse Transcriptome SO GENETICS LA English DT Article DE gene expression; genotype; random monoallelic expression; imprinting; allele-specific RNA-seq ID MONOALLELIC GENE-EXPRESSION; X-CHROMOSOME INACTIVATION; STEM-CELL DIFFERENTIATION; RNA-SEQ; IMPRINTED GENE; PROXIMAL CHROMOSOME-6; DOSAGE COMPENSATION; MAMMALIAN-CELLS; HUMAN GENOME; SINGLE-CELL AB In mammals, several classes of monoallelic genes have been identified, including those subject to X-chromosome inactivation (XCI), genomic imprinting, and random monoallelic expression (RMAE). However, the extent to which these epigenetic phenomena are influenced by underlying genetic variation is unknown. Here we perform a systematic classification of allelic imbalance in mouse hybrids derived from reciprocal crosses of divergent strains. We observe that deviation from balanced biallelic expression is common, occurring in similar to 20% of the mouse transcriptome in a given tissue. Allelic imbalance attributed to genotypic variation is by far the most prevalent class and typically is tissue-specific. However, some genotype-based imbalance is maintained across tissues and is associated with greater genetic variation, especially in 59 and 39 termini of transcripts. We further identify novel random monoallelic and imprinted genes and find that genotype can modify penetrance of parental origin even in the setting of large imprinted regions. Examination of nascent transcripts in single cells from inbred parental strains reveals that genes showing genotype-based imbalance in hybrids can also exhibit monoallelic expression in isogenic backgrounds. This surprising observation may suggest a competition between alleles and/or reflect the combined impact of cis- and trans-acting variation on expression of a given gene. Our findings provide novel insights into gene regulation and may be relevant to human genetic variation and disease. C1 [Pinter, Stefan F.; Colognori, David; Sadreyev, Ruslan I.; Payer, Bernhard; Yildirim, Eda; Lee, Jeannie T.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Pinter, Stefan F.; Colognori, David; Sadreyev, Ruslan I.; Payer, Bernhard; Yildirim, Eda; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Pinter, Stefan F.; Colognori, David; Beliveau, Brian J.; Sadreyev, Ruslan I.; Payer, Bernhard; Yildirim, Eda; Wu, Chao-ting; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Lee, JT (reprint author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. EM lee@molbio.mgh.harvard.edu OI Pinter, Stefan/0000-0003-4750-1403; Payer, Bernhard/0000-0002-4694-2082 FU German Research Foundation (DFG); MGH Fund for Medical Discovery; NIH [2T32GM007226-37A1, R01-GM61936, R01-GM090278]; NIGMS FX We thank A. Saltzman for critical reading of the manuscript, M. Tolstorukov for valuable discussions, and all laboratory members for helpful suggestions. We acknowledge H. Sunwoo for FISH protocols and W. Press for assistance with handling of mice. This work was supported by grants from the German Research Foundation (DFG) and the MGH Fund for Medical Discovery to S.F.P., NIH training grant 2T32GM007226-37A1 to D.C., NIH grant R01-GM61936 and the NIGMS Director's Pioneer Award to C-t.W., and NIH grant R01-GM090278 to J.T.L. J.T.L. is an investigator at the Howard Hughes Medical Institute. The authors declare no conflicts of interest. NR 61 TC 6 Z9 6 U1 1 U2 11 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD JUN PY 2015 VL 200 IS 2 BP 537 EP + DI 10.1534/genetics.115.176263 PG 38 WC Genetics & Heredity SC Genetics & Heredity GA CK8SR UT WOS:000356509100013 PM 25858912 ER PT J AU Gilmore-Bykovskyi, AL Roberts, TJ Bowers, BJ Brown, RL AF Gilmore-Bykovskyi, Andrea L. Roberts, Tonya J. Bowers, Barbara J. Brown, Roger L. TI Caregiver Person-Centeredness and Behavioral Symptoms in Nursing Home Residents with Dementia: A Timed-Event Sequential Analysis SO GERONTOLOGIST LA English DT Article DE Person-centered interaction; Caregiver task-centeredness; Mealtime interactions ID CLUSTER-RANDOMIZED-TRIAL; CARE; AGITATION; ASSISTANTS AB Purpose: Evidence suggests that person-centered caregiving approaches may reduce dementia-related behavioral symptoms; however, little is known about the sequential and temporal associations between specific caregiver actions and behavioral symptoms. The aim of this study was to identify sequential associations between caregiver person-centered actions, task-centered actions, and resident behavioral symptoms and the temporal variation within these associations. Design and Methods: Videorecorded observations of naturally occurring interactions (N = 33; 724 min) between 12 nursing home (NH) residents with dementia and eight certified nursing assistants were coded for caregiver person-centered actions, task-centered actions, and resident behavioral symptoms and analyzed using timed-event sequential analysis. Results: Although caregiver actions were predominantly person-centered, we found that resident behavioral symptoms were significantly more likely to occur following task-centered caregiver actions than person-centered actions. Implications: Findings suggest that the person-centeredness of caregivers is sequentially and temporally related to behavioral symptoms in individuals with dementia. Additional research examining the temporal structure of these relationships may offer valuable insights into the utility of caregiver person-centeredness as a low-cost strategy for improving behavioral symptom management in the NH setting. C1 [Gilmore-Bykovskyi, Andrea L.; Roberts, Tonya J.] US Dept Vet Affairs, William S Middleton Hosp, Geriatr Res Educ & Clin, Madison, WI USA. [Gilmore-Bykovskyi, Andrea L.; Roberts, Tonya J.; Bowers, Barbara J.; Brown, Roger L.] Univ Wisconsin, Madison Sch Nursing, Madison, WI 53705 USA. RP Gilmore-Bykovskyi, AL (reprint author), Univ Wisconsin, Madison Sch Nursing, 5136 Cooper Hall,701 Highland Ave, Madison, WI 53705 USA. EM algilmore@wisc.edu OI Bowers, Barbara/0000-0002-3226-0718 FU National Hartford Centers of Gerontological Nursing Excellence; American Nurses Foundation Virginia Stone Research Grant in Clinical Gerontology; Nurses Foundation of Wisconsin; University of Wisconsin-Madison School of Nursing Eckburg Research Award; Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX This work was supported by the National Hartford Centers of Gerontological Nursing Excellence Patricia G. Archbold Scholar Program and Claire M. Fagin Postdoctoral Fellowship Program, the American Nurses Foundation Virginia Stone Research Grant in Clinical Gerontology, the Nurses Foundation of Wisconsin and the University of Wisconsin-Madison School of Nursing Eckburg Research Award. This work is also support, in part by the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (1UL1RR025011). NR 13 TC 1 Z9 1 U1 4 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2015 VL 55 SU 1 BP S61 EP S66 DI 10.1093/geront/gnu164 PG 6 WC Gerontology SC Geriatrics & Gerontology GA CK4ZJ UT WOS:000356231600006 PM 26055782 ER PT J AU Varela, JC Tomlinson, S AF Varela, Juan Carlos Tomlinson, Stephen TI Complement An Overview for the Clinician SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Complement system; Complement activation; Complement regulation; Complement function; Inflammation; Immune response ID DECAY-ACCELERATING FACTOR; MEMBRANE-ATTACK COMPLEX; C-REACTIVE PROTEIN; CA2+-DEPENDENT ANIMAL LECTINS; VASCULAR ENDOTHELIAL-CELLS; SITE-DIRECTED MUTAGENESIS; HEMOLYTIC-UREMIC SYNDROME; INNATE IMMUNITY; T-CELLS; MICROVASCULAR THROMBOSIS AB The complement system is an essential component of the immune system. It is a highly integrative system and has a number of functions, including host defense, removal of injured cells and debris, modulation of metabolic and regenerative processes, and regulation of adaptive immunity. Complement is activated via different pathways and it is regulated tightly by several mechanisms to prevent host injury. Imbalance between complement activation and regulation can manifest in disease and injury to self. This article provides an outline of complement activation pathways, regulatory mechanisms, and normal physiologic functions of the system. C1 [Varela, Juan Carlos] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol,Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. EM tomlinss@musc.edu FU BLRD VA [I01 BX001218]; NCI NIH HHS [R01 CA158179]; NHLBI NIH HHS [R01 HL086576]; RRD VA [I01 RX001141] NR 102 TC 2 Z9 2 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD JUN PY 2015 VL 29 IS 3 BP 409 EP + DI 10.1016/j.hoc.2015.02.001 PG 20 WC Oncology; Hematology SC Oncology; Hematology GA CK9EX UT WOS:000356544500002 PM 26043382 ER PT J AU Arvikar, SL Steere, AC AF Arvikar, Sheila L. Steere, Allen C. TI Diagnosis and Treatment of Lyme Arthritis SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Lyme disease; Borrelia burgdorferi; Lyme arthritis; Antibiotic-refractory arthritis; Inflammatory arthritis ID ANTIBIOTIC-REFRACTORY ARTHRITIS; CELL GROWTH-FACTOR; BORRELIA-BURGDORFERI; SYNOVIAL-FLUID; UNITED-STATES; DISEASE; THERAPY; RESPONSES; CHILDREN; CEFTRIAXONE AB In the United States, Lyme arthritis is the most common feature of late-stage Borrelia burgdorferi infection, usually beginning months after the initial bite. In some, earlier phases are asymptomatic and arthritis is the presenting manifestation. Patients with Lyme arthritis have intermittent or persistent attacks of joint swelling and pain in 1 or a few large joints. Serologic testing is the mainstay of diagnosis. Synovial fluid polymerase chain reaction for B burgdorferi DNA is often positive before treatment, but is not a reliable marker of spirochetal eradication after therapy. This article reviews the clinical manifestations, diagnosis, and management of Lyme arthritis. C1 [Arvikar, Sheila L.; Steere, Allen C.] Harvard Univ, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA. RP Steere, AC (reprint author), Harvard Univ, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp,Med Sch, 55 Fruit St, Boston, MA 02114 USA. EM asteere@mgh.harvard.edu FU NIAID NIH HHS [R01 AI101175] NR 45 TC 13 Z9 13 U1 3 U2 11 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD JUN PY 2015 VL 29 IS 2 BP 269 EP + DI 10.1016/j.idc.2015.02.004 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL0LT UT WOS:000356634900006 PM 25999223 ER PT J AU Stone, GW Maehara, A Muller, JE Rizik, DG Shunk, KA Ben-Yehuda, O Genereux, P Dressler, O Parvataneni, R Madden, S Shah, P Brilakis, ES Kini, AS AF Stone, Gregg W. Maehara, Akiko Muller, James E. Rizik, David G. Shunk, Kendrick A. Ben-Yehuda, Ori Genereux, Philippe Dressler, Ovidiu Parvataneni, Rupa Madden, Sean Shah, Priti Brilakis, Emmanouil S. Kini, Annapoorna S. CA CANARY Investigators TI Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE atherosclerosis; distal protection; embolization; myocardial infarction; near-infrared spectroscopy ID LIPID-CORE PLAQUES; INTRAPROCEDURAL THROMBOTIC EVENTS; EXPERT CONSENSUS DOCUMENT; INTRAVASCULAR ULTRASOUND; UNIVERSAL DEFINITION; ADVERSE OUTCOMES; ISCHEMIC EVENTS; ELEVATION; REVASCULARIZATION; SPECTROSCOPY AB OBJECTIVES This study sought to determine whether pre-percutaneous coronary intervention (PCI) plaque characterization using near-infrared spectroscopy identifies lipid-rich plaques at risk of periprocedural myonecrosis and whether these events may be prevented by the use of a distal protection filter during PCI. BACKGROUND Lipid-rich plaques may be prone to distal embolization and periprocedural myocardial infarction (MI) in patients undergoing PCI. METHODS Patients undergoing stent implantation of a single native coronary lesion were enrolled in a multicenter, prospective trial. Near-infrared spectroscopy and intravascular ultrasound were performed at baseline, and lesions with a maximal lipid core burden index over any 4-mm length (maxLCBI(4mm)) >= 600 were randomized to PCI with versus without a distal protection filter. The primary endpoint was periprocedural MI, defined as troponin or a creatine kinase-myocardial band increase to 3 or more times the upper limit of normal. RESULTS Eighty-five patients were enrolled at 9 U.S. sites. The median (interquartile range) maxLCBI(4mm) was 448.4 (274.8 to 654.4) pre-PCI and decreased to 156.0 (75.6 to 312.6) post-PCI (p < 0.0001). Periprocedural MI developed in 21 patients (24.7%). The maxLCBI(4mm) was higher in patients with versus without MI (481.5 [425.6 to 679.6] vs. 371.5 [228.9 to 611.6], p = 0.05). Among 31 randomized lesions with maxLCBI(4mm) >= 600, there was no difference in the rates of periprocedural MI with versus without the use of a distal protection filter (35.7% vs. 23.5%, respectively; relative risk: 1.52; 95% confidence interval: 0.50 to 4.60, p = 0.69). CONCLUSIONS Plaque characterization by near-infrared spectroscopy identifies lipid-rich lesions with an increased likelihood of periprocedural MI after stent implantation, presumably due to distal embolization. However, in this pilot randomized trial, the use of a distal protection filter did not prevent myonecrosis after PCI of lipid-rich plaques. (C) 2015 by the American College of Cardiology Foundation. C1 [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori] Columbia Univ, Med Ctr, New York, NY 10022 USA. [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori] New York Presbyterian Hosp, New York, NY USA. [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori; Genereux, Philippe; Dressler, Ovidiu; Parvataneni, Rupa] Cardiovasc Res Fdn, New York, NY USA. [Muller, James E.; Madden, Sean; Shah, Priti] InfraReDx Inc, Burlington, MA USA. [Rizik, David G.] Scottsdale Healthcare, Scottsdale, AZ USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Genereux, Philippe] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada. [Brilakis, Emmanouil S.] North Texas Vet Affairs Med Ctr, Dallas, TX USA. [Kini, Annapoorna S.] Mt Sinai Hosp, New York, NY 10029 USA. RP Stone, GW (reprint author), Columbia Univ, Med Ctr, Cardiovasc Res Fdn, 111 E 59th St,11th Floor, New York, NY 10022 USA. EM gs2184@columbia.edu FU St. Jude Medical; Guerbet; InfraReDx FX The names of the investigators, institutions, and research organizations participating in the CANARY trial are provided in Online Appendix 1. Dr. Stone is a past consultant for Boston Scientific, Volcano, and InfraReDx. Dr. Maehara is a consultant for Boston Scientific and ACIST; and has received speaker fees from St. Jude Medical. Drs. Muller and Madden and Ms. Shah are full-time employees of InfraReDx. Dr. Brilakis has served as a consultant and has received speaker honoraria from St. Jude, Terumo, Asahi, Abbott Vascular, Elsevier, Somahlution, and Boston Scientific; has received research support from Guerbet and InfraReDx; and that his spouse is an employee of Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 25 TC 13 Z9 13 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2015 VL 8 IS 7 BP 927 EP 936 DI 10.1016/j.jcin.2015.01.032 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK5YJ UT WOS:000356303900014 PM 26003018 ER PT J AU Feldman, MD Phipps, JE AF Feldman, Marc D. Phipps, Jennifer E. TI Can Multimodal Invasive Imaging Be Used to Predict Periprocedural Myocardial Infarctions? SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE atherosclerosis; coronary artery disease; distal protection; embolization; fibrous cap thickness; intravascular imaging; myocardial infarction; near-infrared spectroscopy; percutaneous coronary intervention ID OPTICAL COHERENCE TOMOGRAPHY; THIN-CAP FIBROATHEROMA; NEAR-INFRARED SPECTROSCOPY; ACUTE CORONARY SYNDROME; LIPID-CORE PLAQUES; INTRAVASCULAR ULTRASOUND; HIGH-RISK; ARTERY; FREQUENCY; INTRACORONARY C1 [Feldman, Marc D.; Phipps, Jennifer E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Cardiol, 7703 Floyd Curl Dr,MSC 7872, San Antonio, TX 78229 USA. EM feldmanm@uthscsa.edu NR 18 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2015 VL 8 IS 7 BP 946 EP 948 DI 10.1016/j.jcin.2015.04.002 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK5YJ UT WOS:000356303900016 PM 26088512 ER PT J AU Oresanya, L Zhao, SJ Gan, SQ Fries, BE Goodney, PP Covinsky, KE Conte, MS Finlayson, E AF Oresanya, Lawrence Zhao, Shoujun Gan, Siqi Fries, Brant E. Goodney, Philip P. Covinsky, Kenneth E. Conte, Michael S. Finlayson, Emily TI Functional Outcomes After Lower Extremity Revascularization in Nursing Home Residents A National Cohort Study SO JAMA INTERNAL MEDICINE LA English DT Article ID CRITICAL LIMB ISCHEMIA; INFRAINGUINAL BYPASS-SURGERY; AMBULATORY FUNCTION; ELDERLY ADULTS; SALVAGE; MDS AB IMPORTANCE Lower extremity revascularization often seeks to allow patients with peripheral arterial disease to maintain the ability to walk, a key aspect of functional independence. Surgical outcomes in patients with high levels of functional dependence are poorly understood. OBJECTIVE To determine functional status trajectories, changes in ambulatory status, and survival after lower extremity revascularization in nursing home residents. DESIGN Using full Medicare claims data for 2005 to 2009, we identified nursing home residents who underwent lower extremity revascularization. With the Minimum Data Set for Nursing Homes activities of daily living summary score, we examined changes in their ambulatory and functional status after surgery. We identified patient and surgery characteristics associated with a composite measure of clinical and functional failure-death or nonambulatory status 1 year after surgery. SETTING All nursing homes in the United States participating in Medicare or Medicaid. PARTICIPANTS Nursing home residents who underwent lower extremity revascularization. MAIN OUTCOMES AND MEASURES Functional status, ambulatory status, and death. RESULTS During the study period, 10 784 long-term nursing home residents underwent lower extremity revascularization. Prior to surgery, 75% of the residents were not walking; 40% had experienced functional decline. One year after surgery, 51% of patients had died, 28% were nonambulatory, and 32% had sustained functional decline. Among 1672 residents who were ambulatory before surgery, 63% had died or were nonambulatory at 1 year; among 7188 who were nonambulatory, 89% had died or were nonambulatory. After multivariate adjustment, factors independently associated with death or nonambulatory status were 80 years or older (adjusted hazard ratio [AHR], 1.28; 95% CI, 1.16-1.40), cognitive impairment (AHR, 1.23; 95% CI, 1.18-1.29), congestive heart failure (AHR, 1.16; 95% CI, 1.11-1.22), renal failure (AHR, 1.09; 95% CI, 1.04-1.14), emergent surgery (AHR, 1.29; 95% CI, 1.23-1.35), nonambulatory status before surgery (AHR, 1.88; 95% CI, 1.78-1.99), and decline in activities of daily living before surgery (AHR, 1.23; 95% CI, 1.18-1.28). CONCLUSIONS AND RELEVANCE Of nursing home residents in the United States who undergo lower extremity revascularization, few are alive and ambulatory 1 year after surgery. Most who were still alive had gained little, if any, function. C1 [Oresanya, Lawrence; Zhao, Shoujun; Conte, Michael S.; Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Gan, Siqi] Univ Calif San Francisco, Fielding Sch Publ Hlth, San Francisco, CA 94143 USA. [Fries, Brant E.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. [Fries, Brant E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Fries, Brant E.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Goodney, Philip P.] Geisel Sch Med Dartmouth, Dept Surg, Hanover, NH USA. [Goodney, Philip P.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Goodney, Philip P.] VA Outcomes Grp, White River Jct, VT USA. [Covinsky, Kenneth E.; Finlayson, Emily] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Finlayson, Emily] Univ Calif San Francisco, Phillip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Finlayson, E (reprint author), Philip R Lee Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94118 USA. EM emily.finlayson@ucsf.edu FU National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging [K08AG028965]; University of California, San Francisco, Claude D. Pepper Older Americans Independence Center FX Dr Finlayson was supported by a National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging (K08AG028965) and the University of California, San Francisco, Claude D. Pepper Older Americans Independence Center. NR 21 TC 4 Z9 4 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 951 EP 957 DI 10.1001/jamainternmed.2015.0486 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400020 PM 25844523 ER PT J AU Wong, SSPY Kreuter, W Curtis, JR Hall, YN O'Hare, AM AF Wong, Susan P. Y. Kreuter, William Curtis, J. Randall Hall, Yoshio N. O'Hare, Ann M. TI Trends in In-Hospital Cardiopulmonary Resuscitation and Survival in Adults Receiving Maintenance Dialysis SO JAMA INTERNAL MEDICINE LA English DT Article ID LONG-TERM SURVIVAL; OF-LIFE CARE; CARDIAC-ARREST; HEALTH-CARE; HEMODIALYSIS-PATIENTS; PATIENTS PREFERENCES; ADVANCE DIRECTIVES; UNITED-STATES; OUTCOMES; END AB IMPORTANCE Understanding cardiopulmonary resuscitation (CPR) practices and outcomes can help to support advance care planning in patients receiving maintenance dialysis. OBJECTIVE To characterize patterns and outcomes of in-hospital CPR in US adults receiving maintenance dialysis. DESIGN, SETTING, AND PARTICIPANTS This national retrospective cohort study studied 663 734 Medicare beneficiaries 18 years or older from a comprehensive national registry for end-stage renal disease who initiated maintenance dialysis from January 1, 2000, through December 31, 2010. EXPOSURES Receipt of in-hospital CPR from 91 days after dialysis initiation through the time of death, first kidney transplantation, or end of follow-up on December 31, 2011. MAIN OUTCOMES AND MEASURES Incidence of CPR and survival after the first episode of CPR recorded in Medicare claims during follow-up. RESULTS The annual incidence of CPR for the overall cohort was 1.4 events per 1000 in-hospital days (95% CI, 1.3-1.4). A total of 21.9% CPR recipients (95% CI, 21.4%-22.3%) survived to hospital discharge, with a median postdischarge survival of 5.0 months (interquartile range, 0.7-16.8 months). Among patients who died in the hospital, 14.9%(95% CI, 14.8%-15.1%) received CPR during their terminal admission. From 2000 to 2011, there was an increase in the incidence of CPR (1.0 events per 1000 in-hospital days; 95% CI, 0.9-1.1; to 1.6 events per 1000 in-hospital days; 95% CI, 1.6-1.7; P for trend <. 001), the proportion of CPR recipients who survived to discharge (15.2%; 95% CI, 11.1%-20.5%; to 28%; 95% CI, 26.7%-29.4%; P for trend <. 001), and the proportion of in-hospital deaths preceded by CPR (9.5%; 95% CI, 8.4%-10.8%; to 19.8%; 95% CI, 19.2%-20.4%; P for trend <. 001), with no substantial change in duration of postdischarge survival. CONCLUSIONS AND RELEVANCE Among a national cohort of patients receiving maintenance dialysis, the incidence of CPR was higher and long-term survival worse than reported for other populations. C1 [Wong, Susan P. Y.; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Wong, Susan P. Y.; Curtis, J. Randall; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA. [Wong, Susan P. Y.; Curtis, J. Randall; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Kreuter, William] Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA. [Hall, Yoshio N.; O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [O'Hare, Ann M.] Grp Hlth Res Inst, Seattle, WA USA. RP Wong, SSPY (reprint author), Univ Washington, Kidney Res Inst, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU Beeson Career Development Award; National Institute on Aging [U01-DK102105]; Clinical Scientist in Nephrology Award from the American Kidney Fund [T32DK746730] FX This study was supported by a Beeson Career Development Award and grant U01-DK102105 from the National Institute on Aging (Dr O'Hare) and by grant T32DK746730 and the Clinical Scientist in Nephrology Award from the American Kidney Fund (DrWong). NR 45 TC 12 Z9 12 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 1028 EP 1035 DI 10.1001/jamainternmed.2015.0406 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400034 PM 25915762 ER PT J AU Corapi, KM Wenger, JB Bhan, I AF Corapi, Kristin M. Wenger, Julia B. Bhan, Ishir TI Blood Pressure and Serum Parathyroid Hormone Level Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Corapi, Kristin M.; Wenger, Julia B.; Bhan, Ishir] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. RP Corapi, KM (reprint author), Massachusetts Gen Hosp, Div Nephrol, 165 Cambridge St,Ste 302, Boston, MA 02114 USA. EM kcorapi@partners.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 1069 EP + DI 10.1001/jamainternmed.2015.0763 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400050 PM 26030861 ER PT J AU Corapi, KM Wenger, JB Bhan, I AF Corapi, Kristin M. Wenger, Julia B. Bhan, Ishir TI Association of beta-Blocker Therapy With Risks of Adverse Cardiovascular Events and Deaths in Patients With Ischemic Heart Disease Undergoing Noncardiac Surgery: A Danish Nationwide Cohort Study (vol 174, pg 336, 2014) SO JAMA INTERNAL MEDICINE LA English DT Correction C1 [Corapi, Kristin M.; Wenger, Julia B.; Bhan, Ishir] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. RP Corapi, KM (reprint author), Massachusetts Gen Hosp, Div Nephrol, 165 Cambridge St,Ste 302, Boston, MA 02114 USA. EM kcorapi@partners.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 1070 EP 1070 DI 10.1001/jamainternmed.2015.2214 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400051 ER PT J AU Choby, GW Kim, J Ling, DC Abberbock, S Mandal, R Kim, S Ferris, RL Duvvuri, U AF Choby, Garret W. Kim, Jeehong Ling, Diane C. Abberbock, Shira Mandal, Rajarsi Kim, Seungwon Ferris, Robert L. Duvvuri, Umamaheswar TI Transoral Robotic Surgery Alone for Oropharyngeal Cancer Quality-of-Life Outcomes SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; FUNCTIONAL OUTCOMES; ASSISTED SURGERY; NECK; HEAD; IMPACT AB IMPORTANCE Few studies have examined quality-of-life (QOL) outcomes in patients who undergo transoral robotic surgery (TORS) alone (ie, without adjuvant radiotherapy or chemoradiotherapy). OBJECTIVE To report QOL outcomes of patients with oropharyngeal squamous cell carcinoma who receive only TORS. DESIGN, SETTING, AND PARTICIPANTS Medical records for all patients undergoing TORS for treatment of primary oropharyngeal squamous cell carcinoma from May 1, 2010, to March 31, 2014, at a tertiary care academic cancer center were examined from June through September 2014. Thirty-four patients who did not receive adjuvant therapy after TORS were included in the study. INTERVENTION Primary surgical resection via TORS. MAIN OUTCOMES AND MEASURES The University of Washington Quality of Life, version 4, questionnaire was completed by patients preoperatively and at 1-, 6-, 12-, and 24-month intervals after TORS. Demographic, clinicopathologic, and follow-up data were collected. RESULTS Mean follow-up time was 14 months (May 1, 2010, to April 30, 2014). Most patients had T1 (20 [59%]) or T2 (13 [38%]) and N0 (13 [38%]) or N1 (16 [47%]) disease. Statistically significant improvement in QOL outcomes was noted in the following postoperative domains: chewing from 1 month (median, 50 [IQR, 50-100]) to 12 months (100 [IQR, 100-100]; P = .048), swallowing from 1 month (70 [IQR, 30-85]) to 6 months (100 [IQR, 70-100]; P = .047) and 1 to 24 months (100 [IQR, 70-100]; P = .048), pain from 1 month (38 [IQR, 25-75]) to 6 months (88 [IQR, 75-100]; P = .006) and 1 to 12 months after surgery (100 [IQR, 75-100]; P = .01), and activity from 1 month (63 [IQR, 50-88]) to 24 months (100 [IQR, 75-100]; P = .03). Two participants (6%) died during the follow-up period: 1 because of disease and 1 because of amyocardial infarction. Two patients (6%) required temporary gastrostomy tube placement, but none required tracheostomy. CONCLUSIONS AND RELEVANCE Appropriately selected patients who undergo TORS alone for oropharyngeal squamous cell carcinoma experience acceptable short-and long-term QOL outcomes. C1 [Choby, Garret W.; Mandal, Rajarsi; Kim, Seungwon; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Kim, Jeehong; Ling, Diane C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Abberbock, Shira] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Eye & Ear Inst 500, 200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs Career Development Award; PNC Foundation FX This work was funded in part by the Department of Veterans Affairs Career Development Award and the PNC Foundation (Dr Duvvuri). NR 19 TC 8 Z9 8 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD JUN PY 2015 VL 141 IS 6 BP 499 EP 504 DI 10.1001/jamaoto.2015.0347 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CK8AC UT WOS:000356458300001 PM 25834991 ER PT J AU Bergmark, RW Ishman, SL Scangas, GA Cunningham, MJ Sedaghat, AR AF Bergmark, Regan W. Ishman, Stacey L. Scangas, George A. Cunningham, Michael J. Sedaghat, Ahmad R. TI Insurance Status and Quality of Outpatient Care for Uncomplicated Acute Rhinosinusitis SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID EMERGENCY-DEPARTMENT USE; SOCIOECONOMIC DISPARITIES; PATIENT SATISFACTION; HEALTH-INSURANCE; AMBULATORY-CARE; MEDICAID RECIPIENTS; ACCESS; SINUSITIS; APPOINTMENTS; SERVICES AB IMPORTANCE Previous work suggests an association between insurance status and location of presentation (emergency department vs outpatient clinic) for evaluation of uncomplicated acute rhinosinusitis (ARS). OBJECTIVE To investigate whether the quality of outpatient care for ARS likewise differs based on insurance status. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of 13 680 145 pediatric and adult patients from the 2009 and 2010 National Ambulatory Medical Care Survey diagnosed with uncomplicated ARS at an outpatient care facility. EXPOSURES Health insurance status. MAIN OUTCOMES AND MEASURES The primary outcome measures were continuity of care with the patients' primary care physician (PCP) and time spent with a physician, which were chosen as proxies for quality of care. We evaluated associations between insurance status and these quality measures while controlling for clinical, demographic and socioeconomic patient characteristics, and outpatient practice setting. RESULTS Most patients (76.4%) had private insurance vs Medicare (12.3%), Medicaid (8.6%), or self-pay (2.8%). There was no association between insurance status and presentation of patients to their PCP. Physicians spent more time with Medicaid patients compared with patients with private insurance (beta = 4.59; P = .01), independent of other factors. Provision of health education (beta = 4.42; P < .001), necessity of a follow-up visit (beta = 3.20; P = .002), and increasing patient age (beta = 0.07; P = .01) were associated with longer visits. In multivariate analysis, living in a medium or small metropolitan area was associated with higher likelihood of being seen by one's own PCP than living in a large metropolitan area (odds ratio, 6.37; 95% CI, 2.13-19.05; P = .001). CONCLUSIONS AND RELEVANCE This study did not identify any quality of care issues with respect to insurance coverage and primary care encounters for patients with ARS. In contrast to expectations, patients with Medicaid had longer outpatient physician visits and were equally likely to see their own PCP compared with patients with private insurance or Medicare. C1 [Bergmark, Regan W.; Scangas, George A.; Sedaghat, Ahmad R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Bergmark, Regan W.; Scangas, George A.; Cunningham, Michael J.; Sedaghat, Ahmad R.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Div Otolaryngol Head & Neck Surg, Cincinnati, OH 45229 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA. [Ishman, Stacey L.] Univ Cincinnati, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA. [Cunningham, Michael J.] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA USA. RP Sedaghat, AR (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM ahmad_sedaghat@meei.harvard.edu NR 28 TC 2 Z9 2 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD JUN PY 2015 VL 141 IS 6 BP 505 EP 511 DI 10.1001/jamaoto.2015.0530 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CK8AC UT WOS:000356458300002 PM 25879170 ER PT J AU Fontenot, TE Deniwar, A Bhatia, P Al-Qurayshi, Z Randolph, GW Kandil, E AF Fontenot, Tatyana E. Deniwar, Ahmad Bhatia, Parisha Al-Qurayshi, Zaid Randolph, Gregory W. Kandil, Emad TI Percutaneous Ethanol Injection vs Reoperation for Locally Recurrent Papillary Thyroid Cancer A Systematic Review and Pooled Analysis SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Review ID LYMPH-NODE DISSECTION; CENTRAL COMPARTMENT DISSECTION; CENTRAL NECK DISSECTION; SERUM THYROGLOBULIN; DYE INJECTION; CARCINOMA; SURGERY; METASTASES; ABLATION; ULTRASONOGRAPHY AB IMPORTANCE Reoperation for recurrent papillary thyroid cancer (PTC) can be associated with a high rate of complications and failure to provide lasting remission. Percutaneous ethanol injection (PEI) may be an effective nonsurgical management option for locally recurrent PTC. OBJECTIVE This systematic analysis of the current literature compares the efficacy and complications related to PEI vs reoperative surgical intervention for treatment of locally recurrent PTC. DATA SOURCES Original studies were identified using the keywords "thyroid/ethanol" and "recurrent thyroid cancer/repeat surgery." STUDY SELECTION Studies evaluating reoperation or PEI for lymph node metastases in patients with primary surgery of total thyroidectomy with appropriate lymph node dissection where indicated were included in the analysis for both reoperation and PEI. Animal studies, single case reports, and studies with fewer than 10 lesions were excluded. DATA EXTRACTION AND SYNTHESIS Outcomes included interval to detection of recurrence, success and failure rates, recurrence rates, complication rates, and follow-up duration. Between-group outcome differences were calculated using random-effects models, and pooled data cross-tabulation and logistic regression analysis were used. RESULTS In all, 945 publications were identified, and 27 studies met the inclusion criteria. There were no studies that directly compared the 2 treatment techniques. A total of 1617 patients were included in this analysis; 168 (11.4%) were treated with PEI, and 1449 (88.6%) were treated with reoperation. Reoperation was successful in 94.8% of cases compared with an 87.5% success rate for PEI (odds ratio [OR], 2.58; 95% CI, 1.55-4.31; P < .001). The recurrence rates for PEI and reoperation at the site of the treated lesion or elsewhere in the neck were also similar (OR, 1.07; 95% CI, 0.65-1.77; P = .78). Reoperation was associated with a 3.5% pooled risk of complications, while PEI incurred a pooled risk of 1.2%(OR, 2.9; 95% CI, 0.72-12.3; P = .08). However, most studies did not report routine preoperative and postoperative laryngoscopies, an evaluation needed for accurate neural complication analysis associated with each procedure. CONCLUSIONS AND RELEVANCE High-quality, well-designed studies are needed to evaluate the feasibility of incorporating PEI into the treatment protocol of PTC. Although presently inferior to reoperation, PEI has the potential to be a widely accepted and effective nonsurgical treatment option for limited recurrent PTC in poor surgical candidates or patients seeking to avoid multiple reoperations. C1 [Fontenot, Tatyana E.; Deniwar, Ahmad; Bhatia, Parisha; Kandil, Emad] Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA. [Al-Qurayshi, Zaid] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA. [Randolph, Gregory W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Boston, MA USA. [Kandil, Emad] Tulane Univ, Sch Med, Dept Otolaryngol, New Orleans, LA 70112 USA. RP Kandil, E (reprint author), Tulane Dept Surg, Dept Otolaryngol, 1430 Tulane Ave,SL 59, New Orleans, LA 70112 USA. EM ekandil@tulane.edu OI Fontenot, Tatyana/0000-0001-7664-5014 NR 34 TC 3 Z9 3 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD JUN PY 2015 VL 141 IS 6 BP 512 EP 518 DI 10.1001/jamaoto.2015.0596 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CK8AC UT WOS:000356458300003 PM 25928119 ER PT J AU Patti, MG Allaix, ME Fisichella, PM AF Patti, Marco G. Allaix, Marco E. Fisichella, P. Marco TI Analysis of the Causes of Failed Antireflux Surgery and the Principles of Treatment A Review SO JAMA SURGERY LA English DT Review ID GASTROESOPHAGEAL-REFLUX DISEASE; LAPAROSCOPIC NISSEN FUNDOPLICATION; REDO FUNDOPLICATION; TERM; FAILURE; PATHOPHYSIOLOGY; REOPERATION; PERISTALSIS; ACHALASIA; SYMPTOMS AB IMPORTANCE Although the diagnostic evaluation and technical elements for a successful laparoscopic fundoplication have been clearly identified, 10% to 20% of patients will eventually experience recurrence of their symptoms. The management of patients who fail antireflux surgery is complex and not well codified. OBJECTIVE To provide an evidence-and experience-based analysis of the causes of failed antireflux surgery and to underscore the principles of treatment. EVIDENCE REVIEW PubMed was searched for articles published between 1980 and 2014. The search terms included were the following: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, and Nissen fundoplication. FINDINGS Before planning therapy, a careful workup is necessary to determine whether the symptoms are due to recurrent reflux and to understand what caused the recurrence. Subsequently, therapy needs to be individualized based on the symptoms and on the findings of the workup. In some patients, a nonesophageal cause will be identified. Among patients with recurrent reflux, some will do well with acid-reducing medications and others will need another operation. CONCLUSIONS AND RELEVANCE Laparoscopic antireflux surgery is a very effective and long-lasting treatment for gastroesophageal reflux disease. Its success is based on a careful preoperative evaluation and on the performance of a fundoplication that respects the key technical elements. Patients who are still symptomatic postoperatively must be thoroughly evaluated to identify the cause of failure, and treatment must be individualized. C1 [Patti, Marco G.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Allaix, Marco E.] Univ Turin, Dept Surg Sci, Turin, Italy. [Fisichella, P. Marco] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA. [Fisichella, P. Marco] Boston VA Healthcare Syst, Boston, MA USA. RP Patti, MG (reprint author), Univ Chicago, Pritzker Sch Med, Dept Surg, 5841 S Maryland Ave,Room G-207, Chicago, IL 60637 USA. EM mpatti@surgery.bsd.uchicago.edu NR 46 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JUN PY 2015 VL 150 IS 6 BP 585 EP 590 DI 10.1001/jamasurg.2014.3859 PG 6 WC Surgery SC Surgery GA CL0FK UT WOS:000356615400023 PM 25853420 ER PT J AU Beaber, EF Kim, JJ Schapira, MM Tosteson, ANA Zauber, AG Geiger, AM Kamineni, A Weaver, DL Tiro, JA AF Beaber, Elisabeth F. Kim, Jane J. Schapira, Marilyn M. Tosteson, Anna N. A. Zauber, Ann G. Geiger, Ann M. Kamineni, Aruna Weaver, Donald L. Tiro, Jasmin A. CA Population-Based Res Optimizing TI Unifying Screening Processes Within the PROSPR Consortium: A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID SERVICES TASK-FORCE; COMMON DATA ELEMENTS; TIMELY FOLLOW-UP; RECOMMENDATION STATEMENT; PERSONALIZED REGIMENS; RESEARCH PERSPECTIVE; SOCIETY GUIDELINES; MULTILEVEL FACTORS; CARE CONTINUUM; TISSUE-BANK AB General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. We present a trans-organ conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based on clinical guidelines and protocols; the model concepts could be expanded to other organ sites. The model covers four types of care in the screening process: risk assessment, detection, diagnosis, and treatment. Interfaces between different provider teams (eg, primary care and specialty care), including communication and transfer of responsibility, may occur when transitioning between types of care. Our model highlights across each organ site similarities and differences in steps, interfaces, and transitions in the screening process and documents the conclusion of a screening episode. This model was developed within the National Cancer Institute-funded consortium Population-based Research Optimizing Screening through Personalized Regimens (PROSPR). PROSPR aims to optimize the screening process for breast, cervical, and colorectal cancer and includes seven research centers and a statistical coordinating center. Given current health care reform initiatives in the United States, this conceptual model can facilitate the development of comprehensive quality metrics for cancer screening and promote trans-organ comparative cancer screening research. PROSPR findings will support the design of interventions that improve screening outcomes across multiple cancer sites. C1 [Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Kim, Jane J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Schapira, Marilyn M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Tosteson, Anna N. A.] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Dept Med, Lebanon, NH USA. [Tosteson, Anna N. A.] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Geiger, Ann M.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. [Kamineni, Aruna] Grp Hlth Res Inst, Seattle, WA USA. [Weaver, Donald L.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [Weaver, Donald L.] Univ Vermont, Ctr Canc, Burlington, VT USA. [Tiro, Jasmin A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. RP Beaber, EF (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-A306,POB 19024, Seattle, WA 98109 USA. EM ebeaber@fredhutch.org OI Tiro, Jasmin/0000-0001-8300-0441 FU NCI NIH HHS [U54CA163308-04S1, 54CA163262-04S1, P30 CA008748, P30 CA023108, U01 CA163304, U01CA163304, U54 CA163261, U54 CA163262, U54 CA163303, U54 CA163307, U54 CA163308, U54 CA163313, U54 CA164336, U54CA163261, U54CA163261-04S1, U54CA163262, U54CA163303, U54CA163307, U54CA163308, U54CA163313, U54CA164336] NR 67 TC 6 Z9 6 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv120 DI 10.1093/jnci/djv120 PG 8 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500019 PM 25957378 ER PT J AU Kirchhoff, AC Parsons, HM Kuhlthau, KA Leisenring, W Donelan, K Warner, EL Armstrong, GT Robison, LL Oeffinger, KC Park, ER AF Kirchhoff, Anne C. Parsons, Helen M. Kuhlthau, Karen A. Leisenring, Wendy Donelan, Karen Warner, Echo L. Armstrong, Gregory T. Robison, Leslie L. Oeffinger, Kevin C. Park, Elyse R. TI Supplemental Security Income and Social Security Disability Insurance Coverage Among Long-term Childhood Cancer Survivors SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ADULT SURVIVORS; MALIGNANCIES; OUTCOMES; EVENTS; BURDEN; COHORT; HEALTH; RISK AB Supplemental security income (SSI) and social security disability insurance (DI) are federal programs that provide disability benefits. We report on SSI/DI enrollment in a random sample of adult, long-term survivors of childhood cancer (n = 698) vs a comparison group without cancer (n = 210) from the Childhood Cancer Survivor Study who completed a health insurance survey. A total of 13.5% and 10.0% of survivors had ever been enrolled on SSI or DI, respectively, compared with 2.6% and 5.4% of the comparison group. Cranial radiation doses of 25 Gy or more were associated with a higher risk of current SSI (relative risk [RR] = 3.93, 95% confidence interval [CI] = 2.05 to 7.56) and DI (RR = 3.65, 95% CI = 1.65 to 8.06) enrollment. Survivors with severe/life-threatening conditions were more often enrolled on SSI (RR = 3.77, 95% CI = 2.04 to 6.96) and DI (RR = 2.73, 95% CI = 1.45 to 5.14) compared with those with mild/moderate or no health conditions. Further research is needed on disability-related financial challenges after childhood cancer. C1 [Kirchhoff, Anne C.; Warner, Echo L.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Kirchhoff, Anne C.] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Parsons, Helen M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Kuhlthau, Karen A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Donelan, Karen; Park, Elyse R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Armstrong, Gregory T.; Robison, Leslie L.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA. [Oeffinger, Kevin C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Kirchhoff, AC (reprint author), Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA. EM anne.kirchhoff@hci.utah.edu FU Lance Armstrong Foundation; National Cancer Institute [U24 CA 55727]; Huntsman Cancer Institute; Huntsman Cancer Foundation FX This work was supported by the Lance Armstrong Foundation and the National Cancer Institute (U24 CA 55727, Armstrong GT, principal investigator). Dr. Kirchhoff is supported by the Huntsman Cancer Institute and the Huntsman Cancer Foundation. NR 19 TC 3 Z9 3 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv057 DI 10.1093/jnci/djv057 PG 4 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500004 PM 25770148 ER PT J AU Trinh, QD Nguyen, PL Leow, JJ Dalela, D Chao, GF Mahal, BA Nayak, M Schmid, M Choueiri, TK Aizer, AA AF Trinh, Quoc-Dien Nguyen, Paul L. Leow, Jeffrey J. Dalela, Deepansh Chao, Grace F. Mahal, Brandon A. Nayak, Manan Schmid, Marianne Choueiri, Toni K. Aizer, Ayal A. TI Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID CELL LUNG-CANCER; LOCALIZED PROSTATE-CANCER; RACIAL DISPARITIES; AFRICAN-AMERICAN; COLORECTAL-CANCER; UNITED-STATES; BREAST-CANCER; RACIAL/ETHNIC DIFFERENCES; SOCIOECONOMIC-STATUS; ETHNIC-DIFFERENCES AB Background: Racial disparities in cancer survival outcomes have been primarily attributed to underlying biologic mechanisms and the quality of cancer care received. Because prior literature shows little difference exists in the socioeconomic status of non-Hispanic whites and Asian Americans, any difference in cancer survival is less likely to be attributable to inequalities of care. We sought to examine differences in cancer-specific survival between whites and Asian Americans. Methods: The Surveillance, Epidemiology, and End Results Program was used to identify patients with lung (n = 130 852 [16.9%]), breast (n = 313 977 [40.4%]), prostate (n = 166 529 [21.4%]), or colorectal (n = 165 140 [21.3%]) cancer (the three leading causes of cancer-related mortality within each sex) diagnosed between 1991 and 2007. Fine and Gray's competing risks regression compared the cancer-specific mortality (CSM) of eight Asian American groups (Chinese, Filipino, Hawaiian/Pacific Islander, Japanese, Korean, other Asian, South Asian [Indian/Pakistani], and Vietnamese) to non-Hispanic white patients. All P values were two-sided. Results: In competing risks regression, the receipt of definitive treatment was an independent predictor of CSM (hazard ratio [HR] = 0.37, 95% confidence interval [CI] = 0.35 to 0.40; HR = 0.55, 95% CI = 0.53 to 0.58; HR = 0.61, 95% CI = 0.60 to 0.62; and HR = 0.27, 95% CI = 0.25 to 0.29) for prostate, breast, lung, and colorectal cancers respectively, all P <.001). In adjusted analyses, most Asian subgroups (except Hawaiians and Koreans) had lower CSM relative to white patients, with hazard ratios ranging from 0.54 (95% CI = 0.38 to 0.78) to 0.88 (95% CI = 0.84 to 0.93) for Japanese patients with prostate and Chinese patients with lung cancer, respectively. Conclusions: Despite adjustment for potential confounders, including the receipt of definitive treatment and tumor characteristics, most Asian subgroups had better CSM than non-Hispanic white patients. These findings suggest that underlying genetic/biological differences, along with potential cultural variations, may impact survival in Asian American cancer patients. C1 [Trinh, Quoc-Dien; Leow, Jeffrey J.; Chao, Grace F.; Schmid, Marianne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Urol Surg,Brigham & Womens Hosp, Boston, MA 02115 USA. [Trinh, Quoc-Dien; Leow, Jeffrey J.; Chao, Grace F.; Schmid, Marianne] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Surg & Publ Hlth,Brigham & Womens Hosp, Boston, MA 02115 USA. [Nguyen, Paul L.; Mahal, Brandon A.; Nayak, Manan; Aizer, Ayal A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA. [Choueiri, Toni K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Brigham & Womens Hosp, Boston, MA 02115 USA. [Dalela, Deepansh] Henry Ford Hlth Syst, Vattikuti Urol Inst, Ctr Outcomes Res Analyt & Evaluat, Detroit, MI USA. RP Trinh, QD (reprint author), Ctr Surg & Publ Hlth, 45 Francis St,ASB II 3, Boston, MA 02115 USA. EM qtrinh@partners.org FU Vattikuti Urology Institute; Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital FX This work is supported by an unrestricted educational grant from the Vattikuti Urology Institute and the Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital. NR 68 TC 10 Z9 10 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv054 DI 10.1093/jnci/djv054 PG 8 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500003 PM 25794888 ER PT J AU Park, KK Tsai, TY Dimitriou, D Kwon, YM AF Park, Kwan Kyu Tsai, Tsung-Yuan Dimitriou, Dimitris Kwon, Young-Min TI Utility of Preoperative Femoral Neck Geometry in Predicting Femoral Stem Anteversion SO JOURNAL OF ARTHROPLASTY LA English DT Article DE total hip arthroplasty; femoral anteversion; stem anteversion; computed tomography; in-vivo 3-dimensional study ID TOTAL HIP-ARTHROPLASTY; DISLOCATION; ALIGNMENT; ACCURACY; FEMUR; CUP; CT AB This study investigated the relationships between the preoperative femoral anteversions and the femoral stem anteversion using CT scans and CT-based 3D models to determine whether any preoperative anteversion measurement correlates with the postoperative stem anteversion. Pre-operative and post-operative CT scans of 19 hips with THAs were evaluated. Five preoperative anatomical femoral anteversion measurements (CT-Head, CT-Below Head, CT-Neck, 3D-Head, and 3D-Neck) were compared with the postoperative femoral stem anteversion. The preoperative CT-Neck anteversion measurement was most correlated with the postoperative stem anteversion (r = 0.761, P = 0.002) with the narrowest ranges of the differences (-10.2 degrees to 11.0 degrees). The preoperative anteversions using the femoral neck geometry from CT scans can be used for the estimation of the postoperative femoral stem anteversion in THA. (C) 2015 Elsevier Inc. All rights reserved. C1 [Park, Kwan Kyu; Tsai, Tsung-Yuan; Dimitriou, Dimitris; Kwon, Young-Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, Boston, MA USA. [Park, Kwan Kyu] Yonsei Univ, Coll Med, Dept Orthoped Surg, Seoul, South Korea. RP Kwon, YM (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. OI Tsai, Tsung-Yuan/0000-0003-1522-2987; Dimitriou, Dimitris/0000-0002-9558-7080 NR 23 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD JUN PY 2015 VL 30 IS 6 BP 1079 EP 1084 DI 10.1016/j.arth.2015.01.016 PG 6 WC Orthopedics SC Orthopedics GA CK4GY UT WOS:000356183500035 PM 25683295 ER PT J AU Tomer, Y Dolan, LM Kahaly, G Divers, J D'Agostino, RB Imperatore, G Dabelea, D Marcovina, S Black, MH Pihoker, C Hasham, A Hammerstad, SS Greenberg, DA Lotay, V Zhang, WJ Monti, MC Matheis, N AF Tomer, Yaron Dolan, Lawrence M. Kahaly, George Divers, Jasmin D'Agostino, Ralph B., Jr. Imperatore, Giuseppina Dabelea, Dana Marcovina, Santica Black, Mary Helen Pihoker, Catherine Hasham, Alia Hammerstad, Sara Salehi Greenberg, David A. Lotay, Vaneet Zhang, Weijia Monti, Maria Cristina Matheis, Nina CA SEARCH Diabet Youth Study TI Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Type 1 diabetes; Graves' disease; Hashimoto's thyroiditis; Gene; HLA ID HASHIMOTOS-THYROIDITIS; RISK LOCI; SUSCEPTIBILITY; DISEASE; ASSOCIATION; FAMILIES; GENETICS; CHILDREN; MELLITUS; COMMON AB Autoimmune thyroid diseases (AITD) and Type 1 diabetes (T1D) frequently occur in the same individual pointing to a strong shared genetic susceptibility. Indeed, the co-occurrence of T1D and AITD in the same individual is classified as a variant of the autoimmune polyglandular syndrome type 3 (designated APS3v). Our aim was to identify new genes and mechanisms causing the co-occurrence of T1D AITD (APS3v) in the same individual using a genome-wide approach. For our discovery set we analyzed 346 Caucasian APS3v patients and 727 gender and ethnicity matched healthy controls. Genotyping was performed using the Illumina Human660W-Quad.v1. The replication set included 185 APS3v patients and 340 controls. Association analyses were performed using the PLINK program, and pathway analyses were performed using the MAGENTA software. We identified multiple signals within the HLA region and conditioning studies suggested that a few of them contributed independently to the strong association of the HLA locus with APS3v. Outside the HLA region, variants in GPR103, a gene not suggested by previous studies of APS3v, T1D, or AITD, showed genolne-wide significance (p < 5 x 10(-8)). In addition, a locus on 1p13 containing the PTPN22 gene showed genome-wide significant associations. Pathway analysis demonstrated that cell cycle, B-cell development, CD40, and CTLA-4 signaling were the major pathways contributing to the pathogenesis of APS3v. These findings suggest that complex mechanisms involving T-cell and B-cell pathways are involved in the strong genetic association between AITD and T1D. Published by Elsevier Ltd. C1 [Tomer, Yaron; Hasham, Alia; Hammerstad, Sara Salehi] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Endocrinol, Cincinnati, OH 45229 USA. [Kahaly, George; Matheis, Nina] Johannes Gutenberg Univ Mainz, Med Ctr, Thyroid Res Lab, D-55122 Mainz, Germany. [Divers, Jasmin; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Dabelea, Dana] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Marcovina, Santica] Univ Washington, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Black, Mary Helen] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Greenberg, David A.] Nationwide Childrens Hosp, Battelle Ctr Math Med, Columbus, OH USA. [Lotay, Vaneet; Zhang, Weijia] Icahn Sch Med Mt Sinai, Dept Med Bioinformat Core, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Monti, Maria Cristina] Univ Pavia, Dept Publ Hlth Neurosci Expt & Forens Med, I-27100 Pavia, Italy. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu RI Dagostino Jr, Ralph/C-4060-2017; OI Dagostino Jr, Ralph/0000-0002-3550-8395; Monti, Maria Cristina/0000-0003-1586-527X FU NIH-NIDDK [DK61659, DK067555, DK073681]; Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai; Andrea and Charles Bronfman Philanthropies; Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR) [UL1RR029882]; Seattle Children's Hospital (NIH CTSA) of the University of Washington [UL1 TR00423]; University of Colorado Pediatric Clinical and Translational Research Center (CTRC) [UL1 TR000154]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [8 UL1 TR000077] FX We thank the Human Biological Data Interchange (Philadelphia, PA) for assisting with the recruitment of the replication set. This work was supported in part by grants DK61659, DK067555 & DK073681 from NIH-NIDDK (to YT). This study was also supported in part by the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai with funding provided by the Andrea and Charles Bronfman Philanthropies.; Grant Support: SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases.; Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Seattle Children's Hospital (NIH CTSA Grant UL1 TR00423 of the University of Washington); University of Colorado Pediatric Clinical and Translational Research Center (CTRC) (Grant Number UL1 TR000154) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8 UL1 TR000077; and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 40 TC 12 Z9 13 U1 1 U2 9 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD JUN PY 2015 VL 60 BP 32 EP 39 DI 10.1016/j.jaut.2015.03.006 PG 8 WC Immunology SC Immunology GA CK9JX UT WOS:000356557500004 PM 25936594 ER PT J AU Xuan, WJ Agrawal, T Huang, LY Gupta, GK Hamblin, MR AF Xuan, Weijun Agrawal, Tanupriya Huang, Liyi Gupta, Gaurav K. Hamblin, Michael R. TI Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis SO JOURNAL OF BIOPHOTONICS LA English DT Article DE traumatic brain injury; transcranial low level light therapy; synaptogenesis; neurogenesis; BDNF; Synapsin-1 ID TERM NEUROLOGICAL DEFICITS; LIGHT THERAPY; INDUCED NEUROGENESIS; ISCHEMIC-STROKE; EXERCISE; INTERVENTION; MODERATE; MODEL; ZONE AB Transcranial low-level laser (light) therapy (LLLT) is a new non-invasive approach to treating a range of brain disorders including traumatic brain injury (TBI). We (and others) have shown that applying near-infrared light to the head of animals that have suffered TBI produces improvement in neurological functioning, lessens the size of the brain lesion, reduces neuroinflammation, and stimulates the formation of new neurons. In the present study we used a controlled cortical impact TBI in mice and treated the mice either once (4 h post-TBI, 1-laser), or three daily applications (3-laser) with 810 nm CW laser 36 J/cm(2) at 50 mW/cm(2). Similar to previous studies, the neurological severity score improved in laser-treated mice compared to untreated TBI mice at day 14 and continued to further improve at days 21 and 28 with 3-laser being better than 1-laser. Mice were sacrificed at days 7 and 28 and brains removed for immunofluorescence analysis. Brain-derived neurotrophic factor (BDNF) was significantly up-regulated by laser treatment in the dentate gyrus of the hippocampus (DG) and the subventricular zone (SVZ) but not in the perilesional cortex (lesion) at day 7 but not at day 28. Synapsin-1 (a marker for synaptogenesis, the formation of new connections between existing neurons) was significantly upregulated in lesion and SVZ but not DG, at 28 days but not 7 days. The data suggest that the benefit of LLLT to the brain is partly mediated by stimulation of BDNF production, which may in turn encourage synaptogenesis. Moreover the pleiotropic benefits of BDNF in the brain suggest LLLT may have wider applications to neurodegenerative and psychiatric disorders. C1 [Xuan, Weijun] Guangxi Univ Chinese Med, Affiliated Coll & Hosp 1, Dept Otolaryngol, Nanning, Peoples R China. [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Xuan, Weijun; Agrawal, Tanupriya; Huang, Liyi; Gupta, Gaurav K.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China. [Gupta, Gaurav K.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA. [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu FU US NIH [R01AI050875]; Air Force Office of Scientific Research [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity grant [W81XWH-09-1-0514]; US Army Medical Research and Materiel Command [W81XWH-13-2-0067] FX This work was supported by US NIH grant R01AI050875, by Air Force Office of Scientific Research grant FA9550-13-1-0068, by US Army Medical Research Acquisition Activity grant W81XWH-09-1-0514 and by US Army Medical Research and Materiel Command grant W81XWH-13-2-0067. NR 42 TC 18 Z9 19 U1 2 U2 11 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1864-063X EI 1864-0648 J9 J BIOPHOTONICS JI J. Biophotonics PD JUN PY 2015 VL 8 IS 6 BP 502 EP 511 DI 10.1002/jbio.201400069 PG 10 WC Biochemical Research Methods; Biophysics; Optics SC Biochemistry & Molecular Biology; Biophysics; Optics GA CK2VH UT WOS:000356071500006 PM 25196192 ER PT J AU Halushka, MK Eng, G Collins, AB Judge, DP Semigran, MJ Stone, JR AF Halushka, Marc K. Eng, George Collins, A. Bernard Judge, Daniel P. Semigran, Marc J. Stone, James R. TI Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH LA English DT Article DE Amyloid; Immunoglobulin light chain; Transthyretin; Classification; Diagnostic test ID EUROPEAN CARDIOVASCULAR PATHOLOGY; TRANSTHYRETIN AMYLOIDOSIS; MONOCLONAL GAMMOPATHY; CONSENSUS STATEMENT; MULTIPLE-MYELOMA; DIAGNOSIS; ASSOCIATION; DISORDERS; SPECIMENS; SOCIETY AB Accurate and rapid classification of cardiac amyloidosis is important for patient management. We have optimized the use of serum free light chain kappa and lambda values to differentiate immunoglobulin light chain amyloid (AL) amyloidosis from transthyretin amyloid and amyloid A using 85 cases of tissue-proven cardiac amyloidosis, in which there was direct classification of amyloidosis by mass spectrometry or immunofluorescence. The serum free light chain kappa/lambda ratios were non-overlapping for the three major groups: AL-lambda (0.01-0.41, n = 30), non-AL (0.52-2.7, n = 43), and AL-kappa (6.7-967, n = 12). A kappa/lambda ratio value between 0.5 and 5.0 had 100 % sensitivity and 100 % specificity for distinguishing AL amyloidosis from non-AL amyloidosis. This optimized range for serum light chain kappa/lambda ratio provides extremely robust classification of cardiac amyloidosis. Cases of cardiac amyloidosis in which the serum kappa/lambda free light chain ratio falls close to these new cutoff values may benefit most from direct amyloid subtyping. C1 [Halushka, Marc K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Eng, George; Collins, A. Bernard; Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Eng, George; Collins, A. Bernard; Semigran, Marc J.; Stone, James R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Judge, Daniel P.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA. [Semigran, Marc J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. RP Stone, JR (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Simches Res Bldg,Room 8236,185 Cambridge St CPZN, Boston, MA 02114 USA. EM jrstone@mgh.harvard.edu OI Halushka, Marc/0000-0002-7112-7389 FU Massachusetts General Hospital; Johns Hopkins Hospital FX This study was funded by Massachusetts General Hospital and The Johns Hopkins Hospital. NR 24 TC 5 Z9 5 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1937-5387 EI 1937-5395 J9 J CARDIOVASC TRANSL JI J. Cardiovasc. Transl. Res. PD JUN PY 2015 VL 8 IS 4 BP 264 EP 268 DI 10.1007/s12265-015-9628-2 PG 5 WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental SC Cardiovascular System & Cardiology; Research & Experimental Medicine GA CK8SL UT WOS:000356508500007 PM 25925232 ER PT J AU Lewis, MA Zhao, FM Jones, D Loprinzi, CL Brell, J Weiss, M Fisch, MJ AF Lewis, Mark A. Zhao, Fengmin Jones, Desiree Loprinzi, Charles L. Brell, Joanna Weiss, Matthias Fisch, Michael J. TI Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Colorectal cancer; neuropathy; neuropathic pain; numbness/tingling; oxaliplatin ID ADJUVANT TREATMENT; COLON-CANCER; OXALIPLATIN; PAIN; NEUROTOXICITY; FLUOROURACIL; LEUCOVORIN; TRIAL AB Context. Few studies have examined the prevalence and severity of treatment-induced neuropathic symptoms in patients across different cancer types. Objectives. This study aimed to report the prevalence of numbness/tingling (N/T) and neuropathic pain in patients with colorectal cancer (CRC) vs. other cancers, describe the prevalence of moderate-to-severe N/T by specific clinical variables, and examine factors associated with the presence of these symptoms. Methods. A total of 3106 outpatients with colorectal (n = 718), breast (n = 1544), lung (n = 524), or prostate (n = 320) cancer were enrolled at any point in their treatment. Assessments were conducted at the initial visit and 28-35 days later. Patients reported pain and N/T; clinicians reported mechanism of pain and ranked the top three symptoms causing difficulties. Results. Moderate-to-severe N/T was higher in patients with CRC relative to other cancer types (25.8% vs. 17.1%, P < 0.001); 25% vs. 10.5% of clinicians rated N/T as a top three symptom for patients with CRC relative to other cancers (P < 0.001). The prevalence of neuropathic pain was comparable between patients with CRC and other cancers (P = 0.654). Patients with CRC, longer duration of cancer, prior therapy, on current therapy, older patients, and patients of black race experienced worse N/T. Conclusion. Patients with CRC experience significantly higher rates of N/T but comparable neuropathic pain, relative to patients with other cancers. Awareness of the prevalence and severity of neuropathic symptoms and their associated risk factors in this patient population is critical for both clinicians and patients. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Lewis, Mark A.; Jones, Desiree; Fisch, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA. [Zhao, Fengmin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Loprinzi, Charles L.] Mayo Clin, Breast Dept, Rochester, MN USA. [Loprinzi, Charles L.] Mayo Clin, Dept Oncol, Rochester, MN USA. [Brell, Joanna] NCI, Rockville, MD USA. [Weiss, Matthias] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. RP Jones, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, 1515 Holcombe Blvd,Unit 410, Houston, TX 77030 USA. EM djones1@mdanderson.org FU Public Health Service [CA37604, CA17145, CA45809]; National Cancer Institute, National Institutes of Health; Department of Health and Human Services FX This study was supported in part by Public Health Service grants CA37604, CA17145, and CA45809 as well as grants from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Drs. Fisch and Zhao had full access to the data. The authors have no disclosures. NR 24 TC 4 Z9 4 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUN PY 2015 VL 49 IS 6 BP 1016 EP 1024 DI 10.1016/j.jpainsymman.2014.11.300 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CL0BY UT WOS:000356604700010 PM 25596011 ER PT J AU Dain, AS Bradley, EH Hurzeler, R Aldridge, MD AF Dain, Aleksandra S. Bradley, Elizabeth H. Hurzeler, Rosemary Aldridge, Melissa D. TI Massage, Music, and Art Therapy in Hospice: Results of a National Survey SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hospice; complementary and alternative medicine; massage therapy; art therapy; music therapy ID ALTERNATIVE MEDICINE; PALLIATIVE CARE; FOR-PROFIT; MORTALITY; CANCER; COMPLEMENTARY; PATTERNS; QUALITY; ILLNESS; NURSES AB Context. Complementary and alternative medicine (CAM) provides clinical benefits to hospice patients, including decreased pain and improved quality of life. Yet little is known about the extent to which U.S. hospices employ CAM therapists. Objectives. To report the most recent national data regarding the inclusion of art, massage, and music therapists on hospice interdisciplinary teams and how CAM therapist staffing varies by hospice characteristics. Methods. A national cross-sectional survey of a random sample of hospices (n = 591; 84% response rate) from September 2008 to November 2009. Results. Twenty-nine percent of hospices (169 of 591) reported employing an art, massage, or music therapist. Of those hospices, 74% employed a massage therapist, 53% a music therapist, and 22% an art therapist, and 42% expected the therapist to attend interdisciplinary staff meetings, indicating a significant role for these therapists on the patient's care team. In adjusted analyses, larger hospices compared with smaller hospices had significantly higher odds of employing a CAM therapist (adjusted odds ratio 6.38; 95% CI 3.40, 11.99) and for-profit hospices had lower odds of employing a CAM therapist compared with nonprofit hospices (adjusted odds ratio 0.52; 95% CI 0.32, 0.85). Forty-four percent of hospices in the Mountain/Pacific region reported employing a CAM therapist vs. 17% in the South Central region. Conclusion. Less than one-third of U.S. hospices employ art, massage, or music therapists despite the benefits these services may provide to patients and families. A higher proportion of large hospices, nonprofit hospices, and hospices in the Mountain/Pacific region employ CAM therapists, indicating differential access to these important services. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Dain, Aleksandra S.; Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dain, Aleksandra S.] James J Peters VA, Bronx, NY USA. [Bradley, Elizabeth H.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. [Hurzeler, Rosemary] John Thompson Hosp Inst Educ Training & Res Inc, Branford, CT USA. RP Aldridge, MD (reprint author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM Melissa.Aldridge@mssm.edu FU National Cancer Institute [1R01CA116398]; National Institute of Nursing Research [5R01NR013499]; John D. Thompson Foundation; American Federation for Aging Research and Medical Student Training in Aging Research FX This study was supported by the National Cancer Institute 1R01CA116398 (Bradley); National Institute of Nursing Research 5R01NR013499 (Aldridge); the John D. Thompson Foundation (Bradley); and the American Federation for Aging Research and Medical Student Training in Aging Research (Dain). The authors declare no conflicts of interest. NR 36 TC 2 Z9 2 U1 6 U2 40 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUN PY 2015 VL 49 IS 6 BP 1035 EP 1041 DI 10.1016/j.jpainsymman.2014.11.295 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CL0BY UT WOS:000356604700012 PM 25555445 ER PT J AU Dussel, V Orellana, L Soto, N Chen, K Ullrich, C Kang, TI Geyer, JR Feudtner, C Wolfe, J AF Dussel, Veronica Orellana, Liliana Soto, Natalie Chen, Kun Ullrich, Christina Kang, Tammy I. Geyer, Jeffrey R. Feudtner, Chris Wolfe, Joanne TI Feasibility of Conducting a Palliative Care Randomized Controlled Trial in Children With Advanced Cancer: Assessment of the PediQUEST Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Pediatrics; pediatric oncology; supportive care; feasibility; attrition; end-of-life care; patient-reported outcomes; randomized controlled trial; palliative care ID END-OF-LIFE; PEDIATRIC ONCOLOGY; CLINICAL-RESEARCH; PATIENT; INTERVENTIONS; HOME; MASSAGE; RCT AB Context. Pediatric palliative care randomized controlled trials (PPC-RCTs) are uncommon. Objectives. To evaluate the feasibility of conducting a PPC-RCT in pediatric cancer patients. Methods. This was a cohort study embedded in the Pediatric Quality of Life and Evaluation of Symptoms Technology Study (NCT01838564). This multicenter PPC-RCT evaluated an electronic patient-reported outcomes system. Children aged two years and older, with advanced cancer, and potentially eligible for the study were included. Outcomes included: pre-inclusion attrition (patients not approached, refusals); post-inclusion attrition (drop-out, elimination, death, and intermittent attrition (IA; missing surveys) over nine months of follow-up); child/teenager self-report rates; and, reasons to enroll/participate. Results. Over five years, of the 339 identified patients, 231 were eligible (in 22, we could not verify eligibility); 84 eligible patients were not approached and 43 declined participation. Patients not approached were more likely to die or have brain tumors. We enrolled 104 patients. Average enrollment rate was one patient per site per month; shortening follow-up from nine to three months (with optional re-enrollment) increased recruitment by 20%. A total of 87 patients completed the study (24 died) and 17 dropped out. Median IA was 41% in the first 20 weeks of follow-up and more than 60% in the eight weeks preceding death. Child/teenager self-report was 94%. Helping others, low burden procedures, incentives, and staff attitude were frequent reasons to enroll/participate. Conclusion. A PPC-RCT in children with advanced cancer was feasible, post-inclusion retention adequate; many families participated for altruistic reasons. Strategies that may further PPC-RCT feasibility include: increasing target population through large multicenter studies, approaching sicker patients, preventing exclusion of certain patient groups, and improving data collection at end of life. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Dussel, Veronica; Ullrich, Christina; Wolfe, Joanne] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA. [Chen, Kun; Ullrich, Christina; Wolfe, Joanne] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02215 USA. [Dussel, Veronica; Soto, Natalie] Inst Clin Effect & Hlth Policy, Buenos Aires, DF, Argentina. [Orellana, Liliana] Deakin Univ, Biostat Unit Fac Hlth, Geelong, Vic 3217, Australia. [Ullrich, Christina; Wolfe, Joanne] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Ullrich, Christina; Wolfe, Joanne] Harvard Univ, Sch Med, Boston, MA USA. [Kang, Tammy I.; Feudtner, Chris] Childrens Hosp, Dept Pediat, Philadelphia, PA 19104 USA. [Kang, Tammy I.; Feudtner, Chris] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Geyer, Jeffrey R.] Seattle Childrens Hosp, Div Pediat Hematol Oncol, Seattle, WA USA. [Geyer, Jeffrey R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Geyer, Jeffrey R.] Univ Washington, Seattle, WA 98195 USA. RP Wolfe, J (reprint author), Dana Farber Canc Inst, Pediat Palliat Care Serv, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave, Boston, MA 02215 USA. EM joanne_wolfe@dfci.harvard.edu RI Orellana, Liliana/I-5249-2013; Orellana, Liliana/S-3302-2016 OI Orellana, Liliana/0000-0003-3736-4337; Orellana, Liliana/0000-0003-3736-4337 FU National Institutes of Health/National Cancer Institute grant [1K07 CA096746-01]; Charles H. Hood Foundation Child Health Research Award; American Cancer Society Pilot and Exploratory Project Award in Palliative Care of Cancer Patients and Their Families FX The Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology study in children with cancer was supported by National Institutes of Health/National Cancer Institute grant 1K07 CA096746-01, Charles H. Hood Foundation Child Health Research Award, and American Cancer Society Pilot and Exploratory Project Award in Palliative Care of Cancer Patients and Their Families. Funders had no role in the design and conduct of the study, analysis of the data, or preparation of the manuscript. All authors declare no potential conflicts of interest. NR 32 TC 2 Z9 2 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUN PY 2015 VL 49 IS 6 BP 1059 EP 1069 DI 10.1016/j.jpainsymman.2014.12.010 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CL0BY UT WOS:000356604700015 PM 25640275 ER PT J AU Dushay, JR Tecilazich, F Kafanas, A Magargee, ML Auster, ME Gnardellis, C Dinh, T Veves, A AF Dushay, Jody R. Tecilazich, Francesco Kafanas, Antonios Magargee, Mary L. Auster, Michael E. Gnardellis, Charalambos Dinh, Thanh Veves, Aristidis TI Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal function SO JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM LA English DT Article DE Type 2 diabetes; prediabetes; aliskiren; vascular smooth muscle ID RENIN INHIBITOR ALISKIREN; LEFT-VENTRICULAR HYPERTROPHY; MEDIATED VASODILATION; FOOT ULCERATION; LOSARTAN; HYPERTENSION; NEPHROPATHY; DYSFUNCTION; EXPRESSION; REACTIVITY AB Objective: The objective of this paper is to study the effect of aliskiren on metabolic parameters and micro- and macrovascular reactivity in individuals diagnosed with or at high risk for developing type 2 diabetes mellitus (T2DM). Research design and methods: We studied 47 T2DM and 41 at-risk individuals in a randomized, double-blinded, placebo-controlled trial. All subjects were treated with 150 mg aliskiren or placebo daily for 12 weeks. Twenty-six (55%) of T2DM and four (8%) at-risk subjects were also treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers. Results: Aliskiren treatment was associated with improvement in systolic and diastolic blood pressure and endothelium-independent vasodilation at the skin microcirculation in those with T2DM but not in those at risk. There were no incidences of hypotension and no significant changes in serum potassium or creatinine levels with aliskiren treatment in either study group. Conclusions: Aliskiren improves blood pressure and vascular smooth muscle function in the skin microcirculation of T2DM patients. C1 [Tecilazich, Francesco; Kafanas, Antonios; Magargee, Mary L.; Auster, Michael E.; Dinh, Thanh; Veves, Aristidis] Joslin Beth Israel Deaconess Foot Ctr, Boston, MA USA. [Tecilazich, Francesco; Kafanas, Antonios; Magargee, Mary L.; Auster, Michael E.; Dinh, Thanh; Veves, Aristidis] Microcirculat Lab, Boston, MA USA. [Dushay, Jody R.] Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA. [Gnardellis, Charalambos] Technol Educ Inst Messolonghi, Mesolongion, Greece. RP Veves, A (reprint author), Beth Israel Deaconess Med Ctr, 1 Deaconess Rd,PA-321A, Boston, MA 02215 USA. EM aveves@bidmc.harvard.edu FU Novartis Pharmaceuticals Corporation [CSPP100AUS25T]; Clinical Translational Science Award [UL1RR025758]; Beth Israel Deaconess Medical Center from the National Center for Research Resources FX This was an investigator-initiated research study that was supported by a research grant from Novartis Pharmaceuticals Corporation (CSPP100AUS25T) to AV. The project was also supported by the Clinical Translational Science Award UL1RR025758 to Harvard University and Beth Israel Deaconess Medical Center from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Clinical trial registration number: NCT01165983. NR 30 TC 0 Z9 0 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1470-3203 EI 1752-8976 J9 J RENIN-ANGIO-ALDO S JI J. Renin-Angiotensin-Aldosterone Syst. PD JUN PY 2015 VL 16 IS 2 BP 344 EP 352 DI 10.1177/1470320313489060 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CK6BQ UT WOS:000356313200015 PM 23670354 ER PT J AU Vaid, M Katiyar, SK AF Vaid, Mudit Katiyar, Santosh K. TI Grape seed proanthocyanidins inhibit cigarette smoke condensate-induced lung cancer cell migration through inhibition of NADPH oxidase and reduction in the binding of p22(phox) and p47(phox) proteins SO MOLECULAR CARCINOGENESIS LA English DT Article DE cigarette smoke condensate; oxidative stress; lung cancer cells; proanthocyanidins; cancer cell migration; NADPH oxidase ID SKH-1 HAIRLESS MICE; OXIDATIVE STRESS; MESENCHYMAL TRANSITION; LIPID-PEROXIDATION; NITRIC-OXIDE; IN-VITRO; ACTIVATION; EXTRACT; PHOSPHORYLATION; PEROXYNITRITE AB Cigarette smoking is the major cause of lung cancer. It is therefore important to develop effective strategies that target molecular abnormalities induced by cigarette smoke condensate (CSC). Cigarette smoking increases oxidative stress particularly via activation of NADPH oxidase (NOX), a key source of superoxide anion production. Here, we report that grape seed proanthocyanidins (GSPs) exert an inhibitory effect on the CSC-induced migration of non-small cell lung cancer (NSCLC) cells (A549, H460, and H1299). Using an in vitro invasion assay, we found that treatment of NSCLC cells with CSC increased NSCLC cell migration by enhancing NOX mediated-oxidative stress. Treatment of NSCLC cells with GSPs inhibited the CSC-induced cell migration through reduction in oxidative stress levels and a reduction in the epithelial-to-mesenchymal transition. To identify the molecular targets of GSPs, we examined the effects of GSPs on CSC-induced alterations in the levels of key NOX components, namely p22(phox) and p47(phox) proteins, using A549 cells. We also determined the effect of GSPs on CSC-induced interaction/binding between these proteins, which is a key event in NOX activation. We found that treatment of A549 cells with GSPs not only inhibited the CSC-induced increase in the expression levels of p22(phox) and p47(phox), but also reduced the binding of p22(phox) to p47(phox) proteins. This new insight into the anti-lung cancer cell migration activity of GSPs could serve as a basis for development of improved chemopreventive or therapeutic strategies for lung cancer. (c) 2014 Wiley Periodicals, Inc. C1 [Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670,Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. FU Veterans Administration Merit Review Award [1I01BX001410-01] FX Grant sponsor: Veterans Administration Merit Review Award; Grant number: 1I01BX001410-01 NR 39 TC 5 Z9 5 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD JUN PY 2015 VL 54 SU 1 SI SI BP E61 EP E71 DI 10.1002/mc.22173 PG 11 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA CK8UG UT WOS:000356513600008 PM 24798688 ER PT J AU Mamikonyan, E Xie, SX Melvin, E Weintraub, D AF Mamikonyan, Eugenia Xie, Sharon X. Melvin, Emilie Weintraub, Daniel TI Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study SO MOVEMENT DISORDERS LA English DT Article DE clinical trials randomized controlled; mild cognitive impairment; Parkinson's disease; cholinesterase inhibitor; class I ID DEMENTIA RATING-SCALE; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS; DIAGNOSTIC-CRITERIA; MATTIS DEMENTIA; DOUBLE-BLIND; DISABILITY; DONEPEZIL; VALIDITY; TRIAL AB Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n=28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer's Disease Cooperative StudyClinical Global Impression of Change (ADCS-CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale-2 (DRS-2), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson's Disease Questionnaire (PDQ-8). Twenty-six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed-effects model=0.44, F[df]=3.01 [1, 24], P=0.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient=-2.41, F[df]=5.81 [1, 22.05], P=0.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ-8 (regression coefficient=4.55, F[df]=3.93 [1, 14. 79], P=0.09) and the State Anxiety Inventory (regression coefficient=-1.24, F[df]=3.17 [1, 33], P=0.08). Rivastigmine in PD-MCI showed a trend effect for improvements on a global rating of cognition, disease-related health status, and anxiety severity, and significant improvement on a performance-based measure of cognitive abilities. (c) 2015 International Parkinson and Movement Disorder Society C1 [Mamikonyan, Eugenia; Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Melvin, Emilie] Duke Univ, Durham, NC USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Educ & Clin Ctr PADRECC & MIRECC, Parkinsons Dis & Mental Illness Res, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Novartis Pharmaceuticals FX Novartis Pharmaceuticals provided financial support as well as drug supply (rivastigmine and placebo patch) for this investigator initiated clinical trial. NR 46 TC 23 Z9 23 U1 4 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 912 EP 918 DI 10.1002/mds.26236 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600009 PM 25914281 ER PT J AU Weintraub, D Simuni, T Caspell-Garcia, C Coffey, C Lasch, S Siderowf, A Aarsland, D Barone, P Burn, D Chahine, LM Eberling, J Espay, AJ Foster, ED Leverenz, JB Litvan, I Richard, I Troyer, MD Hawkins, KA AF Weintraub, Daniel Simuni, Tanya Caspell-Garcia, Chelsea Coffey, Christopher Lasch, Shirley Siderowf, Andrew Aarsland, Dag Barone, Paolo Burn, David Chahine, Lama M. Eberling, Jamie Espay, Alberto J. Foster, Eric D. Leverenz, James B. Litvan, Irene Richard, Irene Troyer, Matthew D. Hawkins, Keith A. CA Parkinson's Progression Markers In TI Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE anxiety; apathy; cognition; depression; impulse control disorder; Parkinson's disease; psychosis ID IMPULSE CONTROL DISORDERS; NONMOTOR SYMPTOMS; RATING-SCALE; DEPRESSION SCALE; MOTOR SUBTYPE; IMPAIRMENT; DEMENTIA; INCIDENT; COHORT; SPECTRUM AB This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). BackgroundBoth CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. MethodsParkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. ResultsBaseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). ConclusionsApproximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS. (c) 2015 International Parkinson and Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Chahine, Lama M.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Caspell-Garcia, Chelsea; Coffey, Christopher; Foster, Eric D.] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. [Lasch, Shirley] IND, New Haven, CT USA. [Lasch, Shirley] MNI, New Haven, CT USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Aarsland, Dag] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Aarsland, Dag] Karolinska Inst, Alzheimer Dis Res Ctr, Stockholm, Sweden. [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway. [Barone, Paolo] Univ Salerno, Dept Med, Neurosci Sect, Neurodegenerat Dis Ctr, Salerno, Italy. [Burn, David] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Eberling, Jamie] Michael J Fox Fdn Parkinsons Res, New York, NY USA. [Espay, Alberto J.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Litvan, Irene] Univ Calif San Diego, Dept Neurosci, UCSD Movement Disorder Ctr, San Diego, CA 92103 USA. [Richard, Irene] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [Richard, Irene] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Troyer, Matthew D.] Medivation Inc, San Francisco, CA USA. [Hawkins, Keith A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Psychiat & Neurol, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu RI Rowe, Dominic/B-6661-2011; OI Rowe, Dominic/0000-0003-0912-2146; Litvan, Irene/0000-0002-3485-3445; Standaert, David/0000-0003-2921-8348; Aarsland, Dag/0000-0001-6314-216X FU Michael J. Fox Foundation (MJFF) FX The study is funded by the Michael J. Fox Foundation (MJFF). The MJFF designed the study and is overseeing its conduct at the study sites but is not involved in data analysis. The Foundation reviewed and approved this manuscript for submission. Details regarding MJFF's Parkinson Progression Marker Initiative (PPMI) have been previously published (Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95:629-35). NR 44 TC 34 Z9 36 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 919 EP 927 DI 10.1002/mds.26170 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600010 PM 25737166 ER PT J AU Bekris, LM Tsuang, DW Peskind, ER Yu, CE Montine, TJ Zhang, J Zabetian, CP Leverenz, JB AF Bekris, Lynn M. Tsuang, Debby W. Peskind, Elaine R. Yu, Chang E. Montine, Thomas J. Zhang, Jing Zabetian, Cyrus P. Leverenz, James B. TI Cerebrospinal fluid A(42) levels and APP processing pathway genes in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE APP; ADAM10; BACE1; BACE2; PSEN1; PSEN2; PEN2; NCSTN; APH1B; Parkinson's disease; cerebrospinal fluid ID GAMMA-SECRETASE COMPLEX; CSF AMYLOID-BETA; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ALPHA-SECRETASE; DOWN-SYNDROME; LEWY BODIES; PLAQUE-FORMATION; SENILE PLAQUES; TAU PROTEINS AB BackgroundOf recent interest is the finding that certain cerebrospinal fluid (CSF) biomarkers traditionally linked to Alzheimer's disease (AD), specifically amyloid beta protein (A), are abnormal in PD CSF. The aim of this exploratory investigation was to determine whether genetic variation within the amyloid precursor protein (APP) processing pathway genes correlates with CSF A(42) levels in Parkinson's disease (PD). MethodsParkinson's disease (n=86) and control (n=161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP. The SNP genotypes were tested for their association with CSF biomarkers and PD risk while adjusting for age, sex, and APOE 4 status. ResultsSignificant correlation with CSF A(42) levels in PD was observed for two SNPs, (APP rs466448 and APH1B rs2068143). Conversely, significant correlation with CSF A(42) levels in controls was observed for three SNPs (APP rs214484, rs2040273, and PSEN1 rs362344). ConclusionsIn addition, results of this exploratory investigation suggest that an APP SNP and an APH1B SNP are marginally associated with PD CSF A(42) levels in APOE 4 noncarriers. Further hypotheses generated include that decreased CSF A(42) levels are in part driven by genetic variation in APP processing genes. Additional investigation into the relationship between these findings and clinical characteristics of PD, including cognitive impairment, compared with other neurodegenerative diseases, such as AD, are warranted. (c) 2015 International Parkinson and Movement Disorder Society C1 [Bekris, Lynn M.] Cleveland Clin Fdn, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA. [Yu, Chang E.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Yu, Chang E.] Univ Washington, Dept Med, Seattle, WA USA. [Tsuang, Debby W.; Peskind, Elaine R.; Montine, Thomas J.; Zhang, Jing] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr MIRECC, Northwest Network Mental Illness Res, Seattle, WA USA. [Tsuang, Debby W.; Peskind, Elaine R.; Montine, Thomas J.; Zhang, Jing] Univ Washington, Sch Med, Psychiat & Behav Sci, Seattle, WA USA. [Montine, Thomas J.; Zhang, Jing; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Montine, Thomas J.; Zhang, Jing; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr PADRECC, Northwest Network Parkinsons Dis Res, Seattle, WA USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. RP Bekris, LM (reprint author), Cleveland Clin Fdn, Lerner Res Inst, Genom Med Inst, 9500 Euclid Ave,Mailstop NE-50, Cleveland, OH 44195 USA. EM bekrisl@ccf.org RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program; Biomedical Laboratory Research Program; NIH [P50AG005136, P50NS062684, K99AG034214/4R00AG034214]; University of Washington Alzheimer's Disease Research Center NIH [P50-AB005136]; Jane and Lee Seidman Fund, Joseph Hahn MD Endowed Chair FX This work is supported in part by the U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program, the Biomedical Laboratory Research Program and NIH Grants P50AG005136, P50NS062684, K99AG034214/4R00AG034214. Additional support includes University of Washington Alzheimer's Disease Research Center NIH P50-AB005136 and the Jane and Lee Seidman Fund, Joseph Hahn MD Endowed Chair. NR 66 TC 1 Z9 2 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 936 EP 944 DI 10.1002/mds.26172 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600012 PM 25808939 ER PT J AU Khurana, V Tardiff, DE Chung, CY Lindquist, S AF Khurana, Vikram Tardiff, Daniel E. Chung, Chee Yeun Lindquist, Susan TI Toward stem cell-based phenotypic screens for neurodegenerative diseases SO NATURE REVIEWS NEUROLOGY LA English DT Review ID ALPHA-SYNUCLEIN TOXICITY; SPINAL MUSCULAR-ATROPHY; A-BETA TOXICITY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; SPINOCEREBELLAR ATAXIA; FUNCTIONAL-NEURONS; SNAPSHOT GENETICS; HUMAN FIBROBLASTS; KINASE INHIBITOR AB In the absence of a single preventive or disease-modifying strategy, neurodegenerative diseases are becoming increasingly prevalent in our ageing population. The mechanisms underlying neurodegeneration are poorly understood, making the target-based drug screening strategies that are employed by the pharmaceutical industry fraught with difficulty. However, phenotypic screening in neurons and glia derived from patients is now conceivable through unprecedented developments in reprogramming, transdifferentiation, and genome editing. We outline progress in this nascent field, but also consider the formidable hurdles to identifying robust, disease-relevant and screenable cellular phenotypes in patient-derived cells. We illustrate how analysis in the simple baker's yeast cell Saccharaomyces cerevisiae is driving discovery in patient-derived neurons, and how approaches in this model organism can establish a paradigm to guide the development of stem cell-based phenotypic screens. C1 [Khurana, Vikram] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Khurana, Vikram] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Tardiff, Daniel E.; Chung, Chee Yeun; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. RP Khurana, V (reprint author), Massachusetts Gen Hosp, Dept Neurol, WACC 835,15 Parkman St, Boston, MA 02114 USA. EM vkhurana@post.harvard.edu; lindquist_admin@wi.mit.edu FU American Brain and Parkinson's Disease Foundations Clinician-Scientist Development Award; Harvard NeuroDiscovery Center; Multiple System Atrophy Coalition; National Research Service Award fellowship [F32NS061419]; Thome Memorial Foundation; National Institute on Aging; Howard Hughes Medical Institute; JPB Foundation; Eleanor Schwartz Charitable Foundation FX V.K. has received an American Brain and Parkinson's Disease Foundations Clinician-Scientist Development Award, and is also funded by the Harvard NeuroDiscovery Center and the Multiple System Atrophy Coalition. D.F.T. lathe recipient of National Research Service Award fellowship F32NS061419, and is also funded by the Thome Memorial Foundation. C.Y.C. is funded by the National Institute on Aging. S.L. is funded by the Howard Hughes Medical Institute, the JPB Foundation and the Eleanor Schwartz Charitable Foundation. We thank Linda Clayton for comments on the manuscript. NR 86 TC 10 Z9 10 U1 6 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 EI 1759-4766 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD JUN PY 2015 VL 11 IS 6 BP 339 EP 350 DI 10.1038/nrneurol.2015.79 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA CK7HA UT WOS:000356402200007 PM 25986505 ER PT J AU Chang, BH Stein, NR Skarf, LM AF Chang, Bei-Hung Stein, Nathan R. Skarf, Lara M. TI Spiritual distress of military veterans at the end of life SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Spiritual distress; Religion; Spirituality; Veterans; End of life; War ID POSTTRAUMATIC-STRESS-DISORDER; CARE AB Objective: Although combat experiences can have a profound impact on individuals' spirituality, there is a dearth of research in this area. Our recent study indicates that one unique spiritual need of veterans who are at the end of life is to resolve distress caused by combat-related events that conflict with their personal beliefs. This study sought to gain an understanding of chaplains' perspectives on this type of spiritual need, as well as the spiritual care that chaplains provide to help veterans ease this distress. Method: We individually interviewed five chaplains who have provided spiritual care to veterans at the end of life in a Veterans Administration hospital. The interviews were recorded, transcribed, and analyzed based on "grounded theory." Results: Chaplains reported that they frequently encounter veterans at the end of life who are still suffering from thoughts or images of events that occurred during their military career. Although some veterans are hesitant to discuss their experiences, chaplains reported that they have had some success with helping the veterans to open up. Additionally, chaplains reported using both religious (e.g., confessing sins) and nonreligious approaches (e.g., recording military experience) to help veterans to heal. Significance of results: Our pilot study provides some insight into the spiritual distress that many military veterans may be experiencing, as well as methods that a chaplain can employ to help these veterans. Further studies are needed to confirm our findings and to examine the value of integrating the chaplain service into mental health care for veterans. C1 [Chang, Bei-Hung; Skarf, Lara M.] VA Boston Healthcare Syst, Boston, MA USA. [Chang, Bei-Hung] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Stein, Nathan R.] Providence VA Med Ctr, Providence, RI USA. RP Chang, BH (reprint author), 150 S Huntington Ave,152H, Boston, MA 02130 USA. EM bhchang@bu.edu FU VA Health Services Research and Development Services [PPO-10107] FX Our study was funded by the VA Health Services Research and Development Services (PPO-10107). The institutional review board at the VA Boston Healthcare System reviewed and approved the study. We appreciate the time the chaplains spent in the interviews to provide the information for our study. We also thank the research assistant for recruitment and arrangement of interviews. NR 11 TC 1 Z9 1 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD JUN PY 2015 VL 13 IS 3 BP 635 EP 639 DI 10.1017/S1478951514000273 PG 5 WC Health Policy & Services SC Health Care Sciences & Services GA CK9DD UT WOS:000356539900026 PM 24773768 ER PT J AU Martinez-Martin, P Rodriguez-Blazquez, C Forjaz, MJ Frades-Payo, B Agueera-Ortiz, L Weintraub, D Riesco, A Kurtis, MM Chaudhuri, KR AF Martinez-Martin, Pablo Rodriguez-Blazquez, Carmen Forjaz, Maria Joao Frades-Payo, Belen Agueera-Ortiz, Luis Weintraub, Daniel Riesco, Ana Kurtis, Monica M. Chaudhuri, Kallol Ray TI Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; Caregiver burden; Neuropsychiatric symptoms ID QUALITY-OF-LIFE; PSYCHOSIS; DISABILITY; DEMENTIA; DISORDER; STRESS AB Introduction: In Parkinson's disease (PD), neuropsychiatric symptoms (NPS) can be particularly burdensome for caregivers. The main goal of this study was to assess the impact of NPS, assessed by means of a new specific scale, on caregiver burden. Methods: A sample of 584 pairs of PD patients and their primary caregivers was studied. Patients' NPS were measured with the Scale for Evaluation of Neuropsychiatric Disorders in PD (SEND-PD), and the Zarit Caregiver Burden Inventory was used to quantify caregiver burden. Three linear regression models were built to check factors associated with caregiver burden, one for the total sample and two for subgroups stratified by the presence of dementia. Results: The most frequent NPS were depression (in 66% of the sample), anxiety (65%) and mental fatigue (57%). Patients with dementia (n = 94; 16% of sample) consistently presented more NPS than patients without dementia (p < 0.001). On linear regression models, the main determinants of caregiver burden (for the total sample and the sample of patients without dementia) were SEND-PD dimensions mood/apathy and psychosis, PD-related disability and disease duration. For patients with dementia, the only significant caregiver burden determinants were SEND-PD psychosis and mood/apathy subscale scores. Conclusions: NPS in PD are highly associated with and are determinants of caregiver burden, and are more prevalent and burdensome in patients with dementia. Detailed assessment and specific interventions aimed at NPS could alleviate caregiver burden. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain. [Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen] Carlos III Inst Hlth, CIBERNED, Madrid, Spain. [Forjaz, Maria Joao] Carlos III Inst Hlth, Natl Sch Publ Hlth, Madrid, Spain. [Forjaz, Maria Joao] Carlos III Inst Hlth, REDISSEC, Madrid, Spain. [Frades-Payo, Belen; Agueera-Ortiz, Luis; Riesco, Ana] Carlos III Inst Hlth, Res Unit, Alzheimer Ctr Reina Sofia Fdn, Madrid, Spain. [Agueera-Ortiz, Luis] Carlos III Inst Hlth, CIBERSAM, Madrid, Spain. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kurtis, Monica M.] Hosp Ruber Int, Dept Neurol, Madrid, Spain. [Chaudhuri, Kallol Ray] Kings Coll Hosp London, Dept Neurol, Natl Parkinson Fdn Ctr Excellence, London, England. [Chaudhuri, Kallol Ray] Kings Hlth Partners, London, England. RP Martinez-Martin, P (reprint author), Natl Ctr Epidemiol, Av Monforte Lemos 3, Madrid 28029, Spain. EM pmartinez@isciii.es RI Rodriguez-Blazquez, Carmen/K-6447-2012; OI Rodriguez-Blazquez, Carmen/0000-0003-3829-0675; Aguera-Ortiz, Luis/0000-0003-2410-2880; Ray Chaudhuri, K/0000-0003-2815-0505; Forjaz, Maria Joao/0000-0003-3935-962X NR 30 TC 15 Z9 15 U1 2 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JUN PY 2015 VL 21 IS 6 BP 629 EP 634 DI 10.1016/j.parkreldis.2015.03.024 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CK3GX UT WOS:000356105700014 PM 25892660 ER PT J AU Taber, DJ Gebregziabher, MG Srinivas, TR Chavin, KD Baliga, PK Egede, LE AF Taber, David J. Gebregziabher, Mulugeta G. Srinivas, Titte R. Chavin, Kenneth D. Baliga, Prabhakar K. Egede, Leonard E. TI African-American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients SO PHARMACOTHERAPY LA English DT Article DE kidney transplantation; African-American; tacrolimus; therapeutic drug monitoring; acute rejection ID SOLID-ORGAN TRANSPLANTATION; WHOLE-BLOOD CONCENTRATIONS; RENAL-TRANSPLANTATION; IMMUNOSUPPRESSION; RISK; PHARMACOKINETICS; SIROLIMUS; CYP3A5; POLYMORPHISMS; CYCLOSPORINE AB Study ObjectiveTo determine the effect of tacrolimus trough concentrations on clinical outcomes in kidney transplantation, while assessing if African-American (AA) race modifies these associations. DesignRetrospective longitudinal cohort study of solitary adult kidney transplants. SettingLarge tertiary care transplant center. PatientsAdult solitary kidney transplant recipients (n=1078) who were AA (n=567) or non-AA (n=511). ExposureMean and regressed slope of tacrolimus trough concentrations. Subtherapeutic concentrations were lower than 8ng/ml. Measurements and Main ResultsAA patients were 1.7 times less likely than non-AA patients to achieve therapeutic tacrolimus concentrations (8ng/ml or higher) during the first year after kidney transplant (35% vs 21%, respectively, p<0.001). AAs not achieving therapeutic concentrations were 2.4 times more likely to have acute cellular rejection (ACR) as compared with AAs achieving therapeutic concentrations (20.8% vs 8.5%, respectively, p<0.01) and 2.5 times more likely to have antibody-mediated rejection (AMR; 8.9% vs 3.6%, respectively, p<0.01). Rates of ACR (8.3% vs 6.7%) and AMR (2.0% vs 0.9% p=0.131) were similar in non-AAs compared across tacrolimus concentration groups. Multivariate modeling confirmed these findings and demonstrated that AAs with low tacrolimus exposure experienced a mild protective effect for the development of interstitial fibrosis/tubular atrophy (IF/TA; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.47-1.32) with the opposite demonstrated in non-AAs (HR 2.2, 95% CI 0.90-5.1). ConclusionIn contradistinction to non-AAs, AAs who achieve therapeutic tacrolimus concentrations have substantially lower acute rejection rates but are at risk of developing IF/TA. These findings may reflect modifiable time-dependent racial differences in the concentration-effect relationship of tacrolimus. Achievement of therapeutic tacrolimus trough concentrations, potentially through genotyping and more aggressive dosing and monitoring, is essential to minimize the risk of acute rejection in AA kidney transplant recipients. C1 [Taber, David J.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ S Carolina, Div Transplant Surg, Coll Med, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Gebregziabher, Mulugeta G.] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Srinivas, Titte R.] Med Univ S Carolina, Coll Med, Div Transplant Nephrol, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440, T35 DK007431] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Numbers K23DK099440 and T35 DK007431. NR 34 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUN PY 2015 VL 35 IS 6 BP 569 EP 577 DI 10.1002/phar.1591 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CL0DZ UT WOS:000356610700007 PM 26011276 ER PT J AU Dicianno, BE Mahajan, H Cooper, RA AF Dicianno, Brad E. Mahajan, Harshal Cooper, Rory A. TI Advanced Joystick Algorithms for Computer Access Tasks SO PM&R LA English DT Article ID WHEELCHAIR DRIVING PERFORMANCE; SPASTICITY; INJURY; PEOPLE AB Objective: To compare 2 correction algorithms and 2 joysticks (a conventional movement-sensing joystick and a custom-designed isometric joystick) in computer access tasks. Design: Repeated-measures, within-subject. Setting: National Veterans Wheelchair Games. Participants: Fifteen participants with various diagnoses including multiple sclerosis, spinal cord injury, traumatic brain injury, Wilson disease, and Parkinson disease. Methods: A computer access test scenario was used to evaluate the effects of applying proportional integral derivative (PID)-based and least means-based algorithms to suppress unintentional cursor motions by users with upper extremity spasticity. Main Outcome Measures: Trial completion time, reaction time, and trajectory-based measures: movement offset, movement variability, and percentage of out-of-path motion on test tracks. Results: The quantitative outcome measures showed a high correlation with clinical measures for spasticity and functional independence. On small test tracks, compared to when no correction algorithms were used, both algorithms performed equally well in suppressing unintentional cursor motions. On longer test tracks, participants navigated most accurately while using the PID algorithm. Participants moved the cursor more accurately using the isometric joystick compared to the movement-sensing joystick, with only a slight increase in the task completion times. Conclusions: The joysticks and the advanced correction algorithms show promise for use in wide-ranging applications as control interfaces. C1 [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh HealthCare Syst, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Mahajan, Harshal] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), VA Pittsburgh HealthCare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu FU Rehabilitation Medicine Scientist Training Program National Institutes of Health (NIH) K12 Award [K12HD01097] FX Funding was provided by the Rehabilitation Medicine Scientist Training Program National Institutes of Health (NIH) K12 Award (K12HD01097). This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. This study does not involve a Food and Drug Administration-regulated medical device. NR 30 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD JUN PY 2015 VL 7 IS 6 BP 555 EP 561 DI 10.1016/j.pmrj.2014.12.009 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK2PO UT WOS:000356053400001 PM 25595664 ER PT J AU Ducharme, S Dickerson, BC AF Ducharme, Simon Dickerson, Bradford C. TI The Neuropsychiatric Examination of the Young-Onset Dementias SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Neuropsychiatry; Young-onset dementia; Early onset dementia; Frontotemporal dementia; Alzheimer disease; Differential diagnosis; Biomarkers ID FRONTOTEMPORAL LOBAR DEGENERATION; MONTREAL COGNITIVE ASSESSMENT; FRONTAL ASSESSMENT BATTERY; HIGH-FUNCTIONING AUTISM; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; BEHAVIORAL VARIANT; PSYCHIATRIC MANIFESTATIONS; DIAGNOSTIC-CRITERIA; ASPERGER-SYNDROME AB Young-onset dementias frequently present with prominent behavioral features and constitute a diagnostic challenge. Most cases are secondary to neurodegenerative conditions, including the behavioral variant of frontotemporal dementia, which has overlapping symptoms with many primary psychiatric disorders. This article reviews the differential diagnosis and neuropsychiatric assessment of young-onset dementia, which includes detailed history taking, family history, mental status examination, office-based cognitive tests, and a focused neurologic examination. The clinical examination serves to establish the presence of a dementia and the specific clinical syndrome. Biomarkers can be subsequently integrated in a probabilistic model to determine the most likely neuropathological process. C1 [Ducharme, Simon] McGill Univ, Dept Psychiat, Ctr Hlth, Montreal, PQ H3A 2B4, Canada. [Ducharme, Simon] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada. [Ducharme, Simon] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada. [Dickerson, Bradford C.] Massachusetts Gen Hosp, MGH FTD Unit, Charlestown, MA 02129 USA. [Dickerson, Bradford C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RP Ducharme, S (reprint author), McGill Univ, Dept Psychiat, Ctr Hlth, 3801 Univ St, Montreal, PQ H3A 2B4, Canada. EM simon.ducharme@mcgill.ca NR 59 TC 1 Z9 1 U1 1 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD JUN PY 2015 VL 38 IS 2 BP 249 EP + DI 10.1016/j.psc.2015.01.002 PG 17 WC Psychiatry SC Psychiatry GA CL0LR UT WOS:000356634700006 PM 25998114 ER PT J AU Zhang, MS Qiu, Q Li, ZZ Sachdeva, M Min, H Cardona, DM DeLaney, TF Han, T Ma, Y Luo, LX Ilkayeva, OR Lui, K Nichols, AG Newgard, CB Kastan, MB Rathmell, JC Dewhirst, MW Kirsch, DG AF Zhang, Minsi Qiu, Qiong Li, Zhizhong Sachdeva, Mohit Min, Hooney Cardona, Diana M. DeLaney, Thomas F. Han, Tracy Ma, Yan Luo, Lixia Ilkayeva, Olga R. Lui, Ki Nichols, Amanda G. Newgard, Christopher B. Kastan, Michael B. Rathmell, Jeffrey C. Dewhirst, Mark W. Kirsch, David G. TI HIF-1 Alpha Regulates the Response of Primary Sarcomas to Radiation Therapy through a Cell Autonomous Mechanism SO RADIATION RESEARCH LA English DT Article ID SOFT-TISSUE SARCOMAS; EMBRYONAL RHABDOMYOSARCOMA; TUMOR RADIOSENSITIVITY; SATELLITE CELLS; DNA-DAMAGE; HYPOXIA; CANCER; AUTOPHAGY; OXYGEN; RADIOTHERAPY AB Hypoxia is a major cause of radiation resistance, which may predispose to local recurrence after radiation therapy. While hypoxia increases tumor cell survival after radiation exposure because there is less oxygen to oxidize damaged DNA, it remains unclear whether signaling pathways triggered by hypoxia contribute to radiation resistance. For example, intratumoral hypoxia can increase hypoxia inducible factor 1 alpha (HIF-1 alpha), which may regulate pathways that contribute to radiation sensitization or radiation resistance. To clarify the role of HIF-1 alpha in regulating tumor response to radiation, we generated a novel genetically engineered mouse model of soft tissue sarcoma with an intact or deleted HIF-1 alpha. Deletion of HIF-1 alpha sensitized primary sarcomas to radiation exposure in vivo. Moreover, cell lines derived from primary sarcomas lacking HIF-1 alpha, or in which HIF-1 alpha was knocked down, had decreased clonogenic survival in vitro, demonstrating that HIF-1 alpha can promote radiation resistance in a cell autonomous manner. InHIF-1 alpha-intact and - deleted sarcoma cells, radiation-induced reactive oxygen species, DNA damage repair and activation of autophagy were similar. However, sarcoma cells lacking HIF-1 alpha had impaired mitochondrial biogenesis and metabolic response after irradiation, which might contribute to radiation resistance. These results show that HIF-1 alpha promotes radiation resistance in a cell autonomous manner. (C) 2015 by Radiation Research Society C1 [Zhang, Minsi; Lui, Ki; Nichols, Amanda G.; Newgard, Christopher B.; Kastan, Michael B.; Rathmell, Jeffrey C.; Kirsch, David G.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA. [Qiu, Qiong; Li, Zhizhong; Sachdeva, Mohit; Min, Hooney; Han, Tracy; Ma, Yan; Luo, Lixia; Dewhirst, Mark W.; Kirsch, David G.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27708 USA. [Cardona, Diana M.; Dewhirst, Mark W.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27708 USA. [Kastan, Michael B.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27708 USA. [Rathmell, Jeffrey C.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27708 USA. [DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Ilkayeva, Olga R.; Newgard, Christopher B.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27708 USA. RP Kirsch, DG (reprint author), Duke Univ, Med Ctr, Box 91006, Durham, NC 27708 USA. EM david.kirsch@duke.edu FU NIH [F30 CA180680, R01 CA169220]; Cancer Center Support Grant [P30 CA014236] FX We thank Loretta Woodlief, Laura Jeffords, Michael Reinsvold and Hanna Norris for assistance with mouse care and irradiation. We thank other members of the Kirsch laboratory for advice and support. For reagents and advice regarding hypoxia and HIF-1 alpha, we thank Thies Schroeder, Ken Young, Karin Eisinger-Mathason and M. Celeste Simon. This work was supported by NIH grants, F30 CA180680 (MZ), R01 CA169220 (DGK) and partially by the Cancer Center Support Grant P30 CA014236. NR 49 TC 4 Z9 4 U1 0 U2 2 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD JUN PY 2015 VL 183 IS 6 BP 594 EP 609 DI 10.1667/RR14016.1 PG 16 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA CK7YI UT WOS:000356452600002 PM 25973951 ER PT J AU Butterworth, KT McMahon, SJ McKee, JC Patel, G Ghita, M Cole, AJ McGarry, CK O'Sullivan, JM Hounsell, AR Prise, KM AF Butterworth, Karl T. McMahon, Stephen J. McKee, Jamie C. Patel, Gaurang Ghita, Mihaela Cole, Aidan J. McGarry, Conor K. O'Sullivan, Joe M. Hounsell, Alan R. Prise, Kevin M. TI Time and Cell Type Dependency of Survival Responses in Co-cultured Tumor and Fibroblast Cells after Exposure to Modulated Radiation Fields SO RADIATION RESEARCH LA English DT Article ID X-RAYS; IRON-ION; BYSTANDER; THERAPY; P53; RADIOTHERAPY; IRRADIATION; DAMAGE AB Advanced radiotherapy techniques such as intensity-modulated radiation therapy (IMRT) achieve high levels of conformity to the target volume through the sequential delivery of highly spatially and temporally modulated radiation fields, which have been shown to impact radiobiological response. This study aimed to characterize the time and cell type dependency of survival responses to modulated fields using single cell type (SCT) and mixed cell type (MCT) co-culture models of transformed fibroblast (AG0-1522b) cells, prostate (DU-145) and lung (H460) cancer cells. In SCT cultures, in-field responses showed no significant time dependency while out-of-field responses occurred early, and plateaued 6 h after irradiation in both DU-145 and H460 cells. Under modulated beam configurations MCT cocultures showed cell-specific, differential out-of-field responses depending on the irradiated in-field and responding out-of-field cell type. The observed differential out-of-field responses may be due to the genetic background of the cells, in particular p53 status, which has been shown to mediate radiation-induced bystander effects (RIBEs). These data provide further insight into the radiobiological parameters that influence out-of-field responses, which have potential implications for advanced radiotherapy modalities and may provide opportunities for biophysical optimization in radiotherapy treatment planning. (C) 2015 by Radiation Research Society C1 [Butterworth, Karl T.; McMahon, Stephen J.; McKee, Jamie C.; Patel, Gaurang; Ghita, Mihaela; Cole, Aidan J.; O'Sullivan, Joe M.; Prise, Kevin M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland. [Cole, Aidan J.; O'Sullivan, Joe M.] Northern Ireland Canc Ctr, Clin Oncol, Belfast, Antrim, North Ireland. [McGarry, Conor K.; Hounsell, Alan R.] Northern Ireland Canc Ctr, Radiotherapy Phys, Belfast, Antrim, North Ireland. [McMahon, Stephen J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McMahon, Stephen J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Butterworth, KT (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland. EM k.butterworth@qub.ac.uk RI Prise, Kevin/N-7872-2015 OI Prise, Kevin/0000-0001-6134-7946 FU CRUK [C1513/A707, C212/A11342]; Prostate Cancer UK [S10-08] FX The authors wish to acknowledge financial support from CRUK (C1513/A707 and C212/A11342) and Prostate Cancer UK (S10-08). NR 36 TC 0 Z9 0 U1 0 U2 2 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD JUN PY 2015 VL 183 IS 6 BP 656 EP 664 DI 10.1667/RR13992.1 PG 9 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA CK7YI UT WOS:000356452600007 PM 25973952 ER PT J AU Mallick, A Januzzi JL, Jr AF Mallick, Aditi Januzzi, James L., Jr. TI Biomarkers in Acute Heart Failure SO REVISTA ESPANOLA DE CARDIOLOGIA LA English DT Article DE Acute decompensated heart failure; Biomarkers ID BRAIN NATRIURETIC PEPTIDE; FAMILY-MEMBER ST2; EMERGENCY-DEPARTMENT PRIDE; GELATINASE-ASSOCIATED LIPOCALIN; PRESERVED EJECTION FRACTION; SENSITIVITY TROPONIN-T; SHORT-TERM PROGNOSIS; BODY-MASS INDEX; ACUTE DYSPNEA; RISK STRATIFICATION AB The care of patients with acutely decompensated heart failure is being reshaped by the availability and understanding of several novel and emerging heart failure biomarkers. The gold standard biomarkers in heart failure are B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide, which play an important role in the diagnosis, prognosis, and management of acute decompensated heart failure. Novel biomarkers that are increasingly involved in the processes of myocardial injury, neurohormonal activation, and ventricular remodeling are showing promise in improving diagnosis and prognosis among patients with acute decompensated heart failure. These include midregional proatrial natriuretic peptide, soluble ST2, galectin-3, highly-sensitive troponin, and midregional proadrenomedullin. There has also been an emergence of biomarkers for evaluation of acute decompensated heart failure that assist in the differential diagnosis of dyspnea, such as procalcitonin (for identification of acute pneumonia), as well as markers that predict complications of acute decompensated heart failure, such as renal injury markers. In this article, we will review the pathophysiology and usefulness of established and emerging biomarkers for the clinical diagnosis, prognosis, and management of acute decompensated heart failure. (C) 2015 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. C1 [Mallick, Aditi] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA. RP Januzzi JL, Jr (reprint author), Massachusetts Gen Hosp, Div Cardiol, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA. EM jjanuzzi@partners.org FU Desanctis Clinical Scholar Endowment; Hutter Family Chair in Medicine FX Dr. Januzzi is supported in part by the Desanctis Clinical Scholar Endowment and the Hutter Family Chair in Medicine. NR 86 TC 5 Z9 6 U1 3 U2 5 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0300-8932 EI 1579-2242 J9 REV ESP CARDIOL JI Rev. Esp. Cardiol. PD JUN PY 2015 VL 68 IS 6 BP 514 EP 525 DI 10.1016/j.rec.2015.02.009 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK7ZO UT WOS:000356456800011 PM 25911167 ER PT J AU Creswell, KG Wright, AGC Troxel, WM Ferrell, RE Flory, JD Manuck, SB AF Creswell, Kasey G. Wright, Aidan G. C. Troxel, Wendy M. Ferrell, Robert E. Flory, Janine D. Manuck, Stephen B. TI OXTR polymorphism predicts social relationships through its effects on social temperament SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE oxytocin; OXTR; social support; personality; genetics ID OXYTOCIN RECEPTOR GENE; ENVIRONMENTAL CONTRIBUTIONS; SUPPORT; STRESS; BEHAVIOR; HUMANS; INTERACT; ASSOCIATION; PERSONALITY; LONELINESS AB Humans have a fundamental need for strong interpersonal bonds, yet individuals differ appreciably in their degree of social integration. That these differences are also substantially heritable has spurred interest in biological mechanisms underlying the quality and quantity of individuals' social relationships. We propose that polymorphic variation in the oxytocin receptor gene (OXTR) associates with complex social behaviors and social network composition through intermediate effects on negative affectivity and the psychological processing of socially relevant information. We tested a hypothesized social cascade from the molecular level (OXTR variation) to the social environment, through negative affectivity and inhibited sociality, in a sample of 1295 men and women of European American (N = 1081) and African American (N = 214) ancestry. Compared to European Americans having any T allele of rs1042778, individuals homozygous for the alternate G allele reported significantly lower levels of negative affectivity and inhibited sociality, which in turn predicted significantly higher levels of social support and a larger/more diverse social network. Moreover, the effect of rs1042778 variation on social support was fully accounted for by associated differences in negative affectivity and inhibited sociality. Results replicated in the African American sample. Findings suggest that OXTR variation modulates levels of social support via proximal impacts on individual temperament. C1 [Creswell, Kasey G.] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA. [Wright, Aidan G. C.; Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Troxel, Wendy M.] RAND Corp, Behav & Policy Sci, Pittsburgh, PA USA. [Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Flory, Janine D.] James J Peters VAMC, New York, NY USA. RP Creswell, KG (reprint author), Carnegie Mellon Univ, Dept Psychol, 5000 Forbes Ave,Baker Hall 342c, Pittsburgh, PA 15213 USA. EM kasey@andrew.cmu.edu OI Wright, Aidan/0000-0002-2369-0601 FU NHLBI NIH HHS [K23 HL093220, R01 HL065137, HL093220, P01 HL040962]; NIMH NIH HHS [F32 MH097325, F32MH097325, T32 MH018269, T32MH018269] NR 77 TC 3 Z9 3 U1 3 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD JUN PY 2015 VL 10 IS 6 BP 869 EP 876 DI 10.1093/scan/nsu132 PG 8 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA CK5NV UT WOS:000356272800013 PM 25326040 ER PT J AU Forrest, GN Bhalla, P DeBess, EE Winthrop, KL Lockhart, SR Mohammadi, J Cieslak, PR AF Forrest, G. N. Bhalla, P. DeBess, E. E. Winthrop, K. L. Lockhart, S. R. Mohammadi, J. Cieslak, P. R. TI Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Cryptococcus gattii; organ transplantation; antifungals; immunosuppression ID CALCINEURIN-INHIBITOR AGENTS; INVASIVE FUNGAL-INFECTIONS; PACIFIC-NORTHWEST; PRACTICE GUIDELINES; BRITISH-COLUMBIA; UNITED-STATES; IN-VITRO; NEOFORMANS; MANAGEMENT; DISEASE AB Cryptococcus gattii was recognized as an emerging infection in the Pacific Northwest in 2004. Out of 62 total infections in Oregon since the outbreak, 11 were in solid organ transplant (SOT) recipients. SOT recipients were more likely to have disseminated disease and higher mortality than normal hosts, who mostly had isolated mass lesions. The median time from transplantation to C.gattii diagnosis was 17.8months. The primary sites of infection were lung (n=4), central nervous system (n=3), or both (n=4). The Oregon-endemic strain, VGII (subtypes IIa and IIc) was present in 10 of 11 patients; the median fluconazole minimum inhibitory concentration (MIC) was 12g/mL (range 2-32g/mL) for this strain. We found C.gattii infection among organ transplant recipients was disseminated at diagnosis, had low cerebrospinal fluid cryptococcal antigen titers, and was associated with an elevated fluconazole MIC and high attributable mortality. C1 [Forrest, G. N.; Mohammadi, J.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Bhalla, P.; Winthrop, K. L.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Bhalla, P.; DeBess, E. E.; Cieslak, P. R.] Oregon Hlth Author, Publ Hlth Div, Acute & Communicable Dis Prevent, Portland, OR USA. [Lockhart, S. R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Oregon Health Authority; Epidemiology and Laboratory Capacity Cooperative Agreement [5U50CK000218]; Centers for Disease Control and Prevention (CDC) FX The study was conducted under the auspices of the Oregon Health Authority. This publication was supported by the Epidemiology and Laboratory Capacity Cooperative Agreement (number 5U50CK000218) with the Centers for Disease Control and Prevention (CDC). NR 25 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2015 VL 17 IS 3 BP 467 EP 476 DI 10.1111/tid.12370 PG 10 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CK2YW UT WOS:000356082600021 PM 25677448 ER PT J AU El Kholy, K Genco, RJ Van Dyke, TE AF El Kholy, Karim Genco, Robert J. Van Dyke, Thomas E. TI Oral infections and cardiovascular disease SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID PRORESOLVING LIPID MEDIATORS; PORPHYROMONAS-GINGIVALIS; ANTIINFLAMMATORY ACTIONS; DOCOSAHEXAENOIC ACID; PERIODONTAL-DISEASES; ACUTE-INFLAMMATION; HEART-DISEASE; MURINE MODEL; FATTY-ACIDS; RESOLVIN E1 AB Oral infections are the most common diseases of mankind. Numerous reports have implicated oral infections, particularly periodontitis, as a risk factor for atherosclerotic cardiovascular disease (CVD). In this review we examine the epidemiology and biologic plausibility of this association with an emphasis on oral bacteria and inflammation. Longitudinal studies of incident cardiovascular events clearly show excess risk for CVD in individuals with periodontitis. It is likely that systemic exposure to oral bacteria impacts upon the initiation and progression of CVD through triggering of inflammatory processes. Given the high prevalence of periodontitis, any risk attributable to future CVD is important to public health. Unraveling the role of the oral microbiome in CVD will lead to new preventive and treatment approaches. C1 [El Kholy, Karim; Van Dyke, Thomas E.] Forsyth Inst, Cambridge, MA 02142 USA. [El Kholy, Karim] Harvard Univ, Cambridge, MA 02138 USA. [Genco, Robert J.] SUNY Buffalo, Buffalo, NY 14226 USA. RP Van Dyke, TE (reprint author), Forsyth Inst, Cambridge, MA 02142 USA. EM tvandyke@forsyth.org NR 73 TC 3 Z9 3 U1 4 U2 24 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD JUN PY 2015 VL 26 IS 6 BP 315 EP 321 DI 10.1016/j.tem.2015.03.001 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9HG UT WOS:000356550600006 ER PT J AU Stapleton, CJ Walcott, BP Fusco, MR Thomas, AJ Ogilvy, CS AF Stapleton, Christopher J. Walcott, Brian P. Fusco, Matthew R. Thomas, Ajith J. Ogilvy, Christopher S. TI Brain Mapping for Safe Microsurgical Resection of Arteriovenous Malformations in Eloquent Cortex SO WORLD NEUROSURGERY LA English DT Article DE Arteriovenous malformation; Electrocortical stimulation mapping; Eloquent cortex; Functional neuroimaging; Microsurgery ID TRANSCRANIAL MAGNETIC STIMULATION; MOTOR CORTEX; VASCULAR MALFORMATIONS; CLINICAL ARTICLE; GRADING SYSTEM; VISUAL-CORTEX; LANGUAGE; RADIOSURGERY; LOCALIZATION; SURGERY C1 [Stapleton, Christopher J.; Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Stapleton, Christopher J.; Walcott, Brian P.; Fusco, Matthew R.; Thomas, Ajith J.; Ogilvy, Christopher S.] Harvard Univ, Sch Med, Boston, MA USA. [Fusco, Matthew R.; Thomas, Ajith J.; Ogilvy, Christopher S.] Beth Israel Deaconess Med Ctr, Dept Surg, Div Neurosurg, Boston, MA 02215 USA. [Fusco, Matthew R.; Thomas, Ajith J.; Ogilvy, Christopher S.] Beth Israel Deaconess Med Ctr, Brain Aneurysm Inst, Boston, MA 02215 USA. RP Stapleton, CJ (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. EM cstapleton@mgh.harvard.edu NR 64 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD JUN PY 2015 VL 83 IS 6 BP 1148 EP 1156 DI 10.1016/j.wneu.2015.01.040 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CK3TN UT WOS:000356138800054 PM 25683129 ER PT J AU Grieco, J Pulsifer, M Seligsohn, K Skotko, B Schwartz, A AF Grieco, Julie Pulsifer, Margaret Seligsohn, Karen Skotko, Brian Schwartz, Alison TI Down syndrome: Cognitive and behavioral functioning across the lifespan SO AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS LA English DT Editorial Material DE Down syndrome; neurocognitive; neurobehavioral; development ID SHORT-TERM-MEMORY; FRAGILE-X-SYNDROME; AUTISTIC-SPECTRUM DISORDERS; OBSTRUCTIVE SLEEP-APNEA; TYPICALLY DEVELOPING-CHILDREN; ALZHEIMER-TYPE DEMENTIA; WILLIAMS-SYNDROME; WORKING-MEMORY; YOUNG-CHILDREN; INTELLECTUAL DISABILITY AB Individuals with Down syndrome (DS) commonly possess unique neurocognitive and neurobehavioral profiles that emerge within specific developmental periods. These profiles are distinct relative to others with similar intellectual disability (ID) and reflect underlying neuroanatomic findings, providing support for a distinctive phenotypic profile. This review updates what is known about the cognitive and behavioral phenotypes associated with DS across the lifespan. In early childhood, mild deviations from neurotypically developing trajectories emerge. By school-age, delays become pronounced. Nonverbal skills remain on trajectory for mental age, whereas verbal deficits emerge and persist. Nonverbal learning and memory are strengths relative to verbal skills. Expressive language is delayed relative to comprehension. Aspects of language skills continue to develop throughout adolescence, although language skills remain compromised in adulthood. Deficits in attention/executive functions are present in childhood and become more pronounced with age. Characteristic features associated with DS (cheerful, social nature) are personality assets. Children are at a lower risk for psychopathology compared to other children with ID; families report lower levels of stress and a more positive outlook. In youth, externalizing behaviors may be problematic, whereas a shift toward internalizing behaviors emerges with maturity. Changes in emotional/behavioral functioning in adulthood are typically associated with neurodegeneration and individuals with DS are higher risk for dementia of the Alzheimer's type. Individuals with DS possess many unique strengths and weaknesses that should be appreciated as they develop across the lifespan. Awareness of this profile by professionals and caregivers can promote early detection and support cognitive and behavioral development. (c) 2015 Wiley Periodicals, Inc. C1 [Grieco, Julie; Pulsifer, Margaret; Seligsohn, Karen] Massachusetts Gen Hosp, Psychol Assessment Ctr, Boston, MA 02114 USA. [Pulsifer, Margaret; Seligsohn, Karen] Harvard Univ, Sch Med, Dept Psychiat, Psychol, Cambridge, MA 02138 USA. [Skotko, Brian; Schwartz, Alison] Massachusetts Gen Hosp, Down Syndrome Program, Boston, MA 02114 USA. [Skotko, Brian; Schwartz, Alison] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA. RP Grieco, J (reprint author), Massachusetts Gen Hosp, One Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM jagrieco@mgh.harvard.edu NR 269 TC 9 Z9 9 U1 20 U2 73 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4868 EI 1552-4876 J9 AM J MED GENET C JI Am. J. Med. Genet. C PD JUN PY 2015 VL 169 IS 2 BP 135 EP 149 DI 10.1002/ajmg.c.31439 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA CK3CK UT WOS:000356093200002 PM 25989505 ER PT J AU Forghani, R Levental, M Gupta, R Lam, S Dadfar, N Curtin, HD AF Forghani, R. Levental, M. Gupta, R. Lam, S. Dadfar, N. Curtin, H. D. TI Different Spectral Hounsfield Unit Curve and High-Energy Virtual Monochromatic Image Characteristics of Squamous Cell Carcinoma Compared with Nonossified Thyroid Cartilage SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID COMPUTED-TOMOGRAPHY; LARYNGEAL-CANCER; HYPOPHARYNGEAL CANCER; NEOPLASTIC INVASION; ORGAN PRESERVATION; CT; HEAD; DIAGNOSIS; QUALITY AB BACKGROUND AND PURPOSE: The attenuation of normal nonossified thyroid cartilage can be similar to that of head and neck squamous cell carcinoma on CT. We compared dual-energy CT spectral Hounsfield unit attenuation characteristics of nonossified thyroid cartilage with that of squamous cell carcinoma to determine the optimal virtual monochromatic image reconstruction energy levels for distinguishing tumor from normal nonossified thyroid cartilage. MATERIALS AND METHODS: Dual-energy CT scans from 30 patients with histopathology-proved squamous cell carcinoma at different primary sites (laryngeal and nonlaryngeal) and 10 healthy patients were evaluated. Patients were scanned with a 64-section single-source scanner with fast-kilovolt (peak) switching, and scans were reconstructed at different virtual monochromatic energy levels ranging from 40 to 140 keV. Spectral attenuation curves of tumor and nonossified thyroid cartilage were quantitatively evaluated and compared. Any part of the tumor invading the cartilage, when present, was excluded from ROI analysis to avoid cross-contamination from areas where there could be a mixture of cartilage and invading tumor. RESULTS: Normal nonossified thyroid cartilage had a characteristic, predictable spectral attenuation curve that was different from that of tumors. The greatest difference in attenuation of nonossified cartilage compared with tumor was on virtual monochromatic images of 95 keV (P < .0001), with sharp contrast between the relatively high attenuation of nonossified cartilage compared with that of tumor. CONCLUSIONS: Head and neck squamous cell carcinoma has significantly different attenuation on virtual monochromatic images of 95 keV, compared with nonossified thyroid cartilage. C1 [Forghani, R.; Levental, M.; Lam, S.] McGill Univ, Jewish Gen Hosp, Dept Radiol, Montreal, PQ H3T 1E2, Canada. [Gupta, R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Dadfar, N.; Curtin, H. D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Radiol, Boston, MA USA. RP Forghani, R (reprint author), McGill Univ, Jewish Gen Hosp, Dept Radiol, Room C-212-1,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada. EM rforghani@jg.mcgill.ca NR 26 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD JUN PY 2015 VL 36 IS 6 BP 1194 EP 1200 DI 10.3174/ajnr.A4253 PG 7 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CJ9OK UT WOS:000355831700034 PM 25742986 ER PT J AU Kato, S Chen, JS Cornog, KH Zhang, H Roberts, JD AF Kato, Shin Chen, Jingsi Cornog, Katherine H. Zhang, Huili Roberts, Jesse D., Jr. TI The Golgi apparatus regulates cGMP-dependent protein kinase I compartmentation and proteolysis SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE cGMP-dependent protein kinase I; cGMP signaling; Golgi apparatus ID VASCULAR SMOOTH-MUSCLE; REQUIRES NUCLEAR TRANSLOCATION; SOLUBLE GUANYLATE-CYCLASE; CYCLIC-GMP; NITRIC-OXIDE; GENE-EXPRESSION; INTRACELLULAR-LOCALIZATION; SUBCELLULAR-LOCALIZATION; PULMONARY-HYPERTENSION; ENDOPLASMIC-RETICULUM AB cGMP-dependent protein kinase I (PKGI) is an important effector of cGMP signaling that regulates vascular smooth muscle cell (SMC) phenotype and proliferation. PKGI has been detected in the perinuclear region of cells, and recent data indicate that proprotein convertases (PCs) typically resident in the Golgi apparatus (GA) can stimulate PKGI proteolysis and generate a kinase fragment that localizes to the nucleus and regulates gene expression. However, the role of the endomembrane system in PKGI compartmentation and processing is unknown. Here, we demonstrate that PKGI colocalizes with endoplasmic reticulum (ER), ER-Golgi intermediate compartment, GA cisterna, and trans-Golgi network proteins in pulmonary artery SMC and cell lines. Moreover, PKGI localizes with furin, a trans-Golgi network-resident PC known to cleave PKGI. ER protein transport influences PKGI localization because overexpression of a constitutively inactive Sar1 transgene caused PKGI retention in the ER. Additionally, PKGI appears to reside within the GA because PKGI immunoreactivity was determined to be resistant to cytosolic proteinase K treatment in live cells. The GA appears to play a role in PKGI proteolysis because overexpression of inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate, not only tethered heterologous PKGI-beta to the ER and decreased its localization to the GA, but also diminished PKGI proteolysis and nuclear translocation. Also, inhibiting intra-GA protein transport with monensin was observed to decrease PKGI cleavage. These studies detail a role for the endomembrane system in regulating PKGI compartmentation and proteolysis. Moreover, they support the investigation of mechanisms regulating PKGI-dependent nuclear cGMP signaling in the pulmonary vasculature with Golgi dysfunction. C1 [Kato, Shin; Chen, Jingsi; Zhang, Huili; Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA. [Roberts, Jesse D., Jr.] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA. [Roberts, Jesse D., Jr.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA. [Cornog, Katherine H.] Applied Video Res, Medford, MA USA. RP Roberts, JD (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, East 149 13th St, Charlestown, MA 02129 USA. EM roberts@cvrc.mgh.harvard.edu FU National Institutes of Health [1R01HL096779]; Department of Anesthesia, Critical Care, and Pain Medicine FX This work was supported by the National Institutes of Health (1R01HL096779 to J. Roberts, Jr.) and the Department of Anesthesia, Critical Care, and Pain Medicine. NR 99 TC 0 Z9 0 U1 2 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD JUN 1 PY 2015 VL 308 IS 11 BP C944 EP C958 DI 10.1152/ajpcell.00199.2014 PG 15 WC Cell Biology; Physiology SC Cell Biology; Physiology GA CK5CO UT WOS:000356240000009 PM 25855081 ER PT J AU Gorin, Y Cavaglieri, RC Khazim, K Lee, DY Bruno, F Thakur, S Fanti, P Szyndralewiez, C Barnes, JL Block, K Abboud, HE AF Gorin, Yves Cavaglieri, Rita C. Khazim, Khaled Lee, Doug-Yoon Bruno, Francesca Thakur, Sachin Fanti, Paolo Szyndralewiez, Cedric Barnes, Jeffrey L. Block, Karen Abboud, Hanna E. TI Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE diabetic nephropathy; NADPH oxidase; Nox1/Nox4 inhibitor ID INDUCED OXIDATIVE STRESS; KIDNEY-DISEASE; PREVENTS GLOMERULOSCLEROSIS; PHARMACOLOGICAL INHIBITION; CARDIOVASCULAR-SYSTEM; PODOCYTE INJURY; DB/DB MICE; IN-VIVO; NEPHROPATHY; NOX4 AB Reactive oxygen species (ROS) generated by Nox NADPH oxidases may play a critical role in the pathogenesis of diabetic nephropathy (DN). The efficacy of the Nox1/Nox4 inhibitor GKT137831 on the manifestations of DN was studied in OVE26 mice, a model of type 1 diabetes. Starting at 4-5 mo of age, OVE26 mice were treated with GKT137831 at 10 or 40 mg/kg, once-a-day for 4 wk. At both doses, GKT137831 inhibited NADPH oxidase activity, superoxide generation, and hydrogen peroxide production in the renal cortex from diabetic mice without affecting Nox1 or Nox4 protein expression. The increased expression of fibronectin and type IV collagen was reduced in the renal cortex, including glomeruli, of diabetic mice treated with GKT137831. GKT137831 significantly reduced glomerular hypertrophy, mesangial matrix expansion, urinary albumin excretion, and podocyte loss in OVE26 mice. GKT137831 also attenuated macrophage infiltration in glomeruli and tubulointerstitium. Collectively, our data indicate that pharmacological inhibition of Nox1/4 affords broad renoprotection in mice with preexisting diabetes and established kidney disease. This study validates the relevance of targeting Nox4 and identifies GKT137831 as a promising compound for the treatment of DN in type 1 diabetes. C1 [Gorin, Yves; Cavaglieri, Rita C.; Khazim, Khaled; Lee, Doug-Yoon; Bruno, Francesca; Thakur, Sachin; Fanti, Paolo; Barnes, Jeffrey L.; Block, Karen; Abboud, Hanna E.] Univ Texas San Antonio, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA. [Fanti, Paolo; Barnes, Jeffrey L.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX USA. [Szyndralewiez, Cedric] Genkyotex SA, Geneva, Switzerland. RP Gorin, Y (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu FU Juvenile Diabetes Research Foundation; National Center for Advancing Translational Sciences; National Institutes of Health (NIH) [UL1 TR001120, RO1 DK 079996, RO1 CA 131272, RO1 DK 78971]; Department of Veterans Affairs; Juvenile Diabetes Research Foundation [GKT137831] FX This work was supported by Juvenile Diabetes Research Foundation Multiproject Grants (Y. Gorin, K. Block, J. L. Barnes, and H. E. Abboud), the National Center for Advancing Translational Sciences, the National Institutes of Health (NIH) through Grants UL1 TR001120 (Y. Gorin), RO1 DK 079996 (Y. Gorin), RO1 CA 131272 (K. Block), RO1 DK 78971 (H. E. Abboud), and the Department of Veterans Affairs (K. Block, J. L. Barnes, and H. E. Abboud). GKT137831 was provided by Genkyotex through funds from Juvenile Diabetes Research Foundation Multiproject Grants. NR 49 TC 27 Z9 28 U1 5 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUN 1 PY 2015 VL 308 IS 11 BP F1276 EP F1287 DI 10.1152/ajprenal.00396.2014 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CK5BN UT WOS:000356237200011 PM 25656366 ER PT J AU Goff, KL Karimkhani, C Boyers, LN Weinstock, MA Lott, JP Hay, RJ Coffeng, LE Norton, SA Naldi, L Dunnick, C Armstrong, AW Dellavalle, RP AF Goff, K. L. Karimkhani, C. Boyers, L. N. Weinstock, M. A. Lott, J. P. Hay, R. J. Coffeng, L. E. Norton, S. A. Naldi, L. Dunnick, C. Armstrong, A. W. Dellavalle, R. P. TI The global burden of psoriatic skin disease SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID SYSTEMATIC ANALYSIS; GBD 2010; PREVALENCE; INJURIES; LIFE C1 [Goff, K. L.] Univ S Carolina, Sch Med, Columbia, SC USA. [Karimkhani, C.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, L. N.] Georgetown Univ, Sch Med, Washington, DC USA. [Weinstock, M. A.] VA Med Ctr Providence, Dermatoepidemiol Unit, Providence, RI USA. [Weinstock, M. A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA. [Weinstock, M. A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, M. A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Lott, J. P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. [Lott, J. P.] Connecticut Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, West Haven, CT USA. [Hay, R. J.] Kings Coll Hosp NHS Trust, Dept Dermatol, London, England. [Coffeng, L. E.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Norton, S. A.] Childrens Natl Med Ctr, Dermatol Div, Washington, DC 20010 USA. [Naldi, L.] Azienda Osped Papa Giovanni XXIII, Dept Dermatol, Bergamo, Italy. [Dunnick, C.; Armstrong, A. W.; Dellavalle, R. P.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA. [Dellavalle, R. P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dunnick, C.; Armstrong, A. W.; Dellavalle, R. P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. EM robert.dellavalle@ucdenver.edu RI Naldi, Luigi/K-6343-2016 OI Naldi, Luigi/0000-0002-3160-2835 NR 15 TC 6 Z9 6 U1 4 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JUN PY 2015 VL 172 IS 6 BP 1665 EP 1668 DI 10.1111/bjd.13715 PG 4 WC Dermatology SC Dermatology GA CK2LR UT WOS:000356042500043 PM 25645671 ER PT J AU Bellmunt, J Werner, L Bamias, A Fay, AP Park, RS Riester, M Selvarajah, S Barletta, JA Berman, DM de Muga, S Salido, M Gallardo, E Rojo, F Guancial, EA Bambury, R Mullane, SA Choueiri, TK Loda, M Stack, E Rosenberg, J AF Bellmunt, Joaquim Werner, Lillian Bamias, Aristotle Fay, Andre P. Park, Rachel S. Riester, Markus Selvarajah, Shamini Barletta, Justine A. Berman, David M. de Muga, Silvia Salido, Marta Gallardo, Enrique Rojo, Federico Guancial, Elizabeth A. Bambury, Richard Mullane, Stephanie A. Choueiri, Toni K. Loda, Massimo Stack, Edward Rosenberg, Jonathan TI HER2 as a target in invasive urothelial carcinoma SO CANCER MEDICINE LA English DT Article DE ERBB2; genomic alterations; HER2; prognosis; urothelial carcinomas ID TRANSITIONAL-CELL CARCINOMA; HER-2/NEU PROTEIN OVEREXPRESSION; BLADDER-CANCER; GENE AMPLIFICATION; URINARY-BLADDER; GASTRIC-CANCER; BREAST-CANCER; EXPRESSION; THERAPY; TUMORS AB We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of >= 2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), DNA copy number, mRNA expression, and mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival. ERBB2 mutation was determined by hotspot sequencing. mRNA expression was assessed using NanoString counting. Association of overall survival (OS) and HER2 status was assessed by a Cox regression model. NIH-3T3 cells containing HER2 V777L were assessed for growth, invasion, and HER2 kinase activation. In all, 22% of Spanish and 4% of Greek cohorts had 3+ HER2 staining by IHC. FISH amplification was identified in 20% of Spanish and 4% of Greek cohorts. Kappa coefficient between FISH and IHC was 0.47. HER2 status was not associated with OS in univariate (Spanish P=0.34; Greek P=0.11) or multivariate (Spanish P=0.49; Greek P=0.12) analysis. HER2-positive tumors expressed higher levels of HER2 mRNA than HER2-negative tumors (P<0.001). HER2 mutations (V777L and L755S) were identified in two (2%) patients. In vitro analysis of V777L results in transformation of NIH-3T3 cells, leading to increased growth, invasion on soft agar, and HER2 kinase constitutive activation. In summary, HER2 overexpression or amplification in the primary tumor did not predict OS in patients with metastatic UC. HER2 positivity rates can differ between different populations. Further trials in genomically screened patients are needed to assess HER2-targeted therapies in UC. C1 [Bellmunt, Joaquim; Fay, Andre P.; Park, Rachel S.; Guancial, Elizabeth A.; Mullane, Stephanie A.; Choueiri, Toni K.; Rosenberg, Jonathan] Dana Farber Canc Inst, Bladder Canc Ctr, Lank Ctr Genitourinary Oncol, Boston, MA 02215 USA. [Bellmunt, Joaquim] Univ Hosp Mar IMIM, Dept Med Oncol, Barcelona, Spain. [Werner, Lillian; Riester, Markus] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Bamias, Aristotle] Univ Athens, Athens, Greece. [Bamias, Aristotle] Hellen Cooperat Oncol Grp, Athens, Greece. [Selvarajah, Shamini; Stack, Edward] Brigham & Womens Hosp, Dept Pathol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Barletta, Justine A.; Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Berman, David M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [de Muga, Silvia; Salido, Marta; Rojo, Federico] Hosp Mar Res Inst IMIM, Barcelona, Spain. [Gallardo, Enrique] Hosp Parc Tauli, Sabadell, Spain. [Rojo, Federico] IIS Fdn Jimenez Diaz, Madrid, Spain. [Bambury, Richard; Rosenberg, Jonathan] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Bellmunt, J (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 1230, Boston, MA 02215 USA. EM joaquim_bellmunt@dfci.harvard.edu RI Rojo, Federico/S-6551-2016; OI Rosenberg, Jonathan/0000-0003-2637-4249 FU Spanish Health Ministry Grant "Fondo de Investigacion Sanitaria" [PI061513]; RTICC [06/0020/19] FX This work has been supported by PI061513 (Spanish Health Ministry Grant "Fondo de Investigacion Sanitaria") and RTICC 06/0020/19 grants. NR 38 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD JUN PY 2015 VL 4 IS 6 BP 844 EP 852 DI 10.1002/cam4.432 PG 9 WC Oncology SC Oncology GA CK1SQ UT WOS:000355988000007 PM 25720673 ER PT J AU Schnell, P Bartlett, CH Solomon, BJ Tassell, V Shaw, AT de Pas, T Lee, SH Lee, GK Tanaka, K Tan, WW Tang, YY Wilner, KD Safferman, A Han, JY AF Schnell, Patrick Bartlett, Cynthia H. Solomon, Benjamin J. Tassell, Vanessa Shaw, Alice T. de Pas, Tommaso Lee, Soo-Hyun Lee, Geon Kook Tanaka, Kaoru Tan, Weiwei Tang, Yiyun Wilner, Keith D. Safferman, Allan Han, Ji-Youn TI Complex renal cysts associated with crizotinib treatment SO CANCER MEDICINE LA English DT Article DE Crizotinib; independent radiologic review; NSCLC; renal cysts; risk factors ID CELL LUNG-CANCER; HEPATOCYTE GROWTH-FACTOR; C-MET; ANAPLASTIC LYMPHOMA; PREVALENCE; CHEMOTHERAPY; MANAGEMENT; PF-2341066; INHIBITOR; DISEASE AB An apparent causal association between crizotinib treatment and renal cyst development emerged during clinical trials in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Serious adverse event (SAE) reports of renal cysts from a safety database of 1375 patients from four clinical trials were reviewed. A blinded, retrospective, independent radiologic review (IRR) was performed using scans from patients on study for 6months in three clinical trials; risk factors for renal cyst development were assessed. Among 17 patients with renal cysts reported as SAEs, evidence of invasion into adjacent structures was noted in seven patients, with no evidence of malignancy found. These patients generally did not require dose reductions, none required permanent crizotinib discontinuation due to this AE, and most continued treatment with clinical benefit. In the blinded IRR, among 255 crizotinib-treated patients, 22%, 3%, and 2% had preexisting simple cysts, complex cysts, or both, respectively. At the 6-month tumor assessment, 9% of all patients had acquired new cysts, and 2% of patients with preexisting cysts had developed new cysts and enlargements (>50%) of preexisting simple cysts. Asians appeared to have an increased risk of developing new cysts on treatment; Koreans in particular had 5.18 times higher odds of developing cysts than non-Asians (95% confidence interval, 1.51-17.78; P=0.05). Crizotinib treatment appears to be associated with an increased risk of development and progression of renal cysts in patients with ALK-positive NSCLC. While close monitoring is recommended, dosing modification was not generally necessary, allowing patients to remain on crizotinib treatment. C1 [Schnell, Patrick; Bartlett, Cynthia H.; Safferman, Allan] Pfizer Oncol, New York, NY 10017 USA. [Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Tassell, Vanessa; Tan, Weiwei; Tang, Yiyun; Wilner, Keith D.] Pfizer Oncol, La Jolla, CA USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [de Pas, Tommaso] European Inst Oncol, Milan, Italy. [Lee, Soo-Hyun; Lee, Geon Kook; Han, Ji-Youn] Natl Canc Ctr, Goyang, Gyeonggi, South Korea. [Tanaka, Kaoru] Kinki Univ, Fac Med, Osaka, Japan. RP Schnell, P (reprint author), Pfizer Inc, 219 East 42nd St,9th Floor, New York, NY 10017 USA. EM patrick.schnell@pfizer.com FU Pfizer Inc. FX This study was sponsored by Pfizer Inc. NR 29 TC 6 Z9 6 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD JUN PY 2015 VL 4 IS 6 BP 887 EP 896 DI 10.1002/cam4.437 PG 10 WC Oncology SC Oncology GA CK1SQ UT WOS:000355988000011 PM 25756473 ER PT J AU Sinnott, JA Rider, JR Carlsson, J Gerke, T Tyekucheva, S Penney, KL Sesso, HD Loda, M Fall, K Stampfer, MJ Mucci, LA Pawitan, Y Andersson, SO Andren, O AF Sinnott, Jennifer A. Rider, Jennifer R. Carlsson, Jessica Gerke, Travis Tyekucheva, Svitlana Penney, Kathryn L. Sesso, Howard D. Loda, Massimo Fall, Katja Stampfer, Meir J. Mucci, Lorelei A. Pawitan, Yudi Andersson, Sven-Olof Andren, Ove TI Molecular differences in transition zone and peripheral zone prostate tumors SO CARCINOGENESIS LA English DT Article ID PROBE LEVEL DATA; GENE-EXPRESSION; CANCER; REARRANGEMENT; SUMMARIES; DENSITY; GRADE AB Prostate tumors arise primarily in the peripheral zone (PZ) of the prostate, but 20-30% arise in the transition zone (TZ). Zone of origin may have prognostic value or reflect distinct molecular subtypes; however, it can be difficult to determine in practice. Using whole-genome gene expression, we built a signature of zone using normal tissue from five individuals and found that it successfully classified nine tumors of known zone. Hypothesizing that this signature captures tumor zone of origin, we assessed its relationship with clinical factors among 369 tumors of unknown zone from radical prostatectomies (RPs) and found that tumors that molecularly resembled TZ tumors showed lower mortality (P = 0.09) that was explained by lower Gleason scores (P = 0.009). We further applied the signature to an earlier study of 88 RP and 333 transurethral resection of the prostate (TURP) tumor samples, also of unknown zone, with gene expression on similar to 6000 genes. We had observed previously substantial expression differences between RP and TURP specimens, and hypothesized that this might be because RPs capture primarily PZ tumors, whereas TURPs capture more TZ tumors. Our signature distinguished these two groups, with an area under the receiver operating characteristic curve of 87% (P < 0.0001). Our findings that zonal differences in normal tissue persist in tumor tissue and that these differences are associated with Gleason score and sample type suggest that subtypes potentially resulting from different etiologic pathways might arise in these zones. Zone of origin may be important to consider in prostate tumor biomarker research. C1 [Sinnott, Jennifer A.; Rider, Jennifer R.; Penney, Kathryn L.; Sesso, Howard D.; Fall, Katja; Stampfer, Meir J.; Mucci, Lorelei A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Sinnott, Jennifer A.; Tyekucheva, Svitlana] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sinnott, Jennifer A.; Rider, Jennifer R.; Penney, Kathryn L.; Stampfer, Meir J.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Sinnott, Jennifer A.; Rider, Jennifer R.; Penney, Kathryn L.; Sesso, Howard D.; Loda, Massimo; Stampfer, Meir J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Carlsson, Jessica; Andersson, Sven-Olof; Andren, Ove] Univ Orebro, Sch Hlth & Med Sci, Dept Urol, S-70185 Orebro, Sweden. [Gerke, Travis] Univ Florida, Coll Med, Dept Epidemiol, Gainesville, FL 32611 USA. [Gerke, Travis] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA. [Tyekucheva, Svitlana] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA. [Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Loda, Massimo] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Fall, Katja] Univ Orebro, Sch Hlth & Med Sci, Dept Clin Epidemiol & Biostat, S-70185 Orebro, Sweden. [Pawitan, Yudi] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden. RP Rider, JR (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. EM rider@hsph.harvard.edu OI Rider, Jennifer/0000-0002-2637-6036; Fall, Katja/0000-0002-3649-2639 FU National Institutes of Health (NIH) [CA34944, CA40360, CA097193, HL26490, HL34595]; NIH [UM1 CA167552, R01 HL35464, GM074897, CA09001, CA141298, CA136578, CA090381]; Swedish Cancer Foundation; Orebro County Council Research Foundation; A. David Mazzone Career Development Award; Cancerfonden [CAN 2013/650]; Orebro University; Prostate Cancer Foundation FX The Physicians' Health Study was supported by the National Institutes of Health (NIH) grants CA34944, CA40360, CA097193, HL26490 and HL34595. The Health Professionals Follow-up Study was supported by NIH grants UM1 CA167552 and R01 HL35464. The Swedish Watchful Waiting cohort was supported by the Swedish Cancer Foundation and The Orebro County Council Research Foundation. This work was supported by the NIH grants GM074897 and CA09001 to J.A.S., CA141298 to M.J.S., CA136578 and CA090381 to L.A.M.; by the A. David Mazzone Career Development Award (J.A.S.); by Cancerfonden (CAN 2013/650) and Strategic funding from Orebro University (K.F.), and the Prostate Cancer Foundation (J.R.R. and L.A.M.). NR 21 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD JUN PY 2015 VL 36 IS 6 BP 632 EP 638 DI 10.1093/carcin/bgv051 PG 7 WC Oncology SC Oncology GA CK4GK UT WOS:000356181700004 PM 25870172 ER EF